{
    "601cb4541cb411341a000024_1": [
        {
            "start_logit": 8.8359375,
            "end_logit": 8.359375,
            "text": "Eosinophilic Gastritis",
            "probability": 1.0
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -1.552734375,
            "text": "Eosinophilic Gastritis and Duodenitis",
            "probability": 4.988908767700195e-05
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -2.248046875,
            "text": "Eosinophilic",
            "probability": 2.485513687133789e-05
        },
        {
            "start_logit": -2.7421875,
            "end_logit": 8.359375,
            "text": "Gastritis",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -5.83984375,
            "text": "Eosinophilic Gastritis and",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -6.83203125,
            "text": "Eosinophilic Gastritis and Duoden",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -6.9375,
            "text": "Eosinophilic Gastritis and Duodenitis.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 8.359375,
            "text": "for Eosinophilic Gastritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.7421875,
            "end_logit": -1.552734375,
            "text": "Gastritis and Duodenitis",
            "probability": 0.0
        },
        {
            "start_logit": -2.7421875,
            "end_logit": -5.83984375,
            "text": "Gastritis and",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -1.552734375,
            "text": "for Eosinophilic Gastritis and Duodenitis",
            "probability": 0.0
        },
        {
            "start_logit": -2.7421875,
            "end_logit": -6.83203125,
            "text": "Gastritis and Duoden",
            "probability": 0.0
        },
        {
            "start_logit": -2.7421875,
            "end_logit": -6.9375,
            "text": "Gastritis and Duodenitis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -2.248046875,
            "text": "for Eosinophilic",
            "probability": 0.0
        },
        {
            "start_logit": -5.34765625,
            "end_logit": -6.9375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -5.83984375,
            "text": "for Eosinophilic Gastritis and",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -6.83203125,
            "text": "for Eosinophilic Gastritis and Duoden",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -6.9375,
            "text": "for Eosinophilic Gastritis and Duodenitis.",
            "probability": 0.0
        }
    ],
    "601cb4541cb411341a000024_2": [
        {
            "start_logit": 8.8984375,
            "end_logit": 8.3828125,
            "text": "eosinophilic gastritis and duodenitis",
            "probability": 1.0
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -2.064453125,
            "text": "eosinophilic",
            "probability": 2.9087066650390625e-05
        },
        {
            "start_logit": -2.5390625,
            "end_logit": 8.3828125,
            "text": "itis",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -3.50390625,
            "text": "eosinophilic gastritis",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": -3.92578125,
            "end_logit": 8.3828125,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis and duodenitis",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -4.7734375,
            "text": "eosinophilic gastritis and",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -5.3671875,
            "text": "eosinophilic gastritis and duoden",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -5.3984375,
            "text": "eosinophilic gastritis and duodenitis.",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.953125,
            "end_logit": 8.3828125,
            "text": "for eosinophilic gastritis and duodenitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.171875,
            "end_logit": 8.3828125,
            "text": "es eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis and duodenitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 8.3828125,
            "text": "depletes eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis and duodenitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.92578125,
            "end_logit": -2.064453125,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic",
            "probability": 0.0
        },
        {
            "start_logit": -3.92578125,
            "end_logit": -3.50390625,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -2.5390625,
            "end_logit": -5.3984375,
            "text": "itis.",
            "probability": 0.0
        },
        {
            "start_logit": -3.92578125,
            "end_logit": -4.7734375,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis and",
            "probability": 0.0
        },
        {
            "start_logit": -6.953125,
            "end_logit": -2.064453125,
            "text": "for eosinophilic",
            "probability": 0.0
        },
        {
            "start_logit": -7.171875,
            "end_logit": -2.064453125,
            "text": "es eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic",
            "probability": 0.0
        },
        {
            "start_logit": -3.92578125,
            "end_logit": -5.33984375,
            "text": "eosinophils",
            "probability": 0.0
        },
        {
            "start_logit": -3.92578125,
            "end_logit": -5.3671875,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis and duoden",
            "probability": 0.0
        },
        {
            "start_logit": -3.92578125,
            "end_logit": -5.3984375,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis and duodenitis.",
            "probability": 0.0
        }
    ],
    "601cb4541cb411341a000024_3": [
        {
            "start_logit": 8.765625,
            "end_logit": 8.0078125,
            "text": "eosinophilic gastritis and duodenitis",
            "probability": 1.0
        },
        {
            "start_logit": 8.765625,
            "end_logit": -2.3125,
            "text": "eosinophilic",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 8.765625,
            "end_logit": -2.4921875,
            "text": "eosinophilic gastritis",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": -3.04296875,
            "end_logit": 8.0078125,
            "text": "itis",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": 8.765625,
            "end_logit": -4.6328125,
            "text": "eosinophilic gastritis and",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 8.765625,
            "end_logit": -5.76953125,
            "text": "eosinophilic gastritis and duodenitis.",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.765625,
            "end_logit": -5.78515625,
            "text": "eosinophilic gastritis and duoden",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.05078125,
            "end_logit": 8.0078125,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis and duodenitis",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 8.0078125,
            "text": "for eosinophilic gastritis and duodenitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.05078125,
            "end_logit": -2.3125,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic",
            "probability": 0.0
        },
        {
            "start_logit": -6.05078125,
            "end_logit": -2.4921875,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -3.04296875,
            "end_logit": -5.76953125,
            "text": "itis.",
            "probability": 0.0
        },
        {
            "start_logit": -6.9765625,
            "end_logit": -2.3125,
            "text": "for eosinophilic",
            "probability": 0.0
        },
        {
            "start_logit": -6.9765625,
            "end_logit": -2.4921875,
            "text": "for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -4.25390625,
            "end_logit": -5.76953125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.8203125,
            "end_logit": -5.859375,
            "text": "(lirentelimab",
            "probability": 0.0
        },
        {
            "start_logit": -6.05078125,
            "end_logit": -4.6328125,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis and",
            "probability": 0.0
        },
        {
            "start_logit": -4.8203125,
            "end_logit": -6.17578125,
            "text": "(lirentelima",
            "probability": 0.0
        },
        {
            "start_logit": -4.8203125,
            "end_logit": -6.28125,
            "text": "(lirentelimab)",
            "probability": 0.0
        },
        {
            "start_logit": -4.8203125,
            "end_logit": -6.3828125,
            "text": "(lirenteli",
            "probability": 0.0
        }
    ],
    "590c74d170f9fc6f0f00001e_1": [
        {
            "start_logit": 5.1953125,
            "end_logit": 4.26171875,
            "text": "Ecm22",
            "probability": 0.998046875
        },
        {
            "start_logit": 5.1953125,
            "end_logit": -2.169921875,
            "text": "Ecm22 and Upc2 in Saccharomyces cerevisiae filamentation.",
            "probability": 0.00160980224609375
        },
        {
            "start_logit": 5.1953125,
            "end_logit": -4.46875,
            "text": "Ecm22 and Upc2",
            "probability": 0.00016188621520996094
        },
        {
            "start_logit": 5.1953125,
            "end_logit": -4.671875,
            "text": "Ecm22 and Upc2 in",
            "probability": 0.0001322031021118164
        },
        {
            "start_logit": -3.798828125,
            "end_logit": 4.26171875,
            "text": "transcription factors Ecm22",
            "probability": 0.00012409687042236328
        },
        {
            "start_logit": 5.1953125,
            "end_logit": -5.078125,
            "text": "Ecm",
            "probability": 8.803606033325195e-05
        },
        {
            "start_logit": -4.67578125,
            "end_logit": 4.26171875,
            "text": "Here, we examine the role of the related transcription factors Ecm22",
            "probability": 5.173683166503906e-05
        },
        {
            "start_logit": 5.1953125,
            "end_logit": -6.00390625,
            "text": "Ecm22 and",
            "probability": 3.4749507904052734e-05
        },
        {
            "start_logit": 5.1953125,
            "end_logit": -6.0546875,
            "text": "Ecm22 and Upc2 in Saccharomyces cerevisiae",
            "probability": 3.314018249511719e-05
        },
        {
            "start_logit": 5.1953125,
            "end_logit": -6.2734375,
            "text": "Ecm22 and Upc2 in Saccharomyces cerevisiae filamentation",
            "probability": 2.664327621459961e-05
        },
        {
            "start_logit": 5.1953125,
            "end_logit": -6.52734375,
            "text": "Ecm22 and Upc2 in Saccharomyces",
            "probability": 2.0742416381835938e-05
        },
        {
            "start_logit": -5.66796875,
            "end_logit": 4.26171875,
            "text": "22",
            "probability": 1.919269561767578e-05
        },
        {
            "start_logit": 5.1953125,
            "end_logit": -6.78515625,
            "text": "Ecm22 and Upc2 in Saccharomyces cerevisiae filament",
            "probability": 1.5854835510253906e-05
        },
        {
            "start_logit": -5.984375,
            "end_logit": 4.26171875,
            "text": "factors Ecm22",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 4.26171875,
            "text": ", we examine the role of the related transcription factors Ecm22",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": -6.90625,
            "end_logit": 4.26171875,
            "text": "related transcription factors Ecm22",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 4.26171875,
            "text": "examine the role of the related transcription factors Ecm22",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 4.26171875,
            "text": "we examine the role of the related transcription factors Ecm22",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -3.431640625,
            "end_logit": -2.169921875,
            "text": "Upc2 in Saccharomyces cerevisiae filamentation.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -3.798828125,
            "end_logit": -2.169921875,
            "text": "transcription factors Ecm22 and Upc2 in Saccharomyces cerevisiae filamentation.",
            "probability": 1.7881393432617188e-07
        }
    ],
    "590c74d170f9fc6f0f00001e_2": [
        {
            "start_logit": 3.037109375,
            "end_logit": 3.775390625,
            "text": "Upc2 and Ecm22",
            "probability": 0.5830078125
        },
        {
            "start_logit": 2.68359375,
            "end_logit": 3.775390625,
            "text": "Ecm22",
            "probability": 0.410400390625
        },
        {
            "start_logit": 3.037109375,
            "end_logit": -1.3544921875,
            "text": "Upc2 and Ecm22 promote filamentation in Saccharomyces cerevisiae by sterol biosynthesis-dependent and -independent pathways.",
            "probability": 0.0034542083740234375
        },
        {
            "start_logit": 2.68359375,
            "end_logit": -1.3544921875,
            "text": "Ecm22 promote filamentation in Saccharomyces cerevisiae by sterol biosynthesis-dependent and -independent pathways.",
            "probability": 0.0024204254150390625
        },
        {
            "start_logit": -5.6171875,
            "end_logit": 3.775390625,
            "text": "The zinc cluster proteins Upc2 and Ecm22",
            "probability": 0.00010150671005249023
        },
        {
            "start_logit": 3.037109375,
            "end_logit": -5.15234375,
            "text": "Upc2 and Ecm22 promote",
            "probability": 7.724761962890625e-05
        },
        {
            "start_logit": -6.01171875,
            "end_logit": 3.775390625,
            "text": "22",
            "probability": 6.866455078125e-05
        },
        {
            "start_logit": 2.68359375,
            "end_logit": -5.15234375,
            "text": "Ecm22 promote",
            "probability": 5.429983139038086e-05
        },
        {
            "start_logit": 3.037109375,
            "end_logit": -5.65234375,
            "text": "Upc2 and",
            "probability": 4.678964614868164e-05
        },
        {
            "start_logit": 3.037109375,
            "end_logit": -5.89453125,
            "text": "Upc2",
            "probability": 3.6716461181640625e-05
        },
        {
            "start_logit": -6.73046875,
            "end_logit": 3.775390625,
            "text": "proteins Upc2 and Ecm22",
            "probability": 3.349781036376953e-05
        },
        {
            "start_logit": 3.037109375,
            "end_logit": -6.0,
            "text": "Upc2 and Ecm22 promote filamentation in Saccharomyces cerevisiae",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 3.775390625,
            "text": "and Ecm22",
            "probability": 2.771615982055664e-05
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 3.775390625,
            "text": "zinc cluster proteins Upc2 and Ecm22",
            "probability": 2.6881694793701172e-05
        },
        {
            "start_logit": 3.037109375,
            "end_logit": -6.23828125,
            "text": "Upc2 and Ecm22 promote filamentation in Saccharomyces cerevisiae by sterol biosynthesis",
            "probability": 2.6047229766845703e-05
        },
        {
            "start_logit": 3.037109375,
            "end_logit": -6.25,
            "text": "Upc2 and Ecm22 promote filamentation in",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": 2.68359375,
            "end_logit": -6.0,
            "text": "Ecm22 promote filamentation in Saccharomyces cerevisiae",
            "probability": 2.3365020751953125e-05
        },
        {
            "start_logit": 3.037109375,
            "end_logit": -6.35546875,
            "text": "Upc2 and Ecm22 promote filamentation",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 3.775390625,
            "text": "c2 and Ecm22",
            "probability": 2.181529998779297e-05
        },
        {
            "start_logit": 3.037109375,
            "end_logit": -6.46875,
            "text": "Up",
            "probability": 2.0802021026611328e-05
        }
    ],
    "590c74d170f9fc6f0f00001e_3": [
        {
            "start_logit": 9.2265625,
            "end_logit": 4.05078125,
            "text": "Sut1",
            "probability": 0.95166015625
        },
        {
            "start_logit": 9.2265625,
            "end_logit": 0.5986328125,
            "text": "Sut1 and Sut2 have initially been identified as regulators of sterol import in the budding yeast Saccharomyces cerevisiae.",
            "probability": 0.030120849609375
        },
        {
            "start_logit": 9.2265625,
            "end_logit": 0.0816650390625,
            "text": "Sut",
            "probability": 0.017852783203125
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -4.93359375,
            "text": "Sut1 and",
            "probability": 0.00011932849884033203
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -5.546875,
            "text": "Sut1 and Sut2 have",
            "probability": 6.437301635742188e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -5.83203125,
            "text": "Sut1 and Sut2 have initially been identified as regulators of sterol import in the budding yeast Saccharomyces cerevisiae",
            "probability": 4.8220157623291016e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -5.92578125,
            "text": "Sut1 and Sut2 have initially been identified as regulators of sterol import in",
            "probability": 4.392862319946289e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.1875,
            "text": "Sut1 and Sut2 have initially been identified as regulators of sterol import in the",
            "probability": 3.3915042877197266e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.25390625,
            "text": "Sut1 and Sut2 have initially been",
            "probability": 3.159046173095703e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.28125,
            "text": "Sut1 and Sut2 have initially been identified as regulators of sterol import",
            "probability": 3.0875205993652344e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.28515625,
            "text": "Sut1 and Sut2 have initially been identified as",
            "probability": 3.063678741455078e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.35546875,
            "text": "Sut1 and Sut2 have initially been identified as regulators of",
            "probability": 2.872943878173828e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.375,
            "text": "Sut1 and Sut",
            "probability": 2.8133392333984375e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.3828125,
            "text": "Sut1 and Sut2 have initially been identified as regulators of sterol",
            "probability": 2.7894973754882812e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.5546875,
            "text": "Sut1 and Sut2 have initially",
            "probability": 2.3484230041503906e-05
        },
        {
            "start_logit": -2.26953125,
            "end_logit": 4.05078125,
            "text": "Upc2, Sut1",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -5.34375,
            "end_logit": 4.05078125,
            "text": ", Upc2, Sut1",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -2.166015625,
            "end_logit": 0.5986328125,
            "text": ".",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -2.26953125,
            "end_logit": 0.5986328125,
            "text": "Upc2, Sut1 and Sut2 have initially been identified as regulators of sterol import in the budding yeast Saccharomyces cerevisiae.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.17578125,
            "end_logit": 4.05078125,
            "text": ", Sut1",
            "probability": 1.7881393432617188e-07
        }
    ],
    "590c74d170f9fc6f0f00001e_4": [
        {
            "start_logit": 3.689453125,
            "end_logit": -0.73193359375,
            "text": "Upc2 and Ecm22",
            "probability": 0.669921875
        },
        {
            "start_logit": 3.689453125,
            "end_logit": -1.875,
            "text": "Upc2 and Ecm22, which direct transcription of sterol biosynthetic genes.",
            "probability": 0.2137451171875
        },
        {
            "start_logit": 3.689453125,
            "end_logit": -3.134765625,
            "text": "Upc2 and Ecm22,",
            "probability": 0.06060791015625
        },
        {
            "start_logit": 3.689453125,
            "end_logit": -4.34375,
            "text": "Upc2",
            "probability": 0.018096923828125
        },
        {
            "start_logit": -0.27392578125,
            "end_logit": -0.73193359375,
            "text": "Ecm22",
            "probability": 0.01273345947265625
        },
        {
            "start_logit": 3.689453125,
            "end_logit": -5.55078125,
            "text": "Upc2 and Ecm22, which direct transcription of sterol biosynthetic genes",
            "probability": 0.005401611328125
        },
        {
            "start_logit": -0.27392578125,
            "end_logit": -1.875,
            "text": "Ecm22, which direct transcription of sterol biosynthetic genes.",
            "probability": 0.004062652587890625
        },
        {
            "start_logit": 3.689453125,
            "end_logit": -5.90625,
            "text": "Upc2 and Ecm22, which",
            "probability": 0.0037994384765625
        },
        {
            "start_logit": 3.689453125,
            "end_logit": -5.91015625,
            "text": "Up",
            "probability": 0.0037708282470703125
        },
        {
            "start_logit": 3.689453125,
            "end_logit": -6.140625,
            "text": "Upc2 and Ecm22, which direct",
            "probability": 0.0030078887939453125
        },
        {
            "start_logit": 3.689453125,
            "end_logit": -6.2109375,
            "text": "Upc2 and Ecm22, which direct transcription",
            "probability": 0.0028018951416015625
        },
        {
            "start_logit": -0.27392578125,
            "end_logit": -3.134765625,
            "text": "Ecm22,",
            "probability": 0.0011491775512695312
        },
        {
            "start_logit": -2.931640625,
            "end_logit": -1.875,
            "text": ".",
            "probability": 0.00028514862060546875
        },
        {
            "start_logit": -4.421875,
            "end_logit": -0.73193359375,
            "text": ", Upc2 and Ecm22",
            "probability": 0.00020134449005126953
        },
        {
            "start_logit": -0.27392578125,
            "end_logit": -5.55078125,
            "text": "Ecm22, which direct transcription of sterol biosynthetic genes",
            "probability": 0.00010281801223754883
        },
        {
            "start_logit": -0.27392578125,
            "end_logit": -5.90625,
            "text": "Ecm22, which",
            "probability": 7.18235969543457e-05
        },
        {
            "start_logit": -4.421875,
            "end_logit": -1.875,
            "text": ", Upc2 and Ecm22, which direct transcription of sterol biosynthetic genes.",
            "probability": 6.437301635742188e-05
        },
        {
            "start_logit": -0.27392578125,
            "end_logit": -6.140625,
            "text": "Ecm22, which direct",
            "probability": 5.6803226470947266e-05
        },
        {
            "start_logit": -0.27392578125,
            "end_logit": -6.2109375,
            "text": "Ecm22, which direct transcription",
            "probability": 5.334615707397461e-05
        },
        {
            "start_logit": -6.30859375,
            "end_logit": -0.73193359375,
            "text": "genes involved in sterol biosynthesis and two transcription factors, Upc2 and Ecm22",
            "probability": 3.039836883544922e-05
        }
    ],
    "590c74d170f9fc6f0f00001e_5": [
        {
            "start_logit": 5.27734375,
            "end_logit": 4.3203125,
            "text": "Ecm22",
            "probability": 0.9951171875
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -1.28515625,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1, NPR1, PRR2 and sterol biosynthesis genes.",
            "probability": 0.0036754608154296875
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -3.150390625,
            "text": "Ecm22 and Upc2 positively",
            "probability": 0.0005679130554199219
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -3.84375,
            "text": "Ecm22 and Upc2",
            "probability": 0.0002853870391845703
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -4.08984375,
            "text": "Ecm22 and",
            "probability": 0.0002224445343017578
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -4.79296875,
            "text": "Ecm22 and Upc2 positively control the",
            "probability": 0.00011008977890014648
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -5.0390625,
            "text": "Ecm",
            "probability": 8.571147918701172e-05
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -5.40625,
            "text": "Ecm22 and Upc2 positively control",
            "probability": 5.984306335449219e-05
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -5.4765625,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1, NPR1, PRR2 and sterol biosynthesis",
            "probability": 5.53131103515625e-05
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -5.9609375,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1",
            "probability": 3.409385681152344e-05
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -5.98046875,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1, NPR1, PRR2 and sterol biosynthesis genes",
            "probability": 3.355741500854492e-05
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -6.0,
            "text": "Ecm22 and Upc2 positively control the expression",
            "probability": 3.3020973205566406e-05
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -6.0625,
            "text": "Ecm22 and Upc2 positively control the expression of",
            "probability": 3.0994415283203125e-05
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -6.28515625,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1,",
            "probability": 2.473592758178711e-05
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -6.41796875,
            "text": "Ecm22 and Upc2 positively control the expression of FH",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -6.515625,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1, NPR",
            "probability": 1.9729137420654297e-05
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -6.52734375,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1, NPR1",
            "probability": 1.9431114196777344e-05
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -6.546875,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1, NPR1, PRR2 and sterol",
            "probability": 1.913309097290039e-05
        },
        {
            "start_logit": -5.75,
            "end_logit": 4.3203125,
            "text": "22",
            "probability": 1.627206802368164e-05
        },
        {
            "start_logit": 5.27734375,
            "end_logit": -6.7109375,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1, NPR1,",
            "probability": 1.615285873413086e-05
        }
    ],
    "590c74d170f9fc6f0f00001e_6": [
        {
            "start_logit": 9.296875,
            "end_logit": 9.0546875,
            "text": "Ste12",
            "probability": 0.9990234375
        },
        {
            "start_logit": 2.591796875,
            "end_logit": 9.0546875,
            "text": "ECM22 and UPC2 as well as mutation of the three Ste12",
            "probability": 0.0012359619140625
        },
        {
            "start_logit": 9.296875,
            "end_logit": -0.9169921875,
            "text": "Ste",
            "probability": 4.7147274017333984e-05
        },
        {
            "start_logit": -1.412109375,
            "end_logit": 9.0546875,
            "text": "12",
            "probability": 2.2470951080322266e-05
        },
        {
            "start_logit": 2.591796875,
            "end_logit": 1.416015625,
            "text": "ECM22",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.36328125,
            "text": "Ste12-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.56640625,
            "text": "Ste12-binding sites in the PRM1 promoter completely",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.58984375,
            "text": "Ste12-binding sites in the PRM1 promoter completely abolishes basal and pheromone-induced PRM1 expression, indicating that Ste12 and Ecm22",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.61328125,
            "text": "Ste12-binding sites in the PRM1 promoter completely abolishes basal and pheromone-induced PRM1 expression, indicating that Ste12",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.71484375,
            "text": "Ste12-binding sites in the PRM1 promoter",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.80078125,
            "text": "Ste12-binding sites in the PRM1 promoter completely abolishes basal and pheromone-induced PRM1 expression, indicating",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.8125,
            "text": "Ste12-binding sites in the PR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 9.0546875,
            "text": "UPC2 as well as mutation of the three Ste12",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 9.0546875,
            "text": "of ECM22 and UPC2 as well as mutation of the three Ste12",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.591796875,
            "end_logit": -0.9169921875,
            "text": "ECM22 and UPC2 as well as mutation of the three Ste",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 9.0546875,
            "text": "22 and UPC2 as well as mutation of the three Ste12",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.591796875,
            "end_logit": -6.26953125,
            "text": "ECM22 and UPC2 as",
            "probability": 0.0
        },
        {
            "start_logit": 2.591796875,
            "end_logit": -6.36328125,
            "text": "ECM22 and UPC2 as well as mutation of the three Ste12-",
            "probability": 0.0
        },
        {
            "start_logit": 2.591796875,
            "end_logit": -6.4140625,
            "text": "ECM22 and UPC2 as well as",
            "probability": 0.0
        },
        {
            "start_logit": 2.591796875,
            "end_logit": -6.53515625,
            "text": "ECM",
            "probability": 0.0
        }
    ],
    "590c74d170f9fc6f0f00001e_7": [
        {
            "start_logit": 8.953125,
            "end_logit": 8.7265625,
            "text": "Ecm22",
            "probability": 1.0
        },
        {
            "start_logit": 8.953125,
            "end_logit": -1.9375,
            "text": "Ecm",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": -2.154296875,
            "end_logit": 8.7265625,
            "text": "22",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": 8.953125,
            "end_logit": -4.640625,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PRM1 and PRM4.",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 8.953125,
            "end_logit": -5.62890625,
            "text": "Ecm22 and Upc2 positively",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -5.80859375,
            "text": "Ecm22 and",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -6.26953125,
            "text": "Ecm22 and Upc2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -6.4765625,
            "text": "Ecm22 and Upc2 positively regulate basal",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -6.48828125,
            "text": "Ecm22 and Upc2 positively regulate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -6.578125,
            "text": "Ecm22 and Upc2 positively regulate basal expression",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -6.68359375,
            "text": "Ecm22 and Upc2 positively regulate basal expression of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -6.86328125,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PRM1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -6.953125,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PRM1 and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.02734375,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.15625,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PRM1 and PRM4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.17578125,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PRM1 and PRM",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.25,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PRM1 and PR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.154296875,
            "end_logit": -4.640625,
            "text": "22 and Upc2 positively regulate basal expression of PRM1 and PRM4.",
            "probability": 0.0
        },
        {
            "start_logit": -2.154296875,
            "end_logit": -5.62890625,
            "text": "22 and Upc2 positively",
            "probability": 0.0
        },
        {
            "start_logit": -2.154296875,
            "end_logit": -5.80859375,
            "text": "22 and",
            "probability": 0.0
        }
    ],
    "590c74d170f9fc6f0f00001e_8": [
        {
            "start_logit": 8.8203125,
            "end_logit": 8.28125,
            "text": "Ecm22",
            "probability": 0.640625
        },
        {
            "start_logit": 8.078125,
            "end_logit": 8.28125,
            "text": "AR1b elements are absolutely required for auto-induction of UPC2 gene expression and protein and require Upc2 and Ecm22",
            "probability": 0.30712890625
        },
        {
            "start_logit": 8.078125,
            "end_logit": 6.5078125,
            "text": "AR1b",
            "probability": 0.052154541015625
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -2.00390625,
            "text": "Ecm",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": 8.078125,
            "end_logit": -2.00390625,
            "text": "AR1b elements are absolutely required for auto-induction of UPC2 gene expression and protein and require Upc2 and Ecm",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -2.66796875,
            "end_logit": 8.28125,
            "text": "22",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": 8.078125,
            "end_logit": -2.97265625,
            "text": "AR",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -3.84765625,
            "text": "Ecm22 for function.",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 8.078125,
            "end_logit": -3.84765625,
            "text": "AR1b elements are absolutely required for auto-induction of UPC2 gene expression and protein and require Upc2 and Ecm22 for function.",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -4.7109375,
            "end_logit": 8.28125,
            "text": "1b elements are absolutely required for auto-induction of UPC2 gene expression and protein and require Upc2 and Ecm22",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -6.3828125,
            "text": "Ecm22 for",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.02734375,
            "end_logit": 8.28125,
            "text": "Upc2 and Ecm22",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -5.9453125,
            "text": "AR1b elements are",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -6.0546875,
            "text": "AR1b elements are absolutely required for auto-induction of UPC2 gene expression and protein and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -6.26953125,
            "text": "AR1b elements",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.7109375,
            "end_logit": 6.5078125,
            "text": "1b",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -6.2890625,
            "text": "AR1b elements are absolutely",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -6.37109375,
            "text": "AR1b elements are absolutely required for",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -6.3828125,
            "text": "AR1b elements are absolutely required for auto-induction of UPC2 gene expression and protein and require Upc2 and Ecm22 for",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.078125,
            "end_logit": -6.40625,
            "text": "AR1b elements are absolutely required for auto-induction of UPC2 gene",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5896271178275d0c4a000004_1": [
        {
            "start_logit": 8.96875,
            "end_logit": 8.9140625,
            "text": "respiratory distress syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 8.96875,
            "end_logit": -1.8798828125,
            "text": "respiratory",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": -1.8837890625,
            "end_logit": 8.9140625,
            "text": "syndrome",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": -5.7578125,
            "end_logit": 8.9140625,
            "text": "distress syndrome",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.4453125,
            "text": "respiratory distress syndrome in",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.64453125,
            "text": "respiratory distress syndrome in premature infants.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.671875,
            "text": "respiratory distress syndrome in premature infants",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.078125,
            "text": "respiratory distress syndrome in premature",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -7.16015625,
            "text": "respiratory distress",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 8.9140625,
            "text": "of respiratory distress syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 8.9140625,
            "text": "prevention of respiratory distress syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.8837890625,
            "end_logit": -6.4453125,
            "text": "syndrome in",
            "probability": 0.0
        },
        {
            "start_logit": -1.8837890625,
            "end_logit": -6.64453125,
            "text": "syndrome in premature infants.",
            "probability": 0.0
        },
        {
            "start_logit": -1.8837890625,
            "end_logit": -6.671875,
            "text": "syndrome in premature infants",
            "probability": 0.0
        },
        {
            "start_logit": -1.8837890625,
            "end_logit": -7.078125,
            "text": "syndrome in premature",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": -1.8798828125,
            "text": "of respiratory",
            "probability": 0.0
        },
        {
            "start_logit": -7.4296875,
            "end_logit": -1.8798828125,
            "text": "prevention of respiratory",
            "probability": 0.0
        },
        {
            "start_logit": -5.4765625,
            "end_logit": -6.64453125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.7578125,
            "end_logit": -6.4453125,
            "text": "distress syndrome in",
            "probability": 0.0
        },
        {
            "start_logit": -5.7578125,
            "end_logit": -6.64453125,
            "text": "distress syndrome in premature infants.",
            "probability": 0.0
        }
    ],
    "5896271178275d0c4a000004_2": [
        {
            "start_logit": 9.0625,
            "end_logit": 8.984375,
            "text": "respiratory distress syndrome",
            "probability": 1.0
        },
        {
            "start_logit": 9.0625,
            "end_logit": -1.7060546875,
            "text": "respiratory",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": -1.736328125,
            "end_logit": 8.984375,
            "text": "syndrome",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": -5.76953125,
            "end_logit": 8.984375,
            "text": "distress syndrome",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.4921875,
            "text": "respiratory distress syndrome in neonates",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.8984375,
            "text": "respiratory distress syndrome in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.0625,
            "text": "respiratory distress syndrome in neonates.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.09375,
            "text": "respiratory distress",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 8.984375,
            "text": "of respiratory distress syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.984375,
            "text": "treatment of respiratory distress syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 8.984375,
            "text": "the treatment of respiratory distress syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.984375,
            "text": "for the treatment of respiratory distress syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.736328125,
            "end_logit": -6.4921875,
            "text": "syndrome in neonates",
            "probability": 0.0
        },
        {
            "start_logit": -1.736328125,
            "end_logit": -6.8984375,
            "text": "syndrome in",
            "probability": 0.0
        },
        {
            "start_logit": -1.736328125,
            "end_logit": -7.0625,
            "text": "syndrome in neonates.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -1.7060546875,
            "text": "of respiratory",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -1.7060546875,
            "text": "treatment of respiratory",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -1.7060546875,
            "text": "the treatment of respiratory",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -1.7060546875,
            "text": "for the treatment of respiratory",
            "probability": 0.0
        },
        {
            "start_logit": -5.76953125,
            "end_logit": -6.4921875,
            "text": "distress syndrome in neonates",
            "probability": 0.0
        }
    ],
    "5c8974bcd558e5f232000008_1": [
        {
            "start_logit": 9.0078125,
            "end_logit": 8.859375,
            "text": "Chiesi Pharma",
            "probability": 1.0
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -1.8037109375,
            "text": "Chi",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": -1.78125,
            "end_logit": 8.859375,
            "text": "a",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": -4.25,
            "end_logit": 8.859375,
            "text": "from Chiesi Pharma",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -5.453125,
            "text": "Chiesi Pharm",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -5.921875,
            "text": "Chiesi Pharma and Strimvelis\u00ae",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.14453125,
            "text": "Chiesi Pharma and Strimvelis\u00ae from GSK) and Japan (Remestemcel-L from Mesoblast\u00ae).",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.08203125,
            "end_logit": 8.859375,
            "text": "esi Pharma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.15234375,
            "end_logit": 8.859375,
            "text": "Holoclar\u00ae from Chiesi Pharma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.68359375,
            "text": "Chiesi",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.6875,
            "text": "Chiesi Pharma and Strimvelis\u00ae from GSK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.82421875,
            "text": "Chiesi Pharma and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.78125,
            "end_logit": 8.859375,
            "text": "Pharma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 8.859375,
            "text": "(Glybera and Holoclar\u00ae from Chiesi Pharma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 8.859375,
            "text": "clar\u00ae from Chiesi Pharma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.25,
            "end_logit": -1.8037109375,
            "text": "from Chi",
            "probability": 0.0
        },
        {
            "start_logit": -1.78125,
            "end_logit": -5.921875,
            "text": "a and Strimvelis\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": -1.78125,
            "end_logit": -6.14453125,
            "text": "a and Strimvelis\u00ae from GSK) and Japan (Remestemcel-L from Mesoblast\u00ae).",
            "probability": 0.0
        },
        {
            "start_logit": -6.15234375,
            "end_logit": -1.8037109375,
            "text": "Holoclar\u00ae from Chi",
            "probability": 0.0
        },
        {
            "start_logit": -1.78125,
            "end_logit": -6.6875,
            "text": "a and Strimvelis\u00ae from GSK",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_1": [
        {
            "start_logit": 9.2109375,
            "end_logit": 8.9921875,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -1.373046875,
            "text": "X",
            "probability": 3.147125244140625e-05
        },
        {
            "start_logit": -1.6123046875,
            "end_logit": 8.9921875,
            "text": "28",
            "probability": 1.9848346710205078e-05
        },
        {
            "start_logit": -5.26171875,
            "end_logit": 8.9921875,
            "text": "q28",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.34765625,
            "text": "Xq",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.59765625,
            "text": "Xq28) in human.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.9609375,
            "text": "Xq28)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.03515625,
            "end_logit": 8.9921875,
            "text": ": Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 8.9921875,
            "text": "Cytogenetic Location: Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 8.9921875,
            "text": "gene (Cytogenetic Location: Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 8.9921875,
            "text": "by TAZ gene (Cytogenetic Location: Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.9921875,
            "text": "Phospholipid Transacylase involved in Cardiolipin remodeling on mitochondrial membrane and coded by TAZ gene (Cytogenetic Location: Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6123046875,
            "end_logit": -6.59765625,
            "text": "28) in human.",
            "probability": 0.0
        },
        {
            "start_logit": -7.03515625,
            "end_logit": -1.373046875,
            "text": ": X",
            "probability": 0.0
        },
        {
            "start_logit": -1.6123046875,
            "end_logit": -6.9609375,
            "text": "28)",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -1.373046875,
            "text": "Cytogenetic Location: X",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -1.373046875,
            "text": "gene (Cytogenetic Location: X",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -1.373046875,
            "text": "by TAZ gene (Cytogenetic Location: X",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -1.373046875,
            "text": "Phospholipid Transacylase involved in Cardiolipin remodeling on mitochondrial membrane and coded by TAZ gene (Cytogenetic Location: X",
            "probability": 0.0
        },
        {
            "start_logit": -4.3828125,
            "end_logit": -6.59765625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_2": [
        {
            "start_logit": 8.890625,
            "end_logit": 8.6796875,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": 8.890625,
            "end_logit": -1.95703125,
            "text": "X",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -2.16015625,
            "end_logit": 8.6796875,
            "text": "28",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -4.4921875,
            "end_logit": 8.6796875,
            "text": ". Recently, mutations in the G4.5 gene, located in Xq28",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -5.25390625,
            "end_logit": 8.6796875,
            "text": "in Xq28",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -5.47265625,
            "end_logit": 8.6796875,
            "text": "q28",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -5.91015625,
            "text": "Xq28, have been described in four probands with Barth syndrome.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 8.6796875,
            "text": "the G4.5 gene, located in Xq28",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.5703125,
            "text": "Xq28,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.69921875,
            "text": "Xq",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.94921875,
            "text": "Xq28, have",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -7.015625,
            "text": "Xq28, have been",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 8.6796875,
            "text": "in the G4.5 gene, located in Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0078125,
            "end_logit": 8.6796875,
            "text": ", mutations in the G4.5 gene, located in Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 8.6796875,
            "text": "mutations in the G4.5 gene, located in Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 8.6796875,
            "text": "located in Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.140625,
            "end_logit": 8.6796875,
            "text": "Recently, mutations in the G4.5 gene, located in Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 8.6796875,
            "text": "gene, located in Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.4921875,
            "end_logit": -1.95703125,
            "text": ". Recently, mutations in the G4.5 gene, located in X",
            "probability": 0.0
        },
        {
            "start_logit": -5.25390625,
            "end_logit": -1.95703125,
            "text": "in X",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_3": [
        {
            "start_logit": 8.984375,
            "end_logit": 8.8984375,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": 8.8984375,
            "text": "tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": -1.8125,
            "end_logit": 8.8984375,
            "text": "28",
            "probability": 2.0623207092285156e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -1.9033203125,
            "text": "X",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -4.3125,
            "text": "Xq28.",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -5.04296875,
            "end_logit": 8.8984375,
            "text": "on Xq28",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -5.44921875,
            "end_logit": 8.8984375,
            "text": "q28",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.71484375,
            "text": "Xq",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 8.8984375,
            "text": "azzin (TAZ/G4.5) gene located on Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 8.8984375,
            "text": "located on Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 8.8984375,
            "text": "zin (TAZ/G4.5) gene located on Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 8.8984375,
            "text": "the tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 8.8984375,
            "text": "gene located on Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -1.9033203125,
            "text": "tafazzin (TAZ/G4.5) gene located on X",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -4.3125,
            "text": "tafazzin (TAZ/G4.5) gene located on Xq28.",
            "probability": 0.0
        },
        {
            "start_logit": -1.8125,
            "end_logit": -4.3125,
            "text": "28.",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -4.80859375,
            "text": "tafazzin (TAZ/G4.5) gene",
            "probability": 0.0
        },
        {
            "start_logit": -5.04296875,
            "end_logit": -1.9033203125,
            "text": "on X",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -6.2265625,
            "text": "tafazzin",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -6.5,
            "text": "tafazzin (",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_4": [
        {
            "start_logit": 8.6328125,
            "end_logit": 8.515625,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": -0.8310546875,
            "end_logit": 8.515625,
            "text": "tafazzin (TAZ) gene, located at Xq28",
            "probability": 7.724761962890625e-05
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -2.498046875,
            "text": "X",
            "probability": 1.633167266845703e-05
        },
        {
            "start_logit": -2.552734375,
            "end_logit": 8.515625,
            "text": "28",
            "probability": 1.3709068298339844e-05
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -5.5625,
            "text": "Xq28,",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.94921875,
            "end_logit": 8.515625,
            "text": "q28",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 8.515625,
            "text": "at Xq28",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 8.515625,
            "text": "the tafazzin (TAZ) gene, located at Xq28",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -6.8828125,
            "text": "Xq28, cause the disorder by reducing remodeling of cardiolipin, a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -6.90625,
            "text": "Xq",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -6.921875,
            "text": "Xq28, cause the disorder by reducing remodeling of cardiolipin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.6328125,
            "end_logit": -7.00390625,
            "text": "Xq28, cause the disorder by reducing remodeling of cardiolipin,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.203125,
            "end_logit": 8.515625,
            "text": "azzin (TAZ) gene, located at Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 8.515625,
            "text": "located at Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 8.515625,
            "text": "zin (TAZ) gene, located at Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.8310546875,
            "end_logit": -2.498046875,
            "text": "tafazzin (TAZ) gene, located at X",
            "probability": 0.0
        },
        {
            "start_logit": -0.8310546875,
            "end_logit": -4.953125,
            "text": "tafazzin (TAZ) gene",
            "probability": 0.0
        },
        {
            "start_logit": -0.8310546875,
            "end_logit": -5.5625,
            "text": "tafazzin (TAZ) gene, located at Xq28,",
            "probability": 0.0
        },
        {
            "start_logit": -0.8310546875,
            "end_logit": -6.30859375,
            "text": "tafazzin",
            "probability": 0.0
        },
        {
            "start_logit": -0.8310546875,
            "end_logit": -6.4609375,
            "text": "tafazzin (TAZ) gene,",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_5": [
        {
            "start_logit": 8.65625,
            "end_logit": 8.765625,
            "text": "Xq28",
            "probability": 0.9990234375
        },
        {
            "start_logit": 1.859375,
            "end_logit": 8.765625,
            "text": "tafazzin gene (TAZ) is located at Xq28",
            "probability": 0.0011167526245117188
        },
        {
            "start_logit": -2.126953125,
            "end_logit": 8.765625,
            "text": "28",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": 8.65625,
            "end_logit": -2.517578125,
            "text": "X",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -4.9453125,
            "end_logit": 8.765625,
            "text": "The tafazzin gene (TAZ) is located at Xq28",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 8.65625,
            "end_logit": -5.39453125,
            "text": "Xq28 and",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 8.765625,
            "text": "q28",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.46484375,
            "text": "Xq28 and encodes a protein involved in the transacylation of cardiolipin,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.578125,
            "end_logit": 8.765625,
            "text": "at Xq28",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.51953125,
            "text": "Xq28 and encodes a protein involved in the transacylation of cardiolipin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.57421875,
            "text": "Xq28 and encodes a protein involved in the transacylation of cardiolipin, an",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.609375,
            "text": "Xq28 and encodes a protein involved in the transacylation of",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.65234375,
            "text": "Xq28 and encodes a protein involved in the transacylation",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.7109375,
            "text": "Xq28 and encodes a protein involved in the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.73046875,
            "text": "Xq28 and encodes a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.77734375,
            "text": "Xq28 and encodes a protein involved",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.78515625,
            "text": "Xq28 and encodes a protein involved in the transacyl",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 8.765625,
            "text": "azzin gene (TAZ) is located at Xq28",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.765625,
            "text": "zin gene (TAZ) is located at Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 1.859375,
            "end_logit": -2.517578125,
            "text": "tafazzin gene (TAZ) is located at X",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_6": [
        {
            "start_logit": 8.6796875,
            "end_logit": 8.78125,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": -1.296875,
            "end_logit": 8.78125,
            "text": "tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 4.6133995056152344e-05
        },
        {
            "start_logit": -2.09765625,
            "end_logit": 8.78125,
            "text": "28",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -2.515625,
            "text": "X",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": -5.52734375,
            "end_logit": 8.78125,
            "text": "q28",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.703125,
            "end_logit": 8.78125,
            "text": "on Xq28",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -6.96875,
            "text": "Xq",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 8.78125,
            "text": "azzin (TAZ/G4.5) gene located on Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 8.78125,
            "text": "located on Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 8.78125,
            "text": "zin (TAZ/G4.5) gene located on Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 8.78125,
            "text": "the tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.296875,
            "end_logit": -2.515625,
            "text": "tafazzin (TAZ/G4.5) gene located on X",
            "probability": 0.0
        },
        {
            "start_logit": -1.296875,
            "end_logit": -5.22265625,
            "text": "tafazzin (TAZ/G4.5) gene",
            "probability": 0.0
        },
        {
            "start_logit": -1.296875,
            "end_logit": -5.63671875,
            "text": "tafazzin",
            "probability": 0.0
        },
        {
            "start_logit": -1.296875,
            "end_logit": -6.36328125,
            "text": "tafazzin (",
            "probability": 0.0
        },
        {
            "start_logit": -1.296875,
            "end_logit": -6.88671875,
            "text": "tafazzin (TAZ/G4.5) gene located",
            "probability": 0.0
        },
        {
            "start_logit": -1.296875,
            "end_logit": -6.90625,
            "text": "tafazz",
            "probability": 0.0
        },
        {
            "start_logit": -1.296875,
            "end_logit": -6.91796875,
            "text": "tafazzin (TAZ",
            "probability": 0.0
        },
        {
            "start_logit": -5.703125,
            "end_logit": -2.515625,
            "text": "on X",
            "probability": 0.0
        },
        {
            "start_logit": -1.296875,
            "end_logit": -6.96875,
            "text": "tafazzin (TAZ/G4.5) gene located on Xq",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_7": [
        {
            "start_logit": 8.984375,
            "end_logit": 8.8984375,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": 8.8984375,
            "text": "tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": -1.8125,
            "end_logit": 8.8984375,
            "text": "28",
            "probability": 2.0623207092285156e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -1.9033203125,
            "text": "X",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -4.3125,
            "text": "Xq28.",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -5.04296875,
            "end_logit": 8.8984375,
            "text": "on Xq28",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -5.44921875,
            "end_logit": 8.8984375,
            "text": "q28",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.71484375,
            "text": "Xq",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 8.8984375,
            "text": "azzin (TAZ/G4.5) gene located on Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 8.8984375,
            "text": "located on Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 8.8984375,
            "text": "zin (TAZ/G4.5) gene located on Xq28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 8.8984375,
            "text": "the tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 8.8984375,
            "text": "gene located on Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -1.9033203125,
            "text": "tafazzin (TAZ/G4.5) gene located on X",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -4.3125,
            "text": "tafazzin (TAZ/G4.5) gene located on Xq28.",
            "probability": 0.0
        },
        {
            "start_logit": -1.8125,
            "end_logit": -4.3125,
            "text": "28.",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -4.80859375,
            "text": "tafazzin (TAZ/G4.5) gene",
            "probability": 0.0
        },
        {
            "start_logit": -5.04296875,
            "end_logit": -1.9033203125,
            "text": "on X",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -6.2265625,
            "text": "tafazzin",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -6.5,
            "text": "tafazzin (",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_8": [
        {
            "start_logit": 9.0859375,
            "end_logit": 8.9140625,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -1.7421875,
            "text": "X",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": -1.8017578125,
            "end_logit": 8.9140625,
            "text": "28",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -5.67578125,
            "text": "Xq28, have been described in four probands with Barth syndrome.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.69140625,
            "end_logit": 8.9140625,
            "text": "q28",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -6.1171875,
            "text": "Xq28,",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.9921875,
            "end_logit": 8.9140625,
            "text": "in Xq28",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -6.63671875,
            "text": "Xq",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -6.87890625,
            "text": "Xq28, have",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -6.91796875,
            "text": "Xq28, have been described in four probands with Barth syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.015625,
            "text": "Xq28, have been",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.08984375,
            "text": "Xq28, have been described",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.109375,
            "text": "Xq28, have been described in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.1875,
            "text": "Xq28, have been described in four probands with",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.20703125,
            "text": "Xq28, have been described in four probands with Barth",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.171875,
            "end_logit": 8.9140625,
            "text": "Recently, mutations in the G4.5 gene, located in Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.171875,
            "end_logit": 8.9140625,
            "text": ", mutations in the G4.5 gene, located in Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 8.9140625,
            "text": "located in Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 8.9140625,
            "text": "the G4.5 gene, located in Xq28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46875,
            "end_logit": 8.9140625,
            "text": "mutations in the G4.5 gene, located in Xq28",
            "probability": 5.960464477539063e-08
        }
    ],
    "626aeba1e764a53204000040_1": [
        {
            "start_logit": 8.8984375,
            "end_logit": 9.03125,
            "text": "Ionis Pharmaceuticals",
            "probability": 1.0
        },
        {
            "start_logit": -1.494140625,
            "end_logit": 9.03125,
            "text": "Pharmaceuticals",
            "probability": 3.045797348022461e-05
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -2.109375,
            "text": "Ion",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": -5.69921875,
            "end_logit": 9.03125,
            "text": "is Pharmaceuticals",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.359375,
            "text": "Ionis Pharmaceuticals through",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 9.03125,
            "text": "by Ionis Pharmaceuticals",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.703125,
            "text": "Ionis Pharmaceuticals through its subsid",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.8515625,
            "text": "Ionis Pharmaceuticals through its",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.96875,
            "text": "Ionis Pharmaceuticals through its subsidiary",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.046875,
            "text": "Ionis Pharmaceuticals through its subsidiary company, Akcea",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.06640625,
            "text": "Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.11328125,
            "text": "Ionis Pharmaceuticals through its subsidiary company, Akce",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.11328125,
            "text": "Ionis Pharmaceuticals through its subsidiary company",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.15625,
            "text": "Ionis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.19140625,
            "text": "Ionis Pharmaceuticals through its subsidiary company, Ak",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.21484375,
            "text": "Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics, to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.03125,
            "text": "(Waylivra\u00ae), an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis Pharmaceuticals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.265625,
            "text": "Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 9.03125,
            "text": "antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis Pharmaceuticals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 9.03125,
            "text": "Waylivra\u00ae), an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis Pharmaceuticals",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a43a139966455904c000008_1": [
        {
            "start_logit": 8.703125,
            "end_logit": 8.6953125,
            "text": "DNA methylation",
            "probability": 1.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": 8.6953125,
            "text": "methylation",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": 8.703125,
            "end_logit": -2.234375,
            "text": "DNA",
            "probability": 1.7762184143066406e-05
        },
        {
            "start_logit": 8.703125,
            "end_logit": -3.568359375,
            "text": "DNA methylation within individual DNA molecules.",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 8.703125,
            "end_logit": -5.890625,
            "text": "DNA methylation within",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.703125,
            "end_logit": -6.59375,
            "text": "DNA methylation within individual DNA molecules",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 8.6953125,
            "text": "nucleosome positioning and DNA methylation",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.703125,
            "end_logit": -6.7890625,
            "text": "DNA methylation within individual",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.703125,
            "end_logit": -6.96875,
            "text": "DNA methylation within individual DNA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 8.6953125,
            "text": "and DNA methylation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 8.6953125,
            "text": "Genome-wide mapping of nucleosome positioning and DNA methylation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3125,
            "end_logit": 8.6953125,
            "text": "mapping of nucleosome positioning and DNA methylation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 8.6953125,
            "text": "of nucleosome positioning and DNA methylation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 8.6953125,
            "text": "positioning and DNA methylation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.921875,
            "end_logit": -3.568359375,
            "text": "methylation within individual DNA molecules.",
            "probability": 0.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": -5.890625,
            "text": "methylation within",
            "probability": 0.0
        },
        {
            "start_logit": -4.6796875,
            "end_logit": -3.568359375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": -6.59375,
            "text": "methylation within individual DNA molecules",
            "probability": 0.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": -6.7890625,
            "text": "methylation within individual",
            "probability": 0.0
        },
        {
            "start_logit": -1.921875,
            "end_logit": -6.96875,
            "text": "methylation within individual DNA",
            "probability": 0.0
        }
    ],
    "602a84ae1cb411341a000116_1": [
        {
            "start_logit": 8.9609375,
            "end_logit": 8.5859375,
            "text": "Long noncoding RNAs",
            "probability": 0.97705078125
        },
        {
            "start_logit": 8.9609375,
            "end_logit": 4.3828125,
            "text": "Long noncoding RNAs (lncRNAs",
            "probability": 0.0146026611328125
        },
        {
            "start_logit": 8.9609375,
            "end_logit": 3.4609375,
            "text": "Long noncoding RNAs (lncRNAs)",
            "probability": 0.005809783935546875
        },
        {
            "start_logit": 6.66015625,
            "end_logit": 4.3828125,
            "text": "lncRNAs",
            "probability": 0.001468658447265625
        },
        {
            "start_logit": 6.66015625,
            "end_logit": 3.4609375,
            "text": "lncRNAs)",
            "probability": 0.0005841255187988281
        },
        {
            "start_logit": -1.25,
            "end_logit": 8.5859375,
            "text": "RNAs",
            "probability": 3.594160079956055e-05
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -1.666015625,
            "text": "Long",
            "probability": 3.451108932495117e-05
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -4.55078125,
            "text": "Long noncoding RNAs (lncRNAs) constitute",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -5.01953125,
            "text": "Long noncoding RNAs (lncRNAs) constitute the majority",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -5.140625,
            "text": "Long noncoding RNAs (lncRNAs) constitute the",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -1.25,
            "end_logit": 4.3828125,
            "text": "RNAs (lncRNAs",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -5.94140625,
            "text": "Long noncoding RNAs (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.78515625,
            "end_logit": 8.5859375,
            "text": "noncoding RNAs",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -1.25,
            "end_logit": 3.4609375,
            "text": "RNAs (lncRNAs)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.66015625,
            "end_logit": -4.55078125,
            "text": "lncRNAs) constitute",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.66015625,
            "end_logit": -5.01953125,
            "text": "lncRNAs) constitute the majority",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.66015625,
            "end_logit": -5.140625,
            "text": "lncRNAs) constitute the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.583984375,
            "end_logit": 4.3828125,
            "text": "(lncRNAs",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.583984375,
            "end_logit": 3.4609375,
            "text": "(lncRNAs)",
            "probability": 0.0
        },
        {
            "start_logit": -5.78515625,
            "end_logit": 4.3828125,
            "text": "noncoding RNAs (lncRNAs",
            "probability": 0.0
        }
    ],
    "602a84ae1cb411341a000116_2": [
        {
            "start_logit": 7.70703125,
            "end_logit": 7.4609375,
            "text": "lncRNAs",
            "probability": 1.0
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -1.3408203125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE)",
            "probability": 0.0001500844955444336
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -5.10546875,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -5.53515625,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -5.71484375,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -6.1875,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE).",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -6.6171875,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.390625,
            "end_logit": 7.4609375,
            "text": "As part of the FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -6.69921875,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -6.7578125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -6.8359375,
            "text": "lncRNAs in human dermal fibroblasts and",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -6.9140625,
            "text": "lncRNAs in human dermal fibroblasts",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.70703125,
            "end_logit": -7.1171875,
            "text": "lncRNAs in",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 7.4609375,
            "text": "285 lncRNAs",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 7.4609375,
            "text": ", we systematically knocked down the expression of 285 lncRNAs",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 7.4609375,
            "text": "the FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 7.4609375,
            "text": "part of the FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.453125,
            "end_logit": 7.4609375,
            "text": "FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 7.4609375,
            "text": "of the FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 7.4609375,
            "text": "systematically knocked down the expression of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        }
    ],
    "602a84ae1cb411341a000116_3": [
        {
            "start_logit": 8.0,
            "end_logit": 7.08984375,
            "text": "lncRNAs",
            "probability": 1.0
        },
        {
            "start_logit": 8.0,
            "end_logit": -6.76171875,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and cellular phenotyping.",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.0,
            "end_logit": -7.15625,
            "text": "lncRNAs in human dermal fibroblasts;",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.0,
            "end_logit": -7.16796875,
            "text": "lncRNAs in human dermal fibroblasts; this is followed",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.0,
            "end_logit": -7.22265625,
            "text": "lncRNAs in human dermal fibroblasts",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.0,
            "end_logit": -7.23828125,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.0,
            "end_logit": -7.27734375,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.0,
            "end_logit": -7.32421875,
            "text": "lncRNAs in human dermal fibroblasts; this is",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.0,
            "end_logit": -7.328125,
            "text": "lncRNAs in",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.234375,
            "end_logit": 7.08984375,
            "text": "From its creation until 2020, FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 7.08984375,
            "text": "creation until 2020, FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 7.08984375,
            "text": "until 2020, FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 7.08984375,
            "text": ", FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 7.08984375,
            "text": "FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 7.08984375,
            "text": "from the knock-down of 285 lncRNAs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.08984375,
            "text": "to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.08984375,
            "text": "contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 7.08984375,
            "text": "its creation until 2020, FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.453125,
            "end_logit": 7.08984375,
            "text": "the knock-down of 285 lncRNAs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.08984375,
            "text": "2020, FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 1.7881393432617188e-07
        }
    ],
    "602a84ae1cb411341a000116_4": [
        {
            "start_logit": 8.4453125,
            "end_logit": 6.80859375,
            "text": "long non-coding RNAs (lncRNAs)",
            "probability": 0.5458984375
        },
        {
            "start_logit": 8.4453125,
            "end_logit": 6.55859375,
            "text": "long non-coding RNAs",
            "probability": 0.42529296875
        },
        {
            "start_logit": 5.359375,
            "end_logit": 6.80859375,
            "text": "lncRNAs)",
            "probability": 0.025146484375
        },
        {
            "start_logit": 8.4453125,
            "end_logit": 1.6005859375,
            "text": "long non-coding RNAs (lncRNAs",
            "probability": 0.0030040740966796875
        },
        {
            "start_logit": 5.359375,
            "end_logit": 1.6005859375,
            "text": "lncRNAs",
            "probability": 0.00013720989227294922
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -2.720703125,
            "text": "long",
            "probability": 3.993511199951172e-05
        },
        {
            "start_logit": -3.240234375,
            "end_logit": 6.80859375,
            "text": "RNAs (lncRNAs)",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -3.240234375,
            "end_logit": 6.55859375,
            "text": "RNAs",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -5.41796875,
            "text": "long non-coding RNAs (lncRNAs).",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -4.25390625,
            "end_logit": 6.80859375,
            "text": ")",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.359375,
            "text": "long non-coding RNAs (",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.4453125,
            "text": "long non-coding",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.5,
            "text": "long non-",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -5.14453125,
            "end_logit": 6.80859375,
            "text": "(lncRNAs)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.90234375,
            "text": "long non",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.42578125,
            "end_logit": 6.80859375,
            "text": "human long non-coding RNAs (lncRNAs)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.42578125,
            "end_logit": 6.55859375,
            "text": "human long non-coding RNAs",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.2109375,
            "end_logit": 6.80859375,
            "text": "non-coding RNAs (lncRNAs)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.39453125,
            "end_logit": 6.80859375,
            "text": "assess the function of human long non-coding RNAs (lncRNAs)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 6.80859375,
            "text": "coding RNAs (lncRNAs)",
            "probability": 1.7881393432617188e-07
        }
    ],
    "602a84ae1cb411341a000116_5": [
        {
            "start_logit": 7.90234375,
            "end_logit": 7.19921875,
            "text": "lncRNAs",
            "probability": 1.0
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -6.9453125,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and cellular phenotyping.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.2265625,
            "text": "lncRNAs in human dermal fibroblasts; this is followed",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.296875,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and cellular phenotyping. Other",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.3046875,
            "text": "lncRNAs in human dermal fibroblasts;",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.30859375,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and cellular phenotyping. Other updates",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.3125,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.3125,
            "text": "lncRNAs in",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.31640625,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.3359375,
            "text": "lncRNAs in human dermal fibroblasts",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.90234375,
            "end_logit": -7.34375,
            "text": "lncRNAs in human dermal fibroblasts; this is",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.40625,
            "end_logit": 7.19921875,
            "text": "from the knock-down of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 7.19921875,
            "text": "until 2020, FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.453125,
            "end_logit": 7.19921875,
            "text": "to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 7.19921875,
            "text": "contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 7.19921875,
            "text": "community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 7.19921875,
            "text": "research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": 7.19921875,
            "text": "the knock-down of 285 lncRNAs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 7.19921875,
            "text": "2020, FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 7.19921875,
            "text": ", FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 1.7881393432617188e-07
        }
    ],
    "602a84ae1cb411341a000116_6": [
        {
            "start_logit": 7.7109375,
            "end_logit": 7.4609375,
            "text": "lncRNAs",
            "probability": 1.0
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -4.23828125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE)",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -5.62890625,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -5.78125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -5.60546875,
            "end_logit": 7.4609375,
            "text": "rt of the FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -5.86328125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -6.45703125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE).",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -6.67578125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -6.734375,
            "text": "lncRNAs in human dermal fibroblasts and",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -6.7578125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.65234375,
            "end_logit": 7.4609375,
            "text": "of the FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -6.9609375,
            "text": "lncRNAs in",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.0078125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.01171875,
            "text": "lncRNAs in human dermal fibroblasts",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 7.4609375,
            "text": ", we systematically knocked down the expression of 285 lncRNAs",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.21875,
            "end_logit": 7.4609375,
            "text": "the FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 7.4609375,
            "text": "285 lncRNAs",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 7.4609375,
            "text": "FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 7.4609375,
            "text": "down the expression of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 7.4609375,
            "text": "systematically knocked down the expression of 285 lncRNAs",
            "probability": 2.384185791015625e-07
        }
    ],
    "56c1f009ef6e39474100003c_1": [
        {
            "start_logit": 9.21875,
            "end_logit": 9.1796875,
            "text": "Gaucher's disease",
            "probability": 1.0
        },
        {
            "start_logit": -1.2861328125,
            "end_logit": 9.1796875,
            "text": "disease",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": 9.21875,
            "end_logit": -1.466796875,
            "text": "Ga",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": -5.3515625,
            "end_logit": 9.1796875,
            "text": "ucher's disease",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -5.86328125,
            "text": "Gaucher's disease type",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.9453125,
            "end_logit": 9.1796875,
            "text": "'s disease",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.328125,
            "text": "Gaucher's disease type 1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.3671875,
            "text": "Gaucher's disease type 1 stabil",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.37890625,
            "text": "Gaucher's disease type 1 stabilised on enzyme replacement therapy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.359375,
            "end_logit": 9.1796875,
            "text": "s disease",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.53125,
            "text": "Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 9.1796875,
            "text": "with Gaucher's disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.8046875,
            "text": "Gaucher's disease type 1 stabilised",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.92578125,
            "text": "Gaucher's disease type 1 stabilised on enzyme replacement",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.015625,
            "text": "Gaucher's disease type 1 stabilised on enzyme replacement therapy:",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.015625,
            "text": "Gaucher's disease type 1 stabilised on enzyme replacement therapy: a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.015625,
            "text": "Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.12890625,
            "text": "Gaucher's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.16015625,
            "text": "Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.19921875,
            "text": "Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f009ef6e39474100003c_2": [
        {
            "start_logit": 9.109375,
            "end_logit": 8.921875,
            "text": "Gaucher's disease",
            "probability": 1.0
        },
        {
            "start_logit": 9.109375,
            "end_logit": -1.7265625,
            "text": "Ga",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": -1.8701171875,
            "end_logit": 8.921875,
            "text": "disease",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -3.763671875,
            "text": "Gaucher's disease type 1",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": -4.97265625,
            "end_logit": 8.921875,
            "text": "ucher's disease",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -5.49609375,
            "text": "Gaucher's disease type",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -5.5234375,
            "text": "Gaucher's disease type 1 already",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.89453125,
            "end_logit": 8.921875,
            "text": "'s disease",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.7421875,
            "text": "Gaucher's disease type 1 already controlled",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 8.921875,
            "text": "s disease",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.7578125,
            "text": "Gaucher's disease type 1 already controlled by intravenous ERT and could be a useful therapeutic option.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.953125,
            "text": "Gaucher's disease type 1 already controlled by intravenous ERT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.14453125,
            "text": "Gaucher's disease type 1 already controlled by intravenous ERT and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.15234375,
            "text": "Gaucher's disease type 1 already controlled by",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.1796875,
            "text": "Gaucher's disease type 1 already controlled by intravenous ERT and could",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.18359375,
            "text": "Gaucher's",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.046875,
            "end_logit": 8.921875,
            "text": "with Gaucher's disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.8701171875,
            "end_logit": -3.763671875,
            "text": "disease type 1",
            "probability": 0.0
        },
        {
            "start_logit": -1.8701171875,
            "end_logit": -5.49609375,
            "text": "disease type",
            "probability": 0.0
        },
        {
            "start_logit": -1.8701171875,
            "end_logit": -5.5234375,
            "text": "disease type 1 already",
            "probability": 0.0
        }
    ],
    "53130a77e3eabad02100000f_1": [
        {
            "start_logit": 8.8828125,
            "end_logit": 8.046875,
            "text": "growth hormone",
            "probability": 1.0
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -2.06640625,
            "text": "growth",
            "probability": 4.00543212890625e-05
        },
        {
            "start_logit": -3.48046875,
            "end_logit": 8.046875,
            "text": "hormone",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -6.69921875,
            "text": "growth hormone deficiency",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -7.2421875,
            "text": "growth hormone deficiency and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -7.265625,
            "text": "growth hormone deficiency and the presence of more than one papilloma, which were less common in CFC compared to HRAS mutation positive patients.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -7.29296875,
            "text": "growth hormone deficiency and the",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -7.40234375,
            "text": "growth hormone deficiency and the presence",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -7.40625,
            "text": "growth hormone deficiency and the presence of more",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -7.41796875,
            "text": "growth hormone deficiency and the presence of more than one papilloma, which were",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -7.4296875,
            "text": "growth hormone deficiency and the presence of more than one papilloma, which",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -7.4453125,
            "text": "growth hormone deficiency and the presence of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 8.046875,
            "text": ", despite the relatively small number of patients with BRAF and MEK1 mutations reported here, for polyhydramnios, growth hormone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 8.046875,
            "text": ", growth hormone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 8.046875,
            "text": "Statistical significance was achieved, despite the relatively small number of patients with BRAF and MEK1 mutations reported here, for polyhydramnios, growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.359375,
            "end_logit": 8.046875,
            "text": "significance was achieved, despite the relatively small number of patients with BRAF and MEK1 mutations reported here, for polyhydramnios, growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 8.046875,
            "text": ", for polyhydramnios, growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 8.046875,
            "text": "achieved, despite the relatively small number of patients with BRAF and MEK1 mutations reported here, for polyhydramnios, growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 8.046875,
            "text": "1 mutations reported here, for polyhydramnios, growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.08984375,
            "end_logit": -2.06640625,
            "text": ", despite the relatively small number of patients with BRAF and MEK1 mutations reported here, for polyhydramnios, growth",
            "probability": 0.0
        }
    ],
    "53130a77e3eabad02100000f_2": [
        {
            "start_logit": 8.9609375,
            "end_logit": 8.0546875,
            "text": "growth hormone",
            "probability": 1.0
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -1.8896484375,
            "text": "growth",
            "probability": 4.792213439941406e-05
        },
        {
            "start_logit": -3.447265625,
            "end_logit": 8.0546875,
            "text": "hormone",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -6.55859375,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.06640625,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia has been documented due to growth hormone",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.0703125,
            "text": "growth hormone deficiency",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.21875,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia has been documented due to growth hormone and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.2265625,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia has been documented due to growth",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.2578125,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia has been documented",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.27734375,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia has been documented due",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.28515625,
            "text": "growth hormone deficiency,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.2890625,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.29296875,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia has been",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.296875,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia has",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -7.3359375,
            "text": "growth hormone deficiency, adrenal",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.546875,
            "end_logit": 8.0546875,
            "text": "including growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": -1.8896484375,
            "text": "including growth",
            "probability": 0.0
        },
        {
            "start_logit": -3.447265625,
            "end_logit": -6.55859375,
            "text": "hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described.",
            "probability": 0.0
        },
        {
            "start_logit": -3.447265625,
            "end_logit": -6.96875,
            "text": "hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia has been documented due to growth hormone and cortisol",
            "probability": 0.0
        },
        {
            "start_logit": -3.447265625,
            "end_logit": -7.06640625,
            "text": "hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia has been documented due to growth hormone",
            "probability": 0.0
        }
    ],
    "53130a77e3eabad02100000f_3": [
        {
            "start_logit": 9.0546875,
            "end_logit": 8.7265625,
            "text": "Growth hormone",
            "probability": 1.0
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -1.7548828125,
            "text": "Growth",
            "probability": 2.7954578399658203e-05
        },
        {
            "start_logit": -2.275390625,
            "end_logit": 8.7265625,
            "text": "hormone",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.8828125,
            "text": "Growth hormone deficiency",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.11328125,
            "text": "Growth hormone deficiency in Costello syndrome.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.29296875,
            "text": "Growth hormone deficiency in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.296875,
            "text": "Growth hormone deficiency in Costello syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.34375,
            "text": "Growth hormone deficiency in Costello",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.275390625,
            "end_logit": -6.8828125,
            "text": "hormone deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -2.275390625,
            "end_logit": -7.11328125,
            "text": "hormone deficiency in Costello syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -2.275390625,
            "end_logit": -7.29296875,
            "text": "hormone deficiency in",
            "probability": 0.0
        },
        {
            "start_logit": -2.275390625,
            "end_logit": -7.296875,
            "text": "hormone deficiency in Costello syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -2.275390625,
            "end_logit": -7.34375,
            "text": "hormone deficiency in Costello",
            "probability": 0.0
        },
        {
            "start_logit": -5.359375,
            "end_logit": -7.11328125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -7.11328125,
            "text": "Costello syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -7.296875,
            "text": "Costello syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -7.11328125,
            "text": "ello syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -7.34375,
            "text": "Costello",
            "probability": 0.0
        },
        {
            "start_logit": -7.6953125,
            "end_logit": -7.11328125,
            "text": "in Costello syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -7.70703125,
            "end_logit": -7.11328125,
            "text": "syndrome.",
            "probability": 0.0
        }
    ],
    "53130a77e3eabad02100000f_4": [
        {
            "start_logit": 9.0859375,
            "end_logit": 8.734375,
            "text": "growth hormone",
            "probability": 1.0
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -1.6953125,
            "text": "growth",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": -2.279296875,
            "end_logit": 8.734375,
            "text": "hormone",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.41015625,
            "text": "growth hormone deficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.4140625,
            "text": "growth hormone deficiency and hypoglycemia: a new report and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.46484375,
            "text": "growth hormone deficiency and hypoglycemia: a new report and review",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.4921875,
            "text": "growth hormone deficiency and hypoglycemia: a new report and review of the endocrine associations.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.51171875,
            "text": "growth hormone deficiency and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.515625,
            "text": "growth hormone deficiency and hypoglycemia: a new",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.52734375,
            "text": "growth hormone deficiency and hypoglycemia: a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.53515625,
            "text": "growth hormone deficiency and hypoglycemia:",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.53515625,
            "text": "growth hormone deficiency and hypoglycemia: a new report and review of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 8.734375,
            "text": "with growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 8.734375,
            "text": "Costello syndrome with growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 8.734375,
            "text": "ello syndrome with growth hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30078125,
            "end_logit": -1.6953125,
            "text": "with growth",
            "probability": 0.0
        },
        {
            "start_logit": -7.32421875,
            "end_logit": -1.6953125,
            "text": "Costello syndrome with growth",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -1.6953125,
            "text": "ello syndrome with growth",
            "probability": 0.0
        },
        {
            "start_logit": -2.279296875,
            "end_logit": -7.41015625,
            "text": "hormone deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -2.279296875,
            "end_logit": -7.4140625,
            "text": "hormone deficiency and hypoglycemia: a new report and",
            "probability": 0.0
        }
    ],
    "602343051cb411341a00008d_1": [
        {
            "start_logit": 9.1796875,
            "end_logit": 8.953125,
            "text": "apoC-III",
            "probability": 1.0
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -1.474609375,
            "text": "apoC",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": -1.740234375,
            "end_logit": 8.953125,
            "text": "III",
            "probability": 1.817941665649414e-05
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.66015625,
            "text": "apoC-III transcription/translation that has been recently approved in Europe for Familial Chylomicronemia Syndrome (FCS) treatment.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 8.953125,
            "text": "-III",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.921875,
            "text": "apoC-III transcription/translation that has been recently approved in Europe for Familial Chylomicronemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.96875,
            "text": "apoC-III transcription/translation that has been recently approved in Europe for Familial Chylomicronemia Syndrome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.0546875,
            "text": "apoC-III transcription/translation that",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.08984375,
            "text": "apoC-III transcription/translation that has been recently approved in Europe for Familial Chylomicron",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.12109375,
            "text": "apoC-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.14453125,
            "text": "apoC-III transcription/translation that has been recently approved in Europe for Familial Chylomicronemia Syndrome (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.1484375,
            "text": "apoC-III transcription/translation that has been recently",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.16015625,
            "text": "apoC-III transcription/translation that has been recently approved in Europe for Familial Chylomic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.16015625,
            "text": "apoC-III transcription/translation that has",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.18359375,
            "text": "apoC-III transcription",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.21875,
            "text": "apoC-III transcription/",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.2265625,
            "text": "apoC-III transcription/translation that has been",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.28515625,
            "text": "apoC-III transcription/translation that has been recently approved in Europe for Familial Chyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.2890625,
            "text": "apoC-III transcription/translation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 8.953125,
            "text": "Volanesorsen is a second-generation antisense oligonucleotide inhibiting apoC-III",
            "probability": 5.960464477539063e-08
        }
    ],
    "602343051cb411341a00008d_2": [
        {
            "start_logit": 9.109375,
            "end_logit": 8.8984375,
            "text": "apoC-III",
            "probability": 1.0
        },
        {
            "start_logit": 9.109375,
            "end_logit": -1.673828125,
            "text": "apoC",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": -1.8916015625,
            "end_logit": 8.8984375,
            "text": "III",
            "probability": 1.6808509826660156e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -3.353515625,
            "text": "apoC-III has shown reductions in plasma TG levels up to 90%.",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 9.109375,
            "end_logit": -5.359375,
            "text": "apoC-III has shown reductions in plasma TG levels up",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -5.89453125,
            "text": "apoC-III has shown reductions in plasma TG levels up to",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.0390625,
            "text": "apoC-III has shown reductions in plasma TG levels up to 90",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.08984375,
            "text": "apoC-III has shown reductions in plasma TG levels up to 90%",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.1484375,
            "text": "apoC-III has shown reductions in plasma TG",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.1796875,
            "text": "apoC-III has shown reductions in plasma TG levels",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.46875,
            "text": "apoC-III has",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.5546875,
            "text": "apoC-III has shown reductions",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.640625,
            "text": "apoC-III has shown",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.64453125,
            "text": "apoC-III has shown reductions in plasma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.51171875,
            "end_logit": 8.8984375,
            "text": "-III",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.7578125,
            "text": "apoC-III has shown reductions in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 8.8984375,
            "text": "Volanesorsen targeting apoC-III",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.06640625,
            "text": "apoC-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 8.8984375,
            "text": "targeting apoC-III",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.8984375,
            "text": "anesorsen targeting apoC-III",
            "probability": 5.960464477539063e-08
        }
    ],
    "602343051cb411341a00008d_3": [
        {
            "start_logit": 9.265625,
            "end_logit": 9.0859375,
            "text": "apoC-III",
            "probability": 1.0
        },
        {
            "start_logit": 9.265625,
            "end_logit": -1.240234375,
            "text": "apoC",
            "probability": 3.2961368560791016e-05
        },
        {
            "start_logit": -1.458984375,
            "end_logit": 9.0859375,
            "text": "III",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -4.4296875,
            "end_logit": 9.0859375,
            "text": ". As such, apoC-III",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.34765625,
            "text": "apoC-III has",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.171875,
            "end_logit": 9.0859375,
            "text": "-III",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.65234375,
            "text": "apoC-III has been recognised",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.85546875,
            "text": "apoC-III has been recognised as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.87109375,
            "text": "apoC-III has been recognised as a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.89453125,
            "text": "apoC-III has been recognised as a potential",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.91796875,
            "text": "apoC-III has been",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 9.0859375,
            "text": ", apoC-III",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.0859375,
            "text": "apoC-III has been recognised as a potential therapeutic target for patients with severe hypertriglyceridaemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.10546875,
            "text": "apoC-III has been recognised as a potential therapeutic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.1796875,
            "text": "apoC-III has been recognised as a potential therapeutic target",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.21875,
            "text": "apoC-III has been recognised as a potential therapeutic target for patients with severe hypertriglyceridaemia with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.2578125,
            "text": "apoC-III has been recognised as a potential therapeutic target for patients with severe hypertriglycerid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 9.0859375,
            "text": "As such, apoC-III",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.0859375,
            "text": "iants. As such, apoC-III",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.0859375,
            "text": "ariants. As such, apoC-III",
            "probability": 5.960464477539063e-08
        }
    ],
    "602343051cb411341a00008d_4": [
        {
            "start_logit": 9.1640625,
            "end_logit": 8.8828125,
            "text": "apoC-III",
            "probability": 1.0
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -1.498046875,
            "text": "apoC",
            "probability": 3.0934810638427734e-05
        },
        {
            "start_logit": -1.853515625,
            "end_logit": 8.8828125,
            "text": "III",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -5.98046875,
            "text": "apoC-III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.00390625,
            "text": "apoC-III synthesis, significantly reduced triglyceride",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.2109375,
            "text": "apoC-III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia syndrome",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.3359375,
            "end_logit": 8.8828125,
            "text": "-III",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.67578125,
            "text": "apoC-III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicron",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.796875,
            "text": "apoC-III synthesis, significantly reduced triglyceride levels",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.03125,
            "text": "apoC-III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.046875,
            "text": "apoC-III synthesis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 8.8828125,
            "text": "BACKGROUND: Volanesorsen, an investigational inhibitor of apoC-III",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 8.8828125,
            "text": "inhibitor of apoC-III",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.853515625,
            "end_logit": -5.98046875,
            "text": "III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia",
            "probability": 0.0
        },
        {
            "start_logit": -1.853515625,
            "end_logit": -6.00390625,
            "text": "III synthesis, significantly reduced triglyceride",
            "probability": 0.0
        },
        {
            "start_logit": -1.853515625,
            "end_logit": -6.2109375,
            "text": "III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -1.853515625,
            "end_logit": -6.67578125,
            "text": "III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicron",
            "probability": 0.0
        },
        {
            "start_logit": -1.853515625,
            "end_logit": -6.796875,
            "text": "III synthesis, significantly reduced triglyceride levels",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -1.498046875,
            "text": "BACKGROUND: Volanesorsen, an investigational inhibitor of apoC",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": -1.498046875,
            "text": "inhibitor of apoC",
            "probability": 0.0
        }
    ],
    "602343051cb411341a00008d_5": [
        {
            "start_logit": 9.125,
            "end_logit": 8.796875,
            "text": "APOC3",
            "probability": 1.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -1.5029296875,
            "text": "APOC",
            "probability": 3.3736228942871094e-05
        },
        {
            "start_logit": -1.9462890625,
            "end_logit": 8.796875,
            "text": "3",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": 9.125,
            "end_logit": -5.69921875,
            "text": "APOC3 mRNA",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.859375,
            "end_logit": 8.796875,
            "text": "he antisense oligonucleotide (ASO) against APOC3",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.54296875,
            "text": "APOC3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoCIIIRx",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.65625,
            "text": "APOC3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoCIIIR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.73046875,
            "text": "APOC3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoCIII",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.9921875,
            "text": "APOC3 mRNA vol",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.99609375,
            "text": "APOC3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 8.796875,
            "text": "against APOC3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 8.796875,
            "text": "antisense oligonucleotide (ASO) against APOC3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.859375,
            "end_logit": -1.5029296875,
            "text": "he antisense oligonucleotide (ASO) against APOC",
            "probability": 0.0
        },
        {
            "start_logit": -1.9462890625,
            "end_logit": -5.69921875,
            "text": "3 mRNA",
            "probability": 0.0
        },
        {
            "start_logit": -1.9462890625,
            "end_logit": -6.54296875,
            "text": "3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoCIIIRx",
            "probability": 0.0
        },
        {
            "start_logit": -1.9462890625,
            "end_logit": -6.65625,
            "text": "3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoCIIIR",
            "probability": 0.0
        },
        {
            "start_logit": -7.14453125,
            "end_logit": -1.5029296875,
            "text": "against APOC",
            "probability": 0.0
        },
        {
            "start_logit": -1.9462890625,
            "end_logit": -6.73046875,
            "text": "3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoCIII",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -1.5029296875,
            "text": "antisense oligonucleotide (ASO) against APOC",
            "probability": 0.0
        },
        {
            "start_logit": -1.9462890625,
            "end_logit": -6.9921875,
            "text": "3 mRNA vol",
            "probability": 0.0
        }
    ],
    "602343051cb411341a00008d_6": [
        {
            "start_logit": 9.328125,
            "end_logit": 9.125,
            "text": "apoC-III",
            "probability": 1.0
        },
        {
            "start_logit": 9.328125,
            "end_logit": -1.0322265625,
            "text": "apoC",
            "probability": 3.886222839355469e-05
        },
        {
            "start_logit": -1.328125,
            "end_logit": 9.125,
            "text": "III",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": 9.328125,
            "end_logit": -5.96484375,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.0703125,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.12109375,
            "end_logit": 9.125,
            "text": "-III",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.65234375,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and whether apoC-III",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.69140625,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.77734375,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.81640625,
            "text": "apoC-III glycosylation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.84375,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.859375,
            "text": "apoC-III glycosylation impacts TRL (triglyceride",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.8671875,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.91796875,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and whether apoC-III antisense therapy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 9.125,
            "text": "et, it remains unclear whether apoC-III",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.06640625,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and whether apoC-III antisense",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.078125,
            "text": "apoC-III glycosylation impacts",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.08984375,
            "text": "apoC-III glycosylation impacts TR",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.40625,
            "end_logit": 9.125,
            "text": ", it remains unclear whether apoC-III",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.328125,
            "end_logit": -5.96484375,
            "text": "III glycosylation impacts TRL (triglyceride-rich lipoprotein)",
            "probability": 0.0
        }
    ],
    "5e5286036d0a277941000040_1": [
        {
            "start_logit": 9.3828125,
            "end_logit": 9.2890625,
            "text": "chromosome 15",
            "probability": 1.0
        },
        {
            "start_logit": -0.68798828125,
            "end_logit": 9.2890625,
            "text": "15",
            "probability": 4.2319297790527344e-05
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -0.814453125,
            "text": "chromosome",
            "probability": 4.100799560546875e-05
        },
        {
            "start_logit": -3.544921875,
            "end_logit": 9.2890625,
            "text": ". We selected one clone, LiPS-A3 with an integration site in chromosome 15",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -5.83203125,
            "end_logit": 9.2890625,
            "text": "in chromosome 15",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.58203125,
            "end_logit": 9.2890625,
            "text": "integration site in chromosome 15",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -6.6875,
            "text": "chromosome 15 maintaining",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.544921875,
            "end_logit": -0.814453125,
            "text": ". We selected one clone, LiPS-A3 with an integration site in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -5.83203125,
            "end_logit": -0.814453125,
            "text": "in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -0.68798828125,
            "end_logit": -6.6875,
            "text": "15 maintaining",
            "probability": 0.0
        },
        {
            "start_logit": -6.58203125,
            "end_logit": -0.814453125,
            "text": "integration site in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -3.54296875,
            "end_logit": -6.4375,
            "text": ". While in recent years much progress has been made in the development of tools for gene targeting, little",
            "probability": 0.0
        },
        {
            "start_logit": -3.54296875,
            "end_logit": -6.44140625,
            "text": ". While in recent years much progress has been made in the development of tools for gene targeting,",
            "probability": 0.0
        },
        {
            "start_logit": -3.54296875,
            "end_logit": -6.47265625,
            "text": ". While in recent years much progress has been made",
            "probability": 0.0
        },
        {
            "start_logit": -3.54296875,
            "end_logit": -6.6484375,
            "text": ". Targeting transgenes in the LiPS-A3S genomic locus can find broad applications in stem cell research and possibly cell and gene therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -3.54296875,
            "end_logit": -6.6484375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -3.54296875,
            "end_logit": -6.6484375,
            "text": ". The LiPS-A3 line can greatly facilitate the insertion of reporter and other genes in hPSCs.",
            "probability": 0.0
        },
        {
            "start_logit": -3.54296875,
            "end_logit": -6.65234375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -3.54296875,
            "end_logit": -6.65234375,
            "text": ". While in recent years much progress has been",
            "probability": 0.0
        },
        {
            "start_logit": -3.54296875,
            "end_logit": -6.65234375,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5e5286036d0a277941000040_2": [
        {
            "start_logit": 9.2578125,
            "end_logit": 9.2109375,
            "text": "chromosome 15",
            "probability": 1.0
        },
        {
            "start_logit": -1.056640625,
            "end_logit": 9.2109375,
            "text": "15",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -1.2783203125,
            "text": "chromosome",
            "probability": 2.7954578399658203e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.5625,
            "text": "chromosome 15 maintaining",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 9.2109375,
            "text": "in chromosome 15",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 9.2109375,
            "text": "integration site in chromosome 15",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.24609375,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase-mediated cassette exchange (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 9.2109375,
            "text": "selected one clone, LiPS-A3 with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.3203125,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.32421875,
            "text": "chromosome 15 maintaining robust expression without silencing and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.33984375,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.36328125,
            "text": "chromosome 15 maintaining robust",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.37109375,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.2109375,
            "text": ", LiPS-A3 with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.37890625,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.38671875,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 9.2109375,
            "text": "an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.2109375,
            "text": "site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.2109375,
            "text": "with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.2109375,
            "text": "-A3 with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e5286036d0a277941000040_3": [
        {
            "start_logit": 9.140625,
            "end_logit": 9.1328125,
            "text": "chromosome 15",
            "probability": 1.0
        },
        {
            "start_logit": -1.2783203125,
            "end_logit": 9.1328125,
            "text": "15",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -1.5673828125,
            "text": "chromosome",
            "probability": 2.2470951080322266e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -6.76171875,
            "text": "chromosome 15 maintaining",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8828125,
            "end_logit": 9.1328125,
            "text": "in chromosome 15",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 9.1328125,
            "text": "integration site in chromosome 15",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 9.1328125,
            "text": "selected one clone , LiPS-A3 with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.1328125,
            "text": "site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 9.1328125,
            "text": ", LiPS-A3 with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 9.1328125,
            "text": "an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.1328125,
            "text": "with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.44921875,
            "text": "chromosome 15 maintaining robust expression without silencing and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 9.1328125,
            "text": "LiPS-A3 with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.453125,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 9.1328125,
            "text": "A3 with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.46875,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase-mediated cassette exchange",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.1328125,
            "text": "-A3 with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.4765625,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.48828125,
            "text": "chromosome 15 maintaining robust",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.48828125,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase-",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e5286036d0a277941000040_4": [
        {
            "start_logit": 9.2578125,
            "end_logit": 9.2109375,
            "text": "chromosome 15",
            "probability": 1.0
        },
        {
            "start_logit": -1.056640625,
            "end_logit": 9.2109375,
            "text": "15",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -1.2783203125,
            "text": "chromosome",
            "probability": 2.7954578399658203e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.5625,
            "text": "chromosome 15 maintaining",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 9.2109375,
            "text": "in chromosome 15",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 9.2109375,
            "text": "integration site in chromosome 15",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.24609375,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase-mediated cassette exchange (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 9.2109375,
            "text": "selected one clone, LiPS-A3 with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.3203125,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.32421875,
            "text": "chromosome 15 maintaining robust expression without silencing and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.33984375,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.36328125,
            "text": "chromosome 15 maintaining robust",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.37109375,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.2109375,
            "text": ", LiPS-A3 with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.37890625,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.38671875,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 9.2109375,
            "text": "an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.2109375,
            "text": "site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.2109375,
            "text": "with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.2109375,
            "text": "-A3 with an integration site in chromosome 15",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f020ef6e394741000047_1": [
        {
            "start_logit": 7.3984375,
            "end_logit": 9.0,
            "text": "cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -1.4892578125,
            "end_logit": 9.0,
            "text": "dysplasia",
            "probability": 0.00013768672943115234
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -3.490234375,
            "text": "cortical",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -6.24609375,
            "end_logit": 9.0,
            "text": "91 patients, there were 50 patients with ILAE focal cortical dysplasia",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 9.0,
            "text": "ILAE focal cortical dysplasia",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 9.0,
            "text": "Of the 91 patients, there were 50 patients with ILAE focal cortical dysplasia",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 9.0,
            "text": "the 91 patients, there were 50 patients with ILAE focal cortical dysplasia",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 9.0,
            "text": "patients, there were 50 patients with ILAE focal cortical dysplasia",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 9.0,
            "text": "with ILAE focal cortical dysplasia",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 9.0,
            "text": ", there were 50 patients with ILAE focal cortical dysplasia",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.203125,
            "end_logit": 9.0,
            "text": "50 patients with ILAE focal cortical dysplasia",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -6.43359375,
            "text": "cortical dysplasia type",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -6.50390625,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -6.7890625,
            "text": "cortical dysplasia type Ib",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.0234375,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.0546875,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.07421875,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.09765625,
            "text": "cortical dysplasia type Ib,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.125,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia type IA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.22265625,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia type",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f020ef6e394741000047_2": [
        {
            "start_logit": 5.3671875,
            "end_logit": 7.62890625,
            "text": "cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -3.21875,
            "end_logit": 7.62890625,
            "text": "dysplasia",
            "probability": 0.00018525123596191406
        },
        {
            "start_logit": -3.658203125,
            "end_logit": 7.62890625,
            "text": "ILAE focal cortical dysplasia",
            "probability": 0.00011962652206420898
        },
        {
            "start_logit": -5.23828125,
            "end_logit": 7.62890625,
            "text": "focal cortical dysplasia",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": -5.44140625,
            "end_logit": 7.62890625,
            "text": "Crude analysis revealed no significant difference between patients with subtypes of ILAE focal cortical dysplasia",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -6.31640625,
            "end_logit": 7.62890625,
            "text": "patients with subtypes of ILAE focal cortical dysplasia",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": -6.515625,
            "end_logit": 7.62890625,
            "text": "of ILAE focal cortical dysplasia",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 7.62890625,
            "text": "analysis revealed no significant difference between patients with subtypes of ILAE focal cortical dysplasia",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 7.62890625,
            "text": "no significant difference between patients with subtypes of ILAE focal cortical dysplasia",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 7.62890625,
            "text": "between patients with subtypes of ILAE focal cortical dysplasia",
            "probability": 5.125999450683594e-06
        },
        {
            "start_logit": -6.890625,
            "end_logit": 7.62890625,
            "text": "difference between patients with subtypes of ILAE focal cortical dysplasia",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 7.62890625,
            "text": "with subtypes of ILAE focal cortical dysplasia",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 5.3671875,
            "end_logit": -4.72265625,
            "text": "cortical dysplasia type I",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 5.3671875,
            "end_logit": -4.95703125,
            "text": "cortical dysplasia type",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 5.3671875,
            "end_logit": -5.265625,
            "text": "cortical",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 5.3671875,
            "end_logit": -5.36328125,
            "text": "cortical dysplasia type I or Palmini et al focal cortical dysplasia",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": 5.3671875,
            "end_logit": -6.36328125,
            "text": "cortical dysplasia type I or",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 5.3671875,
            "end_logit": -6.83203125,
            "text": "cortical dysplasia type I or Palmini et al focal cortical dysplasia type",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 5.3671875,
            "end_logit": -6.89453125,
            "text": "cortical dysplasia type I or Palmini et al focal cortical dysplasia type I concerning postoperative outcome according to the Engel",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 5.3671875,
            "end_logit": -7.0,
            "text": "cortical dysplasia type I or Palmini et al focal cortical dysplasia type I concerning postoperative outcome according to the Engel and",
            "probability": 4.172325134277344e-07
        }
    ],
    "56c1f020ef6e394741000047_3": [
        {
            "start_logit": 5.19140625,
            "end_logit": 9.1484375,
            "text": "cortical dysplasia",
            "probability": 0.998046875
        },
        {
            "start_logit": -0.9423828125,
            "end_logit": 9.1484375,
            "text": "dysplasia",
            "probability": 0.0021495819091796875
        },
        {
            "start_logit": -6.15234375,
            "end_logit": 9.1484375,
            "text": "focal cortical dysplasia",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 9.1484375,
            "text": "with pathologically confirmed focal cortical dysplasia",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 9.1484375,
            "text": "in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 9.1484375,
            "text": "patients with pathologically confirmed focal cortical dysplasia",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": -7.40625,
            "end_logit": 9.1484375,
            "text": "Rates of high frequency oscillations in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": -7.453125,
            "end_logit": 9.1484375,
            "text": "confirmed focal cortical dysplasia",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.1484375,
            "text": "of high frequency oscillations in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.1484375,
            "text": "pathologically confirmed focal cortical dysplasia",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 9.1484375,
            "text": "oscillations in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 9.1484375,
            "text": "high frequency oscillations in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -5.7734375,
            "text": "cortical",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -6.7890625,
            "text": "cortical dysplasia of Palmini type 1a and b were compared with those in type 2a and b.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -6.8046875,
            "text": "cortical dysplasia of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -6.9453125,
            "text": "cortical dysplasia of Palmini type 1a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -7.16015625,
            "text": "cortical dysplasia of Palm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -7.16796875,
            "text": "cortical dysplasia of Palmini type 1a and b were",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -7.22265625,
            "text": "cortical dysplasia of Palmini type 1a and b were compared",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -7.2578125,
            "text": "cortical dysplasia of Palmini",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f020ef6e394741000047_4": [
        {
            "start_logit": 5.36328125,
            "end_logit": 3.5234375,
            "text": "meningioangiomatosis",
            "probability": 0.537109375
        },
        {
            "start_logit": 5.36328125,
            "end_logit": 3.33203125,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia",
            "probability": 0.442138671875
        },
        {
            "start_logit": 5.36328125,
            "end_logit": 0.228759765625,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with 6 of those (60%) classified as Palmini type IA",
            "probability": 0.019866943359375
        },
        {
            "start_logit": -1.45703125,
            "end_logit": 3.33203125,
            "text": "dysplasia",
            "probability": 0.00048232078552246094
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -4.953125,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with 6 of those (60%) classified as Palmini type IA,",
            "probability": 0.00011104345321655273
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -4.96484375,
            "text": "meningioangiomatosis demonstrated",
            "probability": 0.00011014938354492188
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -5.5234375,
            "text": "meningi",
            "probability": 6.330013275146484e-05
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -5.82421875,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia,",
            "probability": 4.667043685913086e-05
        },
        {
            "start_logit": -1.0791015625,
            "end_logit": 0.228759765625,
            "text": "IA",
            "probability": 3.159046173095703e-05
        },
        {
            "start_logit": -4.6015625,
            "end_logit": 3.5234375,
            "text": "the meningioangiomatosis",
            "probability": 2.5153160095214844e-05
        },
        {
            "start_logit": -1.45703125,
            "end_logit": 0.228759765625,
            "text": "dysplasia, with 6 of those (60%) classified as Palmini type IA",
            "probability": 2.1696090698242188e-05
        },
        {
            "start_logit": -4.6015625,
            "end_logit": 3.33203125,
            "text": "the meningioangiomatosis demonstrated evidence of focal cortical dysplasia",
            "probability": 2.086162567138672e-05
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -6.6484375,
            "text": "meningioangiomatosis demonstrated evidence",
            "probability": 2.0503997802734375e-05
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -6.65234375,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with 6 of those (60",
            "probability": 2.0384788513183594e-05
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -6.71484375,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with 6 of those (60%",
            "probability": 1.913309097290039e-05
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -6.7734375,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with",
            "probability": 1.811981201171875e-05
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -6.7890625,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with 6 of those (60%) classified as Palmini",
            "probability": 1.7821788787841797e-05
        },
        {
            "start_logit": -5.43359375,
            "end_logit": 3.33203125,
            "text": "cortical dysplasia",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 3.5234375,
            "text": "oangiomatosis",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 3.33203125,
            "text": "oangiomatosis demonstrated evidence of focal cortical dysplasia",
            "probability": 4.5299530029296875e-06
        }
    ],
    "56c1f020ef6e394741000047_5": [
        {
            "start_logit": 7.3984375,
            "end_logit": 9.0,
            "text": "cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -1.4892578125,
            "end_logit": 9.0,
            "text": "dysplasia",
            "probability": 0.00013768672943115234
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -3.490234375,
            "text": "cortical",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -6.24609375,
            "end_logit": 9.0,
            "text": "91 patients, there were 50 patients with ILAE focal cortical dysplasia",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 9.0,
            "text": "ILAE focal cortical dysplasia",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 9.0,
            "text": "Of the 91 patients, there were 50 patients with ILAE focal cortical dysplasia",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.8515625,
            "end_logit": 9.0,
            "text": "the 91 patients, there were 50 patients with ILAE focal cortical dysplasia",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 9.0,
            "text": "patients, there were 50 patients with ILAE focal cortical dysplasia",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 9.0,
            "text": "with ILAE focal cortical dysplasia",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 9.0,
            "text": ", there were 50 patients with ILAE focal cortical dysplasia",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.203125,
            "end_logit": 9.0,
            "text": "50 patients with ILAE focal cortical dysplasia",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -6.43359375,
            "text": "cortical dysplasia type",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -6.50390625,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -6.7890625,
            "text": "cortical dysplasia type Ib",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.0234375,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.0546875,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.07421875,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.09765625,
            "text": "cortical dysplasia type Ib,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.125,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia type IA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.3984375,
            "end_logit": -7.22265625,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia type",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f020ef6e394741000047_6": [
        {
            "start_logit": 9.1796875,
            "end_logit": 9.0078125,
            "text": "cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -1.2548828125,
            "text": "cortical",
            "probability": 3.4809112548828125e-05
        },
        {
            "start_logit": -1.5458984375,
            "end_logit": 9.0078125,
            "text": "dysplasia",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.61328125,
            "text": "cortical dysplasia type I (Ib vs Ic) or Palmini et al focal cortical dysplasia type I (IA vs IB).",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.8359375,
            "text": "cortical dysplasia type",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.0078125,
            "text": "cortical dysplasia type I (Ib vs Ic) or Palmini et al focal cortical dysplasia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.078125,
            "text": "cortical dysplasia type I",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.08984375,
            "text": "cortical dysplasia type I (Ib vs Ic) or Palmini et al focal cortical dysplasia type",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.11328125,
            "text": "cortical dysplasia type I (Ib vs Ic) or Palmini et al focal cortical dysplasia type I (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.15234375,
            "text": "cortical dysplasia type I (Ib vs Ic)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.19921875,
            "text": "cortical dysplasia type I (Ib vs Ic) or Palmini et al focal cortical dysplasia type I",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.21875,
            "text": "cortical dysplasia type I (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.2578125,
            "text": "cortical dysplasia type I (Ib vs Ic) or Palmini et",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.2578125,
            "text": "cortical dysplasia type I (Ib vs Ic) or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.140625,
            "end_logit": 9.0078125,
            "text": "Our findings revealed no significant difference concerning surgical outcome with respect to seizure frequency for the histologic subtypes of ILAE focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 9.0078125,
            "text": "histologic subtypes of ILAE focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 9.0078125,
            "text": "findings revealed no significant difference concerning surgical outcome with respect to seizure frequency for the histologic subtypes of ILAE focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 9.0078125,
            "text": "to seizure frequency for the histologic subtypes of ILAE focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 9.0078125,
            "text": "focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 9.0078125,
            "text": "with respect to seizure frequency for the histologic subtypes of ILAE focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f020ef6e394741000047_7": [
        {
            "start_logit": 7.71484375,
            "end_logit": 8.4609375,
            "text": "cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -2.236328125,
            "end_logit": 8.4609375,
            "text": "dysplasia",
            "probability": 4.792213439941406e-05
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -3.412109375,
            "text": "cortical",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": -4.66015625,
            "end_logit": 8.4609375,
            "text": "focal cortical dysplasia",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -4.97265625,
            "text": "cortical dysplasia type",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -5.21875,
            "text": "cortical dysplasia type I",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.11328125,
            "end_logit": 8.4609375,
            "text": "ILAE focal cortical dysplasia",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -5.87109375,
            "text": "cortical dysplasia type I or Palmini et al focal cortical dysplasia",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.6640625,
            "end_logit": 8.4609375,
            "text": "Crude analysis revealed no significant difference between patients with subtypes of ILAE focal cortical dysplasia",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.89453125,
            "end_logit": 8.4609375,
            "text": "of ILAE focal cortical dysplasia",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 8.4609375,
            "text": "AE focal cortical dysplasia",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 8.4609375,
            "text": "no significant difference between patients with subtypes of ILAE focal cortical dysplasia",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 8.4609375,
            "text": "analysis revealed no significant difference between patients with subtypes of ILAE focal cortical dysplasia",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 8.4609375,
            "text": "patients with subtypes of ILAE focal cortical dysplasia",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 8.4609375,
            "text": "difference between patients with subtypes of ILAE focal cortical dysplasia",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -6.609375,
            "text": "cortical dysplasia type I or",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -6.609375,
            "text": "cortical dysplasia type I or Palmini et al focal cortical dysplasia type I concerning postoperative outcome according to the Engel and ILAE scoring systems on seizure frequency",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -6.84765625,
            "text": "cortical dysplasia type I or Palmini et al focal cortical dysplasia type",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -6.97265625,
            "text": "cortical dysplasia type I or Palmini et al focal cortical dysplasia type I concerning postoperative outcome according to the Engel and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.71484375,
            "end_logit": -6.9921875,
            "text": "cortical dysplasia type I or Palmini et al focal cortical dysplasia type I concerning postoperative outcome according",
            "probability": 1.7881393432617188e-07
        }
    ],
    "56c1f020ef6e394741000047_8": [
        {
            "start_logit": 9.25,
            "end_logit": 8.9765625,
            "text": "focal cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 9.25,
            "end_logit": -1.0087890625,
            "text": "focal",
            "probability": 4.649162292480469e-05
        },
        {
            "start_logit": -1.46875,
            "end_logit": 8.9765625,
            "text": "dysplasia",
            "probability": 2.2292137145996094e-05
        },
        {
            "start_logit": 9.25,
            "end_logit": -5.1796875,
            "text": "focal cortical dysplasia (FCD) type II.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -5.53515625,
            "text": "focal cortical dysplasia (FCD) type II",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -5.58984375,
            "text": "focal cortical dysplasia (FCD)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -5.9140625,
            "text": "focal cortical dysplasia (FCD) type",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.1015625,
            "text": "focal cortical dysplasia (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.27734375,
            "text": "focal cortical dysplasia (FCD",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.203125,
            "end_logit": 8.9765625,
            "text": "According to Palmini's classification system, these lesions were categorized as focal cortical dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.51171875,
            "text": "focal cortical dysplasia (FC",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 8.9765625,
            "text": "cortical dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 8.9765625,
            "text": "as focal cortical dysplasia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 8.9765625,
            "text": ", these lesions were categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 8.9765625,
            "text": "to Palmini's classification system, these lesions were categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 8.9765625,
            "text": "categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 8.9765625,
            "text": "lesions were categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 8.9765625,
            "text": "these lesions were categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 8.9765625,
            "text": "were categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.9765625,
            "text": "system, these lesions were categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f020ef6e394741000047_9": [
        {
            "start_logit": 9.25,
            "end_logit": 8.9765625,
            "text": "focal cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 9.25,
            "end_logit": -1.0087890625,
            "text": "focal",
            "probability": 4.649162292480469e-05
        },
        {
            "start_logit": -1.46875,
            "end_logit": 8.9765625,
            "text": "dysplasia",
            "probability": 2.2292137145996094e-05
        },
        {
            "start_logit": 9.25,
            "end_logit": -5.1796875,
            "text": "focal cortical dysplasia (FCD) type II.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -5.53515625,
            "text": "focal cortical dysplasia (FCD) type II",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -5.58984375,
            "text": "focal cortical dysplasia (FCD)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -5.9140625,
            "text": "focal cortical dysplasia (FCD) type",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.1015625,
            "text": "focal cortical dysplasia (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.27734375,
            "text": "focal cortical dysplasia (FCD",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.203125,
            "end_logit": 8.9765625,
            "text": "According to Palmini's classification system, these lesions were categorized as focal cortical dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.51171875,
            "text": "focal cortical dysplasia (FC",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 8.9765625,
            "text": "cortical dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 8.9765625,
            "text": "as focal cortical dysplasia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 8.9765625,
            "text": ", these lesions were categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 8.9765625,
            "text": "to Palmini's classification system, these lesions were categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 8.9765625,
            "text": "categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 8.9765625,
            "text": "lesions were categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 8.9765625,
            "text": "these lesions were categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 8.9765625,
            "text": "were categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.9765625,
            "text": "system, these lesions were categorized as focal cortical dysplasia",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f020ef6e394741000047_10": [
        {
            "start_logit": 4.0859375,
            "end_logit": 8.2890625,
            "text": "focal cortical dysplasia",
            "probability": 0.998046875
        },
        {
            "start_logit": -2.60546875,
            "end_logit": 8.2890625,
            "text": "dysplasia",
            "probability": 0.0012388229370117188
        },
        {
            "start_logit": -4.4921875,
            "end_logit": 8.2890625,
            "text": "cortical dysplasia",
            "probability": 0.00018787384033203125
        },
        {
            "start_logit": -5.9765625,
            "end_logit": 8.2890625,
            "text": "malformations of cortical development (mMCDs) were disclosed in three patients, focal cortical dysplasia",
            "probability": 4.26173210144043e-05
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 8.2890625,
            "text": ", focal cortical dysplasia",
            "probability": 2.7060508728027344e-05
        },
        {
            "start_logit": -6.4765625,
            "end_logit": 8.2890625,
            "text": "mild malformations of cortical development (mMCDs) were disclosed in three patients, focal cortical dysplasia",
            "probability": 2.580881118774414e-05
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 8.2890625,
            "text": "of cortical development (mMCDs) were disclosed in three patients, focal cortical dysplasia",
            "probability": 1.6629695892333984e-05
        },
        {
            "start_logit": -6.921875,
            "end_logit": 8.2890625,
            "text": "according to Palmini's classification, mild malformations of cortical development (mMCDs) were disclosed in three patients, focal cortical dysplasia",
            "probability": 1.6510486602783203e-05
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 8.2890625,
            "text": "In detail, according to Palmini's classification, mild malformations of cortical development (mMCDs) were disclosed in three patients, focal cortical dysplasia",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 8.2890625,
            "text": "to Palmini's classification, mild malformations of cortical development (mMCDs) were disclosed in three patients, focal cortical dysplasia",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 8.2890625,
            "text": "in three patients, focal cortical dysplasia",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -7.21875,
            "end_logit": 8.2890625,
            "text": ", mild malformations of cortical development (mMCDs) were disclosed in three patients, focal cortical dysplasia",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 8.2890625,
            "text": "three patients, focal cortical dysplasia",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 4.0859375,
            "end_logit": -5.7734375,
            "text": "focal",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 4.0859375,
            "end_logit": -6.0546875,
            "text": "focal cortical dysplasia (",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 4.0859375,
            "end_logit": -6.24609375,
            "text": "focal cortical dysplasia (FCD) type Ia in three patients, and FCD type Ib in five patients.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 4.0859375,
            "end_logit": -6.59765625,
            "text": "focal cortical dysplasia (FCD",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 4.0859375,
            "end_logit": -6.63671875,
            "text": "focal cortical dysplasia (FC",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 4.0859375,
            "end_logit": -6.73046875,
            "text": "focal cortical dysplasia (FCD) type Ia",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 4.0859375,
            "end_logit": -6.734375,
            "text": "focal cortical dysplasia (FCD)",
            "probability": 2.980232238769531e-07
        }
    ],
    "56c1f020ef6e394741000047_11": [
        {
            "start_logit": 5.19140625,
            "end_logit": 9.1484375,
            "text": "cortical dysplasia",
            "probability": 0.998046875
        },
        {
            "start_logit": -0.9423828125,
            "end_logit": 9.1484375,
            "text": "dysplasia",
            "probability": 0.0021495819091796875
        },
        {
            "start_logit": -6.15234375,
            "end_logit": 9.1484375,
            "text": "focal cortical dysplasia",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 9.1484375,
            "text": "with pathologically confirmed focal cortical dysplasia",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 9.1484375,
            "text": "in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 9.1484375,
            "text": "patients with pathologically confirmed focal cortical dysplasia",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": -7.40625,
            "end_logit": 9.1484375,
            "text": "Rates of high frequency oscillations in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": -7.453125,
            "end_logit": 9.1484375,
            "text": "confirmed focal cortical dysplasia",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.1484375,
            "text": "of high frequency oscillations in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.1484375,
            "text": "pathologically confirmed focal cortical dysplasia",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 9.1484375,
            "text": "oscillations in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 9.1484375,
            "text": "high frequency oscillations in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -5.7734375,
            "text": "cortical",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -6.7890625,
            "text": "cortical dysplasia of Palmini type 1a and b were compared with those in type 2a and b.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -6.8046875,
            "text": "cortical dysplasia of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -6.9453125,
            "text": "cortical dysplasia of Palmini type 1a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -7.16015625,
            "text": "cortical dysplasia of Palm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -7.16796875,
            "text": "cortical dysplasia of Palmini type 1a and b were",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -7.22265625,
            "text": "cortical dysplasia of Palmini type 1a and b were compared",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.19140625,
            "end_logit": -7.2578125,
            "text": "cortical dysplasia of Palmini",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f020ef6e394741000047_12": [
        {
            "start_logit": 5.36328125,
            "end_logit": 3.5234375,
            "text": "meningioangiomatosis",
            "probability": 0.537109375
        },
        {
            "start_logit": 5.36328125,
            "end_logit": 3.33203125,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia",
            "probability": 0.442138671875
        },
        {
            "start_logit": 5.36328125,
            "end_logit": 0.228759765625,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with 6 of those (60%) classified as Palmini type IA",
            "probability": 0.019866943359375
        },
        {
            "start_logit": -1.45703125,
            "end_logit": 3.33203125,
            "text": "dysplasia",
            "probability": 0.00048232078552246094
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -4.953125,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with 6 of those (60%) classified as Palmini type IA,",
            "probability": 0.00011104345321655273
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -4.96484375,
            "text": "meningioangiomatosis demonstrated",
            "probability": 0.00011014938354492188
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -5.5234375,
            "text": "meningi",
            "probability": 6.330013275146484e-05
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -5.82421875,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia,",
            "probability": 4.667043685913086e-05
        },
        {
            "start_logit": -1.0791015625,
            "end_logit": 0.228759765625,
            "text": "IA",
            "probability": 3.159046173095703e-05
        },
        {
            "start_logit": -4.6015625,
            "end_logit": 3.5234375,
            "text": "the meningioangiomatosis",
            "probability": 2.5153160095214844e-05
        },
        {
            "start_logit": -1.45703125,
            "end_logit": 0.228759765625,
            "text": "dysplasia, with 6 of those (60%) classified as Palmini type IA",
            "probability": 2.1696090698242188e-05
        },
        {
            "start_logit": -4.6015625,
            "end_logit": 3.33203125,
            "text": "the meningioangiomatosis demonstrated evidence of focal cortical dysplasia",
            "probability": 2.086162567138672e-05
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -6.6484375,
            "text": "meningioangiomatosis demonstrated evidence",
            "probability": 2.0503997802734375e-05
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -6.65234375,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with 6 of those (60",
            "probability": 2.0384788513183594e-05
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -6.71484375,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with 6 of those (60%",
            "probability": 1.913309097290039e-05
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -6.7734375,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with",
            "probability": 1.811981201171875e-05
        },
        {
            "start_logit": 5.36328125,
            "end_logit": -6.7890625,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with 6 of those (60%) classified as Palmini",
            "probability": 1.7821788787841797e-05
        },
        {
            "start_logit": -5.43359375,
            "end_logit": 3.33203125,
            "text": "cortical dysplasia",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 3.5234375,
            "text": "oangiomatosis",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 3.33203125,
            "text": "oangiomatosis demonstrated evidence of focal cortical dysplasia",
            "probability": 4.5299530029296875e-06
        }
    ],
    "56c1f020ef6e394741000047_13": [
        {
            "start_logit": 6.33984375,
            "end_logit": 8.7890625,
            "text": "cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -2.123046875,
            "end_logit": 8.7890625,
            "text": "dysplasia",
            "probability": 0.00021159648895263672
        },
        {
            "start_logit": -2.998046875,
            "end_logit": 8.7890625,
            "text": "focal cortical dysplasia",
            "probability": 8.821487426757812e-05
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 8.7890625,
            "text": "of focal cortical dysplasia",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 6.33984375,
            "end_logit": -4.8984375,
            "text": "cortical",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 8.7890625,
            "text": "of the complex structural abnormalities of focal cortical dysplasia",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 8.7890625,
            "text": "complex structural abnormalities of focal cortical dysplasia",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 8.7890625,
            "text": "abnormalities of focal cortical dysplasia",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 8.7890625,
            "text": "classifications of the complex structural abnormalities of focal cortical dysplasia",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.484375,
            "end_logit": 8.7890625,
            "text": "Numerous classifications of the complex structural abnormalities of focal cortical dysplasia",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 6.33984375,
            "end_logit": -6.88671875,
            "text": "cortical dysplasia have been proposed - from Taylor et al. in 1971 to",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.33984375,
            "end_logit": -6.89453125,
            "text": "cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last modification",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.33984375,
            "end_logit": -6.98828125,
            "text": "cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last modification of Palmini classification made by Blumcke in 2011",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.33984375,
            "end_logit": -7.03515625,
            "text": "cortical dysplasia have been proposed - from Taylor et al",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.33984375,
            "end_logit": -7.078125,
            "text": "cortical dysplasia have been proposed - from Taylor et al. in 1971 to the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.33984375,
            "end_logit": -7.1171875,
            "text": "cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last modification of Palmini classification made by Blumcke in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.33984375,
            "end_logit": -7.140625,
            "text": "cortical dysplasia have been proposed - from Taylor et al. in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.33984375,
            "end_logit": -7.1953125,
            "text": "cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last modification of Palmini classification made",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.33984375,
            "end_logit": -7.203125,
            "text": "cortical dysplasia have",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.33984375,
            "end_logit": -7.20703125,
            "text": "cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last modification of Palmini classification made by",
            "probability": 1.1920928955078125e-07
        }
    ],
    "56c1f020ef6e394741000047_14": [
        {
            "start_logit": 9.2109375,
            "end_logit": 9.1328125,
            "text": "cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -1.2998046875,
            "text": "cortical",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -1.2998046875,
            "end_logit": 9.1328125,
            "text": "dysplasia",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": -3.890625,
            "end_logit": 9.1328125,
            "text": ". In general, three types of cortical dysplasia",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -6.21484375,
            "end_logit": 9.1328125,
            "text": "1971 to the last modification of Palmini classification made by Blumcke in 2011. In general, three types of cortical dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.53125,
            "text": "cortical dysplasia are recognized.Type I",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.53125,
            "text": "cortical dysplasia are recognized.Type I focal cortical dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 9.1328125,
            "text": "by Blumcke in 2011. In general, three types of cortical dysplasia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.93359375,
            "text": "cortical dysplasia are recognized.Type",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 9.1328125,
            "text": "Blumcke in 2011. In general, three types of cortical dysplasia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.97265625,
            "text": "cortical dysplasia are recognized.Type I focal cortical dysplasia with",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 9.1328125,
            "text": "last modification of Palmini classification made by Blumcke in 2011. In general, three types of cortical dysplasia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.03125,
            "end_logit": 9.1328125,
            "text": "in 1971 to the last modification of Palmini classification made by Blumcke in 2011. In general, three types of cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.0625,
            "end_logit": 9.1328125,
            "text": "modification of Palmini classification made by Blumcke in 2011. In general, three types of cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 9.1328125,
            "text": "to the last modification of Palmini classification made by Blumcke in 2011. In general, three types of cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.09375,
            "end_logit": 9.1328125,
            "text": "of Palmini classification made by Blumcke in 2011. In general, three types of cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 9.1328125,
            "text": "three types of cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 9.1328125,
            "text": ", three types of cortical dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.890625,
            "end_logit": -1.2998046875,
            "text": ". In general, three types of cortical",
            "probability": 0.0
        },
        {
            "start_logit": -6.21484375,
            "end_logit": -1.2998046875,
            "text": "1971 to the last modification of Palmini classification made by Blumcke in 2011. In general, three types of cortical",
            "probability": 0.0
        }
    ],
    "58e74bff3e8b6dc87c000004_1": [
        {
            "start_logit": 4.10546875,
            "end_logit": 8.6875,
            "text": "ribosomal protein genes",
            "probability": 0.52978515625
        },
        {
            "start_logit": 3.986328125,
            "end_logit": 8.6875,
            "text": "8 different ribosomal protein genes",
            "probability": 0.467529296875
        },
        {
            "start_logit": -1.5556640625,
            "end_logit": 8.6875,
            "text": "Diamond Blackfan anemia (DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 0.0018367767333984375
        },
        {
            "start_logit": -2.265625,
            "end_logit": 8.6875,
            "text": "genes",
            "probability": 0.0009021759033203125
        },
        {
            "start_logit": -5.19140625,
            "end_logit": 8.6875,
            "text": "different ribosomal protein genes",
            "probability": 4.857778549194336e-05
        },
        {
            "start_logit": -5.51171875,
            "end_logit": 8.6875,
            "text": "protein genes",
            "probability": 3.49879264831543e-05
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -2.298828125,
            "text": "ribosomal protein genes.",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": 3.986328125,
            "end_logit": -2.298828125,
            "text": "8 different ribosomal protein genes.",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 8.6875,
            "text": "Blackfan anemia (DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 8.6875,
            "text": "in at least 8 different ribosomal protein genes",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 8.6875,
            "text": "inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 8.6875,
            "text": "mutations in at least 8 different ribosomal protein genes",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 8.6875,
            "text": "with mutations in at least 8 different ribosomal protein genes",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 8.6875,
            "text": "at least 8 different ribosomal protein genes",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 8.6875,
            "text": "anemia (DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 8.6875,
            "text": "associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 8.6875,
            "text": "erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.6875,
            "text": "(DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 5.125999450683594e-06
        },
        {
            "start_logit": 3.986328125,
            "end_logit": -3.60546875,
            "text": "8",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 4.10546875,
            "end_logit": -6.55078125,
            "text": "ribosomal",
            "probability": 1.1920928955078125e-07
        }
    ],
    "58e74bff3e8b6dc87c000004_2": [
        {
            "start_logit": 6.98046875,
            "end_logit": 2.66015625,
            "text": "Ribosomal protein genes RPS10",
            "probability": 0.5859375
        },
        {
            "start_logit": 6.98046875,
            "end_logit": 2.30078125,
            "text": "Ribosomal protein genes",
            "probability": 0.408935546875
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -2.927734375,
            "text": "Ribosomal protein genes RPS10 and RPS26",
            "probability": 0.002197265625
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -3.931640625,
            "text": "Ribosomal protein genes RPS10 and",
            "probability": 0.0008015632629394531
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -4.3046875,
            "text": "Ribosomal",
            "probability": 0.000553131103515625
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -4.36328125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia.",
            "probability": 0.0005216598510742188
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -4.88671875,
            "text": "Ribosomal protein",
            "probability": 0.00030922889709472656
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -5.8203125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are",
            "probability": 0.00012111663818359375
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -5.921875,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly",
            "probability": 0.00011026859283447266
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -6.05859375,
            "text": "Ribosomal protein genes RPS",
            "probability": 9.572505950927734e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -6.234375,
            "text": "Ribosomal protein genes RPS10 and RPS",
            "probability": 8.064508438110352e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -6.609375,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated",
            "probability": 5.543231964111328e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -7.015625,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia",
            "probability": 3.68952751159668e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -7.125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in",
            "probability": 3.30805778503418e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -7.12890625,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Black",
            "probability": 3.2842159271240234e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -7.171875,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond",
            "probability": 3.159046173095703e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -7.17578125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan",
            "probability": 3.129243850708008e-05
        },
        {
            "start_logit": -5.31640625,
            "end_logit": 2.66015625,
            "text": "RPS10",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -6.17578125,
            "end_logit": 2.66015625,
            "text": "genes RPS10",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.17578125,
            "end_logit": 2.30078125,
            "text": "genes",
            "probability": 7.748603820800781e-07
        }
    ],
    "58e74bff3e8b6dc87c000004_3": [
        {
            "start_logit": 8.546875,
            "end_logit": 8.828125,
            "text": "ribosomal protein genes",
            "probability": 1.0
        },
        {
            "start_logit": -1.8994140625,
            "end_logit": 8.828125,
            "text": "genes",
            "probability": 2.9087066650390625e-05
        },
        {
            "start_logit": 8.546875,
            "end_logit": -2.638671875,
            "text": "ribosomal",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 8.546875,
            "end_logit": -3.935546875,
            "text": "ribosomal protein genes which",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -5.9609375,
            "end_logit": 8.828125,
            "text": "protein genes",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.4765625,
            "end_logit": 8.828125,
            "text": "for ribosomal protein genes",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -6.26171875,
            "text": "ribosomal protein genes which are mutated in Diamond-Blackfan Anemia.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -6.69921875,
            "text": "ribosomal protein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -6.75390625,
            "text": "ribosomal protein genes which are",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -6.96875,
            "text": "ribosomal protein genes which are mutated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 8.828125,
            "text": "A new database for ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.109375,
            "text": "ribosomal protein genes which are mutated in Diamond-Blackfan Anemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.171875,
            "text": "ribosomal protein genes which are mutated in Diamond-Blackfan",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.203125,
            "text": "ribosomal protein genes which are mutated in Diamond-Black",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.203125,
            "text": "ribosomal protein genes which are mutated in Diamond",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.203125,
            "text": "ribosomal protein genes which are mutated in Diamond-Blackfa",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.25,
            "text": "ribosomal protein genes which are mutated in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.8994140625,
            "end_logit": -3.935546875,
            "text": "genes which",
            "probability": 0.0
        },
        {
            "start_logit": -1.8994140625,
            "end_logit": -6.26171875,
            "text": "genes which are mutated in Diamond-Blackfan Anemia.",
            "probability": 0.0
        },
        {
            "start_logit": -1.8994140625,
            "end_logit": -6.75390625,
            "text": "genes which are",
            "probability": 0.0
        }
    ],
    "58e74bff3e8b6dc87c000004_4": [
        {
            "start_logit": 6.36328125,
            "end_logit": 4.296875,
            "text": "Ribosomal protein genes",
            "probability": 0.77392578125
        },
        {
            "start_logit": 6.36328125,
            "end_logit": 3.0625,
            "text": "Ribosomal protein genes RPS10",
            "probability": 0.2252197265625
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -3.654296875,
            "text": "Ribosomal protein genes RPS10 and",
            "probability": 0.0002741813659667969
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -4.6328125,
            "text": "Ribosomal protein genes RPS10 and RPS26",
            "probability": 0.00010323524475097656
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -4.765625,
            "text": "Ribosomal",
            "probability": 8.970499038696289e-05
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -5.05078125,
            "text": "Ribosomal protein",
            "probability": 6.771087646484375e-05
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -5.46484375,
            "text": "Ribosomal protein genes RPS",
            "probability": 4.476308822631836e-05
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -5.96484375,
            "text": "Ribosomal protein genes RPS10 and RPS26 are",
            "probability": 2.7179718017578125e-05
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -6.14453125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly",
            "probability": 2.2709369659423828e-05
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -6.24609375,
            "text": "Ribosomal protein genes RPS10 and RPS",
            "probability": 2.0503997802734375e-05
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -6.64453125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated",
            "probability": 1.3768672943115234e-05
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -7.0546875,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -7.06640625,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -7.0703125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -7.2109375,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Black",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -7.27734375,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": -5.65625,
            "end_logit": 4.296875,
            "text": "genes",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -5.65625,
            "end_logit": 3.0625,
            "text": "genes RPS10",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -7.015625,
            "end_logit": 4.296875,
            "text": "protein genes",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -6.0859375,
            "end_logit": 3.0625,
            "text": "RPS10",
            "probability": 8.940696716308594e-07
        }
    ],
    "58e74bff3e8b6dc87c000004_5": [
        {
            "start_logit": 5.6796875,
            "end_logit": 4.26171875,
            "text": "ribosomal protein genes",
            "probability": 0.9677734375
        },
        {
            "start_logit": 5.6796875,
            "end_logit": 0.837890625,
            "text": "ribosomal protein genes that encode structural components of the ribosome essential for the correct assembly of the ribosomal subunits.",
            "probability": 0.0316162109375
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -4.671875,
            "text": "ribosomal protein genes that",
            "probability": 0.00012814998626708984
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -5.15234375,
            "text": "ribosomal",
            "probability": 7.957220077514648e-05
        },
        {
            "start_logit": -3.783203125,
            "end_logit": 4.26171875,
            "text": "one of several ribosomal protein genes",
            "probability": 7.534027099609375e-05
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -5.36328125,
            "text": "ribosomal protein genes that encode structural components of the ribosome essential",
            "probability": 6.389617919921875e-05
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -5.75390625,
            "text": "ribosomal protein genes that encode structural components",
            "probability": 4.3272972106933594e-05
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -5.859375,
            "text": "ribosomal protein genes that encode structural components of the ribosome essential for",
            "probability": 3.904104232788086e-05
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -5.90625,
            "text": "ribosomal protein genes that encode structural components of the ribosome essential for the",
            "probability": 3.725290298461914e-05
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -5.953125,
            "text": "ribosomal protein genes that encode",
            "probability": 3.55839729309082e-05
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -6.078125,
            "text": "ribosomal protein genes that encode structural",
            "probability": 3.141164779663086e-05
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -6.08984375,
            "text": "ribosomal protein genes that encode structural components of",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -6.1484375,
            "text": "ribosomal protein genes that encode structural components of the",
            "probability": 2.9265880584716797e-05
        },
        {
            "start_logit": 5.6796875,
            "end_logit": -6.16796875,
            "text": "ribosomal protein genes that encode structural components of the ribosome",
            "probability": 2.8848648071289062e-05
        },
        {
            "start_logit": -4.890625,
            "end_logit": 4.26171875,
            "text": "several ribosomal protein genes",
            "probability": 2.5033950805664062e-05
        },
        {
            "start_logit": -5.76171875,
            "end_logit": 4.26171875,
            "text": "in one of several ribosomal protein genes",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": -5.89453125,
            "end_logit": 4.26171875,
            "text": "genes",
            "probability": 9.119510650634766e-06
        },
        {
            "start_logit": -6.34765625,
            "end_logit": 4.26171875,
            "text": "protein genes",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": -6.484375,
            "end_logit": 4.26171875,
            "text": "DBA patients exhibit abnormal pre-rRNA maturation patterns and the majority bear mutations in one of several ribosomal protein genes",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 4.26171875,
            "text": "patients exhibit abnormal pre-rRNA maturation patterns and the majority bear mutations in one of several ribosomal protein genes",
            "probability": 4.351139068603516e-06
        }
    ],
    "58e74bff3e8b6dc87c000004_6": [
        {
            "start_logit": 8.546875,
            "end_logit": 8.828125,
            "text": "ribosomal protein genes",
            "probability": 1.0
        },
        {
            "start_logit": -1.8994140625,
            "end_logit": 8.828125,
            "text": "genes",
            "probability": 2.9087066650390625e-05
        },
        {
            "start_logit": 8.546875,
            "end_logit": -2.638671875,
            "text": "ribosomal",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 8.546875,
            "end_logit": -3.935546875,
            "text": "ribosomal protein genes which",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -5.9609375,
            "end_logit": 8.828125,
            "text": "protein genes",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.4765625,
            "end_logit": 8.828125,
            "text": "for ribosomal protein genes",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -6.26171875,
            "text": "ribosomal protein genes which are mutated in Diamond-Blackfan Anemia.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -6.69921875,
            "text": "ribosomal protein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -6.75390625,
            "text": "ribosomal protein genes which are",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -6.96875,
            "text": "ribosomal protein genes which are mutated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 8.828125,
            "text": "A new database for ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.109375,
            "text": "ribosomal protein genes which are mutated in Diamond-Blackfan Anemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.171875,
            "text": "ribosomal protein genes which are mutated in Diamond-Blackfan",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.203125,
            "text": "ribosomal protein genes which are mutated in Diamond-Black",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.203125,
            "text": "ribosomal protein genes which are mutated in Diamond",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.203125,
            "text": "ribosomal protein genes which are mutated in Diamond-Blackfa",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -7.25,
            "text": "ribosomal protein genes which are mutated in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.8994140625,
            "end_logit": -3.935546875,
            "text": "genes which",
            "probability": 0.0
        },
        {
            "start_logit": -1.8994140625,
            "end_logit": -6.26171875,
            "text": "genes which are mutated in Diamond-Blackfan Anemia.",
            "probability": 0.0
        },
        {
            "start_logit": -1.8994140625,
            "end_logit": -6.75390625,
            "text": "genes which are",
            "probability": 0.0
        }
    ],
    "58e74bff3e8b6dc87c000004_7": [
        {
            "start_logit": 8.7734375,
            "end_logit": 8.9140625,
            "text": "ribosomal protein genes",
            "probability": 1.0
        },
        {
            "start_logit": -1.7998046875,
            "end_logit": 8.9140625,
            "text": "genes",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -2.314453125,
            "text": "ribosomal",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -5.6640625,
            "text": "ribosomal protein genes.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.16015625,
            "end_logit": 8.9140625,
            "text": "protein genes",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -6.12890625,
            "text": "ribosomal protein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.3125,
            "end_logit": 8.9140625,
            "text": "in ribosomal protein genes",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.6015625,
            "end_logit": 8.9140625,
            "text": "12 (27%) of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.92578125,
            "end_logit": 8.9140625,
            "text": "(27%) of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 8.9140625,
            "text": ", 12 (27%) of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 8.9140625,
            "text": "Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 8.9140625,
            "text": "Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 8.9140625,
            "text": "of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 8.9140625,
            "text": "the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 8.9140625,
            "text": "mutations in ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.296875,
            "end_logit": 8.9140625,
            "text": "had mutations in ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 8.9140625,
            "text": "patients had mutations in ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 8.9140625,
            "text": "-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 8.9140625,
            "text": ") of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 8.9140625,
            "text": "%) of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 5.960464477539063e-08
        }
    ],
    "58e74bff3e8b6dc87c000004_8": [
        {
            "start_logit": 8.3984375,
            "end_logit": 8.71875,
            "text": "ribosomal protein genes",
            "probability": 1.0
        },
        {
            "start_logit": -2.1875,
            "end_logit": 8.71875,
            "text": "genes",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -2.9453125,
            "text": "ribosomal",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -4.9140625,
            "text": "ribosomal protein genes in",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -5.8046875,
            "end_logit": 8.71875,
            "text": "protein genes",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -6.11328125,
            "text": "ribosomal protein genes in Japanese",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -6.16015625,
            "text": "ribosomal protein genes in Japanese patients with Diamond-Blackfan anemia.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 8.71875,
            "text": "the ribosomal protein genes",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -6.4765625,
            "text": "ribosomal protein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -6.84375,
            "text": "ribosomal protein genes in Japanese patients",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 8.71875,
            "text": "in the ribosomal protein genes",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -7.08203125,
            "text": "ribosomal protein genes in Japanese patients with Diamond-Blackfan anemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -7.12109375,
            "text": "ribosomal protein genes in Japanese patients with Diamond",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 8.71875,
            "text": "Mutations in the ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -7.16796875,
            "text": "ribosomal protein genes in Japanese patients with",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -7.234375,
            "text": "ribosomal protein genes in Japanese patients with Diamond-Black",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -7.23828125,
            "text": "ribosomal protein genes in Japanese patients with Diamond-Blackfa",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3984375,
            "end_logit": -7.2578125,
            "text": "ribosomal protein genes in Japanese patients with Diamond-Blackfan",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.1875,
            "end_logit": -4.9140625,
            "text": "genes in",
            "probability": 0.0
        },
        {
            "start_logit": -2.1875,
            "end_logit": -6.11328125,
            "text": "genes in Japanese",
            "probability": 0.0
        }
    ],
    "58e74bff3e8b6dc87c000004_9": [
        {
            "start_logit": 6.98046875,
            "end_logit": 2.66015625,
            "text": "Ribosomal protein genes RPS10",
            "probability": 0.5859375
        },
        {
            "start_logit": 6.98046875,
            "end_logit": 2.30078125,
            "text": "Ribosomal protein genes",
            "probability": 0.408935546875
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -2.927734375,
            "text": "Ribosomal protein genes RPS10 and RPS26",
            "probability": 0.002197265625
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -3.931640625,
            "text": "Ribosomal protein genes RPS10 and",
            "probability": 0.0008015632629394531
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -4.3046875,
            "text": "Ribosomal",
            "probability": 0.000553131103515625
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -4.36328125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia.",
            "probability": 0.0005216598510742188
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -4.88671875,
            "text": "Ribosomal protein",
            "probability": 0.00030922889709472656
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -5.8203125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are",
            "probability": 0.00012111663818359375
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -5.921875,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly",
            "probability": 0.00011026859283447266
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -6.05859375,
            "text": "Ribosomal protein genes RPS",
            "probability": 9.572505950927734e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -6.234375,
            "text": "Ribosomal protein genes RPS10 and RPS",
            "probability": 8.064508438110352e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -6.609375,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated",
            "probability": 5.543231964111328e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -7.015625,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia",
            "probability": 3.68952751159668e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -7.125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in",
            "probability": 3.30805778503418e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -7.12890625,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Black",
            "probability": 3.2842159271240234e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -7.171875,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond",
            "probability": 3.159046173095703e-05
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -7.17578125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan",
            "probability": 3.129243850708008e-05
        },
        {
            "start_logit": -5.31640625,
            "end_logit": 2.66015625,
            "text": "RPS10",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -6.17578125,
            "end_logit": 2.66015625,
            "text": "genes RPS10",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.17578125,
            "end_logit": 2.30078125,
            "text": "genes",
            "probability": 7.748603820800781e-07
        }
    ],
    "56e857ae42442bac75000004_1": [
        {
            "start_logit": 8.8359375,
            "end_logit": 5.9140625,
            "text": "zinc",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -0.71240234375,
            "text": "zinc ion",
            "probability": 0.0013256072998046875
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -4.76171875,
            "text": "zinc ion at their active site, for proteolityc activity.",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -6.23828125,
            "text": "zinc ion at",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -6.48046875,
            "text": "zinc ion at their active site",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -6.62890625,
            "text": "zinc ion at their active site, for proteolityc activity",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -6.78515625,
            "text": "zinc ion at their active site,",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 8.8359375,
            "end_logit": -7.0078125,
            "text": "zinc ion at their active site, for",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -6.50390625,
            "end_logit": 5.9140625,
            "text": "a zinc",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 5.9140625,
            "text": "ire a zinc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 5.9140625,
            "text": "quire a zinc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 5.9140625,
            "text": "matrix metalloproteinases (MMPs) are a family of endopeptydases which recquire a zinc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 5.9140625,
            "text": "recquire a zinc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 5.9140625,
            "text": "Extracellular matrix metalloproteinases (MMPs) are a family of endopeptydases which recquire a zinc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.50390625,
            "end_logit": -0.71240234375,
            "text": "a zinc ion",
            "probability": 0.0
        },
        {
            "start_logit": -7.2890625,
            "end_logit": -0.71240234375,
            "text": "ire a zinc ion",
            "probability": 0.0
        },
        {
            "start_logit": -7.3046875,
            "end_logit": -0.71240234375,
            "text": "quire a zinc ion",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -0.71240234375,
            "text": "matrix metalloproteinases (MMPs) are a family of endopeptydases which recquire a zinc ion",
            "probability": 0.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": -0.71240234375,
            "text": "recquire a zinc ion",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -0.71240234375,
            "text": "Extracellular matrix metalloproteinases (MMPs) are a family of endopeptydases which recquire a zinc ion",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_1": [
        {
            "start_logit": 9.0078125,
            "end_logit": 9.0546875,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.5478515625,
            "end_logit": 9.0546875,
            "text": "myeloma",
            "probability": 2.6047229766845703e-05
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -1.9111328125,
            "text": "multiple",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": -6.859375,
            "end_logit": 9.0546875,
            "text": "in multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.24609375,
            "text": "multiple myeloma. Some of these agents such",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.29296875,
            "text": "multiple myeloma. Some of these agents such as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.34765625,
            "text": "multiple myeloma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.34765625,
            "text": "multiple myeloma. Some of these agents such as belantamab ma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.35546875,
            "text": "multiple myeloma. Some of these agents such as belantamab mafodotin and idecabtagene vicleucel have already",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.36328125,
            "text": "multiple myeloma. Some of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.39453125,
            "text": "multiple myeloma. Some of these agents such as belantama",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.39453125,
            "text": "multiple myeloma. Some of these agents such as belantamab",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.39453125,
            "text": "multiple myeloma. Some of these agents such as bel",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.0546875,
            "text": "immunotherapies in multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.859375,
            "end_logit": -1.9111328125,
            "text": "in multiple",
            "probability": 0.0
        },
        {
            "start_logit": -1.5478515625,
            "end_logit": -7.24609375,
            "text": "myeloma. Some of these agents such",
            "probability": 0.0
        },
        {
            "start_logit": -1.5478515625,
            "end_logit": -7.29296875,
            "text": "myeloma. Some of these agents such as",
            "probability": 0.0
        },
        {
            "start_logit": -1.5478515625,
            "end_logit": -7.34765625,
            "text": "myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -1.5478515625,
            "end_logit": -7.34765625,
            "text": "myeloma. Some of these agents such as belantamab ma",
            "probability": 0.0
        },
        {
            "start_logit": -1.5478515625,
            "end_logit": -7.35546875,
            "text": "myeloma. Some of these agents such as belantamab mafodotin and idecabtagene vicleucel have already",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_2": [
        {
            "start_logit": 8.84375,
            "end_logit": 9.0625,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.56640625,
            "end_logit": 9.0625,
            "text": "myeloma",
            "probability": 3.0219554901123047e-05
        },
        {
            "start_logit": 8.84375,
            "end_logit": -2.2578125,
            "text": "multiple",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 9.0625,
            "text": "patients with relapsed or refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 9.0625,
            "text": "with relapsed or refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 9.0625,
            "text": "refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.0625,
            "text": "treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 9.0625,
            "text": "of patients with relapsed or refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 9.0625,
            "text": "for the treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.0625,
            "text": "ITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.0625,
            "text": "MMa for the treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5,
            "end_logit": 9.0625,
            "text": "KarMMa for the treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5,
            "end_logit": 9.0625,
            "text": "in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 9.0625,
            "text": "a for the treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 9.0625,
            "text": "versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1953125,
            "end_logit": -2.2578125,
            "text": "patients with relapsed or refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.26171875,
            "end_logit": -2.2578125,
            "text": "with relapsed or refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": -2.2578125,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -2.2578125,
            "text": "treatment of patients with relapsed or refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -2.2578125,
            "text": "of patients with relapsed or refractory multiple",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_3": [
        {
            "start_logit": 8.9140625,
            "end_logit": 9.0625,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.5302734375,
            "end_logit": 9.0625,
            "text": "myeloma",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -2.0859375,
            "text": "multiple",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 9.0625,
            "text": "refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.0625,
            "text": "in relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.0625,
            "text": "outcomes in relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 9.0625,
            "text": "world outcomes in relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -2.0859375,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -2.0859375,
            "text": "in relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -2.0859375,
            "text": "outcomes in relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -2.0859375,
            "text": "world outcomes in relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -7.21875,
            "text": "in relapsed and",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -7.21875,
            "text": "outcomes in relapsed and",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -7.39453125,
            "text": "in relapsed",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -7.21875,
            "text": "world outcomes in relapsed and",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -7.39453125,
            "text": "outcomes in relapsed",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -7.39453125,
            "text": "world outcomes in relapsed",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_4": [
        {
            "start_logit": 8.9609375,
            "end_logit": 9.0703125,
            "text": "Multiple Myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.5234375,
            "end_logit": 9.0703125,
            "text": "Myeloma",
            "probability": 2.7954578399658203e-05
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -1.9794921875,
            "text": "Multiple",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.0703125,
            "text": "Refractory Multiple Myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.0703125,
            "text": "in Relapsed and Refractory Multiple Myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": -1.9794921875,
            "text": "Refractory Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -1.9794921875,
            "text": "in Relapsed and Refractory Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -6.984375,
            "text": "in Relapsed and",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -7.234375,
            "text": "in Relapsed",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -7.37890625,
            "text": "in",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_5": [
        {
            "start_logit": 8.8984375,
            "end_logit": 9.0,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.70703125,
            "end_logit": 9.0,
            "text": "myeloma",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -2.138671875,
            "text": "multiple",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.0,
            "text": "refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -2.138671875,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.546875,
            "end_logit": -2.138671875,
            "text": "discuss the preclinical and clinical development of idecabtagene vicleucel and its future role in the changing treatment landscape of relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.14453125,
            "text": "Here, we will",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.16796875,
            "text": "Here, we will discuss the preclinical and",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.171875,
            "text": "Here, we will discuss the",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.19140625,
            "text": "Here, we will discuss",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.21875,
            "text": "Here, we will discuss the preclinical",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.234375,
            "text": "Here, we",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.2734375,
            "text": "Here, we will discuss the preclinical and clinical development",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.29296875,
            "text": "Here, we will discuss the preclinical and clinical development of idecabtagene vicleucel and",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.30859375,
            "text": "Here, we will discuss the preclinical and clinical development of idecabtagene vicleucel and its future role",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.3125,
            "text": "Here, we will discuss the preclinical and clinical development of idecabtagene vicleucel and its future role in the",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.328125,
            "text": "Here, we will discuss the preclinical and clinical",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.3359375,
            "text": "Here, we will discuss the preclinical and clinical development of idecabtagene vicleucel and its future role in the changing treatment landscape of",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.3515625,
            "text": "Here, we will discuss the preclinical and clinical development of",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -7.35546875,
            "text": "Here, we will discuss the preclinical and clinical development of idecabtagene vicleucel and its future role in",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_6": [
        {
            "start_logit": 8.71875,
            "end_logit": 8.890625,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.9658203125,
            "end_logit": 8.890625,
            "text": "myeloma",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": 8.71875,
            "end_logit": -2.4140625,
            "text": "multiple",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": -7.453125,
            "end_logit": 8.890625,
            "text": "gain regulatory US Food and Drug Administration approval to treat refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 8.890625,
            "text": "refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.3046875,
            "text": "multiple myeloma patients",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.3125,
            "text": "multiple myeloma patients who",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.3203125,
            "text": "multiple myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the last therapy.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.32421875,
            "text": "multiple myeloma patients who have",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.34375,
            "text": "multiple myeloma patients who have already",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.39453125,
            "text": "multiple myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.71875,
            "end_logit": -7.40625,
            "text": "multiple myeloma patients who have already been",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.9658203125,
            "end_logit": -7.3046875,
            "text": "myeloma patients",
            "probability": 0.0
        },
        {
            "start_logit": -1.9658203125,
            "end_logit": -7.3125,
            "text": "myeloma patients who",
            "probability": 0.0
        },
        {
            "start_logit": -1.9658203125,
            "end_logit": -7.3203125,
            "text": "myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the last therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -1.9658203125,
            "end_logit": -7.32421875,
            "text": "myeloma patients who have",
            "probability": 0.0
        },
        {
            "start_logit": -1.9658203125,
            "end_logit": -7.34375,
            "text": "myeloma patients who have already",
            "probability": 0.0
        },
        {
            "start_logit": -1.9658203125,
            "end_logit": -7.39453125,
            "text": "myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the",
            "probability": 0.0
        },
        {
            "start_logit": -1.9658203125,
            "end_logit": -7.40625,
            "text": "myeloma patients who have already been",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -2.4140625,
            "text": "gain regulatory US Food and Drug Administration approval to treat refractory multiple",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_7": [
        {
            "start_logit": 8.9296875,
            "end_logit": 9.09375,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.375,
            "end_logit": 9.09375,
            "text": "myeloma",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -2.015625,
            "text": "multiple",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.01171875,
            "text": "multiple myeloma (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 9.09375,
            "text": "refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.203125,
            "text": "multiple myeloma (MM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.28515625,
            "text": "multiple myeloma (MM) patients who",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.2890625,
            "text": "multiple myeloma (MM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.453125,
            "end_logit": 9.09375,
            "text": "chimeric antigen receptor T-cell (CAR-T) therapies were single-arm studies conducted with relapse refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.3203125,
            "text": "multiple myeloma (MM) patients who were triple-class-exposed (TCE) or triple-class-refractory (TCR).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.328125,
            "text": "multiple myeloma (MM) patients who were",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.33984375,
            "text": "multiple myeloma (MM) patients who were triple-class-exposed (TCE) or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.34375,
            "text": "multiple myeloma (MM) patients",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.375,
            "end_logit": -7.01171875,
            "text": "myeloma (",
            "probability": 0.0
        },
        {
            "start_logit": -1.375,
            "end_logit": -7.203125,
            "text": "myeloma (MM",
            "probability": 0.0
        },
        {
            "start_logit": -1.375,
            "end_logit": -7.28515625,
            "text": "myeloma (MM) patients who",
            "probability": 0.0
        },
        {
            "start_logit": -1.375,
            "end_logit": -7.2890625,
            "text": "myeloma (MM)",
            "probability": 0.0
        },
        {
            "start_logit": -1.375,
            "end_logit": -7.3203125,
            "text": "myeloma (MM) patients who were triple-class-exposed (TCE) or triple-class-refractory (TCR).",
            "probability": 0.0
        },
        {
            "start_logit": -1.375,
            "end_logit": -7.328125,
            "text": "myeloma (MM) patients who were",
            "probability": 0.0
        },
        {
            "start_logit": -1.375,
            "end_logit": -7.33984375,
            "text": "myeloma (MM) patients who were triple-class-exposed (TCE) or",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_8": [
        {
            "start_logit": 8.921875,
            "end_logit": 9.0703125,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.5400390625,
            "end_logit": 9.0703125,
            "text": "myeloma",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": 8.921875,
            "end_logit": -2.083984375,
            "text": "multiple",
            "probability": 1.4185905456542969e-05
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 9.0703125,
            "text": "refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.0703125,
            "text": "antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.44140625,
            "text": "multiple myeloma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.5400390625,
            "end_logit": -7.44140625,
            "text": "myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": -2.083984375,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -2.083984375,
            "text": "chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.4921875,
            "end_logit": -2.083984375,
            "text": "antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -4.24609375,
            "end_logit": -7.44140625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": -7.44140625,
            "text": "refractory multiple myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -7.34375,
            "text": "chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -7.4453125,
            "text": "called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with",
            "probability": 0.0
        },
        {
            "start_logit": -7.4921875,
            "end_logit": -7.34375,
            "text": "antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -7.49609375,
            "text": "also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -7.4140625,
            "text": "chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -7.49609375,
            "text": "called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -7.3984375,
            "text": ": Ide",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -7.4453125,
            "text": "chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_9": [
        {
            "start_logit": 8.8203125,
            "end_logit": 9.0546875,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": 9.0546875,
            "text": "myeloma",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -2.2734375,
            "text": "multiple",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -6.828125,
            "end_logit": 9.0546875,
            "text": "refractory multiple myeloma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 9.0546875,
            "text": "relapsed and refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 9.0546875,
            "text": "with relapsed and refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 9.0546875,
            "text": "patients with relapsed and refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 9.0546875,
            "text": "chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 9.0546875,
            "text": "bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 9.0546875,
            "text": "in patients with relapsed and refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 9.0546875,
            "text": "2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.0546875,
            "text": "cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.1953125,
            "text": "multiple myeloma (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.40234375,
            "text": "multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.44140625,
            "text": "multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.48046875,
            "text": "multiple myeloma (RRMM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.49609375,
            "text": "multiple myeloma (RRMM) who",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.5234375,
            "text": "multiple myeloma (RR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.53515625,
            "text": "multiple myeloma (RRMM) who have",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.8203125,
            "end_logit": -7.55078125,
            "text": "multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm phase",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f7ce26882a024a1000002d_10": [
        {
            "start_logit": 8.7578125,
            "end_logit": 8.7734375,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -2.166015625,
            "end_logit": 8.7734375,
            "text": "myeloma",
            "probability": 1.806020736694336e-05
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -2.3359375,
            "text": "multiple",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.7734375,
            "text": "ucel in patients with heavily pretreated refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.671875,
            "end_logit": 8.7734375,
            "text": "refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6875,
            "end_logit": 8.7734375,
            "text": "The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.703125,
            "end_logit": 8.7734375,
            "text": "leucel in patients with heavily pretreated refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -2.3359375,
            "text": "ucel in patients with heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.671875,
            "end_logit": -2.3359375,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -2.3359375,
            "text": "The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -2.3359375,
            "text": "leucel in patients with heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -6.984375,
            "text": "ucel in patients with heavily",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -6.984375,
            "text": "The role of idecabtagene vicleucel in patients with heavily",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -6.984375,
            "text": "leucel in patients with heavily",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -7.08984375,
            "text": "ucel in",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -7.05859375,
            "text": "The",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -7.1171875,
            "text": "ucel in patients with heavily pretreated",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -7.08984375,
            "text": "The role of idecabtagene vicleucel in",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -7.109375,
            "text": "The role of ide",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -7.08984375,
            "text": "leucel in",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_11": [
        {
            "start_logit": 8.9375,
            "end_logit": 9.0234375,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.630859375,
            "end_logit": 9.0234375,
            "text": "myeloma",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": 8.9375,
            "end_logit": -2.03125,
            "text": "multiple",
            "probability": 1.5676021575927734e-05
        },
        {
            "start_logit": 8.9375,
            "end_logit": -7.3828125,
            "text": "multiple myeloma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.0234375,
            "text": "refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.0234375,
            "text": "The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 9.0234375,
            "text": "patients with heavily pretreated refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.0234375,
            "text": "ucel in patients with heavily pretreated refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.630859375,
            "end_logit": -7.3828125,
            "text": "myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.55859375,
            "end_logit": -2.03125,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": -2.03125,
            "text": "The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": -2.03125,
            "text": "patients with heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -2.03125,
            "text": "ucel in patients with heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -4.71484375,
            "end_logit": -7.3828125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": -7.20703125,
            "text": "The role of idecabtagene vicleucel in patients with heavily",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": -7.20703125,
            "text": "patients with heavily",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": -7.23046875,
            "text": "The role of ide",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": -7.2421875,
            "text": "The role",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -7.20703125,
            "text": "ucel in patients with heavily",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": -7.26171875,
            "text": "The role of idecabtagene vicleucel in",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_12": [
        {
            "start_logit": 8.859375,
            "end_logit": 9.0625,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.52734375,
            "end_logit": 9.0625,
            "text": "myeloma",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": 8.859375,
            "end_logit": -2.189453125,
            "text": "multiple",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -6.796875,
            "end_logit": 9.0625,
            "text": "refractory multiple myeloma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 9.0625,
            "text": "relapsed and refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 9.0625,
            "text": "with relapsed and refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.359375,
            "end_logit": 9.0625,
            "text": "patients with relapsed and refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.1640625,
            "text": "multiple myeloma (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.0625,
            "text": "chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.390625,
            "end_logit": 9.0625,
            "text": "in patients with relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.41796875,
            "text": "multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.42578125,
            "text": "multiple myeloma (RRMM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.45703125,
            "text": "multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.4609375,
            "text": "multiple myeloma (RRMM) who",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.484375,
            "text": "multiple myeloma (RRMM) who have",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.48828125,
            "text": "multiple myeloma (RR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.52734375,
            "end_logit": -7.1640625,
            "text": "myeloma (",
            "probability": 0.0
        },
        {
            "start_logit": -1.52734375,
            "end_logit": -7.41796875,
            "text": "myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the",
            "probability": 0.0
        },
        {
            "start_logit": -1.52734375,
            "end_logit": -7.42578125,
            "text": "myeloma (RRMM)",
            "probability": 0.0
        },
        {
            "start_logit": -1.52734375,
            "end_logit": -7.45703125,
            "text": "myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_13": [
        {
            "start_logit": 8.890625,
            "end_logit": 9.0546875,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.560546875,
            "end_logit": 9.0546875,
            "text": "myeloma",
            "probability": 2.9087066650390625e-05
        },
        {
            "start_logit": 8.890625,
            "end_logit": -2.14453125,
            "text": "multiple",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 9.0546875,
            "text": "refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -7.12890625,
            "text": "multiple myeloma (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -7.3671875,
            "text": "multiple myeloma (RRMM) after multicenter trials have demonstrated unprecedented results in this difficult-to-treat subgroup of patients.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.890625,
            "end_logit": -7.375,
            "text": "multiple myeloma (RR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.890625,
            "end_logit": -7.44140625,
            "text": "multiple myeloma (RRMM) after multicenter trials have demonstrated unprecedented results in this difficult-to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.560546875,
            "end_logit": -7.12890625,
            "text": "myeloma (",
            "probability": 0.0
        },
        {
            "start_logit": -1.560546875,
            "end_logit": -7.3671875,
            "text": "myeloma (RRMM) after multicenter trials have demonstrated unprecedented results in this difficult-to-treat subgroup of patients.",
            "probability": 0.0
        },
        {
            "start_logit": -1.560546875,
            "end_logit": -7.375,
            "text": "myeloma (RR",
            "probability": 0.0
        },
        {
            "start_logit": -1.560546875,
            "end_logit": -7.44140625,
            "text": "myeloma (RRMM) after multicenter trials have demonstrated unprecedented results in this difficult-to",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -2.14453125,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -4.22265625,
            "end_logit": -7.3671875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.12890625,
            "text": "refractory multiple myeloma (",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.3671875,
            "text": "refractory multiple myeloma (RRMM) after multicenter trials have demonstrated unprecedented results in this difficult-to-treat subgroup of patients.",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.375,
            "text": "refractory multiple myeloma (RR",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.44140625,
            "text": "refractory multiple myeloma (RRMM) after multicenter trials have demonstrated unprecedented results in this difficult-to",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -7.3671875,
            "text": "patients.",
            "probability": 0.0
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -7.3671875,
            "text": "difficult-to-treat subgroup of patients.",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_14": [
        {
            "start_logit": 8.9609375,
            "end_logit": 9.0703125,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.5029296875,
            "end_logit": 9.0703125,
            "text": "myeloma",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": 8.9609375,
            "end_logit": -1.966796875,
            "text": "multiple",
            "probability": 1.6033649444580078e-05
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 9.0703125,
            "text": "refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.0703125,
            "text": "CAR T-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 9.0703125,
            "text": "T-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 9.0703125,
            "text": ") CAR T-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.0703125,
            "text": "-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.0703125,
            "text": "cell therapy for relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.0703125,
            "text": "cel) CAR T-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.0703125,
            "text": "-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.0703125,
            "text": "ucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -1.966796875,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -1.966796875,
            "text": "CAR T-cell therapy for relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": -1.966796875,
            "text": "T-cell therapy for relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -1.966796875,
            "text": ") CAR T-cell therapy for relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -1.966796875,
            "text": "-cel) CAR T-cell therapy for relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -1.966796875,
            "text": "cell therapy for relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -1.966796875,
            "text": "cel) CAR T-cell therapy for relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -1.966796875,
            "text": "-cell therapy for relapsed and refractory multiple",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_15": [
        {
            "start_logit": 8.953125,
            "end_logit": 9.0625,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": 9.0625,
            "text": "myeloma",
            "probability": 2.7954578399658203e-05
        },
        {
            "start_logit": 8.953125,
            "end_logit": -2.021484375,
            "text": "multiple",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 9.0625,
            "text": "refractory multiple myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.38671875,
            "text": "multiple myeloma.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.48828125,
            "text": "multiple myeloma.METHODS: In this phase 2 study, we sought to confirm the efficacy and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.49609375,
            "text": "multiple myeloma.METHODS: In this phase 2 study, we sought to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.5078125,
            "text": "multiple myeloma.METHODS: In this phase 2 study",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.5078125,
            "text": "multiple myeloma.METHODS: In",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.515625,
            "text": "multiple myeloma.METHODS: In this",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.51953125,
            "text": "multiple myeloma.METHODS: In this phase 2 study, we sought",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.529296875,
            "end_logit": -7.38671875,
            "text": "myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": -7.48828125,
            "text": "myeloma.METHODS: In this phase 2 study, we sought to confirm the efficacy and",
            "probability": 0.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": -7.49609375,
            "text": "myeloma.METHODS: In this phase 2 study, we sought to",
            "probability": 0.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": -7.5078125,
            "text": "myeloma.METHODS: In this phase 2 study",
            "probability": 0.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": -7.5078125,
            "text": "myeloma.METHODS: In",
            "probability": 0.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": -7.515625,
            "text": "myeloma.METHODS: In this",
            "probability": 0.0
        },
        {
            "start_logit": -1.529296875,
            "end_logit": -7.51953125,
            "text": "myeloma.METHODS: In this phase 2 study, we sought",
            "probability": 0.0
        },
        {
            "start_logit": -7.0390625,
            "end_logit": -2.021484375,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -2.021484375,
            "text": "chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple",
            "probability": 0.0
        }
    ],
    "6200411cc9dfcb9c09000014_1": [
        {
            "start_logit": 9.21875,
            "end_logit": 9.1953125,
            "text": "JUCHMME",
            "probability": 1.0
        },
        {
            "start_logit": -1.2509765625,
            "end_logit": 9.1953125,
            "text": "E",
            "probability": 2.86102294921875e-05
        },
        {
            "start_logit": 9.21875,
            "end_logit": -1.447265625,
            "text": "JU",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": -5.78125,
            "end_logit": 9.1953125,
            "text": "CHMME",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.79296875,
            "end_logit": 9.1953125,
            "text": "MME",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.078125,
            "text": "JUCHMME:",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.4609375,
            "text": "JUCHMME: a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.859375,
            "text": "JUCHMM",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.9375,
            "text": "JUCHMME: a Java Utility",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.96875,
            "text": "JUCHMME: a Ja",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.01171875,
            "text": "JUCH",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.07421875,
            "text": "JUCHMME: a Java Utility for Class Hidden Markov Models and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.078125,
            "text": "JUCHMME: a Java Utility for Class Hidden Markov Models and Extensions for biological sequence analysis.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.09765625,
            "text": "JUCHMME: a Java",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.17578125,
            "text": "JUCHMME: a Java Utility for Class Hidden Markov Models",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.203125,
            "text": "JUCHMME: a Java Utility for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.20703125,
            "text": "JUCHMME: a Java Utility for Class Hidden Markov",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.21484375,
            "text": "JUCHMME: a Java Utility for Class Hidden Markov Models and Extensions for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.2265625,
            "text": "JUCHMME: a Java Utility for Class",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.234375,
            "text": "JUCHMME: a Java Utility for Class Hidden",
            "probability": 5.960464477539063e-08
        }
    ],
    "6200411cc9dfcb9c09000014_2": [
        {
            "start_logit": 9.171875,
            "end_logit": 9.1953125,
            "text": "JUCHMME",
            "probability": 1.0
        },
        {
            "start_logit": -1.2392578125,
            "end_logit": 9.1953125,
            "text": "E",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": 9.171875,
            "end_logit": -1.5537109375,
            "text": "JU",
            "probability": 2.1278858184814453e-05
        },
        {
            "start_logit": 9.171875,
            "end_logit": -5.7265625,
            "text": "JUCHMME is",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.76171875,
            "end_logit": 9.1953125,
            "text": "CHMME",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.0234375,
            "end_logit": 9.1953125,
            "text": "MME",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.6015625,
            "text": "JUCHMME is an",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.8671875,
            "text": "JUCHMME is an open",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.93359375,
            "text": "JUCHMME is an open-source",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.00390625,
            "text": "JUCHMM",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.03125,
            "text": "JUCHMME is an open-source software",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.03515625,
            "text": "JUCHMME is an open-source software package designed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.0546875,
            "text": "JUCHMME is an open-source software package",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.08984375,
            "text": "JUCHMME is an open-source software package designed to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.1484375,
            "text": "JUCHMME is an open-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.16015625,
            "text": "JUCH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.203125,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.2578125,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs) with a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.265625,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.30859375,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models",
            "probability": 5.960464477539063e-08
        }
    ],
    "6200411cc9dfcb9c09000014_3": [
        {
            "start_logit": 9.1875,
            "end_logit": 9.21875,
            "text": "JUCHMME",
            "probability": 1.0
        },
        {
            "start_logit": -1.1845703125,
            "end_logit": 9.21875,
            "text": "E",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.5126953125,
            "text": "JU",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": -5.68359375,
            "end_logit": 9.21875,
            "text": "CHMME",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.9140625,
            "end_logit": 9.21875,
            "text": "MME",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.45703125,
            "text": "JUCHMME is",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.0,
            "text": "JUCHMM",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.015625,
            "text": "JUCHMME is an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.08984375,
            "text": "JUCHMME is an open",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.12109375,
            "text": "JUCHMME is an open-source",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.16015625,
            "text": "JUCH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.171875,
            "text": "JUCHMME is an open-source software",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.1953125,
            "text": "JUCHMME is an open-source software package",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.234375,
            "text": "JUCHMME is an open-source software package designed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.26171875,
            "text": "JUCHMME is an open-source software package designed to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.265625,
            "text": "JUCHMME is an open-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.30078125,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.3125,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs) with a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.3515625,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.359375,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary",
            "probability": 5.960464477539063e-08
        }
    ],
    "54f2210164850a5854000001_1": [
        {
            "start_logit": 8.828125,
            "end_logit": 6.87890625,
            "text": "eight cysteine residues that form four",
            "probability": 0.6279296875
        },
        {
            "start_logit": 7.6875,
            "end_logit": 6.87890625,
            "text": "four",
            "probability": 0.20068359375
        },
        {
            "start_logit": 8.828125,
            "end_logit": 5.578125,
            "text": "eight",
            "probability": 0.171630859375
        },
        {
            "start_logit": 8.828125,
            "end_logit": -3.1875,
            "text": "eight cysteine residues that form four disulfide bridges, which stabilize a hairpin-shaped structure with two beta sheets.",
            "probability": 2.682209014892578e-05
        },
        {
            "start_logit": 7.6875,
            "end_logit": -3.1875,
            "text": "four disulfide bridges, which stabilize a hairpin-shaped structure with two beta sheets.",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": 8.828125,
            "end_logit": -5.1171875,
            "text": "eight cysteine residues",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.33984375,
            "text": "eight cysteine",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.3515625,
            "text": "eight cysteine residues that form four disulfide bridges,",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.5078125,
            "text": "eight cysteine residues that form four disulfide bridges",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.5625,
            "text": "eight cysteine residues that",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.64453125,
            "text": "eight cysteine residues that form four disulfide bridges, which stabilize a hairpin-shaped structure",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.6484375,
            "text": "eight cysteine residues that form four disulfide bridges, which stabilize a",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.703125,
            "text": "eight cysteine residues that form four disulfide bridges, which stabilize a hairpin",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.75390625,
            "text": "eight cysteine residues that form four disulfide bridges, which",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.76953125,
            "text": "eight cysteine residues that form four disulfide bridges, which stabilize a hairpin-shaped structure with",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.77734375,
            "text": "eight cysteine residues that form",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.77734375,
            "text": "eight cysteine residues that form four disulfide bridges, which stabilize",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.796875,
            "text": "eight cysteine residues that form four disulfide bridges, which stabilize a hairpin-shaped",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.84765625,
            "text": "eight cysteine residues that form four disulfide bridges, which stabilize a hairpin-",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.87109375,
            "text": "eight cysteine residues that form four disulfide bridges, which stabilize a hairpin-shaped structure with two beta sheets",
            "probability": 6.556510925292969e-07
        }
    ],
    "5a7428090384be9551000001_1": [
        {
            "start_logit": 9.171875,
            "end_logit": 9.0625,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": 9.171875,
            "end_logit": -1.482421875,
            "text": "pulmonary",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": -1.4619140625,
            "end_logit": 9.0625,
            "text": "embolism",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": 9.171875,
            "end_logit": -4.8046875,
            "text": "pulmonary embolism (PE",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -5.72265625,
            "text": "pulmonary embolism (PE)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.07421875,
            "end_logit": 9.0625,
            "text": "having pulmonary embolism",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.22265625,
            "text": "pulmonary embolism (PE) and who underwent CT pulmonary angiography",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.296875,
            "text": "pulmonary embolism (PE) and who underwent CT pulmonary angiography between January 1, 2011, and August 31, 2013.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.4453125,
            "text": "pulmonary embolism (PE) and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.50390625,
            "text": "pulmonary embolism (PE) and who underwent CT pulmonary angiography between",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 9.0625,
            "text": "suspected of having pulmonary embolism",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.671875,
            "text": "pulmonary embolism (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.6640625,
            "end_logit": 9.0625,
            "text": "patients who were suspected of having pulmonary embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.828125,
            "text": "pulmonary embolism (PE) and who underwent CT pulmonary angiography between January 1, 2011",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.84765625,
            "text": "pulmonary embolism (PE) and who underwent CT pulmonary angiography between January 1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 9.0625,
            "text": "of having pulmonary embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.4619140625,
            "end_logit": -4.8046875,
            "text": "embolism (PE",
            "probability": 0.0
        },
        {
            "start_logit": -1.4619140625,
            "end_logit": -5.72265625,
            "text": "embolism (PE)",
            "probability": 0.0
        },
        {
            "start_logit": -6.07421875,
            "end_logit": -1.482421875,
            "text": "having pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -1.4619140625,
            "end_logit": -6.22265625,
            "text": "embolism (PE) and who underwent CT pulmonary angiography",
            "probability": 0.0
        }
    ],
    "5a7428090384be9551000001_2": [
        {
            "start_logit": 8.9296875,
            "end_logit": 9.015625,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": -1.6494140625,
            "end_logit": 9.015625,
            "text": "embolism",
            "probability": 2.568960189819336e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -1.96484375,
            "text": "pulmonary",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.5390625,
            "text": "pulmonary embolism by means of a Wells score Bayesian model: results from the ACDC collaboration.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.65625,
            "text": "pulmonary embolism by",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.90625,
            "text": "pulmonary embolism by means of a Wells score",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -6.94921875,
            "text": "pulmonary embolism by means",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 9.015625,
            "text": "of pulmonary embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.0234375,
            "text": "pulmonary embolism by means of a Wells score Bayesian",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.03515625,
            "text": "pulmonary embolism by means of a Wells score Bayesian model: results from the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.08203125,
            "text": "pulmonary embolism by means of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.09765625,
            "text": "pulmonary embolism by means of a Wells score Bayesian model: results",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.09765625,
            "text": "pulmonary embolism by means of a Wells score Bayesian model: results from the ACDC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.1171875,
            "text": "pulmonary embolism by means of a Wells score Bayesian model",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.1171875,
            "text": "pulmonary embolism by means of a Wells score Bayesian model: results from",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.17578125,
            "text": "pulmonary embolism by means of a Wells score Bayesian model: results from the ACD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.20703125,
            "text": "pulmonary embolism by means of a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 9.015625,
            "text": "assessment of pulmonary embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.21875,
            "text": "pulmonary embolism by means of a Wells score Bayesian model: results from the ACDC collaboration",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.6494140625,
            "end_logit": -6.5390625,
            "text": "embolism by means of a Wells score Bayesian model: results from the ACDC collaboration.",
            "probability": 0.0
        }
    ],
    "5a7428090384be9551000001_3": [
        {
            "start_logit": 8.5859375,
            "end_logit": 7.9375,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -0.108642578125,
            "text": "pulmonary embolism (PE) by means of a Bayesian statistical model.METHODS: Wells criteria defined pretest probability",
            "probability": 0.00031757354736328125
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -2.529296875,
            "text": "pulmonary",
            "probability": 2.8192996978759766e-05
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -2.662109375,
            "text": "pulmonary embolism (PE)",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": -3.2109375,
            "end_logit": 7.9375,
            "text": "embolism",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -4.3046875,
            "text": "pulmonary embolism (PE",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -5.18359375,
            "text": "pulmonary embolism (PE) by means of a Bayesian statistical model.",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -5.18359375,
            "text": "pulmonary embolism (PE) by means of a Bayesian statistical model.METHODS: Wells criteria defined pretest probability.",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -5.5390625,
            "end_logit": 7.9375,
            "text": "Our objective was to evaluate the diagnostic value of computed tomography angiography (CTA) and ventilation perfusion (V/Q) scan in the assessment of pulmonary embolism",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.296875,
            "text": "pulmonary embolism (",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.84765625,
            "end_logit": 7.9375,
            "text": "of pulmonary embolism",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.78515625,
            "text": "pulmonary embolism (PE) by means of a Bayesian statistical model.METHODS: Wells criteria",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.81640625,
            "text": "pulmonary embolism (PE) by",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.8359375,
            "text": "pulmonary embolism (PE) by means of a Bayesian statistical",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.88671875,
            "text": "pulmonary embolism (PE) by means of a",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.921875,
            "text": "pulmonary embolism (PE) by means",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.96875,
            "text": "pulmonary embolism (PE) by means of",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.640625,
            "end_logit": 7.9375,
            "text": "objective was to evaluate the diagnostic value of computed tomography angiography (CTA) and ventilation perfusion (V/Q) scan in the assessment of pulmonary embolism",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 7.9375,
            "text": "in the assessment of pulmonary embolism",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.953125,
            "end_logit": 7.9375,
            "text": "assessment of pulmonary embolism",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5a7428090384be9551000001_4": [
        {
            "start_logit": 8.984375,
            "end_logit": 9.0078125,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": -1.642578125,
            "end_logit": 9.0078125,
            "text": "embolism",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -1.8671875,
            "text": "pulmonary",
            "probability": 1.8775463104248047e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -3.494140625,
            "text": "pulmonary embolism.",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 9.0078125,
            "text": "patients with pulmonary embolism",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.484375,
            "end_logit": 9.0078125,
            "text": "in patients with pulmonary embolism",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 9.0078125,
            "text": "Wells score and the Quanadli index in patients with pulmonary embolism",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 9.0078125,
            "text": "Correlation between the Wells score and the Quanadli index in patients with pulmonary embolism",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 9.0078125,
            "text": "Quanadli index in patients with pulmonary embolism",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 9.0078125,
            "text": "the Wells score and the Quanadli index in patients with pulmonary embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 9.0078125,
            "text": "with pulmonary embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 9.0078125,
            "text": "score and the Quanadli index in patients with pulmonary embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 9.0078125,
            "text": "adli index in patients with pulmonary embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 9.0078125,
            "text": "between the Wells score and the Quanadli index in patients with pulmonary embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.642578125,
            "end_logit": -3.494140625,
            "text": "embolism.",
            "probability": 0.0
        },
        {
            "start_logit": -6.36328125,
            "end_logit": -1.8671875,
            "text": "patients with pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -6.484375,
            "end_logit": -1.8671875,
            "text": "in patients with pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -6.5390625,
            "end_logit": -1.8671875,
            "text": "Wells score and the Quanadli index in patients with pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -4.92578125,
            "end_logit": -3.494140625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.61328125,
            "end_logit": -1.8671875,
            "text": "Correlation between the Wells score and the Quanadli index in patients with pulmonary",
            "probability": 0.0
        }
    ],
    "5a7428090384be9551000001_5": [
        {
            "start_logit": 8.9140625,
            "end_logit": 8.2421875,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -0.46484375,
            "text": "pulmonary embolism (PE)",
            "probability": 0.00016605854034423828
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -2.009765625,
            "text": "pulmonary",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": -2.646484375,
            "end_logit": 8.2421875,
            "text": "embolism",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -3.453125,
            "text": "pulmonary embolism (PE) with Wells scoring system is the first step towards diagnosis of PE.",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -5.31640625,
            "text": "pulmonary embolism (PE",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -5.13671875,
            "end_logit": 8.2421875,
            "text": "clinical probability of pulmonary embolism",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.13671875,
            "end_logit": 8.2421875,
            "text": "probability of pulmonary embolism",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.33984375,
            "text": "pulmonary embolism (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.48828125,
            "text": "pulmonary embolism (PE) with Wells scoring system",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.8203125,
            "text": "pulmonary embolism (PE) with Wells scoring system is the first step",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.1875,
            "end_logit": 8.2421875,
            "text": "Determining clinical probability of pulmonary embolism",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.8828125,
            "text": "pulmonary embolism (PE) with Wells scoring system is the first",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.90625,
            "text": "pulmonary embolism (PE) with",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.27734375,
            "end_logit": 8.2421875,
            "text": "of pulmonary embolism",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -6.984375,
            "text": "pulmonary embolism (PE) with Wells scoring system is",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.06640625,
            "text": "pulmonary embolism (PE) with Wells scoring system is the",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.13671875,
            "text": "pulmonary embolism (PE) with Wells scoring",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.22265625,
            "text": "pulmonary embolism (PE) with Wells scoring system is the first step towards diagnosis of PE",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9140625,
            "end_logit": -7.28515625,
            "text": "pulmonary embolism (PE) with Wells scoring system is the first step towards",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5a7428090384be9551000001_6": [
        {
            "start_logit": 9.1171875,
            "end_logit": 9.0703125,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": -1.5595703125,
            "end_logit": 9.0703125,
            "text": "embolism",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.630859375,
            "text": "pulmonary",
            "probability": 2.2470951080322266e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.98046875,
            "text": "pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.93359375,
            "end_logit": 9.0703125,
            "text": ", the pulmonary embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 9.0703125,
            "text": "the pulmonary embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 9.0703125,
            "text": "), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.0703125,
            "text": "), or high pretest probability (n=14, 10%), the pulmonary embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.28515625,
            "text": "pulmonary embolism prevalence was 2%, 15%, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.5595703125,
            "end_logit": -6.98046875,
            "text": "embolism prevalence was 2%, 15%, and 43%, respectively.",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -1.630859375,
            "text": ", the pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -1.630859375,
            "text": "the pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -7.00390625,
            "end_logit": -1.630859375,
            "text": "), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -1.630859375,
            "text": "), or high pretest probability (n=14, 10%), the pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -1.5595703125,
            "end_logit": -7.28515625,
            "text": "embolism prevalence was 2%, 15%, and",
            "probability": 0.0
        },
        {
            "start_logit": -4.30859375,
            "end_logit": -6.98046875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -6.98046875,
            "text": ", the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.",
            "probability": 0.0
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -6.98046875,
            "text": "the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.",
            "probability": 0.0
        },
        {
            "start_logit": -7.0234375,
            "end_logit": -6.9375,
            "text": "When Wells Criteria were trichotomized into",
            "probability": 0.0
        },
        {
            "start_logit": -7.0234375,
            "end_logit": -7.03515625,
            "text": "When Wells Criteria were trichotomized",
            "probability": 0.0
        }
    ],
    "5a7428090384be9551000001_7": [
        {
            "start_logit": 8.6875,
            "end_logit": 8.9453125,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": -1.7099609375,
            "end_logit": 8.9453125,
            "text": "embolism",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": 8.6875,
            "end_logit": -2.31640625,
            "text": "pulmonary",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -4.93359375,
            "end_logit": 8.9453125,
            "text": "risk stratify pretest probability in patients with suspected pulmonary embolism",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -5.1796875,
            "end_logit": 8.9453125,
            "text": "suspected pulmonary embolism",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -5.97265625,
            "end_logit": 8.9453125,
            "text": "patients with suspected pulmonary embolism",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.1875,
            "end_logit": 8.9453125,
            "text": ": Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.1953125,
            "end_logit": 8.9453125,
            "text": "Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.6875,
            "end_logit": -5.96484375,
            "text": "pulmonary embolism.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.5625,
            "end_logit": 8.9453125,
            "text": "with suspected pulmonary embolism",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 8.9453125,
            "text": "probability in patients with suspected pulmonary embolism",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.75,
            "end_logit": 8.9453125,
            "text": "in patients with suspected pulmonary embolism",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.953125,
            "end_logit": 8.9453125,
            "text": "CONCLUSION</b>: Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 8.9453125,
            "text": "</b>: Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.93359375,
            "end_logit": -2.31640625,
            "text": "risk stratify pretest probability in patients with suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -2.31640625,
            "text": "suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -1.7099609375,
            "end_logit": -5.96484375,
            "text": "embolism.",
            "probability": 0.0
        },
        {
            "start_logit": -5.97265625,
            "end_logit": -2.31640625,
            "text": "patients with suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -6.1875,
            "end_logit": -2.31640625,
            "text": ": Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -6.1953125,
            "end_logit": -2.31640625,
            "text": "Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary",
            "probability": 0.0
        }
    ],
    "5a7428090384be9551000001_8": [
        {
            "start_logit": 9.109375,
            "end_logit": 9.0703125,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": -1.546875,
            "end_logit": 9.0703125,
            "text": "embolism",
            "probability": 2.3365020751953125e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -1.64453125,
            "text": "pulmonary",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -5.4765625,
            "text": "pulmonary embolism.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 9.0703125,
            "text": "patients with suspected pulmonary embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 9.0703125,
            "text": "evaluation of patients with suspected pulmonary embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.03125,
            "end_logit": 9.0703125,
            "text": "Prospective validation of Wells Criteria in the evaluation of patients with suspected pulmonary embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 9.0703125,
            "text": "suspected pulmonary embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.125,
            "end_logit": 9.0703125,
            "text": "with suspected pulmonary embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 9.0703125,
            "text": "of patients with suspected pulmonary embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 9.0703125,
            "text": "in the evaluation of patients with suspected pulmonary embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 9.0703125,
            "text": "the evaluation of patients with suspected pulmonary embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.0703125,
            "text": "Wells Criteria in the evaluation of patients with suspected pulmonary embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.546875,
            "end_logit": -5.4765625,
            "text": "embolism.",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -1.64453125,
            "text": "patients with suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -1.64453125,
            "text": "evaluation of patients with suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -7.03125,
            "end_logit": -1.64453125,
            "text": "Prospective validation of Wells Criteria in the evaluation of patients with suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -7.12109375,
            "end_logit": -1.64453125,
            "text": "suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -7.125,
            "end_logit": -1.64453125,
            "text": "with suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -7.12890625,
            "end_logit": -1.64453125,
            "text": "of patients with suspected pulmonary",
            "probability": 0.0
        }
    ],
    "5e540c866d0a277941000052_1": [
        {
            "start_logit": 9.1015625,
            "end_logit": 8.8515625,
            "text": "saracatinib",
            "probability": 1.0
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -1.6484375,
            "text": "sar",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": -1.9921875,
            "end_logit": 8.8515625,
            "text": "tinib",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -4.4609375,
            "text": "saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -5.65625,
            "text": "saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.828125,
            "end_logit": 8.8515625,
            "text": "acatinib",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.08984375,
            "text": "saracatinib (AZD0530), a c-Src/Abl kinase inhibitor",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.09375,
            "text": "saracatinib (AZD0530), a c-Src/Abl kinase",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.12109375,
            "text": "saracatinib (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.140625,
            "text": "saracatinib (AZD0530), a c",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.22265625,
            "text": "saracatinib (AZD0530), a c-Src",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.2265625,
            "text": "saracatinib (AZD0530)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.3203125,
            "text": "saracatinib (AZD0530), a c-Src/Abl kinase inhibitor,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.421875,
            "text": "saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.46875,
            "text": "saracatinib (AZD0530), a c-Src/Abl",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.51171875,
            "text": "saracatinib (AZD0530",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.515625,
            "text": "saracatinib (AZD0530), a c-Src/",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.5703125,
            "text": "saracatinib (AZD05",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.58203125,
            "text": "saracatinib (AZD0530),",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.59765625,
            "text": "saracatinib (AZD0530), a c-",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5e540c866d0a277941000052_2": [
        {
            "start_logit": 9.1640625,
            "end_logit": 9.140625,
            "text": "saracatinib",
            "probability": 1.0
        },
        {
            "start_logit": -1.41015625,
            "end_logit": 9.140625,
            "text": "tinib",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -1.5234375,
            "text": "sar",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": -4.87109375,
            "end_logit": 9.140625,
            "text": "acatinib",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.8515625,
            "text": "saracatinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a NCI-N87 xenograft model.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.90625,
            "text": "saracatinib (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.140625,
            "text": "saracatinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.20703125,
            "text": "saracatinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a NCI-N87 xenograft model",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.2265625,
            "text": "saracatinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.140625,
            "text": ", saracatinib",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 9.140625,
            "text": "c-Src/Abl kinase inhibitor, saracatinib",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.41015625,
            "end_logit": -6.8515625,
            "text": "tinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a NCI-N87 xenograft model.",
            "probability": 0.0
        },
        {
            "start_logit": -1.41015625,
            "end_logit": -6.90625,
            "text": "tinib (",
            "probability": 0.0
        },
        {
            "start_logit": -1.41015625,
            "end_logit": -7.140625,
            "text": "tinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a",
            "probability": 0.0
        },
        {
            "start_logit": -1.41015625,
            "end_logit": -7.20703125,
            "text": "tinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a NCI-N87 xenograft model",
            "probability": 0.0
        },
        {
            "start_logit": -1.41015625,
            "end_logit": -7.2265625,
            "text": "tinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": -1.5234375,
            "text": ", sar",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -1.5234375,
            "text": "c-Src/Abl kinase inhibitor, sar",
            "probability": 0.0
        },
        {
            "start_logit": -4.34375,
            "end_logit": -6.8515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.87109375,
            "end_logit": -6.8515625,
            "text": "acatinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a NCI-N87 xenograft model.",
            "probability": 0.0
        }
    ],
    "5c73ad367c78d69471000099_1": [
        {
            "start_logit": 8.546875,
            "end_logit": 8.796875,
            "text": "platelet-derived growth factor receptor-\u03b1",
            "probability": 1.0
        },
        {
            "start_logit": -1.3935546875,
            "end_logit": 8.796875,
            "text": "\u03b1",
            "probability": 4.83393669128418e-05
        },
        {
            "start_logit": 8.546875,
            "end_logit": -1.876953125,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": 8.546875,
            "end_logit": -2.322265625,
            "text": "platelet",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": 8.546875,
            "end_logit": -3.294921875,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1)",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": 8.546875,
            "end_logit": -4.7265625,
            "text": "platelet-derived growth factor receptor",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 8.546875,
            "end_logit": -4.87109375,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1).",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.546875,
            "end_logit": -4.953125,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 8.546875,
            "end_logit": -5.29296875,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGF",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -5.453125,
            "text": "platelet-derived growth factor",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.0859375,
            "end_logit": 8.796875,
            "text": "to platelet-derived growth factor receptor-\u03b1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.125,
            "end_logit": 8.796875,
            "text": "derived growth factor receptor-\u03b1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -5.88671875,
            "text": "platelet-derived growth factor receptor-",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 8.796875,
            "text": "-derived growth factor receptor-\u03b1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.296875,
            "end_logit": 8.796875,
            "text": "growth factor receptor-\u03b1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -6.06640625,
            "text": "platelet-derived growth factor receptor-\u03b1 (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 8.796875,
            "text": "BACKGROUND AND OBJECTIVES: Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -6.984375,
            "text": "platelet-derived growth",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.234375,
            "end_logit": 8.796875,
            "text": "factor receptor-\u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 8.796875,
            "text": "receptor-\u03b1",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5c73ad367c78d69471000099_2": [
        {
            "start_logit": 9.21875,
            "end_logit": 8.90625,
            "text": "platelet-derived growth factor receptor-\u03b1",
            "probability": 1.0
        },
        {
            "start_logit": 9.21875,
            "end_logit": -1.2568359375,
            "text": "platelet",
            "probability": 3.8504600524902344e-05
        },
        {
            "start_logit": -1.59765625,
            "end_logit": 8.90625,
            "text": "\u03b1",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -4.90625,
            "end_logit": 8.90625,
            "text": "human platelet-derived growth factor receptor-\u03b1",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -5.83203125,
            "text": "platelet-derived growth factor receptor",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -5.9296875,
            "text": "platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.30078125,
            "text": "platelet-derived growth factor receptor-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.9921875,
            "end_logit": 8.90625,
            "text": "-derived growth factor receptor-\u03b1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.0078125,
            "end_logit": 8.90625,
            "text": "derived growth factor receptor-\u03b1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.375,
            "text": "platelet-derived growth factor receptor-\u03b1 with",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.58984375,
            "text": "platelet-derived growth factor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.3125,
            "end_logit": 8.90625,
            "text": "growth factor receptor-\u03b1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.78515625,
            "text": "platelet-derived growth factor receptor-\u03b1 with high",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.98046875,
            "text": "platelet-derived growth factor receptor-\u03b1 with high affinity",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.98828125,
            "text": "platelet-derived growth factor receptor-\u03b1 with high affinity and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 8.90625,
            "text": "factor receptor-\u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.765625,
            "end_logit": 8.90625,
            "text": "receptor-\u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 8.90625,
            "text": "external domain of human platelet-derived growth factor receptor-\u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 8.90625,
            "text": "domain of human platelet-derived growth factor receptor-\u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 8.90625,
            "text": "of human platelet-derived growth factor receptor-\u03b1",
            "probability": 5.960464477539063e-08
        }
    ],
    "5c73ad367c78d69471000099_3": [
        {
            "start_logit": 9.03125,
            "end_logit": 8.3828125,
            "text": "platelet-derived growth factor receptor \u03b1",
            "probability": 1.0
        },
        {
            "start_logit": 9.03125,
            "end_logit": -1.75390625,
            "text": "platelet",
            "probability": 4.00543212890625e-05
        },
        {
            "start_logit": -2.306640625,
            "end_logit": 8.3828125,
            "text": "\u03b1",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": 9.03125,
            "end_logit": -3.607421875,
            "text": "platelet-derived growth factor receptor",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -4.77734375,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGFR-\u03b1)",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -5.0546875,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGFR",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -5.15234375,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGFR-\u03b1",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -5.55859375,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGFR-\u03b1) preventing binding of its ligands and receptor activation.",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -5.80859375,
            "text": "platelet-derived growth factor receptor \u03b1 (",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -5.8515625,
            "text": "platelet-derived growth factor",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -5.9375,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGF",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.1328125,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGFR-",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.328125,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGFR-\u03b1) preventing",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.56640625,
            "text": "platelet-derived growth",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.234375,
            "end_logit": 8.3828125,
            "text": "-derived growth factor receptor \u03b1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.95703125,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGFR-\u03b1) preventing binding of its ligands and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.9765625,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGFR-\u03b1) preventing binding of its ligands and receptor activation",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -7.03515625,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGFR-\u03b1) preventing binding of its",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.40625,
            "end_logit": 8.3828125,
            "text": "derived growth factor receptor \u03b1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 8.3828125,
            "text": "to platelet-derived growth factor receptor \u03b1",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5c73ad367c78d69471000099_4": [
        {
            "start_logit": 8.796875,
            "end_logit": 8.8359375,
            "text": "platelet-derived growth factor receptor-\u03b1",
            "probability": 1.0
        },
        {
            "start_logit": -1.2900390625,
            "end_logit": 8.8359375,
            "text": "\u03b1",
            "probability": 4.1961669921875e-05
        },
        {
            "start_logit": 8.796875,
            "end_logit": -2.009765625,
            "text": "platelet",
            "probability": 1.9669532775878906e-05
        },
        {
            "start_logit": 8.796875,
            "end_logit": -2.02734375,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": 8.796875,
            "end_logit": -3.859375,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1)",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 8.796875,
            "end_logit": -4.8515625,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1).",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.796875,
            "end_logit": -4.97265625,
            "text": "platelet-derived growth factor receptor",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.796875,
            "end_logit": -5.01953125,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -5.66015625,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGF",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -5.921875,
            "text": "platelet-derived growth factor",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -6.015625,
            "text": "platelet-derived growth factor receptor-",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.1875,
            "end_logit": 8.8359375,
            "text": "-derived growth factor receptor-\u03b1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 8.8359375,
            "text": "derived growth factor receptor-\u03b1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -6.29296875,
            "text": "platelet-derived growth factor receptor-\u03b1 (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.421875,
            "end_logit": 8.8359375,
            "text": "growth factor receptor-\u03b1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.46484375,
            "end_logit": 8.8359375,
            "text": "to platelet-derived growth factor receptor-\u03b1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -6.87890625,
            "text": "platelet-derived growth",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.03515625,
            "end_logit": 8.8359375,
            "text": "OBJECTIVES Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 8.8359375,
            "text": "factor receptor-\u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 8.8359375,
            "text": "BACKGROUND AND OBJECTIVES Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5c73ad367c78d69471000099_5": [
        {
            "start_logit": 9.328125,
            "end_logit": 9.1484375,
            "text": "platelet-derived growth factor receptor \u03b1",
            "probability": 1.0
        },
        {
            "start_logit": 9.328125,
            "end_logit": -1.068359375,
            "text": "platelet",
            "probability": 3.6776065826416016e-05
        },
        {
            "start_logit": -1.255859375,
            "end_logit": 9.1484375,
            "text": "\u03b1",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": -4.76171875,
            "end_logit": 9.1484375,
            "text": "human platelet-derived growth factor receptor \u03b1",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 9.1484375,
            "text": "factor receptor \u03b1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 9.1484375,
            "text": "-derived growth factor receptor \u03b1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.4609375,
            "text": "platelet-derived growth factor receptor \u03b1,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 9.1484375,
            "text": "receptor \u03b1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4140625,
            "end_logit": 9.1484375,
            "text": "derived growth factor receptor \u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.6640625,
            "text": "platelet-derived growth factor receptor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.78125,
            "text": "platelet-derived growth",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 9.1484375,
            "text": "growth factor receptor \u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.95703125,
            "text": "platelet-derived growth factor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.0234375,
            "text": "platelet-derived",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.14453125,
            "text": "platelet-derived growth factor receptor \u03b1, plus doxorubicin significantly improved overall survival in patients with advanced soft-tissue sarcoma (STS) in a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.18359375,
            "text": "platelet-derived growth factor receptor \u03b1, plus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.18359375,
            "text": "platelet-derived growth factor receptor \u03b1, plus doxorubicin significantly improved overall survival in patients with advanced soft-tissue sarcoma (STS) in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.1953125,
            "text": "platelet-derived growth factor receptor \u03b1, plus doxorubicin significantly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.2109375,
            "text": "platelet-derived growth factor receptor \u03b1, plus doxorubicin significantly improved overall survival in patients with advanced soft-tissue sarcoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.23828125,
            "text": "platelet-derived growth factor receptor \u03b1, plus doxorubicin significantly improved overall survival in patients with advanced",
            "probability": 5.960464477539063e-08
        }
    ],
    "5c73ad367c78d69471000099_6": [
        {
            "start_logit": 9.2265625,
            "end_logit": 8.9453125,
            "text": "platelet-derived growth factor receptor-\u03b1",
            "probability": 1.0
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -1.3056640625,
            "text": "platelet",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": -1.6572265625,
            "end_logit": 8.9453125,
            "text": "\u03b1",
            "probability": 1.8775463104248047e-05
        },
        {
            "start_logit": -4.78125,
            "end_logit": 8.9453125,
            "text": "human platelet-derived growth factor receptor-\u03b1",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.35546875,
            "text": "platelet-derived growth factor receptor",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.40625,
            "text": "platelet-derived growth factor receptor-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.4296875,
            "text": "platelet-derived growth factor receptor-\u03b1 with",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.5,
            "text": "platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.5234375,
            "text": "platelet-derived growth factor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.30859375,
            "end_logit": 8.9453125,
            "text": "derived growth factor receptor-\u03b1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.38671875,
            "end_logit": 8.9453125,
            "text": "-derived growth factor receptor-\u03b1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 8.9453125,
            "text": "receptor-\u03b1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.74609375,
            "text": "platelet-derived growth",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.76171875,
            "text": "platelet-derived growth factor receptor-\u03b1 with high",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.859375,
            "text": "platelet-derived growth factor receptor-\u03b1 with high affinity",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 8.9453125,
            "text": "growth factor receptor-\u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.859375,
            "end_logit": 8.9453125,
            "text": "factor receptor-\u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.90234375,
            "end_logit": 8.9453125,
            "text": "external domain of human platelet-derived growth factor receptor-\u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 8.9453125,
            "text": "of human platelet-derived growth factor receptor-\u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 8.9453125,
            "text": "domain of human platelet-derived growth factor receptor-\u03b1",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5c73ad367c78d69471000099_7": [
        {
            "start_logit": 7.9453125,
            "end_logit": 8.09375,
            "text": "PDGFR\u03b1",
            "probability": 0.73974609375
        },
        {
            "start_logit": 7.59765625,
            "end_logit": 7.38671875,
            "text": "platelet-derived growth factor receptor-\u03b1",
            "probability": 0.259765625
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -2.54296875,
            "text": "PDGF",
            "probability": 1.800060272216797e-05
        },
        {
            "start_logit": -2.98046875,
            "end_logit": 8.09375,
            "text": "\u03b1",
            "probability": 1.33514404296875e-05
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -3.6484375,
            "text": "platelet",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -3.765625,
            "end_logit": 7.38671875,
            "text": "\u03b1",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -4.1875,
            "text": "platelet-derived growth factor",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -5.2890625,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -5.41015625,
            "text": "platelet-derived growth factor receptor",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -5.859375,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGF",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -6.2578125,
            "text": "PDGFR\u03b1 Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -5.94921875,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -6.3046875,
            "text": "PDGFR",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.77734375,
            "end_logit": 7.38671875,
            "text": "to platelet-derived growth factor receptor-\u03b1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -5.9921875,
            "text": "platelet-derived growth factor receptor-",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.5859375,
            "end_logit": 8.09375,
            "text": "-PDGFR\u03b1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -6.4453125,
            "text": "PDGFR\u03b1 Human",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -6.2578125,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1).",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.9453125,
            "end_logit": -6.65234375,
            "text": "PDGFR\u03b1 Human Monoclonal Antibody,",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.59765625,
            "end_logit": -6.484375,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1)",
            "probability": 2.384185791015625e-07
        }
    ],
    "5c8fe1f10101eac87000000a_1": [
        {
            "start_logit": 4.46875,
            "end_logit": 3.076171875,
            "text": "RUNX2 promotes astrocyte maturation.",
            "probability": 0.77734375
        },
        {
            "start_logit": 4.46875,
            "end_logit": 1.6884765625,
            "text": "RUNX2",
            "probability": 0.1934814453125
        },
        {
            "start_logit": 4.46875,
            "end_logit": -0.32568359375,
            "text": "RUNX2 promotes astrocyte maturation",
            "probability": 0.0258941650390625
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": 3.076171875,
            "text": "ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 0.0013141632080078125
        },
        {
            "start_logit": -2.681640625,
            "end_logit": 3.076171875,
            "text": ".",
            "probability": 0.0006089210510253906
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": 1.6884765625,
            "text": "ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2",
            "probability": 0.0003285408020019531
        },
        {
            "start_logit": 4.46875,
            "end_logit": -6.3359375,
            "text": "RUNX2 promotes astrocyte",
            "probability": 6.341934204101562e-05
        },
        {
            "start_logit": -4.98046875,
            "end_logit": 3.076171875,
            "text": ", we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 6.097555160522461e-05
        },
        {
            "start_logit": 4.46875,
            "end_logit": -6.49609375,
            "text": "RUNX2 promotes",
            "probability": 5.3822994232177734e-05
        },
        {
            "start_logit": -5.109375,
            "end_logit": 3.076171875,
            "text": "while RUNX2 promotes astrocyte maturation.",
            "probability": 5.3822994232177734e-05
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": -0.32568359375,
            "text": "ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation",
            "probability": 4.392862319946289e-05
        },
        {
            "start_logit": -5.32421875,
            "end_logit": 3.076171875,
            "text": "astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 4.32133674621582e-05
        },
        {
            "start_logit": -1.9111328125,
            "end_logit": -0.6494140625,
            "text": "ATF3 as drivers of astrocyte differentiation from neural precursor cells",
            "probability": 3.165006637573242e-05
        },
        {
            "start_logit": -5.703125,
            "end_logit": 3.076171875,
            "text": "astrocyte maturation.",
            "probability": 2.968311309814453e-05
        },
        {
            "start_logit": -6.03515625,
            "end_logit": 3.076171875,
            "text": "promotes astrocyte maturation.",
            "probability": 2.1219253540039062e-05
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 3.076171875,
            "text": "transcription factors that function at these elements, we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": -4.98046875,
            "end_logit": 1.6884765625,
            "text": ", we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": -6.41796875,
            "end_logit": 3.076171875,
            "text": "we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": -5.109375,
            "end_logit": 1.6884765625,
            "text": "while RUNX2",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": -6.66796875,
            "end_logit": 3.076171875,
            "text": "from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 1.1265277862548828e-05
        }
    ],
    "5e5438c3b761aafe09000003_1": [
        {
            "start_logit": 9.125,
            "end_logit": 8.921875,
            "text": "senktide",
            "probability": 1.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -1.646484375,
            "text": "sen",
            "probability": 2.568960189819336e-05
        },
        {
            "start_logit": -1.9521484375,
            "end_logit": 8.921875,
            "text": "ide",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": -5.80859375,
            "end_logit": 8.921875,
            "text": "ktide",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.39453125,
            "text": "senktide, highly potent",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.51953125,
            "text": "senktide, highly potent and selective NK3R agonist, resulted",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.625,
            "text": "senktide, highly potent and selective NK3R agonist,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.64453125,
            "text": "senktide, highly",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.71875,
            "text": "senktide, highly potent and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.76953125,
            "text": "senktide,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.88671875,
            "text": "senktide, highly potent and selective NK3R agonist",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.93359375,
            "text": "senktide, highly potent and selective NK3R",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.9609375,
            "text": "senktide, highly potent and selective NK3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.96875,
            "text": "senktide, highly potent and selective",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.78125,
            "end_logit": 8.921875,
            "text": "Administration of senktide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.00390625,
            "text": "senktide, highly potent and selective NK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.0546875,
            "text": "senktide, highly potent and selective NK3R agonist, resulted in increase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 8.921875,
            "text": "of senktide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.9521484375,
            "end_logit": -6.39453125,
            "text": "ide, highly potent",
            "probability": 0.0
        },
        {
            "start_logit": -6.78125,
            "end_logit": -1.646484375,
            "text": "Administration of sen",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_1": [
        {
            "start_logit": 9.328125,
            "end_logit": 9.15625,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.328125,
            "end_logit": -1.0048828125,
            "text": "alpha",
            "probability": 3.8504600524902344e-05
        },
        {
            "start_logit": -1.17578125,
            "end_logit": 9.15625,
            "text": "synuclein",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": -4.1640625,
            "end_logit": 9.15625,
            "text": ". Mutations in the alpha-synuclein",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -5.8671875,
            "end_logit": 9.15625,
            "text": "-synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.59765625,
            "text": "alpha-synuclein (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -6.92578125,
            "text": "alpha-synuclein (alphaSYN) gene cause Parkinson's disease, often associated with dementia.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.03515625,
            "text": "alpha-synuclein (alphaSYN",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.09765625,
            "text": "alpha-synuclein (alphaSYN) gene cause Parkinson's disease, often associated with dementia. Neuropathological",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.13671875,
            "text": "alpha-synuclein (alphaSYN)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 9.15625,
            "text": "the alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.30859375,
            "text": "alpha-synuclein (alphaSYN) gene cause Parkinson's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.3359375,
            "text": "alpha-synuclein (alphaSYN) gene cause Parkinson's disease, often associated with dementia. Neuropathologically",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.33984375,
            "text": "alpha-synuclein (alphaSYN) gene cause Parkinson's disease,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.33984375,
            "text": "alpha-synuclein (alphaS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.35546875,
            "text": "alpha-synuclein (alphaSYN) gene cause Parkinson'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.453125,
            "end_logit": 9.15625,
            "text": "neurological disorders of the elderly. Mutations in the alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.15625,
            "text": "disorders of the elderly. Mutations in the alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.1640625,
            "end_logit": -1.0048828125,
            "text": ". Mutations in the alpha",
            "probability": 0.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": -6.59765625,
            "text": "synuclein (",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_2": [
        {
            "start_logit": 9.3046875,
            "end_logit": 9.109375,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -1.1484375,
            "text": "alpha",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": -1.4169921875,
            "end_logit": 9.109375,
            "text": "synuclein",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -5.96875,
            "end_logit": 9.109375,
            "text": "-synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.359375,
            "text": "alpha-synuclein revealed",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.3671875,
            "text": "alpha-synuclein revealed LBs in 31 of 290 PSP cases (11%).",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.64453125,
            "text": "alpha-synuclein revealed LBs in 31",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.7734375,
            "text": "alpha-synuclein revealed LBs in 31 of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.84375,
            "text": "alpha-synuclein revealed LBs in 31 of 290 PSP cases (11",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.9375,
            "text": "alpha-synuclein revealed LBs in 31 of 290 PSP cases",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.95703125,
            "text": "alpha-synuclein revealed LBs in 31 of 290 PSP cases (11%)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.0,
            "text": "alpha-synuclein revealed LBs in 31 of 290",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 9.109375,
            "text": "for alpha-synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.015625,
            "text": "alpha-synuclein revealed LBs in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.02734375,
            "text": "alpha-synuclein revealed LBs in 31 of 290 PSP cases (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.04296875,
            "text": "alpha-synuclein revealed LBs in 31 of 290 PSP cases (11%",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.234375,
            "text": "alpha-synuclein revealed LBs",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.24609375,
            "text": "alpha-synuclein revealed LBs in 31 of 290 PSP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.109375,
            "text": "Immunohistochemistry for alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.4169921875,
            "end_logit": -6.359375,
            "text": "synuclein revealed",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_3": [
        {
            "start_logit": 9.3359375,
            "end_logit": 9.140625,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -1.0556640625,
            "text": "alpha",
            "probability": 3.7610530853271484e-05
        },
        {
            "start_logit": -1.31640625,
            "end_logit": 9.140625,
            "text": "synuclein",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": -6.609375,
            "end_logit": 9.140625,
            "text": "-synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -6.93359375,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited diffuse or granular alpha-synuclein-immunostaining.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.015625,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.05078125,
            "text": "alpha-synuclein-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.06640625,
            "text": "alpha-synuclein-positive LB-bearing neurons that",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.08203125,
            "text": "alpha-synuclein-positive",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.1015625,
            "text": "alpha-synuclein-positive LB-bearing neurons that were",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.12890625,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.18359375,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.19140625,
            "text": "alpha-synuclein-positive LB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.21484375,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost evenly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.23828125,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.265625,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited diffuse",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.31640625,
            "end_logit": -6.93359375,
            "text": "synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited diffuse or granular alpha-synuclein-immunostaining.",
            "probability": 0.0
        },
        {
            "start_logit": -1.31640625,
            "end_logit": -7.015625,
            "text": "synuclein-positive LB-bearing neurons that were almost evenly distributed, while",
            "probability": 0.0
        },
        {
            "start_logit": -1.31640625,
            "end_logit": -7.05078125,
            "text": "synuclein-",
            "probability": 0.0
        },
        {
            "start_logit": -1.31640625,
            "end_logit": -7.06640625,
            "text": "synuclein-positive LB-bearing neurons that",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_4": [
        {
            "start_logit": 9.1875,
            "end_logit": 9.046875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.4609375,
            "text": "alpha",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": -1.537109375,
            "end_logit": 9.046875,
            "text": "synuclein",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": -5.8046875,
            "end_logit": 9.046875,
            "text": "-synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.0078125,
            "text": "alpha-synuclein,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.046875,
            "text": "Lewy bodies, is considered to be alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.046875,
            "text": "with Lewy bodies, is considered to be alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.046875,
            "text": "Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.046875,
            "text": "bodies, is considered to be alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.046875,
            "text": "protein constituent of Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.537109375,
            "end_logit": -7.0078125,
            "text": "synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": -7.546875,
            "end_logit": -1.4609375,
            "text": "Lewy bodies, is considered to be alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -1.4609375,
            "text": "with Lewy bodies, is considered to be alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -1.4609375,
            "text": "Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -1.4609375,
            "text": "bodies, is considered to be alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -1.4609375,
            "text": "protein constituent of Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha",
            "probability": 0.0
        },
        {
            "start_logit": -5.8046875,
            "end_logit": -7.0078125,
            "text": "-synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": -7.546875,
            "end_logit": -6.3671875,
            "text": "Lewy bodies, is considered to",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -6.3671875,
            "text": "with Lewy bodies, is considered to",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -6.3671875,
            "text": "Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_5": [
        {
            "start_logit": 9.28125,
            "end_logit": 9.1484375,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.28125,
            "end_logit": -1.2099609375,
            "text": "alpha",
            "probability": 3.147125244140625e-05
        },
        {
            "start_logit": -1.2724609375,
            "end_logit": 9.1484375,
            "text": "synuclein",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": -5.7421875,
            "end_logit": 9.1484375,
            "text": "-synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -5.96875,
            "text": "alpha-synuclein (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.20703125,
            "text": "alpha-synuclein (alphaS) has been found to be a central constituent of LB.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.5390625,
            "text": "alpha-synuclein (alphaS)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.5546875,
            "text": "alpha-synuclein (alphaS) has",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.65625,
            "text": "alpha-synuclein (alphaS) has been",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.6875,
            "text": "alpha-synuclein (alphaS) has been found",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.6953125,
            "text": "alpha-synuclein (alphaS",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.80078125,
            "text": "alpha-synuclein (alphaS) has been found to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.83984375,
            "text": "alpha-synuclein (alphaS) has been found to be a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.9609375,
            "text": "alpha-synuclein (alphaS) has been found to be",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 9.1484375,
            "text": ", alpha-synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.01953125,
            "text": "alpha-synuclein (alpha",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.140625,
            "text": "alpha-synuclein (alphaS) has been found to be a central",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.14453125,
            "text": "alpha-synuclein (alphaS) has been found to be a central constituent",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.25,
            "end_logit": 9.1484375,
            "text": "Recently, alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.2724609375,
            "end_logit": -5.96875,
            "text": "synuclein (",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_6": [
        {
            "start_logit": 9.3125,
            "end_logit": 9.109375,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.3125,
            "end_logit": -1.1328125,
            "text": "alpha",
            "probability": 3.5643577575683594e-05
        },
        {
            "start_logit": -1.390625,
            "end_logit": 9.109375,
            "text": "synuclein",
            "probability": 2.2470951080322266e-05
        },
        {
            "start_logit": -5.74609375,
            "end_logit": 9.109375,
            "text": "-synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.50390625,
            "end_logit": 9.109375,
            "text": "to alpha-synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -6.828125,
            "text": "alpha-synuclein to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.28125,
            "text": "alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 9.109375,
            "text": "antibody AFshp raised specifically to alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.34765625,
            "text": "alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.3984375,
            "text": "alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein, an initial attempt is made",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 9.109375,
            "text": "having the antibody AFshp raised specifically to alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 9.109375,
            "text": "the antibody AFshp raised specifically to alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 9.109375,
            "text": "By having the antibody AFshp raised specifically to alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 9.109375,
            "text": "p raised specifically to alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 9.109375,
            "text": "AFshp raised specifically to alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.109375,
            "text": "specifically to alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.50390625,
            "end_logit": -1.1328125,
            "text": "to alpha",
            "probability": 0.0
        },
        {
            "start_logit": -1.390625,
            "end_logit": -6.828125,
            "text": "synuclein to",
            "probability": 0.0
        },
        {
            "start_logit": -7.1328125,
            "end_logit": -1.1328125,
            "text": "antibody AFshp raised specifically to alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.2109375,
            "end_logit": -1.1328125,
            "text": "having the antibody AFshp raised specifically to alpha",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_7": [
        {
            "start_logit": 9.234375,
            "end_logit": 9.0390625,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.234375,
            "end_logit": -1.3466796875,
            "text": "alpha",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -1.57421875,
            "end_logit": 9.0390625,
            "text": "synuclein",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -5.984375,
            "end_logit": 9.0390625,
            "text": "-synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.18359375,
            "text": "alpha-synuclein.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.37890625,
            "end_logit": 9.0390625,
            "text": "tau, and in LBs with antibody against alpha-synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 9.0390625,
            "text": "phosphorylated tau, and in LBs with antibody against alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 9.0390625,
            "text": "against alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.0390625,
            "text": "antibodies against phosphorylated tau, and in LBs with antibody against alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.0390625,
            "text": "in NFTs and neuropil threads with various antibodies against phosphorylated tau, and in LBs with antibody against alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.0390625,
            "text": "against phosphorylated tau, and in LBs with antibody against alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 9.0390625,
            "text": "various antibodies against phosphorylated tau, and in LBs with antibody against alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.0390625,
            "text": "NFTs and neuropil threads with various antibodies against phosphorylated tau, and in LBs with antibody against alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": 9.0390625,
            "text": "antibody against alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 9.0390625,
            "text": "in LBs with antibody against alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.37890625,
            "end_logit": -1.3466796875,
            "text": "tau, and in LBs with antibody against alpha",
            "probability": 0.0
        },
        {
            "start_logit": -1.57421875,
            "end_logit": -6.18359375,
            "text": "synuclein.",
            "probability": 0.0
        },
        {
            "start_logit": -7.0390625,
            "end_logit": -1.3466796875,
            "text": "phosphorylated tau, and in LBs with antibody against alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.2578125,
            "end_logit": -1.3466796875,
            "text": "against alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": -1.3466796875,
            "text": "antibodies against phosphorylated tau, and in LBs with antibody against alpha",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_8": [
        {
            "start_logit": 9.3359375,
            "end_logit": 9.1875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -1.0458984375,
            "text": "alpha",
            "probability": 3.5643577575683594e-05
        },
        {
            "start_logit": -1.1640625,
            "end_logit": 9.1875,
            "text": "synuclein",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": -6.12109375,
            "end_logit": 9.1875,
            "text": "-synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.0,
            "text": "alpha-synuclein gene on",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.04296875,
            "text": "alpha-synuclein gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.08984375,
            "text": "alpha-synuclein gene on chromosome 4q as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.27734375,
            "text": "alpha-synuclein gene on chromosome 4q as a locus for familial Lewy-body parkinsonism and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.28125,
            "text": "alpha-synuclein gene on chromosome 4q as a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 9.1875,
            "text": "The identification of the alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.2890625,
            "text": "alpha-synuclein gene on chromosome 4q",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 9.1875,
            "text": "the alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 9.1875,
            "text": "identification of the alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.1640625,
            "end_logit": -7.0,
            "text": "synuclein gene on",
            "probability": 0.0
        },
        {
            "start_logit": -7.13671875,
            "end_logit": -1.0458984375,
            "text": "The identification of the alpha",
            "probability": 0.0
        },
        {
            "start_logit": -1.1640625,
            "end_logit": -7.04296875,
            "text": "synuclein gene",
            "probability": 0.0
        },
        {
            "start_logit": -1.1640625,
            "end_logit": -7.08984375,
            "text": "synuclein gene on chromosome 4q as",
            "probability": 0.0
        },
        {
            "start_logit": -7.3203125,
            "end_logit": -1.0458984375,
            "text": "the alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -1.0458984375,
            "text": "identification of the alpha",
            "probability": 0.0
        },
        {
            "start_logit": -1.1640625,
            "end_logit": -7.27734375,
            "text": "synuclein gene on chromosome 4q as a locus for familial Lewy-body parkinsonism and",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_9": [
        {
            "start_logit": 9.203125,
            "end_logit": 8.9609375,
            "text": "Alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.203125,
            "end_logit": -1.435546875,
            "text": "Alpha",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -1.7734375,
            "end_logit": 8.9609375,
            "text": "synuclein",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": -6.1640625,
            "end_logit": 8.9609375,
            "text": "-synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.51953125,
            "text": "Alpha-synuclein cortical",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.18359375,
            "text": "Alpha-synuclein cortical Lewy bodies correlate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.3203125,
            "text": "Alpha-synuclein cortical Lewy bodies correlate with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.359375,
            "text": "Alpha-synuclein cortical Lewy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.375,
            "text": "Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.37890625,
            "text": "Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.38671875,
            "text": "Alpha-synuclein cortical Lewy bodies",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.39453125,
            "text": "Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -6.51953125,
            "text": "synuclein cortical",
            "probability": 0.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -7.18359375,
            "text": "synuclein cortical Lewy bodies correlate",
            "probability": 0.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -7.3203125,
            "text": "synuclein cortical Lewy bodies correlate with",
            "probability": 0.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -7.359375,
            "text": "synuclein cortical Lewy",
            "probability": 0.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -7.375,
            "text": "synuclein cortical Lewy bodies correlate with dementia in Parkinson's",
            "probability": 0.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -7.37890625,
            "text": "synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease",
            "probability": 0.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -7.38671875,
            "text": "synuclein cortical Lewy bodies",
            "probability": 0.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -7.39453125,
            "text": "synuclein cortical Lewy bodies correlate with dementia in Parkinson",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_10": [
        {
            "start_logit": 9.2421875,
            "end_logit": 9.0546875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -1.3388671875,
            "text": "alpha",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -1.5439453125,
            "end_logit": 9.0546875,
            "text": "synuclein",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -5.98828125,
            "text": "alpha-synuclein have",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.09375,
            "end_logit": 9.0546875,
            "text": "-synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.7578125,
            "text": "alpha-synuclein have suggested the possible importance of cortical Lewy bodies (CLBs) in the brains of demented patients with PD.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.0390625,
            "text": "alpha-synuclein have suggested",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.19140625,
            "text": "alpha-synuclein have suggested the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 9.0546875,
            "text": "of alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.26171875,
            "text": "alpha-synuclein have suggested the possible",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.28515625,
            "text": "alpha-synuclein have suggested the possible importance of cortical Lewy bodies (CLBs) in the brains of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.30078125,
            "text": "alpha-synuclein have suggested the possible importance of cortical Lewy bodies (CLBs) in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.33203125,
            "text": "alpha-synuclein have suggested the possible importance of cortical Lewy bodies (CLBs)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 9.0546875,
            "text": "in immunostaining of alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.0546875,
            "text": "recent advances in immunostaining of alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 9.0546875,
            "text": "immunostaining of alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.0546875,
            "text": "advances in immunostaining of alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.5439453125,
            "end_logit": -5.98828125,
            "text": "synuclein have",
            "probability": 0.0
        },
        {
            "start_logit": -1.5439453125,
            "end_logit": -6.7578125,
            "text": "synuclein have suggested the possible importance of cortical Lewy bodies (CLBs) in the brains of demented patients with PD.",
            "probability": 0.0
        },
        {
            "start_logit": -7.06640625,
            "end_logit": -1.3388671875,
            "text": "of alpha",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_11": [
        {
            "start_logit": 9.171875,
            "end_logit": 8.984375,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.171875,
            "end_logit": -1.5244140625,
            "text": "alpha",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": -1.69140625,
            "end_logit": 8.984375,
            "text": "synuclein",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": -6.25,
            "end_logit": 8.984375,
            "text": "-synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.96484375,
            "text": "alpha-synuclein are",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.16796875,
            "text": "alpha-synuclein are highly sensitive (91%)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.203125,
            "text": "alpha-synuclein are highly sensitive (91%) and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.22265625,
            "text": "alpha-synuclein are highly sensitive (91%",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.2890625,
            "text": "alpha-synuclein are highly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.359375,
            "text": "alpha-synuclein are highly sensitive (91%) and specific (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.36328125,
            "text": "alpha-synuclein are highly sensitive (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 8.984375,
            "text": "for alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.69140625,
            "end_logit": -6.96484375,
            "text": "synuclein are",
            "probability": 0.0
        },
        {
            "start_logit": -1.69140625,
            "end_logit": -7.16796875,
            "text": "synuclein are highly sensitive (91%)",
            "probability": 0.0
        },
        {
            "start_logit": -1.69140625,
            "end_logit": -7.203125,
            "text": "synuclein are highly sensitive (91%) and",
            "probability": 0.0
        },
        {
            "start_logit": -1.69140625,
            "end_logit": -7.22265625,
            "text": "synuclein are highly sensitive (91%",
            "probability": 0.0
        },
        {
            "start_logit": -1.69140625,
            "end_logit": -7.2890625,
            "text": "synuclein are highly",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -1.5244140625,
            "text": "for alpha",
            "probability": 0.0
        },
        {
            "start_logit": -1.69140625,
            "end_logit": -7.359375,
            "text": "synuclein are highly sensitive (91%) and specific (",
            "probability": 0.0
        },
        {
            "start_logit": -1.69140625,
            "end_logit": -7.36328125,
            "text": "synuclein are highly sensitive (",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_12": [
        {
            "start_logit": 9.1796875,
            "end_logit": 9.046875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -1.4912109375,
            "text": "alpha",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": -1.525390625,
            "end_logit": 9.046875,
            "text": "synuclein",
            "probability": 2.2649765014648438e-05
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 9.046875,
            "text": "-synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.8515625,
            "text": "alpha-synuclein antibodies in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.0625,
            "text": "alpha-synuclein antibodies",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.19140625,
            "text": "alpha-synuclein antibodies in patients with PD are a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.203125,
            "text": "alpha-synuclein antibodies in patients with PD are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.265625,
            "text": "alpha-synuclein antibodies in patients",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.31640625,
            "text": "alpha-synuclein antibodies in patients with PD are a more",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.3203125,
            "text": "alpha-synuclein antibodies in patients with PD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -7.3515625,
            "text": "alpha-synuclein antibodies in patients with PD are a more sensitive and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 9.046875,
            "text": "by alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.046875,
            "text": "Bs detected by alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.525390625,
            "end_logit": -6.8515625,
            "text": "synuclein antibodies in",
            "probability": 0.0
        },
        {
            "start_logit": -1.525390625,
            "end_logit": -7.0625,
            "text": "synuclein antibodies",
            "probability": 0.0
        },
        {
            "start_logit": -1.525390625,
            "end_logit": -7.19140625,
            "text": "synuclein antibodies in patients with PD are a",
            "probability": 0.0
        },
        {
            "start_logit": -1.525390625,
            "end_logit": -7.203125,
            "text": "synuclein antibodies in patients with PD are",
            "probability": 0.0
        },
        {
            "start_logit": -1.525390625,
            "end_logit": -7.265625,
            "text": "synuclein antibodies in patients",
            "probability": 0.0
        },
        {
            "start_logit": -1.525390625,
            "end_logit": -7.31640625,
            "text": "synuclein antibodies in patients with PD are a more",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_13": [
        {
            "start_logit": 9.1953125,
            "end_logit": 9.0078125,
            "text": "alpha-Synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -1.4619140625,
            "text": "alpha",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": -1.6689453125,
            "end_logit": 9.0078125,
            "text": "Synuclein",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": -6.03515625,
            "end_logit": 9.0078125,
            "text": "-Synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.8046875,
            "text": "alpha-Synuclein immunoreactivity in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.91796875,
            "text": "alpha-Synuclein immunoreactivity",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.34375,
            "text": "alpha-Synuclein immunoreactivity in dementia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6689453125,
            "end_logit": -6.8046875,
            "text": "Synuclein immunoreactivity in",
            "probability": 0.0
        },
        {
            "start_logit": -1.6689453125,
            "end_logit": -6.91796875,
            "text": "Synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": -1.6689453125,
            "end_logit": -7.34375,
            "text": "Synuclein immunoreactivity in dementia",
            "probability": 0.0
        },
        {
            "start_logit": -6.03515625,
            "end_logit": -6.8046875,
            "text": "-Synuclein immunoreactivity in",
            "probability": 0.0
        },
        {
            "start_logit": -6.03515625,
            "end_logit": -6.91796875,
            "text": "-Synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": -6.03515625,
            "end_logit": -7.34375,
            "text": "-Synuclein immunoreactivity in dementia",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_14": [
        {
            "start_logit": 9.28125,
            "end_logit": 9.09375,
            "text": "alpha-Synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.28125,
            "end_logit": -1.21484375,
            "text": "alpha",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": 9.09375,
            "text": "Synuclein",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 9.28125,
            "end_logit": -5.46875,
            "text": "alpha-Synuclein is",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.83984375,
            "end_logit": 9.09375,
            "text": "-Synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.62890625,
            "text": "alpha-Synuclein is a presynaptic protein recently identified as a specific component of Lewy bodies (LB) and Lewy neurites.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.64453125,
            "text": "alpha-Synuclein is a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.73828125,
            "text": "alpha-Synuclein is a presynaptic protein recently",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.99609375,
            "text": "alpha-Synuclein is a presynaptic protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.06640625,
            "text": "alpha-Synuclein is a presynaptic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.234375,
            "text": "alpha-Synuclein is a presynaptic protein recently identified as a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.25390625,
            "text": "alpha-Synuclein is a presynaptic protein recently identified as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.28515625,
            "text": "alpha-Synuclein is a presynaptic protein recently identified",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.34375,
            "text": "alpha-Synuclein is a presynaptic protein recently identified as a specific component of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -5.46875,
            "text": "Synuclein is",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -6.62890625,
            "text": "Synuclein is a presynaptic protein recently identified as a specific component of Lewy bodies (LB) and Lewy neurites.",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -6.64453125,
            "text": "Synuclein is a",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -6.73828125,
            "text": "Synuclein is a presynaptic protein recently",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -6.99609375,
            "text": "Synuclein is a presynaptic protein",
            "probability": 0.0
        },
        {
            "start_logit": -1.4658203125,
            "end_logit": -7.06640625,
            "text": "Synuclein is a presynaptic",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_15": [
        {
            "start_logit": 9.2734375,
            "end_logit": 9.078125,
            "text": "alpha-Synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -1.2353515625,
            "text": "alpha",
            "probability": 3.349781036376953e-05
        },
        {
            "start_logit": -1.5029296875,
            "end_logit": 9.078125,
            "text": "Synuclein",
            "probability": 2.110004425048828e-05
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 9.078125,
            "text": "-Synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -6.58984375,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from globose tangles.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -6.71484375,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -6.75,
            "text": "alpha-Synuclein immunostaining was",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -6.84765625,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -6.91015625,
            "text": "alpha-Synuclein immunostaining was more",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -6.9140625,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.109375,
            "text": "alpha-Synuclein immunostaining",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.15625,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.16796875,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.3046875,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.5029296875,
            "end_logit": -6.58984375,
            "text": "Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from globose tangles.",
            "probability": 0.0
        },
        {
            "start_logit": -1.5029296875,
            "end_logit": -6.71484375,
            "text": "Synuclein immunostaining was more specific than ubiquitin",
            "probability": 0.0
        },
        {
            "start_logit": -1.5029296875,
            "end_logit": -6.75,
            "text": "Synuclein immunostaining was",
            "probability": 0.0
        },
        {
            "start_logit": -1.5029296875,
            "end_logit": -6.84765625,
            "text": "Synuclein immunostaining was more specific than ubiquitin immunostaining in",
            "probability": 0.0
        },
        {
            "start_logit": -1.5029296875,
            "end_logit": -6.91015625,
            "text": "Synuclein immunostaining was more",
            "probability": 0.0
        },
        {
            "start_logit": -1.5029296875,
            "end_logit": -6.9140625,
            "text": "Synuclein immunostaining was more specific than ubiquitin immunostaining in that",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_16": [
        {
            "start_logit": 9.3359375,
            "end_logit": 9.0703125,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -1.041015625,
            "text": "alpha",
            "probability": 4.07099723815918e-05
        },
        {
            "start_logit": -1.4697265625,
            "end_logit": 9.0703125,
            "text": "synuclein",
            "probability": 2.0325183868408203e-05
        },
        {
            "start_logit": -3.642578125,
            "end_logit": 9.0703125,
            "text": "as alpha-synuclein",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -5.04296875,
            "end_logit": 9.0703125,
            "text": "known as alpha-synuclein",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.78515625,
            "end_logit": 9.0703125,
            "text": "-synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.796875,
            "end_logit": 9.0703125,
            "text": "also known as alpha-synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.140625,
            "text": "alpha-synuclein) is a presynaptic terminal molecule that abnormally accumulates in the plaques of Alzheimer's disease (AD) and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.234375,
            "text": "alpha-synuclein)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.2890625,
            "text": "alpha-synuclein) is a presynaptic terminal molecule that abnormally accumulates in the plaques of Alzheimer's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.33203125,
            "text": "alpha-synuclein) is a presynaptic terminal molecule that abnormally accumulates in the plaques of Alzheimer's disease (AD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.3359375,
            "text": "alpha-synuclein) is a presynaptic terminal molecule that abnormally accumulates in the plaques of Alzheimer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -7.34375,
            "text": "alpha-synuclein) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.642578125,
            "end_logit": -1.041015625,
            "text": "as alpha",
            "probability": 0.0
        },
        {
            "start_logit": -5.04296875,
            "end_logit": -1.041015625,
            "text": "known as alpha",
            "probability": 0.0
        },
        {
            "start_logit": -5.796875,
            "end_logit": -1.041015625,
            "text": "also known as alpha",
            "probability": 0.0
        },
        {
            "start_logit": -1.4697265625,
            "end_logit": -7.140625,
            "text": "synuclein) is a presynaptic terminal molecule that abnormally accumulates in the plaques of Alzheimer's disease (AD) and",
            "probability": 0.0
        },
        {
            "start_logit": -1.4697265625,
            "end_logit": -7.234375,
            "text": "synuclein)",
            "probability": 0.0
        },
        {
            "start_logit": -1.4697265625,
            "end_logit": -7.2890625,
            "text": "synuclein) is a presynaptic terminal molecule that abnormally accumulates in the plaques of Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": -1.4697265625,
            "end_logit": -7.33203125,
            "text": "synuclein) is a presynaptic terminal molecule that abnormally accumulates in the plaques of Alzheimer's disease (AD",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_17": [
        {
            "start_logit": 9.21875,
            "end_logit": 9.1015625,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.21875,
            "end_logit": -1.33203125,
            "text": "alpha",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": -1.359375,
            "end_logit": 9.1015625,
            "text": "synuclein",
            "probability": 2.568960189819336e-05
        },
        {
            "start_logit": -5.53515625,
            "end_logit": 9.1015625,
            "text": "-synuclein",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.17578125,
            "end_logit": 9.1015625,
            "text": "/alpha-synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.27734375,
            "end_logit": 9.1015625,
            "text": "To better understand the distribution of NACP/alpha-synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.671875,
            "end_logit": 9.1015625,
            "text": "better understand the distribution of NACP/alpha-synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.89453125,
            "text": "alpha-synuclein and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.01171875,
            "text": "alpha-synuclein and its fragments in the LB-bearing neurons and neurites, as well",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.01953125,
            "text": "alpha-synuclein and its fragments",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 9.1015625,
            "text": "understand the distribution of NACP/alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.17578125,
            "end_logit": -1.33203125,
            "text": "/alpha",
            "probability": 0.0
        },
        {
            "start_logit": -6.27734375,
            "end_logit": -1.33203125,
            "text": "To better understand the distribution of NACP/alpha",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -1.33203125,
            "text": "better understand the distribution of NACP/alpha",
            "probability": 0.0
        },
        {
            "start_logit": -1.359375,
            "end_logit": -6.89453125,
            "text": "synuclein and",
            "probability": 0.0
        },
        {
            "start_logit": -1.359375,
            "end_logit": -7.01171875,
            "text": "synuclein and its fragments in the LB-bearing neurons and neurites, as well",
            "probability": 0.0
        },
        {
            "start_logit": -1.359375,
            "end_logit": -7.01953125,
            "text": "synuclein and its fragments",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -1.33203125,
            "text": "understand the distribution of NACP/alpha",
            "probability": 0.0
        },
        {
            "start_logit": -3.724609375,
            "end_logit": -6.26171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.53515625,
            "end_logit": -6.89453125,
            "text": "-synuclein and",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_18": [
        {
            "start_logit": 9.296875,
            "end_logit": 9.1328125,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.296875,
            "end_logit": -1.18359375,
            "text": "alpha",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": -1.3681640625,
            "end_logit": 9.1328125,
            "text": "synuclein",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": -6.125,
            "end_logit": 9.1328125,
            "text": "-synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.83984375,
            "text": "alpha-synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material in the LBs and as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.015625,
            "text": "alpha-synuclein immunoreactivity was",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.09375,
            "text": "alpha-synuclein immunoreactivity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.1171875,
            "text": "alpha-synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material in the LBs and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.1171875,
            "text": "alpha-synuclein immunoreactivity was diffusely",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 9.1328125,
            "text": "/alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.265625,
            "text": "alpha-synuclein immunoreactivity was diffusely distributed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.28125,
            "text": "alpha-synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material in the LBs and as small clusters",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.296875,
            "text": "alpha-synuclein immunoreactivity was diffusely distributed within",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 9.1328125,
            "text": "P/alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 9.1328125,
            "text": "NACP/alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.1328125,
            "text": "that NACP/alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.1328125,
            "text": "Ultrastructural analysis revealed that NACP/alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.99609375,
            "end_logit": -1.18359375,
            "text": "/alpha",
            "probability": 0.0
        },
        {
            "start_logit": -1.3681640625,
            "end_logit": -6.81640625,
            "text": "synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material in the LBs and as small clusters in the filaments of LBs and neurites.",
            "probability": 0.0
        },
        {
            "start_logit": -1.3681640625,
            "end_logit": -6.83984375,
            "text": "synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material in the LBs and as",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_19": [
        {
            "start_logit": 9.25,
            "end_logit": 9.09375,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.25,
            "end_logit": -0.171630859375,
            "text": "alpha-synuclein might",
            "probability": 9.459257125854492e-05
        },
        {
            "start_logit": 9.25,
            "end_logit": -1.296875,
            "text": "alpha",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -1.4287109375,
            "end_logit": 9.09375,
            "text": "synuclein",
            "probability": 2.300739288330078e-05
        },
        {
            "start_logit": 9.25,
            "end_logit": -5.94140625,
            "text": "alpha-synuclein might play an important role in the pathogenesis of disorders associated with LBs.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.97265625,
            "end_logit": 9.09375,
            "text": "-synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.28125,
            "end_logit": 9.09375,
            "text": "/alpha-synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.48828125,
            "text": "alpha-synuclein might play",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 9.09375,
            "text": "results support the view that aggregated NACP/alpha-synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.65234375,
            "text": "alpha-synuclein might play an",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.75390625,
            "text": "alpha-synuclein might play an important",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.7890625,
            "text": "alpha-synuclein might play an important role in the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.63671875,
            "end_logit": 9.09375,
            "text": "These results support the view that aggregated NACP/alpha-synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.8125,
            "text": "alpha-synuclein might play an important role",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.97265625,
            "text": "alpha-synuclein might play an important role in the pathogenesis of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.01171875,
            "text": "alpha-synuclein might play an important role in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.01953125,
            "text": "alpha-synuclein might play an important role in the pathogenesis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 9.09375,
            "text": "the view that aggregated NACP/alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 9.09375,
            "text": "support the view that aggregated NACP/alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 9.09375,
            "text": "view that aggregated NACP/alpha-synuclein",
            "probability": 5.960464477539063e-08
        }
    ],
    "53189656b166e2b80600001c_20": [
        {
            "start_logit": 9.1875,
            "end_logit": 8.96875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.486328125,
            "text": "alpha",
            "probability": 2.8848648071289062e-05
        },
        {
            "start_logit": -1.755859375,
            "end_logit": 8.96875,
            "text": "synuclein",
            "probability": 1.7642974853515625e-05
        },
        {
            "start_logit": -6.0546875,
            "end_logit": 8.96875,
            "text": "-synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.2734375,
            "text": "alpha-synuclein immunoreactivity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.96875,
            "text": "Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.755859375,
            "end_logit": -7.2734375,
            "text": "synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -1.486328125,
            "text": "Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha",
            "probability": 0.0
        },
        {
            "start_logit": -6.0546875,
            "end_logit": -7.2734375,
            "text": "-synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -7.1484375,
            "text": "Lewy bodies and",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -7.2734375,
            "text": "Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_21": [
        {
            "start_logit": 9.296875,
            "end_logit": 9.0859375,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.296875,
            "end_logit": -1.189453125,
            "text": "alpha",
            "probability": 3.4809112548828125e-05
        },
        {
            "start_logit": -1.484375,
            "end_logit": 9.0859375,
            "text": "synuclein",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": -5.9453125,
            "end_logit": 9.0859375,
            "text": "-synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.11328125,
            "text": "alpha-synuclein immunoreactivity",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.18359375,
            "text": "alpha-synuclein immunoreactivity in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.234375,
            "text": "alpha-synuclein immunoreactivity in nigral Lewy bodies, pale bodies and abnormal neurites.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.25,
            "text": "alpha-synuclein immunoreactivity in nigra",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.484375,
            "end_logit": -7.11328125,
            "text": "synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": -1.484375,
            "end_logit": -7.18359375,
            "text": "synuclein immunoreactivity in",
            "probability": 0.0
        },
        {
            "start_logit": -1.484375,
            "end_logit": -7.234375,
            "text": "synuclein immunoreactivity in nigral Lewy bodies, pale bodies and abnormal neurites.",
            "probability": 0.0
        },
        {
            "start_logit": -1.484375,
            "end_logit": -7.25,
            "text": "synuclein immunoreactivity in nigra",
            "probability": 0.0
        },
        {
            "start_logit": -4.59765625,
            "end_logit": -7.234375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -7.11328125,
            "text": "-synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -7.18359375,
            "text": "-synuclein immunoreactivity in",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -7.234375,
            "text": "-synuclein immunoreactivity in nigral Lewy bodies, pale bodies and abnormal neurites.",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -7.25,
            "text": "-synuclein immunoreactivity in nigra",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -7.234375,
            "text": "pale bodies and abnormal neurites.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -7.234375,
            "text": "Lewy bodies, pale bodies and abnormal neurites.",
            "probability": 0.0
        },
        {
            "start_logit": -7.65234375,
            "end_logit": -7.234375,
            "text": "bodies and abnormal neurites.",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_22": [
        {
            "start_logit": 9.3125,
            "end_logit": 9.140625,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.3125,
            "end_logit": -1.142578125,
            "text": "alpha",
            "probability": 3.427267074584961e-05
        },
        {
            "start_logit": -1.33203125,
            "end_logit": 9.140625,
            "text": "synuclein",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": -5.96875,
            "end_logit": 9.140625,
            "text": "-synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.03515625,
            "text": "alpha-synuclein immunoreactivity in cortical Lewy bodies and CA2-3 neurites.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.05078125,
            "text": "alpha-synuclein immunoreactivity",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.171875,
            "text": "alpha-synuclein immunoreactivity in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21875,
            "end_logit": 9.140625,
            "text": "as alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.140625,
            "text": "DLB cases demonstrated these findings as well as alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.140625,
            "text": "findings as well as alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.140625,
            "text": "these findings as well as alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.140625,
            "text": "as well as alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21875,
            "end_logit": -1.142578125,
            "text": "as alpha",
            "probability": 0.0
        },
        {
            "start_logit": -1.33203125,
            "end_logit": -7.03515625,
            "text": "synuclein immunoreactivity in cortical Lewy bodies and CA2-3 neurites.",
            "probability": 0.0
        },
        {
            "start_logit": -1.33203125,
            "end_logit": -7.05078125,
            "text": "synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": -1.33203125,
            "end_logit": -7.171875,
            "text": "synuclein immunoreactivity in",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -1.142578125,
            "text": "DLB cases demonstrated these findings as well as alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -1.142578125,
            "text": "findings as well as alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -1.142578125,
            "text": "these findings as well as alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -1.142578125,
            "text": "as well as alpha",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_23": [
        {
            "start_logit": 9.28125,
            "end_logit": 9.125,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 9.28125,
            "end_logit": -1.2373046875,
            "text": "alpha",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": -1.3857421875,
            "end_logit": 9.125,
            "text": "synuclein",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.08203125,
            "text": "alpha-synuclein in the pathogenesis of PD and the neuropathologically related disorder DLB.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.01171875,
            "end_logit": 9.125,
            "text": "-synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.6953125,
            "text": "alpha-synuclein in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 9.125,
            "text": ", even in sporadic cases, there is an early and direct role for alpha-synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.00390625,
            "text": "alpha-synuclein in the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.05078125,
            "text": "alpha-synuclein in the pathogenesis of PD and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 9.125,
            "text": "These results suggest that, even in sporadic cases, there is an early and direct role for alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.125,
            "text": "results suggest that, even in sporadic cases, there is an early and direct role for alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 9.125,
            "text": ", there is an early and direct role for alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.125,
            "text": "for alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 9.125,
            "text": "in sporadic cases, there is an early and direct role for alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 9.125,
            "text": "that, even in sporadic cases, there is an early and direct role for alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.125,
            "text": "sporadic cases, there is an early and direct role for alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.125,
            "text": "there is an early and direct role for alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3857421875,
            "end_logit": -6.08203125,
            "text": "synuclein in the pathogenesis of PD and the neuropathologically related disorder DLB.",
            "probability": 0.0
        },
        {
            "start_logit": -6.77734375,
            "end_logit": -1.2373046875,
            "text": ", even in sporadic cases, there is an early and direct role for alpha",
            "probability": 0.0
        },
        {
            "start_logit": -1.3857421875,
            "end_logit": -6.6953125,
            "text": "synuclein in",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_1": [
        {
            "start_logit": 8.7734375,
            "end_logit": 8.765625,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -2.25390625,
            "end_logit": 8.765625,
            "text": "domain",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -2.35546875,
            "text": "SET",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -6.50390625,
            "text": "SET domain that",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 8.765625,
            "text": "C-terminal SET domain",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.18359375,
            "text": "SET domain that catalyzes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.203125,
            "text": "SET domain that catalyzes methylation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.20703125,
            "text": "SET domain that catalyzes methylation of histone H3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.21484375,
            "text": "SET domain that catalyzes methylation of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.29296875,
            "text": "SET domain that catalyzes methylation of histone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 8.765625,
            "text": "terminal SET domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.25390625,
            "end_logit": -6.50390625,
            "text": "domain that",
            "probability": 0.0
        },
        {
            "start_logit": -6.74609375,
            "end_logit": -2.35546875,
            "text": "C-terminal SET",
            "probability": 0.0
        },
        {
            "start_logit": -2.25390625,
            "end_logit": -7.18359375,
            "text": "domain that catalyzes",
            "probability": 0.0
        },
        {
            "start_logit": -2.25390625,
            "end_logit": -7.203125,
            "text": "domain that catalyzes methylation",
            "probability": 0.0
        },
        {
            "start_logit": -2.25390625,
            "end_logit": -7.20703125,
            "text": "domain that catalyzes methylation of histone H3",
            "probability": 0.0
        },
        {
            "start_logit": -2.25390625,
            "end_logit": -7.21484375,
            "text": "domain that catalyzes methylation of",
            "probability": 0.0
        },
        {
            "start_logit": -2.25390625,
            "end_logit": -7.29296875,
            "text": "domain that catalyzes methylation of histone",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -2.35546875,
            "text": "terminal SET",
            "probability": 0.0
        },
        {
            "start_logit": -6.74609375,
            "end_logit": -6.50390625,
            "text": "C-terminal SET domain that",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_2": [
        {
            "start_logit": 8.6171875,
            "end_logit": 8.796875,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -2.107421875,
            "end_logit": 8.796875,
            "text": "domain",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 8.6171875,
            "end_logit": -2.525390625,
            "text": "SET",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": 8.6171875,
            "end_logit": -6.93359375,
            "text": "SET domain histone",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 8.796875,
            "text": "a SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6171875,
            "end_logit": -7.04296875,
            "text": "SET domain histone methyltransferase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.107421875,
            "end_logit": -6.93359375,
            "text": "domain histone",
            "probability": 0.0
        },
        {
            "start_logit": -2.107421875,
            "end_logit": -7.04296875,
            "text": "domain histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": -2.525390625,
            "text": "a SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": -6.93359375,
            "text": "a SET domain histone",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": -7.04296875,
            "text": "a SET domain histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": -7.1796875,
            "text": "a",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_3": [
        {
            "start_logit": 7.828125,
            "end_logit": 8.140625,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -3.12109375,
            "end_logit": 8.140625,
            "text": "domain",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": 7.828125,
            "end_logit": -3.4375,
            "text": "SET",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 8.140625,
            "text": "a SET domain",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.31640625,
            "end_logit": -3.4375,
            "text": "a SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.12109375,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.140625,
            "text": "A common feature of the mammalian MLL/SET1 complexes is the",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.24609375,
            "text": "A common feature of the mammalian MLL/SET1 complexes is the presence",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.31640625,
            "text": "A common feature of the mammalian MLL/SET1",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.3203125,
            "text": "A common feature of the mammalian MLL/SET1 complexes is",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.359375,
            "text": "A common feature of the mammalian MLL/SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.41015625,
            "end_logit": -7.140625,
            "text": "MLL/SET1 complexes is the",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.36328125,
            "text": "A common feature of the mammalian MLL/",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.375,
            "text": "A common feature of the mammalian MLL/SET1 complexes",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.41796875,
            "text": "A common feature of the mammalian MLL/SET1 complexes is the presence of",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -7.42578125,
            "text": "A common feature of the mammalian MLL",
            "probability": 0.0
        },
        {
            "start_logit": -7.41015625,
            "end_logit": -7.23046875,
            "text": "MLL/SET1 complexes is the presence of three core components (RbBP5, Ash2L and WDR5) and a catalytic subunit",
            "probability": 0.0
        },
        {
            "start_logit": -7.41015625,
            "end_logit": -7.24609375,
            "text": "MLL/SET1 complexes is the presence",
            "probability": 0.0
        },
        {
            "start_logit": -7.41015625,
            "end_logit": -7.26171875,
            "text": "MLL/SET1 complexes is the presence of three core components (RbBP5, Ash2L and WDR5) and a",
            "probability": 0.0
        },
        {
            "start_logit": -7.41015625,
            "end_logit": -7.265625,
            "text": "MLL/SET1 complexes is the presence of three core components (RbBP5, Ash2L and WDR5)",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_4": [
        {
            "start_logit": 8.703125,
            "end_logit": 8.7421875,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -2.25,
            "end_logit": 8.7421875,
            "text": "domain",
            "probability": 1.7642974853515625e-05
        },
        {
            "start_logit": 8.703125,
            "end_logit": -2.38671875,
            "text": "SET",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": 8.703125,
            "end_logit": -6.5078125,
            "text": "SET domain methyltransferases deposit methyl marks on specific histone tail lysine residues",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.703125,
            "end_logit": -6.796875,
            "text": "SET domain methyltransferase",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.703125,
            "end_logit": -6.8828125,
            "text": "SET domain methyltransferases deposit",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.703125,
            "end_logit": -7.00390625,
            "text": "SET domain methyltransferases deposit methyl marks on specific histone tail",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.703125,
            "end_logit": -7.0078125,
            "text": "SET domain methyltransferases deposit methyl marks on specific histone tail lysine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.703125,
            "end_logit": -7.03515625,
            "text": "SET domain methyltransferases deposit methyl marks on",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.703125,
            "end_logit": -7.06640625,
            "text": "SET domain methyltransferases deposit methyl marks on specific",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.703125,
            "end_logit": -7.09765625,
            "text": "SET domain methyltransferases",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.703125,
            "end_logit": -7.09765625,
            "text": "SET domain methyltransferases deposit methyl marks on specific histone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.703125,
            "end_logit": -7.109375,
            "text": "SET domain methyltransferases deposit methyl marks",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.703125,
            "end_logit": -7.16015625,
            "text": "SET domain methyltransferases deposit methyl",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.25,
            "end_logit": -6.5078125,
            "text": "domain methyltransferases deposit methyl marks on specific histone tail lysine residues",
            "probability": 0.0
        },
        {
            "start_logit": -2.25,
            "end_logit": -6.796875,
            "text": "domain methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -2.25,
            "end_logit": -6.8828125,
            "text": "domain methyltransferases deposit",
            "probability": 0.0
        },
        {
            "start_logit": -2.25,
            "end_logit": -7.00390625,
            "text": "domain methyltransferases deposit methyl marks on specific histone tail",
            "probability": 0.0
        },
        {
            "start_logit": -2.25,
            "end_logit": -7.0078125,
            "text": "domain methyltransferases deposit methyl marks on specific histone tail lysine",
            "probability": 0.0
        },
        {
            "start_logit": -2.25,
            "end_logit": -7.03515625,
            "text": "domain methyltransferases deposit methyl marks on",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_5": [
        {
            "start_logit": 9.046875,
            "end_logit": 8.875,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": 9.046875,
            "end_logit": -1.7158203125,
            "text": "SET",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": -2.00390625,
            "end_logit": 8.875,
            "text": "domain",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": 9.046875,
            "end_logit": -5.37109375,
            "text": "SET domain.",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 8.875,
            "text": "The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 8.875,
            "text": "carboxyl-terminal SET domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.875,
            "text": "H3K4 methyltransferase activity of the carboxyl-terminal SET domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.00390625,
            "end_logit": -5.37109375,
            "text": "domain.",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -1.7158203125,
            "text": "The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -1.7158203125,
            "text": "carboxyl-terminal SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -1.7158203125,
            "text": "H3K4 methyltransferase activity of the carboxyl-terminal SET",
            "probability": 0.0
        },
        {
            "start_logit": -5.3828125,
            "end_logit": -5.37109375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -5.37109375,
            "text": "The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain.",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -5.37109375,
            "text": "carboxyl-terminal SET domain.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -5.37109375,
            "text": "H3K4 methyltransferase activity of the carboxyl-terminal SET domain.",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -6.48828125,
            "text": "The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -6.515625,
            "text": "The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -6.6640625,
            "text": "The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -6.69921875,
            "text": "The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -6.7421875,
            "text": "The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_6": [
        {
            "start_logit": 8.8828125,
            "end_logit": 8.765625,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -2.044921875,
            "text": "SET",
            "probability": 1.996755599975586e-05
        },
        {
            "start_logit": -2.203125,
            "end_logit": 8.765625,
            "text": "domain",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": 8.8828125,
            "end_logit": -5.8671875,
            "text": "SET domain.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 8.765625,
            "text": "paucity of E(z) mutant alleles that alter its SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 8.765625,
            "text": ", and the paucity of E(z) mutant alleles that alter its SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 8.765625,
            "text": "its SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 8.765625,
            "text": "that alter its SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 8.765625,
            "text": "alter its SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 8.765625,
            "text": "the paucity of E(z) mutant alleles that alter its SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 8.765625,
            "text": "of E(z) mutant alleles that alter its SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.203125,
            "end_logit": -5.8671875,
            "text": "domain.",
            "probability": 0.0
        },
        {
            "start_logit": -7.0234375,
            "end_logit": -2.044921875,
            "text": "paucity of E(z) mutant alleles that alter its SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.08984375,
            "end_logit": -2.044921875,
            "text": ", and the paucity of E(z) mutant alleles that alter its SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -2.044921875,
            "text": "its SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -2.044921875,
            "text": "that alter its SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.26171875,
            "end_logit": -2.044921875,
            "text": "alter its SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.3203125,
            "end_logit": -2.044921875,
            "text": "the paucity of E(z) mutant alleles that alter its SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -2.044921875,
            "text": "of E(z) mutant alleles that alter its SET",
            "probability": 0.0
        },
        {
            "start_logit": -4.26953125,
            "end_logit": -5.87109375,
            "text": ".",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_7": [
        {
            "start_logit": 8.828125,
            "end_logit": 8.7734375,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": 8.828125,
            "end_logit": -2.138671875,
            "text": "SET",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": -2.232421875,
            "end_logit": 8.7734375,
            "text": "domain",
            "probability": 1.5795230865478516e-05
        },
        {
            "start_logit": -5.1171875,
            "end_logit": 8.7734375,
            "text": ". PKMTs contain a conserved SET domain",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 8.7734375,
            "text": "a conserved SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 8.7734375,
            "text": "conserved SET domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.1171875,
            "end_logit": -2.138671875,
            "text": ". PKMTs contain a conserved SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -2.138671875,
            "text": "a conserved SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": -2.138671875,
            "text": "conserved SET",
            "probability": 0.0
        },
        {
            "start_logit": -5.1171875,
            "end_logit": -6.5390625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.1171875,
            "end_logit": -6.71484375,
            "text": ". PKMTs contain a conserved",
            "probability": 0.0
        },
        {
            "start_logit": -5.1171875,
            "end_logit": -7.03515625,
            "text": ". PKMTs contain a",
            "probability": 0.0
        },
        {
            "start_logit": -5.1171875,
            "end_logit": -7.18359375,
            "text": ". PKMTs contain",
            "probability": 0.0
        },
        {
            "start_logit": -5.1171875,
            "end_logit": -7.26171875,
            "text": ". PK",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -6.71484375,
            "text": "a conserved",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": -6.71484375,
            "text": "conserved",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -7.03515625,
            "text": "a",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_8": [
        {
            "start_logit": 8.3359375,
            "end_logit": 8.6015625,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -2.396484375,
            "end_logit": 8.6015625,
            "text": "domain",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -2.818359375,
            "text": "SET",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 8.3359375,
            "end_logit": -6.99609375,
            "text": "SET domain protein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 8.6015625,
            "text": "Set1A protein shares 39% identity with an uncharacterized SET domain",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.396484375,
            "end_logit": -6.99609375,
            "text": "domain protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -2.818359375,
            "text": "Set1A protein shares 39% identity with an uncharacterized SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -6.89453125,
            "text": "Set1A protein shares 39",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -6.95703125,
            "text": "Set1A protein shares 39%",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -6.99609375,
            "text": "Set1A protein shares 39% identity with an uncharacterized SET domain protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -7.06640625,
            "text": "Set1A protein shares 39% identity with an",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -7.1015625,
            "text": "Set1A",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -7.1328125,
            "text": "Set",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -7.13671875,
            "text": "Set1A protein shares 39% identity",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -7.203125,
            "text": "Set1A protein shares 39% identity with an uncharacterized",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -7.21875,
            "text": "Set1A protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -7.22265625,
            "text": "Set1A protein shares 39% identity with",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -7.27734375,
            "text": "Set1A protein shares",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_9": [
        {
            "start_logit": 8.6953125,
            "end_logit": 8.8671875,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -2.0078125,
            "end_logit": 8.8671875,
            "text": "domain",
            "probability": 2.2470951080322266e-05
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -2.40625,
            "text": "SET",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.07421875,
            "text": "SET domain protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.07421875,
            "text": "SET domain protein methyltransferase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.1171875,
            "text": "SET domain protein methyltransferases",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.0078125,
            "end_logit": -7.07421875,
            "text": "domain protein",
            "probability": 0.0
        },
        {
            "start_logit": -2.0078125,
            "end_logit": -7.07421875,
            "text": "domain protein methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -2.0078125,
            "end_logit": -7.1171875,
            "text": "domain protein methyltransferases",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_10": [
        {
            "start_logit": 8.9375,
            "end_logit": 8.921875,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -1.8583984375,
            "end_logit": 8.921875,
            "text": "domain",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 8.9375,
            "end_logit": -1.890625,
            "text": "SET",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": 8.9375,
            "end_logit": -6.06640625,
            "text": "SET domain protein lysine methyltransferases.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.9375,
            "end_logit": -6.7734375,
            "text": "SET domain protein lysine methyltransferase",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9375,
            "end_logit": -6.87890625,
            "text": "SET domain protein lysine methyltransferases",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9375,
            "end_logit": -6.9375,
            "text": "SET domain protein lysine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9375,
            "end_logit": -6.94140625,
            "text": "SET domain protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.8583984375,
            "end_logit": -6.06640625,
            "text": "domain protein lysine methyltransferases.",
            "probability": 0.0
        },
        {
            "start_logit": -1.8583984375,
            "end_logit": -6.7734375,
            "text": "domain protein lysine methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -1.8583984375,
            "end_logit": -6.87890625,
            "text": "domain protein lysine methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": -1.8583984375,
            "end_logit": -6.9375,
            "text": "domain protein lysine",
            "probability": 0.0
        },
        {
            "start_logit": -1.8583984375,
            "end_logit": -6.94140625,
            "text": "domain protein",
            "probability": 0.0
        },
        {
            "start_logit": -5.296875,
            "end_logit": -6.06640625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_11": [
        {
            "start_logit": 8.859375,
            "end_logit": 8.8125,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": 8.859375,
            "end_logit": -2.11328125,
            "text": "SET",
            "probability": 1.806020736694336e-05
        },
        {
            "start_logit": -2.099609375,
            "end_logit": 8.8125,
            "text": "domain",
            "probability": 1.7344951629638672e-05
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.8046875,
            "text": "SET domain protein functions",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.8671875,
            "text": "SET domain protein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.9609375,
            "text": "SET domain protein functions as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.99609375,
            "text": "SET domain protein functions as a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.015625,
            "text": "SET domain protein functions as a histone methyltransferase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.1484375,
            "text": "SET domain protein functions as a histone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.099609375,
            "end_logit": -6.8046875,
            "text": "domain protein functions",
            "probability": 0.0
        },
        {
            "start_logit": -2.099609375,
            "end_logit": -6.8671875,
            "text": "domain protein",
            "probability": 0.0
        },
        {
            "start_logit": -2.099609375,
            "end_logit": -6.9609375,
            "text": "domain protein functions as",
            "probability": 0.0
        },
        {
            "start_logit": -2.099609375,
            "end_logit": -6.99609375,
            "text": "domain protein functions as a",
            "probability": 0.0
        },
        {
            "start_logit": -2.099609375,
            "end_logit": -7.015625,
            "text": "domain protein functions as a histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -2.099609375,
            "end_logit": -7.1484375,
            "text": "domain protein functions as a histone",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_12": [
        {
            "start_logit": 4.90625,
            "end_logit": 8.3359375,
            "text": "catalytic SET domain",
            "probability": 0.99609375
        },
        {
            "start_logit": -0.74951171875,
            "end_logit": 8.3359375,
            "text": "SET domain",
            "probability": 0.003482818603515625
        },
        {
            "start_logit": -2.978515625,
            "end_logit": 8.3359375,
            "text": "domain",
            "probability": 0.0003757476806640625
        },
        {
            "start_logit": -6.93359375,
            "end_logit": 8.3359375,
            "text": "SUV39H1 impaired enzyme activity despite the presence of an intact catalytic SET domain",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 8.3359375,
            "text": "intact catalytic SET domain",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 4.90625,
            "end_logit": -6.09765625,
            "text": "catalytic",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -6.09765625,
            "text": "SUV39H1 impaired enzyme activity despite the presence of an intact catalytic",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -6.5,
            "text": "SUV39H1 impaired enzyme activity despite",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -6.09765625,
            "text": "intact catalytic",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -6.68359375,
            "text": "SUV39H1 impaired enzyme activity despite the",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -6.83984375,
            "text": "SUV39H1 impaired enzyme activity despite the presence",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -6.9296875,
            "text": "SUV39H1 impaired enzyme activity despite the presence of",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -6.94921875,
            "text": "SUV39H1 impaired enzyme activity despite the presence of an",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -7.046875,
            "text": "SUV39H1",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -7.06640625,
            "text": "SUV39H1 impaired enzyme activity despite the presence of an intact",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -7.109375,
            "text": "SUV39H1 impaired enzyme activity",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -7.2421875,
            "text": "SUV39H1 impaired enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -7.265625,
            "text": "SUV39",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -7.26953125,
            "text": "SUV39H1 impaired",
            "probability": 0.0
        },
        {
            "start_logit": -6.93359375,
            "end_logit": -7.3125,
            "text": "SUV",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_13": [
        {
            "start_logit": 4.09375,
            "end_logit": 7.78515625,
            "text": "Meisetz (meiosis-induced factor containing a PR/SET domain",
            "probability": 0.634765625
        },
        {
            "start_logit": 3.537109375,
            "end_logit": 7.78515625,
            "text": "PR/SET domain",
            "probability": 0.364501953125
        },
        {
            "start_logit": -3.646484375,
            "end_logit": 7.78515625,
            "text": "domain",
            "probability": 0.0002777576446533203
        },
        {
            "start_logit": -4.38671875,
            "end_logit": 7.78515625,
            "text": "a PR/SET domain",
            "probability": 0.0001322031021118164
        },
        {
            "start_logit": -5.875,
            "end_logit": 7.78515625,
            "text": "SET domain",
            "probability": 2.9742717742919922e-05
        },
        {
            "start_logit": -5.92578125,
            "end_logit": 7.78515625,
            "text": "/SET domain",
            "probability": 2.8371810913085938e-05
        },
        {
            "start_logit": -6.57421875,
            "end_logit": 7.78515625,
            "text": "isetz (meiosis-induced factor containing a PR/SET domain",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 7.78515625,
            "text": "containing a PR/SET domain",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 7.78515625,
            "text": "(meiosis-induced factor containing a PR/SET domain",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -7.453125,
            "end_logit": 7.78515625,
            "text": "tz (meiosis-induced factor containing a PR/SET domain",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.78515625,
            "text": "factor containing a PR/SET domain",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": 4.09375,
            "end_logit": -4.73046875,
            "text": "Meisetz (meiosis-induced factor containing a PR/SET domain and zinc-finger motif)",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 4.09375,
            "end_logit": -4.8671875,
            "text": "Meisetz (meiosis-induced factor containing a PR/SET domain and zinc-finger motif",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 3.537109375,
            "end_logit": -4.73046875,
            "text": "PR/SET domain and zinc-finger motif)",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 3.537109375,
            "end_logit": -4.8671875,
            "text": "PR/SET domain and zinc-finger motif",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 4.09375,
            "end_logit": -6.09765625,
            "text": "Meisetz (meiosis-induced factor containing a PR/SET domain and",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 4.09375,
            "end_logit": -6.32421875,
            "text": "Me",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 4.09375,
            "end_logit": -6.41015625,
            "text": "Meisetz (meiosis-induced factor containing a PR",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 4.09375,
            "end_logit": -6.4140625,
            "text": "Meisetz (meiosis-induced factor containing a PR/SET domain and zinc-finger motif) is a",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 4.09375,
            "end_logit": -6.43359375,
            "text": "Meisetz (meiosis-induced factor containing a PR/SET domain and zinc-finger motif) is a histone methyltransferase",
            "probability": 4.172325134277344e-07
        }
    ],
    "532dcfc9d6d3ac6a34000021_14": [
        {
            "start_logit": 8.546875,
            "end_logit": 8.7421875,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -2.193359375,
            "end_logit": 8.7421875,
            "text": "domain",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": 8.546875,
            "end_logit": -2.564453125,
            "text": "SET",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": 8.546875,
            "end_logit": -5.8984375,
            "text": "SET domain subun",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 8.7421875,
            "text": "catalytic SET domain",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.546875,
            "end_logit": -6.984375,
            "text": "SET domain subuni",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.7421875,
            "text": "fly complex contains a catalytic SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 8.7421875,
            "text": "The fly complex contains a catalytic SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.7421875,
            "text": "complex contains a catalytic SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 8.7421875,
            "text": "a catalytic SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.193359375,
            "end_logit": -5.8984375,
            "text": "domain subun",
            "probability": 0.0
        },
        {
            "start_logit": -2.193359375,
            "end_logit": -6.984375,
            "text": "domain subuni",
            "probability": 0.0
        },
        {
            "start_logit": -7.1328125,
            "end_logit": -2.564453125,
            "text": "catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -2.564453125,
            "text": "fly complex contains a catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -2.564453125,
            "text": "The fly complex contains a catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -2.564453125,
            "text": "complex contains a catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": -2.564453125,
            "text": "a catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.1328125,
            "end_logit": -5.8984375,
            "text": "catalytic SET domain subun",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -5.8984375,
            "text": "fly complex contains a catalytic SET domain subun",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -5.8984375,
            "text": "The fly complex contains a catalytic SET domain subun",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_15": [
        {
            "start_logit": 8.5703125,
            "end_logit": 8.6484375,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -2.396484375,
            "end_logit": 8.6484375,
            "text": "domain",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -2.5625,
            "text": "SET",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": 8.5703125,
            "end_logit": -6.76171875,
            "text": "SET domain and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 8.6484375,
            "text": "G9a is a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 8.6484375,
            "text": "characteristic SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 8.6484375,
            "text": "-K9 methyltransferase that possesses characteristic SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.396484375,
            "end_logit": -6.76171875,
            "text": "domain and",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -2.5625,
            "text": "G9a is a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -2.5625,
            "text": "characteristic SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -2.5625,
            "text": "-K9 methyltransferase that possesses characteristic SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -6.76171875,
            "text": "G9a is a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET domain and",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -6.76171875,
            "text": "characteristic SET domain and",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -6.76171875,
            "text": "-K9 methyltransferase that possesses characteristic SET domain and",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -6.93359375,
            "text": "G9a is a 1263 amino acid H3-K9 methyltransferase that",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -6.9375,
            "text": "G9a is a 1263 amino acid H3-K9 methyltransferase that possesses",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -6.93359375,
            "text": "-K9 methyltransferase that",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -6.9375,
            "text": "-K9 methyltransferase that possesses",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -7.1484375,
            "text": "G9a is a 126",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -7.1640625,
            "text": "G9a is a 1263",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_16": [
        {
            "start_logit": 8.859375,
            "end_logit": 8.7421875,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": 8.859375,
            "end_logit": -2.16796875,
            "text": "SET",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": -2.2734375,
            "end_logit": 8.7421875,
            "text": "domain",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.078125,
            "text": "SET domain,",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.85546875,
            "text": "SET domain, first",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.1015625,
            "text": "SET domain, first identified",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.16015625,
            "text": "SET domain, first identified within and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.1796875,
            "text": "SET domain, first identified within",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.28125,
            "text": "SET domain, first identified within and named after proteins encoded by",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.3203125,
            "text": "SET domain, first identified within and named after proteins encoded by three Drosophila",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.3203125,
            "text": "SET domain, first identified within and named",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.34765625,
            "text": "SET domain, first identified within and named after proteins encoded by three Drosophila genes [",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.35546875,
            "text": "SET domain, first identified within and named after proteins encoded",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.359375,
            "text": "SET domain, first identified within and named after",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.3671875,
            "text": "SET domain, first identified within and named after proteins encoded by three",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.2734375,
            "end_logit": -6.078125,
            "text": "domain,",
            "probability": 0.0
        },
        {
            "start_logit": -2.2734375,
            "end_logit": -6.85546875,
            "text": "domain, first",
            "probability": 0.0
        },
        {
            "start_logit": -2.2734375,
            "end_logit": -7.1015625,
            "text": "domain, first identified",
            "probability": 0.0
        },
        {
            "start_logit": -2.2734375,
            "end_logit": -7.16015625,
            "text": "domain, first identified within and",
            "probability": 0.0
        },
        {
            "start_logit": -2.2734375,
            "end_logit": -7.1796875,
            "text": "domain, first identified within",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_17": [
        {
            "start_logit": 8.40625,
            "end_logit": 8.6328125,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -2.458984375,
            "end_logit": 8.6328125,
            "text": "domain",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": 8.40625,
            "end_logit": -2.8046875,
            "text": "SET",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": -6.63671875,
            "end_logit": 8.6328125,
            "text": "(HMT)(1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 8.6328125,
            "text": "the SET domain",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 8.6328125,
            "text": "HMT)(1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 8.6328125,
            "text": "termed the SET domain",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 8.6328125,
            "text": "enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 8.6328125,
            "text": "that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 8.6328125,
            "text": "methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 8.6328125,
            "text": "lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.63671875,
            "end_logit": -2.8046875,
            "text": "(HMT)(1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET",
            "probability": 0.0
        },
        {
            "start_logit": -6.8046875,
            "end_logit": -2.8046875,
            "text": "the SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.24609375,
            "end_logit": -2.8046875,
            "text": "HMT)(1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.30078125,
            "end_logit": -2.8046875,
            "text": "termed the SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.32421875,
            "end_logit": -2.8046875,
            "text": "enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -2.8046875,
            "text": "that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": -2.8046875,
            "text": "methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -2.8046875,
            "text": "lysine residues of histones or proteins contain a conserved catalytic core termed the SET",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": -6.06640625,
            "text": "(HMT)(1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_18": [
        {
            "start_logit": 8.7734375,
            "end_logit": 8.875,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -1.9462890625,
            "end_logit": 8.875,
            "text": "domain",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -2.17578125,
            "text": "SET",
            "probability": 1.5676021575927734e-05
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.1796875,
            "text": "SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of histone H3-lysine 9 (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.18359375,
            "text": "SET domain, also",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 8.875,
            "text": "ERG-associated protein with a SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.21484375,
            "text": "SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of histone H3-lysine 9",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.234375,
            "text": "SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of histone H3-lysine 9 (H3-K9",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.23828125,
            "text": "SET domain, also called SET",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.2421875,
            "text": "SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of histone H3-lysine 9 (H3-K",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": 8.875,
            "text": "a SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.26171875,
            "text": "SET domain, also called",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.27734375,
            "text": "SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of histone H3-lysine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.29296875,
            "text": "SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of histone H3-lysine 9 (H3-K9)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.30078125,
            "text": "SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of histone H3",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.33203125,
            "text": "SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of histone H3-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.34765625,
            "text": "SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.35546875,
            "text": "SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of histone H3-lysine 9 (H3-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.35546875,
            "text": "SET domain, also called SETDB1) is a novel histone methyltransferase that",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.359375,
            "text": "SET domain, also called SETDB1",
            "probability": 5.960464477539063e-08
        }
    ],
    "532dcfc9d6d3ac6a34000021_19": [
        {
            "start_logit": 8.921875,
            "end_logit": 8.8359375,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": 8.921875,
            "end_logit": -2.037109375,
            "text": "SET",
            "probability": 1.9073486328125e-05
        },
        {
            "start_logit": -2.072265625,
            "end_logit": 8.8359375,
            "text": "domain",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": 8.921875,
            "end_logit": -6.984375,
            "text": "SET domain histone methyltransferase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.0,
            "text": "SET domain histone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.072265625,
            "end_logit": -6.984375,
            "text": "domain histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -2.072265625,
            "end_logit": -7.0,
            "text": "domain histone",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_20": [
        {
            "start_logit": 8.75,
            "end_logit": 8.84375,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -1.998046875,
            "end_logit": 8.84375,
            "text": "domain",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 8.75,
            "end_logit": -2.107421875,
            "text": "SET",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": 8.75,
            "end_logit": -6.625,
            "text": "SET domain,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 8.84375,
            "text": "other histone methyltransferases, Dot1 does not contain a SET domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 8.84375,
            "text": "Dot1 does not contain a SET domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.84375,
            "text": ", Dot1 does not contain a SET domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.998046875,
            "end_logit": -6.625,
            "text": "domain,",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -2.107421875,
            "text": "other histone methyltransferases, Dot1 does not contain a SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.67578125,
            "end_logit": -2.107421875,
            "text": "Dot1 does not contain a SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -2.107421875,
            "text": ", Dot1 does not contain a SET",
            "probability": 0.0
        },
        {
            "start_logit": -5.32421875,
            "end_logit": -6.625,
            "text": ",",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -6.625,
            "text": "other histone methyltransferases, Dot1 does not contain a SET domain,",
            "probability": 0.0
        },
        {
            "start_logit": -7.67578125,
            "end_logit": -6.625,
            "text": "Dot1 does not contain a SET domain,",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -6.625,
            "text": ", Dot1 does not contain a SET domain,",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -6.765625,
            "text": "other histone methyltransferases, Dot1 does not contain",
            "probability": 0.0
        },
        {
            "start_logit": -7.67578125,
            "end_logit": -6.765625,
            "text": "Dot1 does not contain",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -6.765625,
            "text": ", Dot1 does not contain",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -6.83203125,
            "text": "other histone methyltransferases, Dot1 does not",
            "probability": 0.0
        },
        {
            "start_logit": -7.67578125,
            "end_logit": -6.83203125,
            "text": "Dot1 does not",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_21": [
        {
            "start_logit": 8.8984375,
            "end_logit": 8.6953125,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -2.138671875,
            "text": "SET",
            "probability": 1.9669532775878906e-05
        },
        {
            "start_logit": -2.404296875,
            "end_logit": 8.6953125,
            "text": "domain",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.86328125,
            "text": "SET domain contains",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.99609375,
            "text": "SET domain contains the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.0625,
            "text": "SET domain contains the catalytic center",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.1015625,
            "text": "SET domain contains the catalytic center of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.140625,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.18359375,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that target the N-terminal tails of histones and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.1953125,
            "text": "SET domain contains the catalytic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.19921875,
            "text": "SET domain contains the catalytic center of lysine methyltransferase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.20703125,
            "text": "SET domain contains the catalytic center of lysine methyltransferases",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.25390625,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that target the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.28125,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that target the N-terminal tails of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.30859375,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that target the N-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.31640625,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that target",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.33984375,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that target the N",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.34765625,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that target the N-terminal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.375,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that target the N-terminal tails",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -6.86328125,
            "text": "domain contains",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_22": [
        {
            "start_logit": 8.984375,
            "end_logit": 8.8828125,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": 8.984375,
            "end_logit": -1.9072265625,
            "text": "SET",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": -1.98828125,
            "end_logit": 8.8828125,
            "text": "domain",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.94140625,
            "text": "SET domain occurs in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.98828125,
            "text": "SET domain occurs in most proteins known",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.00390625,
            "text": "SET domain occurs",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.01171875,
            "text": "SET domain occurs in most",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.0625,
            "text": "SET domain occurs in most proteins known to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.15234375,
            "text": "SET domain occurs in most proteins known to possess histone lysine methyltransferase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.15625,
            "text": "SET domain occurs in most proteins known to possess",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.15625,
            "text": "SET domain occurs in most proteins known to possess histone lysine methyltransferase activity",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.26953125,
            "text": "SET domain occurs in most proteins",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.35546875,
            "text": "SET domain occurs in most proteins known to possess histone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.3984375,
            "text": "SET domain occurs in most proteins known to possess histone lysine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 8.8828125,
            "text": "The evolutionarily conserved SET domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.98828125,
            "end_logit": -6.94140625,
            "text": "domain occurs in",
            "probability": 0.0
        },
        {
            "start_logit": -1.98828125,
            "end_logit": -6.98828125,
            "text": "domain occurs in most proteins known",
            "probability": 0.0
        },
        {
            "start_logit": -1.98828125,
            "end_logit": -7.00390625,
            "text": "domain occurs",
            "probability": 0.0
        },
        {
            "start_logit": -1.98828125,
            "end_logit": -7.01171875,
            "text": "domain occurs in most",
            "probability": 0.0
        },
        {
            "start_logit": -1.98828125,
            "end_logit": -7.0625,
            "text": "domain occurs in most proteins known to",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_23": [
        {
            "start_logit": 8.8515625,
            "end_logit": 8.8203125,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -2.130859375,
            "end_logit": 8.8203125,
            "text": "domain",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -2.1796875,
            "text": "SET",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.63671875,
            "text": "SET domain, which",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.8046875,
            "text": "SET domain, which requires",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.86328125,
            "text": "SET domain, which requires adjacent cysteine-rich regions",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.9296875,
            "text": "SET domain,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.953125,
            "text": "SET domain, which requires adjacent cysteine-rich regions to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.9921875,
            "text": "SET domain, which requires adjacent",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -7.0546875,
            "text": "SET domain, which requires adjacent cysteine-rich",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -7.109375,
            "text": "SET domain, which requires adjacent cysteine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -7.12109375,
            "text": "SET domain, which requires adjacent cysteine-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -7.22265625,
            "text": "SET domain, which requires adjacent cysteine-rich regions to confer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -7.2890625,
            "text": "SET domain, which requires adjacent cysteine-rich regions to confer histone methyltransferase activity",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -7.3359375,
            "text": "SET domain, which requires adjacent cysteine-rich regions to confer histone methyltransferase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.130859375,
            "end_logit": -6.63671875,
            "text": "domain, which",
            "probability": 0.0
        },
        {
            "start_logit": -2.130859375,
            "end_logit": -6.8046875,
            "text": "domain, which requires",
            "probability": 0.0
        },
        {
            "start_logit": -2.130859375,
            "end_logit": -6.86328125,
            "text": "domain, which requires adjacent cysteine-rich regions",
            "probability": 0.0
        },
        {
            "start_logit": -2.130859375,
            "end_logit": -6.9296875,
            "text": "domain,",
            "probability": 0.0
        },
        {
            "start_logit": -2.130859375,
            "end_logit": -6.953125,
            "text": "domain, which requires adjacent cysteine-rich regions to",
            "probability": 0.0
        }
    ],
    "52bf1f1303868f1b06000014_1": [
        {
            "start_logit": 8.4609375,
            "end_logit": 2.65625,
            "text": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein critical for cell function.",
            "probability": 0.533203125
        },
        {
            "start_logit": 8.4609375,
            "end_logit": 2.474609375,
            "text": "Peroxiredoxin-2 (PRDX-2) is an antioxidant",
            "probability": 0.445556640625
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -1.2236328125,
            "text": "Peroxiredoxin-2",
            "probability": 0.01102447509765625
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -2.607421875,
            "text": "Perox",
            "probability": 0.00275421142578125
        },
        {
            "start_logit": 2.826171875,
            "end_logit": 2.65625,
            "text": "antioxidant and chaperone-like protein critical for cell function.",
            "probability": 0.0019083023071289062
        },
        {
            "start_logit": 2.826171875,
            "end_logit": 2.474609375,
            "text": "antioxidant",
            "probability": 0.0015878677368164062
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -3.712890625,
            "text": "Peroxiredoxin-",
            "probability": 0.00091552734375
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -4.19140625,
            "text": "Peroxiredoxin",
            "probability": 0.0005664825439453125
        },
        {
            "start_logit": 1.25390625,
            "end_logit": 2.65625,
            "text": "(PRDX-2) is an antioxidant and chaperone-like protein critical for cell function.",
            "probability": 0.0003955364227294922
        },
        {
            "start_logit": 1.25390625,
            "end_logit": 2.474609375,
            "text": "(PRDX-2) is an antioxidant",
            "probability": 0.00032901763916015625
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -4.83203125,
            "text": "Peroxiredoxin-2 (",
            "probability": 0.00029850006103515625
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -5.0625,
            "text": "Peroxiredoxin-2 (PRDX-2)",
            "probability": 0.00023698806762695312
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -5.16796875,
            "text": "Peroxiredoxin-2 (PRDX",
            "probability": 0.00021326541900634766
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -5.359375,
            "text": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and",
            "probability": 0.0001760721206665039
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -5.37109375,
            "text": "Peroxiredoxin-2 (PRDX-2) is",
            "probability": 0.00017344951629638672
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -5.48828125,
            "text": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein critical",
            "probability": 0.00015532970428466797
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -5.60546875,
            "text": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone",
            "probability": 0.00013720989227294922
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -5.8984375,
            "text": "Peroxiredoxin-2 (PRDX-",
            "probability": 0.00010275840759277344
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -5.8984375,
            "text": "Peroxiredoxin-2 (PRDX-2",
            "probability": 0.00010275840759277344
        },
        {
            "start_logit": 8.4609375,
            "end_logit": -6.02734375,
            "text": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein",
            "probability": 8.994340896606445e-05
        }
    ],
    "52bf1f1303868f1b06000014_2": [
        {
            "start_logit": 4.52734375,
            "end_logit": 0.116455078125,
            "text": "antioxidant enzyme",
            "probability": 0.689453125
        },
        {
            "start_logit": 4.67578125,
            "end_logit": -1.669921875,
            "text": "peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells.",
            "probability": 0.1339111328125
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -1.669921875,
            "text": "antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells.",
            "probability": 0.115478515625
        },
        {
            "start_logit": 4.67578125,
            "end_logit": -4.4140625,
            "text": "peroxiredoxin-2",
            "probability": 0.00861358642578125
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -4.4140625,
            "text": "antioxidant enzyme peroxiredoxin-2",
            "probability": 0.00742340087890625
        },
        {
            "start_logit": 4.67578125,
            "end_logit": -4.9375,
            "text": "peroxiredoxin",
            "probability": 0.00510406494140625
        },
        {
            "start_logit": 4.67578125,
            "end_logit": -4.98046875,
            "text": "peroxiredoxin-",
            "probability": 0.004886627197265625
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -4.9375,
            "text": "antioxidant enzyme peroxiredoxin",
            "probability": 0.004398345947265625
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -4.98046875,
            "text": "antioxidant enzyme peroxiredoxin-",
            "probability": 0.004215240478515625
        },
        {
            "start_logit": 4.67578125,
            "end_logit": -5.2421875,
            "text": "peroxiredoxin-2 (",
            "probability": 0.00376129150390625
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -5.2421875,
            "text": "antioxidant enzyme peroxiredoxin-2 (",
            "probability": 0.00324249267578125
        },
        {
            "start_logit": 4.67578125,
            "end_logit": -5.56640625,
            "text": "peroxiredoxin-2 (Prx2) inversely",
            "probability": 0.002719879150390625
        },
        {
            "start_logit": 4.67578125,
            "end_logit": -5.71484375,
            "text": "peroxiredoxin-2 (Prx2)",
            "probability": 0.0023441314697265625
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -5.56640625,
            "text": "antioxidant enzyme peroxiredoxin-2 (Prx2) inversely",
            "probability": 0.0023441314697265625
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -5.5859375,
            "text": "antioxidant",
            "probability": 0.002300262451171875
        },
        {
            "start_logit": 4.67578125,
            "end_logit": -5.83984375,
            "text": "perox",
            "probability": 0.0020694732666015625
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -5.71484375,
            "text": "antioxidant enzyme peroxiredoxin-2 (Prx2)",
            "probability": 0.00202178955078125
        },
        {
            "start_logit": 4.67578125,
            "end_logit": -5.9375,
            "text": "peroxiredoxin-2 (Pr",
            "probability": 0.0018768310546875
        },
        {
            "start_logit": 4.52734375,
            "end_logit": -5.83984375,
            "text": "antioxidant enzyme perox",
            "probability": 0.0017843246459960938
        },
        {
            "start_logit": 4.67578125,
            "end_logit": -6.05859375,
            "text": "peroxiredoxin-2 (Prx2",
            "probability": 0.0016641616821289062
        }
    ],
    "52bf1f1303868f1b06000014_3": [
        {
            "start_logit": 5.2109375,
            "end_logit": 3.67578125,
            "text": "antioxidant enzyme",
            "probability": 0.998046875
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -3.75390625,
            "text": "antioxidant",
            "probability": 0.0005903244018554688
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -3.9765625,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions and modification during the ovulatory process in rats.",
            "probability": 0.00047206878662109375
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -5.9765625,
            "text": "antioxidant enzyme sulfiredoxin",
            "probability": 6.389617919921875e-05
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -6.18359375,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions and modification during the ovulatory process in rats",
            "probability": 5.21540641784668e-05
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -6.5390625,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions",
            "probability": 3.641843795776367e-05
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -6.6796875,
            "text": "antioxidant enzyme sulfiredoxin (Srx)",
            "probability": 3.165006637573242e-05
        },
        {
            "start_logit": -5.15234375,
            "end_logit": 3.67578125,
            "text": "The aim of this study was to examine gonadotropin regulation of antioxidant enzyme",
            "probability": 3.141164779663086e-05
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -6.6953125,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions and modification during the ovulatory process",
            "probability": 3.1113624572753906e-05
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -6.78125,
            "text": "antioxidant enzyme sulfiredoxin (",
            "probability": 2.855062484741211e-05
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -6.80859375,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PR",
            "probability": 2.7894973754882812e-05
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -6.93359375,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and",
            "probability": 2.4616718292236328e-05
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -6.9609375,
            "text": "antioxidant enzyme sulfiredoxin (Sr",
            "probability": 2.384185791015625e-05
        },
        {
            "start_logit": 5.2109375,
            "end_logit": -6.96875,
            "text": "antioxidant enzyme sulfiredoxin (Srx",
            "probability": 2.3663043975830078e-05
        },
        {
            "start_logit": -5.43359375,
            "end_logit": 3.67578125,
            "text": "study was to examine gonadotropin regulation of antioxidant enzyme",
            "probability": 2.3663043975830078e-05
        },
        {
            "start_logit": -5.52734375,
            "end_logit": 3.67578125,
            "text": "aim of this study was to examine gonadotropin regulation of antioxidant enzyme",
            "probability": 2.1576881408691406e-05
        },
        {
            "start_logit": -5.66796875,
            "end_logit": 3.67578125,
            "text": "enzyme",
            "probability": 1.8715858459472656e-05
        },
        {
            "start_logit": -6.01171875,
            "end_logit": 3.67578125,
            "text": "this study was to examine gonadotropin regulation of antioxidant enzyme",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": -6.3046875,
            "end_logit": 3.67578125,
            "text": "was to examine gonadotropin regulation of antioxidant enzyme",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": -6.609375,
            "end_logit": 3.67578125,
            "text": "to examine gonadotropin regulation of antioxidant enzyme",
            "probability": 7.271766662597656e-06
        }
    ],
    "52bf1f1303868f1b06000014_4": [
        {
            "start_logit": 7.6171875,
            "end_logit": 8.1328125,
            "text": "antioxidant enzyme",
            "probability": 0.9951171875
        },
        {
            "start_logit": 1.9384765625,
            "end_logit": 8.1328125,
            "text": "Peroxiredoxin 2 (PRDX2) has been known to act as an antioxidant enzyme",
            "probability": 0.0033969879150390625
        },
        {
            "start_logit": 7.6171875,
            "end_logit": 1.7607421875,
            "text": "antioxidant enzyme whose main function is H(2)O(2) reduction in cells.",
            "probability": 0.0016946792602539062
        },
        {
            "start_logit": -2.96484375,
            "end_logit": 8.1328125,
            "text": "enzyme",
            "probability": 2.5331974029541016e-05
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -3.486328125,
            "text": "antioxidant",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -5.1328125,
            "text": "antioxidant enzyme whose",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -5.96484375,
            "end_logit": 8.1328125,
            "text": "an antioxidant enzyme",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 8.1328125,
            "text": "iredoxin 2 (PRDX2) has been known to act as an antioxidant enzyme",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 8.1328125,
            "text": "(PRDX2) has been known to act as an antioxidant enzyme",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -6.05859375,
            "text": "antioxidant enzyme whose main function is H(2)O(2) reduction",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.78515625,
            "end_logit": 8.1328125,
            "text": "oxin 2 (PRDX2) has been known to act as an antioxidant enzyme",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -6.44140625,
            "text": "antioxidant enzyme whose main function is H(2)O(",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 8.1328125,
            "text": "2 (PRDX2) has been known to act as an antioxidant enzyme",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -6.45703125,
            "text": "antioxidant enzyme whose main function is H(2)O",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 8.1328125,
            "text": "been known to act as an antioxidant enzyme",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -6.5546875,
            "text": "antioxidant enzyme whose main function is H(2)O(2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -6.56640625,
            "text": "antioxidant enzyme whose main",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.09765625,
            "end_logit": 8.1328125,
            "text": "known to act as an antioxidant enzyme",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.6171875,
            "end_logit": -6.63671875,
            "text": "antioxidant enzyme whose main function is H(2)O(2)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 8.1328125,
            "text": "has been known to act as an antioxidant enzyme",
            "probability": 3.5762786865234375e-07
        }
    ],
    "52bf1f1303868f1b06000014_5": [
        {
            "start_logit": 6.94921875,
            "end_logit": -0.4521484375,
            "text": "antioxidant enzyme",
            "probability": 0.9140625
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -3.892578125,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2) as a critical cytoplasmic target of cdk5.",
            "probability": 0.029327392578125
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -4.18359375,
            "text": "antioxidant",
            "probability": 0.0219268798828125
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -5.28125,
            "text": "antioxidant enzyme Pr",
            "probability": 0.00731658935546875
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -5.76953125,
            "text": "antioxidant enzyme Prx2",
            "probability": 0.004489898681640625
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -5.77734375,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2)",
            "probability": 0.00445556640625
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -5.9296875,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2) as",
            "probability": 0.003826141357421875
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -6.3046875,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2) as a",
            "probability": 0.0026302337646484375
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -6.65625,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin",
            "probability": 0.001850128173828125
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -6.7109375,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2",
            "probability": 0.001750946044921875
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -6.76171875,
            "text": "antioxidant enzyme Prx2 (perox",
            "probability": 0.0016641616821289062
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -6.7734375,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2) as a critical",
            "probability": 0.0016450881958007812
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -6.8046875,
            "text": "antioxidant enzyme Prx2 (peroxired",
            "probability": 0.00159454345703125
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -6.859375,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2) as a critical cytoplasmic target",
            "probability": 0.0015096664428710938
        },
        {
            "start_logit": 6.94921875,
            "end_logit": -6.859375,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2) as a critical cytoplasmic",
            "probability": 0.0015096664428710938
        },
        {
            "start_logit": -6.4921875,
            "end_logit": -0.4521484375,
            "text": "the antioxidant enzyme",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -7.1953125,
            "end_logit": -0.4521484375,
            "text": ", we also demonstrate the antioxidant enzyme",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": -0.4521484375,
            "text": "demonstrate the antioxidant enzyme",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.3515625,
            "end_logit": -0.4521484375,
            "text": "Importantly, we also demonstrate the antioxidant enzyme",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": -0.4521484375,
            "text": "also demonstrate the antioxidant enzyme",
            "probability": 4.76837158203125e-07
        }
    ],
    "52bf1f1303868f1b06000014_6": [
        {
            "start_logit": 8.578125,
            "end_logit": 5.703125,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose peroxides.",
            "probability": 0.9912109375
        },
        {
            "start_logit": 8.578125,
            "end_logit": 0.88037109375,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme",
            "probability": 0.00799560546875
        },
        {
            "start_logit": 8.578125,
            "end_logit": -2.4765625,
            "text": "Perox",
            "probability": 0.0002779960632324219
        },
        {
            "start_logit": -0.71044921875,
            "end_logit": 5.703125,
            "text": "antioxidant enzyme that uses cysteine residues to decompose peroxides.",
            "probability": 9.161233901977539e-05
        },
        {
            "start_logit": 8.578125,
            "end_logit": -4.68359375,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that",
            "probability": 3.045797348022461e-05
        },
        {
            "start_logit": 8.578125,
            "end_logit": -4.7734375,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to",
            "probability": 2.7954578399658203e-05
        },
        {
            "start_logit": -1.9287109375,
            "end_logit": 5.703125,
            "text": ".",
            "probability": 2.7060508728027344e-05
        },
        {
            "start_logit": 8.578125,
            "end_logit": -4.96484375,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues",
            "probability": 2.300739288330078e-05
        },
        {
            "start_logit": 8.578125,
            "end_logit": -5.30859375,
            "text": "Peroxiredoxin 2 (Prx2) is",
            "probability": 1.633167266845703e-05
        },
        {
            "start_logit": 8.578125,
            "end_logit": -5.49609375,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose peroxide",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": 8.578125,
            "end_logit": -5.62890625,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decomp",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": 8.578125,
            "end_logit": -5.63671875,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose peroxides",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": 8.578125,
            "end_logit": -5.91015625,
            "text": "Peroxiredoxin 2 (Prx2) is an",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -6.04296875,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -6.0546875,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -6.3359375,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -6.52734375,
            "text": "Peroxiredoxin 2 (Prx2)",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -6.87890625,
            "text": "Peroxiredoxin 2 (Prx2",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -6.96875,
            "text": "Peroxiredoxin 2",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 8.578125,
            "end_logit": -7.0390625,
            "text": "Peroxiredoxin 2 (Pr",
            "probability": 2.9206275939941406e-06
        }
    ],
    "52bf1f1303868f1b06000014_7": [
        {
            "start_logit": 8.7890625,
            "end_logit": 0.336669921875,
            "text": "antioxidant enzyme",
            "probability": 0.8505859375
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -1.4541015625,
            "text": "antioxidant",
            "probability": 0.14208984375
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -6.05078125,
            "text": "antioxidant enzyme,",
            "probability": 0.0014324188232421875
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -6.89453125,
            "text": "antioxidant enzyme, was the most upregulated while",
            "probability": 0.0006160736083984375
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -7.0703125,
            "text": "antioxidant enzyme, was",
            "probability": 0.0005168914794921875
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -7.09765625,
            "text": "antioxidant enzyme, was the most upregulated",
            "probability": 0.0005030632019042969
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -7.09765625,
            "text": "antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3)",
            "probability": 0.0005030632019042969
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -7.1640625,
            "text": "antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3), a pro-apoptotic protein, was the most downregulated",
            "probability": 0.0004703998565673828
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -7.1875,
            "text": "antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3), a pro-apoptotic protein, was the most downregulated, implying a",
            "probability": 0.00045943260192871094
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -7.20703125,
            "text": "antioxidant enzyme, was the",
            "probability": 0.0004506111145019531
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -7.23046875,
            "text": "antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3), a pro-apoptotic protein,",
            "probability": 0.0004401206970214844
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -7.2734375,
            "text": "antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3), a",
            "probability": 0.00042176246643066406
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -7.27734375,
            "text": "antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3), a pro-apoptotic protein, was the most downregulated,",
            "probability": 0.0004200935363769531
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -7.27734375,
            "text": "antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3), a pro-apoptotic",
            "probability": 0.0004200935363769531
        },
        {
            "start_logit": 8.7890625,
            "end_logit": -7.27734375,
            "text": "antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3",
            "probability": 0.0004200935363769531
        },
        {
            "start_logit": -5.4609375,
            "end_logit": 0.336669921875,
            "text": "an antioxidant enzyme",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 0.336669921875,
            "text": ", an antioxidant enzyme",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.4609375,
            "end_logit": -1.4541015625,
            "text": "an antioxidant",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 0.336669921875,
            "text": "Peroxiredoxin 2 (PRDX2), an antioxidant enzyme",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 0.336669921875,
            "text": "(PRDX2), an antioxidant enzyme",
            "probability": 5.960464477539063e-08
        }
    ],
    "52bf1f1303868f1b06000014_8": [
        {
            "start_logit": 8.0078125,
            "end_logit": 3.228515625,
            "text": "antioxidant enzyme",
            "probability": 0.9970703125
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -3.1875,
            "text": "antioxidant",
            "probability": 0.0016336441040039062
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -4.41015625,
            "text": "antioxidant enzyme,",
            "probability": 0.00048089027404785156
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -4.6875,
            "text": "antioxidant enzyme, and latexin, an inhibitor of carboxypeptidase, increased.",
            "probability": 0.00036454200744628906
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -5.08203125,
            "text": "antioxidant enzyme, and latexin, an inhibitor of carboxypeptidase",
            "probability": 0.0002446174621582031
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -5.54296875,
            "text": "antioxidant enzyme, and latexin, an inhibitor of carboxypeptidase,",
            "probability": 0.00015556812286376953
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.05078125,
            "text": "antioxidant enzyme, and latexin, an inhibitor of carboxypeptidase, increased",
            "probability": 9.28640365600586e-05
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.19140625,
            "text": "antioxidant enzyme, and",
            "probability": 8.07046890258789e-05
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.73046875,
            "text": "antioxidant enzyme, and latexin, an",
            "probability": 4.744529724121094e-05
        },
        {
            "start_logit": -6.0546875,
            "end_logit": 3.228515625,
            "text": "an antioxidant enzyme",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.734375,
            "end_logit": 3.228515625,
            "text": "enzyme",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 3.228515625,
            "text": ", an antioxidant enzyme",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 3.228515625,
            "text": "peroxiredoxin 2, an antioxidant enzyme",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.0546875,
            "end_logit": -3.1875,
            "text": "an antioxidant",
            "probability": 0.0
        },
        {
            "start_logit": -5.01953125,
            "end_logit": -4.6875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.296875,
            "end_logit": -4.6875,
            "text": "carboxypeptidase, increased.",
            "probability": 0.0
        },
        {
            "start_logit": -5.296875,
            "end_logit": -5.08203125,
            "text": "carboxypeptidase",
            "probability": 0.0
        },
        {
            "start_logit": -6.0546875,
            "end_logit": -4.41015625,
            "text": "an antioxidant enzyme,",
            "probability": 0.0
        },
        {
            "start_logit": -7.33984375,
            "end_logit": -3.1875,
            "text": ", an antioxidant",
            "probability": 0.0
        },
        {
            "start_logit": -6.0546875,
            "end_logit": -4.6875,
            "text": "an antioxidant enzyme, and latexin, an inhibitor of carboxypeptidase, increased.",
            "probability": 0.0
        }
    ],
    "52bf1f1303868f1b06000014_9": [
        {
            "start_logit": 6.1640625,
            "end_logit": 0.3896484375,
            "text": "antioxidant enzymes",
            "probability": 0.98095703125
        },
        {
            "start_logit": 6.1640625,
            "end_logit": -4.4375,
            "text": "antioxidant",
            "probability": 0.00785064697265625
        },
        {
            "start_logit": 6.1640625,
            "end_logit": -5.609375,
            "text": "antioxidant enzymes involved",
            "probability": 0.0024318695068359375
        },
        {
            "start_logit": 6.1640625,
            "end_logit": -5.6796875,
            "text": "antioxidant enzymes involved in protein and lipid protection against oxidative injury and",
            "probability": 0.00226593017578125
        },
        {
            "start_logit": 6.1640625,
            "end_logit": -6.2890625,
            "text": "antioxidant enzymes involved in protein and lipid protection against oxidative injury",
            "probability": 0.001232147216796875
        },
        {
            "start_logit": 6.1640625,
            "end_logit": -6.40625,
            "text": "antioxidant enzymes involved in protein and lipid protection",
            "probability": 0.0010967254638671875
        },
        {
            "start_logit": -0.69970703125,
            "end_logit": 0.3896484375,
            "text": "Peroxiredoxins are antioxidant enzymes",
            "probability": 0.0010251998901367188
        },
        {
            "start_logit": 6.1640625,
            "end_logit": -6.640625,
            "text": "antioxidant enzymes involved in protein and lipid protection against",
            "probability": 0.0008668899536132812
        },
        {
            "start_logit": 6.1640625,
            "end_logit": -6.6640625,
            "text": "antioxidant enzymes involved in protein and lipid protection against oxidative",
            "probability": 0.00084686279296875
        },
        {
            "start_logit": 6.1640625,
            "end_logit": -6.76171875,
            "text": "antioxidant enzymes involved in protein and lipid protection against oxidative injury and in cellular signalling pathways regulating apoptosis",
            "probability": 0.0007681846618652344
        },
        {
            "start_logit": 6.1640625,
            "end_logit": -6.8984375,
            "text": "antioxidant enzymes involved in",
            "probability": 0.0006699562072753906
        },
        {
            "start_logit": -3.65234375,
            "end_logit": 0.3896484375,
            "text": ". Peroxiredoxins are antioxidant enzymes",
            "probability": 5.370378494262695e-05
        },
        {
            "start_logit": -5.44921875,
            "end_logit": 0.3896484375,
            "text": "peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": -0.69970703125,
            "end_logit": -4.4375,
            "text": "Peroxiredoxins are antioxidant",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -0.69970703125,
            "end_logit": -5.609375,
            "text": "Peroxiredoxins are antioxidant enzymes involved",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -0.69970703125,
            "end_logit": -5.6796875,
            "text": "Peroxiredoxins are antioxidant enzymes involved in protein and lipid protection against oxidative injury and",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 0.3896484375,
            "text": "iredoxins are antioxidant enzymes",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -6.984375,
            "end_logit": 0.3896484375,
            "text": "(PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 0.3896484375,
            "text": "of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 0.3896484375,
            "text": "oxins are antioxidant enzymes",
            "probability": 1.4901161193847656e-06
        }
    ],
    "603251f81cb411341a00013a_1": [
        {
            "start_logit": 8.7109375,
            "end_logit": 8.75,
            "text": "c-Myc",
            "probability": 1.0
        },
        {
            "start_logit": -1.888671875,
            "end_logit": 8.75,
            "text": "Myc",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -2.19921875,
            "text": "c",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": -5.83984375,
            "end_logit": 8.75,
            "text": "-Myc",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -6.203125,
            "text": "c-Myc, also found to interact with WDR5.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -6.203125,
            "text": "c-Myc, also found to interact with WDR5. We indeed demonstrate that interaction with c-Myc is critical for this function.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.7109375,
            "end_logit": -6.24609375,
            "text": "c-Myc, also found to interact with WDR5. We indeed demonstrate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.6875,
            "end_logit": 8.75,
            "text": "and c-Myc",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.888671875,
            "end_logit": -6.203125,
            "text": "Myc, also found to interact with WDR5.",
            "probability": 0.0
        },
        {
            "start_logit": -1.888671875,
            "end_logit": -6.203125,
            "text": "Myc, also found to interact with WDR5. We indeed demonstrate that interaction with c-Myc is critical for this function.",
            "probability": 0.0
        },
        {
            "start_logit": -1.888671875,
            "end_logit": -6.24609375,
            "text": "Myc, also found to interact with WDR5. We indeed demonstrate",
            "probability": 0.0
        },
        {
            "start_logit": -1.888671875,
            "end_logit": -6.29296875,
            "text": "Myc, also found to interact with WDR5. We indeed demonstrate that interaction with c-Myc is critical for this function. By showing that ATR",
            "probability": 0.0
        },
        {
            "start_logit": -3.4453125,
            "end_logit": -5.44140625,
            "text": ". Mechanistically, WDR5 functions to sustain proper execution of DNA replication",
            "probability": 0.0
        },
        {
            "start_logit": -6.6875,
            "end_logit": -2.19921875,
            "text": "and c",
            "probability": 0.0
        },
        {
            "start_logit": -3.4453125,
            "end_logit": -6.0859375,
            "text": ". Focusing on epigenetic regulators, we identified",
            "probability": 0.0
        },
        {
            "start_logit": -3.4453125,
            "end_logit": -6.17578125,
            "text": ". Mechanistically, WDR5 functions to sustain proper execution of DNA replication in PDAC",
            "probability": 0.0
        },
        {
            "start_logit": -3.443359375,
            "end_logit": -6.203125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -3.443359375,
            "end_logit": -6.203125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -3.443359375,
            "end_logit": -6.203125,
            "text": ". We indeed demonstrate that interaction with c-Myc is critical for this function.",
            "probability": 0.0
        },
        {
            "start_logit": -3.4453125,
            "end_logit": -6.203125,
            "text": ".",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_1": [
        {
            "start_logit": 9.265625,
            "end_logit": 9.328125,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -0.72705078125,
            "end_logit": 9.328125,
            "text": "cancer",
            "probability": 4.57763671875e-05
        },
        {
            "start_logit": 9.265625,
            "end_logit": -1.263671875,
            "text": "metastatic",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": -5.8046875,
            "end_logit": 9.328125,
            "text": "prostate cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -5.828125,
            "text": "metastatic castration-resistant",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.1015625,
            "text": "metastatic castration-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.22265625,
            "end_logit": 9.328125,
            "text": "castration-resistant prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.47265625,
            "text": "metastatic castration",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.578125,
            "text": "metastatic castration-resistant prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 9.328125,
            "text": "resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.9375,
            "text": "metastatic castration-resistant prostate cancer (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.0703125,
            "text": "metastatic castration-resistant prostate cancer (ELM-PC 4): a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.14453125,
            "text": "metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.16015625,
            "text": "metastatic castration-resistant prostate cancer (ELM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.21875,
            "text": "metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.23046875,
            "text": "metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.23046875,
            "text": "metastatic castration-resistant prostate cancer (ELM-PC 4): a double",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.26171875,
            "text": "metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.26953125,
            "text": "metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 9.328125,
            "text": "naive metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f01def6e394741000045_2": [
        {
            "start_logit": 9.1953125,
            "end_logit": 9.28125,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -0.86865234375,
            "end_logit": 9.28125,
            "text": "cancer",
            "probability": 4.297494888305664e-05
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -1.345703125,
            "text": "metastatic",
            "probability": 2.4497509002685547e-05
        },
        {
            "start_logit": -5.09765625,
            "end_logit": 9.28125,
            "text": "prostate cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.1015625,
            "text": "metastatic castration-resistant",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.265625,
            "end_logit": 9.28125,
            "text": "castration-resistant prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.21484375,
            "text": "metastatic castration-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.55859375,
            "text": "metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.703125,
            "text": "metastatic castration-resistant prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.75390625,
            "text": "metastatic castration",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.84765625,
            "text": "metastatic castration-resistant prostate cancer. We",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9375,
            "end_logit": 9.28125,
            "text": "resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.89453125,
            "text": "metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.8984375,
            "text": "metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.07421875,
            "end_logit": 9.28125,
            "text": "for metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.9921875,
            "text": "metastatic castration-resistant prostate cancer.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.9921875,
            "text": "metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.07421875,
            "text": "metastatic castration-resistant prostate cancer. We assessed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.0859375,
            "text": "metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.17578125,
            "text": "metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f01def6e394741000045_3": [
        {
            "start_logit": 9.2421875,
            "end_logit": 9.2890625,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -0.86865234375,
            "end_logit": 9.2890625,
            "text": "cancer",
            "probability": 4.07099723815918e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -1.33984375,
            "text": "metastatic",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -5.57421875,
            "end_logit": 9.2890625,
            "text": "prostate cancer",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -5.93359375,
            "text": "metastatic castration-resistant",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.1171875,
            "text": "metastatic castration-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 9.2890625,
            "text": "castration-resistant prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.4921875,
            "text": "metastatic castration",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.5859375,
            "text": "metastatic castration-resistant prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 9.2890625,
            "text": "with metastatic castration-resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 9.2890625,
            "text": "resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.08984375,
            "text": "metastatic castration-resistant prostate cancer, radiographic progression-free survival was prolonged with orteronel plus prednisone versus placebo plus prednisone.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 9.2890625,
            "text": "NTERPRETATION: In chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 9.2890625,
            "text": "In chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.25390625,
            "text": "metastatic castration-resistant prostate cancer,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.2890625,
            "text": "patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 9.2890625,
            "text": ": In chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.2890625,
            "text": "ERPRETATION: In chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 9.2890625,
            "text": "-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 9.2890625,
            "text": "TATION: In chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f01def6e394741000045_4": [
        {
            "start_logit": 9.2265625,
            "end_logit": 9.234375,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.013671875,
            "end_logit": 9.234375,
            "text": "cancer",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -1.3369140625,
            "text": "metastatic",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": -5.50390625,
            "end_logit": 9.234375,
            "text": "prostate cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.59765625,
            "end_logit": 9.234375,
            "text": "castration-resistant prostate cancer",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.1015625,
            "text": "metastatic castration-resistant",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.16796875,
            "text": "metastatic castration-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.4140625,
            "text": "metastatic castration-resistant prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.421875,
            "end_logit": 9.234375,
            "text": "in metastatic castration-resistant prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.50390625,
            "end_logit": 9.234375,
            "text": "On the basis of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.54296875,
            "text": "metastatic castration-resistant prostate cancer.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.76171875,
            "end_logit": 9.234375,
            "text": "resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.0546875,
            "text": "metastatic castration",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.078125,
            "end_logit": 9.234375,
            "text": "basis of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.15625,
            "end_logit": 9.234375,
            "text": "the basis of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.234375,
            "text": "orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 9.234375,
            "text": "data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 9.234375,
            "text": "-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 9.234375,
            "text": "of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.390625,
            "end_logit": 9.234375,
            "text": "these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f01def6e394741000045_5": [
        {
            "start_logit": 9.25,
            "end_logit": 9.2890625,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -0.818359375,
            "end_logit": 9.2890625,
            "text": "cancer",
            "probability": 4.267692565917969e-05
        },
        {
            "start_logit": 9.25,
            "end_logit": -1.2666015625,
            "text": "metastatic",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": -5.75,
            "end_logit": 9.2890625,
            "text": "prostate cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.08203125,
            "end_logit": 9.2890625,
            "text": "castration-resistant prostate cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.0546875,
            "text": "metastatic castration-resistant",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.171875,
            "text": "metastatic castration-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.7421875,
            "text": "metastatic castration",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.76171875,
            "text": "metastatic castration-resistant prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8203125,
            "end_logit": 9.2890625,
            "text": "resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.8125,
            "text": "metastatic castration-resistant prostate cancer that",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.125,
            "text": "metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 9.2890625,
            "text": "with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.2890625,
            "text": "metastatic castration-resistant prostate cancer that has",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.29296875,
            "text": "metastatic castration-resistant prostate cancer that has progressed during",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.29296875,
            "text": "metastatic castration-resistant prostate cancer that has progressed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.3046875,
            "text": "metastatic castration-resistant prostate cancer that has progressed during or after",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.2890625,
            "text": "-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.2890625,
            "text": "comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.34765625,
            "text": "metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy:",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f01def6e394741000045_6": [
        {
            "start_logit": 9.28125,
            "end_logit": 9.296875,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -0.83154296875,
            "end_logit": 9.296875,
            "text": "cancer",
            "probability": 4.07099723815918e-05
        },
        {
            "start_logit": 9.28125,
            "end_logit": -1.2080078125,
            "text": "metastatic",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": -5.875,
            "end_logit": 9.296875,
            "text": "prostate cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.015625,
            "end_logit": 9.296875,
            "text": "castration-resistant prostate cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.06640625,
            "text": "metastatic castration-resistant",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.1328125,
            "text": "metastatic castration-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.2734375,
            "text": "metastatic castration-resistant prostate cancer that",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.68359375,
            "text": "metastatic castration-resistant prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.6953125,
            "text": "metastatic castration",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.921875,
            "end_logit": 9.296875,
            "text": "resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.953125,
            "text": "metastatic castration-resistant prostate cancer that progressed after docetaxel therapy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.04296875,
            "text": "metastatic castration-resistant prostate cancer that progressed",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.1484375,
            "text": "metastatic castration-resistant prostate cancer that progressed after",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.203125,
            "text": "metastatic castration-resistant prostate cancer that progressed after docetaxel therapy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.2734375,
            "text": "metastatic castration-resistant prostate cancer that progressed after docetaxel",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34375,
            "end_logit": 9.296875,
            "text": "-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.296875,
            "text": "patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.296875,
            "text": "with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.296875,
            "text": "This study examined orteronel in patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f01def6e394741000045_7": [
        {
            "start_logit": 9.109375,
            "end_logit": 9.28125,
            "text": "castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -0.91064453125,
            "end_logit": 9.28125,
            "text": "cancer",
            "probability": 4.4345855712890625e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -1.646484375,
            "text": "castration",
            "probability": 1.7940998077392578e-05
        },
        {
            "start_logit": -5.59765625,
            "end_logit": 9.28125,
            "text": "prostate cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.1640625,
            "text": "castration-resistant",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.53125,
            "end_logit": 9.28125,
            "text": "-resistant prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.83984375,
            "end_logit": 9.28125,
            "text": "resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.67578125,
            "text": "castration-resistant prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 9.28125,
            "text": "with castration-resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.8203125,
            "text": "castration-resistant prostate cancer.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.14453125,
            "text": "castration-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46875,
            "end_logit": 9.28125,
            "text": "A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 9.28125,
            "text": "patients with castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 9.28125,
            "text": "orteronel in Japanese patients with castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 9.28125,
            "text": "multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75,
            "end_logit": 9.28125,
            "text": "of orteronel in Japanese patients with castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 9.28125,
            "text": "-dose study of orteronel in Japanese patients with castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7578125,
            "end_logit": 9.28125,
            "text": "phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.91064453125,
            "end_logit": -6.8203125,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -6.9296875,
            "end_logit": -1.646484375,
            "text": "with castration",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_8": [
        {
            "start_logit": 9.0078125,
            "end_logit": 9.3359375,
            "text": "castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -0.67822265625,
            "end_logit": 9.3359375,
            "text": "cancer",
            "probability": 6.204843521118164e-05
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -1.6875,
            "text": "castration",
            "probability": 1.633167266845703e-05
        },
        {
            "start_logit": -5.33984375,
            "end_logit": 9.3359375,
            "text": "prostate cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 9.3359375,
            "text": "with castration-resistant prostate cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.55859375,
            "end_logit": 9.3359375,
            "text": "resistant prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.23828125,
            "text": "castration-resistant",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.671875,
            "end_logit": 9.3359375,
            "text": "-resistant prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 9.3359375,
            "text": "safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effect of orteronel with or without prednisolone in Japanese patients with castration-resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.859375,
            "text": "castration-resistant prostate cancer (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 9.3359375,
            "text": "patients with castration-resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.9296875,
            "text": "castration-resistant prostate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.296875,
            "end_logit": 9.3359375,
            "text": "pharmacokinetics, pharmacodynamics, and antitumor effect of orteronel with or without prednisolone in Japanese patients with castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 9.3359375,
            "text": "antitumor effect of orteronel with or without prednisolone in Japanese patients with castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.00390625,
            "text": "castration-resistant prostate cancer (CRPC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.0078125,
            "text": "castration-resistant prostate cancer (CRPC).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.01171875,
            "text": "castration-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 9.3359375,
            "text": "tolerability, pharmacokinetics, pharmacodynamics, and antitumor effect of orteronel with or without prednisolone in Japanese patients with castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 9.3359375,
            "text": ", and antitumor effect of orteronel with or without prednisolone in Japanese patients with castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40625,
            "end_logit": 9.3359375,
            "text": "pharmacodynamics, and antitumor effect of orteronel with or without prednisolone in Japanese patients with castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f01def6e394741000045_9": [
        {
            "start_logit": 8.9921875,
            "end_logit": 9.234375,
            "text": "castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.015625,
            "end_logit": 9.234375,
            "text": "cancer",
            "probability": 4.5418739318847656e-05
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -1.8134765625,
            "text": "castration",
            "probability": 1.6033649444580078e-05
        },
        {
            "start_logit": -5.2578125,
            "end_logit": 9.234375,
            "text": "prostate cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.9296875,
            "end_logit": 9.234375,
            "text": "for castration-resistant prostate cancer",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -6.15625,
            "text": "castration-resistant",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.59765625,
            "end_logit": 9.234375,
            "text": "resistant prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -6.375,
            "text": "castration-resistant prostate cancer.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 9.234375,
            "text": "-resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -6.68359375,
            "text": "castration-resistant prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -6.85546875,
            "text": "castration-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.234375,
            "text": "treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 9.234375,
            "text": "nonsteroidal, selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.234375,
            "text": "selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 9.234375,
            "text": ", selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 9.234375,
            "text": "in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.234375,
            "text": "a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.234375,
            "text": "of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.234375,
            "text": "inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.015625,
            "end_logit": -6.375,
            "text": "cancer.",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_10": [
        {
            "start_logit": 8.65625,
            "end_logit": 9.140625,
            "text": "castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.2509765625,
            "end_logit": 9.140625,
            "text": "cancer",
            "probability": 4.988908767700195e-05
        },
        {
            "start_logit": 8.65625,
            "end_logit": -2.45703125,
            "text": "castration",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -2.98828125,
            "end_logit": 9.140625,
            "text": "of castration-resistant prostate cancer",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -5.37109375,
            "end_logit": 9.140625,
            "text": "prostate cancer",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.4375,
            "end_logit": 9.140625,
            "text": "resistant prostate cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.12890625,
            "text": "castration-resistant prostate cancer.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.625,
            "end_logit": 9.140625,
            "text": "-resistant prostate cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.2265625,
            "text": "castration-resistant",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 9.140625,
            "text": "treatment of castration-resistant prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.25,
            "end_logit": 9.140625,
            "text": "for the treatment of castration-resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.390625,
            "end_logit": 9.140625,
            "text": "selected as a candidate for clinical evaluation and is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.140625,
            "text": "in phase III clinical trials for the treatment of castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.98828125,
            "end_logit": -2.45703125,
            "text": "of castration",
            "probability": 0.0
        },
        {
            "start_logit": -1.2509765625,
            "end_logit": -6.12890625,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -2.98828125,
            "end_logit": -6.12890625,
            "text": "of castration-resistant prostate cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -2.98828125,
            "end_logit": -6.2265625,
            "text": "of castration-resistant",
            "probability": 0.0
        },
        {
            "start_logit": -6.91796875,
            "end_logit": -2.45703125,
            "text": "treatment of castration",
            "probability": 0.0
        },
        {
            "start_logit": -7.25,
            "end_logit": -2.45703125,
            "text": "for the treatment of castration",
            "probability": 0.0
        },
        {
            "start_logit": -7.33984375,
            "end_logit": -2.45703125,
            "text": "orteronel [TAK-700]) was selected as a candidate for clinical evaluation and is currently in phase III clinical trials for the treatment of castration",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_11": [
        {
            "start_logit": 9.2578125,
            "end_logit": 9.296875,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -0.85498046875,
            "end_logit": 9.296875,
            "text": "cancer",
            "probability": 4.035234451293945e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -1.2900390625,
            "text": "metastatic",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": -5.765625,
            "end_logit": 9.296875,
            "text": "prostate cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -5.93359375,
            "text": "metastatic castration-resistant",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.015625,
            "text": "metastatic castration-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.24609375,
            "end_logit": 9.296875,
            "text": "castration-resistant prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.48828125,
            "text": "metastatic castration",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.5390625,
            "text": "metastatic castration-resistant prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 9.296875,
            "text": "resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.109375,
            "text": "metastatic castration-resistant prostate cancer.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 9.296875,
            "text": "with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.296875,
            "text": "-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 9.296875,
            "text": "patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 9.296875,
            "text": "orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": 9.296875,
            "text": "l in chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.296875,
            "text": "in chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.671875,
            "end_logit": 9.296875,
            "text": "assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.85498046875,
            "end_logit": -7.109375,
            "text": "cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -1.2900390625,
            "text": "with metastatic",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_12": [
        {
            "start_logit": 8.9921875,
            "end_logit": 9.234375,
            "text": "castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.015625,
            "end_logit": 9.234375,
            "text": "cancer",
            "probability": 4.5418739318847656e-05
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -1.8134765625,
            "text": "castration",
            "probability": 1.6033649444580078e-05
        },
        {
            "start_logit": -5.2578125,
            "end_logit": 9.234375,
            "text": "prostate cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.9296875,
            "end_logit": 9.234375,
            "text": "for castration-resistant prostate cancer",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -6.15625,
            "text": "castration-resistant",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.59765625,
            "end_logit": 9.234375,
            "text": "resistant prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -6.375,
            "text": "castration-resistant prostate cancer.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 9.234375,
            "text": "-resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -6.68359375,
            "text": "castration-resistant prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -6.85546875,
            "text": "castration-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.234375,
            "text": "treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 9.234375,
            "text": "nonsteroidal, selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.234375,
            "text": "selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 9.234375,
            "text": ", selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 9.234375,
            "text": "in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.234375,
            "text": "a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.234375,
            "text": "of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.234375,
            "text": "inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.015625,
            "end_logit": -6.375,
            "text": "cancer.",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_13": [
        {
            "start_logit": 9.2578125,
            "end_logit": 9.296875,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -0.8251953125,
            "end_logit": 9.296875,
            "text": "cancer",
            "probability": 4.1365623474121094e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -1.240234375,
            "text": "metastatic",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": -5.5234375,
            "end_logit": 9.296875,
            "text": "prostate cancer",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.9140625,
            "end_logit": 9.296875,
            "text": "castration-resistant prostate cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -5.9375,
            "text": "metastatic castration-resistant",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.0703125,
            "text": "metastatic castration-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.6015625,
            "text": "metastatic castration-resistant prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.765625,
            "end_logit": 9.296875,
            "text": "resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.7890625,
            "text": "metastatic castration",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 9.296875,
            "text": "with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.09375,
            "text": "metastatic castration-resistant prostate cancer.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 9.296875,
            "text": "-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 9.296875,
            "text": "investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 9.296875,
            "text": "-in patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 9.296875,
            "text": "patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 9.296875,
            "text": "-an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.296875,
            "text": "in patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.296875,
            "text": "--in patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 9.296875,
            "text": "17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        }
    ],
    "56c1f01def6e394741000045_14": [
        {
            "start_logit": 9.234375,
            "end_logit": 9.21875,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.041015625,
            "end_logit": 9.21875,
            "text": "cancer",
            "probability": 3.451108932495117e-05
        },
        {
            "start_logit": 9.234375,
            "end_logit": -1.322265625,
            "text": "metastatic",
            "probability": 2.6464462280273438e-05
        },
        {
            "start_logit": -5.31640625,
            "end_logit": 9.21875,
            "text": "prostate cancer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.39453125,
            "end_logit": 9.21875,
            "text": "castration-resistant prostate cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.83984375,
            "end_logit": 9.21875,
            "text": "in metastatic castration-resistant prostate cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.03515625,
            "text": "metastatic castration-resistant",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.21484375,
            "text": "metastatic castration-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 9.21875,
            "text": "On the basis of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.31640625,
            "text": "metastatic castration-resistant prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.51953125,
            "text": "metastatic castration-resistant prostate cancer.FUNDING: Millennium Pharmaceuticals",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.67578125,
            "text": "metastatic castration-resistant prostate cancer.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.6953125,
            "text": "metastatic castration-resistant prostate cancer.FUNDING: Millennium Pharmaceuticals, Inc, a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.69140625,
            "end_logit": 9.21875,
            "text": "resistant prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.7265625,
            "text": "metastatic castration-resistant prostate cancer.FUNDING: Millennium Pharmaceuticals, Inc, a wholl",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.76171875,
            "text": "metastatic castration-resistant prostate cancer.FUNDING: Millennium Pharmaceuticals, Inc, a wholly owned subsid",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.84765625,
            "text": "metastatic castration-resistant prostate cancer.FUNDING: Millennium Pharmaceuticals, Inc, a wholly owned subsidiary",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.84765625,
            "text": "metastatic castration-resistant prostate cancer.FUNDING: Millennium",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.8671875,
            "text": "metastatic castration-resistant prostate cancer.FUNDING: Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 9.21875,
            "text": "basis of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 5.960464477539063e-08
        }
    ],
    "61f919cc882a024a10000048_1": [
        {
            "start_logit": 2.80859375,
            "end_logit": 7.51953125,
            "text": "4660 participants from 218",
            "probability": 0.37109375
        },
        {
            "start_logit": 2.67578125,
            "end_logit": 7.51953125,
            "text": "218",
            "probability": 0.32470703125
        },
        {
            "start_logit": 2.80859375,
            "end_logit": 7.28125,
            "text": "46",
            "probability": 0.29345703125
        },
        {
            "start_logit": -2.39453125,
            "end_logit": 7.51953125,
            "text": ". Other parts of this project focus on patients with cancer and infection.METHODS: We conducted a pilot study involving 4660 participants from 218",
            "probability": 0.002040863037109375
        },
        {
            "start_logit": -2.39453125,
            "end_logit": 7.51953125,
            "text": ".METHODS: We conducted a pilot study involving 4660 participants from 218",
            "probability": 0.002040863037109375
        },
        {
            "start_logit": -2.39453125,
            "end_logit": 7.28125,
            "text": ". Other parts of this project focus on patients with cancer and infection.METHODS: We conducted a pilot study involving 46",
            "probability": 0.0016078948974609375
        },
        {
            "start_logit": -2.39453125,
            "end_logit": 7.28125,
            "text": ".METHODS: We conducted a pilot study involving 46",
            "probability": 0.0016078948974609375
        },
        {
            "start_logit": -3.234375,
            "end_logit": 7.51953125,
            "text": "study involving 4660 participants from 218",
            "probability": 0.000881195068359375
        },
        {
            "start_logit": -3.234375,
            "end_logit": 7.28125,
            "text": "study involving 46",
            "probability": 0.00069427490234375
        },
        {
            "start_logit": -4.16015625,
            "end_logit": 7.51953125,
            "text": "involving 4660 participants from 218",
            "probability": 0.0003490447998046875
        },
        {
            "start_logit": -4.17578125,
            "end_logit": 7.51953125,
            "text": "a pilot study involving 4660 participants from 218",
            "probability": 0.00034356117248535156
        },
        {
            "start_logit": -4.296875,
            "end_logit": 7.51953125,
            "text": "from 218",
            "probability": 0.0003044605255126953
        },
        {
            "start_logit": -4.16015625,
            "end_logit": 7.28125,
            "text": "involving 46",
            "probability": 0.0002751350402832031
        },
        {
            "start_logit": -4.17578125,
            "end_logit": 7.28125,
            "text": "a pilot study involving 46",
            "probability": 0.000270843505859375
        },
        {
            "start_logit": -5.30859375,
            "end_logit": 7.51953125,
            "text": "conducted a pilot study involving 4660 participants from 218",
            "probability": 0.00011068582534790039
        },
        {
            "start_logit": -5.37109375,
            "end_logit": 7.51953125,
            "text": "participants from 218",
            "probability": 0.00010401010513305664
        },
        {
            "start_logit": -5.30859375,
            "end_logit": 7.28125,
            "text": "conducted a pilot study involving 46",
            "probability": 8.690357208251953e-05
        },
        {
            "start_logit": -5.82421875,
            "end_logit": 7.51953125,
            "text": "We conducted a pilot study involving 4660 participants from 218",
            "probability": 6.61015510559082e-05
        },
        {
            "start_logit": -5.88671875,
            "end_logit": 7.51953125,
            "text": "METHODS: We conducted a pilot study involving 4660 participants from 218",
            "probability": 6.210803985595703e-05
        },
        {
            "start_logit": -5.82421875,
            "end_logit": 7.28125,
            "text": "We conducted a pilot study involving 46",
            "probability": 5.1856040954589844e-05
        }
    ],
    "606ae4fd94d57fd879000056_1": [
        {
            "start_logit": 7.5625,
            "end_logit": 7.73046875,
            "text": "CYP2D6",
            "probability": 1.0
        },
        {
            "start_logit": 7.5625,
            "end_logit": -6.8828125,
            "text": "CYP2D6 ultrarapid metabolizer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.5625,
            "end_logit": -7.01953125,
            "text": "CYP2D6 ultrarapid metabolizer phenotype",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.5625,
            "end_logit": -7.12109375,
            "text": "CYP2D6 ultrarapi",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.5625,
            "end_logit": -7.125,
            "text": "CYP2D6 ultrarapid metabolizer phenotype may",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.5625,
            "end_logit": -7.1328125,
            "text": "CYP2D6 ultrarapid",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.5625,
            "end_logit": -7.16796875,
            "text": "CYP2D6 ultrarapid metabolizer phenotype may expose their infants",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.5625,
            "end_logit": -7.18359375,
            "text": "CYP2D6 ultra",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.5625,
            "end_logit": -7.20703125,
            "text": "CYP2D6 ultrarapid metabol",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.5625,
            "end_logit": -7.234375,
            "text": "CYP2D6 ultrara",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.5625,
            "end_logit": -7.3359375,
            "text": "CYP2D6 ultrarapid metabolizer phenotype may expose their infants to risk of adverse events when taking codeine while breastfeeding",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.5625,
            "end_logit": -7.3515625,
            "text": "CYP2D6 ultrarapid metabolizer phenotype may expose their infants to risk of adverse events when taking codeine while breastfeeding, by producing more",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.6484375,
            "end_logit": -7.06640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -7.06640625,
            "text": "infants to risk of adverse events when taking codeine while breastfeeding, by producing more of the active metabolite, morphine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -7.06640625,
            "text": ", morphine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -7.06640625,
            "text": "taking codeine while breastfeeding, by producing more of the active metabolite, morphine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -7.06640625,
            "text": "expose their infants to risk of adverse events when taking codeine while breastfeeding, by producing more of the active metabolite, morphine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -7.06640625,
            "text": "adverse events when taking codeine while breastfeeding, by producing more of the active metabolite, morphine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -7.16796875,
            "text": "infants",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -7.16796875,
            "text": "expose their infants",
            "probability": 0.0
        }
    ],
    "5e808ef4835f4e477700002a_1": [
        {
            "start_logit": 9.2265625,
            "end_logit": 8.8359375,
            "text": "angiotensin II",
            "probability": 1.0
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -1.4111328125,
            "text": "angiotensin",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": -2.0703125,
            "end_logit": 8.8359375,
            "text": "II",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.8203125,
            "text": "angiotensin II receptor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.30078125,
            "text": "angiotensin II receptor antagonist for administrating cardiovascular diseases.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 8.8359375,
            "text": "approved angiotensin II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 8.8359375,
            "text": "omil (OM), an FDA-approved angiotensin II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 8.8359375,
            "text": "il (OM), an FDA-approved angiotensin II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 8.8359375,
            "text": "OM), an FDA-approved angiotensin II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 8.8359375,
            "text": "oxomil (OM), an FDA-approved angiotensin II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.8359375,
            "text": "an FDA-approved angiotensin II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.8359375,
            "text": "), an FDA-approved angiotensin II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 8.8359375,
            "text": "-approved angiotensin II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 8.8359375,
            "text": "an medoxomil (OM), an FDA-approved angiotensin II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.0703125,
            "end_logit": -6.8203125,
            "text": "II receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -1.4111328125,
            "text": "approved angiotensin",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -1.4111328125,
            "text": "omil (OM), an FDA-approved angiotensin",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": -1.4111328125,
            "text": "il (OM), an FDA-approved angiotensin",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -1.4111328125,
            "text": "OM), an FDA-approved angiotensin",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": -1.4111328125,
            "text": "oxomil (OM), an FDA-approved angiotensin",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_1": [
        {
            "start_logit": 9.140625,
            "end_logit": 8.921875,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 9.140625,
            "end_logit": -1.5234375,
            "text": "H3K",
            "probability": 2.9087066650390625e-05
        },
        {
            "start_logit": -1.7236328125,
            "end_logit": 8.921875,
            "text": "4",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -6.8125,
            "text": "H3K4 residues",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 8.921875,
            "text": "ates H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 8.921875,
            "text": "histone methyltransferase that methylates H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.921875,
            "text": "MLL1 (Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 8.921875,
            "text": "L1 (Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 8.921875,
            "text": "Lineage Leukemia 1), a histone methyltransferase that methylates H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 8.921875,
            "text": "(Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 8.921875,
            "text": "Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 8.921875,
            "text": "methyltransferase that methylates H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.671875,
            "end_logit": 8.921875,
            "text": "a histone methyltransferase that methylates H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.671875,
            "end_logit": 8.921875,
            "text": "methylates H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7236328125,
            "end_logit": -6.8125,
            "text": "4 residues",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -1.5234375,
            "text": "ates H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": -1.5234375,
            "text": "histone methyltransferase that methylates H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -1.5234375,
            "text": "MLL1 (Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -1.5234375,
            "text": "L1 (Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -1.5234375,
            "text": "Lineage Leukemia 1), a histone methyltransferase that methylates H3K",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_2": [
        {
            "start_logit": 9.2890625,
            "end_logit": 8.9453125,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -1.05078125,
            "text": "H3K",
            "probability": 4.5418739318847656e-05
        },
        {
            "start_logit": -1.6396484375,
            "end_logit": 8.9453125,
            "text": "4",
            "probability": 1.7940998077392578e-05
        }
    ],
    "533be71dfd9a95ea0d000009_3": [
        {
            "start_logit": 9.21875,
            "end_logit": 8.9375,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 9.21875,
            "end_logit": -1.2626953125,
            "text": "H3K",
            "probability": 3.707408905029297e-05
        },
        {
            "start_logit": -1.669921875,
            "end_logit": 8.9375,
            "text": "4",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 8.9375,
            "text": "for H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 8.9375,
            "text": "mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.671875,
            "end_logit": 8.9375,
            "text": "lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.9375,
            "text": "leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6875,
            "end_logit": 8.9375,
            "text": "that the mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 8.9375,
            "text": "(MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 8.9375,
            "text": "the mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 8.9375,
            "text": "1 (MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -1.2626953125,
            "text": "for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -1.2626953125,
            "text": "mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.671875,
            "end_logit": -1.2626953125,
            "text": "lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -1.2626953125,
            "text": "leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -1.2626953125,
            "text": "that the mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.7109375,
            "end_logit": -1.2626953125,
            "text": "(MLL1) protein, a histone methyltransferase specific for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": -1.2626953125,
            "text": "the mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": -1.2626953125,
            "text": "1 (MLL1) protein, a histone methyltransferase specific for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -7.34765625,
            "text": "mixed lineage leukemia 1 (MLL1) protein, a",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_4": [
        {
            "start_logit": 9.140625,
            "end_logit": 8.921875,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 9.140625,
            "end_logit": -1.3271484375,
            "text": "H3K",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": -1.6142578125,
            "end_logit": 8.921875,
            "text": "4",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.16015625,
            "text": "H3K4 methyltransferase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.1875,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter, and the H3K4 trimethyltransferase activity",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.19140625,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.28515625,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter, and the H3K4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.296875,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter, and the H3K",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.296875,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter, and the H3K4 trimethyl",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.30078125,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter, and the H3K4 trimethyltransferase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.3203125,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.3203125,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaB",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.35546875,
            "text": "H3K4 methyltransferase complexes are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.35546875,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.359375,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.3671875,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 8.921875,
            "text": "L2 H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 8.921875,
            "text": "MLL2 H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 8.921875,
            "text": "L1 and MLL2 H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6142578125,
            "end_logit": -7.16015625,
            "text": "4 methyltransferase",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_5": [
        {
            "start_logit": 9.2734375,
            "end_logit": 9.0078125,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -1.134765625,
            "text": "H3K",
            "probability": 3.9458274841308594e-05
        },
        {
            "start_logit": -1.52734375,
            "end_logit": 9.0078125,
            "text": "4",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -6.84375,
            "text": "H3K4 methyltransferase activity of the carboxyl-terminal SET domain.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.0078125,
            "text": "H3K4 methyltransferase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.0234375,
            "text": "H3K4 methyltransferase activity",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.04296875,
            "text": "H3K4 methyltransferase activity of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.109375,
            "text": "H3K4 methyltransferase activity of the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.19921875,
            "text": "H3K4 methyltransferase activity of the carboxyl-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.26171875,
            "text": "H3K4 methyltransferase activity of the carboxyl-terminal SET domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2734375,
            "end_logit": -7.29296875,
            "text": "H3K4 methyltransferase activity of the carboxyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 9.0078125,
            "text": "histone H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.0078125,
            "text": "The biological function of MLL1 is mediated by the histone H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.0078125,
            "text": "MLL1 is mediated by the histone H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.0078125,
            "text": "L1 is mediated by the histone H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.0078125,
            "text": "biological function of MLL1 is mediated by the histone H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.52734375,
            "end_logit": -6.84375,
            "text": "4 methyltransferase activity of the carboxyl-terminal SET domain.",
            "probability": 0.0
        },
        {
            "start_logit": -1.52734375,
            "end_logit": -7.0078125,
            "text": "4 methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -1.52734375,
            "end_logit": -7.0234375,
            "text": "4 methyltransferase activity",
            "probability": 0.0
        },
        {
            "start_logit": -1.52734375,
            "end_logit": -7.04296875,
            "text": "4 methyltransferase activity of",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_6": [
        {
            "start_logit": 9.2578125,
            "end_logit": 9.015625,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -1.103515625,
            "text": "H3K",
            "probability": 4.00543212890625e-05
        },
        {
            "start_logit": -1.4375,
            "end_logit": 9.015625,
            "text": "4",
            "probability": 2.2470951080322266e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.02734375,
            "text": "H3K4, a posttranslational modification associated with actively transcribed genes. There",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.1328125,
            "text": "H3K4, a posttranslational modification associated with actively transcribed genes. There is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.16015625,
            "text": "H3K4, a posttranslational modification associated with actively transcribed genes.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.16015625,
            "text": "H3K4,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.171875,
            "text": "H3K4, a posttranslational modification associated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.21875,
            "text": "H3K4, a posttranslational modification",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.22265625,
            "text": "H3K4, a posttranslational modification associated with actively transcribed genes. There is only",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.22265625,
            "text": "H3K4, a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.3515625,
            "text": "H3K4, a posttranslational modification associated with actively transcribed genes. There is only one Set1 in yeast;",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.36328125,
            "text": "H3K4, a posttranslational modification associated with actively transcribed genes. There is only one Set1 in yeast; yet in mammalian cells there are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.36328125,
            "text": "H3K4, a posttranslational modification associated with actively transcribed genes. There is only one Set1 in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.37109375,
            "text": "H3K4, a posttranslational modification associated with actively transcribed genes. There is only one",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 9.015625,
            "text": "ating H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.015625,
            "text": "methylating H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 9.015625,
            "text": "Set1/COMPASS is capable of methylating H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.015625,
            "text": "COMPASS is capable of methylating H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.015625,
            "text": "1/COMPASS is capable of methylating H3K4",
            "probability": 5.960464477539063e-08
        }
    ],
    "533be71dfd9a95ea0d000009_7": [
        {
            "start_logit": 9.25,
            "end_logit": 8.9296875,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 9.25,
            "end_logit": -1.1884765625,
            "text": "H3K",
            "probability": 4.00543212890625e-05
        },
        {
            "start_logit": -1.748046875,
            "end_logit": 8.9296875,
            "text": "4",
            "probability": 1.6570091247558594e-05
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.2109375,
            "text": "H3K4 histones",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -7.22265625,
            "text": "H3K4 histones and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 8.9296875,
            "text": "trimethylated H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": -1.1884765625,
            "text": "trimethylated H3K",
            "probability": 0.0
        },
        {
            "start_logit": -1.748046875,
            "end_logit": -7.2109375,
            "text": "4 histones",
            "probability": 0.0
        },
        {
            "start_logit": -1.748046875,
            "end_logit": -7.22265625,
            "text": "4 histones and",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -7.1484375,
            "text": "trimethyl",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -7.171875,
            "text": "trimethylated",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -7.2109375,
            "text": "trimethylated H3K4 histones",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -7.22265625,
            "text": "trimethylated H3K4 histones and",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_8": [
        {
            "start_logit": 9.15625,
            "end_logit": 8.8984375,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 9.15625,
            "end_logit": -1.408203125,
            "text": "H3K",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": -1.732421875,
            "end_logit": 8.8984375,
            "text": "4",
            "probability": 1.8477439880371094e-05
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.3515625,
            "text": "H3K4 methylation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 8.8984375,
            "text": "neurons, resulted in decreased H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 8.8984375,
            "text": "decreased H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 8.8984375,
            "text": "histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 8.8984375,
            "text": "cortical neurons, resulted in decreased H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 8.8984375,
            "text": "in allele of mixed-lineage leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 8.8984375,
            "text": "GABAergic and other cortical neurons, resulted in decreased H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.8984375,
            "text": "leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 8.8984375,
            "text": "allele of mixed-lineage leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -1.408203125,
            "text": "neurons, resulted in decreased H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -1.408203125,
            "text": "decreased H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -1.408203125,
            "text": "histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": -1.408203125,
            "text": "cortical neurons, resulted in decreased H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -1.408203125,
            "text": "in allele of mixed-lineage leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -1.408203125,
            "text": "GABAergic and other cortical neurons, resulted in decreased H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -1.408203125,
            "text": "leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -1.408203125,
            "text": "allele of mixed-lineage leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_9": [
        {
            "start_logit": 9.2890625,
            "end_logit": 9.0234375,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -1.0908203125,
            "text": "H3K",
            "probability": 4.035234451293945e-05
        },
        {
            "start_logit": -1.4697265625,
            "end_logit": 9.0234375,
            "text": "4",
            "probability": 2.1278858184814453e-05
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.2265625,
            "text": "H3K4 methylation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.0234375,
            "text": "effectors of H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.0234375,
            "text": "of H3K4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.4697265625,
            "end_logit": -7.2265625,
            "text": "4 methylation",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -1.0908203125,
            "text": "effectors of H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -1.0908203125,
            "text": "of H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -7.2265625,
            "text": "effectors of H3K4 methylation",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -7.2265625,
            "text": "of H3K4 methylation",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_10": [
        {
            "start_logit": 9.03125,
            "end_logit": 8.9140625,
            "text": "Lys4",
            "probability": 1.0
        },
        {
            "start_logit": 9.03125,
            "end_logit": -1.46875,
            "text": "Lys",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": -1.6103515625,
            "end_logit": 8.9140625,
            "text": "4",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": 9.03125,
            "end_logit": -4.03515625,
            "text": "Lys4 of histone H3",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.09765625,
            "text": "Lys4 of",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.6015625,
            "text": "Lys4 of histone H3 (H3K4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.71484375,
            "text": "Lys4 of histone H3 (H3K",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.94921875,
            "text": "Lys4 of histone H3 (H3K4)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -7.13671875,
            "text": "Lys4 of histone H3 (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.03125,
            "end_logit": -7.25,
            "text": "Lys4 of histone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 8.9140625,
            "text": "for Lys4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 8.9140625,
            "text": "L2 histone methyltransferase complexes specific for Lys4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.9140625,
            "text": "/MLL2 histone methyltransferase complexes specific for Lys4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 8.9140625,
            "text": "MLL1/MLL2 histone methyltransferase complexes specific for Lys4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 8.9140625,
            "text": "histone methyltransferase complexes specific for Lys4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 8.9140625,
            "text": "MLL2 histone methyltransferase complexes specific for Lys4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": 8.9140625,
            "text": "L1/MLL2 histone methyltransferase complexes specific for Lys4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6875,
            "end_logit": 8.9140625,
            "text": "specific for Lys4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6103515625,
            "end_logit": -4.03515625,
            "text": "4 of histone H3",
            "probability": 0.0
        },
        {
            "start_logit": -1.6103515625,
            "end_logit": -6.09765625,
            "text": "4 of",
            "probability": 0.0
        }
    ],
    "5fe3131ca43ad31278000048_1": [
        {
            "start_logit": 8.046875,
            "end_logit": 5.046875,
            "text": "G+C content",
            "probability": 0.98095703125
        },
        {
            "start_logit": 8.046875,
            "end_logit": 1.0771484375,
            "text": "G+C content, 10.5 bp periodicity, and poly(dA:dT) tracts",
            "probability": 0.018524169921875
        },
        {
            "start_logit": 8.046875,
            "end_logit": -3.3125,
            "text": "G",
            "probability": 0.00022971630096435547
        },
        {
            "start_logit": -2.212890625,
            "end_logit": 5.046875,
            "text": "This paper rigorously quantifies the contribution of hitherto-debated sequence features-including G+C content",
            "probability": 3.445148468017578e-05
        },
        {
            "start_logit": 8.046875,
            "end_logit": -5.3046875,
            "text": "G+C content,",
            "probability": 3.135204315185547e-05
        },
        {
            "start_logit": 8.046875,
            "end_logit": -5.78125,
            "text": "G+C content, 10.5 bp periodicity, and poly(dA:dT)",
            "probability": 1.9490718841552734e-05
        },
        {
            "start_logit": 8.046875,
            "end_logit": -5.81640625,
            "text": "G+C content, 10.5 bp periodicity, and poly(dA:dT) tracts-",
            "probability": 1.8894672393798828e-05
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.046875,
            "text": "G+C content, 10",
            "probability": 1.4901161193847656e-05
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.16796875,
            "text": "G+C content, 10.5 bp",
            "probability": 1.3172626495361328e-05
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.2265625,
            "text": "G+C content, 10.5 bp periodicity, and poly(dA:dT",
            "probability": 1.245737075805664e-05
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.26953125,
            "text": "G+C content, 10.5 bp periodicity, and poly(dA:dT) tracts-to three",
            "probability": 1.1980533599853516e-05
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.3046875,
            "text": "G+C content, 10.5 bp periodicity, and poly(dA:dT) tracts-to three distinct",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.40625,
            "text": "G+C content, 10.5 bp periodicity, and poly(dA:",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 8.046875,
            "end_logit": -6.42578125,
            "text": "G+C content, 10.5 bp periodicity",
            "probability": 1.0251998901367188e-05
        },
        {
            "start_logit": -5.67578125,
            "end_logit": 5.046875,
            "text": "+C content",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -5.71484375,
            "end_logit": 5.046875,
            "text": "paper rigorously quantifies the contribution of hitherto-debated sequence features-including G+C content",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 5.046875,
            "text": "content",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.4609375,
            "end_logit": 5.046875,
            "text": "including G+C content",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -2.560546875,
            "end_logit": 1.0771484375,
            "text": "poly(dA:dT) tracts",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 5.046875,
            "text": "C content",
            "probability": 4.172325134277344e-07
        }
    ],
    "5fe3131ca43ad31278000048_2": [
        {
            "start_logit": 8.9453125,
            "end_logit": 8.6796875,
            "text": "G+C content",
            "probability": 1.0
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -1.9521484375,
            "text": "G",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": -2.041015625,
            "end_logit": 8.6796875,
            "text": "content",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -4.796875,
            "text": "G+C content is the primary determinant of MNase-derived nucleosome occupancy, MNase digestion biases may substantially influence this GC dependence.",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -5.16015625,
            "text": "G+C content is",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 8.6796875,
            "text": "+C content",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.125,
            "text": "G+C content is the",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.3828125,
            "text": "G+C",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.45703125,
            "text": "G+C content is the primary",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.20703125,
            "end_logit": 8.6796875,
            "text": "We find that although G+C content",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 8.6796875,
            "text": "C content",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.4609375,
            "end_logit": 8.6796875,
            "text": "although G+C content",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 8.6796875,
            "text": "find that although G+C content",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 8.6796875,
            "text": "that although G+C content",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.041015625,
            "end_logit": -4.796875,
            "text": "content is the primary determinant of MNase-derived nucleosome occupancy, MNase digestion biases may substantially influence this GC dependence.",
            "probability": 0.0
        },
        {
            "start_logit": -2.041015625,
            "end_logit": -5.16015625,
            "text": "content is",
            "probability": 0.0
        },
        {
            "start_logit": -6.20703125,
            "end_logit": -1.9521484375,
            "text": "We find that although G",
            "probability": 0.0
        },
        {
            "start_logit": -2.041015625,
            "end_logit": -6.125,
            "text": "content is the",
            "probability": 0.0
        },
        {
            "start_logit": -6.4609375,
            "end_logit": -1.9521484375,
            "text": "although G",
            "probability": 0.0
        },
        {
            "start_logit": -2.041015625,
            "end_logit": -6.45703125,
            "text": "content is the primary",
            "probability": 0.0
        }
    ],
    "5d387c20a1e1595105000010_1": [
        {
            "start_logit": 5.875,
            "end_logit": 6.19921875,
            "text": "78",
            "probability": 0.990234375
        },
        {
            "start_logit": 5.875,
            "end_logit": 1.595703125,
            "text": "783",
            "probability": 0.009857177734375
        },
        {
            "start_logit": 5.875,
            "end_logit": -5.76171875,
            "text": "783 non-pseudoautosomal region (PAR) X",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": 5.875,
            "end_logit": -5.84375,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": -6.359375,
            "end_logit": 6.19921875,
            "text": "Six of 78",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 5.875,
            "end_logit": -6.6328125,
            "text": "783 non-pseudoautosomal region",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 5.875,
            "end_logit": -6.73828125,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes (",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 5.875,
            "end_logit": -6.7578125,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes (ATRX",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 5.875,
            "end_logit": -6.828125,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes (ATR",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 5.875,
            "end_logit": -6.96875,
            "text": "783 non-pseudoautosomal",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 5.875,
            "end_logit": -7.0234375,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 5.875,
            "end_logit": -7.03125,
            "text": "783 non-pseudoautosomal region (PAR)",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 5.875,
            "end_logit": -7.03125,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes (ATRX, CNKSR2, DDX3",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -3.5546875,
            "end_logit": 1.595703125,
            "text": "3",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.359375,
            "end_logit": 1.595703125,
            "text": "Six of 783",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.5546875,
            "end_logit": -5.76171875,
            "text": "3 non-pseudoautosomal region (PAR) X",
            "probability": 0.0
        },
        {
            "start_logit": -3.5546875,
            "end_logit": -5.84375,
            "text": "3 non-pseudoautosomal region (PAR) X-chromosome genes",
            "probability": 0.0
        },
        {
            "start_logit": -3.5546875,
            "end_logit": -6.6328125,
            "text": "3 non-pseudoautosomal region",
            "probability": 0.0
        },
        {
            "start_logit": -3.5546875,
            "end_logit": -6.73828125,
            "text": "3 non-pseudoautosomal region (PAR) X-chromosome genes (",
            "probability": 0.0
        },
        {
            "start_logit": -3.5546875,
            "end_logit": -6.7578125,
            "text": "3 non-pseudoautosomal region (PAR) X-chromosome genes (ATRX",
            "probability": 0.0
        }
    ],
    "5d387c20a1e1595105000010_2": [
        {
            "start_logit": 5.54296875,
            "end_logit": 6.96484375,
            "text": "18",
            "probability": 0.6123046875
        },
        {
            "start_logit": 5.54296875,
            "end_logit": 6.5,
            "text": "18,055",
            "probability": 0.38623046875
        },
        {
            "start_logit": -0.449462890625,
            "end_logit": 6.5,
            "text": "5",
            "probability": 0.0009608268737792969
        },
        {
            "start_logit": -1.091796875,
            "end_logit": 6.5,
            "text": "055",
            "probability": 0.0005044937133789062
        },
        {
            "start_logit": -3.71484375,
            "end_logit": 6.96484375,
            "text": "zero of 18",
            "probability": 5.835294723510742e-05
        },
        {
            "start_logit": -3.71484375,
            "end_logit": 6.5,
            "text": "zero of 18,055",
            "probability": 3.6835670471191406e-05
        },
        {
            "start_logit": -4.390625,
            "end_logit": 6.5,
            "text": ",055",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -4.453125,
            "text": "18,05",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 6.96484375,
            "text": "comparison to zero of 18",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 6.96484375,
            "text": "to zero of 18",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 6.5,
            "text": "comparison to zero of 18,055",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -5.44140625,
            "text": "18,055 autosomal and PAR genes",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 6.5,
            "text": "to zero of 18,055",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -6.27734375,
            "text": "18,055 autosomal and PAR genes (Fisher's exact P < 0.0001).",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -6.3203125,
            "text": "18,055 autosomal and PAR genes (Fisher's exact P < 0",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -6.375,
            "text": "18,",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -6.3984375,
            "text": "18,055 autosomal and PAR genes (Fisher's exact P < 0.0001",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -6.4765625,
            "text": "18,055 autosomal and PAR genes (Fisher's exact P",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 5.54296875,
            "end_logit": -6.57421875,
            "text": "18,055 autosomal and PAR genes (Fisher's exact P < 0.0001)",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -1.091796875,
            "end_logit": -4.453125,
            "text": "05",
            "probability": 0.0
        }
    ],
    "5c9791d2ecadf2e73f000026_1": [
        {
            "start_logit": 8.6796875,
            "end_logit": 8.7734375,
            "text": "Cat fleas",
            "probability": 0.984375
        },
        {
            "start_logit": 4.5078125,
            "end_logit": 8.7734375,
            "text": "fleas",
            "probability": 0.01519012451171875
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -2.005859375,
            "text": "Cat fleas (Ctenocephalides",
            "probability": 2.0503997802734375e-05
        },
        {
            "start_logit": -2.181640625,
            "end_logit": 8.7734375,
            "text": "as",
            "probability": 1.895427703857422e-05
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -2.314453125,
            "text": "Cat",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": 6.86328125,
            "end_logit": -2.005859375,
            "text": "Ctenocephalides",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -4.33203125,
            "text": "Cat fleas (Ctenocephalides felis",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -4.57421875,
            "text": "Cat fleas (Ct",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -5.29296875,
            "text": "Cat fleas (Ctenocephal",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -5.71875,
            "text": "Cat fleas (Ctenocephalides fel",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -5.9453125,
            "text": "Cat fle",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 6.86328125,
            "end_logit": -4.33203125,
            "text": "Ctenocephalides felis",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 4.5078125,
            "end_logit": -2.005859375,
            "text": "fleas (Ctenocephalides",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 6.86328125,
            "end_logit": -4.57421875,
            "text": "Ct",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -6.59375,
            "text": "Cat fleas (Ctenocephalides felis) carrying Rickettsia felis and Bartonella species in Hong Kong.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -6.8671875,
            "text": "Cat fleas (Cteno",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -7.07421875,
            "text": "Cat fleas (Ctenocephalides felis) carrying",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.86328125,
            "end_logit": -5.29296875,
            "text": "Ctenocephal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -7.12109375,
            "text": "Cat fleas (Ctenocephalides felis) carrying Rickettsia felis and Bartonella species in Hong Kong",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -7.125,
            "text": "Cat fleas (Ctenocephalides felis) carrying Rickettsia felis and Bartonella species in Hong",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5c9791d2ecadf2e73f000026_2": [
        {
            "start_logit": 9.0625,
            "end_logit": 5.8046875,
            "text": "Ctenocephalides",
            "probability": 0.61083984375
        },
        {
            "start_logit": 7.61328125,
            "end_logit": 6.33984375,
            "text": "fleas",
            "probability": 0.2447509765625
        },
        {
            "start_logit": 7.61328125,
            "end_logit": 5.8046875,
            "text": "fleas from dogs and cats living in Hong Kong revealed only cat fleas (Ctenocephalides",
            "probability": 0.1439208984375
        },
        {
            "start_logit": 9.0625,
            "end_logit": -1.6376953125,
            "text": "Ct",
            "probability": 0.0003581047058105469
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -1.6376953125,
            "text": "fleas from dogs and cats living in Hong Kong revealed only cat fleas (Ct",
            "probability": 8.410215377807617e-05
        },
        {
            "start_logit": 9.0625,
            "end_logit": -4.65234375,
            "text": "Ctenocephalides felis).",
            "probability": 1.7642974853515625e-05
        },
        {
            "start_logit": 9.0625,
            "end_logit": -4.66796875,
            "text": "Ctenocephalides felis",
            "probability": 1.7344951629638672e-05
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -3.4375,
            "text": "fle",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": 9.0625,
            "end_logit": -5.11328125,
            "text": "Ctenocephalides fel",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": 9.0625,
            "end_logit": -5.46875,
            "text": "Ctenocephal",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -4.65234375,
            "text": "fleas from dogs and cats living in Hong Kong revealed only cat fleas (Ctenocephalides felis).",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -4.66796875,
            "text": "fleas from dogs and cats living in Hong Kong revealed only cat fleas (Ctenocephalides felis",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.55078125,
            "text": "Ctenocephalides felis)",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -5.11328125,
            "text": "fleas from dogs and cats living in Hong Kong revealed only cat fleas (Ctenocephalides fel",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.63671875,
            "text": "Cteno",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -5.46875,
            "text": "fleas from dogs and cats living in Hong Kong revealed only cat fleas (Ctenocephal",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -4.96875,
            "end_logit": 6.33984375,
            "text": "as",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -6.32421875,
            "text": "fleas from dogs",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -6.48046875,
            "text": "fleas from dogs and cats living in Hong Kong revealed only cat fleas",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.61328125,
            "end_logit": -6.546875,
            "text": "fleas from",
            "probability": 5.960464477539062e-07
        }
    ],
    "571f609c0fd6f91b6800000c_1": [
        {
            "start_logit": 3.744140625,
            "end_logit": 1.4609375,
            "text": "\u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 0.68701171875
        },
        {
            "start_logit": 3.744140625,
            "end_logit": 0.284912109375,
            "text": "\u03b2-galactosidase",
            "probability": 0.2119140625
        },
        {
            "start_logit": 3.744140625,
            "end_logit": -0.5986328125,
            "text": "\u03b2-galactosidase and \u03b2-hexosaminidase respectively",
            "probability": 0.08770751953125
        },
        {
            "start_logit": 3.744140625,
            "end_logit": -2.609375,
            "text": "\u03b2-galactosidase and",
            "probability": 0.01172637939453125
        },
        {
            "start_logit": -3.24609375,
            "end_logit": 1.4609375,
            "text": "\u03b2-hexosaminidase",
            "probability": 0.0006337165832519531
        },
        {
            "start_logit": -3.703125,
            "end_logit": 1.4609375,
            "text": "and \u03b2-hexosaminidase",
            "probability": 0.0004012584686279297
        },
        {
            "start_logit": 3.744140625,
            "end_logit": -6.18359375,
            "text": "\u03b2",
            "probability": 0.0003299713134765625
        },
        {
            "start_logit": 3.744140625,
            "end_logit": -6.890625,
            "text": "\u03b2-",
            "probability": 0.0001621246337890625
        },
        {
            "start_logit": 3.744140625,
            "end_logit": -7.11328125,
            "text": "\u03b2-galactosidase and \u03b2-hex",
            "probability": 0.0001302957534790039
        },
        {
            "start_logit": -3.24609375,
            "end_logit": -0.5986328125,
            "text": "\u03b2-hexosaminidase respectively",
            "probability": 8.088350296020508e-05
        },
        {
            "start_logit": -5.6484375,
            "end_logit": 1.4609375,
            "text": "hexosaminidase",
            "probability": 5.733966827392578e-05
        },
        {
            "start_logit": -3.703125,
            "end_logit": -0.5986328125,
            "text": "and \u03b2-hexosaminidase respectively",
            "probability": 5.143880844116211e-05
        },
        {
            "start_logit": -5.76171875,
            "end_logit": 1.4609375,
            "text": "-hexosaminidase",
            "probability": 5.143880844116211e-05
        },
        {
            "start_logit": -5.96875,
            "end_logit": 1.4609375,
            "text": "deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 4.1604042053222656e-05
        },
        {
            "start_logit": -6.203125,
            "end_logit": 1.4609375,
            "text": "GM1 and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 3.2901763916015625e-05
        },
        {
            "start_logit": -6.37890625,
            "end_logit": 1.4609375,
            "text": "-galactosidase and \u03b2-hexosaminidase",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 1.4609375,
            "text": "of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 1.4609375,
            "text": "2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 1.4609375,
            "text": "with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": -7.078125,
            "end_logit": 1.4609375,
            "text": "associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 1.3709068298339844e-05
        }
    ],
    "571f609c0fd6f91b6800000c_2": [
        {
            "start_logit": 5.390625,
            "end_logit": 1.8994140625,
            "text": "\u03b2-galactosidase",
            "probability": 0.529296875
        },
        {
            "start_logit": 5.390625,
            "end_logit": 1.73046875,
            "text": "\u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 0.447265625
        },
        {
            "start_logit": 5.390625,
            "end_logit": -1.833984375,
            "text": "\u03b2-galactosidase and \u03b2-hexosaminidase respectively",
            "probability": 0.01267242431640625
        },
        {
            "start_logit": 5.390625,
            "end_logit": -2.25390625,
            "text": "\u03b2-galactosidase and",
            "probability": 0.00832366943359375
        },
        {
            "start_logit": 5.390625,
            "end_logit": -3.705078125,
            "text": "\u03b2-galactosidase and \u03b2-hexosaminidase respectively.",
            "probability": 0.0019550323486328125
        },
        {
            "start_logit": 5.390625,
            "end_logit": -5.37890625,
            "text": "\u03b2",
            "probability": 0.0003657341003417969
        },
        {
            "start_logit": -2.8984375,
            "end_logit": 1.73046875,
            "text": "\u03b2-hexosaminidase",
            "probability": 0.00011283159255981445
        },
        {
            "start_logit": 5.390625,
            "end_logit": -6.83203125,
            "text": "\u03b2-galactosidase and \u03b2-hex",
            "probability": 8.51750373840332e-05
        },
        {
            "start_logit": 5.390625,
            "end_logit": -6.8515625,
            "text": "\u03b2-",
            "probability": 8.386373519897461e-05
        },
        {
            "start_logit": -3.2265625,
            "end_logit": 1.73046875,
            "text": "and \u03b2-hexosaminidase",
            "probability": 8.124113082885742e-05
        },
        {
            "start_logit": -5.55859375,
            "end_logit": 1.8994140625,
            "text": "GM1 and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -5.55859375,
            "end_logit": 1.73046875,
            "text": "GM1 and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 7.867813110351562e-06
        },
        {
            "start_logit": -5.796875,
            "end_logit": 1.8994140625,
            "text": "deficiency of \u03b2-galactosidase",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": -5.796875,
            "end_logit": 1.73046875,
            "text": "deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": -5.90234375,
            "end_logit": 1.73046875,
            "text": "-hexosaminidase",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": -6.08984375,
            "end_logit": 1.73046875,
            "text": "hexosaminidase",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 1.8994140625,
            "text": "-galactosidase",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -6.59375,
            "end_logit": 1.8994140625,
            "text": "of \u03b2-galactosidase",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 1.73046875,
            "text": "-galactosidase and \u03b2-hexosaminidase",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -2.8984375,
            "end_logit": -1.833984375,
            "text": "\u03b2-hexosaminidase respectively",
            "probability": 3.159046173095703e-06
        }
    ],
    "601ebde11cb411341a00005d_1": [
        {
            "start_logit": 9.234375,
            "end_logit": 8.8828125,
            "text": "signatureSearch",
            "probability": 1.0
        },
        {
            "start_logit": 9.234375,
            "end_logit": -1.31640625,
            "text": "signatureS",
            "probability": 3.707408905029297e-05
        },
        {
            "start_logit": -2.033203125,
            "end_logit": 8.8828125,
            "text": "earch",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.26953125,
            "text": "signatureSearch: environment",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -6.3984375,
            "text": "signatureSearch:",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.17578125,
            "text": "signatureSearch: environment for gene expression signature searching and functional interpretation.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.2109375,
            "text": "signatureSearch: environment for",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.3125,
            "text": "signatureSearch: environment for gene expression signature",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.328125,
            "text": "signatureSearch: environment for gene expression signature searching",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.3359375,
            "text": "signatureSearch: environment for gene expression signature searching and functional interpretation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.234375,
            "end_logit": -7.36328125,
            "text": "signatureSearch: environment for gene expression signature searching and functional",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.033203125,
            "end_logit": -6.26953125,
            "text": "earch: environment",
            "probability": 0.0
        },
        {
            "start_logit": -2.033203125,
            "end_logit": -6.3984375,
            "text": "earch:",
            "probability": 0.0
        },
        {
            "start_logit": -2.033203125,
            "end_logit": -7.17578125,
            "text": "earch: environment for gene expression signature searching and functional interpretation.",
            "probability": 0.0
        },
        {
            "start_logit": -2.033203125,
            "end_logit": -7.2109375,
            "text": "earch: environment for",
            "probability": 0.0
        },
        {
            "start_logit": -2.033203125,
            "end_logit": -7.3125,
            "text": "earch: environment for gene expression signature",
            "probability": 0.0
        },
        {
            "start_logit": -2.033203125,
            "end_logit": -7.328125,
            "text": "earch: environment for gene expression signature searching",
            "probability": 0.0
        },
        {
            "start_logit": -2.033203125,
            "end_logit": -7.3359375,
            "text": "earch: environment for gene expression signature searching and functional interpretation",
            "probability": 0.0
        },
        {
            "start_logit": -2.033203125,
            "end_logit": -7.36328125,
            "text": "earch: environment for gene expression signature searching and functional",
            "probability": 0.0
        },
        {
            "start_logit": -4.6484375,
            "end_logit": -7.17578125,
            "text": ".",
            "probability": 0.0
        }
    ],
    "601ebde11cb411341a00005d_2": [
        {
            "start_logit": 9.1875,
            "end_logit": 8.984375,
            "text": "signatureSearch",
            "probability": 1.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.3896484375,
            "text": "signatureS",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": -1.7841796875,
            "end_logit": 8.984375,
            "text": "earch",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -3.837890625,
            "text": "signatureSearch is",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.81640625,
            "text": "signatureSearch is an",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.1953125,
            "text": "signatureSearch is an R/Bioconductor package",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.1953125,
            "text": "signatureSearch is an R",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.2421875,
            "text": "signatureSearch is an R/Bioconductor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.31640625,
            "text": "signatureSearch is an R/Bioconduc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7841796875,
            "end_logit": -3.837890625,
            "text": "earch is",
            "probability": 0.0
        },
        {
            "start_logit": -1.7841796875,
            "end_logit": -6.81640625,
            "text": "earch is an",
            "probability": 0.0
        },
        {
            "start_logit": -1.7841796875,
            "end_logit": -7.1953125,
            "text": "earch is an R/Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": -1.7841796875,
            "end_logit": -7.1953125,
            "text": "earch is an R",
            "probability": 0.0
        },
        {
            "start_logit": -1.7841796875,
            "end_logit": -7.2421875,
            "text": "earch is an R/Bioconductor",
            "probability": 0.0
        },
        {
            "start_logit": -1.7841796875,
            "end_logit": -7.31640625,
            "text": "earch is an R/Bioconduc",
            "probability": 0.0
        },
        {
            "start_logit": -2.830078125,
            "end_logit": -6.79296875,
            "text": ". To identify which processes are predominantly modulated in the GESS results, we developed specialized FEA methods combined with drug-target network visualization tools.",
            "probability": 0.0
        },
        {
            "start_logit": -2.830078125,
            "end_logit": -6.79296875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -2.830078125,
            "end_logit": -6.79296875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -2.830078125,
            "end_logit": -6.79296875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -2.830078125,
            "end_logit": -6.79296875,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5e2a080caa19d7443100000a_1": [
        {
            "start_logit": 9.0703125,
            "end_logit": 7.7734375,
            "text": "AMPK/Sirt1 pathway",
            "probability": 0.92578125
        },
        {
            "start_logit": 9.0703125,
            "end_logit": 5.24609375,
            "text": "AMPK/Sirt1",
            "probability": 0.07366943359375
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -1.521484375,
            "text": "AMPK",
            "probability": 8.493661880493164e-05
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -3.048828125,
            "text": "AMPK/Sirt1 pathway.",
            "probability": 1.8477439880371094e-05
        },
        {
            "start_logit": -2.82421875,
            "end_logit": 7.7734375,
            "text": "pathway",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -4.5859375,
            "end_logit": 7.7734375,
            "text": "Sirt1 pathway",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 7.7734375,
            "text": "/Sirt1 pathway",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.17578125,
            "end_logit": 7.7734375,
            "text": "via the AMPK/Sirt1 pathway",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.265625,
            "end_logit": 7.7734375,
            "text": "PP2A inhibition by LB100 significantly ameliorates hepatic steatosis by regulating hepatic lipogenesis and fatty acid oxidation via the AMPK/Sirt1 pathway",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.625,
            "end_logit": 7.7734375,
            "text": "the AMPK/Sirt1 pathway",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.5859375,
            "end_logit": 5.24609375,
            "text": "Sirt1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 5.24609375,
            "text": "/Sirt1",
            "probability": 0.0
        },
        {
            "start_logit": -6.17578125,
            "end_logit": 5.24609375,
            "text": "via the AMPK/Sirt1",
            "probability": 0.0
        },
        {
            "start_logit": -6.265625,
            "end_logit": 5.24609375,
            "text": "PP2A inhibition by LB100 significantly ameliorates hepatic steatosis by regulating hepatic lipogenesis and fatty acid oxidation via the AMPK/Sirt1",
            "probability": 0.0
        },
        {
            "start_logit": -6.625,
            "end_logit": 5.24609375,
            "text": "the AMPK/Sirt1",
            "probability": 0.0
        },
        {
            "start_logit": -2.82421875,
            "end_logit": -3.048828125,
            "text": "pathway.",
            "probability": 0.0
        },
        {
            "start_logit": -4.5703125,
            "end_logit": -3.048828125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.5859375,
            "end_logit": -3.048828125,
            "text": "Sirt1 pathway.",
            "probability": 0.0
        },
        {
            "start_logit": -6.17578125,
            "end_logit": -1.521484375,
            "text": "via the AMPK",
            "probability": 0.0
        },
        {
            "start_logit": -6.265625,
            "end_logit": -1.521484375,
            "text": "PP2A inhibition by LB100 significantly ameliorates hepatic steatosis by regulating hepatic lipogenesis and fatty acid oxidation via the AMPK",
            "probability": 0.0
        }
    ],
    "621ec0313a8413c65300005e_1": [
        {
            "start_logit": 7.4375,
            "end_logit": 9.3359375,
            "text": "cytotoxic drugs",
            "probability": 0.96875
        },
        {
            "start_logit": 7.4375,
            "end_logit": 5.765625,
            "text": "cytotoxic drugs which are most often implicated in causing this are bleomycin",
            "probability": 0.0270538330078125
        },
        {
            "start_logit": 5.3515625,
            "end_logit": 5.765625,
            "text": "bleomycin",
            "probability": 0.0033588409423828125
        },
        {
            "start_logit": -0.313232421875,
            "end_logit": 9.3359375,
            "text": "drugs",
            "probability": 0.00041413307189941406
        },
        {
            "start_logit": -0.313232421875,
            "end_logit": 5.765625,
            "text": "drugs which are most often implicated in causing this are bleomycin",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": 7.4375,
            "end_logit": -4.08984375,
            "text": "cytotoxic",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.3359375,
            "text": "The cytotoxic drugs",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -5.93359375,
            "text": "cytotoxic drugs which",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -6.51953125,
            "text": "cytotoxic drugs which are most often implicated in causing this are bleomycin, methotrexate, cyclophosphamide and busulfan.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -6.8203125,
            "text": "cytotoxic drugs which are most",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -6.82421875,
            "text": "cytotoxic drugs which are",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.09375,
            "text": "cytotoxic drugs which are most often implicated in causing this are bleomycin,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.140625,
            "text": "cytotoxic drugs which are most often",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.14453125,
            "text": "cytotoxic drugs which are most often implicated in causing this are bleomycin, methotrexate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.17578125,
            "text": "cytotoxic drugs which are most often implicated in causing this are bleomycin, methotrexate, cyclophosphamide and busulfan",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.18359375,
            "text": "cytotoxic drugs which are most often implicated in causing this are",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.19921875,
            "text": "cytotoxic drugs which are most often implicated in causing this are bleomycin, methotrexate, cyclophosphamide and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.30078125,
            "text": "cytotoxic drugs which are most often implicated in causing this are bleomycin, methotrexate,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.4375,
            "end_logit": -7.328125,
            "text": "cytotoxic drugs which are most often implicated in causing this are bleomycin, methotrexate, cyclophosphamide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.3515625,
            "end_logit": -6.51953125,
            "text": "bleomycin, methotrexate, cyclophosphamide and busulfan.",
            "probability": 0.0
        }
    ],
    "621ec0313a8413c65300005e_2": [
        {
            "start_logit": 8.875,
            "end_logit": 9.28125,
            "text": "Cytotoxic drugs",
            "probability": 1.0
        },
        {
            "start_logit": -0.81982421875,
            "end_logit": 9.28125,
            "text": "drugs",
            "probability": 6.157159805297852e-05
        },
        {
            "start_logit": 8.875,
            "end_logit": -2.052734375,
            "text": "Cytotoxic",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.1796875,
            "text": "Cytotoxic drugs are",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.59765625,
            "text": "Cytotoxic drugs are the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.78125,
            "text": "Cytotoxic drugs are the most common cause of toxic lung disease.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -6.80078125,
            "text": "Cytotoxic drugs are the most",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.03515625,
            "text": "Cytotoxic drugs are the most common",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.875,
            "end_logit": -7.19921875,
            "text": "Cytotoxic drugs are the most common cause",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.81982421875,
            "end_logit": -6.1796875,
            "text": "drugs are",
            "probability": 0.0
        },
        {
            "start_logit": -0.81982421875,
            "end_logit": -6.59765625,
            "text": "drugs are the",
            "probability": 0.0
        },
        {
            "start_logit": -0.81982421875,
            "end_logit": -6.78125,
            "text": "drugs are the most common cause of toxic lung disease.",
            "probability": 0.0
        },
        {
            "start_logit": -0.81982421875,
            "end_logit": -6.80078125,
            "text": "drugs are the most",
            "probability": 0.0
        },
        {
            "start_logit": -0.81982421875,
            "end_logit": -7.03515625,
            "text": "drugs are the most common",
            "probability": 0.0
        },
        {
            "start_logit": -0.81982421875,
            "end_logit": -7.19921875,
            "text": "drugs are the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -5.35546875,
            "end_logit": -6.78125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -6.78125,
            "text": "toxic lung disease.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -6.78125,
            "text": "lung disease.",
            "probability": 0.0
        }
    ],
    "56cae3eb5795f9a73e000021_1": [
        {
            "start_logit": 9.125,
            "end_logit": 9.1328125,
            "text": "20 and 50 years",
            "probability": 0.9990234375
        },
        {
            "start_logit": 1.2841796875,
            "end_logit": 9.1328125,
            "text": "50 years",
            "probability": 0.0003948211669921875
        },
        {
            "start_logit": 9.125,
            "end_logit": -0.70068359375,
            "text": "20",
            "probability": 5.3882598876953125e-05
        },
        {
            "start_logit": -1.126953125,
            "end_logit": 9.1328125,
            "text": "years",
            "probability": 3.55839729309082e-05
        },
        {
            "start_logit": 9.125,
            "end_logit": -4.58203125,
            "text": "20 and 50 years) may represent different phenotypes or different genetic and/or environmental influences between younger- and older-onset individuals.",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 9.125,
            "end_logit": -4.84765625,
            "text": "20 and 50 years) may",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -5.42578125,
            "end_logit": 9.1328125,
            "text": ". The peaks (20 and 50 years",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.9609375,
            "end_logit": 9.1328125,
            "text": "disease onset diagnosis. The peaks (20 and 50 years",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 9.1328125,
            "text": "Crohn's disease has a bimodal age distribution of disease onset diagnosis. The peaks (20 and 50 years",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.3203125,
            "text": "20 and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.46875,
            "text": "20 and 50 years)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 9.1328125,
            "text": "and 50 years",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.734375,
            "end_logit": 9.1328125,
            "text": "(20 and 50 years",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.73828125,
            "end_logit": 9.1328125,
            "text": "age distribution of disease onset diagnosis. The peaks (20 and 50 years",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.82421875,
            "text": "20 and 50 years) may represent different",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 9.1328125,
            "text": "'s disease has a bimodal age distribution of disease onset diagnosis. The peaks (20 and 50 years",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.9453125,
            "text": "20 and 50 years) may represent different phenotypes or different genetic and/or environmental influences between younger- and older",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.96875,
            "text": "20 and 50 years) may represent different phenotypes or",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.984375,
            "end_logit": 9.1328125,
            "text": "bimodal age distribution of disease onset diagnosis. The peaks (20 and 50 years",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 9.1328125,
            "text": "of disease onset diagnosis. The peaks (20 and 50 years",
            "probability": 5.960464477539063e-08
        }
    ],
    "601dbe2b1cb411341a00004d_1": [
        {
            "start_logit": 7.4140625,
            "end_logit": 7.88671875,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": -6.0390625,
            "end_logit": 7.88671875,
            "text": "for migraine",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 7.88671875,
            "text": "here are many new treatment options available for migraine",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.4140625,
            "end_logit": -6.97265625,
            "text": "migraine and more are coming.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.4140625,
            "end_logit": -7.0,
            "text": "migraine and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.4140625,
            "end_logit": -7.0234375,
            "text": "migraine and more are coming. Three calcitonin gene-related peptide (CGRP) antagonist monoclonal antibodies have been approved",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.4140625,
            "end_logit": -7.1328125,
            "text": "migraine and more are coming. Three calcitonin gene-related peptide (CGRP) antagonist monoclonal antibodies have been approved and a 4th is due in early 2020",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.4140625,
            "end_logit": -7.17578125,
            "text": "migraine and more are coming. Three calcitonin gene-related peptide (CGRP",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.4140625,
            "end_logit": -7.1796875,
            "text": "migraine and more are coming. Three calcitonin gene-related peptide (CGRP) antagonist monoclonal antibodies have been approved and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.4140625,
            "end_logit": -7.31640625,
            "text": "migraine and more are coming. Three calcitonin gene-related peptide (CGRP) antagonist monoclonal antibodies have been approved and a 4th is due in",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.4140625,
            "end_logit": -7.3203125,
            "text": "migraine and more are coming. Three calcitonin gene-related peptide (CGRP)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -4.109375,
            "end_logit": -6.97265625,
            "text": ". Three calcitonin gene-related peptide (CGRP) antagonist monoclonal antibodies have been approved and a 4th is due in early 2020.",
            "probability": 0.0
        },
        {
            "start_logit": -4.109375,
            "end_logit": -6.97265625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.109375,
            "end_logit": -6.97265625,
            "text": ". Small molecule CGRP receptor-blocking oral compounds, both for acute care and prevention, are also coming.",
            "probability": 0.0
        },
        {
            "start_logit": -4.109375,
            "end_logit": -6.97265625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.109375,
            "end_logit": -6.97265625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.109375,
            "end_logit": -6.97265625,
            "text": ". Four neurostimulators are available, with others on the way.",
            "probability": 0.0
        },
        {
            "start_logit": -4.109375,
            "end_logit": -6.97265625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.109375,
            "end_logit": -7.0234375,
            "text": ". Three calcitonin gene-related peptide (CGRP) antagonist monoclonal antibodies have been approved",
            "probability": 0.0
        },
        {
            "start_logit": -4.109375,
            "end_logit": -7.1328125,
            "text": ". Three calcitonin gene-related peptide (CGRP) antagonist monoclonal antibodies have been approved and a 4th is due in early 2020",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_2": [
        {
            "start_logit": 8.3046875,
            "end_logit": 6.87890625,
            "text": "Migraine",
            "probability": 1.0
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -4.203125,
            "text": "Migraine has recently become a major interest to the neuroscientists. Zolmitriptan is an effective medicine used in the treatment of migraine.",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -4.203125,
            "text": "Migraine has recently become a major interest to the neuroscientists.",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.02734375,
            "text": "Migraine has",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.3828125,
            "text": "Migraine has recently",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.39453125,
            "text": "Migraine has recently become a major interest to the neuroscientists. Zolmitriptan is an effective medicine used in the treatment of migraine",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.53125,
            "text": "Migraine has recently become",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.53125,
            "text": "Migraine has recently become a major",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.546875,
            "text": "Migraine has recently become a",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.76171875,
            "text": "Migraine has recently become a major interest to",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.76953125,
            "text": "Migraine has recently become a major interest",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.9921875,
            "text": "Migraine has recently become a major interest to the neuroscientists",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.9921875,
            "text": "Migraine has recently become a major interest to the neuroscientists. Zolmitriptan is an effective medicine used in the treatment of",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.0078125,
            "text": "Migraine has recently become a major interest to the neuroscientists. Zolmitriptan is an effective medicine used",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.04296875,
            "text": "Migraine has recently become a major interest to the neuroscientists. Zolmitriptan is an",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.05078125,
            "text": "Migraine has recently become a major interest to the",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.0703125,
            "text": "Migraine has recently become a major interest to the neuroscientists. Zolmitriptan is an effective medicine used in the",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -5.16015625,
            "end_logit": -4.203125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.16015625,
            "end_logit": -4.203125,
            "text": ". Zolmitriptan is an effective medicine used in the treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -5.16015625,
            "end_logit": -4.203125,
            "text": ".",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_3": [
        {
            "start_logit": 7.39453125,
            "end_logit": 8.8125,
            "text": "acute treatment of migraine",
            "probability": 1.0
        },
        {
            "start_logit": -2.0234375,
            "end_logit": 8.8125,
            "text": "migraine",
            "probability": 8.153915405273438e-05
        },
        {
            "start_logit": 7.39453125,
            "end_logit": -3.85546875,
            "text": "acute",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -5.68359375,
            "end_logit": 8.8125,
            "text": "of migraine",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -5.73046875,
            "end_logit": 8.8125,
            "text": "treatment of migraine",
            "probability": 1.9669532775878906e-06
        }
    ],
    "601dbe2b1cb411341a00004d_4": [
        {
            "start_logit": 6.3828125,
            "end_logit": 8.6328125,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 8.6328125,
            "text": "for migraine",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 8.6328125,
            "text": "Zolmitriptan is a novel and highly selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -7.078125,
            "end_logit": 8.6328125,
            "text": "acute oral treatment for migraine",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 8.6328125,
            "text": "mitriptan is a novel and highly selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 8.6328125,
            "text": "treatment for migraine",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 8.6328125,
            "text": "5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 8.6328125,
            "text": "oral treatment for migraine",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 6.3828125,
            "end_logit": -5.41796875,
            "text": "migraine.",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.86328125,
            "end_logit": -5.41796875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -5.41796875,
            "text": "for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -5.41796875,
            "text": "Zolmitriptan is a novel and highly selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.078125,
            "end_logit": -5.41796875,
            "text": "acute oral treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": -5.41796875,
            "text": "mitriptan is a novel and highly selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.33984375,
            "end_logit": -5.41796875,
            "text": "treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.37890625,
            "end_logit": -5.41796875,
            "text": "5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.42578125,
            "end_logit": -5.41796875,
            "text": "oral treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -7.12890625,
            "text": "for",
            "probability": 0.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -6.97265625,
            "text": "Zolmitriptan is a novel and highly selective 5-HT(",
            "probability": 0.0
        },
        {
            "start_logit": -6.97265625,
            "end_logit": -6.9921875,
            "text": "Zolmitriptan is a novel and highly selective 5-HT(1B",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_5": [
        {
            "start_logit": 8.7265625,
            "end_logit": 9.1640625,
            "text": "acute migraine",
            "probability": 1.0
        },
        {
            "start_logit": -1.029296875,
            "end_logit": 9.1640625,
            "text": "migraine",
            "probability": 5.7816505432128906e-05
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -2.3671875,
            "text": "acute",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -6.66015625,
            "text": "acute migraine therapy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -6.7421875,
            "text": "acute migraine therapy.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 9.1640625,
            "text": "Zolmitriptan is a potent selective 5HT1B/1D receptor agonist for acute migraine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.1640625,
            "text": "mitriptan is a potent selective 5HT1B/1D receptor agonist for acute migraine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.029296875,
            "end_logit": -6.66015625,
            "text": "migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -1.029296875,
            "end_logit": -6.7421875,
            "text": "migraine therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -2.3671875,
            "text": "Zolmitriptan is a potent selective 5HT1B/1D receptor agonist for acute",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -2.3671875,
            "text": "mitriptan is a potent selective 5HT1B/1D receptor agonist for acute",
            "probability": 0.0
        },
        {
            "start_logit": -5.62890625,
            "end_logit": -6.7421875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -6.66015625,
            "text": "Zolmitriptan is a potent selective 5HT1B/1D receptor agonist for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -6.7421875,
            "text": "Zolmitriptan is a potent selective 5HT1B/1D receptor agonist for acute migraine therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -6.66015625,
            "text": "mitriptan is a potent selective 5HT1B/1D receptor agonist for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -6.7421875,
            "text": "mitriptan is a potent selective 5HT1B/1D receptor agonist for acute migraine therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -7.0625,
            "text": "Zolmitriptan is a potent selective 5HT1B/1D receptor agonist",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -7.09375,
            "text": "Zolmitriptan is a potent",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -7.12109375,
            "text": "Zolmitriptan is a",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -7.1328125,
            "text": "Zolmitriptan is a potent selective 5HT1B/1D receptor",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_6": [
        {
            "start_logit": 8.9765625,
            "end_logit": 8.859375,
            "text": "cluster headache",
            "probability": 1.0
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -1.9638671875,
            "text": "cluster",
            "probability": 1.9848346710205078e-05
        },
        {
            "start_logit": -2.091796875,
            "end_logit": 8.859375,
            "text": "headache",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -7.21875,
            "text": "cluster headache.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 8.859375,
            "text": "SIONS: The 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 8.859375,
            "text": "symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 8.859375,
            "text": "NS: The 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 8.859375,
            "text": ": The 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 8.859375,
            "text": "for the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 8.859375,
            "text": "mitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 8.859375,
            "text": "zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.091796875,
            "end_logit": -7.21875,
            "text": "headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -1.9638671875,
            "text": "SIONS: The 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -1.9638671875,
            "text": "symptomatic treatment of cluster",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -1.9638671875,
            "text": "NS: The 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster",
            "probability": 0.0
        },
        {
            "start_logit": -7.59765625,
            "end_logit": -1.9638671875,
            "text": ": The 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -1.9638671875,
            "text": "for the symptomatic treatment of cluster",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -1.9638671875,
            "text": "mitriptan is a potential new option for the symptomatic treatment of cluster",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -1.9638671875,
            "text": "zolmitriptan is a potential new option for the symptomatic treatment of cluster",
            "probability": 0.0
        },
        {
            "start_logit": -4.4375,
            "end_logit": -7.21875,
            "text": ".",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_7": [
        {
            "start_logit": 6.7265625,
            "end_logit": 8.4296875,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 8.4296875,
            "text": "for migraine",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 8.4296875,
            "text": "acute treatment for migraine",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 8.4296875,
            "text": ", oral, acute treatment for migraine",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.359375,
            "end_logit": 8.4296875,
            "text": "Zolmitriptan (Zomig, formerly 311C90) is a novel, oral, acute treatment for migraine",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 8.4296875,
            "text": "treatment for migraine",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 8.4296875,
            "text": ", acute treatment for migraine",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 8.4296875,
            "text": "oral, acute treatment for migraine",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 8.4296875,
            "text": "mitriptan (Zomig, formerly 311C90) is a novel, oral, acute treatment for migraine",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 8.4296875,
            "text": "novel, oral, acute treatment for migraine",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 6.7265625,
            "end_logit": -6.5859375,
            "text": "migraine.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.328125,
            "end_logit": -6.5859375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.9453125,
            "end_logit": -6.5859375,
            "text": "for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.2109375,
            "end_logit": -6.5859375,
            "text": "acute treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.24609375,
            "end_logit": -6.5859375,
            "text": ", oral, acute treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.359375,
            "end_logit": -6.5859375,
            "text": "Zolmitriptan (Zomig, formerly 311C90) is a novel, oral, acute treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.42578125,
            "end_logit": -6.5859375,
            "text": "treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -6.5859375,
            "text": ", acute treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -6.5859375,
            "text": "oral, acute treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -6.5859375,
            "text": "mitriptan (Zomig, formerly 311C90) is a novel, oral, acute treatment for migraine.",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_8": [
        {
            "start_logit": 2.068359375,
            "end_logit": 9.53125,
            "text": "migraine",
            "probability": 0.994140625
        },
        {
            "start_logit": -3.10546875,
            "end_logit": 9.53125,
            "text": "acute treatment of migraine",
            "probability": 0.005619049072265625
        },
        {
            "start_logit": -5.78125,
            "end_logit": 9.53125,
            "text": "of migraine",
            "probability": 0.0003867149353027344
        },
        {
            "start_logit": -7.046875,
            "end_logit": 9.53125,
            "text": "treatment of migraine",
            "probability": 0.00010913610458374023
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.53125,
            "text": "for the acute treatment of migraine",
            "probability": 8.046627044677734e-05
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 9.53125,
            "text": "the acute treatment of migraine",
            "probability": 7.677078247070312e-05
        },
        {
            "start_logit": 2.068359375,
            "end_logit": -6.3984375,
            "text": "migraine.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.10546875,
            "end_logit": -6.3984375,
            "text": "acute treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -3.10546875,
            "end_logit": -7.01171875,
            "text": "acute treatment",
            "probability": 0.0
        },
        {
            "start_logit": -4.9609375,
            "end_logit": -6.3984375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.78125,
            "end_logit": -6.3984375,
            "text": "of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.046875,
            "end_logit": -6.3984375,
            "text": "treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -6.3984375,
            "text": "for the acute treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -6.3984375,
            "text": "the acute treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -6.82421875,
            "text": "Zolmitriptan (Zomig, formerly 311C90) is a selective 5-hydroxytryptamine (5-HT",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -6.8984375,
            "text": "Zolmitriptan (Zomig, formerly 311C90) is a selective 5-hydroxytryptamine (5-HT)1B",
            "probability": 0.0
        },
        {
            "start_logit": -7.046875,
            "end_logit": -7.01171875,
            "text": "treatment",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -6.984375,
            "text": "Zolmitriptan (Zomig, formerly 311C90) is a selective 5-hydroxytryptamine (5-HT)",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -7.0078125,
            "text": "Zolmitriptan (Zomig, formerly 311C90) is a selective 5-hydroxytryptamine (5-HT)1B/",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -7.0390625,
            "text": "Zolmitriptan (Zomig, formerly 311C90) is a selective 5-hydroxytryptamine (5-HT)1B/1D",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_9": [
        {
            "start_logit": 2.80859375,
            "end_logit": 9.609375,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": -6.41796875,
            "end_logit": 9.609375,
            "text": "Zolmitriptan is an effective medicine used in the treatment of migraine",
            "probability": 9.763240814208984e-05
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 9.609375,
            "text": "treatment of migraine",
            "probability": 9.459257125854492e-05
        },
        {
            "start_logit": -6.4609375,
            "end_logit": 9.609375,
            "text": "of migraine",
            "probability": 9.387731552124023e-05
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 9.609375,
            "text": "mitriptan is an effective medicine used in the treatment of migraine",
            "probability": 4.4345855712890625e-05
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 9.609375,
            "text": "in the treatment of migraine",
            "probability": 4.100799560546875e-05
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 9.609375,
            "text": "the treatment of migraine",
            "probability": 3.3974647521972656e-05
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.609375,
            "text": "an is an effective medicine used in the treatment of migraine",
            "probability": 3.0934810638427734e-05
        },
        {
            "start_logit": 2.80859375,
            "end_logit": -5.78125,
            "text": "migraine.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.80078125,
            "end_logit": -5.78125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.41796875,
            "end_logit": -5.78125,
            "text": "Zolmitriptan is an effective medicine used in the treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -6.45703125,
            "end_logit": -5.78125,
            "text": "treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -6.4609375,
            "end_logit": -5.78125,
            "text": "of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.2109375,
            "end_logit": -5.78125,
            "text": "mitriptan is an effective medicine used in the treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.2890625,
            "end_logit": -5.78125,
            "text": "in the treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -5.78125,
            "text": "the treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -5.78125,
            "text": "an is an effective medicine used in the treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -6.41796875,
            "end_logit": -7.1171875,
            "text": "Zolmitriptan is an effective medicine used in the",
            "probability": 0.0
        },
        {
            "start_logit": -6.41796875,
            "end_logit": -7.1640625,
            "text": "Zolmitriptan is an effective medicine used in the treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -6.41796875,
            "end_logit": -7.1640625,
            "text": "Zolmitriptan is an",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_10": [
        {
            "start_logit": 5.984375,
            "end_logit": 9.34375,
            "text": "acute oral treatment of migraine",
            "probability": 0.998046875
        },
        {
            "start_logit": -0.343505859375,
            "end_logit": 9.34375,
            "text": "migraine",
            "probability": 0.001781463623046875
        },
        {
            "start_logit": -6.01171875,
            "end_logit": 9.34375,
            "text": "of migraine",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -7.140625,
            "end_logit": 9.34375,
            "text": "treatment of migraine",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -7.203125,
            "end_logit": 9.34375,
            "text": "oral treatment of migraine",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 5.984375,
            "end_logit": -4.73046875,
            "text": "acute",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 5.984375,
            "end_logit": -6.77734375,
            "text": "acute oral treatment of migraine.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.984375,
            "end_logit": -6.91015625,
            "text": "acute oral",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.984375,
            "end_logit": -6.9921875,
            "text": "acute oral treatment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.343505859375,
            "end_logit": -6.77734375,
            "text": "migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -4.4609375,
            "end_logit": -6.77734375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.01171875,
            "end_logit": -6.77734375,
            "text": "of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.140625,
            "end_logit": -6.77734375,
            "text": "treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.203125,
            "end_logit": -6.77734375,
            "text": "oral treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.203125,
            "end_logit": -6.91015625,
            "text": "oral",
            "probability": 0.0
        },
        {
            "start_logit": -7.140625,
            "end_logit": -6.9921875,
            "text": "treatment",
            "probability": 0.0
        },
        {
            "start_logit": -7.203125,
            "end_logit": -6.9921875,
            "text": "oral treatment",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": -7.0,
            "text": "311C90 (Zomig; zolmitriptan) is a novel, selective serotonin (5HT)1B",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": -7.08984375,
            "text": "311C90 (Zomig; zolmitriptan) is a novel, selective serotonin (5HT)1B/",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": -7.1015625,
            "text": "311C90 (Zomig; zolmitri",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_11": [
        {
            "start_logit": 5.79296875,
            "end_logit": 8.6953125,
            "text": "headache",
            "probability": 0.9990234375
        },
        {
            "start_logit": -0.97119140625,
            "end_logit": 8.6953125,
            "text": "moderate and severe headache",
            "probability": 0.001155853271484375
        },
        {
            "start_logit": -5.625,
            "end_logit": 8.6953125,
            "text": "severe headache",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -6.359375,
            "end_logit": 8.6953125,
            "text": "either rizatriptan or zolmitriptan would be appropriate for moderate and severe headache",
            "probability": 5.304813385009766e-06
        },
        {
            "start_logit": -6.484375,
            "end_logit": 8.6953125,
            "text": "for moderate and severe headache",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 8.6953125,
            "text": "and severe headache",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 8.6953125,
            "text": "zolmitriptan would be appropriate for moderate and severe headache",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 8.6953125,
            "text": "mitriptan would be appropriate for moderate and severe headache",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 5.79296875,
            "end_logit": -6.53125,
            "text": "headache.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.79296875,
            "end_logit": -6.859375,
            "text": "headache. Rizatriptan has a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.79296875,
            "end_logit": -6.98828125,
            "text": "headache. Ri",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 5.79296875,
            "end_logit": -7.0703125,
            "text": "headache. Riz",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.79296875,
            "end_logit": -7.08984375,
            "text": "headache. Rizatript",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.79296875,
            "end_logit": -7.10546875,
            "text": "headache. Rizatriptan has a more",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.79296875,
            "end_logit": -7.11328125,
            "text": "headache. Rizatri",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.79296875,
            "end_logit": -7.1328125,
            "text": "headache. Rizatriptan",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.79296875,
            "end_logit": -7.15234375,
            "text": "headache. Rizatriptan has",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.97119140625,
            "end_logit": -6.53125,
            "text": "moderate and severe headache.",
            "probability": 0.0
        },
        {
            "start_logit": -0.97119140625,
            "end_logit": -6.859375,
            "text": "moderate and severe headache. Rizatriptan has a",
            "probability": 0.0
        },
        {
            "start_logit": -0.97119140625,
            "end_logit": -6.98828125,
            "text": "moderate and severe headache. Ri",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_12": [
        {
            "start_logit": 4.171875,
            "end_logit": 9.390625,
            "text": "acute attacks of migraine",
            "probability": 0.98388671875
        },
        {
            "start_logit": 0.039520263671875,
            "end_logit": 9.390625,
            "text": "migraine",
            "probability": 0.015777587890625
        },
        {
            "start_logit": -6.28125,
            "end_logit": 9.390625,
            "text": "of migraine",
            "probability": 2.8371810913085938e-05
        },
        {
            "start_logit": -6.82421875,
            "end_logit": 9.390625,
            "text": "attacks of migraine",
            "probability": 1.6391277313232422e-05
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 9.390625,
            "text": "treatment of acute attacks of migraine",
            "probability": 1.615285873413086e-05
        },
        {
            "start_logit": -6.859375,
            "end_logit": 9.390625,
            "text": "of acute attacks of migraine",
            "probability": 1.5974044799804688e-05
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 9.390625,
            "text": "in the treatment of acute attacks of migraine",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 9.390625,
            "text": "mitriptan (311C90) has been shown to be effective in the treatment of acute attacks of migraine",
            "probability": 9.655952453613281e-06
        },
        {
            "start_logit": -7.40625,
            "end_logit": 9.390625,
            "text": "zolmitriptan (311C90) has been shown to be effective in the treatment of acute attacks of migraine",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 9.390625,
            "text": ") has been shown to be effective in the treatment of acute attacks of migraine",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 4.171875,
            "end_logit": -5.71484375,
            "text": "acute attacks of migraine and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 4.171875,
            "end_logit": -5.96875,
            "text": "acute attacks of migraine and experimental data suggest that it may have both peripheral and central sites of action.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 4.171875,
            "end_logit": -6.33984375,
            "text": "acute",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.171875,
            "end_logit": -6.57421875,
            "text": "acute attacks of migraine and experimental data suggest that it may",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.171875,
            "end_logit": -6.734375,
            "text": "acute attacks of migraine and experimental data suggest",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.171875,
            "end_logit": -6.80078125,
            "text": "acute attacks",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.171875,
            "end_logit": -7.01171875,
            "text": "acute attacks of migraine and experimental data",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.039520263671875,
            "end_logit": -5.71484375,
            "text": "migraine and",
            "probability": 0.0
        },
        {
            "start_logit": 0.039520263671875,
            "end_logit": -5.96875,
            "text": "migraine and experimental data suggest that it may have both peripheral and central sites of action.",
            "probability": 0.0
        },
        {
            "start_logit": 0.039520263671875,
            "end_logit": -6.57421875,
            "text": "migraine and experimental data suggest that it may",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_13": [
        {
            "start_logit": 0.089111328125,
            "end_logit": 7.59765625,
            "text": "headache",
            "probability": 0.91015625
        },
        {
            "start_logit": -2.484375,
            "end_logit": 7.59765625,
            "text": "recurrent headache",
            "probability": 0.06939697265625
        },
        {
            "start_logit": -3.970703125,
            "end_logit": 7.59765625,
            "text": "Naratriptan would appear to have a lower recurrent headache",
            "probability": 0.0156707763671875
        },
        {
            "start_logit": -6.2265625,
            "end_logit": 7.59765625,
            "text": "lower recurrent headache",
            "probability": 0.001644134521484375
        },
        {
            "start_logit": -6.48828125,
            "end_logit": 7.59765625,
            "text": "atriptan would appear to have a lower recurrent headache",
            "probability": 0.0012655258178710938
        },
        {
            "start_logit": -6.58984375,
            "end_logit": 7.59765625,
            "text": "appear to have a lower recurrent headache",
            "probability": 0.0011434555053710938
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 7.59765625,
            "text": "would appear to have a lower recurrent headache",
            "probability": 0.0007891654968261719
        },
        {
            "start_logit": 0.089111328125,
            "end_logit": -3.921875,
            "text": "headache rate than sumatriptan, rizatriptan or zolmitriptan.",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": 0.089111328125,
            "end_logit": -5.51953125,
            "text": "headache rate",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 0.089111328125,
            "end_logit": -6.1171875,
            "text": "headache rate than sumatriptan",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 0.089111328125,
            "end_logit": -6.40234375,
            "text": "headache rate than",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -2.484375,
            "end_logit": -3.921875,
            "text": "recurrent headache rate than sumatriptan, rizatriptan or zolmitriptan.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 0.089111328125,
            "end_logit": -6.546875,
            "text": "headache rate than sumatript",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 0.089111328125,
            "end_logit": -6.9453125,
            "text": "headache rate than sumatriptan, rizatriptan or zolmitri",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 0.089111328125,
            "end_logit": -6.98828125,
            "text": "headache rate than sumatriptan, rizatriptan or zolmitript",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 0.089111328125,
            "end_logit": -7.04296875,
            "text": "headache rate than sumatriptan, rizatriptan or zolmit",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 0.089111328125,
            "end_logit": -7.04296875,
            "text": "headache rate than sumatriptan, rizatriptan or zolmitriptan",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 0.089111328125,
            "end_logit": -7.09765625,
            "text": "headache rate than sumatriptan, rizatriptan",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 0.089111328125,
            "end_logit": -7.125,
            "text": "headache rate than sumatri",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 0.089111328125,
            "end_logit": -7.1875,
            "text": "headache rate than sumatriptan, rizatriptan or zol",
            "probability": 2.980232238769531e-07
        }
    ],
    "601dbe2b1cb411341a00004d_14": [
        {
            "start_logit": 7.7109375,
            "end_logit": 7.54296875,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.12890625,
            "text": "migraine management",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.34765625,
            "text": "migraine management: Both ri",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.37109375,
            "text": "migraine management: Both rizatriptan (10 mg) and zolmitriptan (2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.37890625,
            "text": "migraine management: Both rizatriptan (10 mg) and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.3828125,
            "text": "migraine management: Both riz",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.7109375,
            "end_logit": -7.41015625,
            "text": "migraine management: Both rizatript",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.37890625,
            "end_logit": -7.1015625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_15": [
        {
            "start_logit": 3.265625,
            "end_logit": 8.2890625,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": -6.265625,
            "end_logit": 8.2890625,
            "text": "Zolmitriptan is effective in the treatment of migraine",
            "probability": 7.253885269165039e-05
        },
        {
            "start_logit": -7.140625,
            "end_logit": 8.2890625,
            "text": "of migraine",
            "probability": 3.0219554901123047e-05
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 8.2890625,
            "text": "mitriptan is effective in the treatment of migraine",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": -7.40625,
            "end_logit": 8.2890625,
            "text": "treatment of migraine",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 8.2890625,
            "text": "in the treatment of migraine",
            "probability": 2.2649765014648438e-05
        },
        {
            "start_logit": 3.265625,
            "end_logit": -6.3125,
            "text": "migraine associated",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 3.265625,
            "end_logit": -6.75,
            "text": "migraine associated with menses and migraine with aura",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 3.265625,
            "end_logit": -6.8046875,
            "text": "migraine associated with menses",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 3.265625,
            "end_logit": -7.01171875,
            "text": "migraine associated with mense",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 3.265625,
            "end_logit": -7.01953125,
            "text": "migraine associated with menses and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 3.265625,
            "end_logit": -7.12890625,
            "text": "migraine associated with",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 3.265625,
            "end_logit": -7.203125,
            "text": "migraine associated with men",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 3.265625,
            "end_logit": -7.20703125,
            "text": "migraine associated with menses and migraine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 3.265625,
            "end_logit": -7.23046875,
            "text": "migraine associated with menses and migraine with",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.265625,
            "end_logit": -6.3125,
            "text": "Zolmitriptan is effective in the treatment of migraine associated",
            "probability": 0.0
        },
        {
            "start_logit": -6.265625,
            "end_logit": -6.75,
            "text": "Zolmitriptan is effective in the treatment of migraine associated with menses and migraine with aura",
            "probability": 0.0
        },
        {
            "start_logit": -6.265625,
            "end_logit": -6.8046875,
            "text": "Zolmitriptan is effective in the treatment of migraine associated with menses",
            "probability": 0.0
        },
        {
            "start_logit": -6.265625,
            "end_logit": -7.01171875,
            "text": "Zolmitriptan is effective in the treatment of migraine associated with mense",
            "probability": 0.0
        },
        {
            "start_logit": -6.265625,
            "end_logit": -7.01953125,
            "text": "Zolmitriptan is effective in the treatment of migraine associated with menses and",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_16": [
        {
            "start_logit": 6.828125,
            "end_logit": 8.359375,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 8.359375,
            "text": "in migraine",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.359375,
            "text": "Zolmitriptan: a review of its use in migraine",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 8.359375,
            "text": "review of its use in migraine",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 6.828125,
            "end_logit": -6.94921875,
            "text": "migraine.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.4453125,
            "end_logit": -6.94921875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.0234375,
            "end_logit": -6.94921875,
            "text": "in migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -6.9375,
            "text": "Zolmitriptan: a",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -6.94921875,
            "text": "Zolmitriptan: a review of its use in migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -6.94921875,
            "text": "review of its use in migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.2109375,
            "text": "Zolmitriptan: a review",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.2109375,
            "text": "Zolmitri",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.26953125,
            "text": "Zolmitriptan: a review of",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.29296875,
            "text": "Zolmitript",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.30078125,
            "text": "Zolmitriptan",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.3203125,
            "text": "Zolmitriptan: a review of its use",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.328125,
            "text": "Zolmit",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -7.2109375,
            "text": "review",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.3515625,
            "text": "Zol",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -7.26953125,
            "text": "review of",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_17": [
        {
            "start_logit": 8.6640625,
            "end_logit": 8.734375,
            "text": "migraine headache",
            "probability": 1.0
        },
        {
            "start_logit": -2.287109375,
            "end_logit": 8.734375,
            "text": "headache",
            "probability": 1.7344951629638672e-05
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -2.427734375,
            "text": "migraine",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": -7.21875,
            "end_logit": 8.734375,
            "text": "For relief of migraine headache",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.234375,
            "end_logit": 8.734375,
            "text": "of migraine headache",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.40625,
            "end_logit": 8.734375,
            "text": "relief of migraine headache",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -7.4609375,
            "text": "migraine headache, zolmitriptan 5mg had similar efficacy to sumatriptan 100mg for a single attack, but",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -7.515625,
            "text": "migraine headache,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -7.54296875,
            "text": "migraine headache, zolmitriptan 5mg had similar",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -7.54296875,
            "text": "migraine headache, zolmitriptan 5mg had",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -7.5625,
            "text": "migraine headache, zolmitriptan 5mg had similar efficacy to sumatriptan 100mg for a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -7.578125,
            "text": "migraine headache, zolmitriptan 5mg had similar efficacy to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21875,
            "end_logit": -2.427734375,
            "text": "For relief of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": -2.427734375,
            "text": "of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -2.287109375,
            "end_logit": -7.4609375,
            "text": "headache, zolmitriptan 5mg had similar efficacy to sumatriptan 100mg for a single attack, but",
            "probability": 0.0
        },
        {
            "start_logit": -2.287109375,
            "end_logit": -7.515625,
            "text": "headache,",
            "probability": 0.0
        },
        {
            "start_logit": -2.287109375,
            "end_logit": -7.54296875,
            "text": "headache, zolmitriptan 5mg had similar",
            "probability": 0.0
        },
        {
            "start_logit": -2.287109375,
            "end_logit": -7.54296875,
            "text": "headache, zolmitriptan 5mg had",
            "probability": 0.0
        },
        {
            "start_logit": -7.40625,
            "end_logit": -2.427734375,
            "text": "relief of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -2.287109375,
            "end_logit": -7.5625,
            "text": "headache, zolmitriptan 5mg had similar efficacy to sumatriptan 100mg for a",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_18": [
        {
            "start_logit": 7.609375,
            "end_logit": 7.640625,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": 7.609375,
            "end_logit": -5.62890625,
            "text": "migraine subtypes",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 7.609375,
            "end_logit": -6.1171875,
            "text": "migraine subtypes, maintains efficacy when used in the long term and is generally well tolerated.",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 7.609375,
            "end_logit": -6.79296875,
            "text": "migraine subtypes,",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.609375,
            "end_logit": -6.85546875,
            "text": "migraine subtypes, maintains efficacy when used in the long term and",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.04296875,
            "text": "migraine subtypes, maintains efficacy when used in the long term and is",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.06640625,
            "text": "migraine subtypes, maintains efficacy when",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.0703125,
            "text": "migraine subtypes, maintains efficacy when used in the",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.08203125,
            "text": "migraine subtypes, maintains efficacy when used in the long term",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.0859375,
            "text": "migraine subtypes, maintains",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.125,
            "text": "migraine subtypes, maintains efficacy",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.12890625,
            "text": "migraine subtypes, maintains efficacy when used in the long term and is generally well",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.14453125,
            "text": "migraine subtypes, maintains efficacy when used in",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.265625,
            "end_logit": 7.640625,
            "text": "of migraine",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 7.640625,
            "text": "NCLUSION: Zolmitriptan is effective across a wide range of migraine",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 7.640625,
            "text": "Zolmitriptan is effective across a wide range of migraine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 7.640625,
            "text": "LUSION: Zolmitriptan is effective across a wide range of migraine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 7.640625,
            "text": "mitriptan is effective across a wide range of migraine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.23046875,
            "end_logit": -6.1171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.265625,
            "end_logit": -5.62890625,
            "text": "of migraine subtypes",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_19": [
        {
            "start_logit": 8.84375,
            "end_logit": 8.5,
            "text": "migraine headache",
            "probability": 1.0
        },
        {
            "start_logit": 8.84375,
            "end_logit": -2.244140625,
            "text": "migraine",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": -2.5859375,
            "end_logit": 8.5,
            "text": "headache",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": -7.484375,
            "end_logit": 8.5,
            "text": "in the treatment of persistent and/or recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 8.5,
            "text": "recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 8.5,
            "text": "treatment of persistent and/or recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 8.5,
            "text": "mitriptan has also demonstrated efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": -2.244140625,
            "text": "in the treatment of persistent and/or recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -2.244140625,
            "text": "recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -2.244140625,
            "text": "treatment of persistent and/or recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -2.244140625,
            "text": "mitriptan has also demonstrated efficacy in the treatment of persistent and/or recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -7.0859375,
            "text": "in the treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -7.14453125,
            "text": "in the treatment of persistent and/",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -7.0859375,
            "text": "treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -7.0859375,
            "text": "mitriptan has also demonstrated efficacy in the treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -7.203125,
            "text": "in the treatment of persistent",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -7.20703125,
            "text": "in the",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -7.14453125,
            "text": "treatment of persistent and/",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -7.2109375,
            "text": "in the treatment of persistent and",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -7.22265625,
            "text": "in the treatment of persistent and/or",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_20": [
        {
            "start_logit": 4.1328125,
            "end_logit": 8.796875,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": -5.69140625,
            "end_logit": 8.796875,
            "text": "with migraine",
            "probability": 5.3942203521728516e-05
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 8.796875,
            "text": "There is some evidence to support the use of zolmitriptan in patients with migraine",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 8.796875,
            "text": "zolmitriptan in patients with migraine",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -7.28125,
            "end_logit": 8.796875,
            "text": "patients with migraine",
            "probability": 1.1026859283447266e-05
        },
        {
            "start_logit": -7.296875,
            "end_logit": 8.796875,
            "text": "mitriptan in patients with migraine",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": -7.375,
            "end_logit": 8.796875,
            "text": "in patients with migraine",
            "probability": 1.0073184967041016e-05
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 8.796875,
            "text": "of zolmitriptan in patients with migraine",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 8.796875,
            "text": "support the use of zolmitriptan in patients with migraine",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": -7.46875,
            "end_logit": 8.796875,
            "text": "riptan in patients with migraine",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 8.796875,
            "text": "use of zolmitriptan in patients with migraine",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 8.796875,
            "text": "an in patients with migraine",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": 4.1328125,
            "end_logit": -6.08984375,
            "text": "migraine who",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 4.1328125,
            "end_logit": -6.66015625,
            "text": "migraine who have had a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.1328125,
            "end_logit": -6.69921875,
            "text": "migraine who have",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.1328125,
            "end_logit": -6.78125,
            "text": "migraine who have had",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.1328125,
            "end_logit": -6.8125,
            "text": "migraine who have had a poor response to previous",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.1328125,
            "end_logit": -6.87890625,
            "text": "migraine who have had a poor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.1328125,
            "end_logit": -6.890625,
            "text": "migraine who have had a poor response to",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.1328125,
            "end_logit": -7.01171875,
            "text": "migraine who have had a poor response to previous therapy",
            "probability": 1.1920928955078125e-07
        }
    ],
    "601dbe2b1cb411341a00004d_21": [
        {
            "start_logit": 6.90234375,
            "end_logit": 8.171875,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 8.171875,
            "text": "of migraine",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 8.171875,
            "text": ", with no tachyphylaxis, following repeated administration for multiple attacks of migraine",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -7.01171875,
            "text": "migraine over",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -7.1171875,
            "text": "migraine over a",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -7.15625,
            "text": "migraine over a prolonged period",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -7.1640625,
            "text": "migraine over a prolonged period of time, with high headache response rates reported",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -7.17578125,
            "text": "migraine over a prolonged",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -7.23046875,
            "text": "migraine over a prolonged period of time, with high",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -7.23046875,
            "text": "migraine over a prolonged period of time",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -7.2421875,
            "text": "migraine over a prolonged period of time, with high headache response rates",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -7.26953125,
            "text": "migraine over a prolonged period of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -7.2890625,
            "text": "migraine over a prolonged period of time, with high headache response",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.90234375,
            "end_logit": -7.29296875,
            "text": "migraine over a prolonged period of time, with",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -7.01171875,
            "text": "of migraine over",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -7.1171875,
            "text": "of migraine over a",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -7.01171875,
            "text": ", with no tachyphylaxis, following repeated administration for multiple attacks of migraine over",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -7.15625,
            "text": "of migraine over a prolonged period",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -7.1640625,
            "text": "of migraine over a prolonged period of time, with high headache response rates reported",
            "probability": 0.0
        },
        {
            "start_logit": -7.3984375,
            "end_logit": -7.17578125,
            "text": "of migraine over a prolonged",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_22": [
        {
            "start_logit": 8.7578125,
            "end_logit": 8.78125,
            "text": "migraine headache",
            "probability": 1.0
        },
        {
            "start_logit": -2.138671875,
            "end_logit": 8.78125,
            "text": "headache",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -2.212890625,
            "text": "migraine",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.03515625,
            "text": "migraine headache is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.19140625,
            "text": "migraine headache is reduced",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.2890625,
            "text": "migraine headache is reduced by zolmitriptan and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.375,
            "text": "migraine headache is reduced by zolmitriptan and recurrent migraine headache occurs",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.39453125,
            "text": "migraine headache is reduced by zolmitriptan and recurrent migraine headache occurs less frequently",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.40234375,
            "text": "migraine headache is reduced by zolmitriptan and recurrent migraine headache occurs less",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.41015625,
            "text": "migraine headache is reduced by zolmitriptan and recurrent migraine headache occurs less frequently with the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.43359375,
            "text": "migraine headache is reduced by",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.4375,
            "text": "migraine headache is reduced by zolmitriptan and recurrent migraine headache occurs less frequently with",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 8.78125,
            "text": "In comparison with placebo, the incidence of persistent migraine headache",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.45703125,
            "text": "migraine headache is reduced by zolmitriptan and recurrent migraine headache occurs less frequently with the active",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 8.78125,
            "text": "persistent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.4609375,
            "text": "migraine headache is reduced by zolmitriptan and recurrent",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.138671875,
            "end_logit": -7.03515625,
            "text": "headache is",
            "probability": 0.0
        },
        {
            "start_logit": -2.138671875,
            "end_logit": -7.19140625,
            "text": "headache is reduced",
            "probability": 0.0
        },
        {
            "start_logit": -2.138671875,
            "end_logit": -7.2890625,
            "text": "headache is reduced by zolmitriptan and",
            "probability": 0.0
        },
        {
            "start_logit": -2.138671875,
            "end_logit": -7.375,
            "text": "headache is reduced by zolmitriptan and recurrent migraine headache occurs",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_23": [
        {
            "start_logit": 8.921875,
            "end_logit": 8.796875,
            "text": "cluster headache",
            "probability": 1.0
        },
        {
            "start_logit": 8.921875,
            "end_logit": -2.08203125,
            "text": "cluster",
            "probability": 1.895427703857422e-05
        },
        {
            "start_logit": -2.22265625,
            "end_logit": 8.796875,
            "text": "headache",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": 8.921875,
            "end_logit": -7.12109375,
            "text": "cluster headache.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 8.796875,
            "text": "symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 8.796875,
            "text": "of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.796875,
            "text": "for the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.22265625,
            "end_logit": -7.12109375,
            "text": "headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -2.08203125,
            "text": "symptomatic treatment of cluster",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -2.08203125,
            "text": "of cluster",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -2.08203125,
            "text": "for the symptomatic treatment of cluster",
            "probability": 0.0
        },
        {
            "start_logit": -4.546875,
            "end_logit": -7.12109375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -7.12109375,
            "text": "symptomatic treatment of cluster headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -7.12109375,
            "text": "of cluster headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -7.17578125,
            "text": "symptomatic treatment",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -7.12109375,
            "text": "for the symptomatic treatment of cluster headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -7.17578125,
            "text": "for the symptomatic treatment",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -7.24609375,
            "text": "symptomatic treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -7.24609375,
            "text": "of",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -7.21484375,
            "text": "for the",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_24": [
        {
            "start_logit": 8.9453125,
            "end_logit": 8.8359375,
            "text": "cluster headache",
            "probability": 1.0
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -2.044921875,
            "text": "cluster",
            "probability": 1.8775463104248047e-05
        },
        {
            "start_logit": -2.134765625,
            "end_logit": 8.8359375,
            "text": "headache",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.73046875,
            "text": "cluster headache in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -7.1171875,
            "text": "cluster headache in daily clinical practice",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -7.125,
            "text": "cluster headache in daily clinical practice.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -7.37890625,
            "text": "cluster headache in daily",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -7.390625,
            "text": "cluster headache in daily clinical",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 8.8359375,
            "text": "The objective is to analyse our experience with the new intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 8.8359375,
            "text": "experience with the new intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 8.8359375,
            "text": "in the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 8.8359375,
            "text": "treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 8.8359375,
            "text": "symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 8.8359375,
            "text": "analyse our experience with the new intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 8.8359375,
            "text": "mg in the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5,
            "end_logit": 8.8359375,
            "text": "our experience with the new intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 8.8359375,
            "text": "objective is to analyse our experience with the new intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 8.8359375,
            "text": "intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 8.8359375,
            "text": "with the new intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.134765625,
            "end_logit": -6.73046875,
            "text": "headache in",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_25": [
        {
            "start_logit": 8.6953125,
            "end_logit": 6.26953125,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -3.33984375,
            "text": "migraine attacks",
            "probability": 6.711483001708984e-05
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -6.3203125,
            "text": "migraine attacks and",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -6.4375,
            "text": "migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks.",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.04296875,
            "text": "migraine attacks and there is recent",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.078125,
            "text": "migraine attacks and there is recent literature",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.09375,
            "text": "migraine attacks and there",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.14453125,
            "text": "migraine attacks and there is",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.171875,
            "text": "migraine attacks and there is recent literature demonstrating its efficacy in the",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.21875,
            "text": "migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.22265625,
            "text": "migraine attacks and there is recent literature demonstrating its efficacy",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.2421875,
            "text": "migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.25390625,
            "text": "migraine attacks and there is recent literature demonstrating",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -6.09375,
            "end_logit": 6.26953125,
            "text": "acute migraine",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 6.26953125,
            "text": "Zolmitriptan is FDA approved for the treatment of acute migraine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 6.26953125,
            "text": "treatment of acute migraine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 6.26953125,
            "text": "mitriptan is FDA approved for the treatment of acute migraine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 6.26953125,
            "text": "for the treatment of acute migraine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": 6.26953125,
            "text": "of acute migraine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.09375,
            "end_logit": -3.33984375,
            "text": "acute migraine attacks",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_26": [
        {
            "start_logit": 8.578125,
            "end_logit": -0.57763671875,
            "text": "migraine",
            "probability": 0.955078125
        },
        {
            "start_logit": 8.578125,
            "end_logit": -4.30078125,
            "text": "migraine with or without preceding aura",
            "probability": 0.0230865478515625
        },
        {
            "start_logit": 8.578125,
            "end_logit": -5.2265625,
            "text": "migraine with or without preceding aura.",
            "probability": 0.00914764404296875
        },
        {
            "start_logit": 8.578125,
            "end_logit": -6.078125,
            "text": "migraine with or",
            "probability": 0.003902435302734375
        },
        {
            "start_logit": 8.578125,
            "end_logit": -6.26171875,
            "text": "migraine with",
            "probability": 0.0032482147216796875
        },
        {
            "start_logit": 8.578125,
            "end_logit": -6.37890625,
            "text": "migraine with or without",
            "probability": 0.0028896331787109375
        },
        {
            "start_logit": 8.578125,
            "end_logit": -6.61328125,
            "text": "migraine with or without preceding",
            "probability": 0.0022869110107421875
        },
        {
            "start_logit": -5.02734375,
            "end_logit": -0.57763671875,
            "text": "of migraine",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -5.6796875,
            "end_logit": -0.57763671875,
            "text": "acute treatment of migraine",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": -0.57763671875,
            "text": "treatment of migraine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": -0.57763671875,
            "text": "in the acute treatment of migraine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.02734375,
            "end_logit": -4.30078125,
            "text": "of migraine with or without preceding aura",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.6796875,
            "end_logit": -4.30078125,
            "text": "acute treatment of migraine with or without preceding aura",
            "probability": 0.0
        },
        {
            "start_logit": -5.02734375,
            "end_logit": -5.2265625,
            "text": "of migraine with or without preceding aura.",
            "probability": 0.0
        },
        {
            "start_logit": -5.05078125,
            "end_logit": -5.2265625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.6796875,
            "end_logit": -5.2265625,
            "text": "acute treatment of migraine with or without preceding aura.",
            "probability": 0.0
        },
        {
            "start_logit": -5.02734375,
            "end_logit": -6.078125,
            "text": "of migraine with or",
            "probability": 0.0
        },
        {
            "start_logit": -5.02734375,
            "end_logit": -6.26171875,
            "text": "of migraine with",
            "probability": 0.0
        },
        {
            "start_logit": -5.02734375,
            "end_logit": -6.37890625,
            "text": "of migraine with or without",
            "probability": 0.0
        },
        {
            "start_logit": -7.14453125,
            "end_logit": -4.30078125,
            "text": "treatment of migraine with or without preceding aura",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_27": [
        {
            "start_logit": 9.2421875,
            "end_logit": 9.40625,
            "text": "acute treatment for migraine",
            "probability": 1.0
        },
        {
            "start_logit": -0.332275390625,
            "end_logit": 9.40625,
            "text": "migraine",
            "probability": 6.866455078125e-05
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -1.1669921875,
            "text": "acute",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": -5.98828125,
            "end_logit": 9.40625,
            "text": "for migraine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.234375,
            "end_logit": 9.40625,
            "text": "treatment for migraine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.61328125,
            "text": "acute treatment for migraine.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.05078125,
            "end_logit": 9.40625,
            "text": "Zolmitriptan is a suitable first-line drug for acute treatment for migraine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.0625,
            "text": "acute treatment for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.16015625,
            "text": "acute treatment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 9.40625,
            "text": "mitriptan is a suitable first-line drug for acute treatment for migraine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.332275390625,
            "end_logit": -6.61328125,
            "text": "migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.05078125,
            "end_logit": -1.1669921875,
            "text": "Zolmitriptan is a suitable first-line drug for acute",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -1.1669921875,
            "text": "mitriptan is a suitable first-line drug for acute",
            "probability": 0.0
        },
        {
            "start_logit": -5.46875,
            "end_logit": -6.61328125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.98828125,
            "end_logit": -6.61328125,
            "text": "for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -6.234375,
            "end_logit": -6.61328125,
            "text": "treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -5.98828125,
            "end_logit": -7.0625,
            "text": "for",
            "probability": 0.0
        },
        {
            "start_logit": -6.234375,
            "end_logit": -7.0625,
            "text": "treatment for",
            "probability": 0.0
        },
        {
            "start_logit": -6.234375,
            "end_logit": -7.16015625,
            "text": "treatment",
            "probability": 0.0
        },
        {
            "start_logit": -7.05078125,
            "end_logit": -6.61328125,
            "text": "Zolmitriptan is a suitable first-line drug for acute treatment for migraine.",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_28": [
        {
            "start_logit": 6.58203125,
            "end_logit": 9.6484375,
            "text": "acute treatment of migraine",
            "probability": 0.994140625
        },
        {
            "start_logit": 1.513671875,
            "end_logit": 9.6484375,
            "text": "migraine",
            "probability": 0.0062408447265625
        },
        {
            "start_logit": -6.39453125,
            "end_logit": 9.6484375,
            "text": "treatment of migraine",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 9.6484375,
            "text": "of migraine",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -7.078125,
            "end_logit": 9.6484375,
            "text": "for the acute treatment of migraine",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 9.6484375,
            "text": "Zolmitriptan, a selective 5-HT(1B/D) agonist was developed for the acute treatment of migraine",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.40625,
            "end_logit": 9.6484375,
            "text": "the acute treatment of migraine",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 9.6484375,
            "text": "5-HT(1B/D) agonist was developed for the acute treatment of migraine",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 9.6484375,
            "text": "mitriptan, a selective 5-HT(1B/D) agonist was developed for the acute treatment of migraine",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 9.6484375,
            "text": "selective 5-HT(1B/D) agonist was developed for the acute treatment of migraine",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 6.58203125,
            "end_logit": -4.51171875,
            "text": "acute",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 6.58203125,
            "end_logit": -6.10546875,
            "text": "acute treatment of migraine.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.58203125,
            "end_logit": -6.6796875,
            "text": "acute treatment of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.58203125,
            "end_logit": -7.1484375,
            "text": "acute treatment",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.513671875,
            "end_logit": -6.10546875,
            "text": "migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.078125,
            "end_logit": -4.51171875,
            "text": "for the acute",
            "probability": 0.0
        },
        {
            "start_logit": -5.59765625,
            "end_logit": -6.10546875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -4.51171875,
            "text": "Zolmitriptan, a selective 5-HT(1B/D) agonist was developed for the acute",
            "probability": 0.0
        },
        {
            "start_logit": -7.40625,
            "end_logit": -4.51171875,
            "text": "the acute",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -4.51171875,
            "text": "5-HT(1B/D) agonist was developed for the acute",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_29": [
        {
            "start_logit": 6.27734375,
            "end_logit": 8.5078125,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": -4.70703125,
            "end_logit": 8.5078125,
            "text": ". Zolmitriptan is effective in the treatment of migraine",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": -6.90234375,
            "end_logit": 8.5078125,
            "text": "of migraine",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -6.90625,
            "end_logit": 8.5078125,
            "text": "Zolmitriptan is effective in the treatment of migraine",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 8.5078125,
            "text": "treatment of migraine",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.390625,
            "end_logit": 8.5078125,
            "text": "in the treatment of migraine",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 8.5078125,
            "text": "mitriptan is effective in the treatment of migraine",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -6.33203125,
            "text": "migraine associated",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -6.9609375,
            "text": "migraine associated with",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -7.0703125,
            "text": "migraine associated with menses",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -7.1328125,
            "text": "migraine associated with menses and migrain",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -7.16796875,
            "text": "migraine associated with men",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -7.19921875,
            "text": "migraine associated with menses and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -7.234375,
            "text": "migraine associated with mense",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.27734375,
            "end_logit": -7.30078125,
            "text": "migraine associated with menses and migr",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.70703125,
            "end_logit": -6.33203125,
            "text": ". Zolmitriptan is effective in the treatment of migraine associated",
            "probability": 0.0
        },
        {
            "start_logit": -4.70703125,
            "end_logit": -6.9609375,
            "text": ". Zolmitriptan is effective in the treatment of migraine associated with",
            "probability": 0.0
        },
        {
            "start_logit": -4.70703125,
            "end_logit": -6.984375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.70703125,
            "end_logit": -7.0703125,
            "text": ". Zolmitriptan is effective in the treatment of migraine associated with menses",
            "probability": 0.0
        },
        {
            "start_logit": -4.70703125,
            "end_logit": -7.1328125,
            "text": ". Zolmitriptan is effective in the treatment of migraine associated with menses and migrain",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_30": [
        {
            "start_logit": 7.0546875,
            "end_logit": 7.3671875,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -4.453125,
            "text": "migraine associated with menses and migraine with aura.",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": -6.19140625,
            "end_logit": 7.3671875,
            "text": "Zolmitriptan is effective in the treatment of migraine",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -6.16796875,
            "text": "migraine associated with menses",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -6.4140625,
            "text": "migraine associated",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -6.48046875,
            "text": "migraine associated with menses and migraine with aura",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -6.61328125,
            "text": "migraine associated with menses and",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -6.72265625,
            "text": "migraine associated with mense",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 7.3671875,
            "text": "of migraine",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -6.90625,
            "text": "migraine associated with men",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -6.92578125,
            "text": "migraine associated with",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -6.94140625,
            "text": "migraine associated with menses and migraine",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.3203125,
            "end_logit": 7.3671875,
            "text": "mitriptan is effective in the treatment of migraine",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 7.3671875,
            "text": "treatment of migraine",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 7.3671875,
            "text": "in the treatment of migraine",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.0546875,
            "end_logit": -7.19140625,
            "text": "migraine associated with menses and migraine with",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.59375,
            "end_logit": -4.453125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.19140625,
            "end_logit": -4.453125,
            "text": "Zolmitriptan is effective in the treatment of migraine associated with menses and migraine with aura.",
            "probability": 0.0
        },
        {
            "start_logit": -6.3828125,
            "end_logit": -4.453125,
            "text": "migraine with aura.",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -4.453125,
            "text": "of migraine associated with menses and migraine with aura.",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_31": [
        {
            "start_logit": 8.9765625,
            "end_logit": 9.3125,
            "text": "acute migraine",
            "probability": 1.0
        },
        {
            "start_logit": -0.54833984375,
            "end_logit": 9.3125,
            "text": "migraine",
            "probability": 7.367134094238281e-05
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -1.9072265625,
            "text": "acute",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -4.8515625,
            "text": "acute migraine therapy",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.9765625,
            "end_logit": -6.73046875,
            "text": "acute migraine therapy.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 9.3125,
            "text": "in acute migraine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": 9.3125,
            "text": "Zolmitriptan, a 5-hydroxytryptophan(1B/1D) receptor agonist, is once such drug that is used in acute migraine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 9.3125,
            "text": "drug that is used in acute migraine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.54833984375,
            "end_logit": -4.8515625,
            "text": "migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -0.54833984375,
            "end_logit": -6.73046875,
            "text": "migraine therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.09375,
            "end_logit": -1.9072265625,
            "text": "in acute",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -1.9072265625,
            "text": "Zolmitriptan, a 5-hydroxytryptophan(1B/1D) receptor agonist, is once such drug that is used in acute",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -1.9072265625,
            "text": "drug that is used in acute",
            "probability": 0.0
        },
        {
            "start_logit": -7.09375,
            "end_logit": -4.8515625,
            "text": "in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -5.46875,
            "end_logit": -6.73046875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -4.8515625,
            "text": "drug that is used in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -7.09375,
            "end_logit": -6.73046875,
            "text": "in acute migraine therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -6.73046875,
            "text": "drug that is used in acute migraine therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -7.21875,
            "text": "Zolmitri",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -7.234375,
            "text": "Zolmitriptan, a 5-hydroxytryptophan(1B/1D) receptor agonist, is once such drug that is used",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_32": [
        {
            "start_logit": 9.265625,
            "end_logit": 8.953125,
            "text": "migraine headache",
            "probability": 1.0
        },
        {
            "start_logit": 9.265625,
            "end_logit": -1.259765625,
            "text": "migraine",
            "probability": 3.6776065826416016e-05
        },
        {
            "start_logit": -1.8291015625,
            "end_logit": 8.953125,
            "text": "headache",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.9140625,
            "text": "migraine headache.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 8.953125,
            "text": "treatment of persistent and/or recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 8.953125,
            "text": "recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34375,
            "end_logit": 8.953125,
            "text": "in the treatment of persistent and/or recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 8.953125,
            "text": "Zolmitriptan has also shown efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 8.953125,
            "text": "mitriptan has also shown efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1953125,
            "end_logit": -1.259765625,
            "text": "treatment of persistent and/or recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.28515625,
            "end_logit": -1.259765625,
            "text": "recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -1.259765625,
            "text": "in the treatment of persistent and/or recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -1.8291015625,
            "end_logit": -6.9140625,
            "text": "headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.515625,
            "end_logit": -1.259765625,
            "text": "Zolmitriptan has also shown efficacy in the treatment of persistent and/or recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -1.259765625,
            "text": "mitriptan has also shown efficacy in the treatment of persistent and/or recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -5.0546875,
            "end_logit": -6.9140625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.1953125,
            "end_logit": -6.9140625,
            "text": "treatment of persistent and/or recurrent migraine headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.28515625,
            "end_logit": -6.9140625,
            "text": "recurrent migraine headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -6.9140625,
            "text": "in the treatment of persistent and/or recurrent migraine headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.1953125,
            "end_logit": -7.1171875,
            "text": "treatment of",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_33": [
        {
            "start_logit": 9.1640625,
            "end_logit": 8.9140625,
            "text": "migraine headache",
            "probability": 1.0
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -1.529296875,
            "text": "migraine",
            "probability": 2.9087066650390625e-05
        },
        {
            "start_logit": -1.9365234375,
            "end_logit": 8.9140625,
            "text": "headache",
            "probability": 1.5079975128173828e-05
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.80078125,
            "text": "migraine headache.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": 8.9140625,
            "text": "Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 8.9140625,
            "text": "treatment of persistent and recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 8.9140625,
            "text": "mitriptan is effective for the treatment of persistent and recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.9140625,
            "text": "recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.9365234375,
            "end_logit": -6.80078125,
            "text": "headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -1.529296875,
            "text": "Zolmitriptan is effective for the treatment of persistent and recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -1.529296875,
            "text": "treatment of persistent and recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -1.529296875,
            "text": "mitriptan is effective for the treatment of persistent and recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -1.529296875,
            "text": "recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -5.38671875,
            "end_logit": -6.80078125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -6.80078125,
            "text": "Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -6.80078125,
            "text": "treatment of persistent and recurrent migraine headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -6.80078125,
            "text": "mitriptan is effective for the treatment of persistent and recurrent migraine headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -6.80078125,
            "text": "recurrent migraine headache.",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -7.06640625,
            "text": "Zolmitriptan is effective for the treatment of persistent and",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -7.1015625,
            "text": "Zolmitriptan is effective for the treatment of persistent",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_34": [
        {
            "start_logit": 2.998046875,
            "end_logit": 9.5546875,
            "text": "acute oral migraine",
            "probability": 0.83203125
        },
        {
            "start_logit": 1.3974609375,
            "end_logit": 9.5546875,
            "text": "migraine",
            "probability": 0.1676025390625
        },
        {
            "start_logit": -4.99609375,
            "end_logit": 9.5546875,
            "text": "oral migraine",
            "probability": 0.00028014183044433594
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 9.5546875,
            "text": "Zolmitriptan is a selective 5-HT1B/1D receptor agonist for acute oral migraine",
            "probability": 3.838539123535156e-05
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 9.5546875,
            "text": "for acute oral migraine",
            "probability": 2.849102020263672e-05
        },
        {
            "start_logit": -7.453125,
            "end_logit": 9.5546875,
            "text": "mitriptan is a selective 5-HT1B/1D receptor agonist for acute oral migraine",
            "probability": 2.4020671844482422e-05
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.5546875,
            "text": "5-HT1B/1D receptor agonist for acute oral migraine",
            "probability": 2.288818359375e-05
        },
        {
            "start_logit": 2.998046875,
            "end_logit": -5.7578125,
            "text": "acute oral migraine therapy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 2.998046875,
            "end_logit": -5.859375,
            "text": "acute oral migraine therapy.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.998046875,
            "end_logit": -6.875,
            "text": "acute",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.3974609375,
            "end_logit": -5.7578125,
            "text": "migraine therapy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.3974609375,
            "end_logit": -5.859375,
            "text": "migraine therapy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.99609375,
            "end_logit": -5.7578125,
            "text": "oral migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -4.99609375,
            "end_logit": -5.859375,
            "text": "oral migraine therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -5.90625,
            "end_logit": -5.859375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.98046875,
            "end_logit": -5.7578125,
            "text": "Zolmitriptan is a selective 5-HT1B/1D receptor agonist for acute oral migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -6.98046875,
            "end_logit": -5.859375,
            "text": "Zolmitriptan is a selective 5-HT1B/1D receptor agonist for acute oral migraine therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.28515625,
            "end_logit": -5.7578125,
            "text": "for acute oral migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -7.28515625,
            "end_logit": -5.859375,
            "text": "for acute oral migraine therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -5.7578125,
            "text": "mitriptan is a selective 5-HT1B/1D receptor agonist for acute oral migraine therapy",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_35": [
        {
            "start_logit": 4.921875,
            "end_logit": 9.2109375,
            "text": "migraine",
            "probability": 0.9990234375
        },
        {
            "start_logit": -1.9599609375,
            "end_logit": 9.2109375,
            "text": "acute treatment of migraine",
            "probability": 0.0010242462158203125
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 9.2109375,
            "text": "treatment of migraine",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -6.875,
            "end_logit": 9.2109375,
            "text": "Zolmitriptan is a 5-HT1B/1D receptor agonist for the acute treatment of migraine",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 9.2109375,
            "text": "of migraine",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 9.2109375,
            "text": "for the acute treatment of migraine",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 9.2109375,
            "text": "mitriptan is a 5-HT1B/1D receptor agonist for the acute treatment of migraine",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.2109375,
            "text": "the acute treatment of migraine",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.2109375,
            "text": "5-HT1B/1D receptor agonist for the acute treatment of migraine",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 4.921875,
            "end_logit": -5.51171875,
            "text": "migraine.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -1.9599609375,
            "end_logit": -5.51171875,
            "text": "acute treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -1.9599609375,
            "end_logit": -6.20703125,
            "text": "acute treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -1.9599609375,
            "end_logit": -6.8515625,
            "text": "acute treatment",
            "probability": 0.0
        },
        {
            "start_logit": -6.0625,
            "end_logit": -5.51171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.7265625,
            "end_logit": -5.51171875,
            "text": "treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -6.875,
            "end_logit": -5.51171875,
            "text": "Zolmitriptan is a 5-HT1B/1D receptor agonist for the acute treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.24609375,
            "end_logit": -5.51171875,
            "text": "of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.30078125,
            "end_logit": -5.51171875,
            "text": "for the acute treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": -5.51171875,
            "text": "mitriptan is a 5-HT1B/1D receptor agonist for the acute treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": -5.51171875,
            "text": "the acute treatment of migraine.",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_36": [
        {
            "start_logit": 9.125,
            "end_logit": 8.890625,
            "text": "migraine headache",
            "probability": 1.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -1.572265625,
            "text": "migraine",
            "probability": 2.86102294921875e-05
        },
        {
            "start_logit": -1.98046875,
            "end_logit": 8.890625,
            "text": "headache",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.48046875,
            "text": "migraine headache and its associated symptoms.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.57421875,
            "text": "migraine headache and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.1171875,
            "text": "migraine headache and its",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 8.890625,
            "text": "of migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.25,
            "end_logit": 8.890625,
            "text": "acute treatment of migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 8.890625,
            "text": ", oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.390625,
            "end_logit": 8.890625,
            "text": "in the acute treatment of migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.421875,
            "end_logit": 8.890625,
            "text": "treatment of migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 8.890625,
            "text": "oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.98046875,
            "end_logit": -6.48046875,
            "text": "headache and its associated symptoms.",
            "probability": 0.0
        },
        {
            "start_logit": -1.98046875,
            "end_logit": -6.57421875,
            "text": "headache and",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -1.572265625,
            "text": "of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.25,
            "end_logit": -1.572265625,
            "text": "acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -1.572265625,
            "text": ", oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -1.572265625,
            "text": "in the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.421875,
            "end_logit": -1.572265625,
            "text": "treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -1.572265625,
            "text": "oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine",
            "probability": 0.0
        }
    ],
    "5fe3131fa43ad3127800004a_1": [
        {
            "start_logit": 7.66796875,
            "end_logit": 7.67578125,
            "text": "TGF\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -6.6328125,
            "text": "TGF\u03b2 signaling",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -6.63671875,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3, which associate with a variety of nuclear factors to regulate gene transcription.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.078125,
            "text": "TGF\u03b2 signaling activates",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.21875,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3, which",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.21875,
            "text": "TGF\u03b2 signaling activates receptor SMADs",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.23828125,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3,",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.24609375,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3, which associate with a",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.25390625,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3, which associate with a variety",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.26171875,
            "text": "TGF\u03b2 signaling activates receptor SMAD",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.265625,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.27734375,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3, which associate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.27734375,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.296875,
            "text": "TGF\u03b2 signaling activates receptor SMADs,",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.30859375,
            "text": "TGF\u03b2 signaling activates receptor",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.3125,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3, which associate with a variety of",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.66796875,
            "end_logit": -7.32421875,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3, which associate with a variety of nuclear factors to regulate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.15625,
            "end_logit": -6.63671875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -6.63671875,
            "text": ", which associate with a variety of nuclear factors to regulate gene transcription.",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -6.63671875,
            "text": "a variety of nuclear factors to regulate gene transcription.",
            "probability": 0.0
        }
    ],
    "5fe3131fa43ad3127800004a_2": [
        {
            "start_logit": 7.671875,
            "end_logit": 7.6484375,
            "text": "TGF\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": 7.671875,
            "end_logit": -4.765625,
            "text": "TGF\u03b2 promotes Th17 cell differentiation.",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 7.671875,
            "end_logit": -6.10546875,
            "text": "TGF\u03b2 promotes",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 7.671875,
            "end_logit": -6.8984375,
            "text": "TGF\u03b2 promotes Th17 cell differentiation",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.671875,
            "end_logit": -6.94140625,
            "text": "TGF\u03b2 promotes Th17 cell",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.671875,
            "end_logit": -6.9453125,
            "text": "TGF\u03b2 promotes Th17",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 7.6484375,
            "text": "conjunction with the inflammatory cytokine IL-6, TGF\u03b2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 7.6484375,
            "text": "in conjunction with the inflammatory cytokine IL-6, TGF\u03b2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.21875,
            "end_logit": 7.6484375,
            "text": "with the inflammatory cytokine IL-6, TGF\u03b2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 7.6484375,
            "text": ", TGF\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 7.6484375,
            "text": "inflammatory cytokine IL-6, TGF\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 7.6484375,
            "text": "cytokine IL-6, TGF\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 7.6484375,
            "text": "the inflammatory cytokine IL-6, TGF\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 7.6484375,
            "text": ", in conjunction with the inflammatory cytokine IL-6, TGF\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.5,
            "end_logit": 7.6484375,
            "text": "IL-6, TGF\u03b2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 7.6484375,
            "text": "Conversely, in conjunction with the inflammatory cytokine IL-6, TGF\u03b2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -4.765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.00390625,
            "end_logit": -4.765625,
            "text": "conjunction with the inflammatory cytokine IL-6, TGF\u03b2 promotes Th17 cell differentiation.",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": -4.765625,
            "text": "in conjunction with the inflammatory cytokine IL-6, TGF\u03b2 promotes Th17 cell differentiation.",
            "probability": 0.0
        },
        {
            "start_logit": -7.21875,
            "end_logit": -4.765625,
            "text": "with the inflammatory cytokine IL-6, TGF\u03b2 promotes Th17 cell differentiation.",
            "probability": 0.0
        }
    ],
    "5fe3131fa43ad3127800004a_3": [
        {
            "start_logit": 7.79296875,
            "end_logit": 7.57421875,
            "text": "TGF\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -6.359375,
            "text": "TGF\u03b2 is the quintessential cytokine of T cell homeostasis.",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -6.87890625,
            "text": "TGF\u03b2 is",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.03125,
            "text": "TGF\u03b2 is the quintessential cytokine of T cell homeostasis",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.08984375,
            "text": "TGF\u03b2 is the",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.09375,
            "text": "TGF\u03b2 is the quintessential cytokine of",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.109375,
            "text": "TGF\u03b2 is the quintessential cytokine",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.23046875,
            "text": "TGF\u03b2 is the quintesse",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.234375,
            "text": "TGF\u03b2 is the quintessential cytokine of T cell",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.24609375,
            "text": "TGF\u03b2 is the quin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.24609375,
            "text": "TGF\u03b2 is the quintessential",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.25,
            "text": "TGF\u03b2 is the quintessent",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.26171875,
            "text": "TGF\u03b2 is the quintes",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.26171875,
            "text": "TGF\u03b2 is the quintessential cytokine of T",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.046875,
            "end_logit": -6.359375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.66796875,
            "end_logit": -6.359375,
            "text": "quintessential cytokine of T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.69921875,
            "end_logit": -6.359375,
            "text": "T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -6.359375,
            "text": "cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": -6.359375,
            "text": "tessential cytokine of T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.73828125,
            "end_logit": -6.359375,
            "text": "ntial cytokine of T cell homeostasis.",
            "probability": 0.0
        }
    ],
    "5fe3131fa43ad3127800004a_4": [
        {
            "start_logit": 7.44921875,
            "end_logit": 7.8515625,
            "text": "TGFbeta",
            "probability": 1.0
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -6.1640625,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the plasma membrane activates Smad molecules and additional signaling proteins that together regulate gene expression.",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -6.79296875,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the plasma membrane",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -6.890625,
            "text": "TGFbeta binding to serine/threonine kinase receptors on",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -6.9296875,
            "text": "TGFbeta binding to",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -6.9453125,
            "text": "TGFbeta binding to serine/threonine kinase receptors",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -6.9921875,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -6.99609375,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the plasma",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -7.0234375,
            "text": "TGFbeta binding",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -7.22265625,
            "text": "TGFbeta binding to serine/threonine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -7.2421875,
            "text": "TGFbeta binding to serine/threonine kinase",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -7.25390625,
            "text": "TGFbeta binding to serine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -7.27734375,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the plasma membrane activates",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.44921875,
            "end_logit": -7.3125,
            "text": "TGFbeta binding to serine/",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.55078125,
            "end_logit": -6.1640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -6.1640625,
            "text": "binding to serine/threonine kinase receptors on the plasma membrane activates Smad molecules and additional signaling proteins that together regulate gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -6.1640625,
            "text": "signaling proteins that together regulate gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -6.1640625,
            "text": "together regulate gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -7.546875,
            "end_logit": -6.1640625,
            "text": "on the plasma membrane activates Smad molecules and additional signaling proteins that together regulate gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -6.1640625,
            "text": "proteins that together regulate gene expression.",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_1": [
        {
            "start_logit": 8.5859375,
            "end_logit": 5.6796875,
            "text": "activin type II receptors",
            "probability": 0.9970703125
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -0.47509765625,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin",
            "probability": 0.0021152496337890625
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -1.3681640625,
            "text": "activin type II",
            "probability": 0.0008678436279296875
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -2.21875,
            "text": "activin",
            "probability": 0.000370025634765625
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -5.35546875,
            "text": "activin type",
            "probability": 1.615285873413086e-05
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.67578125,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.96484375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.96484375,
            "text": "activin type II receptors (Act",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.9765625,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -6.99609375,
            "text": "activin type II receptors (",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.00390625,
            "text": "activin type II receptors (ActRII",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.0234375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.02734375,
            "text": "activin type II receptors (ActRI",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.0390625,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators of muscle",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.04296875,
            "text": "activin type II receptors (ActRII)",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.078125,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": 8.5859375,
            "end_logit": -7.0859375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -5.12890625,
            "end_logit": 5.6796875,
            "text": "receptors",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.26953125,
            "end_logit": 5.6796875,
            "text": "type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 5.6796875,
            "text": "of activin type II receptors",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5e44b04c48dab47f26000016_2": [
        {
            "start_logit": 8.828125,
            "end_logit": 7.8828125,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": 8.828125,
            "end_logit": -2.044921875,
            "text": "activin",
            "probability": 4.83393669128418e-05
        },
        {
            "start_logit": 8.828125,
            "end_logit": -3.291015625,
            "text": "activin type II",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": -3.216796875,
            "end_logit": 7.8828125,
            "text": "receptors",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.0,
            "text": "activin type",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.3828125,
            "text": "activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.546875,
            "text": "activin type II receptors, preventing the activity of myostatin",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.58203125,
            "text": "activin type II receptors,",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.0234375,
            "text": "activin type II receptors, preventing the activity of myostatin and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.171875,
            "text": "activin type II receptors, preventing the",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.26171875,
            "text": "activin type II receptors, preventing the activity of myostatin and other",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.36328125,
            "text": "activin type II receptors, preventing",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.38671875,
            "text": "activin type II receptors, preventing the activity of",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.98828125,
            "end_logit": 7.8828125,
            "text": "type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.8828125,
            "text": "the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.8828125,
            "text": "blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 7.8828125,
            "text": "RATIONALE: Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 7.8828125,
            "text": "Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 7.8828125,
            "text": "agrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 7.8828125,
            "text": "antibody that blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e44b04c48dab47f26000016_3": [
        {
            "start_logit": 8.6953125,
            "end_logit": 7.5078125,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -1.9609375,
            "text": "activin type II",
            "probability": 7.724761962890625e-05
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -2.40234375,
            "text": "activin",
            "probability": 4.988908767700195e-05
        },
        {
            "start_logit": -3.583984375,
            "end_logit": 7.5078125,
            "text": "receptors",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -5.84765625,
            "text": "activin type",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -6.2265625,
            "text": "activin type II receptors with",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -6.74609375,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD and low muscle mass.",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.1328125,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.15234375,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.17578125,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.18359375,
            "text": "activin type II receptors with bim",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.25390625,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.2578125,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD and low muscle mass",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.265625,
            "text": "activin type II receptors with bimagrumab",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 7.5078125,
            "text": "type II receptors",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 7.5078125,
            "text": "CONCLUSIONS: Blocking the action of negative muscle regulators through the activin type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 7.5078125,
            "text": ": Blocking the action of negative muscle regulators through the activin type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 7.5078125,
            "text": "through the activin type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 7.5078125,
            "text": "Blocking the action of negative muscle regulators through the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 7.5078125,
            "text": "the activin type II receptors",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e44b04c48dab47f26000016_4": [
        {
            "start_logit": 8.3203125,
            "end_logit": 3.8359375,
            "text": "activin type II receptors",
            "probability": 0.9951171875
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -2.2890625,
            "text": "activin type II",
            "probability": 0.0021762847900390625
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -2.384765625,
            "text": "activin",
            "probability": 0.0019817352294921875
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -5.0703125,
            "text": "activin type",
            "probability": 0.0001348257064819336
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -5.9296875,
            "text": "activin type II receptors (ActRII).",
            "probability": 5.710124969482422e-05
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -6.80078125,
            "text": "activin type II receptors (",
            "probability": 2.378225326538086e-05
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -6.8515625,
            "text": "activin type II receptors (ActRII)",
            "probability": 2.2709369659423828e-05
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -6.90625,
            "text": "activin type II receptors (ActRII",
            "probability": 2.1517276763916016e-05
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.046875,
            "text": "activin type II receptors (Act",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.046875,
            "text": "activin type II receptors (ActRI",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": -6.109375,
            "end_logit": 3.8359375,
            "text": "blocking activin type II receptors",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.1640625,
            "end_logit": 3.8359375,
            "text": "receptors",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 3.8359375,
            "text": "type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 3.8359375,
            "text": "yogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.109375,
            "end_logit": -2.2890625,
            "text": "blocking activin type II",
            "probability": 0.0
        },
        {
            "start_logit": -6.109375,
            "end_logit": -2.384765625,
            "text": "blocking activin",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -2.2890625,
            "text": "type II",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -2.2890625,
            "text": "yogenic effects on skeletal muscle by blocking activin type II",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -2.384765625,
            "text": "yogenic effects on skeletal muscle by blocking activin",
            "probability": 0.0
        },
        {
            "start_logit": -4.3984375,
            "end_logit": -5.9296875,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_5": [
        {
            "start_logit": 8.3828125,
            "end_logit": 5.46875,
            "text": "activin type II receptors",
            "probability": 0.99609375
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -0.57861328125,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin",
            "probability": 0.0023555755615234375
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -1.2255859375,
            "text": "activin type II",
            "probability": 0.001232147216796875
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -2.58984375,
            "text": "activin",
            "probability": 0.0003139972686767578
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -5.35546875,
            "text": "activin type",
            "probability": 1.9788742065429688e-05
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.5859375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.859375,
            "text": "activin type II receptors (ActRII",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.87109375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.90234375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.90234375,
            "text": "activin type II receptors (ActRI",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.91015625,
            "text": "activin type II receptors (Act",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.9296875,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.9609375,
            "text": "activin type II receptors (ActRII)",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.96484375,
            "text": "activin type II receptors (",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -7.00390625,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators of muscle",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -7.0078125,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -7.01171875,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -5.24609375,
            "end_logit": 5.46875,
            "text": "receptors",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 5.46875,
            "text": "type II receptors",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 5.46875,
            "text": "of activin type II receptors",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5e44b04c48dab47f26000016_6": [
        {
            "start_logit": 8.8125,
            "end_logit": 8.0625,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": 8.8125,
            "end_logit": -2.029296875,
            "text": "activin",
            "probability": 4.1365623474121094e-05
        },
        {
            "start_logit": -3.015625,
            "end_logit": 8.0625,
            "text": "receptors",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 8.8125,
            "end_logit": -3.927734375,
            "text": "activin type II",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": 8.8125,
            "end_logit": -5.9921875,
            "text": "activin type",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -6.30859375,
            "text": "activin type II receptors,",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -6.31640625,
            "text": "activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -6.484375,
            "text": "activin type II receptors, preventing the activity of myostatin",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -6.953125,
            "text": "activin type II receptors, preventing the activity of myostatin and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.06640625,
            "text": "activin type II receptors, preventing the",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.21875,
            "text": "activin type II receptors, preventing the activity of myostatin and other",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.29296875,
            "text": "activin type II receptors, preventing",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.32421875,
            "text": "activin type II receptors, preventing the activity of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 8.0625,
            "text": "type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.0625,
            "text": "the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 8.0625,
            "text": "blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 8.0625,
            "text": "RATIONALE  Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.0625,
            "text": "agrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.0625,
            "text": "Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 8.0625,
            "text": "II receptors",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e44b04c48dab47f26000016_7": [
        {
            "start_logit": 7.609375,
            "end_logit": 4.30859375,
            "text": "activin type II receptors",
            "probability": 0.96240234375
        },
        {
            "start_logit": 7.609375,
            "end_logit": 0.91015625,
            "text": "activin type II receptors ( ActRII) , with anabolic action on skeletal muscle mass by blocking binding of myostatin",
            "probability": 0.03192138671875
        },
        {
            "start_logit": 7.609375,
            "end_logit": -0.88232421875,
            "text": "activin type II",
            "probability": 0.00533294677734375
        },
        {
            "start_logit": 7.609375,
            "end_logit": -3.458984375,
            "text": "activin",
            "probability": 0.0004050731658935547
        },
        {
            "start_logit": 7.609375,
            "end_logit": -5.31640625,
            "text": "activin type",
            "probability": 6.35385513305664e-05
        },
        {
            "start_logit": 7.609375,
            "end_logit": -6.8359375,
            "text": "activin type II receptors ( ActRII) , with anabolic action on skeletal muscle mass by blocking binding of myostatin and",
            "probability": 1.3887882232666016e-05
        },
        {
            "start_logit": 7.609375,
            "end_logit": -6.88671875,
            "text": "activin type II receptors (",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": 7.609375,
            "end_logit": -6.90234375,
            "text": "activin type II receptors ( Act",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.00390625,
            "text": "activin type II receptors ( ActRII",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.0078125,
            "text": "activin type II receptors ( ActRII) , with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative",
            "probability": 1.1622905731201172e-05
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.0390625,
            "text": "activin type II receptors ( ActRII) , with anabolic action on skeletal muscle mass by",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.04296875,
            "text": "activin type II receptors ( ActRII) , with anabolic action on skeletal muscle mass by blocking",
            "probability": 1.1265277862548828e-05
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.0703125,
            "text": "activin type II receptors ( ActRI",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.10546875,
            "text": "activin type II receptors ( ActRII) , with anabolic action on skeletal muscle mass by blocking binding of myost",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.10546875,
            "text": "activin type II receptors ( ActRII) , with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators of muscle",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": 7.609375,
            "end_logit": -7.1328125,
            "text": "activin type II receptors ( ActRII) , with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -0.88427734375,
            "end_logit": 0.91015625,
            "text": "myostatin",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -5.875,
            "end_logit": 4.30859375,
            "text": "receptors",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 4.30859375,
            "text": "of activin type II receptors",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 4.30859375,
            "text": "type II receptors",
            "probability": 3.5762786865234375e-07
        }
    ],
    "5e44b04c48dab47f26000016_8": [
        {
            "start_logit": 8.015625,
            "end_logit": 2.75,
            "text": "activin type II receptors",
            "probability": 0.97412109375
        },
        {
            "start_logit": 8.015625,
            "end_logit": -1.1484375,
            "text": "activin type II",
            "probability": 0.0197601318359375
        },
        {
            "start_logit": 8.015625,
            "end_logit": -2.50390625,
            "text": "activin",
            "probability": 0.005092620849609375
        },
        {
            "start_logit": 8.015625,
            "end_logit": -4.7734375,
            "text": "activin type",
            "probability": 0.00052642822265625
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.484375,
            "text": "activin type II receptors (",
            "probability": 9.512901306152344e-05
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.6953125,
            "text": "activin type II receptors ( ActRII",
            "probability": 7.700920104980469e-05
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.7109375,
            "text": "activin type II receptors ( Act",
            "probability": 7.581710815429688e-05
        },
        {
            "start_logit": 8.015625,
            "end_logit": -6.71875,
            "text": "activin type II receptors ( ActRI",
            "probability": 7.528066635131836e-05
        },
        {
            "start_logit": -5.94921875,
            "end_logit": 2.75,
            "text": "blocking activin type II receptors",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.640625,
            "end_logit": 2.75,
            "text": "receptors",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 2.75,
            "text": "yogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 2.75,
            "text": "type II receptors",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.94921875,
            "end_logit": -1.1484375,
            "text": "blocking activin type II",
            "probability": 0.0
        },
        {
            "start_logit": -5.94921875,
            "end_logit": -2.50390625,
            "text": "blocking activin",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -1.1484375,
            "text": "yogenic effects on skeletal muscle by blocking activin type II",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -1.1484375,
            "text": "type II",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -2.50390625,
            "text": "yogenic effects on skeletal muscle by blocking activin",
            "probability": 0.0
        },
        {
            "start_logit": -5.94921875,
            "end_logit": -4.7734375,
            "text": "blocking activin type",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -4.7734375,
            "text": "yogenic effects on skeletal muscle by blocking activin type",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -4.7734375,
            "text": "type",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_9": [
        {
            "start_logit": 8.3203125,
            "end_logit": 3.8359375,
            "text": "activin type II receptors",
            "probability": 0.9951171875
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -2.2890625,
            "text": "activin type II",
            "probability": 0.0021762847900390625
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -2.384765625,
            "text": "activin",
            "probability": 0.0019817352294921875
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -5.0703125,
            "text": "activin type",
            "probability": 0.0001348257064819336
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -5.9296875,
            "text": "activin type II receptors (ActRII).",
            "probability": 5.710124969482422e-05
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -6.80078125,
            "text": "activin type II receptors (",
            "probability": 2.378225326538086e-05
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -6.8515625,
            "text": "activin type II receptors (ActRII)",
            "probability": 2.2709369659423828e-05
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -6.90625,
            "text": "activin type II receptors (ActRII",
            "probability": 2.1517276763916016e-05
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.046875,
            "text": "activin type II receptors (Act",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": 8.3203125,
            "end_logit": -7.046875,
            "text": "activin type II receptors (ActRI",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": -6.109375,
            "end_logit": 3.8359375,
            "text": "blocking activin type II receptors",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.1640625,
            "end_logit": 3.8359375,
            "text": "receptors",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 3.8359375,
            "text": "type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 3.8359375,
            "text": "yogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.109375,
            "end_logit": -2.2890625,
            "text": "blocking activin type II",
            "probability": 0.0
        },
        {
            "start_logit": -6.109375,
            "end_logit": -2.384765625,
            "text": "blocking activin",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -2.2890625,
            "text": "type II",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -2.2890625,
            "text": "yogenic effects on skeletal muscle by blocking activin type II",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -2.384765625,
            "text": "yogenic effects on skeletal muscle by blocking activin",
            "probability": 0.0
        },
        {
            "start_logit": -4.3984375,
            "end_logit": -5.9296875,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_10": [
        {
            "start_logit": 8.3828125,
            "end_logit": 5.46875,
            "text": "activin type II receptors",
            "probability": 0.99609375
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -0.57861328125,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin",
            "probability": 0.0023555755615234375
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -1.2255859375,
            "text": "activin type II",
            "probability": 0.001232147216796875
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -2.58984375,
            "text": "activin",
            "probability": 0.0003139972686767578
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -5.35546875,
            "text": "activin type",
            "probability": 1.9788742065429688e-05
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.5859375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.859375,
            "text": "activin type II receptors (ActRII",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.87109375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.90234375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.90234375,
            "text": "activin type II receptors (ActRI",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.91015625,
            "text": "activin type II receptors (Act",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.9296875,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.9609375,
            "text": "activin type II receptors (ActRII)",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.96484375,
            "text": "activin type II receptors (",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -7.00390625,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators of muscle",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -7.0078125,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -7.01171875,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -5.24609375,
            "end_logit": 5.46875,
            "text": "receptors",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 5.46875,
            "text": "type II receptors",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 5.46875,
            "text": "of activin type II receptors",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5e44b04c48dab47f26000016_11": [
        {
            "start_logit": 8.8125,
            "end_logit": 8.0625,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": 8.8125,
            "end_logit": -2.029296875,
            "text": "activin",
            "probability": 4.1365623474121094e-05
        },
        {
            "start_logit": -3.015625,
            "end_logit": 8.0625,
            "text": "receptors",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": 8.8125,
            "end_logit": -3.927734375,
            "text": "activin type II",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": 8.8125,
            "end_logit": -5.9921875,
            "text": "activin type",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -6.30859375,
            "text": "activin type II receptors,",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -6.31640625,
            "text": "activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -6.484375,
            "text": "activin type II receptors, preventing the activity of myostatin",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -6.953125,
            "text": "activin type II receptors, preventing the activity of myostatin and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.06640625,
            "text": "activin type II receptors, preventing the",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.21875,
            "text": "activin type II receptors, preventing the activity of myostatin and other",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.29296875,
            "text": "activin type II receptors, preventing",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.32421875,
            "text": "activin type II receptors, preventing the activity of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 8.0625,
            "text": "type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.0625,
            "text": "the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 8.0625,
            "text": "blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 8.0625,
            "text": "RATIONALE Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.0625,
            "text": "agrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.0625,
            "text": "Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 8.0625,
            "text": "II receptors",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e44b04c48dab47f26000016_12": [
        {
            "start_logit": 8.1640625,
            "end_logit": 3.505859375,
            "text": "activin type II receptors",
            "probability": 0.80322265625
        },
        {
            "start_logit": 8.1640625,
            "end_logit": 1.99609375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin",
            "probability": 0.176513671875
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -0.266845703125,
            "text": "activin type II",
            "probability": 0.018463134765625
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -2.865234375,
            "text": "activin",
            "probability": 0.0013675689697265625
        },
        {
            "start_logit": 0.97509765625,
            "end_logit": 1.99609375,
            "text": "myostatin",
            "probability": 0.00013339519500732422
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -5.2734375,
            "text": "activin type",
            "probability": 0.0001232624053955078
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.5546875,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and",
            "probability": 3.427267074584961e-05
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.80859375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by",
            "probability": 2.664327621459961e-05
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.8203125,
            "text": "activin type II receptors (ActRII",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.87890625,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.87890625,
            "text": "activin type II receptors (Act",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.88671875,
            "text": "activin type II receptors (ActRII)",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.890625,
            "text": "activin type II receptors (ActRI",
            "probability": 2.4437904357910156e-05
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.91015625,
            "text": "activin type II receptors (",
            "probability": 2.396106719970703e-05
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.921875,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.9921875,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other negative regulators",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.99609375,
            "text": "activin type II receptors (ActRII),",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": -6.21484375,
            "end_logit": 3.505859375,
            "text": "receptors",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.25390625,
            "end_logit": 3.505859375,
            "text": "type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 3.505859375,
            "text": "of activin type II receptors",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5e44b04c48dab47f26000016_13": [
        {
            "start_logit": 8.6640625,
            "end_logit": 7.83984375,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -2.244140625,
            "text": "activin",
            "probability": 4.1961669921875e-05
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -3.951171875,
            "text": "activin type II",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": -3.275390625,
            "end_logit": 7.83984375,
            "text": "receptors",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -5.8984375,
            "text": "activin type",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -6.0234375,
            "text": "activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -6.02734375,
            "text": "activin type II receptors, preventing the activity of myostatin",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -6.1484375,
            "text": "activin type II receptors,",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -6.7890625,
            "text": "activin type II receptors, preventing the activity of myostatin and",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -7.0625,
            "text": "activin type II receptors, preventing the",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -7.16015625,
            "text": "activin type II receptors, preventing the activity of myostatin and other",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.6640625,
            "end_logit": -7.26171875,
            "text": "activin type II receptors, preventing",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 7.83984375,
            "text": "type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 7.83984375,
            "text": "blocks the activin type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 7.83984375,
            "text": "the activin type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 7.83984375,
            "text": "Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 7.83984375,
            "text": "agrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.275390625,
            "end_logit": -6.0234375,
            "text": "receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
            "probability": 0.0
        },
        {
            "start_logit": -3.275390625,
            "end_logit": -6.02734375,
            "text": "receptors, preventing the activity of myostatin",
            "probability": 0.0
        },
        {
            "start_logit": -3.275390625,
            "end_logit": -6.1484375,
            "text": "receptors,",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_14": [
        {
            "start_logit": 8.84375,
            "end_logit": 8.4140625,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": 8.84375,
            "end_logit": -2.125,
            "text": "activin",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": -2.47265625,
            "end_logit": 8.4140625,
            "text": "receptors",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": 8.84375,
            "end_logit": -4.21875,
            "text": "activin type II",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": 8.84375,
            "end_logit": -5.98828125,
            "text": "activin type",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -6.1953125,
            "text": "activin type II receptors with",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -6.6171875,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD and low muscle mass.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -7.06640625,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -7.11328125,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -7.12109375,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -7.16015625,
            "text": "activin type II receptors with bim",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -7.1875,
            "text": "activin type II receptors with bimagrumab",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.84375,
            "end_logit": -7.23046875,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 8.4140625,
            "text": "type II receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 8.4140625,
            "text": "through the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 8.4140625,
            "text": "II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 8.4140625,
            "text": "the activin type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -6.1953125,
            "text": "receptors with",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -6.6171875,
            "text": "receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD and low muscle mass.",
            "probability": 0.0
        },
        {
            "start_logit": -2.47265625,
            "end_logit": -7.06640625,
            "text": "receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD",
            "probability": 0.0
        }
    ],
    "5e776443835f4e4777000008_1": [
        {
            "start_logit": 9.078125,
            "end_logit": 8.6640625,
            "text": "Astellas Pharma",
            "probability": 1.0
        },
        {
            "start_logit": 9.078125,
            "end_logit": -1.671875,
            "text": "Ast",
            "probability": 3.218650817871094e-05
        },
        {
            "start_logit": -2.0859375,
            "end_logit": 8.6640625,
            "text": "a",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": 9.078125,
            "end_logit": -5.234375,
            "text": "Astellas",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -5.28515625,
            "end_logit": 8.6640625,
            "text": "s Pharma",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -5.9765625,
            "text": "Astellas Pharm",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.58984375,
            "end_logit": 8.6640625,
            "text": "ellas Pharma",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -6.01953125,
            "text": "Astellas Pharma Gm",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -6.25,
            "text": "Astellas Pharma GmbH",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -6.390625,
            "text": "Astellas Pharma GmbH) in patients with advanced prostate cancer treated in routine clinical practice in Germany.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.1640625,
            "end_logit": 8.6640625,
            "text": "Pharma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -6.67578125,
            "text": "Astellas Pharma Gmb",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -6.8671875,
            "text": "Astellas Pharma GmbH) in patients with advanced prostate cancer treated in routine clinical practice in Germany",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.09375,
            "text": "Astellas Pharma GmbH) in patients with advanced prostate cancer treated in routine clinical practice",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.09765625,
            "text": "Astellas Pharma GmbH)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.98828125,
            "end_logit": 8.6640625,
            "text": ", Astellas Pharma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.0859375,
            "end_logit": -6.01953125,
            "text": "a Gm",
            "probability": 0.0
        },
        {
            "start_logit": -2.0859375,
            "end_logit": -6.25,
            "text": "a GmbH",
            "probability": 0.0
        },
        {
            "start_logit": -2.0859375,
            "end_logit": -6.390625,
            "text": "a GmbH) in patients with advanced prostate cancer treated in routine clinical practice in Germany.",
            "probability": 0.0
        },
        {
            "start_logit": -6.98828125,
            "end_logit": -1.671875,
            "text": ", Ast",
            "probability": 0.0
        }
    ],
    "5e7641a0c6a8763d23000011_1": [
        {
            "start_logit": 9.109375,
            "end_logit": 8.84375,
            "text": "Vaxchora",
            "probability": 1.0
        },
        {
            "start_logit": 9.109375,
            "end_logit": -1.724609375,
            "text": "Va",
            "probability": 2.568960189819336e-05
        },
        {
            "start_logit": -2.068359375,
            "end_logit": 8.84375,
            "text": "ora",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -5.4765625,
            "text": "Vaxchora: The First FDA",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -5.51953125,
            "text": "Vaxchora: The First FDA-Approved Cholera Vaccination in the United States.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.203125,
            "text": "Vaxchora:",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.01953125,
            "end_logit": 8.84375,
            "text": "xchora",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.32421875,
            "text": "Vaxchora: The First FDA-Approved Cholera Vaccination in the United States",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.3359375,
            "text": "Vaxchora: The",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.55078125,
            "text": "Vaxchora: The First",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.62890625,
            "text": "Vaxchora: The First FDA-Approved",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.65625,
            "text": "Vaxchora: The First FDA-Approved Cholera Vaccination",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.66015625,
            "text": "Vaxchora: The First FDA-Approved Cholera Vaccination in the United",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4140625,
            "end_logit": 8.84375,
            "text": "chora",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.71484375,
            "text": "Vaxchora: The First FDA-Approved Cholera Vaccination in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.73828125,
            "text": "Vaxchora: The First FDA-Approved Cholera Vaccination in the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.81640625,
            "text": "Vaxchora: The First FDA-Approved Cholera",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.83203125,
            "text": "Vaxchora: The First FDA-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.87890625,
            "text": "Vaxch",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.068359375,
            "end_logit": -5.4765625,
            "text": "ora: The First FDA",
            "probability": 0.0
        }
    ],
    "5e7641a0c6a8763d23000011_2": [
        {
            "start_logit": 9.1640625,
            "end_logit": 8.609375,
            "text": "Vaxchora",
            "probability": 1.0
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -1.6005859375,
            "text": "Va",
            "probability": 3.647804260253906e-05
        },
        {
            "start_logit": -2.466796875,
            "end_logit": 8.609375,
            "text": "ora",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -3.48046875,
            "text": "Vaxchora is the first vaccine approved by the Food and Drug Administration for the prophylaxis of cholera infection.",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -5.79296875,
            "text": "Vaxchora is",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -5.80859375,
            "text": "Vaxchora is the first vaccine approved by the Food and Drug Administration",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.28125,
            "text": "Vaxchora is the",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.5859375,
            "text": "Vaxchora is the first",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.6171875,
            "text": "Vaxchora is the first vaccine approved",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.64453125,
            "text": "Vaxchora is the first vaccine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.66015625,
            "text": "Vaxchora is the first vaccine approved by the Food and Drug Administration for the prophylaxis",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.6640625,
            "text": "Vaxch",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.765625,
            "text": "Vaxchora is the first vaccine approved by the Food and Drug",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.78515625,
            "text": "Vaxchora is the first vaccine approved by the Food and Drug Administration for",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.265625,
            "end_logit": 8.609375,
            "text": "xchora",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.83984375,
            "text": "Vaxchora is the first vaccine approved by the Food",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.84765625,
            "text": "Vaxchora is the first vaccine approved by the Food and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.8515625,
            "text": "Vaxchora is the first vaccine approved by the Food and Drug Administration for the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.90625,
            "text": "Vaxchora is the first vaccine approved by the Food and Drug Administration for the prophylaxis of cholera",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.99609375,
            "text": "Vaxchora is the first vaccine approved by",
            "probability": 1.7881393432617188e-07
        }
    ],
    "571f5c150fd6f91b68000009_1": [
        {
            "start_logit": 9.1015625,
            "end_logit": 8.9765625,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -1.736328125,
            "text": "fra",
            "probability": 2.2292137145996094e-05
        },
        {
            "start_logit": -1.828125,
            "end_logit": 8.9765625,
            "text": "xin",
            "probability": 1.7940998077392578e-05
        },
        {
            "start_logit": -6.02734375,
            "end_logit": 8.9765625,
            "text": "taxin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.1484375,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.1484375,
            "text": "frataxin expression, a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.18359375,
            "text": "frataxin expression, a mitochondrial protein involved",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.25390625,
            "text": "frataxin expression, a mitochondrial protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.3046875,
            "text": "frataxin expression, a mitochondrial",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.30859375,
            "text": "frataxin expression, a mitochondrial protein involved in iron homeostasis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.36328125,
            "text": "frataxin expression, a mitochondrial protein involved in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 8.9765625,
            "text": "in frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 8.9765625,
            "text": "It is generally accepted that Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 8.9765625,
            "text": "that Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 8.9765625,
            "text": "Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 8.9765625,
            "text": "FRDA) is caused by a deficiency in frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.828125,
            "end_logit": -7.1484375,
            "text": "xin expression, a",
            "probability": 0.0
        },
        {
            "start_logit": -1.828125,
            "end_logit": -7.18359375,
            "text": "xin expression, a mitochondrial protein involved",
            "probability": 0.0
        },
        {
            "start_logit": -1.828125,
            "end_logit": -7.25390625,
            "text": "xin expression, a mitochondrial protein",
            "probability": 0.0
        },
        {
            "start_logit": -1.828125,
            "end_logit": -7.3046875,
            "text": "xin expression, a mitochondrial",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_2": [
        {
            "start_logit": 9.0,
            "end_logit": 8.9609375,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.8623046875,
            "end_logit": 8.9609375,
            "text": "xin",
            "probability": 1.895427703857422e-05
        },
        {
            "start_logit": 9.0,
            "end_logit": -1.9765625,
            "text": "fra",
            "probability": 1.7642974853515625e-05
        },
        {
            "start_logit": -6.09765625,
            "end_logit": 8.9609375,
            "text": "taxin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.5234375,
            "text": "frataxin, a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.72265625,
            "text": "frataxin,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.0859375,
            "text": "frataxin, a mitochondrial",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.10546875,
            "text": "frataxin, a mitochondrial protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.109375,
            "text": "frataxin, a mitochondrial protein that",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.23046875,
            "text": "frataxin, a mitochondrial protein that stimulates iron-sulfur (Fe-S)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.26171875,
            "text": "frata",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.9609375,
            "text": "of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.8623046875,
            "end_logit": -6.5234375,
            "text": "xin, a",
            "probability": 0.0
        },
        {
            "start_logit": -1.8623046875,
            "end_logit": -6.72265625,
            "text": "xin,",
            "probability": 0.0
        },
        {
            "start_logit": -1.8623046875,
            "end_logit": -7.0859375,
            "text": "xin, a mitochondrial",
            "probability": 0.0
        },
        {
            "start_logit": -1.8623046875,
            "end_logit": -7.10546875,
            "text": "xin, a mitochondrial protein",
            "probability": 0.0
        },
        {
            "start_logit": -1.8623046875,
            "end_logit": -7.109375,
            "text": "xin, a mitochondrial protein that",
            "probability": 0.0
        },
        {
            "start_logit": -1.8623046875,
            "end_logit": -7.23046875,
            "text": "xin, a mitochondrial protein that stimulates iron-sulfur (Fe-S)",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -1.9765625,
            "text": "of fra",
            "probability": 0.0
        },
        {
            "start_logit": -6.09765625,
            "end_logit": -6.5234375,
            "text": "taxin, a",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_3": [
        {
            "start_logit": 9.0546875,
            "end_logit": 8.8984375,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -1.84765625,
            "text": "fra",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": -1.994140625,
            "end_logit": 8.8984375,
            "text": "xin",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -5.96875,
            "end_logit": 8.8984375,
            "text": "taxin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.17578125,
            "text": "frataxin deficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.203125,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.23046875,
            "text": "frataxin deficiency (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.26953125,
            "text": "frataxin deficiency (FXN)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.32421875,
            "text": "frataxin deficiency (FXN",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.34765625,
            "text": "frataxin deficiency (FXN) causes severe phenotypes including loss of iron-sulfur (Fe-S)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.40234375,
            "text": "frataxin deficiency (FX",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.41015625,
            "text": "frataxin deficiency (FXN) causes severe phenotypes including loss of iron-sulfur (Fe",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.4140625,
            "text": "frataxin deficiency (FXN) causes severe phenotypes including loss of iron-sulfur (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 8.8984375,
            "text": ", frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 8.8984375,
            "text": "In eukaryotes, frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 8.8984375,
            "text": "eukaryotes, frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.994140625,
            "end_logit": -7.17578125,
            "text": "xin deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -1.994140625,
            "end_logit": -7.23046875,
            "text": "xin deficiency (",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -1.84765625,
            "text": ", fra",
            "probability": 0.0
        },
        {
            "start_logit": -1.994140625,
            "end_logit": -7.26953125,
            "text": "xin deficiency (FXN)",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_4": [
        {
            "start_logit": 9.0546875,
            "end_logit": 9.0,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": 9.0,
            "text": "xin",
            "probability": 1.9669532775878906e-05
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -1.84765625,
            "text": "fra",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": -5.984375,
            "end_logit": 9.0,
            "text": "taxin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.62109375,
            "text": "frataxin,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.77734375,
            "text": "frataxin, the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.80859375,
            "text": "frataxin, the mitochondrial protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.8203125,
            "text": "frataxin, the mitochondrial",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.921875,
            "text": "frataxin, the mitochondrial protein defective in patients with Friedreich's ataxia, is lethal in C. elegans",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.93359375,
            "text": "frataxin, the mitochondrial protein defective in patients with Friedreich's ataxia, is lethal in C. elegans, while its partial",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.93359375,
            "text": "frataxin, the mitochondrial protein defective in patients with Friedreich's ataxia,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.94921875,
            "text": "frataxin, the mitochondrial protein defective in patients with Friedreich's ataxia, is lethal in C. elegans, while",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.01171875,
            "text": "frataxin, the mitochondrial protein defective in patients with Friedreich's ataxia, is lethal in C. elegans, while its partial deficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.0,
            "text": "of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.0,
            "text": "absence of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -6.62109375,
            "text": "xin,",
            "probability": 0.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -6.77734375,
            "text": "xin, the",
            "probability": 0.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -6.80859375,
            "text": "xin, the mitochondrial protein",
            "probability": 0.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -6.8203125,
            "text": "xin, the mitochondrial",
            "probability": 0.0
        },
        {
            "start_logit": -1.7734375,
            "end_logit": -6.921875,
            "text": "xin, the mitochondrial protein defective in patients with Friedreich's ataxia, is lethal in C. elegans",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_5": [
        {
            "start_logit": 9.0625,
            "end_logit": 9.015625,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.7431640625,
            "end_logit": 9.015625,
            "text": "xin",
            "probability": 2.0325183868408203e-05
        },
        {
            "start_logit": 9.0625,
            "end_logit": -1.8271484375,
            "text": "fra",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": -5.9921875,
            "end_logit": 9.015625,
            "text": "taxin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.5,
            "text": "frataxin.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.73828125,
            "end_logit": 9.015625,
            "text": "protein frataxin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.14453125,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 9.015625,
            "text": "mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.015625,
            "text": "Friedreich ataxia (FRDA) is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.015625,
            "text": "(FRDA) is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.734375,
            "end_logit": 9.015625,
            "text": "FRDA) is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.734375,
            "end_logit": 9.015625,
            "text": "the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73828125,
            "end_logit": 9.015625,
            "text": "of the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7431640625,
            "end_logit": -6.5,
            "text": "xin.",
            "probability": 0.0
        },
        {
            "start_logit": -6.73828125,
            "end_logit": -1.8271484375,
            "text": "protein fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -1.8271484375,
            "text": "mitochondrial protein fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -1.8271484375,
            "text": "Friedreich ataxia (FRDA) is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -1.8271484375,
            "text": "(FRDA) is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -1.8271484375,
            "text": "FRDA) is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.734375,
            "end_logit": -1.8271484375,
            "text": "the mitochondrial protein fra",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_6": [
        {
            "start_logit": 9.015625,
            "end_logit": 9.0546875,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.6337890625,
            "end_logit": 9.0546875,
            "text": "xin",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": 9.015625,
            "end_logit": -1.939453125,
            "text": "fra",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": -5.6953125,
            "end_logit": 9.0546875,
            "text": "protein frataxin",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -5.703125,
            "text": "frataxin, which carries single point mutations in some patients.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.2265625,
            "end_logit": 9.0546875,
            "text": "taxin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -6.265625,
            "text": "frataxin,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -6.6328125,
            "text": "frataxin, which",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 9.0546875,
            "text": "Friedreich's ataxia results from a deficiency in the mitochondrial protein frataxin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -6.98828125,
            "text": "frataxin, which carries single point mutations in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.0234375,
            "text": "frataxin, which carries",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 9.0546875,
            "text": "mitochondrial protein frataxin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.06640625,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.0859375,
            "text": "frataxin, which carries single point mutations",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.1015625,
            "text": "frataxin, which carries single point",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.1328125,
            "text": "frataxin, which carries single point mutations in some",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.19921875,
            "text": "frataxin, which carries single",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 9.0546875,
            "text": "in the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 9.0546875,
            "text": "ataxia results from a deficiency in the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 9.0546875,
            "text": "reich's ataxia results from a deficiency in the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        }
    ],
    "571f5c150fd6f91b68000009_7": [
        {
            "start_logit": 9.1015625,
            "end_logit": 9.0078125,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -1.7490234375,
            "text": "fra",
            "probability": 2.1278858184814453e-05
        },
        {
            "start_logit": -1.7734375,
            "end_logit": 9.0078125,
            "text": "xin",
            "probability": 1.895427703857422e-05
        },
        {
            "start_logit": -6.08203125,
            "end_logit": 9.0078125,
            "text": "taxin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.34765625,
            "text": "frataxin, a",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.49609375,
            "text": "frataxin, a small mitochondrial protein, encoded in the nucleus.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.546875,
            "text": "frataxin, a small mitochondrial protein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.609375,
            "text": "frataxin,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.74609375,
            "text": "frataxin, a small mitochondrial",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.78125,
            "text": "frataxin, a small",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.96484375,
            "text": "frataxin, a small mitochondrial protein,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.99609375,
            "text": "frataxin, a small mitochondrial protein, encoded in the nucleus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.02734375,
            "text": "frataxin, a small mitochondrial protein, encoded in the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.06640625,
            "text": "frataxin, a small mitochondrial protein, encoded",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.140625,
            "text": "frataxin, a small mitochondrial protein, encoded in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.140625,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.0078125,
            "text": "Friedreich's ataxia (FRDA), an autosomal recessive cardio- and neurodegenerative disease, is caused by low expression of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 9.0078125,
            "text": "of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 9.0078125,
            "text": ", is caused by low expression of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.0078125,
            "text": ", an autosomal recessive cardio- and neurodegenerative disease, is caused by low expression of frataxin",
            "probability": 5.960464477539063e-08
        }
    ],
    "571f5c150fd6f91b68000009_8": [
        {
            "start_logit": 9.0,
            "end_logit": 9.0078125,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.74609375,
            "end_logit": 9.0078125,
            "text": "xin",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": 9.0,
            "end_logit": -1.9658203125,
            "text": "fra",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": -6.1796875,
            "end_logit": 9.0078125,
            "text": "taxin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.328125,
            "text": "frataxin, encoded by the X25 gene, causes Friedreich ataxia (FRDA), the most common form of recessive hereditary ataxia.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.63671875,
            "end_logit": 9.0078125,
            "text": "protein frataxin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.71484375,
            "text": "frataxin,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.98046875,
            "text": "frataxin, encoded by the X25 gene,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.99609375,
            "text": "frataxin, encoded",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.01953125,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.0546875,
            "text": "frataxin, encoded by the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.09765625,
            "text": "frataxin, encoded by the X25 gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 9.0078125,
            "text": "mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 9.0078125,
            "text": "in mRNA and protein levels of the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.74609375,
            "end_logit": -6.328125,
            "text": "xin, encoded by the X25 gene, causes Friedreich ataxia (FRDA), the most common form of recessive hereditary ataxia.",
            "probability": 0.0
        },
        {
            "start_logit": -1.74609375,
            "end_logit": -6.71484375,
            "text": "xin,",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": -1.9658203125,
            "text": "protein fra",
            "probability": 0.0
        },
        {
            "start_logit": -1.74609375,
            "end_logit": -6.98046875,
            "text": "xin, encoded by the X25 gene,",
            "probability": 0.0
        },
        {
            "start_logit": -1.74609375,
            "end_logit": -6.99609375,
            "text": "xin, encoded",
            "probability": 0.0
        },
        {
            "start_logit": -1.74609375,
            "end_logit": -7.0546875,
            "text": "xin, encoded by the",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_9": [
        {
            "start_logit": 9.015625,
            "end_logit": 9.0234375,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.7236328125,
            "end_logit": 9.0234375,
            "text": "xin",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": 9.015625,
            "end_logit": -1.9384765625,
            "text": "fra",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": -6.07421875,
            "end_logit": 9.0234375,
            "text": "taxin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -6.66796875,
            "text": "frataxin,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -6.70703125,
            "text": "frataxin, the protein deficient in Friedreich ataxia.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.04296875,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.15234375,
            "text": "frataxin, the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.2109375,
            "text": "frataxin, the protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.015625,
            "end_logit": -7.265625,
            "text": "frataxin, the protein deficient",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 9.0234375,
            "text": "human frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 9.0234375,
            "text": "iron-binding properties of human frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6875,
            "end_logit": 9.0234375,
            "text": "Assembly and iron-binding properties of human frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7236328125,
            "end_logit": -6.66796875,
            "text": "xin,",
            "probability": 0.0
        },
        {
            "start_logit": -1.7236328125,
            "end_logit": -6.70703125,
            "text": "xin, the protein deficient in Friedreich ataxia.",
            "probability": 0.0
        },
        {
            "start_logit": -1.7236328125,
            "end_logit": -7.15234375,
            "text": "xin, the",
            "probability": 0.0
        },
        {
            "start_logit": -1.7236328125,
            "end_logit": -7.2109375,
            "text": "xin, the protein",
            "probability": 0.0
        },
        {
            "start_logit": -1.7236328125,
            "end_logit": -7.265625,
            "text": "xin, the protein deficient",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": -1.9384765625,
            "text": "human fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -1.9384765625,
            "text": "iron-binding properties of human fra",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_10": [
        {
            "start_logit": 9.046875,
            "end_logit": 9.0,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.7724609375,
            "end_logit": 9.0,
            "text": "xin",
            "probability": 1.996755599975586e-05
        },
        {
            "start_logit": 9.046875,
            "end_logit": -1.8701171875,
            "text": "fra",
            "probability": 1.895427703857422e-05
        },
        {
            "start_logit": -6.07421875,
            "end_logit": 9.0,
            "text": "taxin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.4609375,
            "text": "frataxin.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 9.0,
            "text": "protein frataxin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.0625,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 9.0,
            "text": "mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 9.0,
            "text": "Friedreich ataxia is a human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.0,
            "text": "the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.703125,
            "end_logit": 9.0,
            "text": "of the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 9.0,
            "text": "ataxia is a human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 9.0,
            "text": "human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 9.0,
            "text": "ich ataxia is a human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7724609375,
            "end_logit": -6.4609375,
            "text": "xin.",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": -1.8701171875,
            "text": "protein fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -1.8701171875,
            "text": "mitochondrial protein fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -1.8701171875,
            "text": "Friedreich ataxia is a human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.69921875,
            "end_logit": -1.8701171875,
            "text": "the mitochondrial protein fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -1.8701171875,
            "text": "of the mitochondrial protein fra",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_11": [
        {
            "start_logit": 9.125,
            "end_logit": 9.0625,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -1.6875,
            "text": "fra",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": -1.626953125,
            "end_logit": 9.0625,
            "text": "xin",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": -5.9765625,
            "end_logit": 9.0625,
            "text": "taxin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.109375,
            "text": "frataxin, an essential mitochondrial protein.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.3984375,
            "text": "frataxin, an",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.46875,
            "text": "frataxin,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.78515625,
            "text": "frataxin, an essential mitochondrial protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.87890625,
            "text": "frataxin, an essential",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -6.93359375,
            "text": "frataxin, an essential mitochondrial",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.10546875,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 9.0625,
            "text": "Friedreich ataxia, an autosomal recessive neurodegenerative and cardiac disease, is caused by abnormally low levels of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 9.0625,
            "text": ", an autosomal recessive neurodegenerative and cardiac disease, is caused by abnormally low levels of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.0625,
            "text": "of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 9.0625,
            "text": "autosomal recessive neurodegenerative and cardiac disease, is caused by abnormally low levels of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.0625,
            "text": "by abnormally low levels of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.671875,
            "end_logit": 9.0625,
            "text": "ataxia, an autosomal recessive neurodegenerative and cardiac disease, is caused by abnormally low levels of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 9.0625,
            "text": "abnormally low levels of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 9.0625,
            "text": ", is caused by abnormally low levels of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.626953125,
            "end_logit": -6.109375,
            "text": "xin, an essential mitochondrial protein.",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_12": [
        {
            "start_logit": 9.09375,
            "end_logit": 9.03125,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": 9.09375,
            "end_logit": -1.7587890625,
            "text": "fra",
            "probability": 2.0623207092285156e-05
        },
        {
            "start_logit": -1.6982421875,
            "end_logit": 9.03125,
            "text": "xin",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": -6.0234375,
            "end_logit": 9.03125,
            "text": "taxin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.21875,
            "text": "frataxin, a",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.40234375,
            "text": "frataxin, a conserved mitochondrial protein of unknown function.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.578125,
            "text": "frataxin,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.80078125,
            "text": "frataxin, a conserved mitochondrial protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.94140625,
            "text": "frataxin, a conserved mitochondrial",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.9765625,
            "text": "frataxin, a conserved",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.984375,
            "text": "frataxin, a conserved mitochondrial protein of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.06640625,
            "text": "frataxin, a conserved mitochondrial protein of unknown function",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.09375,
            "text": "frataxin, a conserved mitochondrial protein of unknown",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.13671875,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.03125,
            "text": "Friedreich ataxia (FRDA) is an autosomal recessive degenerative disease caused by a deficiency of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.03125,
            "text": "of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6875,
            "end_logit": 9.03125,
            "text": "by a deficiency of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 9.03125,
            "text": "(FRDA) is an autosomal recessive degenerative disease caused by a deficiency of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.03125,
            "text": "deficiency of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.03125,
            "text": "ataxia (FRDA) is an autosomal recessive degenerative disease caused by a deficiency of frataxin",
            "probability": 5.960464477539063e-08
        }
    ],
    "571f5c150fd6f91b68000009_13": [
        {
            "start_logit": 9.09375,
            "end_logit": 9.0390625,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.681640625,
            "end_logit": 9.0390625,
            "text": "xin",
            "probability": 2.110004425048828e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -1.7568359375,
            "text": "fra",
            "probability": 2.0623207092285156e-05
        },
        {
            "start_logit": -5.8203125,
            "end_logit": 9.0390625,
            "text": "taxin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.64453125,
            "text": "frataxin message and protein.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.140625,
            "text": "frataxin message",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.17578125,
            "text": "frataxin message and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.2109375,
            "text": "frataxin message and protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 9.0390625,
            "text": "on the progress of potential treatment strategies for Friedreich ataxia that target the GAA expanded gene and seek to increase the level of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 9.0390625,
            "text": "for Friedreich ataxia that target the GAA expanded gene and seek to increase the level of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.0390625,
            "text": "of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 9.0390625,
            "text": "the progress of potential treatment strategies for Friedreich ataxia that target the GAA expanded gene and seek to increase the level of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.0390625,
            "text": "GAA expanded gene and seek to increase the level of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 9.0390625,
            "text": "the GAA expanded gene and seek to increase the level of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.0390625,
            "text": "gene and seek to increase the level of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.0390625,
            "text": "focus on the progress of potential treatment strategies for Friedreich ataxia that target the GAA expanded gene and seek to increase the level of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 9.0390625,
            "text": "Friedreich ataxia that target the GAA expanded gene and seek to increase the level of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.0390625,
            "text": "progress of potential treatment strategies for Friedreich ataxia that target the GAA expanded gene and seek to increase the level of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.681640625,
            "end_logit": -6.64453125,
            "text": "xin message and protein.",
            "probability": 0.0
        },
        {
            "start_logit": -1.681640625,
            "end_logit": -7.140625,
            "text": "xin message",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_14": [
        {
            "start_logit": 8.984375,
            "end_logit": 8.9453125,
            "text": "Frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.896484375,
            "end_logit": 8.9453125,
            "text": "xin",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -2.0234375,
            "text": "Fra",
            "probability": 1.710653305053711e-05
        },
        {
            "start_logit": -6.0390625,
            "end_logit": 8.9453125,
            "text": "taxin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.53515625,
            "text": "Frataxin is",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.83984375,
            "text": "Frataxin is a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.0546875,
            "text": "Frataxin is a mitochondrial",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.15234375,
            "text": "Frataxin is a mitochondrial protein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.1953125,
            "text": "Frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.29296875,
            "text": "Frataxin is a mitochondrial protein deficient",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.30078125,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA) and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.3515625,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA) and which",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.3671875,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA) and which is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.41796875,
            "text": "Frataxin is a mitochondrial protein deficient in Friedre",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.421875,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.4296875,
            "text": "Frataxin is a mitochondrial protein deficient in Fried",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.4375,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA) and which is associated",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.4375,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA) and which is associated with abnormal intramitochondrial",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.4453125,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA) and which is associated with abnormal intramitochondrial iron",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.896484375,
            "end_logit": -6.53515625,
            "text": "xin is",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_15": [
        {
            "start_logit": 9.171875,
            "end_logit": 9.0078125,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": 9.171875,
            "end_logit": -1.5498046875,
            "text": "fra",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": -1.75390625,
            "end_logit": 9.0078125,
            "text": "xin",
            "probability": 1.7762184143066406e-05
        },
        {
            "start_logit": -6.01953125,
            "end_logit": 9.0078125,
            "text": "taxin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.00390625,
            "text": "frataxin, a putative iron chaperone, and is due to the presence of a high number of GAA repeats in the coding regions of both alleles",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.0078125,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.0390625,
            "text": "frataxin, a putative",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.06640625,
            "text": "frataxin, a putative iron chaperone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.11328125,
            "text": "frataxin,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.14453125,
            "text": "frataxin, a putative iron chaperone, and is due to the presence of a high number of GAA repeats in the coding regions of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.16015625,
            "text": "frataxin, a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.19140625,
            "text": "frataxin, a putative iron",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.19140625,
            "text": "frataxin, a putative iron chaperone, and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.19921875,
            "text": "frataxin, a putative iron chaperone, and is due to the presence of a high number of GAA repeats in the coding regions of both",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 9.0078125,
            "text": "in frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4375,
            "end_logit": 9.0078125,
            "text": "(Friedreich&apos;s ataxia) results from a deficiency in frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 9.0078125,
            "text": "DA (Friedreich&apos;s ataxia) results from a deficiency in frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.0078125,
            "text": "neurodegenerative disorder FRDA (Friedreich&apos;s ataxia) results from a deficiency in frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.0078125,
            "text": "The neurodegenerative disorder FRDA (Friedreich&apos;s ataxia) results from a deficiency in frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.0078125,
            "text": "ich&apos;s ataxia) results from a deficiency in frataxin",
            "probability": 5.960464477539063e-08
        }
    ],
    "571f5c150fd6f91b68000009_16": [
        {
            "start_logit": 8.953125,
            "end_logit": 8.90625,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -2.009765625,
            "end_logit": 8.90625,
            "text": "xin",
            "probability": 1.7344951629638672e-05
        },
        {
            "start_logit": 8.953125,
            "end_logit": -2.076171875,
            "text": "fra",
            "probability": 1.6987323760986328e-05
        },
        {
            "start_logit": 8.953125,
            "end_logit": -6.3046875,
            "text": "frataxin modulates DNA base excision repair in prokaryotes and mammals.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.28515625,
            "end_logit": 8.90625,
            "text": "taxin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -6.76171875,
            "text": "frataxin modulates DNA base excision repair in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -6.76953125,
            "text": "frataxin modulates",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -6.90234375,
            "text": "frataxin modulates DNA base excision repair in prokaryotes and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.078125,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.12890625,
            "text": "frataxin modulates DNA base excision repair in prokaryotes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.13671875,
            "text": "frataxin modulates DNA base",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.15234375,
            "text": "frataxin modulates DNA base excision repair",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.18359375,
            "text": "frataxin modulates DNA",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.2109375,
            "text": "frataxin modulates DNA base excision repair in prokaryotes and mammals",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.953125,
            "end_logit": -7.2109375,
            "text": "frataxin modulates DNA base excision",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 8.90625,
            "text": "protein frataxin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 8.90625,
            "text": "The Friedreich's ataxia protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 8.90625,
            "text": "ataxia protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.90625,
            "text": "Friedreich's ataxia protein frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.90625,
            "text": "'s ataxia protein frataxin",
            "probability": 5.960464477539063e-08
        }
    ],
    "571f5c150fd6f91b68000009_17": [
        {
            "start_logit": 9.09375,
            "end_logit": 9.0390625,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.6787109375,
            "end_logit": 9.0390625,
            "text": "xin",
            "probability": 2.110004425048828e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -1.75390625,
            "text": "fra",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -5.31640625,
            "text": "frataxin, a highly conserved nuclear-encoded protein localized in mitochondria.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -5.6640625,
            "text": "frataxin, a",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -5.89453125,
            "text": "frataxin,",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.0234375,
            "end_logit": 9.0390625,
            "text": "taxin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.1875,
            "text": "frataxin, a highly",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.26171875,
            "text": "frataxin, a highly conserved nuclear-encoded protein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.265625,
            "text": "frataxin, a highly conserved nuclear-encoded protein localized",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.2734375,
            "text": "frataxin, a highly conserved nuclear",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.43359375,
            "text": "frataxin, a highly conserved nuclear-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.5859375,
            "text": "frataxin, a highly conserved",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.71484375,
            "text": "frataxin, a highly conserved nuclear-encoded protein localized in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.76953125,
            "text": "frataxin, a highly conserved nuclear-encoded",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.79296875,
            "text": "frataxin, a highly conserved nuclear-encoded protein localized in mitochondria",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 9.0390625,
            "text": "It is caused by deficiency of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 9.0390625,
            "text": "deficiency of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 9.0390625,
            "text": "caused by deficiency of frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6787109375,
            "end_logit": -5.31640625,
            "text": "xin, a highly conserved nuclear-encoded protein localized in mitochondria.",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_18": [
        {
            "start_logit": 9.0859375,
            "end_logit": 9.046875,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.6494140625,
            "end_logit": 9.046875,
            "text": "xin",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -1.7685546875,
            "text": "fra",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -5.74609375,
            "end_logit": 9.046875,
            "text": "taxin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -6.46875,
            "text": "frataxin gene",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -6.85546875,
            "text": "frataxin gene.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.21875,
            "end_logit": 9.046875,
            "text": "the frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 9.046875,
            "text": "of the frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.046875,
            "text": "of Friedreich's ataxia chromosomes is the unstable hyperexpansion of a GAA triplet repeat in the first intron of the frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 9.046875,
            "text": "unstable hyperexpansion of a GAA triplet repeat in the first intron of the frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.609375,
            "end_logit": 9.046875,
            "text": "Friedreich's ataxia chromosomes is the unstable hyperexpansion of a GAA triplet repeat in the first intron of the frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.046875,
            "text": "chromosomes is the unstable hyperexpansion of a GAA triplet repeat in the first intron of the frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6494140625,
            "end_logit": -6.46875,
            "text": "xin gene",
            "probability": 0.0
        },
        {
            "start_logit": -1.6494140625,
            "end_logit": -6.85546875,
            "text": "xin gene.",
            "probability": 0.0
        },
        {
            "start_logit": -7.21875,
            "end_logit": -1.7685546875,
            "text": "the fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.4296875,
            "end_logit": -1.7685546875,
            "text": "of the fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -1.7685546875,
            "text": "98% of Friedreich's ataxia chromosomes is the unstable hyperexpansion of a GAA triplet repeat in the first intron of the fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.546875,
            "end_logit": -1.7685546875,
            "text": "of Friedreich's ataxia chromosomes is the unstable hyperexpansion of a GAA triplet repeat in the first intron of the fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -1.7685546875,
            "text": "unstable hyperexpansion of a GAA triplet repeat in the first intron of the fra",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": -1.7685546875,
            "text": "Friedreich's ataxia chromosomes is the unstable hyperexpansion of a GAA triplet repeat in the first intron of the fra",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_19": [
        {
            "start_logit": 9.0625,
            "end_logit": 9.0078125,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": 9.0625,
            "end_logit": -1.810546875,
            "text": "fra",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -1.759765625,
            "end_logit": 9.0078125,
            "text": "xin",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -5.83203125,
            "end_logit": 9.0078125,
            "text": "taxin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.4453125,
            "text": "frataxin (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.62890625,
            "text": "frataxin (dfh), which causes Friedreich's ataxia if mutated in humans, displayed",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.80859375,
            "text": "frataxin (df",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.859375,
            "text": "frataxin (dfh)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.87890625,
            "text": "frataxin (dfh), which causes Friedreich's ataxia if mutated in humans,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.92578125,
            "text": "frataxin (dfh),",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.9453125,
            "text": "frataxin (dfh",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -6.984375,
            "text": "frataxin (dfh), which causes Friedreich's ataxia if mutated in humans, displayed an",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.01171875,
            "text": "frataxin (dfh), which",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.08203125,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0625,
            "end_logit": -7.13671875,
            "text": "frataxin (dfh), which causes Friedreich's ataxia if mutated in humans, displayed an interacting effect with Al,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.296875,
            "end_logit": 9.0078125,
            "text": "Drosophila frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.0078125,
            "text": ", Drosophila frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 9.0078125,
            "text": "Interestingly, Drosophila frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.759765625,
            "end_logit": -6.4453125,
            "text": "xin (",
            "probability": 0.0
        },
        {
            "start_logit": -1.759765625,
            "end_logit": -6.62890625,
            "text": "xin (dfh), which causes Friedreich's ataxia if mutated in humans, displayed",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_20": [
        {
            "start_logit": 9.0390625,
            "end_logit": 9.03125,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.6962890625,
            "end_logit": 9.03125,
            "text": "xin",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -1.8916015625,
            "text": "fra",
            "probability": 1.817941665649414e-05
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -5.8125,
            "text": "frataxin, mitochondrial myopathy has not been described as a feature of the disease.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 9.03125,
            "text": "taxin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.734375,
            "end_logit": 9.03125,
            "text": ", frataxin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.86328125,
            "text": "frataxin,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.10546875,
            "text": "frata",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 9.03125,
            "text": "Friedreich's ataxia phenotype results from decreased expression of a mitochondrially targeted protein, frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 9.03125,
            "text": "the Friedreich's ataxia phenotype results from decreased expression of a mitochondrially targeted protein, frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40625,
            "end_logit": 9.03125,
            "text": "Although the Friedreich's ataxia phenotype results from decreased expression of a mitochondrially targeted protein, frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 9.03125,
            "text": "protein, frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.03125,
            "text": "mitochondrially targeted protein, frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 9.03125,
            "text": "reich's ataxia phenotype results from decreased expression of a mitochondrially targeted protein, frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.03125,
            "text": "a mitochondrially targeted protein, frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 9.03125,
            "text": "decreased expression of a mitochondrially targeted protein, frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 9.03125,
            "text": "ich's ataxia phenotype results from decreased expression of a mitochondrially targeted protein, frataxin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6962890625,
            "end_logit": -5.8125,
            "text": "xin, mitochondrial myopathy has not been described as a feature of the disease.",
            "probability": 0.0
        },
        {
            "start_logit": -1.6962890625,
            "end_logit": -6.86328125,
            "text": "xin,",
            "probability": 0.0
        },
        {
            "start_logit": -6.734375,
            "end_logit": -1.8916015625,
            "text": ", fra",
            "probability": 0.0
        }
    ],
    "57136a7e1174fb1755000006_1": [
        {
            "start_logit": 9.203125,
            "end_logit": 8.703125,
            "text": "first trimester",
            "probability": 1.0
        },
        {
            "start_logit": 9.203125,
            "end_logit": -0.9228515625,
            "text": "first",
            "probability": 6.604194641113281e-05
        },
        {
            "start_logit": -2.060546875,
            "end_logit": 8.703125,
            "text": "trimester",
            "probability": 1.2814998626708984e-05
        },
        {
            "start_logit": 9.203125,
            "end_logit": -5.8125,
            "text": "first trimester of pregnancy",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.20703125,
            "text": "first trimester of pregnancy of",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.484375,
            "text": "first trimester of pregnancy of female DMD carriers.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.04296875,
            "end_logit": 8.703125,
            "text": "the first trimester",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.9375,
            "text": "first trimester of pregnancy of female DMD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.9765625,
            "text": "first trimester of pregnancy of female",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.984375,
            "text": "first trimester of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.02734375,
            "text": "first trimester of pregnancy of female DMD carriers",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 8.703125,
            "text": "during the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34375,
            "end_logit": 8.703125,
            "text": "fetal sex determination during the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.04296875,
            "end_logit": -0.9228515625,
            "text": "the first",
            "probability": 0.0
        },
        {
            "start_logit": -2.060546875,
            "end_logit": -5.8125,
            "text": "trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -7.1953125,
            "end_logit": -0.9228515625,
            "text": "during the first",
            "probability": 0.0
        },
        {
            "start_logit": -2.060546875,
            "end_logit": -6.20703125,
            "text": "trimester of pregnancy of",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -0.9228515625,
            "text": "fetal sex determination during the first",
            "probability": 0.0
        },
        {
            "start_logit": -2.060546875,
            "end_logit": -6.484375,
            "text": "trimester of pregnancy of female DMD carriers.",
            "probability": 0.0
        },
        {
            "start_logit": -2.060546875,
            "end_logit": -6.9375,
            "text": "trimester of pregnancy of female DMD",
            "probability": 0.0
        }
    ],
    "57136a7e1174fb1755000006_2": [
        {
            "start_logit": 9.2109375,
            "end_logit": 8.359375,
            "text": "first trimester",
            "probability": 1.0
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -1.0849609375,
            "text": "first",
            "probability": 7.969141006469727e-05
        },
        {
            "start_logit": -2.748046875,
            "end_logit": 8.359375,
            "text": "trimester",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -5.3125,
            "text": "first trimester of pregnancy",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.5546875,
            "text": "first trimester of pregnancy.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 8.359375,
            "text": "Considerable 97.3% sensitivity and 97.3% specificity were obtained in fetal gender determination which is significant in the first trimester",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 8.359375,
            "text": "the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1875,
            "end_logit": 8.359375,
            "text": "in fetal gender determination which is significant in the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 8.359375,
            "text": "in the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 8.359375,
            "text": "sensitivity and 97.3% specificity were obtained in fetal gender determination which is significant in the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -1.0849609375,
            "text": "Considerable 97.3% sensitivity and 97.3% specificity were obtained in fetal gender determination which is significant in the first",
            "probability": 0.0
        },
        {
            "start_logit": -2.748046875,
            "end_logit": -5.3125,
            "text": "trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -1.0849609375,
            "text": "the first",
            "probability": 0.0
        },
        {
            "start_logit": -7.1875,
            "end_logit": -1.0849609375,
            "text": "in fetal gender determination which is significant in the first",
            "probability": 0.0
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -1.0849609375,
            "text": "in the first",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": -1.0849609375,
            "text": "sensitivity and 97.3% specificity were obtained in fetal gender determination which is significant in the first",
            "probability": 0.0
        },
        {
            "start_logit": -2.748046875,
            "end_logit": -6.5546875,
            "text": "trimester of pregnancy.",
            "probability": 0.0
        },
        {
            "start_logit": -4.71875,
            "end_logit": -6.5546875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.5078125,
            "end_logit": -5.3125,
            "text": "Considerable 97.3% sensitivity and 97.3% specificity were obtained in fetal gender determination which is significant in the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -6.92578125,
            "end_logit": -5.3125,
            "text": "of pregnancy",
            "probability": 0.0
        }
    ],
    "57136a7e1174fb1755000006_3": [
        {
            "start_logit": 8.65625,
            "end_logit": 8.546875,
            "text": "first trimester",
            "probability": 1.0
        },
        {
            "start_logit": 8.65625,
            "end_logit": -1.98828125,
            "text": "first",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": -2.28515625,
            "end_logit": 8.546875,
            "text": "trimester",
            "probability": 1.7762184143066406e-05
        },
        {
            "start_logit": -4.5625,
            "end_logit": 8.546875,
            "text": "the first trimester",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.078125,
            "text": "first trimester of pregnancy",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.40625,
            "text": "first trimester of pregnancy and test its clinical utility in the diagnosis of potentially affected pregnancies in carriers of X-linked disorders.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -6.93359375,
            "text": "first trimester of pregnancy and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 8.546875,
            "text": "in the first trimester",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -7.14453125,
            "text": "first trimester of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.65625,
            "end_logit": -7.28515625,
            "text": "first trimester of pregnancy and test its clinical utility in the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.5625,
            "end_logit": -1.98828125,
            "text": "the first",
            "probability": 0.0
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -6.078125,
            "text": "trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -6.40625,
            "text": "trimester of pregnancy and test its clinical utility in the diagnosis of potentially affected pregnancies in carriers of X-linked disorders.",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -1.98828125,
            "text": "in the first",
            "probability": 0.0
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -6.93359375,
            "text": "trimester of pregnancy and",
            "probability": 0.0
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -7.14453125,
            "text": "trimester of",
            "probability": 0.0
        },
        {
            "start_logit": -2.28515625,
            "end_logit": -7.28515625,
            "text": "trimester of pregnancy and test its clinical utility in the",
            "probability": 0.0
        },
        {
            "start_logit": -4.1484375,
            "end_logit": -6.40625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.5625,
            "end_logit": -6.078125,
            "text": "the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -4.5625,
            "end_logit": -6.40625,
            "text": "the first trimester of pregnancy and test its clinical utility in the diagnosis of potentially affected pregnancies in carriers of X-linked disorders.",
            "probability": 0.0
        }
    ],
    "57136a7e1174fb1755000006_4": [
        {
            "start_logit": 8.6796875,
            "end_logit": 8.1328125,
            "text": "first trimester",
            "probability": 1.0
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -2.224609375,
            "text": "first",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -2.884765625,
            "text": "first trimester of pregnancy",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": -3.0859375,
            "end_logit": 8.1328125,
            "text": "trimester",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -4.65234375,
            "end_logit": 8.1328125,
            "text": "the first trimester",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 8.6796875,
            "end_logit": -6.08984375,
            "text": "first trimester of pregnancy.",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.75,
            "end_logit": 8.1328125,
            "text": "We performed a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.25,
            "end_logit": 8.1328125,
            "text": "a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 8.1328125,
            "text": "performed a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.0859375,
            "end_logit": -2.884765625,
            "text": "trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -4.65234375,
            "end_logit": -2.224609375,
            "text": "the first",
            "probability": 0.0
        },
        {
            "start_logit": -4.65234375,
            "end_logit": -2.884765625,
            "text": "the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -6.75,
            "end_logit": -2.224609375,
            "text": "We performed a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first",
            "probability": 0.0
        },
        {
            "start_logit": -3.0859375,
            "end_logit": -6.08984375,
            "text": "trimester of pregnancy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.25,
            "end_logit": -2.224609375,
            "text": "a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first",
            "probability": 0.0
        },
        {
            "start_logit": -7.2734375,
            "end_logit": -2.224609375,
            "text": "performed a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first",
            "probability": 0.0
        },
        {
            "start_logit": -6.75,
            "end_logit": -2.884765625,
            "text": "We performed a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -2.884765625,
            "text": "of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -7.25,
            "end_logit": -2.884765625,
            "text": "a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -7.2734375,
            "end_logit": -2.884765625,
            "text": "performed a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester of pregnancy",
            "probability": 0.0
        }
    ],
    "57136a7e1174fb1755000006_5": [
        {
            "start_logit": 8.8046875,
            "end_logit": 8.5390625,
            "text": "first trimester",
            "probability": 1.0
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -1.78125,
            "text": "first",
            "probability": 3.2961368560791016e-05
        },
        {
            "start_logit": -2.32421875,
            "end_logit": 8.5390625,
            "text": "trimester",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -4.90625,
            "text": "first trimester of pregnancy",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -6.33203125,
            "text": "first trimester of pregnancy of",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.203125,
            "end_logit": 8.5390625,
            "text": "the first trimester",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -7.12109375,
            "text": "first trimester of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -7.2421875,
            "text": "first trimester of pregnancy of female",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -7.2890625,
            "text": "first trimester of pregnancy of female DMD carriers",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8046875,
            "end_logit": -7.296875,
            "text": "first trimester of pregnancy of female DMD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 8.5390625,
            "text": "during the first trimester",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 8.5390625,
            "text": "fetal sex determination during the first trimester",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.32421875,
            "end_logit": -4.90625,
            "text": "trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -6.203125,
            "end_logit": -1.78125,
            "text": "the first",
            "probability": 0.0
        },
        {
            "start_logit": -2.32421875,
            "end_logit": -6.33203125,
            "text": "trimester of pregnancy of",
            "probability": 0.0
        },
        {
            "start_logit": -7.09375,
            "end_logit": -1.78125,
            "text": "during the first",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -1.78125,
            "text": "fetal sex determination during the first",
            "probability": 0.0
        },
        {
            "start_logit": -2.32421875,
            "end_logit": -7.12109375,
            "text": "trimester of",
            "probability": 0.0
        },
        {
            "start_logit": -2.32421875,
            "end_logit": -7.2421875,
            "text": "trimester of pregnancy of female",
            "probability": 0.0
        },
        {
            "start_logit": -2.32421875,
            "end_logit": -7.2890625,
            "text": "trimester of pregnancy of female DMD carriers",
            "probability": 0.0
        }
    ],
    "57136a7e1174fb1755000006_6": [
        {
            "start_logit": 7.39453125,
            "end_logit": 7.625,
            "text": "first trimester",
            "probability": 1.0
        },
        {
            "start_logit": 7.39453125,
            "end_logit": -2.751953125,
            "text": "first trimester of pregnancy",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": -3.828125,
            "end_logit": 7.625,
            "text": "trimester",
            "probability": 1.341104507446289e-05
        },
        {
            "start_logit": 7.39453125,
            "end_logit": -4.10546875,
            "text": "first",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": -5.19921875,
            "end_logit": 7.625,
            "text": "the first trimester",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 7.39453125,
            "end_logit": -6.875,
            "text": "first trimester of",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.19921875,
            "end_logit": 7.625,
            "text": "We performed a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -3.828125,
            "end_logit": -2.751953125,
            "text": "trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -5.19921875,
            "end_logit": -2.751953125,
            "text": "the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -5.19921875,
            "end_logit": -4.10546875,
            "text": "the first",
            "probability": 0.0
        },
        {
            "start_logit": -7.19921875,
            "end_logit": -2.751953125,
            "text": "We performed a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -3.828125,
            "end_logit": -6.875,
            "text": "trimester of",
            "probability": 0.0
        },
        {
            "start_logit": -7.19921875,
            "end_logit": -4.10546875,
            "text": "We performed a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first",
            "probability": 0.0
        },
        {
            "start_logit": -5.19921875,
            "end_logit": -6.875,
            "text": "the first trimester of",
            "probability": 0.0
        },
        {
            "start_logit": -7.19921875,
            "end_logit": -6.65234375,
            "text": "We",
            "probability": 0.0
        },
        {
            "start_logit": -7.19921875,
            "end_logit": -6.875,
            "text": "We performed a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester of",
            "probability": 0.0
        },
        {
            "start_logit": -7.19921875,
            "end_logit": -6.9296875,
            "text": "We performed a review of the published literature",
            "probability": 0.0
        },
        {
            "start_logit": -7.19921875,
            "end_logit": -6.9375,
            "text": "We performed",
            "probability": 0.0
        },
        {
            "start_logit": -7.19921875,
            "end_logit": -6.953125,
            "text": "We performed a",
            "probability": 0.0
        },
        {
            "start_logit": -7.19921875,
            "end_logit": -7.03125,
            "text": "We performed a review of the published",
            "probability": 0.0
        }
    ],
    "587f795d92a5b8ad44000007_1": [
        {
            "start_logit": 6.421875,
            "end_logit": 8.953125,
            "text": "Left-Right Asymmetry",
            "probability": 0.55078125
        },
        {
            "start_logit": 6.21875,
            "end_logit": 8.953125,
            "text": "Formin Is Associated with Left-Right Asymmetry",
            "probability": 0.449462890625
        },
        {
            "start_logit": -1.525390625,
            "end_logit": 8.953125,
            "text": "Asymmetry",
            "probability": 0.00019502639770507812
        },
        {
            "start_logit": -5.4296875,
            "end_logit": 8.953125,
            "text": "in Is Associated with Left-Right Asymmetry",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 8.953125,
            "text": "-Right Asymmetry",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 8.953125,
            "text": "Right Asymmetry",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -6.4140625,
            "end_logit": 8.953125,
            "text": "with Left-Right Asymmetry",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -6.55859375,
            "end_logit": 8.953125,
            "text": "Associated with Left-Right Asymmetry",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 6.421875,
            "end_logit": -4.89453125,
            "text": "Left",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 6.21875,
            "end_logit": -4.8515625,
            "text": "Form",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 6.21875,
            "end_logit": -4.89453125,
            "text": "Formin Is Associated with Left",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 6.421875,
            "end_logit": -5.4765625,
            "text": "Left-Right Asymmetry in the Pond Snail and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 6.21875,
            "end_logit": -5.4765625,
            "text": "Formin Is Associated with Left-Right Asymmetry in the Pond Snail and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.421875,
            "end_logit": -6.5078125,
            "text": "Left-Right Asymmetry in the Pond Snail and the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.421875,
            "end_logit": -6.515625,
            "text": "Left-Right Asymmetry in the Pond Snail and the Frog",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.421875,
            "end_logit": -6.69921875,
            "text": "Left-Right Asymmetry in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.21875,
            "end_logit": -6.5,
            "text": "Formin Is Associated with",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.21875,
            "end_logit": -6.5078125,
            "text": "Formin Is Associated with Left-Right Asymmetry in the Pond Snail and the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.21875,
            "end_logit": -6.515625,
            "text": "Formin Is Associated with Left-Right Asymmetry in the Pond Snail and the Frog",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.421875,
            "end_logit": -6.74609375,
            "text": "Left-Right Asymmetry in the Pond Snail",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5a72302b2dc08e987e000005_1": [
        {
            "start_logit": 8.7578125,
            "end_logit": 8.6171875,
            "text": "Patent foramen ovale",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.7578125,
            "end_logit": 1.5869140625,
            "text": "Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke",
            "probability": 0.0008831024169921875
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -1.75,
            "text": "Patent foramen ovale closure",
            "probability": 3.141164779663086e-05
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -2.41015625,
            "text": "Patent",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": -2.369140625,
            "end_logit": 8.6171875,
            "text": "e",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": 2.947265625,
            "end_logit": 1.5869140625,
            "text": "stroke",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -5.99609375,
            "text": "Patent foramen ovale closure with",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -6.1015625,
            "text": "Patent foramen oval",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -6.30859375,
            "text": "Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.53125,
            "end_logit": 8.6171875,
            "text": "ovale",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -6.8046875,
            "text": "Patent foramen ovale closure with GOR",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -6.88671875,
            "text": "Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -6.8984375,
            "text": "Patent foramen",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -6.94921875,
            "text": "Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.84375,
            "end_logit": 8.6171875,
            "text": "foramen ovale",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.369140625,
            "end_logit": 1.5869140625,
            "text": "e closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke",
            "probability": 0.0
        },
        {
            "start_logit": 2.947265625,
            "end_logit": -6.375,
            "text": "stroke or new brain infarct in patients with prior cryptogenic stroke",
            "probability": 0.0
        },
        {
            "start_logit": 2.947265625,
            "end_logit": -6.734375,
            "text": "stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study.",
            "probability": 0.0
        },
        {
            "start_logit": 2.947265625,
            "end_logit": -6.94921875,
            "text": "stroke or",
            "probability": 0.0
        },
        {
            "start_logit": 2.947265625,
            "end_logit": -7.046875,
            "text": "stroke or new brain infarct in patients with prior crypt",
            "probability": 0.0
        }
    ],
    "5a72302b2dc08e987e000005_2": [
        {
            "start_logit": 9.1015625,
            "end_logit": 9.0859375,
            "text": "patent foramen ovale",
            "probability": 1.0
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -1.0537109375,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke",
            "probability": 3.9458274841308594e-05
        },
        {
            "start_logit": -1.4521484375,
            "end_logit": 9.0859375,
            "text": "e",
            "probability": 2.6047229766845703e-05
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -1.716796875,
            "text": "patent",
            "probability": 2.0325183868408203e-05
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -3.16796875,
            "text": "patent foramen ovale closure",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -5.8359375,
            "end_logit": 9.0859375,
            "text": "ovale",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.1484375,
            "text": "patent foramen ovale closure in conjunction",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 9.0859375,
            "text": "foramen ovale",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.4609375,
            "text": "patent foramen ovale closure in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.54296875,
            "text": "patent foramen oval",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.625,
            "end_logit": 9.0859375,
            "text": "The Gore REDUCE Clinical Study (REDUCE) aims to establish superiority of patent foramen ovale",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.87890625,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 9.0859375,
            "text": "of patent foramen ovale",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.02734375,
            "text": "patent foramen ovale closure in conjunction with",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.04296875,
            "text": "patent foramen ovale closure in conjunction with antiplatelet",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.08203125,
            "text": "patent foramen",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.08203125,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.08203125,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.08984375,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": 9.0859375,
            "text": "Aims The Gore REDUCE Clinical Study (REDUCE) aims to establish superiority of patent foramen ovale",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a72302b2dc08e987e000005_3": [
        {
            "start_logit": 9.1015625,
            "end_logit": 9.0859375,
            "text": "patent foramen ovale",
            "probability": 1.0
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -1.0537109375,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke",
            "probability": 3.9458274841308594e-05
        },
        {
            "start_logit": -1.4521484375,
            "end_logit": 9.0859375,
            "text": "e",
            "probability": 2.6047229766845703e-05
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -1.716796875,
            "text": "patent",
            "probability": 2.0325183868408203e-05
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -3.16796875,
            "text": "patent foramen ovale closure",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -5.8359375,
            "end_logit": 9.0859375,
            "text": "ovale",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.1484375,
            "text": "patent foramen ovale closure in conjunction",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 9.0859375,
            "text": "foramen ovale",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.4609375,
            "text": "patent foramen ovale closure in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.54296875,
            "text": "patent foramen oval",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.625,
            "end_logit": 9.0859375,
            "text": "The Gore REDUCE Clinical Study (REDUCE) aims to establish superiority of patent foramen ovale",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.87890625,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 9.0859375,
            "text": "of patent foramen ovale",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.02734375,
            "text": "patent foramen ovale closure in conjunction with",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.04296875,
            "text": "patent foramen ovale closure in conjunction with antiplatelet",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.08203125,
            "text": "patent foramen",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.08203125,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.08203125,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -7.08984375,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": 9.0859375,
            "text": "Aims The Gore REDUCE Clinical Study (REDUCE) aims to establish superiority of patent foramen ovale",
            "probability": 5.960464477539063e-08
        }
    ],
    "6026ef311cb411341a0000d4_1": [
        {
            "start_logit": 7.69921875,
            "end_logit": 3.908203125,
            "text": "Lundbeck",
            "probability": 0.9892578125
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -0.85009765625,
            "text": "Lundbeck Seattle",
            "probability": 0.00846099853515625
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -3.17578125,
            "text": "Lundbeck Seattle BioPharmaceuticals",
            "probability": 0.000827789306640625
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -3.55859375,
            "text": "Lun",
            "probability": 0.0005645751953125
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -5.2890625,
            "text": "Lundbeck Seattle BioPharmaceuticals for the prevention of migraine.",
            "probability": 9.965896606445312e-05
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -5.69921875,
            "text": "Lundbeck Seattle BioPharmaceuticals for the prevention of migraine",
            "probability": 6.639957427978516e-05
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -5.95703125,
            "text": "Lundbeck Seat",
            "probability": 5.131959915161133e-05
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -6.18359375,
            "text": "Lundbeck Seattle BioPharmaceuticals for",
            "probability": 4.094839096069336e-05
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -6.62109375,
            "text": "Lundbeck Seattle BioPharmaceut",
            "probability": 2.6404857635498047e-05
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -6.80859375,
            "text": "Lundbeck Seattle BioPharmaceuticals for the",
            "probability": 2.187490463256836e-05
        },
        {
            "start_logit": 7.69921875,
            "end_logit": -6.8515625,
            "text": "Lundbeck Seattle BioPharmaceuticals for the prevention",
            "probability": 2.086162567138672e-05
        },
        {
            "start_logit": -5.4609375,
            "end_logit": 3.908203125,
            "text": "eck",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -5.9140625,
            "end_logit": 3.908203125,
            "text": "dbeck",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -6.640625,
            "end_logit": 3.908203125,
            "text": "by Lundbeck",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 3.908203125,
            "text": ", delivered by intravenous (IV) administration, is being developed by Lundbeck",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 3.908203125,
            "text": "by intravenous (IV) administration, is being developed by Lundbeck",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 3.908203125,
            "text": "(IV) administration, is being developed by Lundbeck",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.4609375,
            "end_logit": -0.85009765625,
            "text": "eck Seattle",
            "probability": 0.0
        },
        {
            "start_logit": -5.8515625,
            "end_logit": -0.85009765625,
            "text": "Seattle",
            "probability": 0.0
        },
        {
            "start_logit": -5.9140625,
            "end_logit": -0.85009765625,
            "text": "dbeck Seattle",
            "probability": 0.0
        }
    ],
    "624c838ee764a53204000001_1": [
        {
            "start_logit": 9.0,
            "end_logit": 9.1953125,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -1.24609375,
            "end_logit": 9.1953125,
            "text": "disease",
            "probability": 3.594160079956055e-05
        },
        {
            "start_logit": 9.0,
            "end_logit": -1.9267578125,
            "text": "Alzheimer",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -5.875,
            "end_logit": 9.1953125,
            "text": "'s disease",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.16015625,
            "end_logit": 9.1953125,
            "text": "s disease",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.67578125,
            "text": "Alzheimer's disease, harboring ~300 causative mutations, and representing ~90% of all mutations associated with a very aggressive disease form.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.7890625,
            "text": "Alzheimer's disease, harboring ~300 causative mutations, and representing",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.7890625,
            "text": "Alzheimer's disease,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.96875,
            "text": "Alzheimer's disease, harboring ~300 causative mutations, and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.984375,
            "text": "Alzheimer's disease, harboring ~300 causative mutations, and representing ~90%",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -6.98828125,
            "text": "Alzheimer's disease, harboring ~",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.015625,
            "text": "Alzheimer's disease, harboring ~300 causative mutations, and representing ~90",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.0625,
            "text": "Alzheimer's disease, harboring",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.1015625,
            "text": "Alzheimer'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.1484375,
            "text": "Alzheimer's disease, harboring ~300 causative mutations, and representing ~",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34375,
            "end_logit": 9.1953125,
            "text": "The presenilin genes (PSEN1 and PSEN2) are mainly responsible for causing early-onset familial Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.203125,
            "text": "Alzheimer's disease, harboring ~300",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.2109375,
            "text": "Alzheimer's disease, harboring ~300 causative mutations, and representing ~90% of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.2109375,
            "text": "Alzheimer's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0,
            "end_logit": -7.2109375,
            "text": "Alzheimer's disease, harboring ~300 causative mutations, and representing ~90% of all mutations associated with a",
            "probability": 5.960464477539063e-08
        }
    ],
    "624c838ee764a53204000001_2": [
        {
            "start_logit": 9.109375,
            "end_logit": 9.203125,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -1.216796875,
            "end_logit": 9.203125,
            "text": "disease",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 9.109375,
            "end_logit": -1.6826171875,
            "text": "Alzheimer",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": -5.94140625,
            "end_logit": 9.203125,
            "text": "'s disease",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.24609375,
            "text": "Alzheimer's disease (fAD).",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4609375,
            "end_logit": 9.203125,
            "text": "s disease",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.59375,
            "text": "Alzheimer's disease (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.890625,
            "text": "Alzheimer's disease (fAD)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.8984375,
            "text": "Alzheimer's disease (fAD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -6.96875,
            "text": "Alzheimer'",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 9.203125,
            "text": "familial Alzheimer's disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.109375,
            "end_logit": -7.1015625,
            "text": "Alzheimer's",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 9.203125,
            "text": "in PSEN1/2 genes are the leading cause of familial Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 9.203125,
            "text": "Loss-of-function mutations in PSEN1/2 genes are the leading cause of familial Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.216796875,
            "end_logit": -6.24609375,
            "text": "disease (fAD).",
            "probability": 0.0
        },
        {
            "start_logit": -1.216796875,
            "end_logit": -6.59375,
            "text": "disease (",
            "probability": 0.0
        },
        {
            "start_logit": -1.216796875,
            "end_logit": -6.890625,
            "text": "disease (fAD)",
            "probability": 0.0
        },
        {
            "start_logit": -1.216796875,
            "end_logit": -6.8984375,
            "text": "disease (fAD",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": -1.6826171875,
            "text": "familial Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": -1.6826171875,
            "text": "in PSEN1/2 genes are the leading cause of familial Alzheimer",
            "probability": 0.0
        }
    ],
    "624c838ee764a53204000001_3": [
        {
            "start_logit": 9.15625,
            "end_logit": 9.2890625,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -0.93212890625,
            "end_logit": 9.2890625,
            "text": "disease",
            "probability": 4.1961669921875e-05
        },
        {
            "start_logit": 9.15625,
            "end_logit": -1.53515625,
            "text": "Alzheimer",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -5.67578125,
            "end_logit": 9.2890625,
            "text": "'s disease",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.85546875,
            "end_logit": 9.2890625,
            "text": "s disease",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -6.01171875,
            "text": "Alzheimer's disease (AD).",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -6.26953125,
            "text": "Alzheimer's disease (AD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -6.54296875,
            "text": "Alzheimer's disease (AD)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.828125,
            "end_logit": 9.2890625,
            "text": "familial Alzheimer's disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -6.83203125,
            "text": "Alzheimer's disease (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.515625,
            "end_logit": 9.2890625,
            "text": "in familial Alzheimer's disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.93212890625,
            "end_logit": -6.01171875,
            "text": "disease (AD).",
            "probability": 0.0
        },
        {
            "start_logit": -0.93212890625,
            "end_logit": -6.26953125,
            "text": "disease (AD",
            "probability": 0.0
        },
        {
            "start_logit": -0.93212890625,
            "end_logit": -6.54296875,
            "text": "disease (AD)",
            "probability": 0.0
        },
        {
            "start_logit": -0.93212890625,
            "end_logit": -6.83203125,
            "text": "disease (",
            "probability": 0.0
        },
        {
            "start_logit": -6.828125,
            "end_logit": -1.53515625,
            "text": "familial Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": -7.515625,
            "end_logit": -1.53515625,
            "text": "in familial Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": -4.96875,
            "end_logit": -6.01171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.67578125,
            "end_logit": -6.01171875,
            "text": "'s disease (AD).",
            "probability": 0.0
        },
        {
            "start_logit": -5.85546875,
            "end_logit": -6.01171875,
            "text": "s disease (AD).",
            "probability": 0.0
        }
    ],
    "587e07023ec846c24f000001_1": [
        {
            "start_logit": 8.8984375,
            "end_logit": 8.7578125,
            "text": "PHYLUCE",
            "probability": 1.0
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -2.142578125,
            "text": "PHYL",
            "probability": 1.8477439880371094e-05
        },
        {
            "start_logit": -2.271484375,
            "end_logit": 8.7578125,
            "text": "UCE",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -5.9609375,
            "text": "PHYLUCE is a",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.02734375,
            "text": "PHYLUCE is",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.7421875,
            "text": "PHYLUCE is a software",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.8984375,
            "text": "PHYLUCE is a software package",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.16796875,
            "text": "PHYLUCE is a software package for the analysis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.22265625,
            "text": "PHYLUCE is a software package for",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.2265625,
            "text": "PHYLUCE is a software package for the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.28515625,
            "text": "PHYLUCE is a software package for the analysis of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.30078125,
            "text": "PHYLUCE is a software package for the analysis of conserved genomic loci",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.31640625,
            "text": "PHYLUCE is a software package for the analysis of conserved",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.31640625,
            "text": "PHYLUCE is a software package for the analysis of conserved genomic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -5.9609375,
            "text": "UCE is a",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -6.02734375,
            "text": "UCE is",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -6.7421875,
            "text": "UCE is a software",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -6.8984375,
            "text": "UCE is a software package",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -7.16796875,
            "text": "UCE is a software package for the analysis",
            "probability": 0.0
        },
        {
            "start_logit": -2.271484375,
            "end_logit": -7.22265625,
            "text": "UCE is a software package for",
            "probability": 0.0
        }
    ],
    "587e07023ec846c24f000001_2": [
        {
            "start_logit": 8.984375,
            "end_logit": 8.8046875,
            "text": "PHYLUCE",
            "probability": 1.0
        },
        {
            "start_logit": 8.984375,
            "end_logit": -1.931640625,
            "text": "PHYL",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": -2.13671875,
            "end_logit": 8.8046875,
            "text": "UCE",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -3.583984375,
            "end_logit": 8.8046875,
            "text": ". PHYLUCE",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.3359375,
            "text": "PHYLUCE is",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.0390625,
            "text": "PHYLUCE is an efficient and easy-to-install software package that accomplishes these tasks across hundreds of taxa and thousands of enriched loci.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.08984375,
            "text": "PHYLUCE is an",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.09765625,
            "text": "PHYLUCE is an efficient and easy-to-install",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.25,
            "text": "PHYLUCE is an efficient and easy-to-install software package",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.27734375,
            "text": "PHYLUCE is an efficient and easy-to-install software",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.28125,
            "text": "PHYLUCE is an efficient and easy-to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.29296875,
            "text": "PHYLUCE is an efficient and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 8.8046875,
            "text": "align enriched contigs representing conserved loci to one another; and prepare and manipulate these alignments for subsequent phylogenomic inference. PHYLUCE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 8.8046875,
            "text": "alignments for subsequent phylogenomic inference. PHYLUCE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 8.8046875,
            "text": "; and prepare and manipulate these alignments for subsequent phylogenomic inference. PHYLUCE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5,
            "end_logit": 8.8046875,
            "text": "; align enriched contigs representing conserved loci to one another; and prepare and manipulate these alignments for subsequent phylogenomic inference. PHYLUCE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 8.8046875,
            "text": "prepare and manipulate these alignments for subsequent phylogenomic inference. PHYLUCE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 8.8046875,
            "text": "manipulate these alignments for subsequent phylogenomic inference. PHYLUCE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.8046875,
            "text": "enriched contigs representing conserved loci to one another; and prepare and manipulate these alignments for subsequent phylogenomic inference. PHYLUCE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.583984375,
            "end_logit": -1.931640625,
            "text": ". PHYL",
            "probability": 0.0
        }
    ],
    "587e07023ec846c24f000001_3": [
        {
            "start_logit": 9.1328125,
            "end_logit": 8.875,
            "text": "PHYLUCE",
            "probability": 1.0
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -1.6259765625,
            "text": "PHYL",
            "probability": 2.777576446533203e-05
        },
        {
            "start_logit": -2.017578125,
            "end_logit": 8.875,
            "text": "UCE",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.10546875,
            "text": "PHYLUCE is a",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.2109375,
            "text": "PHYLUCE is",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.83984375,
            "text": "PHYLUCE is a software",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -6.9921875,
            "text": "PHYLUCE is a software package",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.09765625,
            "text": "PHYLUCE is a software package for the analysis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.12109375,
            "text": "PHYLUCE is a software package for the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.140625,
            "text": "PHYLUCE is a software package for",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.15234375,
            "text": "PHYLUCE is a software package for the analysis of conserved genomic loci.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.25,
            "text": "PHYLUCE is a software package for the analysis of conserved genomic loci",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.25,
            "text": "PHYLUCE is a software package for the analysis of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1328125,
            "end_logit": -7.25390625,
            "text": "PHYLUCE is a software package for the analysis of conserved genomic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.017578125,
            "end_logit": -6.10546875,
            "text": "UCE is a",
            "probability": 0.0
        },
        {
            "start_logit": -2.017578125,
            "end_logit": -6.2109375,
            "text": "UCE is",
            "probability": 0.0
        },
        {
            "start_logit": -2.017578125,
            "end_logit": -6.83984375,
            "text": "UCE is a software",
            "probability": 0.0
        },
        {
            "start_logit": -2.017578125,
            "end_logit": -6.9921875,
            "text": "UCE is a software package",
            "probability": 0.0
        },
        {
            "start_logit": -2.017578125,
            "end_logit": -7.09765625,
            "text": "UCE is a software package for the analysis",
            "probability": 0.0
        },
        {
            "start_logit": -2.017578125,
            "end_logit": -7.12109375,
            "text": "UCE is a software package for the",
            "probability": 0.0
        }
    ],
    "554356d0ed966d112c000005_1": [
        {
            "start_logit": 9.046875,
            "end_logit": 8.6640625,
            "text": "delta-distance",
            "probability": 1.0
        },
        {
            "start_logit": 9.046875,
            "end_logit": -1.6611328125,
            "text": "delta",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": -1.599609375,
            "end_logit": 8.6640625,
            "text": "termed delta-distance",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": 9.046875,
            "end_logit": -2.4609375,
            "text": "delta-distance,",
            "probability": 1.4603137969970703e-05
        },
        {
            "start_logit": -2.228515625,
            "end_logit": 8.6640625,
            "text": "distance",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.16015625,
            "text": "delta-distance, has been commonly",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.2109375,
            "text": "delta-distance, has",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.2265625,
            "text": "delta-distance, has been",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.0234375,
            "end_logit": 8.6640625,
            "text": "-distance",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.4140625,
            "text": "delta-distance, has been commonly used",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.7109375,
            "text": "delta-distance, has been commonly used to",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.73046875,
            "text": "delta-distance, has been commonly used to measure differences",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.75390625,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.7890625,
            "text": "delta-distance, has been commonly used to measure",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.87109375,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.69140625,
            "end_logit": 8.6640625,
            "text": ", termed delta-distance",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.015625,
            "end_logit": 8.6640625,
            "text": "The average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.599609375,
            "end_logit": -1.6611328125,
            "text": "termed delta",
            "probability": 0.0
        },
        {
            "start_logit": -1.599609375,
            "end_logit": -2.4609375,
            "text": "termed delta-distance,",
            "probability": 0.0
        },
        {
            "start_logit": -2.228515625,
            "end_logit": -2.4609375,
            "text": "distance,",
            "probability": 0.0
        }
    ],
    "554356d0ed966d112c000005_2": [
        {
            "start_logit": 9.1796875,
            "end_logit": 8.8203125,
            "text": "delta-distance",
            "probability": 1.0
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -0.81494140625,
            "text": "delta-distance,",
            "probability": 6.556510925292969e-05
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -1.353515625,
            "text": "delta",
            "probability": 3.820657730102539e-05
        },
        {
            "start_logit": -1.892578125,
            "end_logit": 8.8203125,
            "text": "distance",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": -2.515625,
            "end_logit": 8.8203125,
            "text": "termed delta-distance",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -4.40234375,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids.",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.16015625,
            "text": "delta-distance, has",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.28125,
            "text": "delta-distance, has been commonly",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.9609375,
            "end_logit": 8.8203125,
            "text": "-distance",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.3984375,
            "text": "delta-distance, has been commonly used",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.53125,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.63671875,
            "text": "delta-distance, has been",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.34765625,
            "end_logit": 8.8203125,
            "text": "The average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.78515625,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.83984375,
            "text": "delta-distance, has been commonly used to",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.6953125,
            "end_logit": 8.8203125,
            "text": ", termed delta-distance",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.892578125,
            "end_logit": -0.81494140625,
            "text": "distance,",
            "probability": 0.0
        },
        {
            "start_logit": -2.515625,
            "end_logit": -0.81494140625,
            "text": "termed delta-distance,",
            "probability": 0.0
        },
        {
            "start_logit": -2.515625,
            "end_logit": -1.353515625,
            "text": "termed delta",
            "probability": 0.0
        },
        {
            "start_logit": -1.892578125,
            "end_logit": -4.40234375,
            "text": "distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids.",
            "probability": 0.0
        }
    ],
    "554356d0ed966d112c000005_3": [
        {
            "start_logit": 9.1015625,
            "end_logit": 8.6875,
            "text": "delta-distance",
            "probability": 1.0
        },
        {
            "start_logit": 9.1015625,
            "end_logit": 0.744140625,
            "text": "delta-distance,",
            "probability": 0.0003571510314941406
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -1.5576171875,
            "text": "delta",
            "probability": 3.594160079956055e-05
        },
        {
            "start_logit": -2.0859375,
            "end_logit": 8.6875,
            "text": "termed delta-distance",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": -2.15234375,
            "end_logit": 8.6875,
            "text": "distance",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -4.5078125,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or genomic signature, between bacterial chromosomes and plasmids.",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -5.9140625,
            "text": "delta-distance, has",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.12890625,
            "text": "delta-distance, has been commonly",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.2421875,
            "text": "delta-distance, has been commonly used",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.9609375,
            "end_logit": 8.6875,
            "text": "-distance",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.49609375,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.6171875,
            "text": "delta-distance, has been",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.375,
            "end_logit": 8.6875,
            "text": "The average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.796875,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or genomic signature, between bacterial chromosomes and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1015625,
            "end_logit": -6.85546875,
            "text": "delta-distance, has been commonly used to",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 8.6875,
            "text": ", termed delta-distance",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.0859375,
            "end_logit": 0.744140625,
            "text": "termed delta-distance,",
            "probability": 0.0
        },
        {
            "start_logit": -2.15234375,
            "end_logit": 0.744140625,
            "text": "distance,",
            "probability": 0.0
        },
        {
            "start_logit": -2.0859375,
            "end_logit": -1.5576171875,
            "text": "termed delta",
            "probability": 0.0
        },
        {
            "start_logit": -5.9609375,
            "end_logit": 0.744140625,
            "text": "-distance,",
            "probability": 0.0
        }
    ],
    "554356d0ed966d112c000005_4": [
        {
            "start_logit": 8.2265625,
            "end_logit": 8.1171875,
            "text": "Mahalanobis distance",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.2265625,
            "end_logit": 1.2275390625,
            "text": "Mahalanobis distance is better than the delta-distance",
            "probability": 0.0010166168212890625
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -1.3681640625,
            "text": "Mahalanobis distance is",
            "probability": 7.599592208862305e-05
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -2.96875,
            "text": "Mah",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": -2.919921875,
            "end_logit": 8.1171875,
            "text": "distance",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -3.181640625,
            "text": "Mahalanobis distance is better than the delta-distance at measuring genomic signature differences between plasmids and chromosomes of potential hosts.",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -3.33984375,
            "text": "Mahalanobis distance is better",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -4.2890625,
            "text": "Mahalanobis distance is better than the delta-distance at",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": -4.19140625,
            "end_logit": 8.1171875,
            "text": "We demonstrate that the Mahalanobis distance",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": -4.3515625,
            "end_logit": 8.1171875,
            "text": "the Mahalanobis distance",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -5.546875,
            "text": "Mahalanobis distance is better than",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -6.0,
            "text": "Mahalanobis distance is better than the delta-distance at measuring genomic signature differences between plasmids",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -5.9140625,
            "end_logit": 8.1171875,
            "text": "bis distance",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -6.07421875,
            "text": "Mahalanobis distance is better than the delta-distance at measuring genomic signature differences",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.15234375,
            "end_logit": 8.1171875,
            "text": "s distance",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -6.28125,
            "text": "Mahalanobis distance is better than the delta-distance at measuring",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.20703125,
            "end_logit": 8.1171875,
            "text": "alanobis distance",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -6.34765625,
            "text": "Mahalanobis distance is better than the delta-distance at measuring genomic signature differences between plasmids and chromosomes",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -6.359375,
            "text": "Mahalanobis distance is better than the delta-distance at measuring genomic signature",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.2265625,
            "end_logit": -6.41015625,
            "text": "Mahalano",
            "probability": 4.76837158203125e-07
        }
    ],
    "554356d0ed966d112c000005_5": [
        {
            "start_logit": 9.1796875,
            "end_logit": 8.8203125,
            "text": "delta-distance",
            "probability": 1.0
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -0.81494140625,
            "text": "delta-distance,",
            "probability": 6.556510925292969e-05
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -1.353515625,
            "text": "delta",
            "probability": 3.820657730102539e-05
        },
        {
            "start_logit": -1.892578125,
            "end_logit": 8.8203125,
            "text": "distance",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": -2.515625,
            "end_logit": 8.8203125,
            "text": "termed delta-distance",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -4.40234375,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids.",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.16015625,
            "text": "delta-distance, has",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.28125,
            "text": "delta-distance, has been commonly",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.9609375,
            "end_logit": 8.8203125,
            "text": "-distance",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.3984375,
            "text": "delta-distance, has been commonly used",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.53125,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.63671875,
            "text": "delta-distance, has been",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.34765625,
            "end_logit": 8.8203125,
            "text": "The average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.78515625,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1796875,
            "end_logit": -6.83984375,
            "text": "delta-distance, has been commonly used to",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.6953125,
            "end_logit": 8.8203125,
            "text": ", termed delta-distance",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.892578125,
            "end_logit": -0.81494140625,
            "text": "distance,",
            "probability": 0.0
        },
        {
            "start_logit": -2.515625,
            "end_logit": -0.81494140625,
            "text": "termed delta-distance,",
            "probability": 0.0
        },
        {
            "start_logit": -2.515625,
            "end_logit": -1.353515625,
            "text": "termed delta",
            "probability": 0.0
        },
        {
            "start_logit": -1.892578125,
            "end_logit": -4.40234375,
            "text": "distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids.",
            "probability": 0.0
        }
    ],
    "554356d0ed966d112c000005_6": [
        {
            "start_logit": 9.0078125,
            "end_logit": 8.65625,
            "text": "delta-distance",
            "probability": 1.0
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -1.73828125,
            "text": "delta",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -2.20703125,
            "end_logit": 8.65625,
            "text": "distance",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -2.716796875,
            "text": "delta-distance,",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": -2.552734375,
            "end_logit": 8.65625,
            "text": "termed delta-distance",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -6.02734375,
            "end_logit": 8.65625,
            "text": "-distance",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.5546875,
            "text": "delta-distance, has been commonly",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.57421875,
            "text": "delta-distance, has",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.66015625,
            "text": "delta-distance, has been commonly used",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.8515625,
            "text": "delta-distance, has been",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.91015625,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.00390625,
            "text": "delta-distance, has been commonly used to measure differences",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.0234375,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.6796875,
            "end_logit": 8.65625,
            "text": ", termed delta-distance",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -7.0390625,
            "text": "delta-distance, has been commonly used to",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.94140625,
            "end_logit": 8.65625,
            "text": "The average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.552734375,
            "end_logit": -1.73828125,
            "text": "termed delta",
            "probability": 0.0
        },
        {
            "start_logit": -2.20703125,
            "end_logit": -2.716796875,
            "text": "distance,",
            "probability": 0.0
        },
        {
            "start_logit": -2.552734375,
            "end_logit": -2.716796875,
            "text": "termed delta-distance,",
            "probability": 0.0
        },
        {
            "start_logit": -6.6796875,
            "end_logit": -1.73828125,
            "text": ", termed delta",
            "probability": 0.0
        }
    ],
    "5a7d5ce0faa1ab7d2e00001b_1": [
        {
            "start_logit": 7.859375,
            "end_logit": 6.39453125,
            "text": "obesity",
            "probability": 0.9990234375
        },
        {
            "start_logit": 7.859375,
            "end_logit": -1.0166015625,
            "text": "obesity reduces body weight, at least in part, by decreasing food intake.",
            "probability": 0.0006070137023925781
        },
        {
            "start_logit": 7.859375,
            "end_logit": -2.033203125,
            "text": "obesity reduces body weight, at least in part, by decreasing food intake",
            "probability": 0.00021982192993164062
        },
        {
            "start_logit": 7.859375,
            "end_logit": -5.703125,
            "text": "obesity reduces body weight, at least in part",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": 7.859375,
            "end_logit": -5.921875,
            "text": "obesity reduces body weight, at least",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": 7.859375,
            "end_logit": -6.0078125,
            "text": "obesity reduces body weight",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 7.859375,
            "end_logit": -6.03515625,
            "text": "obesity reduces body weight, at",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 7.859375,
            "end_logit": -6.03515625,
            "text": "obesity reduces body weight, at least in part, by decreasing food intake. The mechanisms through which GDF15 reduces body weight remain poorly understood",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 7.859375,
            "end_logit": -6.0859375,
            "text": "obesity reduces",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 7.859375,
            "end_logit": -6.125,
            "text": "obesity reduces body weight,",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -4.84765625,
            "end_logit": 6.39453125,
            "text": "In humans, elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -5.4921875,
            "end_logit": 6.39453125,
            "text": "humans, elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -5.80078125,
            "end_logit": 6.39453125,
            "text": "with obesity",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -6.09765625,
            "end_logit": 6.39453125,
            "text": "elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.14453125,
            "end_logit": 6.39453125,
            "text": "GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -1.4638671875,
            "end_logit": -0.85546875,
            "text": "obesity",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.4638671875,
            "end_logit": -1.017578125,
            "text": "obesity.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.53515625,
            "end_logit": -0.85546875,
            "text": "Here we show that recombinant GDF15 induces weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity",
            "probability": 0.0
        },
        {
            "start_logit": -2.53515625,
            "end_logit": -1.017578125,
            "text": "Here we show that recombinant GDF15 induces weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity.",
            "probability": 0.0
        },
        {
            "start_logit": -3.453125,
            "end_logit": -0.85546875,
            "text": ". Here we show that recombinant GDF15 induces weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity",
            "probability": 0.0
        }
    ],
    "61f7d683882a024a10000036_1": [
        {
            "start_logit": 9.0078125,
            "end_logit": 8.53125,
            "text": "stearoyl-CoA desaturase 1",
            "probability": 0.83740234375
        },
        {
            "start_logit": 9.0078125,
            "end_logit": 6.87890625,
            "text": "stearoyl-CoA desaturase",
            "probability": 0.162353515625
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -1.833984375,
            "text": "stear",
            "probability": 2.6524066925048828e-05
        },
        {
            "start_logit": -2.185546875,
            "end_logit": 8.53125,
            "text": "1",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": -3.63671875,
            "end_logit": 8.53125,
            "text": "desaturase 1",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -5.71484375,
            "text": "stearoyl-CoA desaturase 1 (SCD",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -3.63671875,
            "end_logit": 6.87890625,
            "text": "desaturase",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -5.828125,
            "text": "stearoyl-CoA",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.02734375,
            "text": "stearoyl-CoA desaturase 1 (SCD1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.04296875,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 8.53125,
            "text": "oyl-CoA desaturase 1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.4296875,
            "text": "stearoyl-CoA desaturase 1 (SCD1)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.5546875,
            "text": "stearoyl-CoA desaturase 1 (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.55859375,
            "text": "stearoyl-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.8046875,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.81640625,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.8203125,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.83984375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.84375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 8.53125,
            "text": "hepatic stearoyl-CoA desaturase 1",
            "probability": 1.7881393432617188e-07
        }
    ],
    "61f7d683882a024a10000036_2": [
        {
            "start_logit": 9.0078125,
            "end_logit": 8.53125,
            "text": "stearoyl-CoA desaturase 1",
            "probability": 0.83740234375
        },
        {
            "start_logit": 9.0078125,
            "end_logit": 6.87890625,
            "text": "stearoyl-CoA desaturase",
            "probability": 0.162353515625
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -1.833984375,
            "text": "stear",
            "probability": 2.6524066925048828e-05
        },
        {
            "start_logit": -2.185546875,
            "end_logit": 8.53125,
            "text": "1",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": -3.63671875,
            "end_logit": 8.53125,
            "text": "desaturase 1",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -5.71484375,
            "text": "stearoyl-CoA desaturase 1 (SCD",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -3.63671875,
            "end_logit": 6.87890625,
            "text": "desaturase",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -5.828125,
            "text": "stearoyl-CoA",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.02734375,
            "text": "stearoyl-CoA desaturase 1 (SCD1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.04296875,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 8.53125,
            "text": "oyl-CoA desaturase 1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.4296875,
            "text": "stearoyl-CoA desaturase 1 (SCD1)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.5546875,
            "text": "stearoyl-CoA desaturase 1 (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.55859375,
            "text": "stearoyl-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.8046875,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.81640625,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.8203125,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.83984375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.84375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 8.53125,
            "text": "hepatic stearoyl-CoA desaturase 1",
            "probability": 1.7881393432617188e-07
        }
    ],
    "61f7d683882a024a10000036_3": [
        {
            "start_logit": 8.890625,
            "end_logit": 8.203125,
            "text": "stearoyl-CoA desaturase 1",
            "probability": 0.65869140625
        },
        {
            "start_logit": 8.890625,
            "end_logit": 7.54296875,
            "text": "stearoyl-CoA desaturase",
            "probability": 0.341552734375
        },
        {
            "start_logit": 8.890625,
            "end_logit": -2.04296875,
            "text": "stear",
            "probability": 2.3305416107177734e-05
        },
        {
            "start_logit": -2.658203125,
            "end_logit": 8.203125,
            "text": "1",
            "probability": 6.377696990966797e-06
        },
        {
            "start_logit": -3.30078125,
            "end_logit": 8.203125,
            "text": "desaturase 1",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": -3.30078125,
            "end_logit": 7.54296875,
            "text": "desaturase",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 8.890625,
            "end_logit": -5.59375,
            "text": "stearoyl-CoA",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -5.9296875,
            "text": "stearoyl-CoA desaturase 1 (SCD",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.1484375,
            "text": "stearoyl-CoA desaturase 1 (SCD1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.8515625,
            "end_logit": 8.203125,
            "text": "oyl-CoA desaturase 1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.62109375,
            "text": "stearoyl-CoA desaturase 1 (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.71875,
            "text": "stearoyl-CoA desaturase 1 (SCD1)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.734375,
            "text": "stearoyl-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.8828125,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.984375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.98828125,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -6.9921875,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -7.0625,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -7.06640625,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -7.078125,
            "text": "stearoyl",
            "probability": 1.7881393432617188e-07
        }
    ],
    "61f7d683882a024a10000036_4": [
        {
            "start_logit": 8.8984375,
            "end_logit": 8.2734375,
            "text": "stearoyl-CoA desaturase 1",
            "probability": 0.7158203125
        },
        {
            "start_logit": 8.8984375,
            "end_logit": 7.34765625,
            "text": "stearoyl-CoA desaturase",
            "probability": 0.28466796875
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -2.03515625,
            "text": "stear",
            "probability": 2.378225326538086e-05
        },
        {
            "start_logit": -2.5546875,
            "end_logit": 8.2734375,
            "text": "1",
            "probability": 7.569789886474609e-06
        },
        {
            "start_logit": -3.470703125,
            "end_logit": 8.2734375,
            "text": "desaturase 1",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -3.470703125,
            "end_logit": 7.34765625,
            "text": "desaturase",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -5.6015625,
            "text": "stearoyl-CoA",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -5.78125,
            "text": "stearoyl-CoA desaturase 1 (SCD",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.08984375,
            "text": "stearoyl-CoA desaturase 1 (SCD1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.90625,
            "end_logit": 8.2734375,
            "text": "oyl-CoA desaturase 1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.66015625,
            "text": "stearoyl-CoA desaturase 1 (SCD1)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.7109375,
            "text": "stearoyl-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.734375,
            "text": "stearoyl-CoA desaturase 1 (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.828125,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.96484375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.33984375,
            "end_logit": 8.2734375,
            "text": "hepatic stearoyl-CoA desaturase 1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.96875,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.98828125,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.03125,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.0390625,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and",
            "probability": 1.7881393432617188e-07
        }
    ],
    "60527e8c94d57fd879000012_1": [
        {
            "start_logit": 9.328125,
            "end_logit": 9.0859375,
            "text": "phase IV",
            "probability": 1.0
        },
        {
            "start_logit": 9.328125,
            "end_logit": -0.7119140625,
            "text": "phase",
            "probability": 5.608797073364258e-05
        },
        {
            "start_logit": -1.0546875,
            "end_logit": 9.0859375,
            "text": "IV",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": -6.59765625,
            "end_logit": 9.0859375,
            "text": ", phase IV",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.0,
            "text": "phase IV,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.76171875,
            "end_logit": 9.0859375,
            "text": "In this longitudinal, 2-year prospective, phase IV",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.17578125,
            "text": "phase IV, single-blind study, 40 MS patients treated with fingolimod and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.328125,
            "end_logit": -7.21875,
            "text": "phase IV, single-blind study, 40 MS patients treated with fingolimod and 39 untreated age, gender, and disability-matched MS patients were",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 9.0859375,
            "text": "longitudinal, 2-year prospective, phase IV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 9.0859375,
            "text": "this longitudinal, 2-year prospective, phase IV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 9.0859375,
            "text": "2-year prospective, phase IV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 9.0859375,
            "text": ", 2-year prospective, phase IV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40625,
            "end_logit": 9.0859375,
            "text": "prospective, phase IV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.59765625,
            "end_logit": -0.7119140625,
            "text": ", phase",
            "probability": 0.0
        },
        {
            "start_logit": -6.76171875,
            "end_logit": -0.7119140625,
            "text": "In this longitudinal, 2-year prospective, phase",
            "probability": 0.0
        },
        {
            "start_logit": -7.23828125,
            "end_logit": -0.7119140625,
            "text": "longitudinal, 2-year prospective, phase",
            "probability": 0.0
        },
        {
            "start_logit": -7.2734375,
            "end_logit": -0.7119140625,
            "text": "this longitudinal, 2-year prospective, phase",
            "probability": 0.0
        },
        {
            "start_logit": -7.33203125,
            "end_logit": -0.7119140625,
            "text": "2-year prospective, phase",
            "probability": 0.0
        },
        {
            "start_logit": -7.3359375,
            "end_logit": -0.7119140625,
            "text": ", 2-year prospective, phase",
            "probability": 0.0
        },
        {
            "start_logit": -1.0546875,
            "end_logit": -7.0,
            "text": "IV,",
            "probability": 0.0
        }
    ],
    "56ffdc1ccf1c32585100000b_1": [
        {
            "start_logit": 7.37109375,
            "end_logit": 8.859375,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 0.74169921875
        },
        {
            "start_logit": 6.3203125,
            "end_logit": 8.859375,
            "text": "inosine",
            "probability": 0.25830078125
        },
        {
            "start_logit": -1.4169921875,
            "end_logit": 8.859375,
            "text": "adenosine is deaminated to inosine",
            "probability": 0.00011205673217773438
        },
        {
            "start_logit": -1.56640625,
            "end_logit": 8.859375,
            "text": "ine",
            "probability": 9.739398956298828e-05
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -0.60205078125,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.",
            "probability": 5.728006362915039e-05
        },
        {
            "start_logit": -2.333984375,
            "end_logit": 8.859375,
            "text": "One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 4.494190216064453e-05
        },
        {
            "start_logit": 6.3203125,
            "end_logit": -0.60205078125,
            "text": "inosine, which is read as guanosine during translation.",
            "probability": 2.008676528930664e-05
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -2.787109375,
            "text": "A-to-I editing",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -3.404296875,
            "text": "A",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -3.638671875,
            "text": "A-to-I editing,",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -4.05078125,
            "text": "A-to-I",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -4.515625,
            "text": "A-to-I editing, in which adenosine",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.13671875,
            "end_logit": 8.859375,
            "text": "deaminated to inosine",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.27734375,
            "end_logit": 8.859375,
            "text": "which adenosine is deaminated to inosine",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -4.80078125,
            "text": "A-to-I editing, in which adenosine is deaminated to",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 8.859375,
            "text": "-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -4.97265625,
            "text": "A-to-I editing, in which adenosine is deaminated to inos",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 8.859375,
            "text": "to inosine",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -5.39453125,
            "text": "A-to-I editing, in which adenosine is deaminated",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 8.859375,
            "text": "editing, in which adenosine is deaminated to inosine",
            "probability": 4.76837158203125e-07
        }
    ],
    "56ffdc1ccf1c32585100000b_2": [
        {
            "start_logit": 9.203125,
            "end_logit": 9.0078125,
            "text": "A-to-I",
            "probability": 1.0
        },
        {
            "start_logit": 9.203125,
            "end_logit": -1.3095703125,
            "text": "A",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": -1.25,
            "end_logit": 9.0078125,
            "text": "I",
            "probability": 2.86102294921875e-05
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.3671875,
            "text": "A-to-I editing",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.609375,
            "text": "A-to-I editing events in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 9.0078125,
            "text": "to-I",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.8046875,
            "text": "A-to-I editing events",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.8359375,
            "text": "A-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.89453125,
            "text": "A-to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 9.0078125,
            "text": "-I",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.00390625,
            "text": "A-to-I editing events in normal and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.09765625,
            "text": "A-to-I editing events in normal and cancerous human keratinocytes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.171875,
            "text": "A-to-I editing events in normal and cancerous human",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.1875,
            "text": "A-to-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.1953125,
            "text": "A-to-I editing events in normal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.22265625,
            "text": "A-to-I editing events in normal and cancerous",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21875,
            "end_logit": 9.0078125,
            "text": "-to-I",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.25,
            "end_logit": -6.3671875,
            "text": "I editing",
            "probability": 0.0
        },
        {
            "start_logit": -1.25,
            "end_logit": -6.609375,
            "text": "I editing events in",
            "probability": 0.0
        },
        {
            "start_logit": -1.25,
            "end_logit": -6.8046875,
            "text": "I editing events",
            "probability": 0.0
        }
    ],
    "56ffdc1ccf1c32585100000b_3": [
        {
            "start_logit": 9.2578125,
            "end_logit": 9.015625,
            "text": "A-to-I",
            "probability": 1.0
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -1.158203125,
            "text": "A",
            "probability": 3.790855407714844e-05
        },
        {
            "start_logit": -1.205078125,
            "end_logit": 9.015625,
            "text": "I",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -5.92578125,
            "text": "A-to-I RNA editing can alter codons, substitute amino acids and affect protein sequence, structure, and function.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.2734375,
            "text": "A-to-I RNA editing",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.30078125,
            "text": "A-to-I RNA editing can",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.6796875,
            "text": "A-to",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.69921875,
            "text": "A-to-I RNA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 9.015625,
            "text": "to-I",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.9765625,
            "text": "A-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -6.98046875,
            "text": "A-to-I RNA editing can alter codons, substitute amino acids and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.0234375,
            "text": "A-to-I RNA editing can alter codons,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 9.015625,
            "text": "-I",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.078125,
            "text": "A-to-I RNA editing can alter codons",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.09375,
            "text": "A-to-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.1015625,
            "text": "A-to-I RNA editing can alter",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.875,
            "end_logit": 9.015625,
            "text": "-to-I",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.140625,
            "text": "A-to-I RNA editing can alter codons, substitute amino acids and affect protein sequence, structure, and function",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.171875,
            "text": "A-to-I RNA editing can alter codons, substitute amino acids and affect protein sequence, structure, and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2578125,
            "end_logit": -7.1796875,
            "text": "A-to-I RNA editing can alter codons, substitute amino acids and affect protein sequence, structure,",
            "probability": 1.1920928955078125e-07
        }
    ],
    "56ffdc1ccf1c32585100000b_4": [
        {
            "start_logit": 9.2109375,
            "end_logit": 8.8359375,
            "text": "A-to-I",
            "probability": 1.0
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -1.3271484375,
            "text": "A",
            "probability": 3.8504600524902344e-05
        },
        {
            "start_logit": -1.685546875,
            "end_logit": 8.8359375,
            "text": "I",
            "probability": 1.8477439880371094e-05
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -4.25390625,
            "text": "A-to-I editing",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -6.25390625,
            "end_logit": 8.8359375,
            "text": "to-I",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 8.8359375,
            "text": "-to-I",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.7109375,
            "text": "A-to",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -6.8359375,
            "text": "A-to-I editing in",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.53515625,
            "end_logit": 8.8359375,
            "text": "-I",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.0234375,
            "text": "A-to-I editing in the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.05078125,
            "text": "A-to-I editing in the coding sequence",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.13671875,
            "text": "A-to-I editing in the coding sequence of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.14453125,
            "text": "A-to-I editing in the coding sequence of a tumor suppressor gene in humans,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.18359375,
            "text": "A-to-I editing in the coding sequence of a tumor suppressor gene in humans, and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.2265625,
            "text": "A-to-I editing in the coding sequence of a tumor suppressor gene in humans, and suggests that IGFBP7 editing serves as a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.25,
            "text": "A-to-I editing in the coding sequence of a tumor suppressor gene in humans, and suggests that IGFBP7 editing serves",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2109375,
            "end_logit": -7.26171875,
            "text": "A-to-I editing in the coding sequence of a tumor suppressor gene in humans, and suggests that IGFBP7",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 8.8359375,
            "text": "time A-to-I",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 8.8359375,
            "text": "describes for the first time A-to-I",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 8.8359375,
            "text": "This study describes for the first time A-to-I",
            "probability": 5.960464477539063e-08
        }
    ],
    "56ffdc1ccf1c32585100000b_5": [
        {
            "start_logit": 7.51953125,
            "end_logit": 8.6015625,
            "text": "adenosine-to-inosine",
            "probability": 0.9912109375
        },
        {
            "start_logit": 2.78125,
            "end_logit": 8.6015625,
            "text": "Adenosine deaminases that act on RNA (ADARs) catalyze the adenosine-to-inosine",
            "probability": 0.00864410400390625
        },
        {
            "start_logit": -1.53125,
            "end_logit": 8.6015625,
            "text": "ine",
            "probability": 0.00011581182479858398
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -1.75390625,
            "text": "adenosine-to-inosine (A-to-I) conversion, the most common type of RNA editing in higher eukaryotes.",
            "probability": 3.141164779663086e-05
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -2.83203125,
            "text": "adenosine-to-inosine (A-to-I) conversion",
            "probability": 1.0669231414794922e-05
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -2.92578125,
            "text": "adenosine-to-inosine (A-to-I",
            "probability": 9.775161743164062e-06
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -3.150390625,
            "text": "adenosine",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -5.046875,
            "end_logit": 8.6015625,
            "text": "ADARs) catalyze the adenosine-to-inosine",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -4.46875,
            "text": "adenosine-to-inosine (A",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -5.66796875,
            "end_logit": 8.6015625,
            "text": "inosine",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -4.68359375,
            "text": "adenosine-to-inosine (A-to",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -4.91015625,
            "text": "adenosine-to-inosine (A-to-I)",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -5.12890625,
            "text": "adenosine-to-inosine (",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -6.37890625,
            "end_logit": 8.6015625,
            "text": "(ADARs) catalyze the adenosine-to-inosine",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.48828125,
            "end_logit": 8.6015625,
            "text": "-to-inosine",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 8.6015625,
            "text": "-inosine",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 8.6015625,
            "text": "to-inosine",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -5.66796875,
            "text": "adenosine-to-inosine (A-to-I) conversion,",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.51953125,
            "end_logit": -5.80078125,
            "text": "adenosine-to",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.96875,
            "end_logit": 8.6015625,
            "text": "the adenosine-to-inosine",
            "probability": 5.364418029785156e-07
        }
    ],
    "56ffdc1ccf1c32585100000b_6": [
        {
            "start_logit": 8.0078125,
            "end_logit": 8.6484375,
            "text": "adenosine residue is base-modified to inosine",
            "probability": 0.9951171875
        },
        {
            "start_logit": 2.537109375,
            "end_logit": 8.6484375,
            "text": "inosine",
            "probability": 0.0041961669921875
        },
        {
            "start_logit": 8.0078125,
            "end_logit": 0.9814453125,
            "text": "adenosine",
            "probability": 0.00046706199645996094
        },
        {
            "start_logit": -2.1953125,
            "end_logit": 8.6484375,
            "text": "ine",
            "probability": 3.68952751159668e-05
        },
        {
            "start_logit": -4.203125,
            "end_logit": 8.6484375,
            "text": ". The most common RNA editing in the mammalian central nervous system is a base modification, where the adenosine residue is base-modified to inosine",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -5.671875,
            "text": "adenosine residue",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -5.82421875,
            "text": "adenosine residue is base-modified to inosine (A to I).",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.48046875,
            "end_logit": 8.6484375,
            "text": "where the adenosine residue is base-modified to inosine",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -5.8984375,
            "text": "adenosine residue is base-modified to",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.59375,
            "end_logit": 8.6484375,
            "text": "to inosine",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.62109375,
            "end_logit": 8.6484375,
            "text": "the adenosine residue is base-modified to inosine",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.37890625,
            "text": "adenosine residue is base-modified to inosine (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.54296875,
            "text": "adenosine residue is base-modified to inosine (A to I)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.56640625,
            "text": "adenosine residue is",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.57421875,
            "text": "adenosine residue is base-modified",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.65625,
            "text": "adenosine residue is base-modified to inosine (A to I",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 8.6484375,
            "text": "residue is base-modified to inosine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 8.6484375,
            "text": "a base modification, where the adenosine residue is base-modified to inosine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 8.6484375,
            "text": "is base-modified to inosine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.0078125,
            "end_logit": -6.83984375,
            "text": "adenosine residue is base-",
            "probability": 1.7881393432617188e-07
        }
    ],
    "56ffdc1ccf1c32585100000b_7": [
        {
            "start_logit": 8.3515625,
            "end_logit": 8.6171875,
            "text": "adenosine is deaminated to inosine",
            "probability": 0.97607421875
        },
        {
            "start_logit": 4.296875,
            "end_logit": 8.6171875,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 0.0169219970703125
        },
        {
            "start_logit": 3.083984375,
            "end_logit": 8.6171875,
            "text": "inosine",
            "probability": 0.00504302978515625
        },
        {
            "start_logit": 8.3515625,
            "end_logit": 2.080078125,
            "text": "adenosine",
            "probability": 0.00141143798828125
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -1.517578125,
            "text": "adenosine is deaminated to inosine, which is read as guanosine during translation.",
            "probability": 3.88026237487793e-05
        },
        {
            "start_logit": -1.953125,
            "end_logit": 8.6171875,
            "text": "ine",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 4.296875,
            "end_logit": 2.080078125,
            "text": "A-to-I editing, in which adenosine",
            "probability": 2.4497509002685547e-05
        },
        {
            "start_logit": -2.482421875,
            "end_logit": 8.6171875,
            "text": "One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 1.919269561767578e-05
        },
        {
            "start_logit": -4.33203125,
            "end_logit": 8.6171875,
            "text": ". One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -4.92578125,
            "text": "adenosine is deaminated to",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 4.296875,
            "end_logit": -0.95849609375,
            "text": "A-to-I editing",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -5.2109375,
            "text": "adenosine is deaminated",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 4.296875,
            "end_logit": -1.517578125,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -5.94921875,
            "end_logit": 8.6171875,
            "text": "to inosine",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.1328125,
            "end_logit": 8.6171875,
            "text": "-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -5.87890625,
            "text": "adenosine is",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 8.6171875,
            "text": "which adenosine is deaminated to inosine",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -6.234375,
            "text": "adenosine is deaminated to inosine,",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.5234375,
            "end_logit": 8.6171875,
            "text": "deaminated to inosine",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 8.6171875,
            "text": "to-I editing, in which adenosine is deaminated to inosine",
            "probability": 2.980232238769531e-07
        }
    ],
    "56ffdc1ccf1c32585100000b_8": [
        {
            "start_logit": 9.140625,
            "end_logit": 9.078125,
            "text": "inosine",
            "probability": 1.0
        },
        {
            "start_logit": -1.4091796875,
            "end_logit": 9.078125,
            "text": "ine",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -1.501953125,
            "text": "inos",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -4.3984375,
            "text": "inosine (A to I).",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -4.69921875,
            "end_logit": 9.078125,
            "text": "adenosine residue is base-modified to inosine",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -6.52734375,
            "text": "inosine (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -6.6640625,
            "text": "inosine (A to I)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -6.8359375,
            "text": "inosine (A to I",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 9.078125,
            "text": "The most common RNA editing in the mammalian central nervous system is a base modification, where the adenosine residue is base-modified to inosine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.265625,
            "end_logit": 9.078125,
            "text": "the adenosine residue is base-modified to inosine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 9.078125,
            "text": "to inosine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40625,
            "end_logit": 9.078125,
            "text": "where the adenosine residue is base-modified to inosine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5,
            "end_logit": 9.078125,
            "text": "residue is base-modified to inosine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 9.078125,
            "text": "base modification, where the adenosine residue is base-modified to inosine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.078125,
            "text": "RNA editing in the mammalian central nervous system is a base modification, where the adenosine residue is base-modified to inosine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 9.078125,
            "text": "in the mammalian central nervous system is a base modification, where the adenosine residue is base-modified to inosine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.4091796875,
            "end_logit": -4.3984375,
            "text": "ine (A to I).",
            "probability": 0.0
        },
        {
            "start_logit": -4.69921875,
            "end_logit": -1.501953125,
            "text": "adenosine residue is base-modified to inos",
            "probability": 0.0
        },
        {
            "start_logit": -1.4091796875,
            "end_logit": -6.52734375,
            "text": "ine (",
            "probability": 0.0
        },
        {
            "start_logit": -1.4091796875,
            "end_logit": -6.6640625,
            "text": "ine (A to I)",
            "probability": 0.0
        }
    ],
    "56ffdc1ccf1c32585100000b_9": [
        {
            "start_logit": 7.37109375,
            "end_logit": 8.859375,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 0.74169921875
        },
        {
            "start_logit": 6.3203125,
            "end_logit": 8.859375,
            "text": "inosine",
            "probability": 0.25830078125
        },
        {
            "start_logit": -1.4169921875,
            "end_logit": 8.859375,
            "text": "adenosine is deaminated to inosine",
            "probability": 0.00011205673217773438
        },
        {
            "start_logit": -1.56640625,
            "end_logit": 8.859375,
            "text": "ine",
            "probability": 9.739398956298828e-05
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -0.60205078125,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.",
            "probability": 5.728006362915039e-05
        },
        {
            "start_logit": -2.333984375,
            "end_logit": 8.859375,
            "text": "One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 4.494190216064453e-05
        },
        {
            "start_logit": 6.3203125,
            "end_logit": -0.60205078125,
            "text": "inosine, which is read as guanosine during translation.",
            "probability": 2.008676528930664e-05
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -2.787109375,
            "text": "A-to-I editing",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -3.404296875,
            "text": "A",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -3.638671875,
            "text": "A-to-I editing,",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -4.05078125,
            "text": "A-to-I",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -4.515625,
            "text": "A-to-I editing, in which adenosine",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.13671875,
            "end_logit": 8.859375,
            "text": "deaminated to inosine",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.27734375,
            "end_logit": 8.859375,
            "text": "which adenosine is deaminated to inosine",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -4.80078125,
            "text": "A-to-I editing, in which adenosine is deaminated to",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 8.859375,
            "text": "-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -4.97265625,
            "text": "A-to-I editing, in which adenosine is deaminated to inos",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 8.859375,
            "text": "to inosine",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.37109375,
            "end_logit": -5.39453125,
            "text": "A-to-I editing, in which adenosine is deaminated",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 8.859375,
            "text": "editing, in which adenosine is deaminated to inosine",
            "probability": 4.76837158203125e-07
        }
    ],
    "56ffdc1ccf1c32585100000b_10": [
        {
            "start_logit": 8.515625,
            "end_logit": 6.265625,
            "text": "adenosine",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.515625,
            "end_logit": -0.48828125,
            "text": "adenosine deamination (A-to-I",
            "probability": 0.0011701583862304688
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -0.48828125,
            "text": "A-to-I",
            "probability": 0.0001354217529296875
        },
        {
            "start_logit": 8.515625,
            "end_logit": -4.15234375,
            "text": "adenosine deamination",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": 8.515625,
            "end_logit": -4.89453125,
            "text": "adenosine deamination (A",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": 8.515625,
            "end_logit": -5.80078125,
            "text": "adenosine deamination (A-to-I)",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": 8.515625,
            "end_logit": -6.28125,
            "text": "adenosine de",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 8.515625,
            "end_logit": -6.44140625,
            "text": "adenosine deamination (A-to",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 8.515625,
            "end_logit": -6.4453125,
            "text": "adenosine deamination (",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 8.515625,
            "end_logit": -6.48046875,
            "text": "adenosine deamination (A-to-I) is",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 8.515625,
            "end_logit": -6.69921875,
            "text": "adenosine deamination (A-to-I) is widespread in humans and",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 8.515625,
            "end_logit": -6.78515625,
            "text": "adenosine deamination (A-to-I) is widespread",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 8.515625,
            "end_logit": -6.91015625,
            "text": "adenosine deamination (A-to-",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.02734375,
            "text": "adenosine deamination (A-to-I) is widespread in humans and can",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.03125,
            "text": "adenosine deamination (A-to-I) is widespread in humans and can lead to a",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -4.89453125,
            "text": "A",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.06640625,
            "text": "adenosine deamination (A-to-I) is widespread in",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 8.515625,
            "end_logit": -7.1328125,
            "text": "adenosine deamination (A-",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -5.80078125,
            "text": "A-to-I)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 6.36328125,
            "end_logit": -6.44140625,
            "text": "A-to",
            "probability": 3.5762786865234375e-07
        }
    ],
    "5a7d6287faa1ab7d2e00001c_1": [
        {
            "start_logit": 7.734375,
            "end_logit": -0.2218017578125,
            "text": "GDNF family receptor \u03b1-like (GFRAL)",
            "probability": 0.6640625
        },
        {
            "start_logit": 7.734375,
            "end_logit": -1.2353515625,
            "text": "GDNF family receptor \u03b1-like",
            "probability": 0.241455078125
        },
        {
            "start_logit": 7.734375,
            "end_logit": -2.759765625,
            "text": "GDNF family receptor \u03b1-like (GFRAL",
            "probability": 0.0526123046875
        },
        {
            "start_logit": 7.734375,
            "end_logit": -3.66015625,
            "text": "GDNF",
            "probability": 0.0213470458984375
        },
        {
            "start_logit": 7.734375,
            "end_logit": -5.234375,
            "text": "GDNF family receptor \u03b1-like (GFRAL) with",
            "probability": 0.004421234130859375
        },
        {
            "start_logit": 7.734375,
            "end_logit": -5.57421875,
            "text": "GDNF family receptor",
            "probability": 0.0031490325927734375
        },
        {
            "start_logit": 7.734375,
            "end_logit": -5.875,
            "text": "GDNF family receptor \u03b1",
            "probability": 0.002330780029296875
        },
        {
            "start_logit": 7.734375,
            "end_logit": -6.12109375,
            "text": "GDNF family receptor \u03b1-like (GFRAL) with high affinity, and",
            "probability": 0.0018224716186523438
        },
        {
            "start_logit": 7.734375,
            "end_logit": -6.234375,
            "text": "GDNF family receptor \u03b1-like (GFRAL) with high affinity,",
            "probability": 0.0016260147094726562
        },
        {
            "start_logit": 7.734375,
            "end_logit": -6.34375,
            "text": "GDNF family receptor \u03b1-like (GFR",
            "probability": 0.0014581680297851562
        },
        {
            "start_logit": 7.734375,
            "end_logit": -6.453125,
            "text": "GDNF family receptor \u03b1-like (GFRAL) with high",
            "probability": 0.0013074874877929688
        },
        {
            "start_logit": 7.734375,
            "end_logit": -6.5859375,
            "text": "GDNF family",
            "probability": 0.0011444091796875
        },
        {
            "start_logit": 7.734375,
            "end_logit": -6.66015625,
            "text": "GDNF family receptor \u03b1-like (GFRAL) with high affinity, and that GFRAL requires association with the coreceptor RET to",
            "probability": 0.0010623931884765625
        },
        {
            "start_logit": 7.734375,
            "end_logit": -6.72265625,
            "text": "GDNF family receptor \u03b1-like (GFRAL) with high affinity, and that GFRAL requires association with the coreceptor RET",
            "probability": 0.0009984970092773438
        },
        {
            "start_logit": 7.734375,
            "end_logit": -6.734375,
            "text": "GDNF family receptor \u03b1-",
            "probability": 0.0009870529174804688
        },
        {
            "start_logit": -1.5927734375,
            "end_logit": -0.2218017578125,
            "text": "GFRAL)",
            "probability": 5.900859832763672e-05
        },
        {
            "start_logit": -1.5927734375,
            "end_logit": -2.759765625,
            "text": "GFRAL",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -4.328125,
            "end_logit": -0.2218017578125,
            "text": "Here we show that GDF15 binds specifically to GDNF family receptor \u03b1-like (GFRAL)",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -4.328125,
            "end_logit": -1.2353515625,
            "text": "Here we show that GDF15 binds specifically to GDNF family receptor \u03b1-like",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -5.37109375,
            "end_logit": -0.2218017578125,
            "text": "(GFRAL)",
            "probability": 1.3709068298339844e-06
        }
    ],
    "5abcf0b0fcf4565872000024_1": [
        {
            "start_logit": 9.1171875,
            "end_logit": 8.84375,
            "text": "Leishmania species",
            "probability": 1.0
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.5107421875,
            "text": "Leishmania",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": -1.783203125,
            "end_logit": 8.84375,
            "text": "species",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.50390625,
            "text": "Leishmania species cause leishmaniasis, a disease that ranges from self-healing but scarring cutaneous lesions to",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.63671875,
            "text": "Leishmania species cause",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.7578125,
            "text": "Leishmania species cause leishmaniasis, a disease that",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.7578125,
            "text": "Leishmania species cause leishmaniasis,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.79296875,
            "text": "Leishmania species cause leishmaniasis, a",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.85546875,
            "text": "Leishmania species cause leishmaniasis, a disease that ranges from self-healing but scarring cutaneous lesions to fatal visceral leishmaniasis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.90234375,
            "text": "Leishmania species cause leishmaniasis, a disease that ranges from self-healing but scarring cutaneous lesions to fatal visceral leishmaniasis in which parasites disseminate to the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.90625,
            "text": "Leishmania species cause leishmaniasis, a disease that ranges from self-healing but scarring cutaneous lesions",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.921875,
            "text": "Leishmania species cause leishmaniasis, a disease that ranges",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.921875,
            "text": "Leishmania species cause leishmaniasis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.9609375,
            "text": "Leishmania species cause leishmaniasis, a disease that ranges from self-healing but scarring cutaneous lesions to fatal visceral leishmaniasis in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.96875,
            "text": "Leishmania species cause leishmaniasis, a disease",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.015625,
            "text": "Leishmania species cause leishmaniasis, a disease that ranges from self-healing but",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 8.84375,
            "text": ", Leishmania species",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.02734375,
            "text": "Leishmania species cause leishmaniasis, a disease that ranges from self-healing but scarring cutaneous lesions to fatal visceral leishmaniasis in which parasites disseminate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 8.84375,
            "text": "Finally, Leishmania species",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.74609375,
            "end_logit": -1.5107421875,
            "text": ", Leishmania",
            "probability": 0.0
        }
    ],
    "5abcf0b0fcf4565872000024_2": [
        {
            "start_logit": 7.87109375,
            "end_logit": 3.56640625,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for visceral leishmaniasis (VL).",
            "probability": 0.947265625
        },
        {
            "start_logit": 7.87109375,
            "end_logit": 0.50341796875,
            "text": "Leishmania species",
            "probability": 0.0443115234375
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -1.451171875,
            "text": "Leishmania",
            "probability": 0.006282806396484375
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -4.37109375,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for visceral leishmaniasis",
            "probability": 0.0003383159637451172
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -4.78125,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than",
            "probability": 0.00022530555725097656
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -5.23828125,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are",
            "probability": 0.00014221668243408203
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -5.23828125,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL)",
            "probability": 0.00014221668243408203
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -5.4140625,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for visceral leishmaniasis (VL",
            "probability": 0.00011879205703735352
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -5.4296875,
            "text": "Leishmania species causing cutaneous leishmaniasis (",
            "probability": 0.00011688470840454102
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -5.5078125,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III)",
            "probability": 0.0001081228256225586
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -5.6484375,
            "text": "Leishmania species causing",
            "probability": 9.393692016601562e-05
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -5.75390625,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more",
            "probability": 8.487701416015625e-05
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -5.80859375,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for visceral leishmaniasis (VL)",
            "probability": 8.034706115722656e-05
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -5.81640625,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL",
            "probability": 7.975101470947266e-05
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -6.02734375,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the",
            "probability": 6.455183029174805e-05
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -6.09765625,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III",
            "probability": 6.020069122314453e-05
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -6.1015625,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for",
            "probability": 5.9664249420166016e-05
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -6.109375,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb",
            "probability": 5.9664249420166016e-05
        },
        {
            "start_logit": 7.87109375,
            "end_logit": -6.11328125,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for visceral leishmaniasis (",
            "probability": 5.924701690673828e-05
        },
        {
            "start_logit": -1.935546875,
            "end_logit": 3.56640625,
            "text": "cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for visceral leishmaniasis (VL).",
            "probability": 5.227327346801758e-05
        }
    ],
    "5abcf0b0fcf4565872000024_3": [
        {
            "start_logit": 9.03125,
            "end_logit": 7.4609375,
            "text": "Leishmania viannia braziliensis",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.03125,
            "end_logit": -0.2978515625,
            "text": "Leishmania viannia braziliensis complex parasites. L. braziliensis and Leishmania viannia peruviana are the 2 predominant Leishmania species in Peru.",
            "probability": 0.00042366981506347656
        },
        {
            "start_logit": 9.03125,
            "end_logit": -0.298583984375,
            "text": "Leishmania viannia braziliensis complex parasites.",
            "probability": 0.00042366981506347656
        },
        {
            "start_logit": 9.03125,
            "end_logit": -1.6689453125,
            "text": "Leishmania",
            "probability": 0.00010710954666137695
        },
        {
            "start_logit": 9.03125,
            "end_logit": -3.328125,
            "text": "Leishmania viannia brazil",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 9.03125,
            "end_logit": -4.09375,
            "text": "Leishmania viannia braziliensis complex",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -4.95703125,
            "text": "Leishmania viannia braziliensis complex parasites",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": -3.537109375,
            "end_logit": 7.4609375,
            "text": "Tegumentary leishmaniasis in Latin America is caused mainly by Leishmania viannia braziliensis",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -3.591796875,
            "end_logit": 7.4609375,
            "text": "iensis",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -5.56640625,
            "text": "Leishmania viannia",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -5.73828125,
            "text": "Leishmania viannia braziliensis complex parasites. L. braziliensis and Leishmania viannia peruviana are the 2 predominant Leishmania species in Peru",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -5.78125,
            "text": "Leishmania viann",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 9.03125,
            "end_logit": -6.41015625,
            "text": "Leishmania viannia braziliensis complex parasites. L. braziliensis",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.3828125,
            "end_logit": 7.4609375,
            "text": "viannia braziliensis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4453125,
            "end_logit": 7.4609375,
            "text": "leishmaniasis in Latin America is caused mainly by Leishmania viannia braziliensis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.48828125,
            "end_logit": 7.4609375,
            "text": "ary leishmaniasis in Latin America is caused mainly by Leishmania viannia braziliensis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.5234375,
            "end_logit": 7.4609375,
            "text": "umentary leishmaniasis in Latin America is caused mainly by Leishmania viannia braziliensis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 7.4609375,
            "text": "in Latin America is caused mainly by Leishmania viannia braziliensis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.05078125,
            "end_logit": 7.4609375,
            "text": "by Leishmania viannia braziliensis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 7.4609375,
            "text": "ia braziliensis",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5abcf0b0fcf4565872000024_4": [
        {
            "start_logit": 9.2890625,
            "end_logit": 8.640625,
            "text": "Leishmania species",
            "probability": 1.0
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -0.95361328125,
            "text": "Leishmania",
            "probability": 6.765127182006836e-05
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -2.12109375,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-PCR) in Kharve, Iran.",
            "probability": 2.110004425048828e-05
        },
        {
            "start_logit": -2.1640625,
            "end_logit": 8.640625,
            "text": "species",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -5.80078125,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-PCR)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -5.859375,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-PCR) in Kharve, Iran",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.00390625,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.0625,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-PCR",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.5,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-PCR) in Kharve",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.53125,
            "text": "Leishmania species causing",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.609375,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-PCR) in Kharve,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.6171875,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.6171875,
            "text": "Leishmania species causing cutaneous leishmaniasis using",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.7890625,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.84375,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.8671875,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.875,
            "text": "Leishmania species causing cutaneous leishmaniasis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.88671875,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 8.640625,
            "text": "Identification of Leishmania species",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 8.640625,
            "text": "of Leishmania species",
            "probability": 5.960464477539063e-08
        }
    ],
    "550c4011a103b78016000009_1": [
        {
            "start_logit": 8.7734375,
            "end_logit": 8.875,
            "text": "serine 129",
            "probability": 1.0
        },
        {
            "start_logit": -1.80859375,
            "end_logit": 8.875,
            "text": "129",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -1.984375,
            "text": "serine",
            "probability": 1.9073486328125e-05
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -4.765625,
            "text": "serine 129 (S129)",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -5.546875,
            "text": "serine 129 (S129",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -6.06640625,
            "text": "serine 129 (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -6.51953125,
            "text": "serine 129 (S1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -6.63671875,
            "text": "serine 129 (S129) is",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -6.7734375,
            "text": "serine 129 (S129) is highly",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.0,
            "end_logit": 8.875,
            "text": "at serine 129",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.10546875,
            "text": "serine 129 (S129) is highly elevated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.23828125,
            "text": "serine 129 (S129) is highly elevated in Parkinson",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.30078125,
            "text": "serine 129 (S129) is highly elevated in Parkinson's disease patients where it",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.7734375,
            "end_logit": -7.3125,
            "text": "serine 129 (S129) is highly elevated in Parkinson'",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.875,
            "text": "phosphorylated at serine 129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.80859375,
            "end_logit": -4.765625,
            "text": "129 (S129)",
            "probability": 0.0
        },
        {
            "start_logit": -1.80859375,
            "end_logit": -5.546875,
            "text": "129 (S129",
            "probability": 0.0
        },
        {
            "start_logit": -1.80859375,
            "end_logit": -6.06640625,
            "text": "129 (",
            "probability": 0.0
        },
        {
            "start_logit": -1.80859375,
            "end_logit": -6.51953125,
            "text": "129 (S1",
            "probability": 0.0
        },
        {
            "start_logit": -1.80859375,
            "end_logit": -6.63671875,
            "text": "129 (S129) is",
            "probability": 0.0
        }
    ],
    "550c4011a103b78016000009_2": [
        {
            "start_logit": 8.796875,
            "end_logit": 8.6015625,
            "text": "serine 129",
            "probability": 0.98193359375
        },
        {
            "start_logit": 8.796875,
            "end_logit": 4.625,
            "text": "serine 129 (Ser129",
            "probability": 0.0182647705078125
        },
        {
            "start_logit": 8.796875,
            "end_logit": -1.5693359375,
            "text": "serine",
            "probability": 3.719329833984375e-05
        },
        {
            "start_logit": -2.19140625,
            "end_logit": 8.6015625,
            "text": "129",
            "probability": 1.6391277313232422e-05
        },
        {
            "start_logit": 8.796875,
            "end_logit": -3.609375,
            "text": "serine 129 (Ser",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 8.796875,
            "end_logit": -4.07421875,
            "text": "serine 129 (Ser129)",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 8.796875,
            "end_logit": -4.30078125,
            "text": "serine 129 (Ser12",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 8.796875,
            "end_logit": -5.73046875,
            "text": "serine 129 (Ser129).",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.078125,
            "end_logit": 8.6015625,
            "text": "at serine 129",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -2.19140625,
            "end_logit": 4.625,
            "text": "129 (Ser129",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -6.51953125,
            "text": "serine 129 (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.796875,
            "end_logit": -6.5390625,
            "text": "serine 129 (Ser129). In contrast, only 4% or less of total \u03b1-syn is phosphorylated at this residue in the normal brain",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.58203125,
            "end_logit": 8.6015625,
            "text": "90% of \u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 8.6015625,
            "text": "Approximately 90% of \u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 8.6015625,
            "text": "\u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 8.6015625,
            "text": "phosphorylated at serine 129",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.31640625,
            "end_logit": 4.625,
            "text": "Ser129",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 8.6015625,
            "text": "of \u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.6484375,
            "end_logit": 4.625,
            "text": "(Ser129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.88671875,
            "end_logit": 4.625,
            "text": "9",
            "probability": 0.0
        }
    ],
    "550c4011a103b78016000009_3": [
        {
            "start_logit": 8.90625,
            "end_logit": 8.8203125,
            "text": "serine 129",
            "probability": 1.0
        },
        {
            "start_logit": 8.90625,
            "end_logit": -1.7578125,
            "text": "serine",
            "probability": 2.568960189819336e-05
        },
        {
            "start_logit": -1.9013671875,
            "end_logit": 8.8203125,
            "text": "129",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 8.90625,
            "end_logit": -4.12890625,
            "text": "serine 129 (Ser129)",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 8.90625,
            "end_logit": -5.10546875,
            "text": "serine 129 (Ser129",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -5.9609375,
            "text": "serine 129 (Ser12",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -6.4609375,
            "text": "serine 129 (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -6.4921875,
            "text": "serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -6.671875,
            "text": "serine 129 (Ser",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 8.8203125,
            "text": "at serine 129",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.046875,
            "text": "serine 129 (Ser129) in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.2734375,
            "text": "serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies. These inclusion bodies are the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.28515625,
            "text": "serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies. These",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": 8.8203125,
            "text": "phosphorylated at serine 129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40625,
            "end_logit": 8.8203125,
            "text": "Alpha-synuclein is phosphorylated at serine 129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.9013671875,
            "end_logit": -4.12890625,
            "text": "129 (Ser129)",
            "probability": 0.0
        },
        {
            "start_logit": -1.9013671875,
            "end_logit": -5.10546875,
            "text": "129 (Ser129",
            "probability": 0.0
        },
        {
            "start_logit": -1.9013671875,
            "end_logit": -5.9609375,
            "text": "129 (Ser12",
            "probability": 0.0
        },
        {
            "start_logit": -1.9013671875,
            "end_logit": -6.4609375,
            "text": "129 (",
            "probability": 0.0
        },
        {
            "start_logit": -1.9013671875,
            "end_logit": -6.4921875,
            "text": "129 (Ser129) in intracellular protein aggregates called Lewy bodies.",
            "probability": 0.0
        }
    ],
    "550c4011a103b78016000009_4": [
        {
            "start_logit": 9.09375,
            "end_logit": 8.9375,
            "text": "serine 129",
            "probability": 1.0
        },
        {
            "start_logit": 9.09375,
            "end_logit": -1.4541015625,
            "text": "serine",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": -1.6953125,
            "end_logit": 8.9375,
            "text": "129",
            "probability": 2.0623207092285156e-05
        },
        {
            "start_logit": 9.09375,
            "end_logit": -4.8359375,
            "text": "serine 129 (Ser129)",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 9.09375,
            "end_logit": -5.4765625,
            "text": "serine 129 (Ser129",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.140625,
            "text": "serine 129 (Ser12",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.2578125,
            "text": "serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.5546875,
            "text": "serine 129 (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.734375,
            "text": "serine 129 (Ser",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -6.921875,
            "text": "serine 129 (Ser129) in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.96875,
            "end_logit": 8.9375,
            "text": "at serine 129",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.09375,
            "end_logit": -7.3359375,
            "text": "serine 129 (Ser129) in intracellular protein aggregates",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 8.9375,
            "text": "phosphorylated at serine 129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 8.9375,
            "text": "Alpha-synuclein is phosphorylated at serine 129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 8.9375,
            "text": "-synuclein is phosphorylated at serine 129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -4.8359375,
            "text": "129 (Ser129)",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -5.4765625,
            "text": "129 (Ser129",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -6.140625,
            "text": "129 (Ser12",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -6.2578125,
            "text": "129 (Ser129) in intracellular protein aggregates called Lewy bodies.",
            "probability": 0.0
        },
        {
            "start_logit": -1.6953125,
            "end_logit": -6.5546875,
            "text": "129 (",
            "probability": 0.0
        }
    ],
    "550c4011a103b78016000009_5": [
        {
            "start_logit": 8.984375,
            "end_logit": 8.8984375,
            "text": "serine 129",
            "probability": 1.0
        },
        {
            "start_logit": 8.984375,
            "end_logit": -1.3720703125,
            "text": "serine 129 (Ser129",
            "probability": 3.4809112548828125e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -1.5283203125,
            "text": "serine",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": -1.65234375,
            "end_logit": 8.8984375,
            "text": "129",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -3.654296875,
            "text": "serine 129 (Ser129)",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 8.984375,
            "end_logit": -5.328125,
            "text": "serine 129 (Ser129).",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -5.72265625,
            "text": "serine 129 (Ser12",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.24609375,
            "end_logit": 8.8984375,
            "text": "at serine 129",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.43359375,
            "text": "serine 129 (Ser",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.5390625,
            "text": "serine 129 (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 8.8984375,
            "text": "\u00ce\u00b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 8.8984375,
            "text": "90% of \u00ce\u00b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 8.8984375,
            "text": "phosphorylated at serine 129",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.15625,
            "end_logit": 8.8984375,
            "text": "of \u00ce\u00b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1875,
            "end_logit": 8.8984375,
            "text": "Approximately 90% of \u00ce\u00b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 8.8984375,
            "text": "in Lewy bodies is phosphorylated at serine 129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 8.8984375,
            "text": "Lewy bodies is phosphorylated at serine 129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 8.8984375,
            "text": "\u00b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 8.8984375,
            "text": "bodies is phosphorylated at serine 129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 8.8984375,
            "text": "-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 5.960464477539063e-08
        }
    ],
    "550c4011a103b78016000009_6": [
        {
            "start_logit": 8.8125,
            "end_logit": 8.84375,
            "text": "serine 129",
            "probability": 1.0
        },
        {
            "start_logit": -1.84375,
            "end_logit": 8.84375,
            "text": "129",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": 8.8125,
            "end_logit": -1.900390625,
            "text": "serine",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": 8.8125,
            "end_logit": -5.44921875,
            "text": "serine 129 (Ser129)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -5.85546875,
            "text": "serine 129 (Ser129",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -6.21875,
            "text": "serine 129 (Ser12",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -6.62890625,
            "text": "serine 129 (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -6.80078125,
            "text": "serine 129 (Ser",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.90625,
            "end_logit": 8.84375,
            "text": "at serine 129",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.05859375,
            "text": "serine 129 (Ser129) in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 8.84375,
            "text": "phosphorylated at serine 129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.84375,
            "end_logit": -5.44921875,
            "text": "129 (Ser129)",
            "probability": 0.0
        },
        {
            "start_logit": -1.84375,
            "end_logit": -5.85546875,
            "text": "129 (Ser129",
            "probability": 0.0
        },
        {
            "start_logit": -1.84375,
            "end_logit": -6.21875,
            "text": "129 (Ser12",
            "probability": 0.0
        },
        {
            "start_logit": -1.84375,
            "end_logit": -6.62890625,
            "text": "129 (",
            "probability": 0.0
        },
        {
            "start_logit": -1.84375,
            "end_logit": -6.80078125,
            "text": "129 (Ser",
            "probability": 0.0
        },
        {
            "start_logit": -6.90625,
            "end_logit": -1.900390625,
            "text": "at serine",
            "probability": 0.0
        },
        {
            "start_logit": -1.84375,
            "end_logit": -7.05859375,
            "text": "129 (Ser129) in",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -1.900390625,
            "text": "phosphorylated at serine",
            "probability": 0.0
        },
        {
            "start_logit": -6.26171875,
            "end_logit": -5.44921875,
            "text": "(Ser129)",
            "probability": 0.0
        }
    ],
    "56d19a363975bb303a000017_1": [
        {
            "start_logit": 2.20703125,
            "end_logit": 8.984375,
            "text": "MDM two binding protein (MTBP)",
            "probability": 0.9482421875
        },
        {
            "start_logit": -1.591796875,
            "end_logit": 8.984375,
            "text": ")",
            "probability": 0.0212860107421875
        },
        {
            "start_logit": -1.875,
            "end_logit": 8.984375,
            "text": "We identified MDM two binding protein (MTBP)",
            "probability": 0.01605224609375
        },
        {
            "start_logit": -2.6484375,
            "end_logit": 8.984375,
            "text": "(MTBP)",
            "probability": 0.00740814208984375
        },
        {
            "start_logit": -3.21875,
            "end_logit": 8.984375,
            "text": "identified MDM two binding protein (MTBP)",
            "probability": 0.00418853759765625
        },
        {
            "start_logit": -4.25,
            "end_logit": 8.984375,
            "text": "MTBP)",
            "probability": 0.0014934539794921875
        },
        {
            "start_logit": -4.859375,
            "end_logit": 8.984375,
            "text": "protein (MTBP)",
            "probability": 0.0008120536804199219
        },
        {
            "start_logit": -5.80078125,
            "end_logit": 8.984375,
            "text": "M two binding protein (MTBP)",
            "probability": 0.0003180503845214844
        },
        {
            "start_logit": -5.83984375,
            "end_logit": 8.984375,
            "text": "P)",
            "probability": 0.00030350685119628906
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 8.984375,
            "text": "binding protein (MTBP)",
            "probability": 0.00022912025451660156
        },
        {
            "start_logit": 2.20703125,
            "end_logit": -2.99609375,
            "text": "MDM two binding protein (MTBP) as",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -1.748046875,
            "end_logit": -1.19921875,
            "text": "p53",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 2.20703125,
            "end_logit": -5.23828125,
            "text": "MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR throughout the cell cycle.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 2.20703125,
            "end_logit": -5.83203125,
            "text": "MDM two binding protein (MTBP) as a",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 2.20703125,
            "end_logit": -6.1328125,
            "text": "MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR throughout",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 2.20703125,
            "end_logit": -6.18359375,
            "text": "MDM two binding protein (MTBP) as a factor",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 2.20703125,
            "end_logit": -6.38671875,
            "text": "MD",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 2.20703125,
            "end_logit": -6.38671875,
            "text": "MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR throughout the cell cycle",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -3.248046875,
            "end_logit": -1.19921875,
            "text": ". Although MTBP has been implicated in the function of the p53",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.591796875,
            "end_logit": -2.99609375,
            "text": ") as",
            "probability": 1.1920928955078125e-07
        }
    ],
    "56d19a363975bb303a000017_2": [
        {
            "start_logit": 4.37890625,
            "end_logit": 9.2265625,
            "text": "MDM two binding protein (MTBP)",
            "probability": 0.9951171875
        },
        {
            "start_logit": -1.0478515625,
            "end_logit": 9.2265625,
            "text": ")",
            "probability": 0.004360198974609375
        },
        {
            "start_logit": -4.03125,
            "end_logit": 9.2265625,
            "text": "identified MDM two binding protein (MTBP)",
            "probability": 0.0002206563949584961
        },
        {
            "start_logit": -5.07421875,
            "end_logit": 9.2265625,
            "text": "We identified MDM two binding protein (MTBP)",
            "probability": 7.808208465576172e-05
        },
        {
            "start_logit": -6.0078125,
            "end_logit": 9.2265625,
            "text": "protein (MTBP)",
            "probability": 3.0517578125e-05
        },
        {
            "start_logit": -6.29296875,
            "end_logit": 9.2265625,
            "text": "P)",
            "probability": 2.3066997528076172e-05
        },
        {
            "start_logit": -6.421875,
            "end_logit": 9.2265625,
            "text": "(MTBP)",
            "probability": 2.0205974578857422e-05
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 9.2265625,
            "text": "M two binding protein (MTBP)",
            "probability": 1.537799835205078e-05
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 9.2265625,
            "text": "MTBP)",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -7.25,
            "end_logit": 9.2265625,
            "text": "binding protein (MTBP)",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 9.2265625,
            "text": "two binding protein (MTBP)",
            "probability": 8.58306884765625e-06
        },
        {
            "start_logit": 4.37890625,
            "end_logit": -3.236328125,
            "text": "MDM two binding protein (MTBP) as",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 4.37890625,
            "end_logit": -5.8515625,
            "text": "MDM two binding protein (MTBP) as a",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 4.37890625,
            "end_logit": -6.20703125,
            "text": "MD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.37890625,
            "end_logit": -6.40234375,
            "text": "MDM two binding protein (MTBP) as a factor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.37890625,
            "end_logit": -6.4296875,
            "text": "MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR throughout",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.37890625,
            "end_logit": -6.50390625,
            "text": "MDM two binding protein (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.37890625,
            "end_logit": -6.6953125,
            "text": "MDM two",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.37890625,
            "end_logit": -6.71875,
            "text": "MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR throughout the cell cycle",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.37890625,
            "end_logit": -6.7734375,
            "text": "MDM",
            "probability": 1.1920928955078125e-07
        }
    ],
    "56d19a363975bb303a000017_3": [
        {
            "start_logit": 5.74609375,
            "end_logit": 8.5859375,
            "text": "DNA replication factor that is regulated by cyclin-dependent kinases and the DNA damage checkpoint. We identified MDM two binding protein (MTBP)",
            "probability": 0.9892578125
        },
        {
            "start_logit": 5.74609375,
            "end_logit": 4.0234375,
            "text": "DNA replication factor",
            "probability": 0.01032257080078125
        },
        {
            "start_logit": -2.05078125,
            "end_logit": 8.5859375,
            "text": ")",
            "probability": 0.00040841102600097656
        },
        {
            "start_logit": -3.541015625,
            "end_logit": 8.5859375,
            "text": "identified MDM two binding protein (MTBP)",
            "probability": 9.21487808227539e-05
        },
        {
            "start_logit": 0.89208984375,
            "end_logit": 4.0234375,
            "text": "Sld3 protein, is an essential DNA replication factor",
            "probability": 8.064508438110352e-05
        },
        {
            "start_logit": -3.830078125,
            "end_logit": 8.5859375,
            "text": ". We identified MDM two binding protein (MTBP)",
            "probability": 6.908178329467773e-05
        },
        {
            "start_logit": -5.5078125,
            "end_logit": 8.5859375,
            "text": "factor that is regulated by cyclin-dependent kinases and the DNA damage checkpoint. We identified MDM two binding protein (MTBP)",
            "probability": 1.2874603271484375e-05
        },
        {
            "start_logit": -5.58203125,
            "end_logit": 8.5859375,
            "text": "protein (MTBP)",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -5.92578125,
            "end_logit": 8.5859375,
            "text": "replication factor that is regulated by cyclin-dependent kinases and the DNA damage checkpoint. We identified MDM two binding protein (MTBP)",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": -5.93359375,
            "end_logit": 8.5859375,
            "text": "essential DNA replication factor that is regulated by cyclin-dependent kinases and the DNA damage checkpoint. We identified MDM two binding protein (MTBP)",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": -6.26953125,
            "end_logit": 8.5859375,
            "text": "MDM two binding protein (MTBP)",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": 5.74609375,
            "end_logit": -3.712890625,
            "text": "DNA replication factor that is regulated by cyclin-dependent kinases and the DNA damage checkpoint.",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": 5.74609375,
            "end_logit": -4.578125,
            "text": "DNA",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 5.74609375,
            "end_logit": -4.64453125,
            "text": "DNA replication factor that",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 5.74609375,
            "end_logit": -4.84765625,
            "text": "DNA replication factor that is regulated by cyclin-dependent kinases and the DNA damage checkpoint. We identified MDM two binding protein (MTBP) as",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 5.74609375,
            "end_logit": -5.70703125,
            "text": "DNA replication",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 5.74609375,
            "end_logit": -5.81640625,
            "text": "DNA replication factor that is regulated by cyclin-dependent kinases and the DNA damage checkpoint. We",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.5078125,
            "end_logit": 4.0234375,
            "text": "factor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.55859375,
            "end_logit": 4.0234375,
            "text": "yeast Sld3 protein, is an essential DNA replication factor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.92578125,
            "end_logit": 4.0234375,
            "text": "replication factor",
            "probability": 5.960464477539063e-08
        }
    ],
    "620c28d03a8413c653000007_1": [
        {
            "start_logit": 8.6015625,
            "end_logit": 8.9140625,
            "text": "myeloid leukaemia",
            "probability": 1.0
        },
        {
            "start_logit": -1.734375,
            "end_logit": 8.9140625,
            "text": "leukaemia",
            "probability": 3.24249267578125e-05
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -2.455078125,
            "text": "myeloid",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 8.9140625,
            "text": "against myeloid leukaemia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.6015625,
            "end_logit": -7.01953125,
            "text": "myeloid leukaemia.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.34375,
            "end_logit": 8.9140625,
            "text": "Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.453125,
            "end_logit": 8.9140625,
            "text": "of METTL3 as a strategy against myeloid leukaemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 8.9140625,
            "text": "strategy against myeloid leukaemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 8.9140625,
            "text": "-molecule inhibition of METTL3 as a strategy against myeloid leukaemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 8.9140625,
            "text": "TL3 as a strategy against myeloid leukaemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 8.9140625,
            "text": "inhibition of METTL3 as a strategy against myeloid leukaemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 8.9140625,
            "text": "molecule inhibition of METTL3 as a strategy against myeloid leukaemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 8.9140625,
            "text": "a strategy against myeloid leukaemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 8.9140625,
            "text": "3 as a strategy against myeloid leukaemia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.734375,
            "end_logit": -7.01953125,
            "text": "leukaemia.",
            "probability": 0.0
        },
        {
            "start_logit": -6.8046875,
            "end_logit": -2.455078125,
            "text": "against myeloid",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -2.455078125,
            "text": "Small-molecule inhibition of METTL3 as a strategy against myeloid",
            "probability": 0.0
        },
        {
            "start_logit": -7.453125,
            "end_logit": -2.455078125,
            "text": "of METTL3 as a strategy against myeloid",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -2.455078125,
            "text": "strategy against myeloid",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -2.455078125,
            "text": "-molecule inhibition of METTL3 as a strategy against myeloid",
            "probability": 0.0
        }
    ],
    "5ad6e431133db5eb7800000e_1": [
        {
            "start_logit": 8.75,
            "end_logit": 3.810546875,
            "text": "Ishihara test",
            "probability": 0.7509765625
        },
        {
            "start_logit": 8.75,
            "end_logit": 2.69921875,
            "text": "Ishihara",
            "probability": 0.24755859375
        },
        {
            "start_logit": 8.75,
            "end_logit": -2.40234375,
            "text": "Ish",
            "probability": 0.0015010833740234375
        },
        {
            "start_logit": 8.75,
            "end_logit": -6.52734375,
            "text": "Ishih",
            "probability": 2.4139881134033203e-05
        },
        {
            "start_logit": -5.95703125,
            "end_logit": 3.810546875,
            "text": "test",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.51953125,
            "end_logit": 3.810546875,
            "text": "ara test",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 3.810546875,
            "text": "ihara test",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 3.810546875,
            "text": "the Ishihara test",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 3.810546875,
            "text": "on the Ishihara test",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.51953125,
            "end_logit": 2.69921875,
            "text": "ara",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 2.69921875,
            "text": "ihara",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": 2.69921875,
            "text": "the Ishihara",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 2.69921875,
            "text": "on the Ishihara",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.328125,
            "end_logit": -2.40234375,
            "text": "the Ish",
            "probability": 0.0
        },
        {
            "start_logit": -7.41796875,
            "end_logit": -2.40234375,
            "text": "on the Ish",
            "probability": 0.0
        },
        {
            "start_logit": -6.60546875,
            "end_logit": -6.52734375,
            "text": "ih",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -6.52734375,
            "text": "the Ishih",
            "probability": 0.0
        },
        {
            "start_logit": -7.41796875,
            "end_logit": -6.52734375,
            "text": "on the Ishih",
            "probability": 0.0
        },
        {
            "start_logit": -7.41796875,
            "end_logit": -7.15625,
            "text": "on",
            "probability": 0.0
        },
        {
            "start_logit": -7.328125,
            "end_logit": -7.26171875,
            "text": "the",
            "probability": 0.0
        }
    ],
    "5ad6e431133db5eb7800000e_2": [
        {
            "start_logit": 8.96875,
            "end_logit": 8.9453125,
            "text": "Ishihara",
            "probability": 1.0
        },
        {
            "start_logit": -1.70703125,
            "end_logit": 8.9453125,
            "text": "ara",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": 8.96875,
            "end_logit": -1.9482421875,
            "text": "Ish",
            "probability": 1.8656253814697266e-05
        },
        {
            "start_logit": 8.96875,
            "end_logit": -4.828125,
            "text": "Ishihara test",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -5.67578125,
            "end_logit": 8.9453125,
            "text": "ihara",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -5.74609375,
            "text": "Ishihara test cards (1987",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -5.86328125,
            "text": "Ishihara test cards",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.15625,
            "text": "Ishihara test cards (1987).",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.61328125,
            "text": "Ishihara test cards (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.96875,
            "end_logit": -6.79296875,
            "text": "Ishihara test cards (1987)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 8.9453125,
            "text": "the Ishihara",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 8.9453125,
            "text": "using the Ishihara",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.9453125,
            "text": ", using the Ishihara",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.70703125,
            "end_logit": -4.828125,
            "text": "ara test",
            "probability": 0.0
        },
        {
            "start_logit": -1.70703125,
            "end_logit": -5.74609375,
            "text": "ara test cards (1987",
            "probability": 0.0
        },
        {
            "start_logit": -1.70703125,
            "end_logit": -5.86328125,
            "text": "ara test cards",
            "probability": 0.0
        },
        {
            "start_logit": -1.70703125,
            "end_logit": -6.15625,
            "text": "ara test cards (1987).",
            "probability": 0.0
        },
        {
            "start_logit": -1.70703125,
            "end_logit": -6.61328125,
            "text": "ara test cards (",
            "probability": 0.0
        },
        {
            "start_logit": -1.70703125,
            "end_logit": -6.79296875,
            "text": "ara test cards (1987)",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": -1.9482421875,
            "text": "the Ish",
            "probability": 0.0
        }
    ],
    "5ad6e431133db5eb7800000e_3": [
        {
            "start_logit": 9.046875,
            "end_logit": 7.07421875,
            "text": "Ishihara Test",
            "probability": 0.96435546875
        },
        {
            "start_logit": 9.046875,
            "end_logit": 3.775390625,
            "text": "Ishihara",
            "probability": 0.035400390625
        },
        {
            "start_logit": 9.046875,
            "end_logit": -1.787109375,
            "text": "Ish",
            "probability": 0.00013589859008789062
        },
        {
            "start_logit": -4.00390625,
            "end_logit": 7.07421875,
            "text": "Test",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.78125,
            "text": "Ishih",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.078125,
            "text": "Ishihara Test.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -5.578125,
            "end_logit": 7.07421875,
            "text": "ara Test",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.203125,
            "end_logit": 7.07421875,
            "text": "ihara Test",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 7.07421875,
            "text": "by Ishihara Test",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.578125,
            "end_logit": 3.775390625,
            "text": "ara",
            "probability": 0.0
        },
        {
            "start_logit": -6.203125,
            "end_logit": 3.775390625,
            "text": "ihara",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 3.775390625,
            "text": "by Ishihara",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -1.787109375,
            "text": "by Ish",
            "probability": 0.0
        },
        {
            "start_logit": -4.00390625,
            "end_logit": -7.078125,
            "text": "Test.",
            "probability": 0.0
        },
        {
            "start_logit": -4.28515625,
            "end_logit": -7.078125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.578125,
            "end_logit": -7.078125,
            "text": "ara Test.",
            "probability": 0.0
        },
        {
            "start_logit": -6.203125,
            "end_logit": -6.78125,
            "text": "ih",
            "probability": 0.0
        },
        {
            "start_logit": -6.203125,
            "end_logit": -7.078125,
            "text": "ihara Test.",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -6.78125,
            "text": "by Ishih",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": -6.78125,
            "text": "A cross-sectional descriptive and analytical study was conducted",
            "probability": 0.0
        }
    ],
    "5321bc309b2d7acc7e00000d_1": [
        {
            "start_logit": 9.15625,
            "end_logit": 9.078125,
            "text": "PI3K-\u03b4",
            "probability": 1.0
        },
        {
            "start_logit": 9.15625,
            "end_logit": -1.490234375,
            "text": "PI3K",
            "probability": 2.568960189819336e-05
        },
        {
            "start_logit": -1.455078125,
            "end_logit": 9.078125,
            "text": "\u03b4",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": -6.125,
            "end_logit": 9.078125,
            "text": "-\u03b4",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -6.9921875,
            "text": "PI3K-\u03b4 inhibitor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.01171875,
            "text": "PI3K-\u03b4 inhibitor ide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.08984375,
            "text": "PI3K-\u03b4 inhibitor idelalisib",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.09375,
            "text": "PI3K-\u03b4 inhibitor idelalisi",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.1328125,
            "text": "PI3K-\u03b4 inhibitor idela",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -7.16015625,
            "text": "PI3K-\u03b4 inhibitor idelali",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.455078125,
            "end_logit": -6.9921875,
            "text": "\u03b4 inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -1.455078125,
            "end_logit": -7.01171875,
            "text": "\u03b4 inhibitor ide",
            "probability": 0.0
        },
        {
            "start_logit": -1.455078125,
            "end_logit": -7.08984375,
            "text": "\u03b4 inhibitor idelalisib",
            "probability": 0.0
        },
        {
            "start_logit": -1.455078125,
            "end_logit": -7.09375,
            "text": "\u03b4 inhibitor idelalisi",
            "probability": 0.0
        },
        {
            "start_logit": -1.455078125,
            "end_logit": -7.1328125,
            "text": "\u03b4 inhibitor idela",
            "probability": 0.0
        },
        {
            "start_logit": -1.455078125,
            "end_logit": -7.16015625,
            "text": "\u03b4 inhibitor idelali",
            "probability": 0.0
        },
        {
            "start_logit": -6.125,
            "end_logit": -6.9921875,
            "text": "-\u03b4 inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -6.125,
            "end_logit": -7.01171875,
            "text": "-\u03b4 inhibitor ide",
            "probability": 0.0
        },
        {
            "start_logit": -6.125,
            "end_logit": -7.08984375,
            "text": "-\u03b4 inhibitor idelalisib",
            "probability": 0.0
        },
        {
            "start_logit": -6.125,
            "end_logit": -7.09375,
            "text": "-\u03b4 inhibitor idelalisi",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_1": [
        {
            "start_logit": 7.52734375,
            "end_logit": 7.75,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -6.58203125,
            "text": "BRAF inhibitors",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 7.75,
            "text": "the BRAF",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -6.94921875,
            "text": "BRAF inhibitors (BRAF",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.04296875,
            "text": "BRAF inhibitors (BRAFi) vemurafenib",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.07421875,
            "text": "BRAF inhibitors (BRAFi) ve",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.10546875,
            "text": "BRAF inhibitors (BRAFi",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.171875,
            "text": "BRAF inhibitors (BRAFi) vemurafenib (PLX4032), dabrafenib, or encorafenib with",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 7.75,
            "text": ", combination of the BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.1953125,
            "text": "BRAF inhibitors (BRAFi) vemurafenib (PLX4032)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.203125,
            "text": "BRAF inhibitors (BRAFi) vemurafenib (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -7.203125,
            "text": "BRAF inhibitors (BRAFi)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 7.75,
            "text": "Importantly, combination of the BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.515625,
            "end_logit": 7.75,
            "text": "of the BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.33203125,
            "end_logit": -6.64453125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -6.0,
            "text": "EGFR",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -6.421875,
            "text": "EGFR and HER2",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -6.64453125,
            "text": "EGFR and HER2 (such as lapatinib, canertinib, and afatinib) significantly reduced the metabolic activity and proliferative potential of CRC cells.",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -6.0,
            "text": "the EGFR",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -6.83203125,
            "text": "EGFR and",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_2": [
        {
            "start_logit": 8.0234375,
            "end_logit": 7.94140625,
            "text": "novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF",
            "probability": 0.8447265625
        },
        {
            "start_logit": 5.96875,
            "end_logit": 7.94140625,
            "text": "BRAF",
            "probability": 0.10736083984375
        },
        {
            "start_logit": 8.0234375,
            "end_logit": 4.515625,
            "text": "novel V-Raf Murine Sarcoma Viral Oncogene Homolog B",
            "probability": 0.0273895263671875
        },
        {
            "start_logit": 4.2578125,
            "end_logit": 7.94140625,
            "text": "V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF",
            "probability": 0.019561767578125
        },
        {
            "start_logit": 4.2578125,
            "end_logit": 4.515625,
            "text": "V-Raf Murine Sarcoma Viral Oncogene Homolog B",
            "probability": 0.0006337165832519531
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -2.37109375,
            "text": "novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF)",
            "probability": 2.8073787689208984e-05
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -2.908203125,
            "text": "novel",
            "probability": 1.6391277313232422e-05
        },
        {
            "start_logit": 5.96875,
            "end_logit": -2.37109375,
            "text": "BRAF)",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -5.70703125,
            "end_logit": 7.94140625,
            "text": "B (BRAF",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -5.74609375,
            "end_logit": 7.94140625,
            "text": "(BRAF",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -5.83203125,
            "end_logit": 7.94140625,
            "text": "-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 4.2578125,
            "end_logit": -2.37109375,
            "text": "V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.28125,
            "end_logit": 7.94140625,
            "text": "Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -6.52734375,
            "text": "novel V",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -6.54296875,
            "text": "novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF)-inhibitor",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 7.94140625,
            "text": "Murine Sarcoma Viral Oncogene Homolog B (BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -6.84765625,
            "text": "novel V-Raf Murine Sarcoma Viral Oncogene Homolog",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -6.8828125,
            "text": "novel V-Raf Murine Sarcoma Viral Oncogene",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -6.8984375,
            "text": "novel V-Raf Murine Sarcoma Viral",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.0234375,
            "end_logit": -6.921875,
            "text": "novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF)-",
            "probability": 2.980232238769531e-07
        }
    ],
    "5e319789fbd6abf43b00004a_3": [
        {
            "start_logit": 7.31640625,
            "end_logit": 8.015625,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 8.015625,
            "text": "a BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -7.29296875,
            "text": "BRAF inhibitor",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -7.32421875,
            "text": "BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -7.3359375,
            "text": "BRAF inhibitor with",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -7.34375,
            "text": "BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -7.3515625,
            "text": "BRAF inhibitor with unique target-binding properties",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -7.35546875,
            "text": "BRAF inhibitor with unique target-binding properties,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -7.390625,
            "text": "BRAF inhibitor with unique target-binding properties, alone",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -7.41796875,
            "text": "BRAF inhibitor with unique target-",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.31640625,
            "end_logit": -7.4296875,
            "text": "BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.23828125,
            "end_logit": -7.171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.53125,
            "end_logit": -7.171875,
            "text": "advanced BRAFV600-mutant melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -7.171875,
            "text": "imetinib, versus vemurafenib in patients with advanced BRAFV600-mutant melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -7.171875,
            "text": "binimetinib, versus vemurafenib in patients with advanced BRAFV600-mutant melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -7.171875,
            "text": "BRAFV600-mutant melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": -7.171875,
            "text": "patients with advanced BRAFV600-mutant melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": -7.171875,
            "text": "with advanced BRAFV600-mutant melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": -7.171875,
            "text": "with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAFV600-mutant melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -7.171875,
            "text": "in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAFV600-mutant melanoma.",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_4": [
        {
            "start_logit": 7.56640625,
            "end_logit": 7.71875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.0390625,
            "text": "BRAF mutant cells. Cell lines and PDXs were treated with BRAF",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.05859375,
            "text": "BRAF mutant cells.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.26171875,
            "text": "BRAF mutant cells. Cell lines and PDXs were treated with BRAFi (vemurafenib, dabrafenib",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.29296875,
            "text": "BRAF mutant cells. Cell lines and PDXs were treated with BRAFi (ve",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.30078125,
            "text": "BRAF mutant cells. Cell lines and PDXs were treated with BRAFi (vemurafenib",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.71875,
            "text": ") mutations and compared these with WT or V600E/K BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 7.71875,
            "text": "-loop) mutations and compared these with WT or V600E/K BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.33984375,
            "text": "BRAF mutant cells. Cell lines and PDXs were treated with BRAFi",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.33984375,
            "text": "BRAF mutant cells. Cell lines and PDXs were treated with BRAFi (vemurafenib,",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.36328125,
            "text": "BRAF mutant cells. Cell lines and PDXs were treated with BRAFi (vemurafenib, dab",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.1953125,
            "end_logit": -6.80859375,
            "text": ". We identified 2 patients with BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -4.1953125,
            "end_logit": -7.0390625,
            "text": ". Cell lines and PDXs were treated with BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -4.1953125,
            "end_logit": -7.05859375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.1953125,
            "end_logit": -7.05859375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.1953125,
            "end_logit": -7.05859375,
            "text": ". We identified 2 patients with BRAF L597S metastatic melanoma who were treated with dMAPKi.",
            "probability": 0.0
        },
        {
            "start_logit": -4.1953125,
            "end_logit": -7.05859375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.1953125,
            "end_logit": -7.21484375,
            "text": ". We identified 2 patients with BRAF L597S metastatic melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -4.1953125,
            "end_logit": -7.26171875,
            "text": ". Cell lines and PDXs were treated with BRAFi (vemurafenib, dabrafenib",
            "probability": 0.0
        },
        {
            "start_logit": -4.1953125,
            "end_logit": -7.29296875,
            "text": ". Cell lines and PDXs were treated with BRAFi (ve",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_5": [
        {
            "start_logit": 9.8203125,
            "end_logit": 8.6328125,
            "text": "BRAF/MEK",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.8203125,
            "end_logit": 2.048828125,
            "text": "BRAF",
            "probability": 0.0013790130615234375
        },
        {
            "start_logit": -2.220703125,
            "end_logit": 8.6328125,
            "text": "MEK",
            "probability": 5.900859832763672e-06
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -6.8359375,
            "text": "BRAF/MEK inhibitor",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.14453125,
            "text": "BRAF/MEK inhibitor combination enc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.15625,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or inoperable melanoma with a BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.17578125,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or inoperable melanoma with a BRAF V600E or",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.18359375,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or inoperable melanoma with a BRAF V600",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.19140625,
            "text": "BRAF/MEK inhibitor combination encorafenib",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.1953125,
            "text": "BRAF/MEK inhibitor combination",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.203125,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or inoperable melanoma with a BRAF V600E",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.2265625,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or inoperable melanoma with a BRAF V",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.2265625,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or inoperable melanoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.23046875,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8203125,
            "end_logit": -7.234375,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 8.6328125,
            "text": "/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 8.6328125,
            "text": "The FDA approved the BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 8.6328125,
            "text": "FDA approved the BRAF/MEK",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": 8.6328125,
            "text": "the BRAF/MEK",
            "probability": 0.0
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 2.048828125,
            "text": "The FDA approved the BRAF",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_6": [
        {
            "start_logit": 7.421875,
            "end_logit": 7.03125,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 7.421875,
            "end_logit": -3.421875,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK",
            "probability": 2.8848648071289062e-05
        },
        {
            "start_logit": 7.421875,
            "end_logit": -6.7421875,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally bioavailable drugs developed by Array BioPharma.",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 7.421875,
            "end_logit": -6.83984375,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally bioavailable drugs developed by Array BioPharma",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -6.87109375,
            "text": "BRAF inhibitor,",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.484375,
            "end_logit": 7.03125,
            "text": "a BRAF",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -6.96875,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -6.99609375,
            "text": "BRAF inhibitor, and binimetinib (Mek",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.015625,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.0390625,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.0390625,
            "text": "BRAF inhibitor, and",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.0625,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally bioavailable drugs developed by Array BioP",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.078125,
            "text": "BRAF inhibitor",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.0859375,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally bioavailable drugs developed by Array BioPhar",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.09375,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.1015625,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally bioavailable drugs developed",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.1015625,
            "text": "BRAF inhibitor, and binimetinib",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.1171875,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor,",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 7.03125,
            "text": "Braftovi\u2122), a BRAF",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.3515625,
            "end_logit": 7.03125,
            "text": ", a BRAF",
            "probability": 3.5762786865234375e-07
        }
    ],
    "5e319789fbd6abf43b00004a_7": [
        {
            "start_logit": 7.44140625,
            "end_logit": 7.91796875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 7.44140625,
            "end_logit": -6.9296875,
            "text": "BRAF mutations",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 7.91796875,
            "text": "with BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 7.91796875,
            "text": "metastatic melanoma with BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.91796875,
            "text": "melanoma with BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.44140625,
            "end_logit": -7.0390625,
            "text": "BRAF mutations.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 7.91796875,
            "text": "binimetinib for unresectable or metastatic melanoma with BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 7.91796875,
            "text": "or metastatic melanoma with BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 7.91796875,
            "text": "orafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 7.91796875,
            "text": "Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 7.91796875,
            "text": "imetinib for unresectable or metastatic melanoma with BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 7.91796875,
            "text": "unresectable or metastatic melanoma with BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 7.91796875,
            "text": "fenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.91796875,
            "text": "tinib for unresectable or metastatic melanoma with BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.59375,
            "end_logit": 7.91796875,
            "text": "with binimetinib for unresectable or metastatic melanoma with BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 7.91796875,
            "text": "combination with binimetinib for unresectable or metastatic melanoma with BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 7.91796875,
            "text": "ib in combination with binimetinib for unresectable or metastatic melanoma with BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.61328125,
            "end_logit": -7.0390625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.41015625,
            "end_logit": -6.9296875,
            "text": "with BRAF mutations",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": -6.9296875,
            "text": "metastatic melanoma with BRAF mutations",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_8": [
        {
            "start_logit": 9.0703125,
            "end_logit": 9.2578125,
            "text": "BRAF/MEK",
            "probability": 1.0
        },
        {
            "start_logit": -0.432861328125,
            "end_logit": 9.2578125,
            "text": "MEK",
            "probability": 7.486343383789062e-05
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -0.935546875,
            "text": "BRAF",
            "probability": 3.737211227416992e-05
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -5.8984375,
            "text": "BRAF/MEK inhibitor combinations.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.1484375,
            "end_logit": 9.2578125,
            "text": "/MEK",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -6.60546875,
            "text": "BRAF/MEK inhibitor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0703125,
            "end_logit": -6.9765625,
            "text": "BRAF/MEK inhibitor combinations",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 9.2578125,
            "text": "tinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 9.2578125,
            "text": "binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 9.2578125,
            "text": "imetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 9.2578125,
            "text": "established BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.453125,
            "end_logit": 9.2578125,
            "text": "to established BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 9.2578125,
            "text": "Encorafenib plus binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.2578125,
            "text": "orafenib plus binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.2578125,
            "text": "therapeutic alternative to established BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.2578125,
            "text": "likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.2578125,
            "text": "fenib plus binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 9.2578125,
            "text": "plus binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.432861328125,
            "end_logit": -5.8984375,
            "text": "MEK inhibitor combinations.",
            "probability": 0.0
        },
        {
            "start_logit": -0.432861328125,
            "end_logit": -6.60546875,
            "text": "MEK inhibitor",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_9": [
        {
            "start_logit": 7.2734375,
            "end_logit": 8.0546875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 8.0546875,
            "text": "to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 8.0546875,
            "text": "improved efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 8.0546875,
            "text": "efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 8.0546875,
            "text": ", with prolonged binding to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.0546875,
            "text": "target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.0546875,
            "text": "binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 8.0546875,
            "text": "the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.0546875,
            "text": "orafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 8.0546875,
            "text": "This improved efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 8.0546875,
            "text": "encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 8.0546875,
            "text": "pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.71875,
            "end_logit": 8.0546875,
            "text": "fenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 8.0546875,
            "text": "prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -6.984375,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same class.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.25,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.26171875,
            "text": "BRAF inhibition",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.2734375,
            "text": "BRAF inhibition and increased potency compared",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.28125,
            "text": "BRAF inhibition and increased potency compared with",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.30078125,
            "text": "BRAF inhibition and increased potency compared with other drugs in the",
            "probability": 2.384185791015625e-07
        }
    ],
    "5e319789fbd6abf43b00004a_10": [
        {
            "start_logit": 9.59375,
            "end_logit": 9.0390625,
            "text": "BRAF/MEK",
            "probability": 1.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -0.028106689453125,
            "text": "BRAF",
            "probability": 0.00011593103408813477
        },
        {
            "start_logit": -1.283203125,
            "end_logit": 9.0390625,
            "text": "MEK",
            "probability": 1.9073486328125e-05
        },
        {
            "start_logit": 9.59375,
            "end_logit": -6.53515625,
            "text": "BRAF/MEK inhibitor combinations.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.203125,
            "end_logit": 9.0390625,
            "text": "Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.59375,
            "end_logit": -6.8046875,
            "text": "BRAF/MEK inhibitor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.09375,
            "text": "BRAF/MEK inhibitor combinations",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.69140625,
            "end_logit": 9.0390625,
            "text": "/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 9.0390625,
            "text": "etinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.0390625,
            "text": "covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.0390625,
            "text": "nib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.0390625,
            "text": "that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.0390625,
            "text": "existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.0390625,
            "text": "bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.0390625,
            "text": "approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.0390625,
            "text": "b offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.0390625,
            "text": "Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 9.0390625,
            "text": "may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.0390625,
            "text": "orafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 9.0390625,
            "text": "new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e319789fbd6abf43b00004a_11": [
        {
            "start_logit": 7.41796875,
            "end_logit": 7.9296875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 7.9296875,
            "text": "generation BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.9296875,
            "text": "818) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 7.9296875,
            "text": "-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 7.9296875,
            "text": "X818) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 7.9296875,
            "text": "new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.640625,
            "end_logit": 7.9296875,
            "text": "a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 7.9296875,
            "text": "LGX818) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 7.9296875,
            "text": ") is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 7.9296875,
            "text": "Encorafenib (LGX818) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 7.9296875,
            "text": "8) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 7.9296875,
            "text": "orafenib (LGX818) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 7.9296875,
            "text": "is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 7.9296875,
            "text": "fenib (LGX818) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.21875,
            "text": "BRAF inhibitor that is",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.23828125,
            "text": "BRAF inhibitor that",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.2421875,
            "text": "BRAF inhibitor that is under",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.25,
            "text": "BRAF inhibitor that is under evaluation in clinical trials.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.296875,
            "text": "BRAF inhibitor",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.3046875,
            "text": "BRAF inhibitor that is under evaluation",
            "probability": 2.384185791015625e-07
        }
    ],
    "5e319789fbd6abf43b00004a_12": [
        {
            "start_logit": 8.4453125,
            "end_logit": 7.36328125,
            "text": "BRAF/MEK",
            "probability": 1.0
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -2.23046875,
            "text": "BRAF",
            "probability": 6.812810897827148e-05
        },
        {
            "start_logit": -3.701171875,
            "end_logit": 7.36328125,
            "text": "MEK",
            "probability": 5.304813385009766e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -5.140625,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -5.46875,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.08203125,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.59375,
            "text": "BRAF/MEK inhibitor",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.81640625,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma treated",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.8203125,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.87890625,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.96484375,
            "text": "BRAF/MEK inhibitor combinations have",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -7.0078125,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 7.36328125,
            "text": "/MEK",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 7.36328125,
            "text": "While other BRAF/MEK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 7.36328125,
            "text": "Expert Opinion: While other BRAF/MEK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 7.36328125,
            "text": "other BRAF/MEK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 7.36328125,
            "text": ": While other BRAF/MEK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.701171875,
            "end_logit": -5.140625,
            "text": "MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -3.701171875,
            "end_logit": -5.46875,
            "text": "MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -6.9921875,
            "end_logit": -2.23046875,
            "text": "While other BRAF",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_13": [
        {
            "start_logit": 7.8828125,
            "end_logit": 7.3984375,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -4.88671875,
            "text": "BRAF __sup__ V600E",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.72265625,
            "text": "BRAF __sup__ V600E _",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.92578125,
            "text": "BRAF _",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.95703125,
            "text": "BRAF __sup__ V600E __end_sup__  inhibitor that has efficacy against metastatic melanoma.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.95703125,
            "text": "BRAF __sup__ V600E __end_sup__  inhibitor that has efficacy against metastatic melanoma",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.125,
            "text": "BRAF __sup__ V600E __",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.1640625,
            "text": "BRAF __sup__ V600E __end_sup__  inhibitor that has efficacy",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.171875,
            "text": "BRAF __",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.1875,
            "text": "BRAF __sup__ V600E __end_sup__  inhibitor that has",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.19140625,
            "text": "BRAF __sup__ V600E __end_sup__  inhibitor that",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.19921875,
            "text": "BRAF __sup",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.2265625,
            "text": "BRAF __sup__ V600E __end_sup__",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.234375,
            "text": "BRAF __sup__ V600E __end_sup_",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 7.3984375,
            "text": "promising BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 7.3984375,
            "text": "X818) is a promising BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.3984375,
            "text": "(LGX818) is a promising BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 7.3984375,
            "text": "818) is a promising BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 7.3984375,
            "text": "Encorafenib (LGX818) is a promising BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 7.3984375,
            "text": "LGX818) is a promising BRAF",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5e319789fbd6abf43b00004a_14": [
        {
            "start_logit": 7.57421875,
            "end_logit": 7.7890625,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.12109375,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.13671875,
            "text": "BRAF inhibitor",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.20703125,
            "text": "BRAF inhibitor (BRAFi)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.25,
            "text": "BRAF inhibitor (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.2578125,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.2734375,
            "text": "BRAF inhibitor (BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.2734375,
            "text": "BRAF inhibitor (BRAFi",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.28125,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.28515625,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.28515625,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.29296875,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.296875,
            "text": "BRAF inhibitor (BRAFi),",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.30078125,
            "text": "BRAF inhibitor (BRAFi), has a",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.3125,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.31640625,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.3203125,
            "text": "BRAF inhibitor (BRAFi), has",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.7890625,
            "text": "selective BRAF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.703125,
            "end_logit": 7.7890625,
            "text": "Purpose:  Encorafenib, a selective BRAF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 7.7890625,
            "text": ":  Encorafenib, a selective BRAF",
            "probability": 2.384185791015625e-07
        }
    ],
    "5e319789fbd6abf43b00004a_15": [
        {
            "start_logit": 9.4609375,
            "end_logit": -0.2802734375,
            "text": "BRAF",
            "probability": 0.97314453125
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -5.3125,
            "text": "BRAF V600E/K-mutated melanoma",
            "probability": 0.00635528564453125
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -5.51171875,
            "text": "BRAF V600E",
            "probability": 0.00521087646484375
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -6.01953125,
            "text": "BRAF V600",
            "probability": 0.0031337738037109375
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -6.3046875,
            "text": "BRAF V600E/",
            "probability": 0.0023555755615234375
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -6.3359375,
            "text": "BRAF V600E/K-mutated melanoma.",
            "probability": 0.0022830963134765625
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -6.3515625,
            "text": "BRAF V600E/K",
            "probability": 0.0022487640380859375
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -6.48046875,
            "text": "BRAF V",
            "probability": 0.0019779205322265625
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -6.75390625,
            "text": "BRAF V600E/K-",
            "probability": 0.0015039443969726562
        },
        {
            "start_logit": 9.4609375,
            "end_logit": -6.875,
            "text": "BRAF V600E/K-mutated",
            "probability": 0.0013322830200195312
        },
        {
            "start_logit": -7.4375,
            "end_logit": -0.2802734375,
            "text": "binimetinib for the treatment of BRAF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44140625,
            "end_logit": -0.2802734375,
            "text": "Encorafenib and binimetinib for the treatment of BRAF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46484375,
            "end_logit": -0.2802734375,
            "text": "of BRAF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -0.2802734375,
            "text": "imetinib for the treatment of BRAF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -0.2802734375,
            "text": "tinib for the treatment of BRAF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -0.2802734375,
            "text": "orafenib and binimetinib for the treatment of BRAF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.21484375,
            "end_logit": -6.3359375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": -5.3125,
            "text": "V600E/K-mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": -5.51171875,
            "text": "V600E",
            "probability": 0.0
        },
        {
            "start_logit": -7.41015625,
            "end_logit": -5.3125,
            "text": "mutated melanoma",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_16": [
        {
            "start_logit": 8.15625,
            "end_logit": 6.5546875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 8.15625,
            "end_logit": -3.705078125,
            "text": "BRAF and MEK",
            "probability": 3.510713577270508e-05
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.3671875,
            "text": "BRAF and MEK, respectively",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.6484375,
            "text": "BRAF and MEK, respectively.",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.90625,
            "text": "BRAF and MEK,",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.9140625,
            "text": "BRAF and",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 6.5546875,
            "text": "of BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.96875,
            "end_logit": 6.5546875,
            "text": ", Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 6.5546875,
            "text": "small-molecule inhibitors of BRAF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 6.5546875,
            "text": "binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 6.5546875,
            "text": "Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 6.5546875,
            "text": ") and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 6.5546875,
            "text": "imetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 6.5546875,
            "text": "(MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 6.5546875,
            "text": "and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.88671875,
            "end_logit": -3.705078125,
            "text": "of BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": -3.705078125,
            "text": ", Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -7.109375,
            "end_logit": -3.705078125,
            "text": "small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -3.705078125,
            "text": "binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -7.2734375,
            "end_logit": -3.705078125,
            "text": "Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_17": [
        {
            "start_logit": 8.15625,
            "end_logit": 6.5546875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 8.15625,
            "end_logit": -3.705078125,
            "text": "BRAF and MEK",
            "probability": 3.510713577270508e-05
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.3671875,
            "text": "BRAF and MEK , respectively",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.6484375,
            "text": "BRAF and MEK , respectively .",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.90625,
            "text": "BRAF and MEK ,",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.9140625,
            "text": "BRAF and",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 6.5546875,
            "text": "of BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.96875,
            "end_logit": 6.5546875,
            "text": ", Braftovi ) and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 6.5546875,
            "text": "small-molecule inhibitors of BRAF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 6.5546875,
            "text": "binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 6.5546875,
            "text": "Braftovi ) and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 6.5546875,
            "text": ") and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 6.5546875,
            "text": "imetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 6.5546875,
            "text": "( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 6.5546875,
            "text": "and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.88671875,
            "end_logit": -3.705078125,
            "text": "of BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": -3.705078125,
            "text": ", Braftovi ) and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -7.109375,
            "end_logit": -3.705078125,
            "text": "small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -3.705078125,
            "text": "binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -7.2734375,
            "end_logit": -3.705078125,
            "text": "Braftovi ) and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_18": [
        {
            "start_logit": 7.2734375,
            "end_logit": 8.0546875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 8.0546875,
            "text": "to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 8.0546875,
            "text": "improved efficacy may be related to the distinct pharmacokinetics of encorafenib , with prolonged binding to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 8.0546875,
            "text": "efficacy may be related to the distinct pharmacokinetics of encorafenib , with prolonged binding to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 8.0546875,
            "text": ", with prolonged binding to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.0546875,
            "text": "target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.0546875,
            "text": "binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 8.0546875,
            "text": "the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.0546875,
            "text": "orafenib , with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 8.0546875,
            "text": "This improved efficacy may be related to the distinct pharmacokinetics of encorafenib , with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 8.0546875,
            "text": "encorafenib , with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 8.0546875,
            "text": "pharmacokinetics of encorafenib , with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.71875,
            "end_logit": 8.0546875,
            "text": "fenib , with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 8.0546875,
            "text": "prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -6.984375,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same class .",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.25,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.26171875,
            "text": "BRAF inhibition",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.2734375,
            "text": "BRAF inhibition and increased potency compared",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.28125,
            "text": "BRAF inhibition and increased potency compared with",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.30078125,
            "text": "BRAF inhibition and increased potency compared with other drugs in the",
            "probability": 2.384185791015625e-07
        }
    ],
    "5e319789fbd6abf43b00004a_19": [
        {
            "start_logit": 0.654296875,
            "end_logit": 3.28515625,
            "text": "binimetinib",
            "probability": 0.3330078125
        },
        {
            "start_logit": 7.25,
            "end_logit": -3.70703125,
            "text": "BRAF",
            "probability": 0.22412109375
        },
        {
            "start_logit": 7.25,
            "end_logit": -4.41015625,
            "text": "BRAF V600E",
            "probability": 0.11090087890625
        },
        {
            "start_logit": 7.25,
            "end_logit": -4.43359375,
            "text": "BRAF V600E/K-mutated melanoma",
            "probability": 0.10833740234375
        },
        {
            "start_logit": 7.25,
            "end_logit": -5.22265625,
            "text": "BRAF V600E/K-mutated melanoma in June 2018 .",
            "probability": 0.04925537109375
        },
        {
            "start_logit": 7.25,
            "end_logit": -5.3046875,
            "text": "BRAF V600E/K",
            "probability": 0.04534912109375
        },
        {
            "start_logit": 7.25,
            "end_logit": -5.69140625,
            "text": "BRAF V600",
            "probability": 0.0308074951171875
        },
        {
            "start_logit": 7.25,
            "end_logit": -5.80859375,
            "text": "BRAF V600E/",
            "probability": 0.02740478515625
        },
        {
            "start_logit": 7.25,
            "end_logit": -6.13671875,
            "text": "BRAF V600E/K-",
            "probability": 0.0197296142578125
        },
        {
            "start_logit": 7.25,
            "end_logit": -6.25,
            "text": "BRAF V",
            "probability": 0.0176239013671875
        },
        {
            "start_logit": 7.25,
            "end_logit": -6.25390625,
            "text": "BRAF V600E/K-mutated melanoma in",
            "probability": 0.017547607421875
        },
        {
            "start_logit": 7.25,
            "end_logit": -6.46484375,
            "text": "BRAF V600E/K-mutated",
            "probability": 0.01421356201171875
        },
        {
            "start_logit": 0.654296875,
            "end_logit": -3.70703125,
            "text": "binimetinib are the newest combination , which received approval by the Food and Drug Administration ( FDA ) for the treatment of BRAF",
            "probability": 0.00030612945556640625
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 3.28515625,
            "text": "tinib",
            "probability": 0.00019156932830810547
        },
        {
            "start_logit": -6.84375,
            "end_logit": 3.28515625,
            "text": "imetinib",
            "probability": 0.0001842975616455078
        },
        {
            "start_logit": -6.96875,
            "end_logit": 3.28515625,
            "text": "Of these inhibitors , encorafenib and binimetinib",
            "probability": 0.00016260147094726562
        },
        {
            "start_logit": 0.654296875,
            "end_logit": -4.41015625,
            "text": "binimetinib are the newest combination , which received approval by the Food and Drug Administration ( FDA ) for the treatment of BRAF V600E",
            "probability": 0.00015151500701904297
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 3.28515625,
            "text": ", encorafenib and binimetinib",
            "probability": 0.00013589859008789062
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 3.28515625,
            "text": "and binimetinib",
            "probability": 0.00012767314910888672
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 3.28515625,
            "text": "encorafenib and binimetinib",
            "probability": 0.00011801719665527344
        }
    ],
    "5e319789fbd6abf43b00004a_20": [
        {
            "start_logit": 7.55859375,
            "end_logit": 7.8125,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -6.97265625,
            "text": "BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination with binimetinib.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 7.8125,
            "text": "generation BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.2109375,
            "text": "BRAF inhibitor, has been approved by FDA for the treatment of melanoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.2265625,
            "text": "BRAF inhibitor",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 7.8125,
            "text": "new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.26953125,
            "text": "BRAF inhibitor, has been approved by FDA for the treatment of melanoma in",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.27734375,
            "text": "BRAF inhibitor, has been approved by FDA",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 7.8125,
            "text": "-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.30859375,
            "text": "BRAF inhibitor, has been approved",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.30859375,
            "text": "BRAF inhibitor,",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.3203125,
            "text": "BRAF inhibitor, has been approved by",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 7.8125,
            "text": "a new-generation BRAF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.34375,
            "text": "BRAF inhibitor, has",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.34375,
            "text": "BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.55859375,
            "end_logit": -7.3671875,
            "text": "BRAF inhibitor, has been",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.65625,
            "end_logit": 7.8125,
            "text": "Encorafenib, a new-generation BRAF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.07421875,
            "end_logit": -6.97265625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -6.97265625,
            "text": "generation BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination with binimetinib.",
            "probability": 0.0
        },
        {
            "start_logit": -7.49609375,
            "end_logit": -6.97265625,
            "text": "new-generation BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination with binimetinib.",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_21": [
        {
            "start_logit": 8.15625,
            "end_logit": 6.5546875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 8.15625,
            "end_logit": -3.705078125,
            "text": "BRAF and MEK",
            "probability": 3.510713577270508e-05
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.3671875,
            "text": "BRAF and MEK, respectively",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.6484375,
            "text": "BRAF and MEK, respectively.",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.90625,
            "text": "BRAF and MEK,",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.9140625,
            "text": "BRAF and",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 6.5546875,
            "text": "of BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.96875,
            "end_logit": 6.5546875,
            "text": ", Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 6.5546875,
            "text": "small-molecule inhibitors of BRAF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 6.5546875,
            "text": "binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 6.5546875,
            "text": "Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 6.5546875,
            "text": ") and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 6.5546875,
            "text": "imetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 6.5546875,
            "text": "(MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 6.5546875,
            "text": "and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.88671875,
            "end_logit": -3.705078125,
            "text": "of BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -6.96875,
            "end_logit": -3.705078125,
            "text": ", Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -7.109375,
            "end_logit": -3.705078125,
            "text": "small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -7.18359375,
            "end_logit": -3.705078125,
            "text": "binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -7.2734375,
            "end_logit": -3.705078125,
            "text": "Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_22": [
        {
            "start_logit": 0.654296875,
            "end_logit": 3.28515625,
            "text": "binimetinib",
            "probability": 0.3330078125
        },
        {
            "start_logit": 7.25,
            "end_logit": -3.70703125,
            "text": "BRAF",
            "probability": 0.22412109375
        },
        {
            "start_logit": 7.25,
            "end_logit": -4.41015625,
            "text": "BRAF V600E",
            "probability": 0.11090087890625
        },
        {
            "start_logit": 7.25,
            "end_logit": -4.43359375,
            "text": "BRAF V600E/K-mutated melanoma",
            "probability": 0.10833740234375
        },
        {
            "start_logit": 7.25,
            "end_logit": -5.22265625,
            "text": "BRAF V600E/K-mutated melanoma in June 2018.",
            "probability": 0.04925537109375
        },
        {
            "start_logit": 7.25,
            "end_logit": -5.3046875,
            "text": "BRAF V600E/K",
            "probability": 0.04534912109375
        },
        {
            "start_logit": 7.25,
            "end_logit": -5.69140625,
            "text": "BRAF V600",
            "probability": 0.0308074951171875
        },
        {
            "start_logit": 7.25,
            "end_logit": -5.80859375,
            "text": "BRAF V600E/",
            "probability": 0.02740478515625
        },
        {
            "start_logit": 7.25,
            "end_logit": -6.13671875,
            "text": "BRAF V600E/K-",
            "probability": 0.0197296142578125
        },
        {
            "start_logit": 7.25,
            "end_logit": -6.25,
            "text": "BRAF V",
            "probability": 0.0176239013671875
        },
        {
            "start_logit": 7.25,
            "end_logit": -6.25390625,
            "text": "BRAF V600E/K-mutated melanoma in",
            "probability": 0.017547607421875
        },
        {
            "start_logit": 7.25,
            "end_logit": -6.46484375,
            "text": "BRAF V600E/K-mutated",
            "probability": 0.01421356201171875
        },
        {
            "start_logit": 0.654296875,
            "end_logit": -3.70703125,
            "text": "binimetinib are the newest combination, which received approval by the Food and Drug Administration (FDA) for the treatment of BRAF",
            "probability": 0.00030612945556640625
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 3.28515625,
            "text": "tinib",
            "probability": 0.00019156932830810547
        },
        {
            "start_logit": -6.84375,
            "end_logit": 3.28515625,
            "text": "imetinib",
            "probability": 0.0001842975616455078
        },
        {
            "start_logit": -6.96875,
            "end_logit": 3.28515625,
            "text": "Of these inhibitors, encorafenib and binimetinib",
            "probability": 0.00016260147094726562
        },
        {
            "start_logit": 0.654296875,
            "end_logit": -4.41015625,
            "text": "binimetinib are the newest combination, which received approval by the Food and Drug Administration (FDA) for the treatment of BRAF V600E",
            "probability": 0.00015151500701904297
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 3.28515625,
            "text": ", encorafenib and binimetinib",
            "probability": 0.00013589859008789062
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 3.28515625,
            "text": "and binimetinib",
            "probability": 0.00012767314910888672
        },
        {
            "start_logit": -7.2890625,
            "end_logit": 3.28515625,
            "text": "encorafenib and binimetinib",
            "probability": 0.00011801719665527344
        }
    ],
    "5e319789fbd6abf43b00004a_23": [
        {
            "start_logit": 8.7265625,
            "end_logit": 2.76171875,
            "text": "BRAF V600-mutated melanoma",
            "probability": 0.9931640625
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -2.412109375,
            "text": "BRAF",
            "probability": 0.005634307861328125
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -4.63671875,
            "text": "BRAF V600-mutated",
            "probability": 0.0006103515625
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -5.09375,
            "text": "BRAF V600",
            "probability": 0.0003864765167236328
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -5.71484375,
            "text": "BRAF V600-",
            "probability": 0.0002084970474243164
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -5.8671875,
            "text": "BRAF V600-mutated melanoma.",
            "probability": 0.00017833709716796875
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -6.171875,
            "text": "BRAF V",
            "probability": 0.00013148784637451172
        },
        {
            "start_logit": -5.609375,
            "end_logit": 2.76171875,
            "text": "This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of encorafenib and binimetinib in BRAF V600-mutated melanoma",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.66796875,
            "end_logit": 2.76171875,
            "text": "review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of encorafenib and binimetinib in BRAF V600-mutated melanoma",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.96875,
            "end_logit": 2.76171875,
            "text": "melanoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 2.76171875,
            "text": "in BRAF V600-mutated melanoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 2.76171875,
            "text": "V600-mutated melanoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 2.76171875,
            "text": "will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of encorafenib and binimetinib in BRAF V600-mutated melanoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 2.76171875,
            "text": "imetinib in BRAF V600-mutated melanoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 2.76171875,
            "text": "focus on the preclinical pharmacology, pharmacokinetics and clinical utility of encorafenib and binimetinib in BRAF V600-mutated melanoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 2.76171875,
            "text": "on the preclinical pharmacology, pharmacokinetics and clinical utility of encorafenib and binimetinib in BRAF V600-mutated melanoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.515625,
            "end_logit": 2.76171875,
            "text": "binimetinib in BRAF V600-mutated melanoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 2.76171875,
            "text": "clinical utility of encorafenib and binimetinib in BRAF V600-mutated melanoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 2.76171875,
            "text": "tinib in BRAF V600-mutated melanoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.609375,
            "end_logit": -2.412109375,
            "text": "This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of encorafenib and binimetinib in BRAF",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_24": [
        {
            "start_logit": 7.421875,
            "end_logit": 7.921875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 7.921875,
            "text": "potent BRAF",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -6.85546875,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 7.921875,
            "text": "Encorafenib (LGX818), a potent BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.921875,
            "text": ", a potent BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.921875,
            "text": "X818), a potent BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 7.921875,
            "text": "a potent BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.1171875,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy in BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 7.921875,
            "text": "(LGX818), a potent BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 7.921875,
            "text": "818), a potent BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.13671875,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 7.921875,
            "text": "orafenib (LGX818), a potent BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.16796875,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.171875,
            "text": "BRAF inhibitor",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 7.921875,
            "text": "LGX818), a potent BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.17578125,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.203125,
            "text": "BRAF inhibitor, induces senescence accompanied",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.22265625,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.2265625,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy in",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.421875,
            "end_logit": -7.2578125,
            "text": "BRAF inhibitor, induces",
            "probability": 2.384185791015625e-07
        }
    ],
    "5e319789fbd6abf43b00004a_25": [
        {
            "start_logit": 7.41796875,
            "end_logit": 7.9296875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 7.9296875,
            "text": "generation BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.9296875,
            "text": "818) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 7.9296875,
            "text": "-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 7.9296875,
            "text": "X818) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 7.9296875,
            "text": "new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.640625,
            "end_logit": 7.9296875,
            "text": "a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 7.9296875,
            "text": "LGX818) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 7.9296875,
            "text": ") is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 7.9296875,
            "text": "Encorafenib (LGX818) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 7.9296875,
            "text": "8) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 7.9296875,
            "text": "orafenib (LGX818) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 7.9296875,
            "text": "is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 7.9296875,
            "text": "fenib (LGX818) is a new-generation BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.21875,
            "text": "BRAF inhibitor that is",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.23828125,
            "text": "BRAF inhibitor that",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.2421875,
            "text": "BRAF inhibitor that is under",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.25,
            "text": "BRAF inhibitor that is under evaluation in clinical trials.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.296875,
            "text": "BRAF inhibitor",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.41796875,
            "end_logit": -7.3046875,
            "text": "BRAF inhibitor that is under evaluation",
            "probability": 2.384185791015625e-07
        }
    ],
    "5e319789fbd6abf43b00004a_26": [
        {
            "start_logit": 7.2734375,
            "end_logit": 8.0546875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 8.0546875,
            "text": "to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 8.0546875,
            "text": "improved efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 8.0546875,
            "text": "efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 8.0546875,
            "text": ", with prolonged binding to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.0546875,
            "text": "target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.0546875,
            "text": "binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 8.0546875,
            "text": "the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.0546875,
            "text": "orafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 8.0546875,
            "text": "This improved efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 8.0546875,
            "text": "encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 8.0546875,
            "text": "pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.71875,
            "end_logit": 8.0546875,
            "text": "fenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 8.0546875,
            "text": "prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -6.984375,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same class.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.25,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.26171875,
            "text": "BRAF inhibition",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.2734375,
            "text": "BRAF inhibition and increased potency compared",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.28125,
            "text": "BRAF inhibition and increased potency compared with",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.30078125,
            "text": "BRAF inhibition and increased potency compared with other drugs in the",
            "probability": 2.384185791015625e-07
        }
    ],
    "5e319789fbd6abf43b00004a_27": [
        {
            "start_logit": 8.4453125,
            "end_logit": 7.36328125,
            "text": "BRAF/MEK",
            "probability": 1.0
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -2.23046875,
            "text": "BRAF",
            "probability": 6.812810897827148e-05
        },
        {
            "start_logit": -3.701171875,
            "end_logit": 7.36328125,
            "text": "MEK",
            "probability": 5.304813385009766e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -5.140625,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -5.46875,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.08203125,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.59375,
            "text": "BRAF/MEK inhibitor",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.81640625,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma treated",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.8203125,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.87890625,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.96484375,
            "text": "BRAF/MEK inhibitor combinations have",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -7.0078125,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 7.36328125,
            "text": "/MEK",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 7.36328125,
            "text": "While other BRAF/MEK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 7.36328125,
            "text": "Expert opinion: While other BRAF/MEK",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 7.36328125,
            "text": "other BRAF/MEK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 7.36328125,
            "text": ": While other BRAF/MEK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.701171875,
            "end_logit": -5.140625,
            "text": "MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -3.701171875,
            "end_logit": -5.46875,
            "text": "MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -6.9921875,
            "end_logit": -2.23046875,
            "text": "While other BRAF",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_28": [
        {
            "start_logit": 9.59375,
            "end_logit": 9.0390625,
            "text": "BRAF/MEK",
            "probability": 1.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -0.028106689453125,
            "text": "BRAF",
            "probability": 0.00011593103408813477
        },
        {
            "start_logit": -1.283203125,
            "end_logit": 9.0390625,
            "text": "MEK",
            "probability": 1.9073486328125e-05
        },
        {
            "start_logit": 9.59375,
            "end_logit": -6.53515625,
            "text": "BRAF/MEK inhibitor combinations.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.203125,
            "end_logit": 9.0390625,
            "text": "Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.59375,
            "end_logit": -6.8046875,
            "text": "BRAF/MEK inhibitor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.09375,
            "text": "BRAF/MEK inhibitor combinations",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.69140625,
            "end_logit": 9.0390625,
            "text": "/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 9.0390625,
            "text": "etinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 9.0390625,
            "text": "covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.625,
            "end_logit": 9.0390625,
            "text": "nib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.0390625,
            "text": "that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 9.0390625,
            "text": "existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.0390625,
            "text": "bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.0390625,
            "text": "approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 9.0390625,
            "text": "b offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 9.0390625,
            "text": "Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 9.0390625,
            "text": "may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.0390625,
            "text": "orafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 9.0390625,
            "text": "new approach that may offer benefits over existing BRAF/MEK",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e319789fbd6abf43b00004a_29": [
        {
            "start_logit": 8.375,
            "end_logit": 6.69921875,
            "text": "BRAFV600E",
            "probability": 1.0
        },
        {
            "start_logit": 8.375,
            "end_logit": -2.955078125,
            "text": "BRAFV600E-mutated melanoma who developed pyogenic granulomas 16, 10, and 12 weeks after treatment initiation with the selective BRAF",
            "probability": 6.401538848876953e-05
        },
        {
            "start_logit": 8.375,
            "end_logit": -3.029296875,
            "text": "BRAF",
            "probability": 5.918741226196289e-05
        },
        {
            "start_logit": 8.375,
            "end_logit": -6.0625,
            "text": "BRAFV600E-mutated melanoma",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": 8.375,
            "end_logit": -6.27734375,
            "text": "BRAFV600",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -4.7578125,
            "end_logit": 6.69921875,
            "text": "E",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 8.375,
            "end_logit": -6.6171875,
            "text": "BRAFV600E-mutated",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 8.375,
            "end_logit": -6.7734375,
            "text": "BRAFV600E-",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.375,
            "end_logit": -6.93359375,
            "text": "BRAFV6",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.375,
            "end_logit": -7.15625,
            "text": "BRAFV600E-mutated melanoma who",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.375,
            "end_logit": -7.20703125,
            "text": "BRAFV600E-mutated melanoma who developed pyogenic granulomas 16, 10, and 12 weeks after treatment initiation with the selective BRAF inhibitors",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.375,
            "end_logit": -7.2109375,
            "text": "BRAFV600E-mutated melanoma who developed pyogenic granulomas 16",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.375,
            "end_logit": -7.25,
            "text": "BRAFV600E-mutated melanoma who developed pyogenic granulomas 16, 10, and 12 weeks after treatment initiation with the selective BRAF inhibitors ve",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.375,
            "end_logit": -7.30078125,
            "text": "BRAFV600E-mutated melanoma who developed pyogenic granulomas 16, 10, and 12 weeks after treatment initiation with the selective BRAF inhibitors vemu",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.375,
            "end_logit": -7.3203125,
            "text": "BRAFV600E-mutated melanoma who developed pyogenic granulomas 16, 10, and 12 weeks after treatment initiation with the selective BRAF inhibitors vemura",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.38671875,
            "end_logit": 6.69921875,
            "text": "metastatic BRAFV600E",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 6.69921875,
            "text": "V600E",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.93359375,
            "end_logit": 6.69921875,
            "text": "with metastatic BRAFV600E",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 6.69921875,
            "text": "00E",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 6.69921875,
            "text": "male patients with metastatic BRAFV600E",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5e319789fbd6abf43b00004a_30": [
        {
            "start_logit": 8.40625,
            "end_logit": 6.828125,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 8.40625,
            "end_logit": -5.2890625,
            "text": "BRAF and MEK",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": 8.40625,
            "end_logit": -6.921875,
            "text": "BRAF and MEK inhibitors, respectively.",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 8.40625,
            "end_logit": -6.9765625,
            "text": "BRAF and MEK inhibitors, respectively",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.01953125,
            "text": "BRAF and MEK inhibitors",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.14453125,
            "text": "BRAF and",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.40625,
            "end_logit": -7.28515625,
            "text": "BRAF and MEK inhibitors,",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 6.828125,
            "text": "new BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 6.828125,
            "text": ", with Encorafenib and Binimetinib, new BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 6.828125,
            "text": ", new BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 6.828125,
            "text": "with Encorafenib and Binimetinib, new BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.625,
            "end_logit": 6.828125,
            "text": "Treatment started in November 2015, with Encorafenib and Binimetinib, new BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 6.828125,
            "text": "Binimetinib, new BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.703125,
            "end_logit": 6.828125,
            "text": "Encorafenib and Binimetinib, new BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.71875,
            "end_logit": 6.828125,
            "text": "imetinib, new BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 6.828125,
            "text": "orafenib and Binimetinib, new BRAF",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.796875,
            "end_logit": -5.2890625,
            "text": "MEK",
            "probability": 0.0
        },
        {
            "start_logit": -5.6640625,
            "end_logit": -6.921875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -5.2890625,
            "text": "new BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -5.2890625,
            "text": ", with Encorafenib and Binimetinib, new BRAF and MEK",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_31": [
        {
            "start_logit": 7.3359375,
            "end_logit": 7.79296875,
            "text": "MET",
            "probability": 1.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 7.79296875,
            "text": "of MET",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.3359375,
            "end_logit": -7.0703125,
            "text": "MET was observed in 3 PDX models, a higher frequency than expected and a possible novel mechanism of resistance.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.79296875,
            "text": "binimetinib) inhibitor combination or the ERK inhibitor VX-11e was confirmed in vivo Amplification of MET",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 7.79296875,
            "text": "Amplification of MET",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.3359375,
            "end_logit": -7.1796875,
            "text": "MET was observed",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 7.79296875,
            "text": "imetinib) inhibitor combination or the ERK inhibitor VX-11e was confirmed in vivo Amplification of MET",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.3359375,
            "end_logit": -7.28515625,
            "text": "MET was observed in 3 PDX models, a higher",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -2.2421875,
            "end_logit": -1.5732421875,
            "text": "BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -2.2421875,
            "end_logit": -6.69921875,
            "text": "BRAF (",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -1.5732421875,
            "text": "BKM120 with either BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": -1.5732421875,
            "text": "-PI3K inhibitor BKM120 with either BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": -1.5732421875,
            "text": "either BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -2.2421875,
            "end_logit": -7.171875,
            "text": "BRAF (encorafenib)/MEK",
            "probability": 0.0
        },
        {
            "start_logit": -2.2421875,
            "end_logit": -7.31640625,
            "text": "BRAF (enc",
            "probability": 0.0
        },
        {
            "start_logit": -2.2421875,
            "end_logit": -7.32421875,
            "text": "BRAF (encorafen",
            "probability": 0.0
        },
        {
            "start_logit": -2.2421875,
            "end_logit": -7.328125,
            "text": "BRAF (encorafenib)/MEK (binimetinib) inhibitor combination or the ERK inhibitor VX-11e was confirmed",
            "probability": 0.0
        },
        {
            "start_logit": -2.2421875,
            "end_logit": -7.33203125,
            "text": "BRAF (encorafenib)/MEK (binimetinib) inhibitor combination or the ERK inhibitor VX-11e was",
            "probability": 0.0
        },
        {
            "start_logit": -4.8828125,
            "end_logit": -7.0703125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -6.69921875,
            "text": "BKM120 with either BRAF (",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_32": [
        {
            "start_logit": 6.54296875,
            "end_logit": 7.375,
            "text": "C-KIT",
            "probability": 1.0
        },
        {
            "start_logit": -3.1640625,
            "end_logit": 7.375,
            "text": "Areas covered: A brief review of current BRAF, NRAS, and C-KIT",
            "probability": 6.0617923736572266e-05
        },
        {
            "start_logit": -3.912109375,
            "end_logit": 7.375,
            "text": "KIT",
            "probability": 2.86102294921875e-05
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -4.203125,
            "text": "C",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -5.859375,
            "end_logit": 7.375,
            "text": "BRAF, NRAS, and C-KIT",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": -6.2109375,
            "end_logit": 7.375,
            "text": "-KIT",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -6.4609375,
            "end_logit": 7.375,
            "text": "brief review of current BRAF, NRAS, and C-KIT",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -6.51171875,
            "end_logit": 7.375,
            "text": "NRAS, and C-KIT",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -6.578125,
            "end_logit": 7.375,
            "text": "current BRAF, NRAS, and C-KIT",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 7.375,
            "text": "and C-KIT",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 7.375,
            "text": "covered: A brief review of current BRAF, NRAS, and C-KIT",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -6.203125,
            "text": "C-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -6.52734375,
            "text": "C-KIT inhibitors provides",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -6.60546875,
            "text": "C-KIT inhibitors provides background for a",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -6.6875,
            "text": "C-KIT inhibitors provides background for a thorough review of newly",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -6.7578125,
            "text": "C-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -6.921875,
            "text": "C-KIT inhibitors provides background for a thorough review",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 6.54296875,
            "end_logit": -6.9453125,
            "text": "C-KIT inhibitors provides background for a thorough",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -1.6748046875,
            "end_logit": -0.1536865234375,
            "text": "C-KIT",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.57421875,
            "end_logit": -0.1536865234375,
            "text": "inhibits C-KIT",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_33": [
        {
            "start_logit": 8.8984375,
            "end_logit": 7.87890625,
            "text": "BRAF V600E kinase",
            "probability": 0.9208984375
        },
        {
            "start_logit": 8.8984375,
            "end_logit": 5.42578125,
            "text": "BRAF V600E",
            "probability": 0.07916259765625
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -2.1015625,
            "text": "BRAF",
            "probability": 4.2498111724853516e-05
        },
        {
            "start_logit": -3.05859375,
            "end_logit": 7.87890625,
            "text": "kinase",
            "probability": 5.900859832763672e-06
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -5.89453125,
            "text": "BRAF V600E kinase activity",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -4.91015625,
            "end_logit": 7.87890625,
            "text": "E kinase",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.296875,
            "text": "BRAF V600",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.703125,
            "text": "BRAF V600E kinase activity with a prolonged off-rate and suppressed proliferation and tumor growth of BRAF V600E-mutant melanoma models.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.90234375,
            "text": "BRAF V",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.9765625,
            "text": "BRAF V600E kinase activity with a",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -6.9921875,
            "text": "BRAF V600E kinase activity with",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.1875,
            "text": "BRAF V600E kinase activity with a prolonged",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.2734375,
            "text": "BRAF V600E kinase activity with a prolonged off-rate and suppressed proliferation and tumor growth of BRAF V600E",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.28125,
            "text": "BRAF V600E kinase activity with a prolonged off-rate and suppressed proliferation and tumor growth of BRAF V600E-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.28515625,
            "text": "BRAF V600E kinase activity with a prolonged off-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8984375,
            "end_logit": -7.29296875,
            "text": "BRAF V600E kinase activity with a prolonged off-rate and suppressed proliferation and tumor growth of BRAF V600E-mutant melanoma models",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 7.87890625,
            "text": "V600E kinase",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.87890625,
            "end_logit": 7.87890625,
            "text": "600E kinase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.91015625,
            "end_logit": 5.42578125,
            "text": "E",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 7.87890625,
            "text": ": Preclinical data demonstrated that encorafenib inhibited BRAF V600E kinase",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e319789fbd6abf43b00004a_34": [
        {
            "start_logit": 7.2734375,
            "end_logit": 8.0546875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 8.0546875,
            "text": "to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 8.0546875,
            "text": "improved efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 8.0546875,
            "text": "efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 8.0546875,
            "text": ", with prolonged binding to the target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 8.0546875,
            "text": "target molecule providing greater BRAF",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.0546875,
            "text": "binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 8.0546875,
            "text": "the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.0546875,
            "text": "orafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 8.0546875,
            "text": "This improved efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 8.0546875,
            "text": "encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 8.0546875,
            "text": "pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.71875,
            "end_logit": 8.0546875,
            "text": "fenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 8.0546875,
            "text": "prolonged binding to the target molecule providing greater BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -6.984375,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same class.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.25,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.26171875,
            "text": "BRAF inhibition",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.2734375,
            "text": "BRAF inhibition and increased potency compared",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.28125,
            "text": "BRAF inhibition and increased potency compared with",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2734375,
            "end_logit": -7.30078125,
            "text": "BRAF inhibition and increased potency compared with other drugs in the",
            "probability": 2.384185791015625e-07
        }
    ],
    "5e319789fbd6abf43b00004a_35": [
        {
            "start_logit": 7.42578125,
            "end_logit": 7.9140625,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 7.9140625,
            "text": "Phase I Dose-Escalation and -Expansion Study of the BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 7.9140625,
            "text": "the BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 7.9140625,
            "text": "Dose-Escalation and -Expansion Study of the BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.328125,
            "text": "BRAF Inhibitor",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.34375,
            "text": "BRAF Inhibitor Enc",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.37109375,
            "text": "BRAF Inhibitor Encorafenib",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.390625,
            "text": "BRAF Inhibitor Encorafen",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.41015625,
            "text": "BRAF Inhibitor Encorafenib (LGX818) in",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.4296875,
            "text": "BRAF Inhibitor Encora",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.44140625,
            "text": "BRAF Inhibitor Encorafenib (LGX818) in Metastatic",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.42578125,
            "end_logit": -7.4609375,
            "text": "BRAF Inhibitor Encorafenib (LGX818)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -7.328125,
            "text": "Phase I Dose-Escalation and",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -7.328125,
            "text": "Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -7.33984375,
            "text": "Phase I Dose-Escalation",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -7.41015625,
            "text": "X818) in",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -7.34375,
            "text": "Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Enc",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -7.34375,
            "text": "Phase I Dose-Escalation and -Expansion Study",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -7.37109375,
            "text": "Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -7.44140625,
            "text": "X818) in Metastatic",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_36": [
        {
            "start_logit": 7.57421875,
            "end_logit": 7.7890625,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.12109375,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.13671875,
            "text": "BRAF inhibitor",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.20703125,
            "text": "BRAF inhibitor (BRAFi)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.25,
            "text": "BRAF inhibitor (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.2578125,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.2734375,
            "text": "BRAF inhibitor (BRAF",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.2734375,
            "text": "BRAF inhibitor (BRAFi",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.28125,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.28515625,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.28515625,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.29296875,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.296875,
            "text": "BRAF inhibitor (BRAFi),",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.30078125,
            "text": "BRAF inhibitor (BRAFi), has a",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.3125,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.31640625,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.3203125,
            "text": "BRAF inhibitor (BRAFi), has",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 7.7890625,
            "text": "selective BRAF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.703125,
            "end_logit": 7.7890625,
            "text": "Purpose: Encorafenib, a selective BRAF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 7.7890625,
            "text": ": Encorafenib, a selective BRAF",
            "probability": 2.384185791015625e-07
        }
    ],
    "5a89800efcd1d6a10c00000c_1": [
        {
            "start_logit": -1.4326171875,
            "end_logit": 1.7294921875,
            "text": "A secreted enzyme, PM20D1, enriched in UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids.",
            "probability": 0.2401123046875
        },
        {
            "start_logit": -1.4326171875,
            "end_logit": 1.56640625,
            "text": "A secreted enzyme, PM20D1, enriched in UCP1+ adipocytes,",
            "probability": 0.2039794921875
        },
        {
            "start_logit": -1.4326171875,
            "end_logit": 1.3291015625,
            "text": "A secreted enzyme, PM20D1, enriched in UCP1+ adipocytes",
            "probability": 0.160888671875
        },
        {
            "start_logit": -2.546875,
            "end_logit": 1.7294921875,
            "text": ".",
            "probability": 0.07879638671875
        },
        {
            "start_logit": -3.240234375,
            "end_logit": 1.7294921875,
            "text": "in UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids.",
            "probability": 0.039398193359375
        },
        {
            "start_logit": -3.240234375,
            "end_logit": 1.56640625,
            "text": "in UCP1+ adipocytes,",
            "probability": 0.033477783203125
        },
        {
            "start_logit": -3.412109375,
            "end_logit": 1.7294921875,
            "text": "UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids.",
            "probability": 0.033172607421875
        },
        {
            "start_logit": -3.412109375,
            "end_logit": 1.56640625,
            "text": "UCP1+ adipocytes,",
            "probability": 0.0281829833984375
        },
        {
            "start_logit": -3.240234375,
            "end_logit": 1.3291015625,
            "text": "in UCP1+ adipocytes",
            "probability": 0.02642822265625
        },
        {
            "start_logit": -3.412109375,
            "end_logit": 1.3291015625,
            "text": "UCP1+ adipocytes",
            "probability": 0.022247314453125
        },
        {
            "start_logit": -3.845703125,
            "end_logit": 1.7294921875,
            "text": ", PM20D1, enriched in UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids.",
            "probability": 0.021484375
        },
        {
            "start_logit": -3.845703125,
            "end_logit": 1.56640625,
            "text": ", PM20D1, enriched in UCP1+ adipocytes,",
            "probability": 0.0182647705078125
        },
        {
            "start_logit": -4.08984375,
            "end_logit": 1.7294921875,
            "text": "secreted enzyme, PM20D1, enriched in UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids.",
            "probability": 0.0168609619140625
        },
        {
            "start_logit": -4.125,
            "end_logit": 1.7294921875,
            "text": "form N-acyl amino acids.",
            "probability": 0.0162811279296875
        },
        {
            "start_logit": -3.845703125,
            "end_logit": 1.3291015625,
            "text": ", PM20D1, enriched in UCP1+ adipocytes",
            "probability": 0.0144195556640625
        },
        {
            "start_logit": -4.08984375,
            "end_logit": 1.56640625,
            "text": "secreted enzyme, PM20D1, enriched in UCP1+ adipocytes,",
            "probability": 0.014312744140625
        },
        {
            "start_logit": -4.08984375,
            "end_logit": 1.3291015625,
            "text": "secreted enzyme, PM20D1, enriched in UCP1+ adipocytes",
            "probability": 0.0112762451171875
        },
        {
            "start_logit": -4.8828125,
            "end_logit": 1.7294921875,
            "text": "PM20D1, enriched in UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids.",
            "probability": 0.00762939453125
        },
        {
            "start_logit": -4.8828125,
            "end_logit": 1.56640625,
            "text": "PM20D1, enriched in UCP1+ adipocytes,",
            "probability": 0.006473541259765625
        },
        {
            "start_logit": -5.046875,
            "end_logit": 1.7294921875,
            "text": "enriched in UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids.",
            "probability": 0.006473541259765625
        }
    ],
    "5319ac36b166e2b806000031_1": [
        {
            "start_logit": 9.203125,
            "end_logit": 8.984375,
            "text": "GIT1",
            "probability": 1.0
        },
        {
            "start_logit": 9.203125,
            "end_logit": -1.44921875,
            "text": "GI",
            "probability": 2.9325485229492188e-05
        },
        {
            "start_logit": -1.771484375,
            "end_logit": 8.984375,
            "text": "T1",
            "probability": 1.710653305053711e-05
        },
        {
            "start_logit": 9.203125,
            "end_logit": -5.16796875,
            "text": "GIT1 is required for GIT1-cortactin complex localization to the leading edge",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -5.77734375,
            "text": "GIT1 is required for GIT1-cortactin complex localization to the leading edge.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.7265625,
            "text": "GIT1 is",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.6171875,
            "end_logit": 8.984375,
            "text": "of GIT1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.9140625,
            "text": "GIT1 is required",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.01171875,
            "text": "GIT1 is required for GIT1-cortactin complex localization to the leading edge. The mechanisms involved extracellular signal-regulated kinases 1 and 2-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.0234375,
            "text": "GIT1 is required for",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 8.984375,
            "text": "the Spa homology domain (aa 250-420) of GIT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 8.984375,
            "text": "that the Spa homology domain (aa 250-420) of GIT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 8.984375,
            "text": "Spa homology domain (aa 250-420) of GIT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 8.984375,
            "text": "identified that the Spa homology domain (aa 250-420) of GIT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 8.984375,
            "text": "specifically identified that the Spa homology domain (aa 250-420) of GIT1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.771484375,
            "end_logit": -5.16796875,
            "text": "T1 is required for GIT1-cortactin complex localization to the leading edge",
            "probability": 0.0
        },
        {
            "start_logit": -1.771484375,
            "end_logit": -5.77734375,
            "text": "T1 is required for GIT1-cortactin complex localization to the leading edge.",
            "probability": 0.0
        },
        {
            "start_logit": -6.6171875,
            "end_logit": -1.44921875,
            "text": "of GI",
            "probability": 0.0
        },
        {
            "start_logit": -1.771484375,
            "end_logit": -6.7265625,
            "text": "T1 is",
            "probability": 0.0
        },
        {
            "start_logit": -1.771484375,
            "end_logit": -6.9140625,
            "text": "T1 is required",
            "probability": 0.0
        }
    ],
    "5319ac36b166e2b806000031_2": [
        {
            "start_logit": 7.15625,
            "end_logit": 8.1015625,
            "text": "Rac1",
            "probability": 1.0
        },
        {
            "start_logit": 7.15625,
            "end_logit": -4.21875,
            "text": "Rac1 to the plasma membrane and induce the local formation of lamellipodia in response to focal illumination.",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -5.9296875,
            "end_logit": 8.1015625,
            "text": "small G-protein Rac1",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 7.15625,
            "end_logit": -5.23046875,
            "text": "Rac1 to the plasma membrane",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -6.5234375,
            "end_logit": 8.1015625,
            "text": "G-protein Rac1",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -6.7890625,
            "end_logit": 8.1015625,
            "text": "protein Rac1",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 8.1015625,
            "text": "LAD constructs that can recruit the small G-protein Rac1",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 7.15625,
            "end_logit": -5.94140625,
            "text": "Rac1 to",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.96875,
            "end_logit": 8.1015625,
            "text": "recruit the small G-protein Rac1",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.15625,
            "end_logit": -6.05078125,
            "text": "Rac1 to the plasma membrane and",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.03125,
            "end_logit": 8.1015625,
            "text": "-protein Rac1",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.125,
            "end_logit": 8.1015625,
            "text": "the small G-protein Rac1",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 8.1015625,
            "text": "demonstrated the utility of this system with LAD constructs that can recruit the small G-protein Rac1",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 8.1015625,
            "text": "constructs that can recruit the small G-protein Rac1",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 8.1015625,
            "text": "system with LAD constructs that can recruit the small G-protein Rac1",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.390625,
            "end_logit": 8.1015625,
            "text": "this system with LAD constructs that can recruit the small G-protein Rac1",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.15625,
            "end_logit": -6.8359375,
            "text": "Rac1 to the plasma membrane and induce the",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.15625,
            "end_logit": -6.87109375,
            "text": "Rac1 to the",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.15625,
            "end_logit": -6.94140625,
            "text": "Rac1 to the plasma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.171875,
            "end_logit": -4.21875,
            "text": ".",
            "probability": 0.0
        }
    ],
    "6217db1b3a8413c653000027_1": [
        {
            "start_logit": 9.1484375,
            "end_logit": 9.296875,
            "text": "haemophagocytic lymphohistiocytosis",
            "probability": 1.0
        },
        {
            "start_logit": -0.8173828125,
            "end_logit": 9.296875,
            "text": "ocytosis",
            "probability": 4.7206878662109375e-05
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -1.4384765625,
            "text": "haem",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": -3.845703125,
            "end_logit": 9.296875,
            "text": "of haemophagocytic lymphohistiocytosis",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -4.9921875,
            "end_logit": 9.296875,
            "text": ". Most such cases lead to clinical manifestations of haemophagocytic lymphohistiocytosis",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -5.328125,
            "end_logit": 9.296875,
            "text": "ophagocytic lymphohistiocytosis",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -5.98828125,
            "text": "haemophagocytic lymphohistiocytosis (HLH",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.125,
            "text": "haemophagocytic lympho",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.1953125,
            "text": "haemophagocytic lymphohistiocytosis (HLH).",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.22265625,
            "text": "haemophagocytic lymphohis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.23046875,
            "text": "haemophagocytic",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.2578125,
            "text": "haemophagocytic lymphohistiocytosis (HL",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.53515625,
            "end_logit": 9.296875,
            "text": "tiocytosis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.63671875,
            "text": "haemophagocytic lymphohistiocytosis (HLH)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.640625,
            "text": "haemophagocytic lymphohistiocytosis (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.71484375,
            "text": "haemophagocytic lymphohisti",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 9.296875,
            "text": "histiocytosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 9.296875,
            "text": "ocytic lymphohistiocytosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 9.296875,
            "text": "manifestations of haemophagocytic lymphohistiocytosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 9.296875,
            "text": "immune deregulation. Most such cases lead to clinical manifestations of haemophagocytic lymphohistiocytosis",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a9d8a651d1251d03b00001f_1": [
        {
            "start_logit": 8.3125,
            "end_logit": 2.412109375,
            "text": "Mini-BioArchive system",
            "probability": 0.623046875
        },
        {
            "start_logit": 8.3125,
            "end_logit": 1.4501953125,
            "text": "Mini-BioArchive system)",
            "probability": 0.2384033203125
        },
        {
            "start_logit": 8.3125,
            "end_logit": 0.80615234375,
            "text": "Mini-BioArchive system) used in the banking of umbilical cord blood (UCB) units was evaluated.",
            "probability": 0.12469482421875
        },
        {
            "start_logit": 8.3125,
            "end_logit": -1.6611328125,
            "text": "Mini",
            "probability": 0.01059722900390625
        },
        {
            "start_logit": 8.3125,
            "end_logit": -3.796875,
            "text": "Mini-BioArchive system) used",
            "probability": 0.0012502670288085938
        },
        {
            "start_logit": 8.3125,
            "end_logit": -4.3515625,
            "text": "Mini-BioArchive",
            "probability": 0.0007185935974121094
        },
        {
            "start_logit": 8.3125,
            "end_logit": -5.03515625,
            "text": "Mini-BioArch",
            "probability": 0.00036263465881347656
        },
        {
            "start_logit": 8.3125,
            "end_logit": -5.09375,
            "text": "Mini-BioArchive system) used in the banking of umbilical cord blood (UCB) units was evaluated",
            "probability": 0.0003421306610107422
        },
        {
            "start_logit": 8.3125,
            "end_logit": -5.3671875,
            "text": "Mini-BioArchive system) used in the banking of umbilical cord blood (UCB) units was",
            "probability": 0.0002601146697998047
        },
        {
            "start_logit": -3.212890625,
            "end_logit": 4.19921875,
            "text": "automated cryopreservation and storage system",
            "probability": 3.6656856536865234e-05
        },
        {
            "start_logit": -3.533203125,
            "end_logit": 4.19921875,
            "text": "a small-scale automated cryopreservation and storage system",
            "probability": 2.658367156982422e-05
        },
        {
            "start_logit": -0.62744140625,
            "end_logit": 0.80615234375,
            "text": ".",
            "probability": 1.6391277313232422e-05
        },
        {
            "start_logit": -4.859375,
            "end_logit": 4.19921875,
            "text": "The performance of a small-scale automated cryopreservation and storage system",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": -3.087890625,
            "end_logit": 2.412109375,
            "text": "(Mini-BioArchive system",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -3.212890625,
            "end_logit": 2.412109375,
            "text": "automated cryopreservation and storage system (Mini-BioArchive system",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -5.08203125,
            "end_logit": 4.19921875,
            "text": "system",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": -3.533203125,
            "end_logit": 2.412109375,
            "text": "a small-scale automated cryopreservation and storage system (Mini-BioArchive system",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -5.5234375,
            "end_logit": 4.19921875,
            "text": "performance of a small-scale automated cryopreservation and storage system",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -3.087890625,
            "end_logit": 1.4501953125,
            "text": "(Mini-BioArchive system)",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -3.212890625,
            "end_logit": 1.4501953125,
            "text": "automated cryopreservation and storage system (Mini-BioArchive system)",
            "probability": 2.3245811462402344e-06
        }
    ],
    "56f961b3cf1c325851000003_1": [
        {
            "start_logit": 7.79296875,
            "end_logit": 7.40234375,
            "text": "blue",
            "probability": 1.0
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -6.23046875,
            "text": "blue protein from a different species of frog, displays a novel structure with a unique chromophoric crosslink.",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.0625,
            "text": "blue protein from a",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.10546875,
            "text": "blue protein",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.12109375,
            "text": "blue protein from",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.17578125,
            "text": "blue protein from a different species of frog, displays",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.1796875,
            "text": "blue protein from a different species of frog, displays a novel structure with a unique chromophoric",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.203125,
            "text": "blue protein from a different species of frog, displays a",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.22265625,
            "text": "blue protein from a different species of frog, displays a novel structure with a",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.2421875,
            "text": "blue protein from a different species",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.24609375,
            "text": "blue protein from a different",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.25,
            "text": "blue protein from a different species of frog,",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.2578125,
            "text": "blue protein from a different species of frog, displays a novel",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.28515625,
            "text": "blue protein from a different species of frog, displays a novel structure with a unique chromophoric crosslink",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.296875,
            "text": "blue protein from a different species of frog, displays a novel structure with",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.31640625,
            "text": "blue protein from a different species of",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.79296875,
            "end_logit": -7.33203125,
            "text": "blue protein from a different species of frog, displays a novel structure",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 7.40234375,
            "text": "a blue",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.6640625,
            "end_logit": -6.23046875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.20703125,
            "end_logit": -6.23046875,
            "text": "a blue protein from a different species of frog, displays a novel structure with a unique chromophoric crosslink.",
            "probability": 0.0
        }
    ],
    "56f961b3cf1c325851000003_2": [
        {
            "start_logit": 5.1328125,
            "end_logit": 5.25,
            "text": "blue",
            "probability": 1.0
        },
        {
            "start_logit": 5.1328125,
            "end_logit": -4.4140625,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax, has been purified and crystallized. The crystals are an intense blue colour",
            "probability": 6.35385513305664e-05
        },
        {
            "start_logit": 5.1328125,
            "end_logit": -5.90625,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax, has been purified and crystallized. The crystals are an intense blue",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": 5.1328125,
            "end_logit": -6.484375,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax, has been purified and crystallized.",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": 5.1328125,
            "end_logit": -6.80859375,
            "text": "blue protein found",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": 5.1328125,
            "end_logit": -6.94140625,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax, has been",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 5.1328125,
            "end_logit": -7.109375,
            "text": "blue protein",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 5.1328125,
            "end_logit": -7.11328125,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax, has been purified and",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 5.1328125,
            "end_logit": -7.15234375,
            "text": "blue protein found in the",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 5.1328125,
            "end_logit": -7.1796875,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax, has been purified and crystallized. The crystals",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": 5.1328125,
            "end_logit": -7.2578125,
            "text": "blue protein found in the nests of the",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 5.1328125,
            "end_logit": -7.2578125,
            "text": "blue protein found in the nests",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 5.1328125,
            "end_logit": -7.2890625,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax, has",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 5.1328125,
            "end_logit": -7.296875,
            "text": "blue protein found in the nests of the frog Polyp",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -4.55859375,
            "end_logit": -4.4140625,
            "text": ". The crystals are an intense blue colour",
            "probability": 0.0
        },
        {
            "start_logit": -5.125,
            "end_logit": -4.4140625,
            "text": "blue colour",
            "probability": 0.0
        },
        {
            "start_logit": -5.29296875,
            "end_logit": -4.4140625,
            "text": "intense blue colour",
            "probability": 0.0
        },
        {
            "start_logit": -4.55859375,
            "end_logit": -5.90625,
            "text": ". The crystals are an intense blue",
            "probability": 0.0
        },
        {
            "start_logit": -5.125,
            "end_logit": -5.90625,
            "text": "blue",
            "probability": 0.0
        },
        {
            "start_logit": -4.55859375,
            "end_logit": -6.484375,
            "text": ".",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_1": [
        {
            "start_logit": 8.984375,
            "end_logit": 8.46875,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": 8.984375,
            "end_logit": -1.89453125,
            "text": "experimental",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -2.501953125,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 1.722574234008789e-05
        },
        {
            "start_logit": -2.390625,
            "end_logit": 8.46875,
            "text": "encephalomyelitis",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -4.9453125,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -5.51171875,
            "end_logit": 8.46875,
            "text": "autoimmune encephalomyelitis",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.51953125,
            "text": "experimental autoimmune encephalomyelitis (EAE) animal",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.765625,
            "text": "experimental autoimmune encephalomyelitis (EAE) animal model",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.0625,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.1875,
            "text": "experimental autoimmune",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.25,
            "text": "experimental autoimmune encephalomyelitis (EAE) animal model of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.31640625,
            "text": "experimental autoimmune encephalomyelitis (EAE) animal model of multiple sclerosis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -7.31640625,
            "text": "experimental autoimmune encephalomyelitis (EAE) animal model of multiple",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.390625,
            "end_logit": -2.501953125,
            "text": "encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -2.390625,
            "end_logit": -4.9453125,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -5.51171875,
            "end_logit": -2.501953125,
            "text": "autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -5.53125,
            "end_logit": -2.501953125,
            "text": "(EAE",
            "probability": 0.0
        },
        {
            "start_logit": -6.31640625,
            "end_logit": -2.501953125,
            "text": "EAE",
            "probability": 0.0
        },
        {
            "start_logit": -2.390625,
            "end_logit": -6.51953125,
            "text": "encephalomyelitis (EAE) animal",
            "probability": 0.0
        },
        {
            "start_logit": -2.390625,
            "end_logit": -6.765625,
            "text": "encephalomyelitis (EAE) animal model",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_2": [
        {
            "start_logit": 8.453125,
            "end_logit": 4.984375,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.50537109375
        },
        {
            "start_logit": 8.453125,
            "end_logit": 4.85546875,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 0.44580078125
        },
        {
            "start_logit": 8.453125,
            "end_logit": 2.640625,
            "text": "experimental autoimmune encephalomyelitis (EAE) mouse",
            "probability": 0.0484619140625
        },
        {
            "start_logit": 8.453125,
            "end_logit": -2.806640625,
            "text": "experimental",
            "probability": 0.0002092123031616211
        },
        {
            "start_logit": 8.453125,
            "end_logit": -3.296875,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.00012791156768798828
        },
        {
            "start_logit": 8.453125,
            "end_logit": -5.2890625,
            "text": "experimental autoimmune encephalomyelitis (EAE) mouse model",
            "probability": 1.7404556274414062e-05
        },
        {
            "start_logit": 8.453125,
            "end_logit": -5.76171875,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": 8.453125,
            "end_logit": -6.8203125,
            "text": "experimental autoimmune encephalomyelitis (EAE) mouse model of",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -5.1484375,
            "end_logit": 4.984375,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.18359375,
            "end_logit": 4.984375,
            "text": ")",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.1484375,
            "end_logit": 4.85546875,
            "text": "autoimmune encephalomyelitis",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.3515625,
            "end_logit": 4.984375,
            "text": "encephalomyelitis (EAE)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.3515625,
            "end_logit": 4.85546875,
            "text": "encephalomyelitis",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.97265625,
            "end_logit": 4.984375,
            "text": "EAE)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.66796875,
            "end_logit": 4.984375,
            "text": "chronic experimental autoimmune encephalomyelitis (EAE)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7734375,
            "end_logit": 4.984375,
            "text": "(EAE)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.66796875,
            "end_logit": 4.85546875,
            "text": "chronic experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 4.984375,
            "text": "the chronic experimental autoimmune encephalomyelitis (EAE)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.09375,
            "end_logit": 4.85546875,
            "text": "the chronic experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.1484375,
            "end_logit": 2.640625,
            "text": "autoimmune encephalomyelitis (EAE) mouse",
            "probability": 5.960464477539063e-08
        }
    ],
    "5139b31dbee46bd34c000004_3": [
        {
            "start_logit": 8.8125,
            "end_logit": 8.0703125,
            "text": "Experimental Autoimmune Encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": 8.8125,
            "end_logit": -0.91748046875,
            "text": "Experimental Autoimmune Encephalomyelitis (EAE)",
            "probability": 0.00012540817260742188
        },
        {
            "start_logit": 8.8125,
            "end_logit": -2.1796875,
            "text": "Experimental",
            "probability": 3.5643577575683594e-05
        },
        {
            "start_logit": 8.8125,
            "end_logit": -3.0078125,
            "text": "Experimental Autoimmune Encephalomyelitis (EAE",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": -2.71875,
            "end_logit": 8.0703125,
            "text": "Encephalomyelitis",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": 8.8125,
            "end_logit": -4.4765625,
            "text": "Experimental Autoimmune Encephalomyelitis (EAE) in the rat",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 8.8125,
            "end_logit": -4.80859375,
            "text": "Experimental Autoimmune Encephalomyelitis (",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 8.8125,
            "end_logit": -5.765625,
            "text": "Experimental Autoimmune Encephalomyelitis (EAE) in",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.8125,
            "end_logit": -6.52734375,
            "text": "Experimental Autoimmune Encephalomyelitis (EAE) in the",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.11328125,
            "end_logit": 8.0703125,
            "text": "Autoimmune Encephalomyelitis",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.8125,
            "end_logit": -7.1484375,
            "text": "Experimental Autoimmune",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 8.0703125,
            "text": "study was to characterize the sensory abnormalities and in particular the clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 8.0703125,
            "text": "aim of our study was to characterize the sensory abnormalities and in particular the clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.8359375,
            "end_logit": 8.0703125,
            "text": "of Experimental Autoimmune Encephalomyelitis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 8.0703125,
            "text": "The aim of our study was to characterize the sensory abnormalities and in particular the clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 8.0703125,
            "text": "our study was to characterize the sensory abnormalities and in particular the clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.11328125,
            "end_logit": 8.0703125,
            "text": "of our study was to characterize the sensory abnormalities and in particular the clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.203125,
            "end_logit": 8.0703125,
            "text": "was to characterize the sensory abnormalities and in particular the clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 8.0703125,
            "text": "characterize the sensory abnormalities and in particular the clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 8.0703125,
            "text": "to characterize the sensory abnormalities and in particular the clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 5.960464477539063e-08
        }
    ],
    "5139b31dbee46bd34c000004_4": [
        {
            "start_logit": 8.859375,
            "end_logit": 7.9609375,
            "text": "Experimental autoimmune encephalomyelitis (EAE)",
            "probability": 1.0
        },
        {
            "start_logit": 8.859375,
            "end_logit": -2.15625,
            "text": "Experimental",
            "probability": 4.07099723815918e-05
        },
        {
            "start_logit": 8.859375,
            "end_logit": -2.8515625,
            "text": "Experimental autoimmune encephalomyelitis",
            "probability": 2.0325183868408203e-05
        },
        {
            "start_logit": -2.96875,
            "end_logit": 7.9609375,
            "text": ")",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": 8.859375,
            "end_logit": -4.5390625,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": 8.859375,
            "end_logit": -5.6875,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.859375,
            "end_logit": -5.859375,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.859375,
            "end_logit": -5.99609375,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -5.38671875,
            "end_logit": 7.9609375,
            "text": "EAE)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.31640625,
            "text": "Experimental autoimmune encephalomyelitis (",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.42578125,
            "end_logit": 7.9609375,
            "text": "(EAE)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.37109375,
            "text": "Experimental autoimmune encephalomyelitis (EAE",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.66015625,
            "end_logit": 7.9609375,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.84765625,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model for studying",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.8828125,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model for",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.0546875,
            "end_logit": 7.9609375,
            "text": "encephalomyelitis (EAE)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.07421875,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model for studying multiple",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.16015625,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model for studying multiple sclerosis",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.23046875,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model for studying multiple sclerosis (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.859375,
            "end_logit": -7.27734375,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model for studying multiple sclerosis (MS",
            "probability": 2.384185791015625e-07
        }
    ],
    "5139b31dbee46bd34c000004_5": [
        {
            "start_logit": 8.828125,
            "end_logit": 7.09375,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 1.0
        },
        {
            "start_logit": 8.828125,
            "end_logit": -1.7685546875,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 0.00014209747314453125
        },
        {
            "start_logit": 8.828125,
            "end_logit": -2.2109375,
            "text": "experimental",
            "probability": 9.101629257202148e-05
        },
        {
            "start_logit": 8.828125,
            "end_logit": -4.875,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -3.4375,
            "end_logit": 7.09375,
            "text": ")",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.19140625,
            "text": "experimental autoimmune encephalomyelitis (EAE),",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.24609375,
            "text": "experimental autoimmune encephalomyelitis (EAE), an",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -4.53515625,
            "end_logit": 7.09375,
            "text": "(EAE)",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.37109375,
            "text": "experimental autoimmune encephalomyelitis (EAE), an animal",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.43359375,
            "text": "experimental autoimmune encephalomyelitis (EAE), an animal model",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -4.92578125,
            "end_logit": 7.09375,
            "text": "EAE)",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -4.9453125,
            "end_logit": 7.09375,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.828125,
            "end_logit": -6.81640625,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -5.1015625,
            "end_logit": 7.09375,
            "text": "encephalomyelitis (EAE)",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.01953125,
            "text": "experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.03515625,
            "text": "experimental autoimmune encephalomyelitis (EAE), an animal model of",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.1015625,
            "text": "experimental autoimmune encephalomyelitis (EAE), an animal model of multiple",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.125,
            "text": "experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.23046875,
            "text": "experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -4.9453125,
            "end_logit": -1.7685546875,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_6": [
        {
            "start_logit": 8.90625,
            "end_logit": 6.3671875,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.78759765625
        },
        {
            "start_logit": 8.90625,
            "end_logit": 5.0546875,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 0.2119140625
        },
        {
            "start_logit": 8.90625,
            "end_logit": -1.9619140625,
            "text": "experimental",
            "probability": 0.00019037723541259766
        },
        {
            "start_logit": 8.90625,
            "end_logit": -4.69140625,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": 8.90625,
            "end_logit": -5.9375,
            "text": "experimental autoimmune encephalomyelitis (EAE),",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -3.697265625,
            "end_logit": 6.3671875,
            "text": "in experimental autoimmune encephalomyelitis (EAE)",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 8.90625,
            "end_logit": -6.3359375,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -3.939453125,
            "end_logit": 6.3671875,
            "text": "EAE)",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -4.24609375,
            "end_logit": 6.3671875,
            "text": "encephalomyelitis (EAE)",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 8.90625,
            "end_logit": -6.890625,
            "text": "experimental autoimmune encephalomyelitis (EAE), similar",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -4.43359375,
            "end_logit": 6.3671875,
            "text": ")",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 8.90625,
            "end_logit": -7.12890625,
            "text": "experimental autoimmune",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -3.697265625,
            "end_logit": 5.0546875,
            "text": "in experimental autoimmune encephalomyelitis",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -4.24609375,
            "end_logit": 5.0546875,
            "text": "encephalomyelitis",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.72265625,
            "end_logit": 6.3671875,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.078125,
            "end_logit": 6.3671875,
            "text": "(EAE)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 6.3671875,
            "text": "study we investigated whether in an animal model for MS, namely in experimental autoimmune encephalomyelitis (EAE)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4140625,
            "end_logit": 6.3671875,
            "text": "In this study we investigated whether in an animal model for MS, namely in experimental autoimmune encephalomyelitis (EAE)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 6.3671875,
            "text": "this study we investigated whether in an animal model for MS, namely in experimental autoimmune encephalomyelitis (EAE)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.72265625,
            "end_logit": 5.0546875,
            "text": "autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5139b31dbee46bd34c000004_7": [
        {
            "start_logit": 8.8515625,
            "end_logit": 7.703125,
            "text": "Experimental autoimmune encephalomyelitis (EAE)",
            "probability": 1.0
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -2.15234375,
            "text": "Experimental",
            "probability": 5.227327346801758e-05
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -2.828125,
            "text": "Experimental autoimmune encephalomyelitis",
            "probability": 2.6464462280273438e-05
        },
        {
            "start_logit": -2.93359375,
            "end_logit": 7.703125,
            "text": ")",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -4.8828125,
            "text": "Experimental autoimmune encephalomyelitis (EAE",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -5.984375,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a widely",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -4.88671875,
            "end_logit": 7.703125,
            "text": "(EAE)",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.0703125,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -4.92578125,
            "end_logit": 7.703125,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.21875,
            "text": "Experimental autoimmune encephalomyelitis (EAE),",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -5.1171875,
            "end_logit": 7.703125,
            "text": "encephalomyelitis (EAE)",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.29296875,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a widely recognized animal",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.3046875,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a widely recognized",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -5.31640625,
            "end_logit": 7.703125,
            "text": "EAE)",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.6328125,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a widely recognized animal model",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.79296875,
            "text": "Experimental autoimmune encephalomyelitis (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -7.26953125,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a widely recognized animal model of",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -7.38671875,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a widely recognized animal model of multiple sclerosis (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -7.38671875,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a widely recognized animal model of multiple",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.92578125,
            "end_logit": -2.828125,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_8": [
        {
            "start_logit": 8.8515625,
            "end_logit": 4.6015625,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 0.57373046875
        },
        {
            "start_logit": 8.8515625,
            "end_logit": 3.685546875,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice",
            "probability": 0.22998046875
        },
        {
            "start_logit": 8.8515625,
            "end_logit": 3.51953125,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.1951904296875
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -2.130859375,
            "text": "experimental",
            "probability": 0.0006823539733886719
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -3.3671875,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.00019860267639160156
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -5.5078125,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 2.3365020751953125e-05
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -5.51171875,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice lacking",
            "probability": 2.3365020751953125e-05
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.578125,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin D",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.66015625,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice lacking cyclo",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.765625,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin D (CyPD",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.8359375,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin D (",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.9296875,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.98828125,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin D (CyP",
            "probability": 5.304813385009766e-06
        },
        {
            "start_logit": -4.796875,
            "end_logit": 4.6015625,
            "text": "encephalomyelitis",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -5.0625,
            "end_logit": 4.6015625,
            "text": "autoimmune encephalomyelitis",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -4.796875,
            "end_logit": 3.685546875,
            "text": "encephalomyelitis (EAE) mice",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.796875,
            "end_logit": 3.51953125,
            "text": "encephalomyelitis (EAE)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.0625,
            "end_logit": 3.685546875,
            "text": "autoimmune encephalomyelitis (EAE) mice",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.16796875,
            "end_logit": 3.685546875,
            "text": "EAE) mice",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.0625,
            "end_logit": 3.51953125,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5139b31dbee46bd34c000004_9": [
        {
            "start_logit": 9.140625,
            "end_logit": 8.8984375,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": 9.140625,
            "end_logit": -1.0234375,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 4.947185516357422e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -1.5126953125,
            "text": "experimental",
            "probability": 3.0219554901123047e-05
        },
        {
            "start_logit": -1.6513671875,
            "end_logit": 8.8984375,
            "text": "encephalomyelitis",
            "probability": 2.0802021026611328e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -5.83984375,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.66015625,
            "end_logit": 8.8984375,
            "text": "autoimmune encephalomyelitis",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -6.90625,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.10546875,
            "text": "experimental autoimmune",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 8.8984375,
            "text": "model experimental autoimmune encephalomyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5625,
            "end_logit": 8.8984375,
            "text": "MS model experimental autoimmune encephalomyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 8.8984375,
            "text": "classical MS model experimental autoimmune encephalomyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.6513671875,
            "end_logit": -1.0234375,
            "text": "encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -5.08203125,
            "end_logit": -1.0234375,
            "text": "(EAE",
            "probability": 0.0
        },
        {
            "start_logit": -5.61328125,
            "end_logit": -1.0234375,
            "text": "EAE",
            "probability": 0.0
        },
        {
            "start_logit": -5.66015625,
            "end_logit": -1.0234375,
            "text": "autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -1.6513671875,
            "end_logit": -5.83984375,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -1.6513671875,
            "end_logit": -6.90625,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -1.0234375,
            "text": "model experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -7.5625,
            "end_logit": -1.0234375,
            "text": "MS model experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -7.65234375,
            "end_logit": -1.0234375,
            "text": "classical MS model experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_10": [
        {
            "start_logit": 9.0234375,
            "end_logit": 8.84375,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -1.7861328125,
            "text": "experimental",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": -1.763671875,
            "end_logit": 8.84375,
            "text": "encephalomyelitis",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -2.146484375,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -5.64453125,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.484375,
            "end_logit": 8.84375,
            "text": "autoimmune encephalomyelitis",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 8.84375,
            "text": ", experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.16796875,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.26171875,
            "text": "experimental autoimmune",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 8.84375,
            "text": "The conventional animal model of MS, experimental autoimmune encephalomyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 8.84375,
            "text": "MS, experimental autoimmune encephalomyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 8.84375,
            "text": "conventional animal model of MS, experimental autoimmune encephalomyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 8.84375,
            "text": "of MS, experimental autoimmune encephalomyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.763671875,
            "end_logit": -2.146484375,
            "text": "encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -1.763671875,
            "end_logit": -5.64453125,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -5.3515625,
            "end_logit": -2.146484375,
            "text": "(EAE",
            "probability": 0.0
        },
        {
            "start_logit": -5.484375,
            "end_logit": -2.146484375,
            "text": "autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -5.66015625,
            "end_logit": -2.146484375,
            "text": "EAE",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -1.7861328125,
            "text": ", experimental",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": -2.146484375,
            "text": ", experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_11": [
        {
            "start_logit": 8.6875,
            "end_logit": 6.8671875,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 0.98291015625
        },
        {
            "start_logit": 8.6875,
            "end_logit": 2.806640625,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.0169219970703125
        },
        {
            "start_logit": 8.6875,
            "end_logit": -1.0419921875,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0003604888916015625
        },
        {
            "start_logit": 8.6875,
            "end_logit": -2.36328125,
            "text": "experimental",
            "probability": 9.59634780883789e-05
        },
        {
            "start_logit": -3.556640625,
            "end_logit": 6.8671875,
            "text": "encephalomyelitis",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 8.6875,
            "end_logit": -6.48046875,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -4.7421875,
            "end_logit": 6.8671875,
            "text": "of experimental autoimmune encephalomyelitis",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -5.734375,
            "end_logit": 6.8671875,
            "text": "autoimmune encephalomyelitis",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 6.8671875,
            "text": "To assess neurological impairments quantitatively in an animal model of multiple sclerosis (MS), we have used a targeted model of experimental autoimmune encephalomyelitis",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 6.8671875,
            "text": "model of experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.25,
            "end_logit": 6.8671875,
            "text": "), we have used a targeted model of experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.30078125,
            "end_logit": 6.8671875,
            "text": "in an animal model of multiple sclerosis (MS), we have used a targeted model of experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 6.8671875,
            "text": "assess neurological impairments quantitatively in an animal model of multiple sclerosis (MS), we have used a targeted model of experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.33984375,
            "end_logit": 6.8671875,
            "text": "multiple sclerosis (MS), we have used a targeted model of experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 6.8671875,
            "text": "MS), we have used a targeted model of experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.390625,
            "end_logit": 6.8671875,
            "text": "we have used a targeted model of experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 6.8671875,
            "text": "sclerosis (MS), we have used a targeted model of experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.556640625,
            "end_logit": 2.806640625,
            "text": "encephalomyelitis (EAE)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.7421875,
            "end_logit": 2.806640625,
            "text": "of experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -5.734375,
            "end_logit": 2.806640625,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_12": [
        {
            "start_logit": 9.046875,
            "end_logit": 8.484375,
            "text": "Experimental autoimmune encephalomyelitis (EAE)",
            "probability": 1.0
        },
        {
            "start_logit": 9.046875,
            "end_logit": -1.77734375,
            "text": "Experimental",
            "probability": 3.4809112548828125e-05
        },
        {
            "start_logit": -2.349609375,
            "end_logit": 8.484375,
            "text": ")",
            "probability": 1.1205673217773438e-05
        },
        {
            "start_logit": 9.046875,
            "end_logit": -4.41015625,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 9.046875,
            "end_logit": -4.875,
            "text": "Experimental autoimmune encephalomyelitis",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 9.046875,
            "end_logit": -5.70703125,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a well",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -5.25390625,
            "end_logit": 8.484375,
            "text": "(EAE)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.26953125,
            "end_logit": 8.484375,
            "text": "EAE)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.2890625,
            "end_logit": 8.484375,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.33203125,
            "end_logit": 8.484375,
            "text": "encephalomyelitis (EAE)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.2109375,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.390625,
            "text": "Experimental autoimmune encephalomyelitis (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.40234375,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a well-studied disease in rodents",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.63671875,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a well-",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.8203125,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a well-studied",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -6.984375,
            "text": "Experimental autoimmune encephalomyelitis (EAE",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.02734375,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a well-studied disease",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.16015625,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a well-studied disease in rodents that",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.1953125,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a well-studied disease in rodents that mimics many clinical and pathological features of MS, including central nervous system",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.20703125,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a well-studied disease in rodents that mimics",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5139b31dbee46bd34c000004_13": [
        {
            "start_logit": 8.9453125,
            "end_logit": 8.3515625,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.9453125,
            "end_logit": 1.140625,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.0007376670837402344
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -1.9501953125,
            "text": "experimental",
            "probability": 3.36766242980957e-05
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -2.3125,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 2.3365020751953125e-05
        },
        {
            "start_logit": -2.40625,
            "end_logit": 8.3515625,
            "text": "encephalomyelitis",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.046875,
            "text": "experimental autoimmune encephalomyelitis (EAE),",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.58984375,
            "end_logit": 8.3515625,
            "text": "autoimmune encephalomyelitis",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.42578125,
            "text": "experimental autoimmune encephalomyelitis (EAE), its animal model",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.5625,
            "text": "experimental autoimmune encephalomyelitis (EAE), its animal",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.65625,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.84765625,
            "text": "experimental autoimmune encephalomyelitis (EAE), its animal model, involve inflammatory attack on central nervous system (CNS",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.8515625,
            "text": "experimental autoimmune encephalomyelitis (EAE), its",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.87109375,
            "text": "experimental autoimmune encephalomyelitis (EAE), its animal model, involve inflammatory attack on central nervous system",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -6.95703125,
            "text": "experimental autoimmune encephalomyelitis (EAE), its animal model, involve inflammatory attack on",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -7.02734375,
            "text": "experimental autoimmune encephalomyelitis (EAE), its animal model, involve inflammatory attack on central nervous system (CNS)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -7.03125,
            "text": "experimental autoimmune encephalomyelitis (EAE), its animal model, involve inflammatory attack on central nervous system (CNS) white matter",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -7.07421875,
            "text": "experimental autoimmune encephalomyelitis (EAE), its animal model, involve inflammatory attack on central nervous system (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -7.09765625,
            "text": "experimental autoimmune encephalomyelitis (EAE), its animal model, involve inflammatory attack",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9453125,
            "end_logit": -7.11328125,
            "text": "experimental autoimmune encephalomyelitis (EAE), its animal model, involve inflammatory attack on central nervous system (CNS) white",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.1875,
            "end_logit": 8.3515625,
            "text": "multiple sclerosis (MS) and experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5139b31dbee46bd34c000004_14": [
        {
            "start_logit": 9.046875,
            "end_logit": 8.6484375,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.046875,
            "end_logit": 1.2646484375,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0006260871887207031
        },
        {
            "start_logit": 9.046875,
            "end_logit": -1.689453125,
            "text": "experimental",
            "probability": 3.266334533691406e-05
        },
        {
            "start_logit": -1.955078125,
            "end_logit": 8.6484375,
            "text": "encephalomyelitis",
            "probability": 1.6808509826660156e-05
        },
        {
            "start_logit": 9.046875,
            "end_logit": -5.3984375,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -5.41015625,
            "end_logit": 8.6484375,
            "text": "autoimmune encephalomyelitis",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.9921875,
            "end_logit": 8.6484375,
            "text": ", experimental autoimmune encephalomyelitis",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.046875,
            "end_logit": -7.234375,
            "text": "experimental autoimmune",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 8.6484375,
            "text": "MS patients and the MS animal model, experimental autoimmune encephalomyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 8.6484375,
            "text": "both MS patients and the MS animal model, experimental autoimmune encephalomyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 8.6484375,
            "text": "and the MS animal model, experimental autoimmune encephalomyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 8.6484375,
            "text": "patients and the MS animal model, experimental autoimmune encephalomyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.955078125,
            "end_logit": 1.2646484375,
            "text": "encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -4.25,
            "end_logit": 1.2646484375,
            "text": "EAE",
            "probability": 0.0
        },
        {
            "start_logit": -4.73046875,
            "end_logit": 1.2646484375,
            "text": "(EAE",
            "probability": 0.0
        },
        {
            "start_logit": -5.41015625,
            "end_logit": 1.2646484375,
            "text": "autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -5.9921875,
            "end_logit": 1.2646484375,
            "text": ", experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 1.2646484375,
            "text": "MS patients and the MS animal model, experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 1.2646484375,
            "text": "both MS patients and the MS animal model, experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -7.546875,
            "end_logit": 1.2646484375,
            "text": "and the MS animal model, experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_15": [
        {
            "start_logit": 8.7265625,
            "end_logit": 6.5,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 0.98388671875
        },
        {
            "start_logit": 8.7265625,
            "end_logit": 1.9638671875,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.01050567626953125
        },
        {
            "start_logit": 8.7265625,
            "end_logit": 1.294921875,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.00540924072265625
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -2.306640625,
            "text": "experimental",
            "probability": 0.0001475811004638672
        },
        {
            "start_logit": -4.1640625,
            "end_logit": 6.5,
            "text": "encephalomyelitis",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 8.7265625,
            "end_logit": -6.91796875,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -5.015625,
            "end_logit": 6.5,
            "text": "autoimmune encephalomyelitis",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 6.5,
            "text": "MS animal model experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 6.5,
            "text": "In the MS animal model experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 6.5,
            "text": "model experimental autoimmune encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.546875,
            "end_logit": 6.5,
            "text": "animal model experimental autoimmune encephalomyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.1640625,
            "end_logit": 1.9638671875,
            "text": "encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -4.1640625,
            "end_logit": 1.294921875,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -5.015625,
            "end_logit": 1.9638671875,
            "text": "autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -5.40625,
            "end_logit": 1.9638671875,
            "text": "EAE",
            "probability": 0.0
        },
        {
            "start_logit": -5.46484375,
            "end_logit": 1.9638671875,
            "text": "(EAE",
            "probability": 0.0
        },
        {
            "start_logit": -5.015625,
            "end_logit": 1.294921875,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -5.40625,
            "end_logit": 1.294921875,
            "text": "EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -5.46484375,
            "end_logit": 1.294921875,
            "text": "(EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 1.9638671875,
            "text": "MS animal model experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_16": [
        {
            "start_logit": 2.41796875,
            "end_logit": 7.48046875,
            "text": "EAE",
            "probability": 0.8642578125
        },
        {
            "start_logit": 0.546875,
            "end_logit": 7.48046875,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.133544921875
        },
        {
            "start_logit": 0.546875,
            "end_logit": 2.283203125,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 0.0007348060607910156
        },
        {
            "start_logit": -5.12109375,
            "end_logit": 7.48046875,
            "text": "autoimmune encephalomyelitis (EAE",
            "probability": 0.00045943260192871094
        },
        {
            "start_logit": -5.59765625,
            "end_logit": 7.48046875,
            "text": "(EAE",
            "probability": 0.0002853870391845703
        },
        {
            "start_logit": -6.046875,
            "end_logit": 7.48046875,
            "text": "and experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.00018143653869628906
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 7.48046875,
            "text": "encephalomyelitis (EAE",
            "probability": 9.709596633911133e-05
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 7.48046875,
            "text": "lesions and experimental autoimmune encephalomyelitis (EAE",
            "probability": 4.482269287109375e-05
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 7.48046875,
            "text": ") lesions and experimental autoimmune encephalomyelitis (EAE",
            "probability": 4.3392181396484375e-05
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 7.48046875,
            "text": "MS) lesions and experimental autoimmune encephalomyelitis (EAE",
            "probability": 4.309415817260742e-05
        },
        {
            "start_logit": -7.546875,
            "end_logit": 7.48046875,
            "text": "multiple sclerosis (MS) lesions and experimental autoimmune encephalomyelitis (EAE",
            "probability": 4.0471553802490234e-05
        },
        {
            "start_logit": -7.59375,
            "end_logit": 7.48046875,
            "text": "sclerosis (MS) lesions and experimental autoimmune encephalomyelitis (EAE",
            "probability": 3.8623809814453125e-05
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 7.48046875,
            "text": "(MS) lesions and experimental autoimmune encephalomyelitis (EAE",
            "probability": 3.68952751159668e-05
        },
        {
            "start_logit": -5.12109375,
            "end_logit": 2.283203125,
            "text": "autoimmune encephalomyelitis",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 2.41796875,
            "end_logit": -5.83203125,
            "text": "EAE)",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -6.046875,
            "end_logit": 2.283203125,
            "text": "and experimental autoimmune encephalomyelitis",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 2.283203125,
            "text": "encephalomyelitis",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 2.283203125,
            "text": "lesions and experimental autoimmune encephalomyelitis",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 2.283203125,
            "text": ") lesions and experimental autoimmune encephalomyelitis",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 2.283203125,
            "text": "MS) lesions and experimental autoimmune encephalomyelitis",
            "probability": 2.384185791015625e-07
        }
    ],
    "553ca8d8f32186855800000d_1": [
        {
            "start_logit": 8.46875,
            "end_logit": 8.8046875,
            "text": "replication defects",
            "probability": 1.0
        },
        {
            "start_logit": -1.92578125,
            "end_logit": 8.8046875,
            "text": "defects",
            "probability": 3.0219554901123047e-05
        },
        {
            "start_logit": 8.46875,
            "end_logit": -2.79296875,
            "text": "replication",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": -4.82421875,
            "end_logit": 8.8046875,
            "text": "DNA helicase causes replication defects",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 8.46875,
            "end_logit": -5.0703125,
            "text": "replication defects at",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -5.87890625,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -5.8828125,
            "text": "replication defects at multiple",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -5.90234375,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA),",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -5.9375,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -5.94921875,
            "text": "replication defects at multiple sites within ribosomal DNA",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -6.03125,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -6.2578125,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.6640625,
            "end_logit": 8.8046875,
            "text": "Lack of the yeast Rrm3p DNA helicase causes replication defects",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -6.375,
            "text": "replication defects at multiple sites within ribosomal DNA (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -6.5078125,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 8.8046875,
            "text": "p DNA helicase causes replication defects",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -6.625,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -6.6328125,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA), including",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -6.63671875,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.46875,
            "end_logit": -6.63671875,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RF",
            "probability": 1.7881393432617188e-07
        }
    ],
    "58e9f0ba3e8b6dc87c00000e_1": [
        {
            "start_logit": 8.4140625,
            "end_logit": 5.66796875,
            "text": "Sulcia muelleri",
            "probability": 0.89892578125
        },
        {
            "start_logit": 8.4140625,
            "end_logit": 3.275390625,
            "text": "Sulcia muelleri and Nasuia deltocephalinicola, of the phloem-feeding pest insect, Macrosteles quadrilineatus",
            "probability": 0.08233642578125
        },
        {
            "start_logit": 6.8984375,
            "end_logit": 3.275390625,
            "text": "Macrosteles quadrilineatus",
            "probability": 0.0180816650390625
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -2.427734375,
            "text": "Sul",
            "probability": 0.000274658203125
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -3.62109375,
            "text": "Sulcia",
            "probability": 8.374452590942383e-05
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -4.28515625,
            "text": "Sulcia muelleri and Nasuia deltocephalinicola, of the phloem-feeding pest insect, Macros",
            "probability": 4.273653030395508e-05
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -5.0078125,
            "text": "Sulcia mueller",
            "probability": 2.086162567138672e-05
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -5.359375,
            "text": "Sulcia muelleri and",
            "probability": 1.4662742614746094e-05
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -5.41015625,
            "text": "Sulcia mu",
            "probability": 1.3887882232666016e-05
        },
        {
            "start_logit": 6.8984375,
            "end_logit": -4.28515625,
            "text": "Macros",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": 6.8984375,
            "end_logit": -4.59375,
            "text": "Macrosteles quadrilineatus (Auchenorrhyncha: Cicadellidae).",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -6.2578125,
            "text": "Sulcia muelleri and Nasuia deltocephalinicola, of the phloem-feeding pest insect, Macrosteles",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -6.36328125,
            "text": "Sulcia muelleri and Nasuia deltocephalinicola,",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -6.42578125,
            "text": "Sulcia muelleri and Nas",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -6.44140625,
            "text": "Sulcia muelleri and Nasuia deltocephalinicola, of the phloem-feeding pest insect, Macrosteles quadr",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -6.4921875,
            "text": "Sulcia muelleri and Nasui",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": 6.8984375,
            "end_logit": -6.1328125,
            "text": "Macrosteles quadrilineatus (Auchenorrhyncha",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -4.9375,
            "end_logit": 5.66796875,
            "text": "symbionts, Sulcia muelleri",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 6.8984375,
            "end_logit": -6.2578125,
            "text": "Macrosteles",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 6.8984375,
            "end_logit": -6.41796875,
            "text": "Macrosteles quadrilineatus (Auchenorrhyncha: Cicadellidae",
            "probability": 1.1324882507324219e-06
        }
    ],
    "5a6e2578b750ff445500003d_1": [
        {
            "start_logit": 9.171875,
            "end_logit": 9.109375,
            "text": "diffloop",
            "probability": 1.0
        },
        {
            "start_logit": 9.171875,
            "end_logit": -1.5361328125,
            "text": "diff",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": -1.5146484375,
            "end_logit": 9.109375,
            "text": "op",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": -5.4921875,
            "end_logit": 9.109375,
            "text": "loop",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.859375,
            "text": "diffloop:",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.8828125,
            "text": "difflo",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.08203125,
            "text": "diffloop: a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.28515625,
            "text": "diffloop: a computational framework for identifying and analyzing differential DNA loops from sequencing data.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.33203125,
            "text": "diffloop: a computational framework",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.5146484375,
            "end_logit": -6.859375,
            "text": "op:",
            "probability": 0.0
        },
        {
            "start_logit": -1.5146484375,
            "end_logit": -7.08203125,
            "text": "op: a",
            "probability": 0.0
        },
        {
            "start_logit": -1.5146484375,
            "end_logit": -7.28515625,
            "text": "op: a computational framework for identifying and analyzing differential DNA loops from sequencing data.",
            "probability": 0.0
        },
        {
            "start_logit": -1.5146484375,
            "end_logit": -7.33203125,
            "text": "op: a computational framework",
            "probability": 0.0
        },
        {
            "start_logit": -4.23046875,
            "end_logit": -7.28515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.4921875,
            "end_logit": -6.859375,
            "text": "loop:",
            "probability": 0.0
        },
        {
            "start_logit": -5.4921875,
            "end_logit": -6.8828125,
            "text": "lo",
            "probability": 0.0
        },
        {
            "start_logit": -5.4921875,
            "end_logit": -7.08203125,
            "text": "loop: a",
            "probability": 0.0
        },
        {
            "start_logit": -5.4921875,
            "end_logit": -7.28515625,
            "text": "loop: a computational framework for identifying and analyzing differential DNA loops from sequencing data.",
            "probability": 0.0
        },
        {
            "start_logit": -5.4921875,
            "end_logit": -7.33203125,
            "text": "loop: a computational framework",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -7.28515625,
            "text": "identifying and analyzing differential DNA loops from sequencing data.",
            "probability": 0.0
        }
    ],
    "5a6e2578b750ff445500003d_2": [
        {
            "start_logit": 9.1875,
            "end_logit": 9.1171875,
            "text": "diffloop",
            "probability": 1.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.4970703125,
            "text": "diff",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -1.455078125,
            "end_logit": 9.1171875,
            "text": "op",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": -5.09375,
            "end_logit": 9.1171875,
            "text": "loop",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.0078125,
            "text": "diffloop,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.41796875,
            "end_logit": 9.1171875,
            "text": "introduce diffloop",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.8203125,
            "text": "diffloop, an",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.89453125,
            "text": "diffloop, an R",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.92578125,
            "text": "diffloop, an R/Bioconductor package",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.9375,
            "text": "difflo",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.01171875,
            "text": "diffloop, an R/Bioconductor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.0625,
            "text": "diffloop, an R/Bioconduc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.08984375,
            "text": "diffloop, an R/Bioconductor package that",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.14453125,
            "text": "diffloop, an R/Bioc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.234375,
            "text": "diffloop, an R/Bioconductor package that provides a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.2890625,
            "text": "diffloop, an R/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.1171875,
            "text": "To systematically assess changes in DNA looping architecture between samples, we introduce diffloop",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.1171875,
            "text": "between samples, we introduce diffloop",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.1171875,
            "text": "samples, we introduce diffloop",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.1171875,
            "text": ", we introduce diffloop",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a6e2578b750ff445500003d_3": [
        {
            "start_logit": 9.1875,
            "end_logit": 9.1171875,
            "text": "diffloop",
            "probability": 1.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.4970703125,
            "text": "diff",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -1.455078125,
            "end_logit": 9.1171875,
            "text": "op",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": -5.09375,
            "end_logit": 9.1171875,
            "text": "loop",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.0078125,
            "text": "diffloop,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.41796875,
            "end_logit": 9.1171875,
            "text": "introduce diffloop",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.8203125,
            "text": "diffloop, an",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.89453125,
            "text": "diffloop, an R",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.92578125,
            "text": "diffloop, an R/Bioconductor package",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.9375,
            "text": "difflo",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.01171875,
            "text": "diffloop, an R/Bioconductor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.0625,
            "text": "diffloop, an R/Bioconduc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.08984375,
            "text": "diffloop, an R/Bioconductor package that",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.14453125,
            "text": "diffloop, an R/Bioc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.234375,
            "text": "diffloop, an R/Bioconductor package that provides a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.2890625,
            "text": "diffloop, an R/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.1171875,
            "text": "To systematically assess changes in DNA looping architecture between samples, we introduce diffloop",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.1171875,
            "text": "between samples, we introduce diffloop",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.1171875,
            "text": "samples, we introduce diffloop",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.1171875,
            "text": ", we introduce diffloop",
            "probability": 5.960464477539063e-08
        }
    ],
    "5a6e2578b750ff445500003d_4": [
        {
            "start_logit": 9.171875,
            "end_logit": 9.109375,
            "text": "diffloop",
            "probability": 1.0
        },
        {
            "start_logit": 9.171875,
            "end_logit": -1.5361328125,
            "text": "diff",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": -1.5146484375,
            "end_logit": 9.109375,
            "text": "op",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": -5.4921875,
            "end_logit": 9.109375,
            "text": "loop",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.859375,
            "text": "diffloop:",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.8828125,
            "text": "difflo",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.08203125,
            "text": "diffloop: a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.28515625,
            "text": "diffloop: a computational framework for identifying and analyzing differential DNA loops from sequencing data.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.33203125,
            "text": "diffloop: a computational framework",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.5146484375,
            "end_logit": -6.859375,
            "text": "op:",
            "probability": 0.0
        },
        {
            "start_logit": -1.5146484375,
            "end_logit": -7.08203125,
            "text": "op: a",
            "probability": 0.0
        },
        {
            "start_logit": -1.5146484375,
            "end_logit": -7.28515625,
            "text": "op: a computational framework for identifying and analyzing differential DNA loops from sequencing data.",
            "probability": 0.0
        },
        {
            "start_logit": -1.5146484375,
            "end_logit": -7.33203125,
            "text": "op: a computational framework",
            "probability": 0.0
        },
        {
            "start_logit": -4.23046875,
            "end_logit": -7.28515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.4921875,
            "end_logit": -6.859375,
            "text": "loop:",
            "probability": 0.0
        },
        {
            "start_logit": -5.4921875,
            "end_logit": -6.8828125,
            "text": "lo",
            "probability": 0.0
        },
        {
            "start_logit": -5.4921875,
            "end_logit": -7.08203125,
            "text": "loop: a",
            "probability": 0.0
        },
        {
            "start_logit": -5.4921875,
            "end_logit": -7.28515625,
            "text": "loop: a computational framework for identifying and analyzing differential DNA loops from sequencing data.",
            "probability": 0.0
        },
        {
            "start_logit": -5.4921875,
            "end_logit": -7.33203125,
            "text": "loop: a computational framework",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -7.28515625,
            "text": "identifying and analyzing differential DNA loops from sequencing data.",
            "probability": 0.0
        }
    ],
    "5a6e2578b750ff445500003d_5": [
        {
            "start_logit": 9.1875,
            "end_logit": 9.1171875,
            "text": "diffloop",
            "probability": 1.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.4970703125,
            "text": "diff",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -1.455078125,
            "end_logit": 9.1171875,
            "text": "op",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": -5.09375,
            "end_logit": 9.1171875,
            "text": "loop",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.0078125,
            "text": "diffloop,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.41796875,
            "end_logit": 9.1171875,
            "text": "introduce diffloop",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.8203125,
            "text": "diffloop, an",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.89453125,
            "text": "diffloop, an R",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.92578125,
            "text": "diffloop, an R/Bioconductor package",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -6.9375,
            "text": "difflo",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.01171875,
            "text": "diffloop, an R/Bioconductor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.0625,
            "text": "diffloop, an R/Bioconduc",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.08984375,
            "text": "diffloop, an R/Bioconductor package that",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.14453125,
            "text": "diffloop, an R/Bioc",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.234375,
            "text": "diffloop, an R/Bioconductor package that provides a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.2890625,
            "text": "diffloop, an R/",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.1171875,
            "text": "To systematically assess changes in DNA looping architecture between samples, we introduce diffloop",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.1171875,
            "text": "between samples, we introduce diffloop",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.1171875,
            "text": "samples, we introduce diffloop",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 9.1171875,
            "text": ", we introduce diffloop",
            "probability": 5.960464477539063e-08
        }
    ],
    "5e29fb27aa19d74431000005_1": [
        {
            "start_logit": 4.88671875,
            "end_logit": 0.45751953125,
            "text": "hyperphosphorylation of DDR proteins (BRCA1, Chk2, and \u03b3H2AX), altered the chronology and persistence of JNK",
            "probability": 0.72509765625
        },
        {
            "start_logit": 3.197265625,
            "end_logit": 0.45751953125,
            "text": "JNK",
            "probability": 0.1339111328125
        },
        {
            "start_logit": 4.88671875,
            "end_logit": -1.6787109375,
            "text": "hyperphosphorylation",
            "probability": 0.08563232421875
        },
        {
            "start_logit": 4.88671875,
            "end_logit": -2.7890625,
            "text": "hyperphosphorylation of DDR proteins (BRCA1, Chk2, and \u03b3H2AX), altered the chronology and persistence of JNK activation",
            "probability": 0.0282440185546875
        },
        {
            "start_logit": 3.197265625,
            "end_logit": -2.7890625,
            "text": "JNK activation",
            "probability": 0.005199432373046875
        },
        {
            "start_logit": 4.88671875,
            "end_logit": -4.80859375,
            "text": "hyperphosphorylation of DDR proteins (BRCA1, Chk2, and \u03b3H2AX)",
            "probability": 0.00374603271484375
        },
        {
            "start_logit": 4.88671875,
            "end_logit": -4.90625,
            "text": "hyperphosphorylation of DDR proteins (BRCA1, Chk2, and \u03b3H2AX), altered the chronology and persistence of JNK activation,",
            "probability": 0.0033969879150390625
        },
        {
            "start_logit": -0.6552734375,
            "end_logit": 0.45751953125,
            "text": "constitutive hyperphosphorylation of DDR proteins (BRCA1, Chk2, and \u03b3H2AX), altered the chronology and persistence of JNK",
            "probability": 0.002838134765625
        },
        {
            "start_logit": 3.197265625,
            "end_logit": -4.01171875,
            "text": "JNK activation, and modulated the expression of 14-3-3 binding sites.",
            "probability": 0.0015382766723632812
        },
        {
            "start_logit": 4.88671875,
            "end_logit": -5.73046875,
            "text": "hyperphosph",
            "probability": 0.0014896392822265625
        },
        {
            "start_logit": 4.88671875,
            "end_logit": -5.8359375,
            "text": "hyperphosphorylation of DDR proteins (BRCA1, Chk2, and \u03b3H2AX),",
            "probability": 0.0013408660888671875
        },
        {
            "start_logit": 4.88671875,
            "end_logit": -5.890625,
            "text": "hyperphosphorylation of DD",
            "probability": 0.0012693405151367188
        },
        {
            "start_logit": 4.88671875,
            "end_logit": -5.8984375,
            "text": "hyperphosphorylation of",
            "probability": 0.0012598037719726562
        },
        {
            "start_logit": 4.88671875,
            "end_logit": -5.96484375,
            "text": "hyperphosphorylation of DDR proteins (BRCA1, Chk2, and \u03b3H2AX), altered the chronology and persistence of JNK activation, and",
            "probability": 0.001178741455078125
        },
        {
            "start_logit": 4.88671875,
            "end_logit": -6.18359375,
            "text": "hyperphosphorylation of DDR",
            "probability": 0.0009474754333496094
        },
        {
            "start_logit": 4.88671875,
            "end_logit": -6.30078125,
            "text": "hyperphosphorylation of DDR proteins",
            "probability": 0.0008425712585449219
        },
        {
            "start_logit": 4.88671875,
            "end_logit": -6.36328125,
            "text": "hyperphosphorylation of DDR proteins (BRCA1, Chk2, and \u03b3H2AX",
            "probability": 0.0007910728454589844
        },
        {
            "start_logit": 3.197265625,
            "end_logit": -4.90625,
            "text": "JNK activation,",
            "probability": 0.0006260871887207031
        },
        {
            "start_logit": 4.88671875,
            "end_logit": -6.61328125,
            "text": "hyperphosphorylation of DDR proteins (BRCA1",
            "probability": 0.0006165504455566406
        },
        {
            "start_logit": -0.6552734375,
            "end_logit": -1.6787109375,
            "text": "constitutive hyperphosphorylation",
            "probability": 0.0003349781036376953
        }
    ],
    "5c6e0f537c78d6947100004a_1": [
        {
            "start_logit": 4.65625,
            "end_logit": 1.3134765625,
            "text": "tropomyosin receptor kinases",
            "probability": 0.98388671875
        },
        {
            "start_logit": 4.65625,
            "end_logit": -4.33203125,
            "text": "tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase",
            "probability": 0.00347900390625
        },
        {
            "start_logit": 4.65625,
            "end_logit": -4.44921875,
            "text": "tropomyosin receptor kinases (TR",
            "probability": 0.003093719482421875
        },
        {
            "start_logit": 4.65625,
            "end_logit": -4.7578125,
            "text": "tropomyosin receptor kinases (TRK",
            "probability": 0.0022716522216796875
        },
        {
            "start_logit": 4.65625,
            "end_logit": -4.92578125,
            "text": "tropomyosin receptor kinases (",
            "probability": 0.0019216537475585938
        },
        {
            "start_logit": 4.65625,
            "end_logit": -5.5546875,
            "text": "tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (NTRK",
            "probability": 0.0010242462158203125
        },
        {
            "start_logit": -2.583984375,
            "end_logit": 1.3134765625,
            "text": "of tropomyosin receptor kinases",
            "probability": 0.0007066726684570312
        },
        {
            "start_logit": 4.65625,
            "end_logit": -6.03125,
            "text": "tropomyosin",
            "probability": 0.0006361007690429688
        },
        {
            "start_logit": 4.65625,
            "end_logit": -6.046875,
            "text": "tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (NTR",
            "probability": 0.0006260871887207031
        },
        {
            "start_logit": 4.65625,
            "end_logit": -6.19921875,
            "text": "tropomyosin receptor kinases (TRK),",
            "probability": 0.0005373954772949219
        },
        {
            "start_logit": 4.65625,
            "end_logit": -6.3125,
            "text": "tropomyosin receptor kinases (TRK), demonstrated",
            "probability": 0.0004801750183105469
        },
        {
            "start_logit": 4.65625,
            "end_logit": -6.44921875,
            "text": "tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (",
            "probability": 0.0004189014434814453
        },
        {
            "start_logit": 4.65625,
            "end_logit": -6.56640625,
            "text": "tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (NTRK)",
            "probability": 0.0003724098205566406
        },
        {
            "start_logit": 4.65625,
            "end_logit": -6.75,
            "text": "tropomyosin receptor",
            "probability": 0.00030994415283203125
        },
        {
            "start_logit": -6.61328125,
            "end_logit": 1.3134765625,
            "text": "receptor kinases",
            "probability": 1.2576580047607422e-05
        },
        {
            "start_logit": -6.72265625,
            "end_logit": 1.3134765625,
            "text": ", larotrectinib (LOXO-101), Loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 1.3134765625,
            "text": "(LOXO-101), Loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases",
            "probability": 8.52346420288086e-06
        },
        {
            "start_logit": -7.046875,
            "end_logit": 1.3134765625,
            "text": ", Loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases",
            "probability": 8.165836334228516e-06
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 1.3134765625,
            "text": "inhibitor of tropomyosin receptor kinases",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 1.3134765625,
            "text": "LOXO-101), Loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases",
            "probability": 6.854534149169922e-06
        }
    ],
    "58dbb8968acda3452900001b_1": [
        {
            "start_logit": 9.1171875,
            "end_logit": 9.4375,
            "text": "Sudden Unexpected Death in Epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": 9.4375,
            "text": "Epilepsy",
            "probability": 9.995698928833008e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.6064453125,
            "text": "Sudden",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 9.4375,
            "text": "in Epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.19921875,
            "text": "Sudden Unexpected Death in Epilepsy (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 9.4375,
            "text": "Unexpected Death in Epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 9.4375,
            "text": "Death in Epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.91796875,
            "text": "Sudden Unexpected Death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.05078125,
            "text": "Sudden Unexpected Death in Epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.0546875,
            "text": "Sudden Unexpected Death in Epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.3671875,
            "text": "Sudden Unexpected Death in Epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -6.19921875,
            "text": "Epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.05078125,
            "text": "Epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.0546875,
            "text": "Epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.3671875,
            "text": "Epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -6.19921875,
            "text": "in Epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.56640625,
            "end_logit": -6.19921875,
            "text": "Unexpected Death in Epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -6.19921875,
            "text": "Death in Epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -7.05078125,
            "text": "in Epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -7.0546875,
            "text": "in Epilepsy (SUD",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_2": [
        {
            "start_logit": 9.1640625,
            "end_logit": 9.5390625,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": 0.5654296875,
            "end_logit": 9.5390625,
            "text": "epilepsy",
            "probability": 0.0001838207244873047
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -1.470703125,
            "text": "sudden",
            "probability": 1.6570091247558594e-05
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 9.5390625,
            "text": "in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.234375,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 9.5390625,
            "text": "unexpected death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0,
            "end_logit": 9.5390625,
            "text": "death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.828125,
            "text": "sudden unexpected death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.921875,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.95703125,
            "text": "sudden unexpected death in epilepsy (SUDEP),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.98828125,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.0859375,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.5654296875,
            "end_logit": -6.234375,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 0.5654296875,
            "end_logit": -6.921875,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 0.5654296875,
            "end_logit": -6.95703125,
            "text": "epilepsy (SUDEP),",
            "probability": 0.0
        },
        {
            "start_logit": 0.5654296875,
            "end_logit": -6.98828125,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 0.5654296875,
            "end_logit": -7.0859375,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -5.07421875,
            "end_logit": -6.95703125,
            "text": ",",
            "probability": 0.0
        },
        {
            "start_logit": -6.55078125,
            "end_logit": -6.234375,
            "text": "in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.66015625,
            "end_logit": -6.234375,
            "text": "unexpected death in epilepsy (",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_3": [
        {
            "start_logit": 9.0546875,
            "end_logit": 9.6640625,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 0.9990234375
        },
        {
            "start_logit": 1.48046875,
            "end_logit": 9.6640625,
            "text": "epilepsy",
            "probability": 0.00051116943359375
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -1.71875,
            "text": "Sudden",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 9.6640625,
            "text": "in epilepsy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 9.6640625,
            "text": "unexpected death in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.55078125,
            "text": "Sudden unexpected death",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.67578125,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.6640625,
            "text": "death in epilepsy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.06640625,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.07421875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is the most",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.10546875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.125,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.16015625,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.16015625,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.171875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is the most important",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.28125,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is the most important direct seizure-related cause of death, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.34375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is the most important direct seizure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.3515625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is the most important direct seizure-related cause",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is the most important direct seizure-related cause of death,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.390625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is the most important direct seizure-",
            "probability": 5.960464477539063e-08
        }
    ],
    "58dbb8968acda3452900001b_4": [
        {
            "start_logit": 8.9375,
            "end_logit": 9.546875,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": 0.8095703125,
            "end_logit": 9.546875,
            "text": "epilepsy",
            "probability": 0.0002961158752441406
        },
        {
            "start_logit": 8.9375,
            "end_logit": -1.9482421875,
            "text": "Sudden",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -6.37109375,
            "end_logit": 9.546875,
            "text": "in epilepsy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 9.546875,
            "text": "unexpected death in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 9.546875,
            "text": "death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.9375,
            "end_logit": -6.7734375,
            "text": "Sudden unexpected death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9375,
            "end_logit": -6.77734375,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9375,
            "end_logit": -7.1171875,
            "text": "Sudden unexpected death in epilepsy (SUDEP): what do patients think?",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.8095703125,
            "end_logit": -6.77734375,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 0.8095703125,
            "end_logit": -7.1171875,
            "text": "epilepsy (SUDEP): what do patients think?",
            "probability": 0.0
        },
        {
            "start_logit": -6.37109375,
            "end_logit": -6.77734375,
            "text": "in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.37109375,
            "end_logit": -7.1171875,
            "text": "in epilepsy (SUDEP): what do patients think?",
            "probability": 0.0
        },
        {
            "start_logit": -6.7421875,
            "end_logit": -6.7734375,
            "text": "unexpected death",
            "probability": 0.0
        },
        {
            "start_logit": -6.7421875,
            "end_logit": -6.77734375,
            "text": "unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.7421875,
            "end_logit": -7.1171875,
            "text": "unexpected death in epilepsy (SUDEP): what do patients think?",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -6.7734375,
            "text": "death",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -6.77734375,
            "text": "death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -7.1171875,
            "text": "death in epilepsy (SUDEP): what do patients think?",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -7.1171875,
            "text": "patients think?",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_5": [
        {
            "start_logit": 9.1484375,
            "end_logit": 9.5078125,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": 0.06488037109375,
            "end_logit": 9.5078125,
            "text": "epilepsy",
            "probability": 0.00011324882507324219
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -1.5556640625,
            "text": "Sudden",
            "probability": 1.5676021575927734e-05
        },
        {
            "start_logit": -6.140625,
            "end_logit": 9.5078125,
            "text": "in epilepsy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.2734375,
            "end_logit": 9.5078125,
            "text": "unexpected death in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.50390625,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9765625,
            "end_logit": 9.5078125,
            "text": "death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.62890625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a major cause of mortality in epilepsy.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.76953125,
            "text": "Sudden unexpected death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.890625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a major",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.90625,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.91015625,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -6.9609375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.01953125,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a major cause",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.0546875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.078125,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.13671875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a major cause of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 9.5078125,
            "text": ": Sudden unexpected death in epilepsy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.2109375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a major cause of mortality",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1484375,
            "end_logit": -7.21875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a major cause of mortality in epilepsy",
            "probability": 5.960464477539063e-08
        }
    ],
    "58dbb8968acda3452900001b_6": [
        {
            "start_logit": 6.296875,
            "end_logit": 8.640625,
            "text": "epilepsy",
            "probability": 0.67724609375
        },
        {
            "start_logit": 5.5546875,
            "end_logit": 8.640625,
            "text": "sudden unexpected death in epilepsy",
            "probability": 0.322509765625
        },
        {
            "start_logit": -6.87109375,
            "end_logit": 8.640625,
            "text": "in epilepsy",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 8.640625,
            "text": "unexpected death in epilepsy",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 8.640625,
            "text": "In 11 patients cause of death was sudden unexpected death in epilepsy",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 8.640625,
            "text": "death in epilepsy",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.59375,
            "end_logit": 8.640625,
            "text": "death was sudden unexpected death in epilepsy",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 8.640625,
            "text": "patients cause of death was sudden unexpected death in epilepsy",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 8.640625,
            "text": "was sudden unexpected death in epilepsy",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 5.5546875,
            "end_logit": -5.78125,
            "text": "sudden",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.296875,
            "end_logit": -6.89453125,
            "text": "epilepsy (SUDEP).",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.296875,
            "end_logit": -6.94140625,
            "text": "epilepsy (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.296875,
            "end_logit": -7.046875,
            "text": "epilepsy (SUDEP",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.296875,
            "end_logit": -7.20703125,
            "text": "epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.296875,
            "end_logit": -7.2578125,
            "text": "epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.5546875,
            "end_logit": -6.6953125,
            "text": "sudden unexpected death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.5546875,
            "end_logit": -6.89453125,
            "text": "sudden unexpected death in epilepsy (SUDEP).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.5546875,
            "end_logit": -6.94140625,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.5546875,
            "end_logit": -7.046875,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.5546875,
            "end_logit": -7.1640625,
            "text": "sudden unexpected",
            "probability": 5.960464477539063e-08
        }
    ],
    "58dbb8968acda3452900001b_7": [
        {
            "start_logit": 7.765625,
            "end_logit": 7.578125,
            "text": "Epilepsy",
            "probability": 0.9990234375
        },
        {
            "start_logit": 7.765625,
            "end_logit": -0.0224761962890625,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy",
            "probability": 0.0004992485046386719
        },
        {
            "start_logit": 4.41796875,
            "end_logit": -0.0224761962890625,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": 7.765625,
            "end_logit": -6.1015625,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 7.765625,
            "end_logit": -6.31640625,
            "text": "Epilepsy-related death, particularly sudden",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 7.765625,
            "end_logit": -6.7890625,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.765625,
            "end_logit": -6.796875,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.765625,
            "end_logit": -6.8125,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.765625,
            "end_logit": -6.87890625,
            "text": "Epilepsy-",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.765625,
            "end_logit": -6.90234375,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is still underestimated",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.765625,
            "end_logit": -6.9375,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is still",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.765625,
            "end_logit": -6.953125,
            "text": "Epilepsy-related",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.765625,
            "end_logit": -6.97265625,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP),",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.765625,
            "end_logit": -7.046875,
            "text": "Epilepsy-related death,",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.765625,
            "end_logit": -7.046875,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.765625,
            "end_logit": -7.11328125,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may reflect",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.765625,
            "end_logit": -7.125,
            "text": "Epilepsy-related death, particularly",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.765625,
            "end_logit": -7.13671875,
            "text": "Epilepsy-related death",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 4.41796875,
            "end_logit": -6.1015625,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.41796875,
            "end_logit": -6.31640625,
            "text": "sudden",
            "probability": 5.960464477539063e-08
        }
    ],
    "58dbb8968acda3452900001b_8": [
        {
            "start_logit": 8.6875,
            "end_logit": 9.65625,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 0.9990234375
        },
        {
            "start_logit": 2.150390625,
            "end_logit": 9.65625,
            "text": "epilepsy",
            "probability": 0.0014448165893554688
        },
        {
            "start_logit": 8.6875,
            "end_logit": -2.400390625,
            "text": "Sudden",
            "probability": 5.841255187988281e-06
        },
        {
            "start_logit": -6.32421875,
            "end_logit": 9.65625,
            "text": "in epilepsy",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.578125,
            "end_logit": 9.65625,
            "text": "unexpected death in epilepsy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.6875,
            "end_logit": -6.328125,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 9.65625,
            "text": "death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6875,
            "end_logit": -6.47265625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6875,
            "end_logit": -6.5234375,
            "text": "Sudden unexpected death",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6875,
            "end_logit": -6.7109375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a - probably",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -6.81640625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -6.859375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a - probably heterogeneous",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -6.94921875,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -6.9765625,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -6.98046875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a - probably heterogeneous - condition where patients with epilepsy die suddenly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -6.98828125,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -7.00390625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a - probably heterogeneous - condition",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -7.09765625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a - probably heterogeneous - condition where patients with epilepsy die suddenly, almost certainly during a seizure and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -7.1640625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a - probably heterogeneous - condition where patients with epilepsy die suddenly, almost",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6875,
            "end_logit": -7.2109375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a - probably heterogeneous - condition where patients with epilepsy die",
            "probability": 5.960464477539063e-08
        }
    ],
    "58dbb8968acda3452900001b_9": [
        {
            "start_logit": 7.8828125,
            "end_logit": 7.4765625,
            "text": "Epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -5.3359375,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -5.79296875,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.2265625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy-related cause of death.",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.31640625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.78515625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.8046875,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.90625,
            "text": "Epilepsy is the most common serious neurological condition and",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.9765625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUD",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.9765625,
            "text": "Epilepsy is",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.984375,
            "text": "Epilepsy is the most common serious neurological condition",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.0546875,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.078125,
            "text": "Epilepsy is the most",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.08203125,
            "text": "Epilepsy is the",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.09375,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.1015625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.20703125,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the most important",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 2.00390625,
            "end_logit": -5.3359375,
            "text": "sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 2.00390625,
            "end_logit": -5.79296875,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_10": [
        {
            "start_logit": 7.8828125,
            "end_logit": 7.4765625,
            "text": "Epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -5.3359375,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -5.79296875,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.2265625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy-related cause of death.",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.31640625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.78515625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.8046875,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.90625,
            "text": "Epilepsy is the most common serious neurological condition and",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.9765625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUD",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.9765625,
            "text": "Epilepsy is",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.984375,
            "text": "Epilepsy is the most common serious neurological condition",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.0546875,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.078125,
            "text": "Epilepsy is the most",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.08203125,
            "text": "Epilepsy is the",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.09375,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.1015625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.20703125,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the most important",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 2.00390625,
            "end_logit": -5.3359375,
            "text": "sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 2.00390625,
            "end_logit": -5.79296875,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_11": [
        {
            "start_logit": 9.2265625,
            "end_logit": 9.578125,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": 0.5703125,
            "end_logit": 9.578125,
            "text": "epilepsy",
            "probability": 0.00017273426055908203
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -1.3505859375,
            "text": "Sudden",
            "probability": 1.7762184143066406e-05
        },
        {
            "start_logit": -6.00390625,
            "end_logit": 9.578125,
            "text": "in epilepsy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.19140625,
            "end_logit": 9.578125,
            "text": "unexpected death in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.109375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally difficult condition to study in humans.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.12890625,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.52734375,
            "text": "Sudden unexpected death",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.046875,
            "end_logit": 9.578125,
            "text": "death in epilepsy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.72265625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.8671875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.92578125,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.00390625,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.03515625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally difficult",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.0390625,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.046875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally difficult condition",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.0625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally difficult condition to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.1953125,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally difficult condition to study",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.3125,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally difficult condition to study in humans",
            "probability": 5.960464477539063e-08
        }
    ],
    "58dbb8968acda3452900001b_12": [
        {
            "start_logit": 9.078125,
            "end_logit": 9.3515625,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.3134765625,
            "end_logit": 9.3515625,
            "text": "epilepsy",
            "probability": 8.285045623779297e-05
        },
        {
            "start_logit": 9.078125,
            "end_logit": -1.6875,
            "text": "Sudden",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -6.48046875,
            "end_logit": 9.3515625,
            "text": "in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.66015625,
            "end_logit": 9.3515625,
            "text": "unexpected death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -6.58984375,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 9.3515625,
            "text": "death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.078125,
            "end_logit": -6.9765625,
            "text": "Sudden unexpected death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.125,
            "text": "Sudden unexpected death in epilepsy (SUDEP): don't ask,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.234375,
            "text": "Sudden unexpected death in epilepsy (SUDEP): don't ask, don't tell?",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.234375,
            "text": "Sudden unexpected death in epilepsy (SUDEP): don'",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.24609375,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.265625,
            "text": "Sudden unexpected death in epilepsy (SUDEP): don't",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.28125,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.296875,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.32421875,
            "text": "Sudden unexpected death in epilepsy (SUDEP): don't ask, don",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.328125,
            "text": "Sudden unexpected death in epilepsy (SUDEP): don",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.078125,
            "end_logit": -7.34375,
            "text": "Sudden unexpected death in epilepsy (SUDEP): don't ask",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.3134765625,
            "end_logit": -6.58984375,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -0.3134765625,
            "end_logit": -7.125,
            "text": "epilepsy (SUDEP): don't ask,",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_13": [
        {
            "start_logit": 7.6953125,
            "end_logit": 7.66796875,
            "text": "epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -6.2734375,
            "text": "epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -6.48046875,
            "text": "epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -6.671875,
            "text": "epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death in",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -6.71484375,
            "text": "epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy (",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -7.0859375,
            "text": "epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -7.11328125,
            "text": "epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy (SUDEP).",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -7.1171875,
            "text": "epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy (SUDEP)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -7.17578125,
            "text": "epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy (SUDEP",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -7.2265625,
            "text": "epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy (SUD",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -7.234375,
            "text": "epilepsy, as well as their partners, relatives, and friends, are unaware of the",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -7.28515625,
            "text": "epilepsy, as",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -7.30078125,
            "text": "epilepsy, as well as their partners, relatives, and friends, are",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.6953125,
            "end_logit": -7.3125,
            "text": "epilepsy, as well",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 7.66796875,
            "text": "with epilepsy",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 7.66796875,
            "text": "individuals with epilepsy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 7.66796875,
            "text": "Many individuals with epilepsy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -2.8671875,
            "end_logit": -6.2734375,
            "text": "sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -2.8671875,
            "end_logit": -6.48046875,
            "text": "sudden unexpected death",
            "probability": 0.0
        },
        {
            "start_logit": -2.8671875,
            "end_logit": -6.671875,
            "text": "sudden unexpected death in",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_14": [
        {
            "start_logit": 7.87890625,
            "end_logit": 7.453125,
            "text": "epilepsy",
            "probability": 0.8232421875
        },
        {
            "start_logit": 8.3125,
            "end_logit": 4.9765625,
            "text": "sudden unexpected death in epilepsy",
            "probability": 0.10711669921875
        },
        {
            "start_logit": 7.87890625,
            "end_logit": 4.9765625,
            "text": "epilepsy and sudden unexpected death in epilepsy",
            "probability": 0.06976318359375
        },
        {
            "start_logit": 8.3125,
            "end_logit": -3.150390625,
            "text": "sudden",
            "probability": 3.170967102050781e-05
        },
        {
            "start_logit": 7.87890625,
            "end_logit": -3.150390625,
            "text": "epilepsy and sudden",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 8.3125,
            "end_logit": -6.58203125,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.3125,
            "end_logit": -6.671875,
            "text": "sudden unexpected death in epilepsy (SUDEP).",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -6.87109375,
            "text": "sudden unexpected death",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.87890625,
            "end_logit": -6.58203125,
            "text": "epilepsy and sudden unexpected death in epilepsy (",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.07421875,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.87890625,
            "end_logit": -6.671875,
            "text": "epilepsy and sudden unexpected death in epilepsy (SUDEP).",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.1484375,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.3125,
            "end_logit": -7.1953125,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.87890625,
            "end_logit": -6.87109375,
            "text": "epilepsy and sudden unexpected death",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.87890625,
            "end_logit": -7.07421875,
            "text": "epilepsy and sudden unexpected death in epilepsy (SUDEP",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.87890625,
            "end_logit": -7.1484375,
            "text": "epilepsy and sudden unexpected death in epilepsy (SUDEP)",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.87890625,
            "end_logit": -7.1953125,
            "text": "epilepsy and sudden unexpected death in epilepsy (SUD",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.87890625,
            "end_logit": -7.2109375,
            "text": "epilepsy and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 7.453125,
            "text": "generalized epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.8203125,
            "end_logit": 4.9765625,
            "text": "epilepsy",
            "probability": 1.1920928955078125e-07
        }
    ],
    "58dbb8968acda3452900001b_15": [
        {
            "start_logit": 9.0390625,
            "end_logit": 9.484375,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": 0.15673828125,
            "end_logit": 9.484375,
            "text": "epilepsy",
            "probability": 0.00013768672943115234
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -1.7958984375,
            "text": "Sudden",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -6.30859375,
            "end_logit": 9.484375,
            "text": "in epilepsy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 9.484375,
            "text": "unexpected death in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.0234375,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.49609375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) refers",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.6015625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) refers to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.6171875,
            "text": "Sudden unexpected death",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.12109375,
            "end_logit": 9.484375,
            "text": "death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.85546875,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.88671875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) refers to the sudden death of a seemingly",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.89453125,
            "text": "Sudden unexpected death in epilepsy (SUDEP) refers to the sudden death of a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.9375,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.03515625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) refers to the sudden death of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.05078125,
            "text": "Sudden unexpected death in epilepsy (SUDEP) refers to the sudden death of a seemingly healthy individual",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.05078125,
            "text": "Sudden unexpected death in epilepsy (SUDEP) refers to the sudden death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.08984375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) refers to the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.09765625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) refers to the sudden death of a seemingly healthy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -7.140625,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539063e-08
        }
    ],
    "58dbb8968acda3452900001b_16": [
        {
            "start_logit": 9.1640625,
            "end_logit": 9.390625,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.455810546875,
            "end_logit": 9.390625,
            "text": "epilepsy",
            "probability": 6.604194641113281e-05
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -1.5634765625,
            "text": "sudden",
            "probability": 1.7344951629638672e-05
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -5.58984375,
            "text": "sudden unexpected death in epilepsy (SUDEP), and it accounts for a large proportion of deaths among people with epilepsy.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -5.8828125,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.11328125,
            "end_logit": 9.390625,
            "text": "unexpected death in epilepsy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.41796875,
            "end_logit": 9.390625,
            "text": "in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.51171875,
            "end_logit": 9.390625,
            "text": "called sudden unexpected death in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.671875,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.90234375,
            "end_logit": 9.390625,
            "text": "death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.70703125,
            "text": "sudden unexpected death in epilepsy (SUDEP),",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.76171875,
            "text": "sudden unexpected death",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.76953125,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.82421875,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.8828125,
            "text": "sudden unexpected death in epilepsy (SUDEP), and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.90234375,
            "text": "sudden unexpected death in epilepsy (SUDEP), and it accounts for a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.9140625,
            "text": "sudden unexpected death in epilepsy (SUDEP), and it accounts for a large",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.140625,
            "end_logit": 9.390625,
            "text": "condition is called sudden unexpected death in epilepsy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.01171875,
            "text": "sudden unexpected death in epilepsy (SUDEP), and it accounts for a large proportion",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -7.015625,
            "text": "sudden unexpected death in epilepsy (SUDEP), and it accounts for",
            "probability": 5.960464477539063e-08
        }
    ],
    "58dbb8968acda3452900001b_17": [
        {
            "start_logit": 7.875,
            "end_logit": 7.47265625,
            "text": "Epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": 7.875,
            "end_logit": -1.4287109375,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy",
            "probability": 0.0001366138458251953
        },
        {
            "start_logit": 4.3046875,
            "end_logit": -1.4287109375,
            "text": "sudden unexpected death in epilepsy",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": 7.875,
            "end_logit": -6.22265625,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 7.875,
            "end_logit": -6.421875,
            "text": "Epilepsy-related death, particularly sudden",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 7.875,
            "end_logit": -6.734375,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.875,
            "end_logit": -6.77734375,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.875,
            "end_logit": -6.7890625,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUD",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.875,
            "end_logit": -6.84765625,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is still underestimated",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.875,
            "end_logit": -6.8671875,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP),",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.875,
            "end_logit": -6.875,
            "text": "Epilepsy-",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.875,
            "end_logit": -6.921875,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is still",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.875,
            "end_logit": -6.9375,
            "text": "Epilepsy-related",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.875,
            "end_logit": -6.9609375,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.875,
            "end_logit": -6.9921875,
            "text": "Epilepsy-related death,",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.875,
            "end_logit": -7.046875,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.875,
            "end_logit": -7.05859375,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may reflect",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.875,
            "end_logit": -7.0625,
            "text": "Epilepsy-related death, particularly",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 4.3046875,
            "end_logit": -6.22265625,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.3046875,
            "end_logit": -6.421875,
            "text": "sudden",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_18": [
        {
            "start_logit": 9.21875,
            "end_logit": 9.40625,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.32568359375,
            "end_logit": 9.40625,
            "text": "epilepsy",
            "probability": 7.140636444091797e-05
        },
        {
            "start_logit": 9.21875,
            "end_logit": -1.388671875,
            "text": "Sudden",
            "probability": 2.0444393157958984e-05
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.01171875,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.390625,
            "end_logit": 9.40625,
            "text": "in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4765625,
            "end_logit": 9.40625,
            "text": "unexpected death in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.91796875,
            "end_logit": 9.40625,
            "text": "death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.87890625,
            "text": "Sudden unexpected death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.9296875,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -6.9453125,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.015625,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.21875,
            "end_logit": -7.07421875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) i",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.32568359375,
            "end_logit": -6.01171875,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -0.32568359375,
            "end_logit": -6.9296875,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -0.32568359375,
            "end_logit": -6.9453125,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -0.32568359375,
            "end_logit": -7.015625,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -0.32568359375,
            "end_logit": -7.07421875,
            "text": "epilepsy (SUDEP) i",
            "probability": 0.0
        },
        {
            "start_logit": -6.390625,
            "end_logit": -6.01171875,
            "text": "in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.4765625,
            "end_logit": -6.01171875,
            "text": "unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.91796875,
            "end_logit": -6.01171875,
            "text": "death in epilepsy (",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_19": [
        {
            "start_logit": 9.1171875,
            "end_logit": 9.4375,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": 9.4375,
            "text": "epilepsy",
            "probability": 9.995698928833008e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.6064453125,
            "text": "sudden",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 9.4375,
            "text": "in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.19921875,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 9.4375,
            "text": "unexpected death in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 9.4375,
            "text": "death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.91796875,
            "text": "sudden unexpected death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.05078125,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.0546875,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.3671875,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -6.19921875,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.05078125,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.0546875,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.3671875,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -6.19921875,
            "text": "in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.56640625,
            "end_logit": -6.19921875,
            "text": "unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -6.19921875,
            "text": "death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -7.05078125,
            "text": "in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -7.0546875,
            "text": "in epilepsy (SUD",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_20": [
        {
            "start_logit": 9.1953125,
            "end_logit": 9.390625,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.358154296875,
            "end_logit": 9.390625,
            "text": "epilepsy",
            "probability": 7.033348083496094e-05
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -1.443359375,
            "text": "sudden",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.078125,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 9.390625,
            "text": "in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 9.390625,
            "text": "unexpected death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 9.390625,
            "text": "death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -6.87109375,
            "text": "sudden unexpected death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.03125,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.046875,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -7.07421875,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.358154296875,
            "end_logit": -6.078125,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -0.358154296875,
            "end_logit": -7.03125,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -0.358154296875,
            "end_logit": -7.046875,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -0.358154296875,
            "end_logit": -7.07421875,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -6.44921875,
            "end_logit": -6.078125,
            "text": "in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.5390625,
            "end_logit": -6.078125,
            "text": "unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.9453125,
            "end_logit": -6.078125,
            "text": "death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.5390625,
            "end_logit": -6.87109375,
            "text": "unexpected death",
            "probability": 0.0
        },
        {
            "start_logit": -6.44921875,
            "end_logit": -7.03125,
            "text": "in epilepsy (SUDEP",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_21": [
        {
            "start_logit": 9.1171875,
            "end_logit": 9.4375,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": 9.4375,
            "text": "epilepsy",
            "probability": 9.995698928833008e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.6064453125,
            "text": "Sudden",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 9.4375,
            "text": "in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.19921875,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 9.4375,
            "text": "unexpected death in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 9.4375,
            "text": "death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.91796875,
            "text": "Sudden unexpected death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.05078125,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.0546875,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.3671875,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -6.19921875,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.05078125,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.0546875,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.3671875,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -6.19921875,
            "text": "in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.56640625,
            "end_logit": -6.19921875,
            "text": "unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -6.19921875,
            "text": "death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -7.05078125,
            "text": "in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -7.0546875,
            "text": "in epilepsy (SUD",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_22": [
        {
            "start_logit": 9.1171875,
            "end_logit": 9.4375,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": 9.4375,
            "text": "epilepsy",
            "probability": 9.995698928833008e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.6064453125,
            "text": "sudden",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 9.4375,
            "text": "in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.19921875,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 9.4375,
            "text": "unexpected death in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 9.4375,
            "text": "death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.91796875,
            "text": "sudden unexpected death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.05078125,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.0546875,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.3671875,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -6.19921875,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.05078125,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.0546875,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.3671875,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -6.19921875,
            "text": "in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.56640625,
            "end_logit": -6.19921875,
            "text": "unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -6.19921875,
            "text": "death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -7.05078125,
            "text": "in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -7.0546875,
            "text": "in epilepsy (SUD",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_23": [
        {
            "start_logit": 9.1171875,
            "end_logit": 9.4375,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": 9.4375,
            "text": "epilepsy",
            "probability": 9.995698928833008e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -1.6064453125,
            "text": "sudden",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 9.4375,
            "text": "in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.19921875,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.56640625,
            "end_logit": 9.4375,
            "text": "unexpected death in epilepsy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 9.4375,
            "text": "death in epilepsy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -6.91796875,
            "text": "sudden unexpected death",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.05078125,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.0546875,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -7.3671875,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -6.19921875,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.05078125,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.0546875,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -0.08697509765625,
            "end_logit": -7.3671875,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -6.19921875,
            "text": "in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.56640625,
            "end_logit": -6.19921875,
            "text": "unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.95703125,
            "end_logit": -6.19921875,
            "text": "death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -7.05078125,
            "text": "in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -7.0546875,
            "text": "in epilepsy (SUD",
            "probability": 0.0
        }
    ],
    "5a87f44061bb38fb2400000f_1": [
        {
            "start_logit": 7.53515625,
            "end_logit": 7.6875,
            "text": "cancer",
            "probability": 1.0
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -5.76171875,
            "text": "cancer. Crizotinib is an ALK inhibitor, which was approved in 2011",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -6.30078125,
            "end_logit": 7.6875,
            "text": "with non-small-cell lung cancer",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -6.328125,
            "text": "cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the treatment of ALK-positive lung cancer.",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -6.328125,
            "text": "cancer.",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 7.6875,
            "text": "non-small-cell lung cancer",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -6.796875,
            "text": "cancer. Crizotinib is an ALK inhibitor, which was approved",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -6.8828125,
            "text": "cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the treatment of ALK-positive lung cancer",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -6.94140625,
            "text": "cancer. Crizotinib",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.203125,
            "end_logit": 7.6875,
            "text": "patients with non-small-cell lung cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.203125,
            "end_logit": 7.6875,
            "text": "-small-cell lung cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -7.0625,
            "text": "cancer. Crizotinib is an ALK inhibitor, which was",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 7.6875,
            "text": "Anaplastic lymphoma kinase (ALK) rearrangement is detected in 3-7% of patients with non-small-cell lung cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -7.1328125,
            "text": "cancer. Crizo",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -7.1328125,
            "text": "cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the treatment of ALK",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -7.140625,
            "text": "cancer. Crizotinib is an ALK inhibitor, which was approved in",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -7.1796875,
            "text": "cancer. Crizotinib is",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 7.6875,
            "text": "lung cancer",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.375,
            "end_logit": 7.6875,
            "text": "-cell lung cancer",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.53515625,
            "end_logit": -7.23046875,
            "text": "cancer. Crizotinib is an ALK inhibitor, which",
            "probability": 3.5762786865234375e-07
        }
    ],
    "6057bf0694d57fd879000031_1": [
        {
            "start_logit": 8.59375,
            "end_logit": 4.6875,
            "text": "apoE4-165",
            "probability": 0.998046875
        },
        {
            "start_logit": 8.59375,
            "end_logit": -1.7958984375,
            "text": "apoE",
            "probability": 0.0015239715576171875
        },
        {
            "start_logit": 8.59375,
            "end_logit": -3.03125,
            "text": "apoE4",
            "probability": 0.00044345855712890625
        },
        {
            "start_logit": 8.59375,
            "end_logit": -5.0625,
            "text": "apoE4-165,",
            "probability": 5.817413330078125e-05
        },
        {
            "start_logit": 8.59375,
            "end_logit": -5.55859375,
            "text": "apoE4-",
            "probability": 3.528594970703125e-05
        },
        {
            "start_logit": -1.669921875,
            "end_logit": 4.6875,
            "text": "a specific apoE4 fragment, apoE4-165",
            "probability": 3.4749507904052734e-05
        },
        {
            "start_logit": 8.59375,
            "end_logit": -5.91015625,
            "text": "apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH cells",
            "probability": 2.5033950805664062e-05
        },
        {
            "start_logit": -2.701171875,
            "end_logit": 4.6875,
            "text": ". We have previously shown that a specific apoE4 fragment, apoE4-165",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -3.400390625,
            "end_logit": 4.6875,
            "text": ", apoE4-165",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": -3.662109375,
            "end_logit": 4.6875,
            "text": "We have previously shown that a specific apoE4 fragment, apoE4-165",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -4.046875,
            "end_logit": 4.6875,
            "text": "previously shown that a specific apoE4 fragment, apoE4-165",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": -5.29296875,
            "end_logit": 4.6875,
            "text": "have previously shown that a specific apoE4 fragment, apoE4-165",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -5.82421875,
            "end_logit": 4.6875,
            "text": "165",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.29296875,
            "end_logit": 4.6875,
            "text": "fragment, apoE4-165",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -1.7958984375,
            "text": "a specific apoE4 fragment, apoE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.701171875,
            "end_logit": -1.7958984375,
            "text": ". We have previously shown that a specific apoE4 fragment, apoE",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -3.03125,
            "text": "a specific apoE4 fragment, apoE4",
            "probability": 0.0
        },
        {
            "start_logit": -1.669921875,
            "end_logit": -3.080078125,
            "text": "a specific apoE4 fragment",
            "probability": 0.0
        },
        {
            "start_logit": -3.400390625,
            "end_logit": -1.7958984375,
            "text": ", apoE",
            "probability": 0.0
        },
        {
            "start_logit": -3.662109375,
            "end_logit": -1.7958984375,
            "text": "We have previously shown that a specific apoE4 fragment, apoE",
            "probability": 0.0
        }
    ],
    "6057bf0694d57fd879000031_2": [
        {
            "start_logit": 6.625,
            "end_logit": 7.42578125,
            "text": "a specific apoE4 fragment, apoE4-165,",
            "probability": 0.9921875
        },
        {
            "start_logit": 1.068359375,
            "end_logit": 7.42578125,
            "text": "We have previously shown that a specific apoE4 fragment, apoE4-165,",
            "probability": 0.0038394927978515625
        },
        {
            "start_logit": 0.8876953125,
            "end_logit": 7.42578125,
            "text": "apoE4-165,",
            "probability": 0.003208160400390625
        },
        {
            "start_logit": -1.9755859375,
            "end_logit": 7.42578125,
            "text": ", apoE4-165,",
            "probability": 0.0001838207244873047
        },
        {
            "start_logit": 6.625,
            "end_logit": -2.138671875,
            "text": "a",
            "probability": 6.979703903198242e-05
        },
        {
            "start_logit": -3.291015625,
            "end_logit": 7.42578125,
            "text": ",",
            "probability": 4.9114227294921875e-05
        },
        {
            "start_logit": 6.625,
            "end_logit": -2.51953125,
            "text": "a specific apoE4 fragment, apoE4-165",
            "probability": 4.798173904418945e-05
        },
        {
            "start_logit": -3.451171875,
            "end_logit": 7.42578125,
            "text": "that a specific apoE4 fragment, apoE4-165,",
            "probability": 4.1961669921875e-05
        },
        {
            "start_logit": 6.625,
            "end_logit": -2.982421875,
            "text": "a specific apoE4 fragment",
            "probability": 2.9981136322021484e-05
        },
        {
            "start_logit": -4.27734375,
            "end_logit": 7.42578125,
            "text": "previously shown that a specific apoE4 fragment, apoE4-165,",
            "probability": 1.8358230590820312e-05
        },
        {
            "start_logit": 6.625,
            "end_logit": -3.880859375,
            "text": "a specific apoE4 fragment, apoE4",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": -5.09765625,
            "end_logit": 7.42578125,
            "text": "have previously shown that a specific apoE4 fragment, apoE4-165,",
            "probability": 8.106231689453125e-06
        },
        {
            "start_logit": 6.625,
            "end_logit": -4.83203125,
            "text": "a specific apoE4 fragment, apoE4-",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": 6.625,
            "end_logit": -5.8515625,
            "text": "a specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 6.625,
            "end_logit": -5.86328125,
            "text": "a specific apoE4",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 6.625,
            "end_logit": -5.953125,
            "text": "a specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242)",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 6.625,
            "end_logit": -6.015625,
            "text": "a specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 1.068359375,
            "end_logit": -2.138671875,
            "text": "We have previously shown that a",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 1.068359375,
            "end_logit": -2.51953125,
            "text": "We have previously shown that a specific apoE4 fragment, apoE4-165",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 0.8876953125,
            "end_logit": -2.51953125,
            "text": "apoE4-165",
            "probability": 1.7881393432617188e-07
        }
    ],
    "6057bf0694d57fd879000031_3": [
        {
            "start_logit": 6.99609375,
            "end_logit": 5.609375,
            "text": "a specific apoE4 fragment, apoE4-165,",
            "probability": 0.998046875
        },
        {
            "start_logit": 6.99609375,
            "end_logit": -1.23828125,
            "text": "a",
            "probability": 0.0010557174682617188
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": 5.609375,
            "text": "e previously shown that a specific apoE4 fragment, apoE4-165,",
            "probability": 0.00025272369384765625
        },
        {
            "start_logit": -2.08203125,
            "end_logit": 5.609375,
            "text": "previously shown that a specific apoE4 fragment, apoE4-165,",
            "probability": 0.00011390447616577148
        },
        {
            "start_logit": 6.99609375,
            "end_logit": -3.4921875,
            "text": "a specific apoE4 fragment",
            "probability": 0.00011038780212402344
        },
        {
            "start_logit": -2.333984375,
            "end_logit": 5.609375,
            "text": ", apoE4-165,",
            "probability": 8.803606033325195e-05
        },
        {
            "start_logit": 6.99609375,
            "end_logit": -4.09765625,
            "text": "a specific apoE4 fragment, apoE4-165",
            "probability": 6.0498714447021484e-05
        },
        {
            "start_logit": 6.99609375,
            "end_logit": -4.3828125,
            "text": "a specific apoE4 fragment, apoE4",
            "probability": 4.5359134674072266e-05
        },
        {
            "start_logit": 6.99609375,
            "end_logit": -4.73046875,
            "text": "a specific apoE4 fragment, apoE4-",
            "probability": 3.212690353393555e-05
        },
        {
            "start_logit": -3.478515625,
            "end_logit": 5.609375,
            "text": "that a specific apoE4 fragment, apoE4-165,",
            "probability": 2.8133392333984375e-05
        },
        {
            "start_logit": -3.63671875,
            "end_logit": 5.609375,
            "text": "apoE4-165,",
            "probability": 2.384185791015625e-05
        },
        {
            "start_logit": 6.99609375,
            "end_logit": -5.98828125,
            "text": "a specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -4.69921875,
            "end_logit": 5.609375,
            "text": ",",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": -5.53125,
            "end_logit": 5.609375,
            "text": "shown that a specific apoE4 fragment, apoE4-165,",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": -1.23828125,
            "text": "e previously shown that a",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -2.08203125,
            "end_logit": -1.23828125,
            "text": "previously shown that a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.71484375,
            "end_logit": -1.6552734375,
            "text": ".",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.478515625,
            "end_logit": -1.23828125,
            "text": "that a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": -3.4921875,
            "text": "e previously shown that a specific apoE4 fragment",
            "probability": 0.0
        },
        {
            "start_logit": -1.2802734375,
            "end_logit": -4.09765625,
            "text": "e previously shown that a specific apoE4 fragment, apoE4-165",
            "probability": 0.0
        }
    ],
    "6057bf0694d57fd879000031_4": [
        {
            "start_logit": 7.52734375,
            "end_logit": 3.669921875,
            "text": "apoE4-165",
            "probability": 0.994140625
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -2.171875,
            "text": "apoE4",
            "probability": 0.00289154052734375
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -2.49609375,
            "text": "apoE",
            "probability": 0.0020923614501953125
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -4.34765625,
            "text": "apoE4-165 is structurally distinct and less thermodynamically stable suggesting",
            "probability": 0.00032830238342285156
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -4.46875,
            "text": "apoE4-165 is",
            "probability": 0.00028967857360839844
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -4.8046875,
            "text": "apoE4-",
            "probability": 0.00020873546600341797
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -5.73828125,
            "text": "apoE4-165 is structurally distinct and less thermodynamically stable suggesting that the combination of a well-folded structure with structural plasticity is",
            "probability": 8.171796798706055e-05
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -6.17578125,
            "text": "apoE4-165 is structurally distinct and less thermodynamically stable suggesting that the combination of a well-folded structure with structural plasticity is a",
            "probability": 5.27501106262207e-05
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -6.25390625,
            "text": "apoE4-165 is structurally distinct and less thermodynamic",
            "probability": 4.881620407104492e-05
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -6.30859375,
            "text": "apoE4-165 is structurally distinct",
            "probability": 4.6193599700927734e-05
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -6.31640625,
            "text": "apoE4-165 is structurally distinct and less thermodynamically stable suggesting that the combination of a well-folded structure with structural plasticity",
            "probability": 4.583597183227539e-05
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -6.34765625,
            "text": "apoE4-165 is structurally",
            "probability": 4.4465065002441406e-05
        },
        {
            "start_logit": 7.52734375,
            "end_logit": -6.4765625,
            "text": "apoE4-165 is structurally distinct and",
            "probability": 3.921985626220703e-05
        },
        {
            "start_logit": -5.484375,
            "end_logit": 3.669921875,
            "text": ", apoE4-165",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -6.21875,
            "end_logit": 3.669921875,
            "text": "to other allelic backgrounds, apoE4-165",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 3.669921875,
            "text": "165",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -2.794921875,
            "end_logit": -2.2109375,
            "text": ".",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.484375,
            "end_logit": -2.171875,
            "text": ", apoE4",
            "probability": 0.0
        },
        {
            "start_logit": -5.484375,
            "end_logit": -2.49609375,
            "text": ", apoE",
            "probability": 0.0
        },
        {
            "start_logit": -6.10546875,
            "end_logit": -2.2109375,
            "text": "stable suggesting that the combination of a well-folded structure with structural plasticity is a unique characteristic of this fragment.",
            "probability": 0.0
        }
    ],
    "606b75c194d57fd87900006c_1": [
        {
            "start_logit": 6.9296875,
            "end_logit": 8.125,
            "text": "2017",
            "probability": 1.0
        },
        {
            "start_logit": -5.86328125,
            "end_logit": 8.125,
            "text": "in 2017",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": -7.25,
            "end_logit": 8.125,
            "text": "European Medicines Agency (EMA) and Federal Drug Administration (FDA) in 2017",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 8.125,
            "text": "prior to the registration of dupilumab by both the European Medicines Agency (EMA) and Federal Drug Administration (FDA) in 2017",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 8.125,
            "text": "binding prior to the registration of dupilumab by both the European Medicines Agency (EMA) and Federal Drug Administration (FDA) in 2017",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 8.125,
            "text": "registration of dupilumab by both the European Medicines Agency (EMA) and Federal Drug Administration (FDA) in 2017",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 8.125,
            "text": "the European Medicines Agency (EMA) and Federal Drug Administration (FDA) in 2017",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 6.9296875,
            "end_logit": -6.671875,
            "text": "2017.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -4.33984375,
            "end_logit": -6.671875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.86328125,
            "end_logit": -6.671875,
            "text": "in 2017.",
            "probability": 0.0
        },
        {
            "start_logit": -5.86328125,
            "end_logit": -6.9375,
            "text": "in",
            "probability": 0.0
        },
        {
            "start_logit": -6.546875,
            "end_logit": -6.64453125,
            "text": "This article covers etiology of the disease and summarizes dermatologic treatment standards of selected countries binding prior to the",
            "probability": 0.0
        },
        {
            "start_logit": -6.546875,
            "end_logit": -6.80859375,
            "text": "This article covers etiology of the disease and",
            "probability": 0.0
        },
        {
            "start_logit": -6.546875,
            "end_logit": -6.83984375,
            "text": "This article covers etiology of the disease and summarizes dermatologic treatment standards of selected countries binding prior",
            "probability": 0.0
        },
        {
            "start_logit": -6.546875,
            "end_logit": -6.88671875,
            "text": "This article covers etiology of the disease and summarizes dermatologic treatment standards of selected countries binding prior to",
            "probability": 0.0
        },
        {
            "start_logit": -6.546875,
            "end_logit": -6.9140625,
            "text": "This article covers etiology of the disease and summarizes dermatologic treatment standards of selected countries binding prior to the registration of dupilumab by both the European Medicines Agency",
            "probability": 0.0
        },
        {
            "start_logit": -6.546875,
            "end_logit": -7.078125,
            "text": "This article covers etiology of the disease and summarizes dermatologic treatment standards of selected countries binding prior to the registration of dupilumab by",
            "probability": 0.0
        },
        {
            "start_logit": -6.546875,
            "end_logit": -7.078125,
            "text": "This article covers etiology of the disease and summarizes dermatologic treatment standards of selected countries binding prior to the registration of",
            "probability": 0.0
        },
        {
            "start_logit": -6.546875,
            "end_logit": -7.08984375,
            "text": "This article covers etiology of the disease and summarizes dermatologic treatment standards of selected countries binding prior to the registration",
            "probability": 0.0
        },
        {
            "start_logit": -6.546875,
            "end_logit": -7.08984375,
            "text": "This article covers etiology of the disease and summarizes dermatologic treatment standards of selected countries binding prior to the registration of dupilumab by both",
            "probability": 0.0
        }
    ],
    "571cdd227de986d80d00000f_1": [
        {
            "start_logit": 9.203125,
            "end_logit": 9.171875,
            "text": "Yersinia pestis",
            "probability": 1.0
        },
        {
            "start_logit": -1.3037109375,
            "end_logit": 9.171875,
            "text": "is",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": 9.203125,
            "end_logit": -1.466796875,
            "text": "Yersinia",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": -5.66015625,
            "end_logit": 9.171875,
            "text": "pestis",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.31640625,
            "text": "Yersinia pestis as an agent of biological warfare have highlighted the need for a safe, efficacious, and rapidly producible vaccine.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.96484375,
            "text": "Yersinia pest",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.12109375,
            "text": "Yersinia pestis as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.171875,
            "text": "the causative bacteria Yersinia pestis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.2109375,
            "text": "Yersinia pestis as an agent of biological warfare have highlighted the need for a safe,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.2109375,
            "text": "Yersinia pestis as an agent of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.21484375,
            "text": "Yersinia pestis as an agent of biological warfare have highlighted the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.234375,
            "text": "Yersinia pestis as an agent of biological warfare have",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 9.171875,
            "text": "bacteria Yersinia pestis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.2421875,
            "text": "Yersinia pestis as an",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.26171875,
            "text": "Yersinia pestis as an agent of biological warfare have highlighted the need for a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.27734375,
            "text": "Yersinia pestis as an agent of biological warfare have highlighted the need for",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.29296875,
            "text": "Yersinia pestis as an agent of biological warfare have highlighted the need for a safe, efficacious, and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.30078125,
            "text": "Yersinia pestis as an agent of biological warfare have highlighted",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.328125,
            "text": "Yersinia pestis as an agent of biological warfare have highlighted the need for a safe, efficacious,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.33203125,
            "text": "Yersinia pestis as an agent",
            "probability": 5.960464477539063e-08
        }
    ],
    "621d02f33a8413c653000047_1": [
        {
            "start_logit": 8.4140625,
            "end_logit": 5.00390625,
            "text": "mechanotransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 0.9716796875
        },
        {
            "start_logit": 8.4140625,
            "end_logit": 1.3837890625,
            "text": "mechanotransduction process",
            "probability": 0.02587890625
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -2.36328125,
            "text": "mechanotransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx,",
            "probability": 0.0006108283996582031
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -2.455078125,
            "text": "mechanotransduction process and",
            "probability": 0.0005588531494140625
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -2.91015625,
            "text": "mechan",
            "probability": 0.00035381317138671875
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -3.29296875,
            "text": "mechanotransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx",
            "probability": 0.0002422332763671875
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -3.640625,
            "text": "mechanotransduction",
            "probability": 0.0001703500747680664
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -4.89453125,
            "text": "mechanotransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx, which",
            "probability": 4.845857620239258e-05
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -5.3984375,
            "text": "mechanotransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations",
            "probability": 2.9385089874267578e-05
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -5.43359375,
            "text": "mechanotrans",
            "probability": 2.849102020263672e-05
        },
        {
            "start_logit": -2.052734375,
            "end_logit": 5.00390625,
            "text": ".",
            "probability": 2.759695053100586e-05
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -5.70703125,
            "text": "mechanotransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx, which in turn",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -5.75,
            "text": "mechanotransduction process and can transduce mechanical signals",
            "probability": 2.0682811737060547e-05
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -5.7578125,
            "text": "mechanotransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates",
            "probability": 2.0503997802734375e-05
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -5.85546875,
            "text": "mechanotransduction process and can transduce mechanical signals into",
            "probability": 1.8715858459472656e-05
        },
        {
            "start_logit": 8.4140625,
            "end_logit": -5.94921875,
            "text": "mechanotransduction process and can transduce mechanical signals into biological signals by",
            "probability": 1.704692840576172e-05
        },
        {
            "start_logit": -4.2890625,
            "end_logit": 5.00390625,
            "text": "Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -5.44140625,
            "end_logit": 5.00390625,
            "text": "mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.1796875,
            "end_logit": 5.00390625,
            "text": "otransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.38671875,
            "end_logit": 5.00390625,
            "text": "+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 3.5762786865234375e-07
        }
    ],
    "6032899c1cb411341a000144_1": [
        {
            "start_logit": 4.4140625,
            "end_logit": 6.375,
            "text": "Integrins are transmembrane glycoproteins that are broadly distributed in living organisms.",
            "probability": 0.900390625
        },
        {
            "start_logit": 2.189453125,
            "end_logit": 6.375,
            "text": "broadly distributed in living organisms.",
            "probability": 0.09716796875
        },
        {
            "start_logit": -1.720703125,
            "end_logit": 6.375,
            "text": ".",
            "probability": 0.0019550323486328125
        },
        {
            "start_logit": 4.4140625,
            "end_logit": -2.123046875,
            "text": "Integrins are transmembrane glycoproteins that are broadly",
            "probability": 0.00018322467803955078
        },
        {
            "start_logit": -5.15625,
            "end_logit": 6.375,
            "text": "in living organisms.",
            "probability": 6.288290023803711e-05
        },
        {
            "start_logit": 4.4140625,
            "end_logit": -3.54296875,
            "text": "Integrins are transmembrane glycoproteins that",
            "probability": 4.4226646423339844e-05
        },
        {
            "start_logit": -5.80078125,
            "end_logit": 6.375,
            "text": "transmembrane glycoproteins that are broadly distributed in living organisms.",
            "probability": 3.2842159271240234e-05
        },
        {
            "start_logit": -6.04296875,
            "end_logit": 6.375,
            "text": "living organisms.",
            "probability": 2.5987625122070312e-05
        },
        {
            "start_logit": 2.189453125,
            "end_logit": -2.123046875,
            "text": "broadly",
            "probability": 1.990795135498047e-05
        },
        {
            "start_logit": -6.328125,
            "end_logit": 6.375,
            "text": "are broadly distributed in living organisms.",
            "probability": 1.9490718841552734e-05
        },
        {
            "start_logit": -6.34375,
            "end_logit": 6.375,
            "text": "glycoproteins that are broadly distributed in living organisms.",
            "probability": 1.919269561767578e-05
        },
        {
            "start_logit": 4.4140625,
            "end_logit": -4.50390625,
            "text": "Integrins are transmembrane glycoproteins that are broadly distributed in living organisms",
            "probability": 1.704692840576172e-05
        },
        {
            "start_logit": 4.4140625,
            "end_logit": -4.5078125,
            "text": "Integrins are transmembrane glycoproteins that are broadly distributed in",
            "probability": 1.6927719116210938e-05
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 6.375,
            "text": "distributed in living organisms.",
            "probability": 1.5497207641601562e-05
        },
        {
            "start_logit": -6.609375,
            "end_logit": 6.375,
            "text": "organisms.",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": -6.625,
            "end_logit": 6.375,
            "text": "that are broadly distributed in living organisms.",
            "probability": 1.4424324035644531e-05
        },
        {
            "start_logit": 4.4140625,
            "end_logit": -4.81640625,
            "text": "Integrins are transmembrane glycoproteins that are broadly distributed",
            "probability": 1.245737075805664e-05
        },
        {
            "start_logit": 4.4140625,
            "end_logit": -4.89453125,
            "text": "Integrins",
            "probability": 1.1563301086425781e-05
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 6.375,
            "text": "are transmembrane glycoproteins that are broadly distributed in living organisms.",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": 4.4140625,
            "end_logit": -5.4140625,
            "text": "Integrins are transmembrane glycoproteins that are",
            "probability": 6.794929504394531e-06
        }
    ],
    "6057c2f894d57fd879000033_1": [
        {
            "start_logit": 9.2890625,
            "end_logit": 9.234375,
            "text": "EpiMethylTag",
            "probability": 1.0
        },
        {
            "start_logit": -1.154296875,
            "end_logit": 9.234375,
            "text": "g",
            "probability": 2.8848648071289062e-05
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -1.2412109375,
            "text": "Epi",
            "probability": 2.7954578399658203e-05
        },
        {
            "start_logit": -5.84375,
            "end_logit": 9.234375,
            "text": "MethylTag",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.046875,
            "end_logit": 9.234375,
            "text": "Tag",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.13671875,
            "text": "EpiMethylTag:",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.57421875,
            "text": "EpiMethylTa",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.8671875,
            "text": "EpiMethylTag: simultaneous",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -6.8828125,
            "text": "EpiMethyl",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.1796875,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq or ChIP-seq signals with DNA methylation.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.1796875,
            "text": "EpiMethylTag: simultaneous detection of ATAC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.1796875,
            "text": "EpiMethylTag: simultaneous detection of ATA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.23046875,
            "text": "EpiMethylTag: simultaneous detection of ATAC-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.30078125,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.3203125,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.34765625,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq or ChIP-seq signals with DNA methylation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.3515625,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq or ChIP-seq signals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.4140625,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq or ChIP-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.41796875,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq or ChIP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2890625,
            "end_logit": -7.42578125,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq or ChIP-seq",
            "probability": 5.960464477539063e-08
        }
    ],
    "6057c2f894d57fd879000033_2": [
        {
            "start_logit": 9.25,
            "end_logit": 9.2265625,
            "text": "EpiMethylTag",
            "probability": 1.0
        },
        {
            "start_logit": -1.1484375,
            "end_logit": 9.2265625,
            "text": "g",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": 9.25,
            "end_logit": -1.330078125,
            "text": "Epi",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": -3.478515625,
            "end_logit": 9.2265625,
            "text": ". We developed a fast, low-input, low sequencing depth method, EpiMethylTag",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -4.359375,
            "end_logit": 9.2265625,
            "text": ", EpiMethylTag",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -5.078125,
            "end_logit": 9.2265625,
            "text": "MethylTag",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.81640625,
            "end_logit": 9.2265625,
            "text": "Tag",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.52734375,
            "text": "EpiMethylTa",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.25,
            "end_logit": -6.62890625,
            "text": "EpiMethylTag,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.75,
            "end_logit": 9.2265625,
            "text": "fast, low-input, low sequencing depth method, EpiMethylTag",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.2421875,
            "end_logit": 9.2265625,
            "text": "input, low sequencing depth method, EpiMethylTag",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.478515625,
            "end_logit": -1.330078125,
            "text": ". We developed a fast, low-input, low sequencing depth method, Epi",
            "probability": 0.0
        },
        {
            "start_logit": -4.359375,
            "end_logit": -1.330078125,
            "text": ", Epi",
            "probability": 0.0
        },
        {
            "start_logit": -1.1484375,
            "end_logit": -6.62890625,
            "text": "g,",
            "probability": 0.0
        },
        {
            "start_logit": -1.1484375,
            "end_logit": -6.7734375,
            "text": "g, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP) with bisulfite conversion, to simultaneously",
            "probability": 0.0
        },
        {
            "start_logit": -6.75,
            "end_logit": -1.330078125,
            "text": "fast, low-input, low sequencing depth method, Epi",
            "probability": 0.0
        },
        {
            "start_logit": -7.2421875,
            "end_logit": -1.330078125,
            "text": "input, low sequencing depth method, Epi",
            "probability": 0.0
        },
        {
            "start_logit": -3.478515625,
            "end_logit": -6.3515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -3.478515625,
            "end_logit": -6.3515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -3.478515625,
            "end_logit": -6.3515625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "6057c2f894d57fd879000033_3": [
        {
            "start_logit": 9.375,
            "end_logit": 9.25,
            "text": "EpiMethylTag",
            "probability": 1.0
        },
        {
            "start_logit": 9.375,
            "end_logit": -0.9736328125,
            "text": "Epi",
            "probability": 3.618001937866211e-05
        },
        {
            "start_logit": -1.109375,
            "end_logit": 9.25,
            "text": "g",
            "probability": 2.7954578399658203e-05
        },
        {
            "start_logit": -5.3671875,
            "end_logit": 9.25,
            "text": "MethylTag",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.75,
            "end_logit": 9.25,
            "text": "Tag",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.375,
            "end_logit": -6.19921875,
            "text": "EpiMethylTag,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.375,
            "end_logit": -6.53515625,
            "text": "EpiMethylTa",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.75390625,
            "end_logit": 9.25,
            "text": ", EpiMethylTag",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.375,
            "end_logit": -6.93359375,
            "text": "EpiMethylTag, that",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.00390625,
            "text": "EpiMethylTag, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP) with bisulfite conversion",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.0703125,
            "text": "EpiMethyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.140625,
            "text": "EpiMethylTag, that combines ATA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.16015625,
            "text": "EpiMethylTag, that combines ATAC-seq or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.17578125,
            "text": "EpiMethylTag, that combines ATAC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.1953125,
            "text": "EpiMethylTag, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP) with bisulfite",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.375,
            "end_logit": -7.19921875,
            "text": "EpiMethylTag, that combines ATAC-seq",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3125,
            "end_logit": 9.25,
            "text": "fast, low-input, low sequencing depth method, EpiMethylTag",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 9.25,
            "text": "input, low sequencing depth method, EpiMethylTag",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4375,
            "end_logit": 9.25,
            "text": "low sequencing depth method, EpiMethylTag",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.484375,
            "end_logit": 9.25,
            "text": "sequencing depth method, EpiMethylTag",
            "probability": 5.960464477539063e-08
        }
    ],
    "6057c2f894d57fd879000033_4": [
        {
            "start_logit": 9.3203125,
            "end_logit": 9.234375,
            "text": "EpiMethylTag",
            "probability": 1.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -1.130859375,
            "text": "Epi",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": -1.162109375,
            "end_logit": 9.234375,
            "text": "g",
            "probability": 2.777576446533203e-05
        },
        {
            "start_logit": -5.3515625,
            "end_logit": 9.234375,
            "text": "MethylTag",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 9.234375,
            "text": "Tag",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.45703125,
            "text": "EpiMethylTag, that",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.45703125,
            "text": "EpiMethylTag,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.68359375,
            "text": "EpiMethylTa",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.75,
            "end_logit": 9.234375,
            "text": ", EpiMethylTag",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 9.234375,
            "text": "veloped a fast, low-input, low sequencing depth method, EpiMethylTag",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.17578125,
            "text": "EpiMethylTag, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP) with bisulfite conversion",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.17578125,
            "text": "EpiMethyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.1796875,
            "text": "EpiMethylTag, that combines ATA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.20703125,
            "text": "EpiMethylTag, that combines ATAC-seq or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.234375,
            "text": "oped a fast, low-input, low sequencing depth method, EpiMethylTag",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 9.234375,
            "text": "input, low sequencing depth method, EpiMethylTag",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.234375,
            "text": "low sequencing depth method, EpiMethylTag",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53125,
            "end_logit": 9.234375,
            "text": "sequencing depth method, EpiMethylTag",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.162109375,
            "end_logit": -6.45703125,
            "text": "g, that",
            "probability": 0.0
        },
        {
            "start_logit": -1.162109375,
            "end_logit": -6.45703125,
            "text": "g,",
            "probability": 0.0
        }
    ],
    "6057c2f894d57fd879000033_5": [
        {
            "start_logit": 9.2265625,
            "end_logit": 9.21875,
            "text": "EpiMethylTag",
            "probability": 1.0
        },
        {
            "start_logit": -1.197265625,
            "end_logit": 9.21875,
            "text": "g",
            "probability": 2.9981136322021484e-05
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -1.4150390625,
            "text": "Epi",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": -5.78125,
            "end_logit": 9.21875,
            "text": "MethylTag",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.125,
            "end_logit": 9.21875,
            "text": "Tag",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.28125,
            "text": "EpiMethylTag:",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -6.75,
            "text": "EpiMethylTa",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.00390625,
            "text": "EpiMethylTag: simultaneous",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.16796875,
            "text": "EpiMethyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.328125,
            "text": "EpiMethylTag: simultaneous detection of ATA",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.34375,
            "text": "EpiMethylTag: simultaneous detection of ATAC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.375,
            "text": "EpiMethylTag: simultaneous detection of ATAC-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.4453125,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.44921875,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq or",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.46484375,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq or ChIP-seq signals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.484375,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq or ChIP-seq signals with DNA methylation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.2265625,
            "end_logit": -7.49609375,
            "text": "EpiMethylTag: simultaneous detection of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.197265625,
            "end_logit": -6.28125,
            "text": "g:",
            "probability": 0.0
        },
        {
            "start_logit": -1.197265625,
            "end_logit": -7.00390625,
            "text": "g: simultaneous",
            "probability": 0.0
        },
        {
            "start_logit": -1.197265625,
            "end_logit": -7.328125,
            "text": "g: simultaneous detection of ATA",
            "probability": 0.0
        }
    ],
    "5ebac76b0d431b5f7300000d_1": [
        {
            "start_logit": 9.28125,
            "end_logit": 9.1015625,
            "text": "H3K9me",
            "probability": 1.0
        },
        {
            "start_logit": 9.28125,
            "end_logit": -1.2177734375,
            "text": "H3K",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": -1.4697265625,
            "end_logit": 9.1015625,
            "text": "me",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": -4.80859375,
            "end_logit": 9.1015625,
            "text": "9me",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.85546875,
            "text": "H3K9me,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.95703125,
            "text": "H3K9",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.97265625,
            "text": "H3K9me, an",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -6.9765625,
            "text": "H3K9me, an epigenetic mark generated",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.0625,
            "text": "H3K9me, an epigenetic mark",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.08203125,
            "text": "H3K9me, an epigenetic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.1171875,
            "text": "H3K9me, an epigenetic mark generated by the histone methyltransferases SU(VAR)3-9 and orthologues.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.2109375,
            "text": "H3K9me, an epigenetic mark generated by the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.2109375,
            "text": "H3K9me, an epigenetic mark generated by",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.30078125,
            "text": "H3K9me, an epigenetic mark generated by the histone methyltransferases SU(VAR)3-9 and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.3125,
            "text": "H3K9me, an epigenetic mark generated by the histone methyltransferase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.32421875,
            "text": "H3K9me, an epigenetic mark generated by the histone methyltransferases SU(VAR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.33203125,
            "text": "H3K9me, an epigenetic mark generated by the histone methyltransferases SU(VAR)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.28125,
            "end_logit": -7.3359375,
            "text": "H3K9me, an epigenetic mark generated by the histone methyltransferases SU(",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 9.1015625,
            "text": "Here we discuss functions of the Heterochromatin Protein 1 (HP1) family of proteins that recognize H3K9me",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 9.1015625,
            "text": "recognize H3K9me",
            "probability": 5.960464477539063e-08
        }
    ],
    "5ebac76b0d431b5f7300000d_2": [
        {
            "start_logit": 9.1640625,
            "end_logit": 9.09375,
            "text": "H3K9me",
            "probability": 1.0
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -1.2880859375,
            "text": "H3K",
            "probability": 3.11732292175293e-05
        },
        {
            "start_logit": -1.373046875,
            "end_logit": 9.09375,
            "text": "me",
            "probability": 2.6702880859375e-05
        },
        {
            "start_logit": -3.197265625,
            "end_logit": 9.09375,
            "text": "methylation of histone H3 lysine 9 (H3K9me",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": -5.4375,
            "end_logit": 9.09375,
            "text": "9me",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -5.87109375,
            "text": "H3K9me)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.17578125,
            "text": "H3K9me),",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.3359375,
            "text": "H3K9me), are important regulators of heterochromatin-mediated gene silencing and chromosome structure.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.390625,
            "end_logit": 9.09375,
            "text": "(H3K9me",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.49609375,
            "end_logit": 9.09375,
            "text": "of histone H3 lysine 9 (H3K9me",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.609375,
            "end_logit": 9.09375,
            "text": "histone H3 lysine 9 (H3K9me",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.859375,
            "text": "H3K9me), are important regulators of heterochromatin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.90234375,
            "text": "H3K9me), are important regulators of heterochromatin-mediated gene silencing",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.91015625,
            "text": "H3K9me), are important",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.9296875,
            "text": "H3K9me), are",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.94140625,
            "text": "H3K9me), are important regulators of heterochromatin-mediated gene silencing and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.953125,
            "text": "H3K9me), are important regulators of heterochromatin-mediated gene silencing and chromosome structure",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -6.97265625,
            "text": "H3K9me), are important regulators of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.015625,
            "end_logit": 9.09375,
            "text": "heterochromatin mark methylation of histone H3 lysine 9 (H3K9me",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.09765625,
            "end_logit": 9.09375,
            "text": "mark methylation of histone H3 lysine 9 (H3K9me",
            "probability": 5.960464477539063e-08
        }
    ],
    "5c632cc1e842deac6700000f_1": [
        {
            "start_logit": 9.15625,
            "end_logit": 9.0859375,
            "text": "primary ovarian insufficiency",
            "probability": 1.0
        },
        {
            "start_logit": -1.333984375,
            "end_logit": 9.0859375,
            "text": "insufficiency",
            "probability": 2.753734588623047e-05
        },
        {
            "start_logit": 9.15625,
            "end_logit": -1.447265625,
            "text": "primary",
            "probability": 2.6464462280273438e-05
        },
        {
            "start_logit": 9.15625,
            "end_logit": -5.08984375,
            "text": "primary ovarian insufficiency.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.28125,
            "end_logit": 9.0859375,
            "text": "ovarian insufficiency",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.15625,
            "end_logit": -6.796875,
            "text": "primary ovarian",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.078125,
            "end_logit": 9.0859375,
            "text": "of primary ovarian insufficiency",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 9.0859375,
            "text": "STAG3 truncating variant as the cause of primary ovarian insufficiency",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 9.0859375,
            "text": "the cause of primary ovarian insufficiency",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.333984375,
            "end_logit": -5.08984375,
            "text": "insufficiency.",
            "probability": 0.0
        },
        {
            "start_logit": -7.078125,
            "end_logit": -1.447265625,
            "text": "of primary",
            "probability": 0.0
        },
        {
            "start_logit": -7.2109375,
            "end_logit": -1.447265625,
            "text": "STAG3 truncating variant as the cause of primary",
            "probability": 0.0
        },
        {
            "start_logit": -7.21484375,
            "end_logit": -1.447265625,
            "text": "the cause of primary",
            "probability": 0.0
        },
        {
            "start_logit": -5.72265625,
            "end_logit": -5.08984375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.28125,
            "end_logit": -5.08984375,
            "text": "ovarian insufficiency.",
            "probability": 0.0
        },
        {
            "start_logit": -7.078125,
            "end_logit": -5.08984375,
            "text": "of primary ovarian insufficiency.",
            "probability": 0.0
        },
        {
            "start_logit": -7.2109375,
            "end_logit": -5.08984375,
            "text": "STAG3 truncating variant as the cause of primary ovarian insufficiency.",
            "probability": 0.0
        },
        {
            "start_logit": -7.21484375,
            "end_logit": -5.08984375,
            "text": "the cause of primary ovarian insufficiency.",
            "probability": 0.0
        },
        {
            "start_logit": -6.28125,
            "end_logit": -6.796875,
            "text": "ovarian",
            "probability": 0.0
        },
        {
            "start_logit": -7.2109375,
            "end_logit": -6.5390625,
            "text": "STAG3 truncating variant as",
            "probability": 0.0
        }
    ],
    "5c632cc1e842deac6700000f_2": [
        {
            "start_logit": 5.1484375,
            "end_logit": -4.5234375,
            "text": "Primary ovarian insufficiency (POI)",
            "probability": 0.32275390625
        },
        {
            "start_logit": 5.1484375,
            "end_logit": -4.80078125,
            "text": "Primary",
            "probability": 0.24462890625
        },
        {
            "start_logit": 5.1484375,
            "end_logit": -5.01953125,
            "text": "Primary ovarian insufficiency (",
            "probability": 0.196533203125
        },
        {
            "start_logit": 5.1484375,
            "end_logit": -5.109375,
            "text": "Primary ovarian insufficiency",
            "probability": 0.1796875
        },
        {
            "start_logit": 2.6875,
            "end_logit": -4.859375,
            "text": "a homozygous two base pair duplication",
            "probability": 0.0196990966796875
        },
        {
            "start_logit": 2.6875,
            "end_logit": -4.89453125,
            "text": "a homozygous two base pair duplication (c.1947",
            "probability": 0.019012451171875
        },
        {
            "start_logit": 2.6875,
            "end_logit": -5.0390625,
            "text": "a",
            "probability": 0.016448974609375
        },
        {
            "start_logit": -2.1015625,
            "end_logit": -4.4140625,
            "text": "STAG3",
            "probability": 0.000255584716796875
        },
        {
            "start_logit": -2.1015625,
            "end_logit": -4.984375,
            "text": "STAG3 gene",
            "probability": 0.00014460086822509766
        },
        {
            "start_logit": -2.1015625,
            "end_logit": -5.1875,
            "text": "STAG3 gene, confirming it as the cause of POI in this family.",
            "probability": 0.00011801719665527344
        },
        {
            "start_logit": -2.9296875,
            "end_logit": -4.859375,
            "text": ". Whole-exome sequencing was done on the proband. Linkage analysis identified a locus on chromosome 7 where exome sequencing successfully identified a homozygous two base pair duplication",
            "probability": 7.158517837524414e-05
        },
        {
            "start_logit": -2.935546875,
            "end_logit": -4.859375,
            "text": ". Linkage analysis identified a locus on chromosome 7 where exome sequencing successfully identified a homozygous two base pair duplication",
            "probability": 7.104873657226562e-05
        },
        {
            "start_logit": -2.935546875,
            "end_logit": -4.89453125,
            "text": ". Linkage analysis identified a locus on chromosome 7 where exome sequencing successfully identified a homozygous two base pair duplication (c.1947",
            "probability": 6.884336471557617e-05
        },
        {
            "start_logit": -2.9296875,
            "end_logit": -5.0390625,
            "text": ". Whole-exome sequencing was done on the proband. Linkage analysis identified a locus on chromosome 7 where exome sequencing successfully identified a",
            "probability": 5.97834587097168e-05
        },
        {
            "start_logit": -2.935546875,
            "end_logit": -5.0390625,
            "text": ". Linkage analysis identified a locus on chromosome 7 where exome sequencing successfully identified a",
            "probability": 5.936622619628906e-05
        },
        {
            "start_logit": -2.9296875,
            "end_logit": -5.18359375,
            "text": ".",
            "probability": 5.1975250244140625e-05
        },
        {
            "start_logit": -2.9296875,
            "end_logit": -5.1875,
            "text": ". Whole-exome sequencing was done on the proband.",
            "probability": 5.155801773071289e-05
        },
        {
            "start_logit": -2.935546875,
            "end_logit": -5.18359375,
            "text": ". Multipoint parametric linkage analysis was performed.",
            "probability": 5.155801773071289e-05
        },
        {
            "start_logit": -2.935546875,
            "end_logit": -5.1875,
            "text": ".",
            "probability": 5.1140785217285156e-05
        },
        {
            "start_logit": -2.935546875,
            "end_logit": -5.1875,
            "text": ". POI is heterogeneous with only a few causative genes having been discovered so far.",
            "probability": 5.1140785217285156e-05
        }
    ],
    "5c632cc1e842deac6700000f_3": [
        {
            "start_logit": 9.0234375,
            "end_logit": 9.0703125,
            "text": "primary ovarian insufficiency",
            "probability": 1.0
        },
        {
            "start_logit": -1.2216796875,
            "end_logit": 9.0703125,
            "text": "insufficiency",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -1.701171875,
            "text": "primary",
            "probability": 2.092123031616211e-05
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -4.55078125,
            "text": "primary ovarian insufficiency.Primary ovarian insufficiency (POI) is a distressing cause of infertility in young women.",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -4.55078125,
            "text": "primary ovarian insufficiency.",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -5.94140625,
            "end_logit": 9.0703125,
            "text": "ovarian insufficiency",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.09375,
            "end_logit": 9.0703125,
            "text": "STAG3 truncating variant as the cause of primary ovarian insufficiency",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -6.625,
            "text": "primary ovarian insufficiency.Primary ovarian insufficiency (POI) is",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7421875,
            "end_logit": 9.0703125,
            "text": "the cause of primary ovarian insufficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -6.73046875,
            "text": "primary ovarian insufficiency.Primary ovarian insufficiency (POI) is a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 9.0703125,
            "text": "cause of primary ovarian insufficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -6.76171875,
            "text": "primary ovarian",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -6.76171875,
            "text": "primary ovarian insufficiency.Primary ovarian insufficiency (POI)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -6.8984375,
            "text": "primary ovarian insufficiency.Primary ovarian insufficiency (POI) is a distress",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0625,
            "end_logit": 9.0703125,
            "text": "of primary ovarian insufficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.0234375,
            "text": "primary ovarian insufficiency.Primary ovarian insufficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.05859375,
            "text": "primary ovarian insufficiency.Primary ovarian insufficiency (POI) is a distressing cause of infertility in young women",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.08203125,
            "text": "primary ovarian insufficiency.Primary ovarian insufficiency (POI",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.0859375,
            "text": "primary ovarian insufficiency.Primary ovarian insufficiency (POI) is a distressing cause of infertility in young",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0234375,
            "end_logit": -7.12890625,
            "text": "primary ovarian insufficiency.Primary ovarian insufficiency (",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5c632cc1e842deac6700000f_4": [
        {
            "start_logit": 9.140625,
            "end_logit": 9.09375,
            "text": "primary ovarian insufficiency",
            "probability": 1.0
        },
        {
            "start_logit": 9.140625,
            "end_logit": 0.01299285888671875,
            "text": "primary ovarian insufficiency.",
            "probability": 0.00011414289474487305
        },
        {
            "start_logit": -1.1767578125,
            "end_logit": 9.09375,
            "text": "insufficiency",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": 9.140625,
            "end_logit": -1.478515625,
            "text": "primary",
            "probability": 2.568960189819336e-05
        },
        {
            "start_logit": -6.3359375,
            "end_logit": 9.09375,
            "text": "ovarian insufficiency",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 9.09375,
            "text": "loss-of-function variants in the STAG3 gene leading to primary ovarian insufficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 9.09375,
            "text": "leading to primary ovarian insufficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.890625,
            "end_logit": 9.09375,
            "text": "in the STAG3 gene leading to primary ovarian insufficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 9.09375,
            "text": "the STAG3 gene leading to primary ovarian insufficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.95703125,
            "end_logit": 9.09375,
            "text": "to primary ovarian insufficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.015625,
            "text": "primary ovarian",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 9.09375,
            "text": "Two rare loss-of-function variants in the STAG3 gene leading to primary ovarian insufficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 9.09375,
            "text": "rare loss-of-function variants in the STAG3 gene leading to primary ovarian insufficiency",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.1767578125,
            "end_logit": 0.01299285888671875,
            "text": "insufficiency.",
            "probability": 0.0
        },
        {
            "start_logit": -4.91015625,
            "end_logit": 0.01299285888671875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.3359375,
            "end_logit": 0.01299285888671875,
            "text": "ovarian insufficiency.",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 0.01299285888671875,
            "text": "loss-of-function variants in the STAG3 gene leading to primary ovarian insufficiency.",
            "probability": 0.0
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 0.01299285888671875,
            "text": "leading to primary ovarian insufficiency.",
            "probability": 0.0
        },
        {
            "start_logit": -6.890625,
            "end_logit": 0.01299285888671875,
            "text": "in the STAG3 gene leading to primary ovarian insufficiency.",
            "probability": 0.0
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 0.01299285888671875,
            "text": "the STAG3 gene leading to primary ovarian insufficiency.",
            "probability": 0.0
        }
    ],
    "5c632cc1e842deac6700000f_5": [
        {
            "start_logit": 8.140625,
            "end_logit": 6.65234375,
            "text": "A homozygous NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 0.9951171875
        },
        {
            "start_logit": 8.140625,
            "end_logit": 1.0478515625,
            "text": "A homozygous NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency",
            "probability": 0.0036468505859375
        },
        {
            "start_logit": 8.140625,
            "end_logit": -1.392578125,
            "text": "A homozygous NOBOX truncating variant causes defective transcriptional activation and",
            "probability": 0.0003185272216796875
        },
        {
            "start_logit": -0.033599853515625,
            "end_logit": 6.65234375,
            "text": "homozygous NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 0.0002789497375488281
        },
        {
            "start_logit": 8.140625,
            "end_logit": -2.28515625,
            "text": "A",
            "probability": 0.00013077259063720703
        },
        {
            "start_logit": -1.587890625,
            "end_logit": 6.65234375,
            "text": "primary ovarian insufficiency.",
            "probability": 5.888938903808594e-05
        },
        {
            "start_logit": -2.029296875,
            "end_logit": 6.65234375,
            "text": ".",
            "probability": 3.802776336669922e-05
        },
        {
            "start_logit": 8.140625,
            "end_logit": -4.171875,
            "text": "A homozygous NOBOX truncating variant causes defective transcriptional activation",
            "probability": 1.9729137420654297e-05
        },
        {
            "start_logit": 8.140625,
            "end_logit": -4.65625,
            "text": "A homozygous NOBOX truncating variant causes defective transcriptional activation and leads to",
            "probability": 1.2159347534179688e-05
        },
        {
            "start_logit": 8.140625,
            "end_logit": -4.73828125,
            "text": "A homozygous NOBOX truncating variant",
            "probability": 1.1265277862548828e-05
        },
        {
            "start_logit": 8.140625,
            "end_logit": -5.0703125,
            "text": "A homozygous NOBOX",
            "probability": 7.987022399902344e-06
        },
        {
            "start_logit": 8.140625,
            "end_logit": -5.140625,
            "text": "A homozygous NOBOX truncating variant causes defective transcriptional activation and leads",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": -4.03125,
            "end_logit": 6.65234375,
            "text": "NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": 8.140625,
            "end_logit": -6.0703125,
            "text": "A homozygous NOBOX truncating",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 8.140625,
            "end_logit": -6.08984375,
            "text": "A homozygous NOBOX trunc",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 8.140625,
            "end_logit": -6.171875,
            "text": "A homozygous NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 8.140625,
            "end_logit": -6.2734375,
            "text": "A homozygous NOBOX truncating variant causes defective transcriptional",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 8.140625,
            "end_logit": -6.50390625,
            "text": "A homozygous NOBOX truncating variant causes",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 8.140625,
            "end_logit": -6.96484375,
            "text": "A homozygous NOBOX truncating variant causes defective",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -5.52734375,
            "end_logit": 6.65234375,
            "text": "defective transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 1.1324882507324219e-06
        }
    ],
    "5c632cc1e842deac6700000f_6": [
        {
            "start_logit": 3.56640625,
            "end_logit": -1.6748046875,
            "text": "that POI is",
            "probability": 0.454345703125
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -2.283203125,
            "text": "that POI",
            "probability": 0.247314453125
        },
        {
            "start_logit": 2.474609375,
            "end_logit": -1.6748046875,
            "text": "POI is",
            "probability": 0.1524658203125
        },
        {
            "start_logit": 2.474609375,
            "end_logit": -2.283203125,
            "text": "POI",
            "probability": 0.08294677734375
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -5.31640625,
            "text": "that POI is caused by pathogenic compound heterozygous variants in the STAG3 gene",
            "probability": 0.0119171142578125
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -5.7578125,
            "text": "that POI is caused",
            "probability": 0.00766754150390625
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -6.15234375,
            "text": "that POI is caused by",
            "probability": 0.005168914794921875
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -6.2265625,
            "text": "that POI is caused by pathogenic compound heterozygous variants in the STAG3 gene,",
            "probability": 0.00479888916015625
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -6.23828125,
            "text": "that POI is caused by pathogenic compound heterozygous variants in the STAG3",
            "probability": 0.004741668701171875
        },
        {
            "start_logit": 2.474609375,
            "end_logit": -5.31640625,
            "text": "POI is caused by pathogenic compound heterozygous variants in the STAG3 gene",
            "probability": 0.003993988037109375
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -6.53125,
            "text": "that POI is caused by pathogenic compound heterozygous variants in the STAG",
            "probability": 0.003536224365234375
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -6.84765625,
            "text": "that POI is caused by pathogenic compound heterozygous variants in the STAG3 gene, supporting the",
            "probability": 0.0025768280029296875
        },
        {
            "start_logit": 2.474609375,
            "end_logit": -5.7578125,
            "text": "POI is caused",
            "probability": 0.0025691986083984375
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -6.8515625,
            "text": "that POI is caused by pathogenic compound heterozygous",
            "probability": 0.0025691986083984375
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -6.86328125,
            "text": "that POI is caused by pathogenic",
            "probability": 0.002536773681640625
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -6.91015625,
            "text": "that POI is caused by pathogenic compound heterozygous variants in the STAG3 gene, supporting",
            "probability": 0.0024204254150390625
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -6.9375,
            "text": "that",
            "probability": 0.00235748291015625
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -6.9765625,
            "text": "that POI is caused by pathogenic compound",
            "probability": 0.00226593017578125
        },
        {
            "start_logit": 3.56640625,
            "end_logit": -6.98046875,
            "text": "that POI is caused by pathogenic compound heterozygous variants",
            "probability": 0.0022563934326171875
        },
        {
            "start_logit": 2.474609375,
            "end_logit": -6.15234375,
            "text": "POI is caused by",
            "probability": 0.0017299652099609375
        }
    ],
    "5c632cc1e842deac6700000f_7": [
        {
            "start_logit": 5.1171875,
            "end_logit": -2.45703125,
            "text": "POI",
            "probability": 0.49365234375
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -3.0,
            "text": "POI is",
            "probability": 0.286865234375
        },
        {
            "start_logit": 0.097900390625,
            "end_logit": 0.2386474609375,
            "text": "primary ovarian insufficiency.",
            "probability": 0.048309326171875
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -5.6796875,
            "text": "POI is caused by pathogenic compound heterozygous variants in the STAG3 gene",
            "probability": 0.019683837890625
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -5.6875,
            "text": "PO",
            "probability": 0.01953125
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -5.80859375,
            "text": "POI is caused by",
            "probability": 0.017303466796875
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -5.88671875,
            "text": "POI is caused by pathogenic compound heterozygous variants in the STAG3 gene,",
            "probability": 0.0160064697265625
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -5.90625,
            "text": "POI is caused",
            "probability": 0.01568603515625
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -6.2265625,
            "text": "POI is caused by pathogenic",
            "probability": 0.011383056640625
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -6.3515625,
            "text": "POI is caused by pathogenic compound heterozygous",
            "probability": 0.01004791259765625
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -6.359375,
            "text": "POI is caused by pathogenic compound heterozygous variants in the STAG3",
            "probability": 0.0099639892578125
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -6.40234375,
            "text": "POI is caused by pathogenic compound heterozygous variants",
            "probability": 0.009552001953125
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -6.4765625,
            "text": "POI is caused by pathogenic compound",
            "probability": 0.0088653564453125
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -6.58203125,
            "text": "POI is caused by pathogenic compound heterozygous variants in the STAG",
            "probability": 0.0079803466796875
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -6.62890625,
            "text": "POI is caused by pathogenic compound heterozygous variants in the STA",
            "probability": 0.007617950439453125
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -6.7734375,
            "text": "POI is caused by pathogenic compound heterozygous variants in the STAG3 gene, supporting the",
            "probability": 0.006591796875
        },
        {
            "start_logit": 5.1171875,
            "end_logit": -6.80078125,
            "text": "POI is caused by pathogenic compound heterozygous variants in the STAG3 gene, supporting the key role of the STAG3 gene in the",
            "probability": 0.006412506103515625
        },
        {
            "start_logit": 0.097900390625,
            "end_logit": -2.392578125,
            "text": "primary ovarian insufficiency",
            "probability": 0.00348663330078125
        },
        {
            "start_logit": -4.04296875,
            "end_logit": 0.2386474609375,
            "text": ".",
            "probability": 0.0007691383361816406
        },
        {
            "start_logit": -6.40234375,
            "end_logit": 0.2386474609375,
            "text": "compound heterozygous variants in the STAG3 gene, supporting the key role of the STAG3 gene in the etiology of primary ovarian insufficiency.",
            "probability": 7.236003875732422e-05
        }
    ],
    "56c1f003ef6e394741000039_1": [
        {
            "start_logit": 8.9921875,
            "end_logit": 7.84375,
            "text": "orexin receptor",
            "probability": 0.8701171875
        },
        {
            "start_logit": 8.9921875,
            "end_logit": 5.953125,
            "text": "orexin",
            "probability": 0.13037109375
        },
        {
            "start_logit": -3.375,
            "end_logit": 7.84375,
            "text": "receptor",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -7.265625,
            "text": "orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -7.34765625,
            "text": "orexin receptor antagonist",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -7.3671875,
            "text": "orexin receptor antagonist for the treatment of sleep onset and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -7.3828125,
            "text": "orexin receptor antagonist for",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.9921875,
            "end_logit": -7.40625,
            "text": "orexin receptor antagonist for the treatment",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 7.84375,
            "text": "dual orexin receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.640625,
            "end_logit": 7.84375,
            "text": ": a dual orexin receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 7.84375,
            "text": "a dual orexin receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.71875,
            "end_logit": 7.84375,
            "text": "orexant: a dual orexin receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 5.953125,
            "text": "dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": 5.953125,
            "text": ": a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 5.953125,
            "text": "a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": 5.953125,
            "text": "orexant: a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -3.375,
            "end_logit": -7.265625,
            "text": "receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.",
            "probability": 0.0
        },
        {
            "start_logit": -3.375,
            "end_logit": -7.34765625,
            "text": "receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -3.375,
            "end_logit": -7.3671875,
            "text": "receptor antagonist for the treatment of sleep onset and",
            "probability": 0.0
        },
        {
            "start_logit": -3.375,
            "end_logit": -7.3828125,
            "text": "receptor antagonist for",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_2": [
        {
            "start_logit": 9.8515625,
            "end_logit": 8.3828125,
            "text": "orexin receptor",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.8515625,
            "end_logit": 1.83203125,
            "text": "orexin",
            "probability": 0.0014333724975585938
        },
        {
            "start_logit": -2.74609375,
            "end_logit": 8.3828125,
            "text": "receptor",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.03125,
            "text": "orexin receptor antagonist approved for the treatment of insomnia.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.26953125,
            "text": "orexin receptor antagonist approved",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.2890625,
            "text": "orexin receptor antagonist",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.31640625,
            "text": "orexin receptor antagonist approved for the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.33203125,
            "text": "orexin receptor antagonist approved for the treatment of insomnia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.34375,
            "text": "orexin receptor antagonist approved for the treatment of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.35546875,
            "text": "orexin receptor antagonist approved for the treatment",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8515625,
            "end_logit": -7.37890625,
            "text": "orexin receptor antagonist approved for",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 8.3828125,
            "text": "CONCLUSION: Suvorexant is the first dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 8.3828125,
            "text": ": Suvorexant is the first dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": 8.3828125,
            "text": "dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 8.3828125,
            "text": "Suvorexant is the first dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 8.3828125,
            "text": "orexant is the first dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 8.3828125,
            "text": "is the first dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 1.83203125,
            "text": "CONCLUSION: Suvorexant is the first dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 1.83203125,
            "text": ": Suvorexant is the first dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": 1.83203125,
            "text": "dual orexin",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_3": [
        {
            "start_logit": 9.265625,
            "end_logit": 8.9375,
            "text": "orexin receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.265625,
            "end_logit": -1.23046875,
            "text": "orexin",
            "probability": 3.820657730102539e-05
        },
        {
            "start_logit": -1.8515625,
            "end_logit": 8.9375,
            "text": "receptor",
            "probability": 1.4841556549072266e-05
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.52734375,
            "text": "orexin receptor bound",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -6.58203125,
            "text": "orexin receptor bound to the insomnia drug suvorexant.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.49609375,
            "end_logit": 8.9375,
            "text": "OX2 orexin receptor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.0703125,
            "text": "orexin receptor bound to the insomnia drug suv",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.07421875,
            "text": "orexin receptor bound to the insomnia drug suvorexant",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.13671875,
            "text": "orexin receptor bound to",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.15625,
            "text": "orexin receptor bound to the insomnia drug suvorex",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.1875,
            "text": "orexin receptor bound to the insomnia drug",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.22265625,
            "text": "orexin receptor bound to the insomnia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.265625,
            "end_logit": -7.22265625,
            "text": "orexin receptor bound to the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 8.9375,
            "text": "2 orexin receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 8.9375,
            "text": "Crystal structure of the human OX2 orexin receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 8.9375,
            "text": "human OX2 orexin receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.703125,
            "end_logit": 8.9375,
            "text": "the human OX2 orexin receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 8.9375,
            "text": "of the human OX2 orexin receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.49609375,
            "end_logit": -1.23046875,
            "text": "OX2 orexin",
            "probability": 0.0
        },
        {
            "start_logit": -1.8515625,
            "end_logit": -6.52734375,
            "text": "receptor bound",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_4": [
        {
            "start_logit": 9.3125,
            "end_logit": 8.8125,
            "text": "Orexin receptor",
            "probability": 1.0
        },
        {
            "start_logit": 9.3125,
            "end_logit": -1.140625,
            "text": "Orexin",
            "probability": 4.756450653076172e-05
        },
        {
            "start_logit": -2.10546875,
            "end_logit": 8.8125,
            "text": "receptor",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.1484375,
            "text": "Orexin receptor antagonism for treatment of insomnia: a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.25,
            "text": "Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suv",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.2578125,
            "text": "Orexin receptor antagonism for treatment of insomnia: a randomized",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.2578125,
            "text": "Orexin receptor antagonism for",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.26171875,
            "text": "Orexin receptor antagonism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.265625,
            "text": "Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.28125,
            "text": "Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorex",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.30078125,
            "text": "Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.30859375,
            "text": "Orexin receptor antagonism for treatment",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.31640625,
            "text": "Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.32421875,
            "text": "Orexin receptor antagonism for treatment of insomnia:",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.328125,
            "text": "Orexin receptor antagonism for treatment of insomnia: a randomized clinical",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.34375,
            "text": "Orexin receptor antagonism for treatment of insomnia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3125,
            "end_logit": -7.34765625,
            "text": "Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.10546875,
            "end_logit": -7.1484375,
            "text": "receptor antagonism for treatment of insomnia: a",
            "probability": 0.0
        },
        {
            "start_logit": -2.10546875,
            "end_logit": -7.25,
            "text": "receptor antagonism for treatment of insomnia: a randomized clinical trial of suv",
            "probability": 0.0
        },
        {
            "start_logit": -2.10546875,
            "end_logit": -7.2578125,
            "text": "receptor antagonism for treatment of insomnia: a randomized",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_5": [
        {
            "start_logit": 8.28125,
            "end_logit": 7.03515625,
            "text": "orexin",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.28125,
            "end_logit": -0.1744384765625,
            "text": "orexin receptor",
            "probability": 0.0007433891296386719
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.05859375,
            "text": "orexin receptor antagonist.",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.28125,
            "end_logit": -7.078125,
            "text": "orexin receptor antagonist",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 7.03515625,
            "text": "dual orexin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 7.03515625,
            "text": "of sleep by suvorexant-a novel dual orexin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -0.1744384765625,
            "text": "receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -0.1744384765625,
            "text": "dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -0.1744384765625,
            "text": "of sleep by suvorexant-a novel dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -5.6953125,
            "end_logit": -7.05859375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -7.05859375,
            "text": "receptor antagonist.",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -7.078125,
            "text": "receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -7.05859375,
            "text": "dual orexin receptor antagonist.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -7.078125,
            "text": "dual orexin receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -7.05859375,
            "text": "of sleep by suvorexant-a novel dual orexin receptor antagonist.",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -7.078125,
            "text": "of sleep by suvorexant-a novel dual orexin receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -7.12109375,
            "text": "of sleep by",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -7.1328125,
            "text": "of sleep by suvorexant",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -7.1484375,
            "text": "of sleep by suvorexant-a novel",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -7.1875,
            "text": "of sleep by suv",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_6": [
        {
            "start_logit": 7.51171875,
            "end_logit": 7.78515625,
            "text": "orexin",
            "probability": 1.0
        },
        {
            "start_logit": 7.51171875,
            "end_logit": -7.1484375,
            "text": "orexin for suvorexant.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 7.78515625,
            "text": ", and orexin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 7.78515625,
            "text": "substance P (or neurokinin) for aprepitant, melatonin for ramelteon, and orexin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.51171875,
            "end_logit": -7.203125,
            "text": "orexin for",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.78515625,
            "text": ", substance P (or neurokinin) for aprepitant, melatonin for ramelteon, and orexin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 7.78515625,
            "text": "varenicline, substance P (or neurokinin) for aprepitant, melatonin for ramelteon, and orexin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.39453125,
            "end_logit": -7.1484375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.39453125,
            "end_logit": -7.1484375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.1484375,
            "text": ", and orexin for suvorexant.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.1484375,
            "text": "substance P (or neurokinin) for aprepitant, melatonin for ramelteon, and orexin for suvorexant.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4296875,
            "end_logit": -7.19921875,
            "text": "The neurotransmitter systems on which the development of these agents were based included",
            "probability": 0.0
        },
        {
            "start_logit": -7.4296875,
            "end_logit": -7.203125,
            "text": "The neurotransmitter systems",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.203125,
            "text": ", and orexin for",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.203125,
            "text": "substance P (or neurokinin) for aprepitant, melatonin for ramelteon, and orexin for",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -7.1484375,
            "text": ", substance P (or neurokinin) for aprepitant, melatonin for ramelteon, and orexin for suvorexant.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -7.19921875,
            "text": "on which the development of these agents were based included",
            "probability": 0.0
        },
        {
            "start_logit": -7.53125,
            "end_logit": -7.1484375,
            "text": ", and insomnia for suvorexant and ramelteon.",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -7.1484375,
            "text": ", weight loss for lorcaserin, and insomnia for suvorexant and ramelteon.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": -7.1484375,
            "text": "and insomnia for suvorexant and ramelteon.",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_7": [
        {
            "start_logit": 9.71875,
            "end_logit": 8.25,
            "text": "orexin receptor",
            "probability": 0.9873046875
        },
        {
            "start_logit": 9.71875,
            "end_logit": 3.873046875,
            "text": "orexin",
            "probability": 0.01242828369140625
        },
        {
            "start_logit": -2.931640625,
            "end_logit": 8.25,
            "text": "receptor",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 9.71875,
            "end_logit": -6.9609375,
            "text": "orexin receptor antagonist for the management of insomnia.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.296875,
            "text": "orexin receptor antagonist for",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.30859375,
            "text": "orexin receptor antagonist",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.328125,
            "text": "orexin receptor antagonist for the management",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.33984375,
            "text": "orexin receptor antagonist for the management of insomnia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.36328125,
            "text": "orexin receptor antagonist for the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.38671875,
            "text": "orexin receptor antagonist for the management of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 8.25,
            "text": "dual orexin receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 8.25,
            "text": ", a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 3.873046875,
            "text": "dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 3.873046875,
            "text": ", a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -2.931640625,
            "end_logit": -6.9609375,
            "text": "receptor antagonist for the management of insomnia.",
            "probability": 0.0
        },
        {
            "start_logit": -2.931640625,
            "end_logit": -7.296875,
            "text": "receptor antagonist for",
            "probability": 0.0
        },
        {
            "start_logit": -2.931640625,
            "end_logit": -7.30859375,
            "text": "receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -2.931640625,
            "end_logit": -7.328125,
            "text": "receptor antagonist for the management",
            "probability": 0.0
        },
        {
            "start_logit": -2.931640625,
            "end_logit": -7.33984375,
            "text": "receptor antagonist for the management of insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -2.931640625,
            "end_logit": -7.36328125,
            "text": "receptor antagonist for the",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_8": [
        {
            "start_logit": 9.71875,
            "end_logit": 8.25,
            "text": "orexin receptor",
            "probability": 0.9873046875
        },
        {
            "start_logit": 9.71875,
            "end_logit": 3.873046875,
            "text": "orexin",
            "probability": 0.01242828369140625
        },
        {
            "start_logit": -2.931640625,
            "end_logit": 8.25,
            "text": "receptor",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 9.71875,
            "end_logit": -6.9609375,
            "text": "orexin receptor antagonist for the management of insomnia.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.296875,
            "text": "orexin receptor antagonist for",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.30859375,
            "text": "orexin receptor antagonist",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.328125,
            "text": "orexin receptor antagonist for the management",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.33984375,
            "text": "orexin receptor antagonist for the management of insomnia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.36328125,
            "text": "orexin receptor antagonist for the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.38671875,
            "text": "orexin receptor antagonist for the management of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 8.25,
            "text": "dual orexin receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 8.25,
            "text": ", a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 3.873046875,
            "text": "dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 3.873046875,
            "text": ", a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -2.931640625,
            "end_logit": -6.9609375,
            "text": "receptor antagonist for the management of insomnia.",
            "probability": 0.0
        },
        {
            "start_logit": -2.931640625,
            "end_logit": -7.296875,
            "text": "receptor antagonist for",
            "probability": 0.0
        },
        {
            "start_logit": -2.931640625,
            "end_logit": -7.30859375,
            "text": "receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -2.931640625,
            "end_logit": -7.328125,
            "text": "receptor antagonist for the management",
            "probability": 0.0
        },
        {
            "start_logit": -2.931640625,
            "end_logit": -7.33984375,
            "text": "receptor antagonist for the management of insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -2.931640625,
            "end_logit": -7.36328125,
            "text": "receptor antagonist for the",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_9": [
        {
            "start_logit": 7.4609375,
            "end_logit": 7.87890625,
            "text": "orexin",
            "probability": 1.0
        },
        {
            "start_logit": 7.4609375,
            "end_logit": -6.5625,
            "text": "orexin activity.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.4609375,
            "end_logit": -6.6796875,
            "text": "orexin activity",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 7.87890625,
            "text": "Suvorexant helps in decreasing wakefulness by counteracting orexin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.59375,
            "end_logit": 7.87890625,
            "text": "orexant helps in decreasing wakefulness by counteracting orexin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 7.87890625,
            "text": "ant helps in decreasing wakefulness by counteracting orexin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.75,
            "end_logit": 7.87890625,
            "text": "ing orexin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.75,
            "end_logit": 7.87890625,
            "text": "in decreasing wakefulness by counteracting orexin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.96875,
            "end_logit": -6.5625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -6.5625,
            "text": "Suvorexant helps in decreasing wakefulness by counteracting orexin activity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": -6.5625,
            "text": "orexant helps in decreasing wakefulness by counteracting orexin activity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -6.5625,
            "text": "ant helps in decreasing wakefulness by counteracting orexin activity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -6.6796875,
            "text": "Suvorexant helps in decreasing wakefulness by counteracting orexin activity",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": -6.6796875,
            "text": "orexant helps in decreasing wakefulness by counteracting orexin activity",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": -6.5625,
            "text": "ing orexin activity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": -6.5625,
            "text": "in decreasing wakefulness by counteracting orexin activity.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": -6.6796875,
            "text": "ant helps in decreasing wakefulness by counteracting orexin activity",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": -6.6796875,
            "text": "ing orexin activity",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": -6.6796875,
            "text": "in decreasing wakefulness by counteracting orexin activity",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -6.99609375,
            "text": "Suvorexant helps in decreasing wakefulness by",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_10": [
        {
            "start_logit": 7.35546875,
            "end_logit": 8.4921875,
            "text": "orexin (hypocretin) system",
            "probability": 1.0
        },
        {
            "start_logit": -2.091796875,
            "end_logit": 8.4921875,
            "text": "system",
            "probability": 7.903575897216797e-05
        },
        {
            "start_logit": 7.35546875,
            "end_logit": -3.03125,
            "text": "orexin",
            "probability": 9.953975677490234e-06
        },
        {
            "start_logit": 7.35546875,
            "end_logit": -3.6328125,
            "text": "orexin (hypocretin",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": -5.6484375,
            "end_logit": 8.4921875,
            "text": "the orexin (hypocretin) system",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -6.265625,
            "end_logit": 8.4921875,
            "text": "(hypocretin) system",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 7.35546875,
            "end_logit": -5.40234375,
            "text": "orexin (hypocretin)",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.6796875,
            "end_logit": 8.4921875,
            "text": ", the orexin (hypocretin) system",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.35546875,
            "end_logit": -5.7890625,
            "text": "orexin (hypocretin) system.",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.35546875,
            "end_logit": -5.81640625,
            "text": "orexin (hypoc",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.26171875,
            "end_logit": 8.4921875,
            "text": "Hypnotic drug development has arguably become more focused in recent years, particularly upon the highly anticipated novel target, the orexin (hypocretin) system",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 8.4921875,
            "text": "hypocretin) system",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 0.4931640625,
            "end_logit": -2.427734375,
            "text": "orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 0.4931640625,
            "end_logit": -3.50390625,
            "text": "orexin",
            "probability": 0.0
        },
        {
            "start_logit": 0.4931640625,
            "end_logit": -4.87890625,
            "text": "orexin receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -2.091796875,
            "end_logit": -2.427734375,
            "text": "system. Merck&apos;s suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 0.4931640625,
            "end_logit": -5.7890625,
            "text": "orexin receptor antagonist (DORA) class expected to be submitted for FDA approval, with a new drug application anticipated in 2012.",
            "probability": 0.0
        },
        {
            "start_logit": -2.091796875,
            "end_logit": -3.50390625,
            "text": "system. Merck&apos;s suvorexant (MK-4305) is the first compound of the so-called dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -3.34375,
            "end_logit": -2.427734375,
            "text": ". Merck&apos;s suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -4.1171875,
            "end_logit": -2.427734375,
            "text": "dual orexin receptor",
            "probability": 0.0
        }
    ],
    "5a70d42899e2c3af26000002_1": [
        {
            "start_logit": 8.8671875,
            "end_logit": 9.125,
            "text": "SLC2A10",
            "probability": 1.0
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -0.61962890625,
            "text": "SLC2A10, a gene that encodes the facilitative glucose transporter GLUT10, cause ATS.",
            "probability": 5.829334259033203e-05
        },
        {
            "start_logit": -1.3798828125,
            "end_logit": 9.125,
            "text": "10",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -2.099609375,
            "text": "SLC",
            "probability": 1.3232231140136719e-05
        },
        {
            "start_logit": -5.49609375,
            "end_logit": 9.125,
            "text": "Mutations in SLC2A10",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -5.5,
            "end_logit": 9.125,
            "text": "2A10",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -5.2734375,
            "text": "SLC2A10, a",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -5.55078125,
            "text": "SLC2A10,",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -5.62109375,
            "text": "SLC2A10, a gene that encodes the facilitative glucose transporter",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -5.6875,
            "text": "SLC2A10, a gene that",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -5.80078125,
            "text": "SLC2A10, a gene",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -5.984375,
            "text": "SLC2A10, a gene that encodes the facilitative glucose transporter GLUT10,",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -5.9921875,
            "text": "SLC2A10, a gene that encodes the facilitative glucose transporter GLUT1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -6.12890625,
            "text": "SLC2A10, a gene that encodes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -6.16796875,
            "text": "SLC2A10, a gene that encodes the",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -6.19140625,
            "text": "SLC2A10, a gene that encodes the facilitative glucose",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -6.234375,
            "text": "SLC2A10, a gene that encodes the facilitative glucose transporter GLUT10",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -6.4375,
            "text": "SLC2A10, a gene that encodes the facilit",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.8671875,
            "end_logit": -6.578125,
            "text": "SLC2A10, a gene that encodes the facilitative",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.03515625,
            "end_logit": 9.125,
            "text": "in SLC2A10",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5a70d42899e2c3af26000002_2": [
        {
            "start_logit": 9.0390625,
            "end_logit": 9.1640625,
            "text": "SLC2A10",
            "probability": 1.0
        },
        {
            "start_logit": -1.2763671875,
            "end_logit": 9.1640625,
            "text": "10",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -1.7880859375,
            "text": "SLC",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": -5.3046875,
            "end_logit": 9.1640625,
            "text": "2A10",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -5.31640625,
            "text": "SLC2A10, which encodes facilitative glucose transporter 10 (GLUT10).",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.19140625,
            "end_logit": 9.1640625,
            "text": "in SLC2A10",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.21875,
            "text": "SLC2A10, which",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.296875,
            "text": "SLC2A10,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.296875,
            "text": "SLC2A10, which encodes facilitative glucose transporter 10 (GLUT10)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.70703125,
            "text": "SLC2A10, which encodes facilitative glucose transporter 10 (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.7109375,
            "text": "SLC2A10, which encodes facilitative glucose transporter 10 (GLUT10",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.78125,
            "text": "SLC2A10, which encodes facilitative glucose transporter 10 (GLUT1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0390625,
            "end_logit": -6.8203125,
            "text": "SLC2A10, which encodes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 9.1640625,
            "text": "Arterial tortuosity syndrome (ATS) is an autosomal recessive connective tissue disorder caused by loss-of-function mutations in SLC2A10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.1640625,
            "text": "tortuosity syndrome (ATS) is an autosomal recessive connective tissue disorder caused by loss-of-function mutations in SLC2A10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 9.1640625,
            "text": "autosomal recessive connective tissue disorder caused by loss-of-function mutations in SLC2A10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.703125,
            "end_logit": 9.1640625,
            "text": "by loss-of-function mutations in SLC2A10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 9.1640625,
            "text": "-of-function mutations in SLC2A10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8515625,
            "end_logit": 9.1640625,
            "text": "uosity syndrome (ATS) is an autosomal recessive connective tissue disorder caused by loss-of-function mutations in SLC2A10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.2763671875,
            "end_logit": -5.31640625,
            "text": "10, which encodes facilitative glucose transporter 10 (GLUT10).",
            "probability": 0.0
        }
    ],
    "5a70d42899e2c3af26000002_3": [
        {
            "start_logit": 9.1875,
            "end_logit": 9.1484375,
            "text": "SLC2A10",
            "probability": 1.0
        },
        {
            "start_logit": -1.3779296875,
            "end_logit": 9.1484375,
            "text": "10",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": 9.1875,
            "end_logit": -1.4921875,
            "text": "SLC",
            "probability": 2.372264862060547e-05
        },
        {
            "start_logit": -5.43359375,
            "end_logit": 9.1484375,
            "text": "2A10",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.078125,
            "text": "SLC2A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.2109375,
            "text": "SLC2A10 missense",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.2421875,
            "text": "SLC2A10 missense mutations in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.265625,
            "text": "SLC2A10 missense mutations in three families with severe cardiopulmonary complications in infancy and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.28125,
            "text": "SLC2A10 missense mutations in three families with severe cardiopulmonary complications in infancy and a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.28125,
            "text": "SLC2A10 missense mutations",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.296875,
            "text": "SLC2A10 missense mutations in three families with severe cardiopulmonary complications in infancy and a literature",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.3671875,
            "text": "SLC2A10 missense mutations in three families with severe cardiopulmonary complications in infancy and a literature review",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 9.1484375,
            "text": "recurrent SLC2A10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.1484375,
            "text": "for two novel and one recurrent SLC2A10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.1484375,
            "text": "homozygosity for two novel and one recurrent SLC2A10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.67578125,
            "end_logit": 9.1484375,
            "text": "two novel and one recurrent SLC2A10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 9.1484375,
            "text": "Arterial Tortuosity Syndrome: homozygosity for two novel and one recurrent SLC2A10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.3779296875,
            "end_logit": -7.2109375,
            "text": "10 missense",
            "probability": 0.0
        },
        {
            "start_logit": -1.3779296875,
            "end_logit": -7.2421875,
            "text": "10 missense mutations in",
            "probability": 0.0
        },
        {
            "start_logit": -1.3779296875,
            "end_logit": -7.265625,
            "text": "10 missense mutations in three families with severe cardiopulmonary complications in infancy and",
            "probability": 0.0
        }
    ],
    "5a70d42899e2c3af26000002_4": [
        {
            "start_logit": 8.984375,
            "end_logit": 7.96484375,
            "text": "SLC2A10",
            "probability": 0.98828125
        },
        {
            "start_logit": 8.984375,
            "end_logit": 3.5234375,
            "text": "SLC2A10 gene",
            "probability": 0.0115966796875
        },
        {
            "start_logit": 8.984375,
            "end_logit": -1.890625,
            "text": "SLC",
            "probability": 5.167722702026367e-05
        },
        {
            "start_logit": 8.984375,
            "end_logit": -3.724609375,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10 (GLUT10).",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -2.890625,
            "end_logit": 7.96484375,
            "text": "10",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": 8.984375,
            "end_logit": -5.6875,
            "text": "SLC2A10 gene, which",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 8.984375,
            "end_logit": -5.85546875,
            "text": "SLC2A10 gene,",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.0546875,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10 (GLUT10). Approximately 100 ATS patients have been described, and 21",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.1171875,
            "text": "SLC2A10 gene, which encodes",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.17578125,
            "text": "SLC2A",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.1796875,
            "text": "SLC2A10 gene, which encodes the",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.30859375,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10 (GLUT10)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.3359375,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10 (GLUT10). Approximately",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.390625,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10 (GLUT10). Approximately 100 ATS patients have been described,",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.45703125,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.5078125,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10 (GLUT10",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.53515625,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10 (",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 8.984375,
            "end_logit": -6.5625,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10 (GLUT10). Approximately 100 ATS patients have been described, and",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 7.96484375,
            "text": "2A10",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 7.96484375,
            "text": "ATS is caused by mutations in the SLC2A10",
            "probability": 1.7881393432617188e-07
        }
    ],
    "5a70d42899e2c3af26000002_5": [
        {
            "start_logit": 8.640625,
            "end_logit": 8.9765625,
            "text": "SLC2A10",
            "probability": 1.0
        },
        {
            "start_logit": -1.6416015625,
            "end_logit": 8.9765625,
            "text": "10",
            "probability": 3.3974647521972656e-05
        },
        {
            "start_logit": 8.640625,
            "end_logit": -2.509765625,
            "text": "SLC",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": 8.640625,
            "end_logit": -5.0703125,
            "text": "SLC2A10/GLUT10, a member of the facilitative glucose transporter family,",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -5.34375,
            "text": "SLC2A10/GLUT10, a member of the facilitative glucose transporter",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -5.41015625,
            "text": "SLC2A10/GLUT10",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -5.78515625,
            "end_logit": 8.9765625,
            "text": "2A10",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -5.4921875,
            "text": "SLC2A10/GLUT10, a member of the facilitative glucose transporter family",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -5.6796875,
            "text": "SLC2A10/GLUT10, a member",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -5.75390625,
            "text": "SLC2A10/GLUT10, a",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -5.859375,
            "text": "SLC2A10/GLUT10,",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -5.87109375,
            "text": "SLC2A10/GLUT1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.40234375,
            "end_logit": 8.9765625,
            "text": "Mutations in SLC2A10",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -6.125,
            "text": "SLC2A10/GLUT10, a member of the facilitative glucose",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -6.28125,
            "text": "SLC2A10/GLUT10, a member of",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -6.3046875,
            "text": "SLC2A10/GLUT10, a member of the",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -6.3359375,
            "text": "SLC2A10/",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -6.54296875,
            "text": "SLC2A10/GLUT10, a member of the facilit",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -6.58203125,
            "text": "SLC2A10/GLUT10, a member of the facilitative glucose transporter family, are",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.640625,
            "end_logit": -6.65234375,
            "text": "SLC2A10/GLUT10, a member of the facilitative",
            "probability": 1.7881393432617188e-07
        }
    ],
    "58da1aa08acda34529000012_1": [
        {
            "start_logit": 6.984375,
            "end_logit": 8.2421875,
            "text": "hCG",
            "probability": 1.0
        },
        {
            "start_logit": -6.76953125,
            "end_logit": 8.2421875,
            "text": "total hCG",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 8.2421875,
            "text": "with total hCG",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 8.2421875,
            "text": "symptoms were associated with total hCG",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 8.2421875,
            "text": "associated with total hCG",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 8.2421875,
            "text": "hyperemesis gravidarum symptoms were associated with total hCG",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 8.2421875,
            "text": "placental weight and hyperemesis gravidarum symptoms were associated with total hCG",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 8.2421875,
            "text": "idarum symptoms were associated with total hCG",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 8.2421875,
            "text": "mesis gravidarum symptoms were associated with total hCG",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 8.2421875,
            "text": "gravidarum symptoms were associated with total hCG",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 6.984375,
            "end_logit": -7.12109375,
            "text": "hCG.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.1875,
            "end_logit": -7.12109375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.76953125,
            "end_logit": -7.12109375,
            "text": "total hCG.",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": -7.12109375,
            "text": "with total hCG.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5234375,
            "end_logit": -7.12109375,
            "text": "symptoms were associated with total hCG.",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -7.12109375,
            "text": "associated with total hCG.",
            "probability": 0.0
        },
        {
            "start_logit": -7.54296875,
            "end_logit": -7.12109375,
            "text": "hyperemesis gravidarum symptoms were associated with total hCG.",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -7.12109375,
            "text": "placental weight and hyperemesis gravidarum symptoms were associated with total hCG.",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -7.12109375,
            "text": "idarum symptoms were associated with total hCG.",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": -7.12109375,
            "text": "mesis gravidarum symptoms were associated with total hCG.",
            "probability": 0.0
        }
    ],
    "58da1aa08acda34529000012_2": [
        {
            "start_logit": 7.09375,
            "end_logit": 8.171875,
            "text": "hCG",
            "probability": 1.0
        },
        {
            "start_logit": 7.09375,
            "end_logit": -7.33984375,
            "text": "hCG promotes",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.09375,
            "end_logit": -7.41796875,
            "text": "hCG promotes progesterone production",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.09375,
            "end_logit": -7.45703125,
            "text": "hCG promotes progesterone production by corpus luteal cells; promotes angiogenesis in uterine vasculature; promoted the fusion of cytotrophoblast cell and differentiation to",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.09375,
            "end_logit": -7.48046875,
            "text": "hCG promotes progesterone",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.09375,
            "end_logit": -7.49609375,
            "text": "hCG promotes progesterone production by corpus luteal cells; promotes angiogenesis in uterine vasculature; promoted the fusion of cytotrophoblast cell and differentiation to make",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.09375,
            "end_logit": -7.50390625,
            "text": "hCG promotes progesterone production by corpus luteal cells; promotes angiogenesis in uterine vasculature; promoted the fusion of cytotrophoblast cell and differentiation to make syncyti",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.09375,
            "end_logit": -7.50390625,
            "text": "hCG promotes progesterone production by corpus luteal cells; promotes angiogenesis in uterine vasculature; promoted the fusion of cytotrophoblast cell",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.09375,
            "end_logit": -7.51171875,
            "text": "hCG promotes progesterone production by corpus luteal cells; promotes angiogenesis in uterine vasculature; promoted the fusion of cytotrophoblast cell and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.71484375,
            "end_logit": -7.140625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.140625,
            "text": "hyperemesis gravidarum, and seemingly promotes growth of fetal organs during pregnancy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4453125,
            "end_logit": -7.140625,
            "text": "brain causing hyperemesis gravidarum, and seemingly promotes growth of fetal organs during pregnancy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -7.25390625,
            "text": "causes uterine growth parallel to fetal growth; suppresses any myometrial contractions during the course of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": -7.25390625,
            "text": "immune or macrophage action by mother on foreign invading placental cells; causes uterine growth parallel to fetal growth; suppresses any myometrial contractions during the course of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.41015625,
            "text": "hyperemesis gravidarum, and seemingly promotes growth of fetal organs during pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -7.4453125,
            "end_logit": -7.41015625,
            "text": "brain causing hyperemesis gravidarum, and seemingly promotes growth of fetal organs during pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.45703125,
            "text": "in uterine vasculature; promoted the fusion of cytotrophoblast cell and differentiation to",
            "probability": 0.0
        },
        {
            "start_logit": -7.43359375,
            "end_logit": -7.48046875,
            "text": "causes uterine growth parallel",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -7.48046875,
            "text": "hyperemesis gravidarum, and seemingly promotes growth of fetal organs during",
            "probability": 0.0
        },
        {
            "start_logit": -7.4453125,
            "end_logit": -7.48046875,
            "text": "brain causing hyperemesis gravidarum, and seemingly promotes growth of fetal organs during",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_1": [
        {
            "start_logit": 8.203125,
            "end_logit": 8.390625,
            "text": "prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -2.54296875,
            "end_logit": 8.390625,
            "text": "cancer",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 8.203125,
            "end_logit": -2.689453125,
            "text": "prostate",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": -6.71875,
            "end_logit": 8.390625,
            "text": "in prostate cancer",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 8.390625,
            "text": "clinical outcome in prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.40625,
            "end_logit": 8.390625,
            "text": "The Gleason score is an important parameter for clinical outcome in prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 8.390625,
            "text": "Gleason score is an important parameter for clinical outcome in prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.203125,
            "end_logit": -7.28515625,
            "text": "prostate cancer patients",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.47265625,
            "end_logit": 8.390625,
            "text": "for clinical outcome in prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 8.390625,
            "text": "outcome in prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.71875,
            "end_logit": -2.689453125,
            "text": "in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -2.54296875,
            "end_logit": -7.28515625,
            "text": "cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -7.39453125,
            "end_logit": -2.689453125,
            "text": "clinical outcome in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -7.40625,
            "end_logit": -2.689453125,
            "text": "The Gleason score is an important parameter for clinical outcome in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": -2.689453125,
            "text": "Gleason score is an important parameter for clinical outcome in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -7.47265625,
            "end_logit": -2.689453125,
            "text": "for clinical outcome in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -7.4765625,
            "end_logit": -2.689453125,
            "text": "outcome in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -6.71875,
            "end_logit": -7.28515625,
            "text": "in prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -7.39453125,
            "end_logit": -7.28515625,
            "text": "clinical outcome in prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -7.40625,
            "end_logit": -7.28515625,
            "text": "The Gleason score is an important parameter for clinical outcome in prostate cancer patients",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_2": [
        {
            "start_logit": 8.0859375,
            "end_logit": 7.1796875,
            "text": "prostate",
            "probability": 0.9970703125
        },
        {
            "start_logit": 8.0859375,
            "end_logit": 1.4033203125,
            "text": "prostate cancer",
            "probability": 0.0030994415283203125
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -6.88671875,
            "text": "prostate cancer patients.",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.3515625,
            "text": "prostate cancer patients",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 7.1796875,
            "text": "8 prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 7.1796875,
            "text": "score 8 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 7.1796875,
            "text": "Gleason score 8 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 1.4033203125,
            "text": "8 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 1.4033203125,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 1.4033203125,
            "text": "score 8 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 1.4033203125,
            "text": "Gleason score 8 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -5.44140625,
            "end_logit": -6.88671875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -6.88671875,
            "text": "8 prostate cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": -6.88671875,
            "text": "cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -7.3515625,
            "text": "8 prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": -7.3515625,
            "text": "cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -6.88671875,
            "text": "score 8 prostate cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": -6.88671875,
            "text": "Gleason score 8 prostate cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -7.3515625,
            "text": "score 8 prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": -7.3515625,
            "text": "Gleason score 8 prostate cancer patients",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_3": [
        {
            "start_logit": 8.0859375,
            "end_logit": 7.1796875,
            "text": "prostate",
            "probability": 0.9970703125
        },
        {
            "start_logit": 8.0859375,
            "end_logit": 1.4033203125,
            "text": "prostate cancer",
            "probability": 0.0030994415283203125
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -6.88671875,
            "text": "prostate cancer patients.",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 8.0859375,
            "end_logit": -7.3515625,
            "text": "prostate cancer patients",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 7.1796875,
            "text": "8 prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 7.1796875,
            "text": "score 8 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 7.1796875,
            "text": "Gleason score 8 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 1.4033203125,
            "text": "8 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 1.4033203125,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 1.4033203125,
            "text": "score 8 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 1.4033203125,
            "text": "Gleason score 8 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -5.44140625,
            "end_logit": -6.88671875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -6.88671875,
            "text": "8 prostate cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": -6.88671875,
            "text": "cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -7.3515625,
            "text": "8 prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": -7.3515625,
            "text": "cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -6.88671875,
            "text": "score 8 prostate cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": -6.88671875,
            "text": "Gleason score 8 prostate cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": -7.3515625,
            "text": "score 8 prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": -7.3515625,
            "text": "Gleason score 8 prostate cancer patients",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_4": [
        {
            "start_logit": 8.3046875,
            "end_logit": 6.91015625,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -1.4384765625,
            "text": "prostate cancer",
            "probability": 0.00023603439331054688
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.640625,
            "text": "prostate cancer have worse outcomes compared to those with Gleason 8 disease.",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.421875,
            "text": "prostate cancer have worse outcomes compared to",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.43359375,
            "text": "prostate cancer have worse outcomes compared",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.51171875,
            "text": "prostate cancer have",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.515625,
            "text": "prostate cancer have worse outcomes compared to those",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.53125,
            "text": "prostate cancer have worse outcomes compared to those with Gleason 8 disease",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.54296875,
            "text": "prostate cancer have worse outcomes compared to those with Gleason",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.55078125,
            "text": "prostate cancer have worse",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.0,
            "end_logit": 6.91015625,
            "text": "10 prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 6.91015625,
            "text": "with Gleason score 9-10 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 6.91015625,
            "text": "Men with Gleason score 9-10 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 6.91015625,
            "text": "-10 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.0,
            "end_logit": -1.4384765625,
            "text": "10 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.26171875,
            "end_logit": -1.4384765625,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": -1.4384765625,
            "text": "with Gleason score 9-10 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -1.4384765625,
            "text": "Men with Gleason score 9-10 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.38671875,
            "end_logit": -1.4384765625,
            "text": "-10 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -5.48046875,
            "end_logit": -6.640625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_5": [
        {
            "start_logit": 7.34765625,
            "end_logit": 7.9296875,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 7.9296875,
            "text": "the prostate",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 7.9296875,
            "text": "OBJECTIVES: Most adenocarcinomas of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 7.9296875,
            "text": ": Most adenocarcinomas of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.546875,
            "end_logit": 7.9296875,
            "text": "adenocarcinomas of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.546875,
            "end_logit": 7.9296875,
            "text": "Most adenocarcinomas of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 7.9296875,
            "text": "of the prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.34765625,
            "end_logit": -7.06640625,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic extension and a high risk of progression.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.34765625,
            "end_logit": -7.28515625,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic extension",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.34765625,
            "end_logit": -7.296875,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic extension and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.34765625,
            "end_logit": -7.30078125,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic extension and a",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.34765625,
            "end_logit": -7.3125,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.34765625,
            "end_logit": -7.33203125,
            "text": "prostate with",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.34765625,
            "end_logit": -7.33984375,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.34765625,
            "end_logit": -7.33984375,
            "text": "prostate with a",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.34765625,
            "end_logit": -7.3515625,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.34765625,
            "end_logit": -7.359375,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extraprost",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.34765625,
            "end_logit": -7.375,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extrap",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.34765625,
            "end_logit": -7.38671875,
            "text": "prostate with a Gleason score greater",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.34765625,
            "end_logit": -7.38671875,
            "text": "prostate with a Gleason",
            "probability": 2.384185791015625e-07
        }
    ],
    "622b9d593a8413c653000095_6": [
        {
            "start_logit": 8.3046875,
            "end_logit": 6.88671875,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -3.44140625,
            "text": "prostate cancer",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.82421875,
            "text": "prostate cancer and an increased Gleason score upgrading.",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.25390625,
            "text": "prostate cancer and an",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.29296875,
            "text": "prostate cancer and",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.4140625,
            "text": "prostate cancer and an increased Gleason score",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.46484375,
            "text": "prostate cancer and an increased Gleason",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.49609375,
            "text": "prostate cancer and an increased Gleason score up",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -7.515625,
            "text": "prostate cancer and an increased",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.8671875,
            "end_logit": 6.88671875,
            "text": "grade prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 6.88671875,
            "text": "with high-grade prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 6.88671875,
            "text": "high-grade prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 6.88671875,
            "text": "-grade prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 6.88671875,
            "text": "low serum testosterone is associated with high-grade prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.4453125,
            "end_logit": 6.88671875,
            "text": "serum testosterone is associated with high-grade prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 6.88671875,
            "text": "testosterone is associated with high-grade prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 6.88671875,
            "text": "Preoperative low serum testosterone is associated with high-grade prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.515625,
            "end_logit": 6.88671875,
            "text": "associated with high-grade prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 6.88671875,
            "text": "is associated with high-grade prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.8671875,
            "end_logit": -3.44140625,
            "text": "grade prostate cancer",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_7": [
        {
            "start_logit": 7.4609375,
            "end_logit": 7.87109375,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 7.87109375,
            "text": "in prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 7.87109375,
            "text": "predominant Gleason pattern were determined in prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.87109375,
            "text": "(GS) and predominant Gleason pattern were determined in prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.515625,
            "end_logit": 7.87109375,
            "text": "eason score (GS) and predominant Gleason pattern were determined in prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 7.87109375,
            "text": "determined in prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 7.87109375,
            "text": "were determined in prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.578125,
            "end_logit": 7.87109375,
            "text": ") and predominant Gleason pattern were determined in prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.578125,
            "end_logit": 7.87109375,
            "text": "on score (GS) and predominant Gleason pattern were determined in prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 7.87109375,
            "text": "and predominant Gleason pattern were determined in prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.59375,
            "end_logit": 7.87109375,
            "text": "score (GS) and predominant Gleason pattern were determined in prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.4609375,
            "end_logit": -7.30078125,
            "text": "prostate biopsies and in prostate tissue specimens",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.4609375,
            "end_logit": -7.3828125,
            "text": "prostate biopsies and in prostate tissue specimens, crosschecked by two uro-pathologists.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.4609375,
            "end_logit": -7.3828125,
            "text": "prostate biopsies and in prostate tissue specimens, cross",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.4609375,
            "end_logit": -7.40625,
            "text": "prostate biopsies and in prostate tissue",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.4609375,
            "end_logit": -7.41015625,
            "text": "prostate biopsies and",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.4609375,
            "end_logit": -7.4296875,
            "text": "prostate biopsies",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.4609375,
            "end_logit": -7.453125,
            "text": "prostate biopsies and in prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.4609375,
            "end_logit": -7.45703125,
            "text": "prostate biopsies and in prostate tissue specimens, crosscheck",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.4609375,
            "end_logit": -7.4609375,
            "text": "prostate biopsies and in prostate tissue specimens, crosschecked",
            "probability": 2.384185791015625e-07
        }
    ],
    "622b9d593a8413c653000095_8": [
        {
            "start_logit": 8.15625,
            "end_logit": 7.046875,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 8.15625,
            "end_logit": -3.826171875,
            "text": "prostate cancer",
            "probability": 1.895427703857422e-05
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.91015625,
            "text": "prostate cancer at radical prostatectomy.",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.30859375,
            "text": "prostate cancer at radical prostatectomy",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -7.41796875,
            "text": "prostate cancer at",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 7.046875,
            "text": "with Gleason score 7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 7.046875,
            "text": "7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 7.046875,
            "text": "in patients with Gleason score 7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 7.046875,
            "text": ", cribriform growth in Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.046875,
            "text": "patients with Gleason score 7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4375,
            "end_logit": 7.046875,
            "text": "for distant metastasis and disease-specific death in patients with Gleason score 7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4765625,
            "end_logit": 7.046875,
            "text": "cribriform growth in Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 7.046875,
            "text": "death in patients with Gleason score 7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.046875,
            "text": "prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 7.046875,
            "text": "-specific death in patients with Gleason score 7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 7.046875,
            "text": "specific death in patients with Gleason score 7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 7.046875,
            "text": "briform growth in Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.24609375,
            "end_logit": -3.826171875,
            "text": "with Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.3359375,
            "end_logit": -3.826171875,
            "text": "7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -3.826171875,
            "text": "in patients with Gleason score 7 prostate cancer",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_9": [
        {
            "start_logit": 7.703125,
            "end_logit": 7.5859375,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 7.703125,
            "end_logit": -7.09765625,
            "text": "prostate adenocarcinoma (PCa) on core biopsy (NBX) is critical because it is associated with disease progression and the worst clinical outcome.",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.703125,
            "end_logit": -7.11328125,
            "text": "prostate adenocarcinoma (PCa",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.703125,
            "end_logit": -7.140625,
            "text": "prostate adenocarcinoma",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.703125,
            "end_logit": -7.265625,
            "text": "prostate adenocarcinoma (PCa)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.703125,
            "end_logit": -7.37109375,
            "text": "prostate adenocarcinoma (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.703125,
            "end_logit": -7.4140625,
            "text": "prostate adenocarcinoma (PCa) on core biopsy (NBX) is critical",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.703125,
            "end_logit": -7.4140625,
            "text": "prostate adenocarcinoma (PCa) on",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.703125,
            "end_logit": -7.42578125,
            "text": "prostate adenocarcinoma (PCa) on core biopsy (NBX",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.703125,
            "end_logit": -7.4375,
            "text": "prostate adenocarcinoma (PCa) on core biopsy (NBX) is critical because it is associated with disease progression and the",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.703125,
            "end_logit": -7.51953125,
            "text": "prostate adenocarcinoma (PCa) on core",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 7.5859375,
            "text": ") prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 7.5859375,
            "text": "of Gleason pattern 5 (GP5) prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 7.5859375,
            "text": "(GP5) prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.06640625,
            "end_logit": -7.09765625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.36328125,
            "end_logit": -7.09765625,
            "text": "clinical outcome.",
            "probability": 0.0
        },
        {
            "start_logit": -7.38671875,
            "end_logit": -7.09765625,
            "text": "worst clinical outcome.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": -7.09765625,
            "text": ") prostate adenocarcinoma (PCa) on core biopsy (NBX) is critical because it is associated with disease progression and the worst clinical outcome.",
            "probability": 0.0
        },
        {
            "start_logit": -7.42578125,
            "end_logit": -7.09765625,
            "text": "with disease progression and the worst clinical outcome.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": -7.11328125,
            "text": ") prostate adenocarcinoma (PCa",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_10": [
        {
            "start_logit": 7.67578125,
            "end_logit": 7.62109375,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -4.61328125,
            "text": "prostate cancer",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.1484375,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly with increasing of single Gleason patterns.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.140625,
            "end_logit": 7.62109375,
            "text": "in prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.2421875,
            "text": "prostate cancer and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.2890625,
            "text": "prostate cancer and not in benign prostate tissue and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.3359375,
            "text": "prostate cancer and not in benign prostate tissue",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.42578125,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.4296875,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.43359375,
            "text": "prostate cancer and not",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.48046875,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.48046875,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly with increasing of single Gleason patterns. This suggests",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.484375,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.5078125,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly with",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.51953125,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 7.62109375,
            "text": "time that reelin is expressed in prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.67578125,
            "end_logit": -7.53125,
            "text": "prostate cancer and not in benign prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 7.62109375,
            "text": "reelin is expressed in prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 7.62109375,
            "text": "lin is expressed in prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5234375,
            "end_logit": 7.62109375,
            "text": "is expressed in prostate",
            "probability": 2.384185791015625e-07
        }
    ],
    "622b9d593a8413c653000095_11": [
        {
            "start_logit": 7.8359375,
            "end_logit": 7.44921875,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.1484375,
            "text": "prostate needle biopsy and radical prostatectomy cases with Gleason score 7 prostatic adenocarcinoma.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.203125,
            "text": "prostate needle biopsy and radical prostatectomy cases with Gleason score 7 prostatic adenocarcinoma",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.390625,
            "text": "prostate needle biopsy and radical prostatectomy cases with Gleason score",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.41015625,
            "text": "prostate needle biopsy and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8359375,
            "end_logit": -7.41015625,
            "text": "prostate needle biopsy and radical prostatectomy cases with Gleason",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 7.44921875,
            "text": "in the Gleason grading system recommended from the International Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.421875,
            "end_logit": 7.44921875,
            "text": "from the International Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 7.44921875,
            "text": "modifications in the Gleason grading system recommended from the International Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 7.44921875,
            "text": "International Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 7.44921875,
            "text": "of prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 7.44921875,
            "text": "the Gleason grading system recommended from the International Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 7.44921875,
            "text": "in the pathology reports of prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 7.44921875,
            "text": "Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 7.44921875,
            "text": "conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 7.44921875,
            "text": "the International Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.890625,
            "end_logit": -7.1484375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.82421875,
            "end_logit": -7.36328125,
            "text": "ne of the",
            "probability": 0.0
        },
        {
            "start_logit": -5.82421875,
            "end_logit": -7.3671875,
            "text": "ne",
            "probability": 0.0
        },
        {
            "start_logit": -5.82421875,
            "end_logit": -7.3671875,
            "text": "ne of the recent important modifications in the Gleason grading system recommended",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_12": [
        {
            "start_logit": 7.1875,
            "end_logit": 7.96875,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 7.96875,
            "text": "the prostate",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.1875,
            "end_logit": -6.71484375,
            "text": "prostate in",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 7.96875,
            "text": "histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 7.96875,
            "text": "patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 7.96875,
            "text": "to 10 adenocarcinoma of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 7.96875,
            "text": "of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.640625,
            "end_logit": 7.96875,
            "text": "Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 7.96875,
            "text": "unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.65625,
            "end_logit": 7.96875,
            "text": "of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.1875,
            "end_logit": -7.3984375,
            "text": "prostate in needle",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.1875,
            "end_logit": -7.421875,
            "text": "prostate in needle biopsy tissue",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.16015625,
            "end_logit": -6.71484375,
            "text": "the prostate in",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -6.71484375,
            "text": "histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -6.71484375,
            "text": "patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": -6.71484375,
            "text": "to 10 adenocarcinoma of the prostate in",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": -6.71484375,
            "text": "of high Gleason score 8 to 10 adenocarcinoma of the prostate in",
            "probability": 0.0
        },
        {
            "start_logit": -7.640625,
            "end_logit": -6.71484375,
            "text": "Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -6.71484375,
            "text": "unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in",
            "probability": 0.0
        },
        {
            "start_logit": -7.65625,
            "end_logit": -6.71484375,
            "text": "of the prostate in",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_13": [
        {
            "start_logit": 7.56640625,
            "end_logit": 7.74609375,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -6.4921875,
            "text": "prostate adenocarcinomas is an important preoperative predictor of cancer behavior, and is used to help guide treatment.",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.15625,
            "text": "prostate adenocarcinomas is an important preoperative predictor of cancer behavior, and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.15625,
            "text": "prostate adenocarcinomas is an important preoperative predictor of cancer behavior,",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 7.74609375,
            "text": "The Gleason score of prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.25390625,
            "text": "prostate adenocarcinomas is",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.43359375,
            "end_logit": 7.74609375,
            "text": "of prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.2578125,
            "text": "prostate adenocarcinomas",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.29296875,
            "text": "prostate adenocarcinomas is an important preoperative predictor of cancer behavior, and is",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.3046875,
            "text": "prostate adenocarcinomas is an important preoperative predictor of cancer behavior",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.3203125,
            "text": "prostate adenocarcinomas is an",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.32421875,
            "text": "prostate adenocarcinomas is an important preoperative predictor of cancer behavior, and is used",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 7.74609375,
            "text": "Gleason score of prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.37109375,
            "text": "prostate adenocarcinomas is an important preoperative predictor of cancer behavior, and is used to",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.3828125,
            "text": "prostate adenocarcinomas is an important",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.3984375,
            "text": "prostate adenocarcinomas is an important preoperative predictor",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.56640625,
            "end_logit": -7.4296875,
            "text": "prostate adenocarcinomas is an important preoperative",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.4375,
            "end_logit": -6.4921875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.359375,
            "end_logit": -6.4921875,
            "text": "cancer behavior, and is used to help guide treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": -6.4921875,
            "text": "of cancer behavior, and is used to help guide treatment.",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_14": [
        {
            "start_logit": 7.57421875,
            "end_logit": 7.47265625,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -6.71875,
            "text": "prostate cancers, we",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -6.7578125,
            "text": "prostate cancers, we explored whether reelin expression is influenced by single Gleason patterns. While",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -6.83984375,
            "text": "prostate cancers",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -6.8671875,
            "text": "prostate cancers, we explored",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -6.99609375,
            "text": "prostate cancers,",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.06640625,
            "text": "prostate cancers, we explored whether reelin expression is influenced by single Gleason patterns.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.140625,
            "text": "prostate cancers, we explored whether reelin expression is influenced by single Gleason patterns. While Gleason",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.16015625,
            "text": "prostate cancers, we explored whether reelin expression is influenced by single Gleason patterns. While Gleason 3 patt",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.18359375,
            "text": "prostate cancers, we explored whether",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.23046875,
            "text": "prostate cancers, we explored whether reelin expression is influenced by single Gleason patterns. While Gleason 3",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.24609375,
            "text": "prostate cancers, we explored whether reelin expression is influenced by single Gleason patterns. While Gleason 3 pat",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.57421875,
            "end_logit": -7.2734375,
            "text": "prostate cancers, we explored whether reelin expression is influenced",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.40625,
            "end_logit": 7.47265625,
            "text": "score prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.49609375,
            "end_logit": 7.47265625,
            "text": "in high Gleason score prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 7.47265625,
            "text": "high Gleason score prostate",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.03515625,
            "end_logit": -6.7578125,
            "text": ". While",
            "probability": 0.0
        },
        {
            "start_logit": -5.03515625,
            "end_logit": -7.06640625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.03515625,
            "end_logit": -7.140625,
            "text": ". While Gleason",
            "probability": 0.0
        },
        {
            "start_logit": -5.03515625,
            "end_logit": -7.16015625,
            "text": ". While Gleason 3 patt",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_15": [
        {
            "start_logit": 7.8828125,
            "end_logit": 7.4296875,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -5.94921875,
            "text": "prostate cancer",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -6.90234375,
            "text": "prostate cancer would occur within Gleason scores 3 to 10 even though higher scores are usually considered more aggressive forms of prostate cancers.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.1015625,
            "text": "prostate cancer would",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.1953125,
            "text": "prostate cancer would occur",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.20703125,
            "text": "prostate cancer would occur within Gleason scores 3 to 10 even",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.890625,
            "end_logit": 7.4296875,
            "text": "of prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.3515625,
            "text": "prostate cancer would occur within",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.3671875,
            "text": "prostate cancer would occur within Gleason scores 3 to 10 even though higher scores are usually considered more aggressive forms of prostate cancers. Since",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.37109375,
            "text": "prostate cancer would occur within Gleason scores 3 to 10 even though higher scores are usually considered more aggressive forms of prostate cancers. Since our study is based",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.375,
            "text": "prostate cancer would occur within Gleason scores 3 to 10",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.3828125,
            "text": "prostate cancer would occur within Gleason",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.3828125,
            "text": "prostate cancer would occur within Gleason scores 3",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.40234375,
            "text": "prostate cancer would occur within Gleason scores 3 to",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.41015625,
            "text": "prostate cancer would occur within Gleason scores 3 to 10 even though higher scores are usually considered more aggressive forms of prostate cancers. Since our study is",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.8828125,
            "end_logit": -7.4140625,
            "text": "prostate cancer would occur within Gleason scores",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -6.90234375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -7.203125,
            "text": ". Since our study is based upon a",
            "probability": 0.0
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -7.2890625,
            "text": ". Since our study is based upon a very li",
            "probability": 0.0
        },
        {
            "start_logit": -5.1796875,
            "end_logit": -7.30078125,
            "text": ". Since our study is based upon a very",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_16": [
        {
            "start_logit": 7.2578125,
            "end_logit": 7.97265625,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 7.97265625,
            "text": "the prostate",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 7.97265625,
            "text": "OBJECTIVES: Most adenocarcinomas of the prostate",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.45703125,
            "end_logit": 7.97265625,
            "text": ": Most adenocarcinomas of the prostate",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 7.97265625,
            "text": "Most adenocarcinomas of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.5625,
            "end_logit": 7.97265625,
            "text": "adenocarcinomas of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 7.97265625,
            "text": "of the prostate",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.375,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic extension",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.38671875,
            "text": "prostate with",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.40234375,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.40234375,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.40234375,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic extension and a",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.40234375,
            "text": "prostate with a",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.40625,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic extension and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.43359375,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.453125,
            "text": "prostate with a Gleason score greater than 8 at",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.453125,
            "text": "prostate with a Gleason score greater",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.45703125,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extrap",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.4609375,
            "text": "prostate with a Gleason",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.2578125,
            "end_logit": -7.46484375,
            "text": "prostate with a Gleason score",
            "probability": 1.7881393432617188e-07
        }
    ],
    "622b9d593a8413c653000095_17": [
        {
            "start_logit": 7.40625,
            "end_logit": 7.8984375,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": -7.27734375,
            "end_logit": 7.8984375,
            "text": "the prostate",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.40625,
            "end_logit": -7.0390625,
            "text": "prostate in",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.55859375,
            "end_logit": 7.8984375,
            "text": "histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 7.8984375,
            "text": "high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.6015625,
            "end_logit": 7.8984375,
            "text": "of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 7.8984375,
            "text": "to 10 adenocarcinoma of the prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 7.8984375,
            "text": "Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 7.8984375,
            "text": "patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 7.8984375,
            "text": "of the prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 7.8984375,
            "text": "unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.640625,
            "end_logit": 7.8984375,
            "text": "adenocarcinoma of the prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 7.40625,
            "end_logit": -7.26171875,
            "text": "prostate in needle biopsy tissue.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.40625,
            "end_logit": -7.3984375,
            "text": "prostate in needle biopsy tissue",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.40625,
            "end_logit": -7.44921875,
            "text": "prostate in needle",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.05859375,
            "end_logit": -7.26171875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.27734375,
            "end_logit": -7.0390625,
            "text": "the prostate in",
            "probability": 0.0
        },
        {
            "start_logit": -7.27734375,
            "end_logit": -7.26171875,
            "text": "the prostate in needle biopsy tissue.",
            "probability": 0.0
        },
        {
            "start_logit": -7.55859375,
            "end_logit": -7.0390625,
            "text": "histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -7.0390625,
            "text": "high Gleason score 8 to 10 adenocarcinoma of the prostate in",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_18": [
        {
            "start_logit": 8.3046875,
            "end_logit": 6.8828125,
            "text": "prostate",
            "probability": 0.98095703125
        },
        {
            "start_logit": 8.3046875,
            "end_logit": 2.958984375,
            "text": "prostate cancer",
            "probability": 0.0194244384765625
        },
        {
            "start_logit": 8.3046875,
            "end_logit": -6.78515625,
            "text": "prostate cancer.",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 6.8828125,
            "text": "in Gleason score 7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.265625,
            "end_logit": 6.8828125,
            "text": "7 prostate",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 6.8828125,
            "text": "for postoperative metastasis and disease-specific death in Gleason score 7 prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 6.8828125,
            "text": "Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 6.8828125,
            "text": "death in Gleason score 7 prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 6.8828125,
            "text": "briform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5078125,
            "end_logit": 6.8828125,
            "text": "postoperative metastasis and disease-specific death in Gleason score 7 prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 6.8828125,
            "text": "-specific death in Gleason score 7 prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.53125,
            "end_logit": 6.8828125,
            "text": "disease-specific death in Gleason score 7 prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 6.8828125,
            "text": "metastasis and disease-specific death in Gleason score 7 prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.31640625,
            "end_logit": 2.958984375,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 2.958984375,
            "text": "in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.265625,
            "end_logit": 2.958984375,
            "text": "7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 2.958984375,
            "text": "for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": 2.958984375,
            "text": "Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 2.958984375,
            "text": "death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 2.958984375,
            "text": "briform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_19": [
        {
            "start_logit": 7.06640625,
            "end_logit": 7.48828125,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -3.2421875,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for prostate cancer",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 7.48828125,
            "text": "in normal prostate",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -6.8359375,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for prostate cancer.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 7.48828125,
            "text": "normal prostate",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -6.96875,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 7.48828125,
            "text": "A were similar in normal prostate",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -7.23046875,
            "text": "prostate and",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -7.3203125,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for prostate cancer. These",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -7.36328125,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for prostate cancer. These variations showed",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -7.37109375,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -7.3828125,
            "text": "prostate and benign prostatic hyperplasia (BPH)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -7.38671875,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -7.39453125,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -7.3984375,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for prostate cancer. These variations",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -7.3984375,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -7.421875,
            "text": "prostate and benign prostatic hyperplasia (BPH",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.06640625,
            "end_logit": -7.4296875,
            "text": "prostate and benign prostatic hyperplasia (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -4.62890625,
            "end_logit": -3.2421875,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.8359375,
            "end_logit": -3.2421875,
            "text": "for prostate cancer",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_1": [
        {
            "start_logit": 9.125,
            "end_logit": 9.03125,
            "text": "adenosylmethionine",
            "probability": 1.0
        },
        {
            "start_logit": 9.125,
            "end_logit": -1.63671875,
            "text": "adenosyl",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": -1.638671875,
            "end_logit": 9.03125,
            "text": "ionine",
            "probability": 2.110004425048828e-05
        },
        {
            "start_logit": -6.32421875,
            "end_logit": 9.03125,
            "text": "methionine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.22265625,
            "text": "adenosylmethionine methyl donor, or a critical tyrosine predicted to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.28515625,
            "text": "adenosylmeth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.36328125,
            "text": "adenosylmethionine methyl donor, or a critical tyrosine predicted",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.38671875,
            "text": "adenosylmethionine methyl donor, or a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.38671875,
            "text": "adenosylmethionine methyl donor,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.42578125,
            "text": "adenosylmethionine methyl donor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.43359375,
            "text": "adenosylmethionine methyl donor, or a critical tyrosine predicted to interact with the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.43359375,
            "text": "adenosylmethionine methyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.125,
            "end_logit": -7.4375,
            "text": "adenosylmethionine methyl donor, or a critical tyrosine predicted to interact with the substrate lysine epsilon",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 9.03125,
            "text": "lysine-substrate binding pocket, the binding site for the adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 9.03125,
            "text": "binding site for the adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 9.03125,
            "text": "affect either the lysine-substrate binding pocket, the binding site for the adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 9.03125,
            "text": "the mutations likely affect either the lysine-substrate binding pocket, the binding site for the adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.03125,
            "text": ", the binding site for the adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46875,
            "end_logit": 9.03125,
            "text": "mutations likely affect either the lysine-substrate binding pocket, the binding site for the adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 9.03125,
            "text": "the adenosylmethionine",
            "probability": 5.960464477539063e-08
        }
    ],
    "516e7fda298dcd4e51000081_2": [
        {
            "start_logit": 6.58203125,
            "end_logit": 6.70703125,
            "text": "methionine",
            "probability": 0.99609375
        },
        {
            "start_logit": 3.140625,
            "end_logit": 4.5078125,
            "text": "homocysteine",
            "probability": 0.0035381317138671875
        },
        {
            "start_logit": -6.0,
            "end_logit": 6.70703125,
            "text": "from methionine",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 6.58203125,
            "end_logit": -6.03125,
            "text": "methionine (Met) and S-adenosylmethionine (AdoMet) in a unique reaction catalyzed by Met S-methyltransferase (MMT).",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 6.58203125,
            "end_logit": -6.70703125,
            "text": "methionine (Met",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -4.63671875,
            "end_logit": 4.5078125,
            "text": ". SMM serves as methyl donor for Met synthesis from homocysteine",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 6.58203125,
            "end_logit": -6.9375,
            "text": "methionine (Met)",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 6.58203125,
            "end_logit": -6.984375,
            "text": "methionine (Met) and S-adenosylmethionine",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -4.93359375,
            "end_logit": 4.5078125,
            "text": "from homocysteine",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 6.58203125,
            "end_logit": -7.046875,
            "text": "methionine (Met) and S-adenosylmethionine (",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 6.58203125,
            "end_logit": -7.0703125,
            "text": "methionine (Met) and S-adenosylmethionine (AdoMet) in a unique reaction catalyzed",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 6.58203125,
            "end_logit": -7.11328125,
            "text": "methionine (Met) and S-adenosylmethionine (AdoMet)",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 6.70703125,
            "text": "methylmethionine (SMM) from methionine",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 6.70703125,
            "text": "methionine (SMM) from methionine",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 6.70703125,
            "text": "S-methylmethionine (SMM) from methionine",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 6.70703125,
            "text": "-methylmethionine (SMM) from methionine",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 6.70703125,
            "text": "Angiosperms synthesize S-methylmethionine (SMM) from methionine",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 6.70703125,
            "text": "sperms synthesize S-methylmethionine (SMM) from methionine",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 3.140625,
            "end_logit": -6.03125,
            "text": "homocysteine, catalyzed by homocysteine S-methyltransferase (HMT).",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 4.5078125,
            "text": "methyl donor for Met synthesis from homocysteine",
            "probability": 5.960464477539063e-08
        }
    ],
    "516e7fda298dcd4e51000081_3": [
        {
            "start_logit": 7.2109375,
            "end_logit": 7.578125,
            "text": "methionine",
            "probability": 1.0
        },
        {
            "start_logit": 7.2109375,
            "end_logit": -4.4375,
            "text": "methionine (Met) by a unique reaction and, like other organisms, use SMM as a methyl donor for Met synthesis from homocysteine (Hcy).",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": 7.2109375,
            "end_logit": -4.56640625,
            "text": "methionine (Met) by a unique reaction and, like other organisms, use SMM as a methyl donor for Met synthesis from homocysteine",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": -5.18359375,
            "end_logit": 7.578125,
            "text": "S-adenosylmethionine (AdoMet), and methionine",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 7.2109375,
            "end_logit": -5.75,
            "text": "methionine (Met) by a unique reaction and, like other organisms, use SMM as a methyl donor for Met synthesis from homocysteine (Hcy)",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 7.2109375,
            "end_logit": -5.83984375,
            "text": "methionine (Met) by a unique reaction and, like other organisms, use SMM as a methyl donor for Met synthesis from homocysteine (Hcy",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -6.2734375,
            "end_logit": 7.578125,
            "text": "adenosylmethionine (AdoMet), and methionine",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -6.50390625,
            "end_logit": 7.578125,
            "text": "from S-adenosylmethionine (AdoMet), and methionine",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -6.66796875,
            "end_logit": 7.578125,
            "text": "-adenosylmethionine (AdoMet), and methionine",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -6.79296875,
            "end_logit": 7.578125,
            "text": "S-methylmethionine (SMM) from S-adenosylmethionine (AdoMet), and methionine",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.2109375,
            "end_logit": -6.44140625,
            "text": "methionine (Met",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.2109375,
            "end_logit": -6.66796875,
            "text": "methionine (Met) by a unique reaction and, like other organisms, use SMM as a methyl donor for Met synthesis",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 7.578125,
            "text": "methionine (AdoMet), and methionine",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.2109375,
            "end_logit": -6.77734375,
            "text": "methionine (Met) by a unique reaction and, like other organisms,",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 7.2109375,
            "end_logit": -6.78515625,
            "text": "methionine (Met) by a unique reaction and",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 7.578125,
            "text": "Plants synthesize S-methylmethionine (SMM) from S-adenosylmethionine (AdoMet), and methionine",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 7.578125,
            "text": "and methionine",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.28125,
            "end_logit": 7.578125,
            "text": "methylmethionine (SMM) from S-adenosylmethionine (AdoMet), and methionine",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -7.390625,
            "end_logit": 7.578125,
            "text": "-methylmethionine (SMM) from S-adenosylmethionine (AdoMet), and methionine",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.484375,
            "end_logit": 7.578125,
            "text": "methionine (SMM) from S-adenosylmethionine (AdoMet), and methionine",
            "probability": 4.172325134277344e-07
        }
    ],
    "516e7fda298dcd4e51000081_4": [
        {
            "start_logit": 9.171875,
            "end_logit": 9.0546875,
            "text": "adenosylmethionine",
            "probability": 1.0
        },
        {
            "start_logit": 9.171875,
            "end_logit": -1.529296875,
            "text": "adenosyl",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": -1.5771484375,
            "end_logit": 9.0546875,
            "text": "ionine",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.16796875,
            "text": "adenosylmethionine and diminished histone methylation activity.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.28515625,
            "end_logit": 9.0546875,
            "text": "methionine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -6.76171875,
            "text": "adenosylmethionine and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.171875,
            "end_logit": -7.07421875,
            "text": "adenosylmethionine and diminished histone methylation activity",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.171875,
            "end_logit": 9.0546875,
            "text": "bind the methyl donor adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.59375,
            "end_logit": 9.0546875,
            "text": "methyl donor adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 9.0546875,
            "text": "the methyl donor adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.0546875,
            "text": "serine residue is mutated to glutamic acid, which mimics the phosphorylated serine residue, the mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65625,
            "end_logit": 9.0546875,
            "text": "mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.0546875,
            "text": "to glutamic acid, which mimics the phosphorylated serine residue, the mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 9.0546875,
            "text": "mimics the phosphorylated serine residue, the mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6875,
            "end_logit": 9.0546875,
            "text": "phosphorylated serine residue, the mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.69140625,
            "end_logit": 9.0546875,
            "text": "diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.5771484375,
            "end_logit": -6.16796875,
            "text": "ionine and diminished histone methylation activity.",
            "probability": 0.0
        },
        {
            "start_logit": -1.5771484375,
            "end_logit": -6.76171875,
            "text": "ionine and",
            "probability": 0.0
        },
        {
            "start_logit": -1.5771484375,
            "end_logit": -7.07421875,
            "text": "ionine and diminished histone methylation activity",
            "probability": 0.0
        },
        {
            "start_logit": -7.171875,
            "end_logit": -1.529296875,
            "text": "bind the methyl donor adenosyl",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_5": [
        {
            "start_logit": 9.296875,
            "end_logit": 9.2734375,
            "text": "S-adenosylmethionine",
            "probability": 1.0
        },
        {
            "start_logit": -0.90625,
            "end_logit": 9.2734375,
            "text": "ionine",
            "probability": 3.737211227416992e-05
        },
        {
            "start_logit": 9.296875,
            "end_logit": -1.1513671875,
            "text": "S",
            "probability": 2.9981136322021484e-05
        },
        {
            "start_logit": -5.8359375,
            "end_logit": 9.2734375,
            "text": "methionine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 9.2734375,
            "text": "-adenosylmethionine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.29296875,
            "end_logit": 9.2734375,
            "text": "adenosylmethionine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.390625,
            "text": "S-adenosylmethionine (",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.42578125,
            "text": "S-adenosyl",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.43359375,
            "text": "S-adenosylmethionine (SAMe), the major",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.75390625,
            "text": "S-adenosylmethionine (SAMe)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.94921875,
            "text": "S-adenosylmethionine (SAMe",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.953125,
            "text": "S-adenosylmethionine (SAMe), the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.9921875,
            "text": "S-adenosylmeth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.109375,
            "text": "S-adenosylmethionine (SAMe), the major methyl donor for DNA and histone methylation was fed with ethanol for 1mon",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.21484375,
            "text": "S-adenosylmethionine (SAMe), the major methyl donor for DNA and histone methylation was fed with ethanol for 1month",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.25390625,
            "text": "S-adenosylmethionine (SAMe), the major methyl donor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.265625,
            "text": "S-adenosylmethionine (SAMe), the major methyl donor for DNA and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.28125,
            "text": "S-adenosylmethionine (SAMe),",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.2890625,
            "text": "S-adenosylmethionine (SAMe), the major methyl donor for DNA and histone methylation was fed with ethanol for 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.3046875,
            "text": "S-adenosylmethionine (SAMe), the major methyl donor for DNA and histone methylation was",
            "probability": 5.960464477539063e-08
        }
    ],
    "516e7fda298dcd4e51000081_6": [
        {
            "start_logit": 9.2421875,
            "end_logit": 9.140625,
            "text": "S-Adenosyl methionine",
            "probability": 1.0
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -1.29296875,
            "text": "S",
            "probability": 2.9802322387695312e-05
        },
        {
            "start_logit": -1.37890625,
            "end_logit": 9.140625,
            "text": "methionine",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": -5.9609375,
            "end_logit": 9.140625,
            "text": "Adenosyl methionine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 9.140625,
            "text": "-Adenosyl methionine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.984375,
            "text": "S-Adenosyl methionine.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -7.30078125,
            "text": "S-Adenosyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34765625,
            "end_logit": 9.140625,
            "text": "with the methyl group donor S-Adenosyl methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 9.140625,
            "text": "competing with the methyl group donor S-Adenosyl methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 9.140625,
            "text": "donor S-Adenosyl methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46875,
            "end_logit": 9.140625,
            "text": "methyl group donor S-Adenosyl methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 9.140625,
            "text": ", which inhibits the enzymatic activity of Ezh2 through direct binding to the enzyme and competing with the methyl group donor S-Adenosyl methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 9.140625,
            "text": ", EI1, which inhibits the enzymatic activity of Ezh2 through direct binding to the enzyme and competing with the methyl group donor S-Adenosyl methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 9.140625,
            "text": "group donor S-Adenosyl methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 9.140625,
            "text": "binding to the enzyme and competing with the methyl group donor S-Adenosyl methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.37890625,
            "end_logit": -6.984375,
            "text": "methionine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.34765625,
            "end_logit": -1.29296875,
            "text": "with the methyl group donor S",
            "probability": 0.0
        },
        {
            "start_logit": -7.37890625,
            "end_logit": -1.29296875,
            "text": "competing with the methyl group donor S",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -1.29296875,
            "text": "donor S",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": -1.29296875,
            "text": "methyl group donor S",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_7": [
        {
            "start_logit": 9.3359375,
            "end_logit": 9.375,
            "text": "S-adenosyl-l-methionine",
            "probability": 1.0
        },
        {
            "start_logit": -0.58837890625,
            "end_logit": 9.375,
            "text": "methionine",
            "probability": 4.869699478149414e-05
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -1.0166015625,
            "text": "S",
            "probability": 3.045797348022461e-05
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -4.21875,
            "text": "S-adenosyl-l-methionine (SAM) as the methyl donor.",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -5.78515625,
            "end_logit": 9.375,
            "text": "-adenosyl-l-methionine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.9765625,
            "end_logit": 9.375,
            "text": "-methionine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -5.94921875,
            "text": "S-adenosyl-l-methionine (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -6.0859375,
            "text": "S-adenosyl-l-methionine (SAM)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -6.08984375,
            "text": "S-adenosyl-l-methionine (SAM) as",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -6.29296875,
            "text": "S-adenosyl-l-methionine (SAM",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 9.375,
            "text": "adenosyl-l-methionine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -6.5859375,
            "text": "S-adenosyl-l-methionine (SAM) as the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.66796875,
            "end_logit": 9.375,
            "text": "l-methionine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 9.375,
            "text": "-l-methionine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -6.80859375,
            "text": "S-adenosyl-l-methionine (SAM) as the methyl donor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 9.375,
            "text": "using S-adenosyl-l-methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -6.89453125,
            "text": "S-adenosyl-l",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3359375,
            "end_logit": -6.92578125,
            "text": "S-adenosyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 9.375,
            "text": "lysine residues in a substrate protein using S-adenosyl-l-methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 9.375,
            "text": "to selected lysine residues in a substrate protein using S-adenosyl-l-methionine",
            "probability": 5.960464477539063e-08
        }
    ],
    "516e7fda298dcd4e51000081_8": [
        {
            "start_logit": 8.1640625,
            "end_logit": 6.9375,
            "text": "SAM",
            "probability": 1.0
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.74609375,
            "text": "SAM is the main methyl group donor for methyltransferases to modify DNA, RNA, protein, metabolites, or phospholipid target substrates.",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -6.859375,
            "text": "SAM is",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.015625,
            "text": "SAM is the main",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.015625,
            "text": "SAM is the",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.21484375,
            "text": "SAM is the main methyl group donor",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.30078125,
            "text": "SAM is the main methyl group donor for",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.3046875,
            "text": "SAM is the main methyl group donor for methyltransferases to modify DNA,",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.3125,
            "text": "SAM is the main methyl group",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.3203125,
            "text": "SAM is the main methyl group donor for methyltransferases to",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.1640625,
            "end_logit": -7.3828125,
            "text": "SAM is the main methyl group donor for methyltransferase",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -4.76171875,
            "end_logit": -6.74609375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.40234375,
            "end_logit": -6.74609375,
            "text": ", or phospholipid target substrates.",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -6.74609375,
            "text": "methyl group donor for methyltransferases to modify DNA, RNA, protein, metabolites, or phospholipid target substrates.",
            "probability": 0.0
        },
        {
            "start_logit": -7.55859375,
            "end_logit": -6.74609375,
            "text": "DNA, RNA, protein, metabolites, or phospholipid target substrates.",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": -6.74609375,
            "text": "modify DNA, RNA, protein, metabolites, or phospholipid target substrates.",
            "probability": 0.0
        },
        {
            "start_logit": -7.58203125,
            "end_logit": -6.74609375,
            "text": "protein, metabolites, or phospholipid target substrates.",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -6.74609375,
            "text": "s to modify DNA, RNA, protein, metabolites, or phospholipid target substrates.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6015625,
            "end_logit": -6.74609375,
            "text": ", metabolites, or phospholipid target substrates.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": -6.74609375,
            "text": "group donor for methyltransferases to modify DNA, RNA, protein, metabolites, or phospholipid target substrates.",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_9": [
        {
            "start_logit": 9.3828125,
            "end_logit": 9.359375,
            "text": "S-adenosyl-l-methionine",
            "probability": 1.0
        },
        {
            "start_logit": -0.64208984375,
            "end_logit": 9.359375,
            "text": "methionine",
            "probability": 4.398822784423828e-05
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -0.8505859375,
            "text": "S",
            "probability": 3.647804260253906e-05
        },
        {
            "start_logit": -5.6953125,
            "end_logit": 9.359375,
            "text": "-adenosyl-l-methionine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.90625,
            "end_logit": 9.359375,
            "text": "-methionine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.07421875,
            "end_logit": 9.359375,
            "text": "adenosyl-l-methionine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.4609375,
            "end_logit": 9.359375,
            "text": "l-methionine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.609375,
            "end_logit": 9.359375,
            "text": "-l-methionine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -6.69921875,
            "text": "S-adenosyl-l-methionine (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.828125,
            "end_logit": 9.359375,
            "text": "To control the enzymatic activity of vSET in vivo with an engineered S-adenosyl-l-methionine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -6.8984375,
            "text": "S-adenosyl-l",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -6.9453125,
            "text": "S-adenosyl-l-methionine (SAM) analogue",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -6.98046875,
            "text": "S-adenosyl-l-methionine (SAM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -6.9921875,
            "text": "S-adenosyl-l-methionine (SAM)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.12109375,
            "text": "S-adenosyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.2734375,
            "text": "S-adenosyl-l-methionine (SAM) analogue as methyl donor cofactor, we have",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.27734375,
            "text": "S-adenosyl-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.30859375,
            "text": "S-adenosyl-l-methionine (SAM) analogue as methyl donor cofactor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3828125,
            "end_logit": -7.31640625,
            "text": "S-adenosyl-l-methionine (SAM) analogue as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 9.359375,
            "text": "with an engineered S-adenosyl-l-methionine",
            "probability": 5.960464477539063e-08
        }
    ],
    "516e7fda298dcd4e51000081_10": [
        {
            "start_logit": 7.4296875,
            "end_logit": 7.7734375,
            "text": "SAM",
            "probability": 1.0
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -5.80078125,
            "text": "SAM as the methyl donor.",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -6.55859375,
            "text": "SAM as",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 7.7734375,
            "text": "with SAM",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.21484375,
            "end_logit": 7.7734375,
            "text": "arginine methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.0625,
            "text": "SAM as the",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 7.7734375,
            "text": "protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 7.7734375,
            "text": ", arginine methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 7.4296875,
            "end_logit": -7.125,
            "text": "SAM as the methyl donor",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 7.7734375,
            "text": "arginine methyltransferases (PRMTs) with SAM",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 7.7734375,
            "text": "PRMTs) with SAM",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 7.7734375,
            "text": "by protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 7.7734375,
            "text": "One of the well-studied PTMs, arginine methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 7.7734375,
            "text": "MTs) with SAM",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 7.7734375,
            "text": "-studied PTMs, arginine methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.671875,
            "end_logit": 7.7734375,
            "text": "of the well-studied PTMs, arginine methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.2890625,
            "end_logit": -5.80078125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": -5.80078125,
            "text": "with SAM as the methyl donor.",
            "probability": 0.0
        },
        {
            "start_logit": -7.21484375,
            "end_logit": -5.80078125,
            "text": "arginine methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM as the methyl donor.",
            "probability": 0.0
        },
        {
            "start_logit": -7.37890625,
            "end_logit": -5.80078125,
            "text": "as the methyl donor.",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_11": [
        {
            "start_logit": 9.203125,
            "end_logit": 9.203125,
            "text": "S-adenosylmethionine",
            "probability": 1.0
        },
        {
            "start_logit": -1.18359375,
            "end_logit": 9.203125,
            "text": "ionine",
            "probability": 3.069639205932617e-05
        },
        {
            "start_logit": 9.203125,
            "end_logit": -1.416015625,
            "text": "S",
            "probability": 2.4497509002685547e-05
        },
        {
            "start_logit": -5.8125,
            "end_logit": 9.203125,
            "text": "methionine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.21484375,
            "end_logit": 9.203125,
            "text": "-adenosylmethionine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.33203125,
            "end_logit": 9.203125,
            "text": "adenosylmethionine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.58203125,
            "text": "S-adenosyl",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.64453125,
            "text": "S-adenosylmethionine as methyl donor.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -6.7265625,
            "text": "S-adenosylmethionine as",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.015625,
            "end_logit": 9.203125,
            "text": "uses S-adenosylmethionine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.03125,
            "text": "S-adenosylmeth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.203125,
            "end_logit": -7.20703125,
            "text": "S-adenosylmethionine as methyl donor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.578125,
            "end_logit": 9.203125,
            "text": "cell extract that uses S-adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 9.203125,
            "text": "extract that uses S-adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 9.203125,
            "text": "the cell extract that uses S-adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 9.203125,
            "text": "purified cytochrome can act as a methyl acceptor for a methyltransferase activity in the cell extract that uses S-adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.65234375,
            "end_logit": 9.203125,
            "text": "The purified cytochrome can act as a methyl acceptor for a methyltransferase activity in the cell extract that uses S-adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.18359375,
            "end_logit": -6.64453125,
            "text": "ionine as methyl donor.",
            "probability": 0.0
        },
        {
            "start_logit": -1.18359375,
            "end_logit": -6.7265625,
            "text": "ionine as",
            "probability": 0.0
        },
        {
            "start_logit": -1.18359375,
            "end_logit": -7.20703125,
            "text": "ionine as methyl donor",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_12": [
        {
            "start_logit": 9.3203125,
            "end_logit": 9.265625,
            "text": "S-adenosyl-L-methionine",
            "probability": 1.0
        },
        {
            "start_logit": -0.99169921875,
            "end_logit": 9.265625,
            "text": "methionine",
            "probability": 3.2961368560791016e-05
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -1.05078125,
            "text": "S",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -5.15234375,
            "text": "S-adenosyl-L-methionine as the methyl donor.",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -5.91796875,
            "text": "S-adenosyl-L-methionine as",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 9.265625,
            "text": "-adenosyl-L-methionine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 9.265625,
            "text": "-methionine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.296875,
            "end_logit": 9.265625,
            "text": "adenosyl-L-methionine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.53125,
            "end_logit": 9.265625,
            "text": "-L-methionine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.58984375,
            "end_logit": 9.265625,
            "text": "L-methionine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.703125,
            "text": "S-adenosyl-L-methionine as the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.90625,
            "text": "S-adenosyl-L",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.9921875,
            "text": "S-adenosyl-L-methionine as the methyl donor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.99609375,
            "text": "S-adenosyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.19921875,
            "text": "S-adenosyl-L-methionine as the methyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.23828125,
            "text": "S-adenosyl-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.23828125,
            "end_logit": 9.265625,
            "text": "utilizes S-adenosyl-L-methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.265625,
            "text": "enzyme utilizes S-adenosyl-L-methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 9.265625,
            "text": "This enzyme utilizes S-adenosyl-L-methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.99169921875,
            "end_logit": -5.15234375,
            "text": "methionine as the methyl donor.",
            "probability": 0.0
        }
    ],
    "602598101cb411341a0000ae_1": [
        {
            "start_logit": 6.0,
            "end_logit": 9.1640625,
            "text": "biological and targeted synthetic disease-modifying antirheumatic drugs",
            "probability": 0.9990234375
        },
        {
            "start_logit": -0.95849609375,
            "end_logit": 9.1640625,
            "text": "drugs",
            "probability": 0.0009474754333496094
        },
        {
            "start_logit": -3.423828125,
            "end_logit": 9.1640625,
            "text": "recommendations suggesting that biological and targeted synthetic disease-modifying antirheumatic drugs",
            "probability": 8.088350296020508e-05
        },
        {
            "start_logit": -4.7421875,
            "end_logit": 9.1640625,
            "text": "Despite recommendations suggesting that biological and targeted synthetic disease-modifying antirheumatic drugs",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": -5.7734375,
            "end_logit": 9.1640625,
            "text": "targeted synthetic disease-modifying antirheumatic drugs",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": -6.03125,
            "end_logit": 9.1640625,
            "text": "that biological and targeted synthetic disease-modifying antirheumatic drugs",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": -6.13671875,
            "end_logit": 9.1640625,
            "text": "disease-modifying antirheumatic drugs",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": -6.55078125,
            "end_logit": 9.1640625,
            "text": "synthetic disease-modifying antirheumatic drugs",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 9.1640625,
            "text": "suggesting that biological and targeted synthetic disease-modifying antirheumatic drugs",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -6.5703125,
            "end_logit": 9.1640625,
            "text": "matic drugs",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 6.0,
            "end_logit": -3.556640625,
            "text": "biological and targeted synthetic disease-modifying antirheumatic drugs (",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 6.0,
            "end_logit": -4.59375,
            "text": "biological",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 6.0,
            "end_logit": -5.7890625,
            "text": "biological and targeted synthetic disease-modifying antirheumatic drugs (b",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 6.0,
            "end_logit": -6.10546875,
            "text": "biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) should",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.0,
            "end_logit": -6.11328125,
            "text": "biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) should be used in combination",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.0,
            "end_logit": -6.18359375,
            "text": "biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) should be",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.0,
            "end_logit": -6.26953125,
            "text": "biological and targeted synthetic disease-modifying antirheumatic",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.0,
            "end_logit": -6.2734375,
            "text": "biological and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.568359375,
            "end_logit": 1.283203125,
            "text": ".",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.203125,
            "end_logit": 1.283203125,
            "text": "up to one-third of patients with RA are treated with monotherapy.",
            "probability": 0.0
        }
    ],
    "626aeab6e764a5320400003e_1": [
        {
            "start_logit": 7.53125,
            "end_logit": 8.9765625,
            "text": "In May 2019",
            "probability": 0.9990234375
        },
        {
            "start_logit": 0.1983642578125,
            "end_logit": 8.9765625,
            "text": "2019",
            "probability": 0.0006561279296875
        },
        {
            "start_logit": 7.53125,
            "end_logit": -2.236328125,
            "text": "In",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": -6.15234375,
            "end_logit": 8.9765625,
            "text": "May 2019",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 7.53125,
            "end_logit": -5.49609375,
            "text": "In May",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -6.6171875,
            "text": "In May 2019,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -6.640625,
            "text": "In May 2019, volanesorsen was approved in the EU",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -6.796875,
            "text": "In May 2019, volanesorsen was",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -6.8203125,
            "text": "In May 2019, volanesorsen was approved",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -6.88671875,
            "text": "In May 2019, volanesorsen was approved in the EU for the treatment of adult patients with",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -6.90234375,
            "text": "In May 2019, volanesorsen was approved in the EU for the treatment of adult",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.0078125,
            "text": "In May 2019, volanesorsen was approved in the EU for the treatment of adult patients with FCS based",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.05078125,
            "text": "In May 2019, volanesorsen",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.05078125,
            "text": "In May 2019, volanesorsen was approved in the EU for the treatment of adult patients with FCS based on positive results from the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.08203125,
            "text": "In May 2019, volanesors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.08203125,
            "text": "In May 2019, volanesorsen was approved in the EU for the treatment of adult patients",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.53125,
            "end_logit": -7.08984375,
            "text": "In May 2019, volanesorsen was approved in the EU for the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 0.1983642578125,
            "end_logit": -6.6171875,
            "text": "2019,",
            "probability": 0.0
        },
        {
            "start_logit": 0.1983642578125,
            "end_logit": -6.640625,
            "text": "2019, volanesorsen was approved in the EU",
            "probability": 0.0
        },
        {
            "start_logit": 0.1983642578125,
            "end_logit": -6.796875,
            "text": "2019, volanesorsen was",
            "probability": 0.0
        }
    ],
    "601db60e1cb411341a000049_1": [
        {
            "start_logit": 9.1953125,
            "end_logit": 8.7734375,
            "text": "chromosome D2",
            "probability": 1.0
        },
        {
            "start_logit": 9.1953125,
            "end_logit": -1.4091796875,
            "text": "chromosome",
            "probability": 3.7610530853271484e-05
        },
        {
            "start_logit": -2.166015625,
            "end_logit": 8.7734375,
            "text": "D2",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": -6.171875,
            "end_logit": 8.7734375,
            "text": "on chromosome D2",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.22265625,
            "end_logit": 8.7734375,
            "text": "Linkage mapping defined a genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 8.7734375,
            "text": "a genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.515625,
            "end_logit": 8.7734375,
            "text": "3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 8.7734375,
            "text": "(95.87-99.21 Mb) on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.56640625,
            "end_logit": 8.7734375,
            "text": "genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 8.7734375,
            "text": "mapping defined a genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.7734375,
            "text": ".3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.7734375,
            "text": "region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.171875,
            "end_logit": -1.4091796875,
            "text": "on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -7.22265625,
            "end_logit": -1.4091796875,
            "text": "Linkage mapping defined a genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": -1.4091796875,
            "text": "a genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -7.515625,
            "end_logit": -1.4091796875,
            "text": "3.3-Mb region, (95.87-99.21 Mb) on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -7.53515625,
            "end_logit": -1.4091796875,
            "text": "(95.87-99.21 Mb) on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -7.56640625,
            "end_logit": -1.4091796875,
            "text": "genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -1.4091796875,
            "text": "mapping defined a genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": -1.4091796875,
            "text": ".3-Mb region, (95.87-99.21 Mb) on chromosome",
            "probability": 0.0
        }
    ],
    "601db60e1cb411341a000049_2": [
        {
            "start_logit": 8.8515625,
            "end_logit": 7.59375,
            "text": "chromosome D2",
            "probability": 1.0
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -2.041015625,
            "text": "chromosome",
            "probability": 6.604194641113281e-05
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -2.6953125,
            "text": "chromosome D2,",
            "probability": 3.427267074584961e-05
        },
        {
            "start_logit": -3.5703125,
            "end_logit": 7.59375,
            "text": "D2",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": -4.92578125,
            "end_logit": 7.59375,
            "text": "on chromosome D2",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 8.8515625,
            "end_logit": -6.98046875,
            "text": "chromosome D2, (peak logarithm of the odds = 10.5, = 0), which",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 7.59375,
            "text": "ge mapping defined a genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.76953125,
            "end_logit": 3.5390625,
            "text": "chromosome 10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.59765625,
            "end_logit": 3.5390625,
            "text": "10",
            "probability": 0.0
        },
        {
            "start_logit": -6.42578125,
            "end_logit": 3.5390625,
            "text": "on chromosome 10",
            "probability": 0.0
        },
        {
            "start_logit": -3.5703125,
            "end_logit": -2.6953125,
            "text": "D2,",
            "probability": 0.0
        },
        {
            "start_logit": -4.92578125,
            "end_logit": -2.041015625,
            "text": "on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -4.92578125,
            "end_logit": -2.6953125,
            "text": "on chromosome D2,",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -2.041015625,
            "text": "ge mapping defined a genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -3.76953125,
            "end_logit": -5.97265625,
            "text": "chromosome 10 in the human genome",
            "probability": 0.0
        },
        {
            "start_logit": -3.76953125,
            "end_logit": -6.71875,
            "text": "chromosome 10 in",
            "probability": 0.0
        },
        {
            "start_logit": -3.5703125,
            "end_logit": -6.98046875,
            "text": "D2, (peak logarithm of the odds = 10.5, = 0), which",
            "probability": 0.0
        },
        {
            "start_logit": -4.59765625,
            "end_logit": -5.97265625,
            "text": "10 in the human genome",
            "probability": 0.0
        },
        {
            "start_logit": -3.76953125,
            "end_logit": -7.05078125,
            "text": "chromosome 10 in the human",
            "probability": 0.0
        },
        {
            "start_logit": -4.59765625,
            "end_logit": -6.71875,
            "text": "10 in",
            "probability": 0.0
        }
    ],
    "601db60e1cb411341a000049_3": [
        {
            "start_logit": 9.0859375,
            "end_logit": 8.09375,
            "text": "chromosome D2",
            "probability": 1.0
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -1.595703125,
            "text": "chromosome",
            "probability": 6.157159805297852e-05
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -1.755859375,
            "text": "chromosome D2,",
            "probability": 5.227327346801758e-05
        },
        {
            "start_logit": -2.9921875,
            "end_logit": 8.09375,
            "text": "D2",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": -4.94140625,
            "end_logit": 8.09375,
            "text": "on chromosome D2",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.046875,
            "text": "chromosome D2, (peak logarithm of the odds = 10",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.0859375,
            "end_logit": -7.08203125,
            "text": "chromosome D2, (peak logarithm of the odds = 10.5, = 0), which",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.234375,
            "end_logit": 8.09375,
            "text": "Linkage mapping defined a genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2734375,
            "end_logit": 8.09375,
            "text": "(95.87-99.21 Mb) on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 8.09375,
            "text": "3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.390625,
            "end_logit": 8.09375,
            "text": "a genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.40234375,
            "end_logit": 8.09375,
            "text": ", (95.87-99.21 Mb) on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.85546875,
            "end_logit": 2.28515625,
            "text": "chromosome 10",
            "probability": 0.0
        },
        {
            "start_logit": -5.4921875,
            "end_logit": 2.28515625,
            "text": "10",
            "probability": 0.0
        },
        {
            "start_logit": -6.4375,
            "end_logit": 2.28515625,
            "text": "on chromosome 10",
            "probability": 0.0
        },
        {
            "start_logit": -2.9921875,
            "end_logit": -1.755859375,
            "text": "D2,",
            "probability": 0.0
        },
        {
            "start_logit": -4.94140625,
            "end_logit": -1.595703125,
            "text": "on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -4.94140625,
            "end_logit": -1.755859375,
            "text": "on chromosome D2,",
            "probability": 0.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": -1.595703125,
            "text": "Linkage mapping defined a genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -7.2734375,
            "end_logit": -1.595703125,
            "text": "(95.87-99.21 Mb) on chromosome",
            "probability": 0.0
        }
    ],
    "5c61f767e842deac67000007_1": [
        {
            "start_logit": 9.296875,
            "end_logit": 8.953125,
            "text": "Telomerecat",
            "probability": 1.0
        },
        {
            "start_logit": 9.296875,
            "end_logit": -1.19921875,
            "text": "Telomere",
            "probability": 3.886222839355469e-05
        },
        {
            "start_logit": -1.873046875,
            "end_logit": 8.953125,
            "text": "t",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": 9.296875,
            "end_logit": -5.88671875,
            "text": "Telomerecat:",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 8.953125,
            "text": "cat",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.8046875,
            "text": "Telomerecat: A ploidy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.81640625,
            "text": "Telomerecat: A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -6.85546875,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.06640625,
            "text": "Telomereca",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.1484375,
            "text": "Telomerecat: A ploidy-agn",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.18359375,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.18359375,
            "text": "Telomerecat: A ploidy-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.20703125,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.23046875,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.265625,
            "text": "Telomerecat: A ploidy-agnostic",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.328125,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.33203125,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.296875,
            "end_logit": -7.33203125,
            "text": "Telomerecat: A ploidy-agnostic method",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.873046875,
            "end_logit": -5.88671875,
            "text": "t:",
            "probability": 0.0
        },
        {
            "start_logit": -1.873046875,
            "end_logit": -6.8046875,
            "text": "t: A ploidy",
            "probability": 0.0
        }
    ],
    "5c61f767e842deac67000007_2": [
        {
            "start_logit": 9.3203125,
            "end_logit": 8.984375,
            "text": "Telomerecat",
            "probability": 1.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -1.0341796875,
            "text": "Telomere",
            "probability": 4.4345855712890625e-05
        },
        {
            "start_logit": -1.671875,
            "end_logit": 8.984375,
            "text": "t",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": -2.861328125,
            "end_logit": 8.984375,
            "text": ". Here we present Telomerecat",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -4.1640625,
            "text": "Telomerecat, a novel approach to the estimation of telomere length. Previous methods have been dependent on the number of telomeres present",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -3.921875,
            "end_logit": 8.984375,
            "text": "present Telomerecat",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -5.328125,
            "text": "Telomerecat, a novel approach to the estimation of telomere length. Previous methods have been dependent on the number of telomeres present in a cell being known",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -5.796875,
            "text": "Telomerecat, a novel approach to the estimation of telomere length.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -5.8125,
            "text": "Telomerecat, a novel approach to the estimation of telomere length. Previous methods have been dependent on the number of telomeres present in",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.51171875,
            "end_logit": 8.984375,
            "text": "cat",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -5.91796875,
            "text": "Telomerecat, a novel approach to the estimation of telomere length. Previous methods have been dependent on the number of telomeres",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.00390625,
            "text": "Telomerecat, a novel approach to the estimation of telomere length. Previous methods have been dependent on the number of",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.0390625,
            "text": "Telomerecat, a novel approach to the estimation of telomere length. Previous methods have been dependent on the number of telomeres present in a",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.015625,
            "end_logit": 8.984375,
            "text": "Here we present Telomerecat",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -2.861328125,
            "end_logit": -1.0341796875,
            "text": ". Here we present Telomere",
            "probability": 0.0
        },
        {
            "start_logit": -3.921875,
            "end_logit": -1.0341796875,
            "text": "present Telomere",
            "probability": 0.0
        },
        {
            "start_logit": -1.671875,
            "end_logit": -4.1640625,
            "text": "t, a novel approach to the estimation of telomere length. Previous methods have been dependent on the number of telomeres present",
            "probability": 0.0
        },
        {
            "start_logit": -1.671875,
            "end_logit": -5.328125,
            "text": "t, a novel approach to the estimation of telomere length. Previous methods have been dependent on the number of telomeres present in a cell being known",
            "probability": 0.0
        },
        {
            "start_logit": -2.859375,
            "end_logit": -4.1640625,
            "text": ". Previous methods have been dependent on the number of telomeres present",
            "probability": 0.0
        },
        {
            "start_logit": -2.861328125,
            "end_logit": -4.1640625,
            "text": ". Here we present Telomerecat, a novel approach to the estimation of telomere length. Previous methods have been dependent on the number of telomeres present",
            "probability": 0.0
        }
    ],
    "5c61f767e842deac67000007_3": [
        {
            "start_logit": 9.3046875,
            "end_logit": 8.921875,
            "text": "Telomerecat",
            "probability": 1.0
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -1.162109375,
            "text": "Telomere",
            "probability": 4.1961669921875e-05
        },
        {
            "start_logit": -1.9072265625,
            "end_logit": 8.921875,
            "text": "t",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": -5.6484375,
            "end_logit": 8.921875,
            "text": "cat",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.37109375,
            "text": "Telomerecat:",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.578125,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.82421875,
            "text": "Telomerecat: A",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -6.98046875,
            "text": "Telomerecat: A ploidy",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.12109375,
            "text": "Telomereca",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.27734375,
            "text": "Telomerecat: A ploidy-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.28515625,
            "text": "Telomerecat: A ploidy-agn",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.30078125,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.Telomere length is a risk factor in disease and the",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.31640625,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3046875,
            "end_logit": -7.32421875,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.9072265625,
            "end_logit": -6.37109375,
            "text": "t:",
            "probability": 0.0
        },
        {
            "start_logit": -1.9072265625,
            "end_logit": -6.578125,
            "text": "t: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.",
            "probability": 0.0
        },
        {
            "start_logit": -1.9072265625,
            "end_logit": -6.82421875,
            "text": "t: A",
            "probability": 0.0
        },
        {
            "start_logit": -1.9072265625,
            "end_logit": -6.98046875,
            "text": "t: A ploidy",
            "probability": 0.0
        },
        {
            "start_logit": -1.9072265625,
            "end_logit": -7.265625,
            "text": "t: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.Telomere length is a risk factor in disease and the dynamics",
            "probability": 0.0
        },
        {
            "start_logit": -1.9072265625,
            "end_logit": -7.27734375,
            "text": "t: A ploidy-",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_1": [
        {
            "start_logit": 7.58203125,
            "end_logit": 6.50390625,
            "text": "Alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 7.58203125,
            "end_logit": -1.68359375,
            "text": "Alpha-synuclein,",
            "probability": 0.0002779960632324219
        },
        {
            "start_logit": 7.58203125,
            "end_logit": -3.546875,
            "text": "Alpha",
            "probability": 4.3332576751708984e-05
        },
        {
            "start_logit": -2.74609375,
            "end_logit": 6.50390625,
            "text": ". Majority of PD are sporadic, for which genetic causes remain largely unknown. Alpha-synuclein",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": -2.748046875,
            "end_logit": 6.50390625,
            "text": ". Alpha-synuclein",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": 7.58203125,
            "end_logit": -3.951171875,
            "text": "Alpha-synuclein, the main component of Lewy bodies,",
            "probability": 2.8848648071289062e-05
        },
        {
            "start_logit": -4.4921875,
            "end_logit": 6.50390625,
            "text": "synuclein",
            "probability": 5.662441253662109e-06
        },
        {
            "start_logit": 7.58203125,
            "end_logit": -5.81640625,
            "text": "Alpha-synuclein, the main component of Lewy bodies, plays",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": 7.58203125,
            "end_logit": -5.828125,
            "text": "Alpha-synuclein, the main component of Lewy bodies, plays a",
            "probability": 4.410743713378906e-06
        },
        {
            "start_logit": 7.58203125,
            "end_logit": -5.84765625,
            "text": "Alpha-synuclein, the",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 7.58203125,
            "end_logit": -5.94921875,
            "text": "Alpha-synuclein, the main component of Lewy bodies, plays a central",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 7.58203125,
            "end_logit": -6.19140625,
            "text": "Alpha-synuclein, the main component of Lewy bodies, plays a central role",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 7.58203125,
            "end_logit": -6.234375,
            "text": "Alpha-synuclein, the main component of Lewy bodies, plays a central role in the PD",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": 7.58203125,
            "end_logit": -6.2421875,
            "text": "Alpha-synuclein, the main",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": -5.875,
            "end_logit": 6.50390625,
            "text": "-synuclein",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -6.515625,
            "end_logit": 6.50390625,
            "text": ", for which genetic causes remain largely unknown. Alpha-synuclein",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -1.1435546875,
            "end_logit": -2.541015625,
            "text": "Parkinson's disease (PD) is one of the most common neurodegenerative diseases.",
            "probability": 0.0
        },
        {
            "start_logit": -1.1435546875,
            "end_logit": -2.54296875,
            "text": "Parkinson's disease (PD) is one of the most common neurodegenerative diseases. Majority of PD are sporadic, for which genetic causes remain largely unknown.",
            "probability": 0.0
        },
        {
            "start_logit": -2.74609375,
            "end_logit": -1.68359375,
            "text": ". Majority of PD are sporadic, for which genetic causes remain largely unknown. Alpha-synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": -2.748046875,
            "end_logit": -1.68359375,
            "text": ". Alpha-synuclein,",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_2": [
        {
            "start_logit": 7.96484375,
            "end_logit": -2.634765625,
            "text": "The",
            "probability": 0.60595703125
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -3.8828125,
            "text": "The main component of Lewy bodies is",
            "probability": 0.17431640625
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -4.80859375,
            "text": "The main component of Lewy bodies is alpha-synuclein",
            "probability": 0.06903076171875
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -5.4140625,
            "text": "The main component",
            "probability": 0.037689208984375
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -5.73828125,
            "text": "The main component of Lewy bodies",
            "probability": 0.027252197265625
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -5.80078125,
            "text": "The main component of Lewy bodies is alpha",
            "probability": 0.025604248046875
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -6.0,
            "text": "The main component of Lewy bodies is alpha-",
            "probability": 0.020965576171875
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -6.21875,
            "text": "The main component of",
            "probability": 0.0168609619140625
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -6.44140625,
            "text": "The main",
            "probability": 0.01348876953125
        },
        {
            "start_logit": 7.96484375,
            "end_logit": -6.8359375,
            "text": "The main component of Lewy",
            "probability": 0.00909423828125
        },
        {
            "start_logit": -6.8125,
            "end_logit": -3.8828125,
            "text": "Lewy bodies is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -3.8828125,
            "text": "main component of Lewy bodies is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8125,
            "end_logit": -4.80859375,
            "text": "Lewy bodies is alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -4.80859375,
            "text": "main component of Lewy bodies is alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8125,
            "end_logit": -5.73828125,
            "text": "Lewy bodies",
            "probability": 0.0
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -5.4140625,
            "text": "main component",
            "probability": 0.0
        },
        {
            "start_logit": -6.8125,
            "end_logit": -5.80078125,
            "text": "Lewy bodies is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -6.8125,
            "end_logit": -6.0,
            "text": "Lewy bodies is alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -5.73828125,
            "text": "main component of Lewy bodies",
            "probability": 0.0
        },
        {
            "start_logit": -7.1640625,
            "end_logit": -5.80078125,
            "text": "main component of Lewy bodies is alpha",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_3": [
        {
            "start_logit": 0.09930419921875,
            "end_logit": 1.12109375,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.54736328125
        },
        {
            "start_logit": -0.263671875,
            "end_logit": 1.12109375,
            "text": "Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.380615234375
        },
        {
            "start_logit": -3.212890625,
            "end_logit": 1.12109375,
            "text": "a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.0199432373046875
        },
        {
            "start_logit": 0.09930419921875,
            "end_logit": -2.21484375,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques",
            "probability": 0.01947021484375
        },
        {
            "start_logit": -0.263671875,
            "end_logit": -2.21484375,
            "text": "Lewy bodies in synucleinopathies and senile plaques",
            "probability": 0.01354217529296875
        },
        {
            "start_logit": -5.21484375,
            "end_logit": 1.12109375,
            "text": "senile plaques in Alzheimer disease,",
            "probability": 0.002696990966796875
        },
        {
            "start_logit": 0.09930419921875,
            "end_logit": -4.33984375,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in",
            "probability": 0.0023250579833984375
        },
        {
            "start_logit": -5.546875,
            "end_logit": 1.12109375,
            "text": "of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.0019283294677734375
        },
        {
            "start_logit": -5.6328125,
            "end_logit": 1.12109375,
            "text": "bodies in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.0017690658569335938
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 1.12109375,
            "text": "synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.0017423629760742188
        },
        {
            "start_logit": -0.263671875,
            "end_logit": -4.33984375,
            "text": "Lewy bodies in synucleinopathies and senile plaques in",
            "probability": 0.0016231536865234375
        },
        {
            "start_logit": -5.7578125,
            "end_logit": 1.12109375,
            "text": "in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.0015621185302734375
        },
        {
            "start_logit": -6.37890625,
            "end_logit": 1.12109375,
            "text": ",",
            "probability": 0.0008425712585449219
        },
        {
            "start_logit": -6.5390625,
            "end_logit": 1.12109375,
            "text": "and senile plaques in Alzheimer disease,",
            "probability": 0.0007152557373046875
        },
        {
            "start_logit": -3.212890625,
            "end_logit": -2.21484375,
            "text": "a main component of Lewy bodies in synucleinopathies and senile plaques",
            "probability": 0.00070953369140625
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 1.12109375,
            "text": "-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.0006718635559082031
        },
        {
            "start_logit": 0.09930419921875,
            "end_logit": -5.59765625,
            "text": "Alpha-synuclein, a",
            "probability": 0.0006613731384277344
        },
        {
            "start_logit": 0.09930419921875,
            "end_logit": -5.66796875,
            "text": "Alpha-synuclein, a main",
            "probability": 0.0006165504455566406
        },
        {
            "start_logit": 0.09930419921875,
            "end_logit": -5.765625,
            "text": "Alpha-synuclein,",
            "probability": 0.00055694580078125
        },
        {
            "start_logit": -6.8828125,
            "end_logit": 1.12109375,
            "text": ", a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.0005068778991699219
        }
    ],
    "550c3d45a103b78016000008_4": [
        {
            "start_logit": 5.93359375,
            "end_logit": 5.6796875,
            "text": "alpha-Synuclein, the main component of LBs,",
            "probability": 0.99609375
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -1.193359375,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140),",
            "probability": 0.00103759765625
        },
        {
            "start_logit": -1.12890625,
            "end_logit": 5.66796875,
            "text": ".",
            "probability": 0.00084686279296875
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -1.7451171875,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140)",
            "probability": 0.0005955696105957031
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -3.443359375,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two",
            "probability": 0.0001093745231628418
        },
        {
            "start_logit": -3.375,
            "end_logit": 5.6796875,
            "text": "LBs,",
            "probability": 9.065866470336914e-05
        },
        {
            "start_logit": -3.375,
            "end_logit": 5.66796875,
            "text": "LBs, is expressed as two main isoforms (112 and 140), but little is known about their differential expression in the brain.",
            "probability": 8.994340896606445e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -3.73046875,
            "text": "alpha-Synuclein,",
            "probability": 8.189678192138672e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -3.904296875,
            "text": "alpha-Synuclein, the main component of LBs, is",
            "probability": 6.890296936035156e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -3.953125,
            "text": "alpha-Synuclein, the main component",
            "probability": 6.580352783203125e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -3.984375,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as",
            "probability": 6.377696990966797e-05
        },
        {
            "start_logit": -3.82421875,
            "end_logit": 5.6796875,
            "text": "the main component of LBs,",
            "probability": 5.805492401123047e-05
        },
        {
            "start_logit": -3.892578125,
            "end_logit": 5.6796875,
            "text": ",",
            "probability": 5.412101745605469e-05
        },
        {
            "start_logit": -3.892578125,
            "end_logit": 5.66796875,
            "text": ", is expressed as two main isoforms (112 and 140), but little is known about their differential expression in the brain.",
            "probability": 5.328655242919922e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -4.3203125,
            "text": "alpha-Synuclein",
            "probability": 4.5239925384521484e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -4.390625,
            "text": "alpha",
            "probability": 4.2498111724853516e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -4.4140625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main",
            "probability": 4.118680953979492e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -4.7578125,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms",
            "probability": 2.9206275939941406e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -4.859375,
            "text": "alpha-Synuclein, the main component of LBs, is expressed",
            "probability": 2.658367156982422e-05
        },
        {
            "start_logit": -4.765625,
            "end_logit": 5.6796875,
            "text": "of LBs,",
            "probability": 2.2590160369873047e-05
        }
    ],
    "550c3d45a103b78016000008_5": [
        {
            "start_logit": -3.640625,
            "end_logit": 1.443359375,
            "text": "alpha-synuclein",
            "probability": 0.4169921875
        },
        {
            "start_logit": -4.39453125,
            "end_logit": 1.443359375,
            "text": "Amyloid precursor protein (APP) is involved in the accumulation of alpha-synuclein",
            "probability": 0.1961669921875
        },
        {
            "start_logit": -5.15625,
            "end_logit": 1.443359375,
            "text": "-synuclein",
            "probability": 0.09161376953125
        },
        {
            "start_logit": -5.3125,
            "end_logit": 1.443359375,
            "text": "of alpha-synuclein",
            "probability": 0.07830810546875
        },
        {
            "start_logit": -5.6015625,
            "end_logit": 1.443359375,
            "text": "accumulation of alpha-synuclein",
            "probability": 0.05877685546875
        },
        {
            "start_logit": -3.640625,
            "end_logit": -0.8251953125,
            "text": "alpha-synuclein,",
            "probability": 0.043182373046875
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 1.443359375,
            "text": "synuclein",
            "probability": 0.025482177734375
        },
        {
            "start_logit": -4.39453125,
            "end_logit": -0.8251953125,
            "text": "Amyloid precursor protein (APP) is involved in the accumulation of alpha-synuclein,",
            "probability": 0.02032470703125
        },
        {
            "start_logit": -6.84375,
            "end_logit": 1.443359375,
            "text": "precursor protein (APP) is involved in the accumulation of alpha-synuclein",
            "probability": 0.0169677734375
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 1.443359375,
            "text": "the accumulation of alpha-synuclein",
            "probability": 0.014404296875
        },
        {
            "start_logit": -5.15625,
            "end_logit": -0.8251953125,
            "text": "-synuclein,",
            "probability": 0.00948333740234375
        },
        {
            "start_logit": -5.3125,
            "end_logit": -0.8251953125,
            "text": "of alpha-synuclein,",
            "probability": 0.00811004638671875
        },
        {
            "start_logit": -5.59375,
            "end_logit": -0.8251953125,
            "text": ",",
            "probability": 0.006137847900390625
        },
        {
            "start_logit": -5.6015625,
            "end_logit": -0.8251953125,
            "text": "accumulation of alpha-synuclein,",
            "probability": 0.0060882568359375
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -0.8251953125,
            "text": "synuclein,",
            "probability": 0.0026378631591796875
        },
        {
            "start_logit": -6.84375,
            "end_logit": -0.8251953125,
            "text": "precursor protein (APP) is involved in the accumulation of alpha-synuclein,",
            "probability": 0.0017576217651367188
        },
        {
            "start_logit": -0.347412109375,
            "end_logit": -7.4375,
            "text": "Lewy bodies",
            "probability": 0.0015630722045898438
        },
        {
            "start_logit": -7.00390625,
            "end_logit": -0.8251953125,
            "text": "the accumulation of alpha-synuclein,",
            "probability": 0.001491546630859375
        },
        {
            "start_logit": -3.640625,
            "end_logit": -5.3359375,
            "text": "alpha-synuclein, the",
            "probability": 0.00047326087951660156
        },
        {
            "start_logit": -3.640625,
            "end_logit": -5.58203125,
            "text": "alpha-synuclein, the main",
            "probability": 0.0003714561462402344
        }
    ],
    "550c3d45a103b78016000008_6": [
        {
            "start_logit": 1.736328125,
            "end_logit": 4.25,
            "text": "Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies.",
            "probability": 0.88720703125
        },
        {
            "start_logit": -1.1220703125,
            "end_logit": 4.25,
            "text": ".",
            "probability": 0.051055908203125
        },
        {
            "start_logit": 1.736328125,
            "end_logit": 0.6064453125,
            "text": "Lewy neurites",
            "probability": 0.0232696533203125
        },
        {
            "start_logit": -2.330078125,
            "end_logit": 4.25,
            "text": "Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies.",
            "probability": 0.0152740478515625
        },
        {
            "start_logit": 0.8017578125,
            "end_logit": 0.6064453125,
            "text": "The pre-synaptic protein alpha-synuclein is the main component of Lewy bodies and Lewy neurites",
            "probability": 0.00911712646484375
        },
        {
            "start_logit": 1.736328125,
            "end_logit": -0.6142578125,
            "text": "Lewy neurites,",
            "probability": 0.006855010986328125
        },
        {
            "start_logit": 0.8017578125,
            "end_logit": -0.6142578125,
            "text": "The pre-synaptic protein alpha-synuclein is the main component of Lewy bodies and Lewy neurites,",
            "probability": 0.0026950836181640625
        },
        {
            "start_logit": -5.20703125,
            "end_logit": 4.25,
            "text": "with Lewy bodies.",
            "probability": 0.000858306884765625
        },
        {
            "start_logit": -5.29296875,
            "end_logit": 4.25,
            "text": "Lewy bodies.",
            "probability": 0.0007872581481933594
        },
        {
            "start_logit": -5.34765625,
            "end_logit": 4.25,
            "text": "dementia with Lewy bodies.",
            "probability": 0.0007457733154296875
        },
        {
            "start_logit": -5.66015625,
            "end_logit": 4.25,
            "text": "alpha-synuclein is the main component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies.",
            "probability": 0.000545501708984375
        },
        {
            "start_logit": -5.8984375,
            "end_logit": 4.25,
            "text": "protein alpha-synuclein is the main component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies.",
            "probability": 0.0004296302795410156
        },
        {
            "start_logit": -2.330078125,
            "end_logit": 0.6064453125,
            "text": "Lewy bodies and Lewy neurites",
            "probability": 0.0003991127014160156
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 4.25,
            "text": "of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies.",
            "probability": 0.0002467632293701172
        },
        {
            "start_logit": -6.84375,
            "end_logit": 4.25,
            "text": "neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies.",
            "probability": 0.00016701221466064453
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 4.25,
            "text": "is the main component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies.",
            "probability": 0.00016438961029052734
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 4.25,
            "text": "bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies.",
            "probability": 0.00013947486877441406
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 4.25,
            "text": "of Parkinson's disease and dementia with Lewy bodies.",
            "probability": 0.00013315677642822266
        },
        {
            "start_logit": -2.330078125,
            "end_logit": -0.6142578125,
            "text": "Lewy bodies and Lewy neurites,",
            "probability": 0.00011754035949707031
        },
        {
            "start_logit": 1.736328125,
            "end_logit": -5.203125,
            "text": "Lewy neurites, the",
            "probability": 6.961822509765625e-05
        }
    ],
    "550c3d45a103b78016000008_7": [
        {
            "start_logit": 3.7890625,
            "end_logit": 4.640625,
            "text": "the main component of Lewy body is alpha-synuclein.",
            "probability": 0.64990234375
        },
        {
            "start_logit": 4.09765625,
            "end_logit": 3.65625,
            "text": "LBD has neuropathological characteristics whereby numerous Lewy bodies are present in the central and sympathetic nervous systems,",
            "probability": 0.33056640625
        },
        {
            "start_logit": -0.90576171875,
            "end_logit": 4.640625,
            "text": ".",
            "probability": 0.005939483642578125
        },
        {
            "start_logit": -1.4140625,
            "end_logit": 4.640625,
            "text": "alpha-synuclein.",
            "probability": 0.003574371337890625
        },
        {
            "start_logit": -0.63427734375,
            "end_logit": 3.65625,
            "text": "Lewy bodies are present in the central and sympathetic nervous systems,",
            "probability": 0.002918243408203125
        },
        {
            "start_logit": 4.09765625,
            "end_logit": -1.26953125,
            "text": "LBD has neuropathological characteristics whereby numerous Lewy bodies are present in the central and sympathetic nervous systems",
            "probability": 0.002399444580078125
        },
        {
            "start_logit": -2.623046875,
            "end_logit": 4.640625,
            "text": "alpha-synucleinopathy because the main component of Lewy body is alpha-synuclein.",
            "probability": 0.001064300537109375
        },
        {
            "start_logit": -3.037109375,
            "end_logit": 4.640625,
            "text": "in the central and sympathetic nervous systems, and it is a type of alpha-synucleinopathy because the main component of Lewy body is alpha-synuclein.",
            "probability": 0.0007033348083496094
        },
        {
            "start_logit": -3.283203125,
            "end_logit": 4.640625,
            "text": "is alpha-synuclein.",
            "probability": 0.0005521774291992188
        },
        {
            "start_logit": -3.55078125,
            "end_logit": 4.640625,
            "text": "Lewy body is alpha-synuclein.",
            "probability": 0.00042176246643066406
        },
        {
            "start_logit": -2.6484375,
            "end_logit": 3.65625,
            "text": "numerous Lewy bodies are present in the central and sympathetic nervous systems,",
            "probability": 0.0003886222839355469
        },
        {
            "start_logit": -3.970703125,
            "end_logit": 4.640625,
            "text": "the central and sympathetic nervous systems, and it is a type of alpha-synucleinopathy because the main component of Lewy body is alpha-synuclein.",
            "probability": 0.0002777576446533203
        },
        {
            "start_logit": -3.037109375,
            "end_logit": 3.65625,
            "text": "in the central and sympathetic nervous systems,",
            "probability": 0.00026297569274902344
        },
        {
            "start_logit": -4.0546875,
            "end_logit": 4.640625,
            "text": ", and it is a type of alpha-synucleinopathy because the main component of Lewy body is alpha-synuclein.",
            "probability": 0.0002548694610595703
        },
        {
            "start_logit": -4.67578125,
            "end_logit": 4.640625,
            "text": "sympathetic nervous systems, and it is a type of alpha-synucleinopathy because the main component of Lewy body is alpha-synuclein.",
            "probability": 0.00013637542724609375
        },
        {
            "start_logit": -4.80078125,
            "end_logit": 4.640625,
            "text": "central and sympathetic nervous systems, and it is a type of alpha-synucleinopathy because the main component of Lewy body is alpha-synuclein.",
            "probability": 0.00012034177780151367
        },
        {
            "start_logit": -3.970703125,
            "end_logit": 3.65625,
            "text": "the central and sympathetic nervous systems,",
            "probability": 0.00010377168655395508
        },
        {
            "start_logit": -4.0546875,
            "end_logit": 3.65625,
            "text": ",",
            "probability": 9.518861770629883e-05
        },
        {
            "start_logit": -5.09375,
            "end_logit": 4.640625,
            "text": "of alpha-synucleinopathy because the main component of Lewy body is alpha-synuclein.",
            "probability": 9.018182754516602e-05
        },
        {
            "start_logit": -5.1953125,
            "end_logit": 4.640625,
            "text": "and sympathetic nervous systems, and it is a type of alpha-synucleinopathy because the main component of Lewy body is alpha-synuclein.",
            "probability": 8.147954940795898e-05
        }
    ],
    "550c3d45a103b78016000008_8": [
        {
            "start_logit": 3.708984375,
            "end_logit": 6.0859375,
            "text": "alpha-synuclein.",
            "probability": 0.59814453125
        },
        {
            "start_logit": 2.841796875,
            "end_logit": 6.0859375,
            "text": "the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.251220703125
        },
        {
            "start_logit": 2.076171875,
            "end_logit": 6.0859375,
            "text": "In Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.11688232421875
        },
        {
            "start_logit": 0.002895355224609375,
            "end_logit": 6.0859375,
            "text": "inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.01468658447265625
        },
        {
            "start_logit": -0.904296875,
            "end_logit": 6.0859375,
            "text": ".",
            "probability": 0.005908966064453125
        },
        {
            "start_logit": -1.4033203125,
            "end_logit": 6.0859375,
            "text": "Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0035991668701171875
        },
        {
            "start_logit": -1.5361328125,
            "end_logit": 6.0859375,
            "text": "is alpha-synuclein.",
            "probability": 0.00315093994140625
        },
        {
            "start_logit": -2.25390625,
            "end_logit": 6.0859375,
            "text": "as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0015354156494140625
        },
        {
            "start_logit": -2.33984375,
            "end_logit": 6.0859375,
            "text": "Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0014085769653320312
        },
        {
            "start_logit": -2.958984375,
            "end_logit": 6.0859375,
            "text": ", the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0007576942443847656
        },
        {
            "start_logit": -3.05859375,
            "end_logit": 6.0859375,
            "text": "referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0006866455078125
        },
        {
            "start_logit": 3.708984375,
            "end_logit": -0.82177734375,
            "text": "alpha-synuclein",
            "probability": 0.0005965232849121094
        },
        {
            "start_logit": 2.841796875,
            "end_logit": -0.82177734375,
            "text": "the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.00025081634521484375
        },
        {
            "start_logit": -4.15625,
            "end_logit": 6.0859375,
            "text": "bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.00022912025451660156
        },
        {
            "start_logit": -4.39453125,
            "end_logit": 6.0859375,
            "text": "to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.00017976760864257812
        },
        {
            "start_logit": -4.609375,
            "end_logit": 6.0859375,
            "text": "are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0001456737518310547
        },
        {
            "start_logit": 2.076171875,
            "end_logit": -0.82177734375,
            "text": "In Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.00011616945266723633
        },
        {
            "start_logit": 2.841796875,
            "end_logit": -2.01171875,
            "text": "the inclusion bodies are referred to as Lewy bodies and",
            "probability": 7.617473602294922e-05
        },
        {
            "start_logit": -5.75,
            "end_logit": 6.0859375,
            "text": "their main component is alpha-synuclein.",
            "probability": 4.655122756958008e-05
        },
        {
            "start_logit": -5.91015625,
            "end_logit": 6.0859375,
            "text": "bodies and their main component is alpha-synuclein.",
            "probability": 3.9517879486083984e-05
        }
    ],
    "550c3d45a103b78016000008_9": [
        {
            "start_logit": 8.78125,
            "end_logit": 5.37109375,
            "text": "The main component of Lewy bodies is alpha-synuclein.",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.78125,
            "end_logit": -1.7509765625,
            "text": "The",
            "probability": 0.0008039474487304688
        },
        {
            "start_logit": 8.78125,
            "end_logit": -3.515625,
            "text": "The main component of Lewy bodies is",
            "probability": 0.00013756752014160156
        },
        {
            "start_logit": 8.78125,
            "end_logit": -5.23046875,
            "text": "The main component of Lewy bodies is alpha-synuclein",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": 8.78125,
            "end_logit": -5.33984375,
            "text": "The main component",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 8.78125,
            "end_logit": -5.8984375,
            "text": "The main component of Lewy bodies is alpha-",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": -2.646484375,
            "end_logit": 5.37109375,
            "text": ".",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": 8.78125,
            "end_logit": -6.1015625,
            "text": "The main component of Lewy bodies",
            "probability": 1.0371208190917969e-05
        },
        {
            "start_logit": 8.78125,
            "end_logit": -6.43359375,
            "text": "The main component of",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": 8.78125,
            "end_logit": -6.5625,
            "text": "The main component of Lewy bodies is alpha",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": 8.78125,
            "end_logit": -6.76171875,
            "text": "The main",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": -5.26953125,
            "end_logit": 5.37109375,
            "text": "Lewy bodies is alpha-synuclein.",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 5.37109375,
            "text": "main component of Lewy bodies is alpha-synuclein.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.421875,
            "end_logit": 5.37109375,
            "text": "alpha-synuclein.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 5.37109375,
            "text": "of Lewy bodies is alpha-synuclein.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.26953125,
            "end_logit": -3.515625,
            "text": "Lewy bodies is",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -3.515625,
            "text": "main component of Lewy bodies is",
            "probability": 0.0
        },
        {
            "start_logit": -6.9140625,
            "end_logit": -3.515625,
            "text": "of Lewy bodies is",
            "probability": 0.0
        },
        {
            "start_logit": -5.26953125,
            "end_logit": -5.23046875,
            "text": "Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -5.26953125,
            "end_logit": -5.8984375,
            "text": "Lewy bodies is alpha-",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_10": [
        {
            "start_logit": 8.859375,
            "end_logit": 5.94140625,
            "text": "The main component of Lewy bodies is alpha-synuclein (AS).",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.859375,
            "end_logit": -1.5126953125,
            "text": "The",
            "probability": 0.0005812644958496094
        },
        {
            "start_logit": 8.859375,
            "end_logit": -2.220703125,
            "text": "The main component of Lewy bodies is alpha-synuclein (AS)",
            "probability": 0.0002865791320800781
        },
        {
            "start_logit": 8.859375,
            "end_logit": -4.359375,
            "text": "The main component of Lewy bodies is",
            "probability": 3.36766242980957e-05
        },
        {
            "start_logit": 8.859375,
            "end_logit": -4.74609375,
            "text": "The main component of Lewy bodies is alpha-synuclein (AS",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": -2.0078125,
            "end_logit": 5.94140625,
            "text": ".",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": 8.859375,
            "end_logit": -5.1953125,
            "text": "The main component of Lewy bodies is alpha-synuclein (",
            "probability": 1.4603137969970703e-05
        },
        {
            "start_logit": 8.859375,
            "end_logit": -5.5546875,
            "text": "The main component",
            "probability": 1.0192394256591797e-05
        },
        {
            "start_logit": 8.859375,
            "end_logit": -5.67578125,
            "text": "The main component of Lewy bodies is alpha-synuclein",
            "probability": 9.059906005859375e-06
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.15234375,
            "text": "The main component of Lewy bodies",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.296875,
            "text": "The main component of Lewy bodies is alpha-",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.46484375,
            "text": "The main component of",
            "probability": 4.112720489501953e-06
        },
        {
            "start_logit": 8.859375,
            "end_logit": -6.69921875,
            "text": "The main",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": -4.84375,
            "end_logit": 5.94140625,
            "text": "alpha-synuclein (AS).",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -5.1015625,
            "end_logit": 5.94140625,
            "text": "Lewy bodies is alpha-synuclein (AS).",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.3671875,
            "end_logit": 5.94140625,
            "text": "main component of Lewy bodies is alpha-synuclein (AS).",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.796875,
            "end_logit": 5.94140625,
            "text": "is alpha-synuclein (AS).",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 5.94140625,
            "text": "of Lewy bodies is alpha-synuclein (AS).",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 5.94140625,
            "text": "bodies is alpha-synuclein (AS).",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.84375,
            "end_logit": -2.220703125,
            "text": "alpha-synuclein (AS)",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_11": [
        {
            "start_logit": 4.640625,
            "end_logit": 5.203125,
            "text": "Lewy bodies.",
            "probability": 0.958984375
        },
        {
            "start_logit": 1.2685546875,
            "end_logit": 5.203125,
            "text": "Amyloid precursor protein (APP) is involved in the accumulation of alpha-synuclein, the main component of Lewy bodies.",
            "probability": 0.032958984375
        },
        {
            "start_logit": -1.138671875,
            "end_logit": 5.203125,
            "text": ".",
            "probability": 0.002956390380859375
        },
        {
            "start_logit": 1.2685546875,
            "end_logit": 2.53125,
            "text": "Amyloid precursor protein (APP) is involved in the accumulation of alpha-synuclein,",
            "probability": 0.002277374267578125
        },
        {
            "start_logit": -1.8017578125,
            "end_logit": 5.203125,
            "text": "the main component of Lewy bodies.",
            "probability": 0.0015287399291992188
        },
        {
            "start_logit": -3.02734375,
            "end_logit": 5.203125,
            "text": "alpha-synuclein, the main component of Lewy bodies.",
            "probability": 0.0004482269287109375
        },
        {
            "start_logit": -3.685546875,
            "end_logit": 5.203125,
            "text": "of Lewy bodies.",
            "probability": 0.00023162364959716797
        },
        {
            "start_logit": -4.109375,
            "end_logit": 5.203125,
            "text": "accumulation of alpha-synuclein, the main component of Lewy bodies.",
            "probability": 0.0001518726348876953
        },
        {
            "start_logit": -4.20703125,
            "end_logit": 5.203125,
            "text": ", the main component of Lewy bodies.",
            "probability": 0.00013828277587890625
        },
        {
            "start_logit": -4.2265625,
            "end_logit": 5.203125,
            "text": "of alpha-synuclein, the main component of Lewy bodies.",
            "probability": 0.00013506412506103516
        },
        {
            "start_logit": -4.265625,
            "end_logit": 5.203125,
            "text": "main component of Lewy bodies.",
            "probability": 0.00012993812561035156
        },
        {
            "start_logit": -4.57421875,
            "end_logit": 5.203125,
            "text": "bodies.",
            "probability": 9.506940841674805e-05
        },
        {
            "start_logit": -5.3984375,
            "end_logit": 5.203125,
            "text": "the accumulation of alpha-synuclein, the main component of Lewy bodies.",
            "probability": 4.190206527709961e-05
        },
        {
            "start_logit": -5.45703125,
            "end_logit": 5.203125,
            "text": "-synuclein, the main component of Lewy bodies.",
            "probability": 3.9637088775634766e-05
        },
        {
            "start_logit": -3.02734375,
            "end_logit": 2.53125,
            "text": "alpha-synuclein,",
            "probability": 3.0875205993652344e-05
        },
        {
            "start_logit": -5.890625,
            "end_logit": 5.203125,
            "text": "in the accumulation of alpha-synuclein, the main component of Lewy bodies.",
            "probability": 2.562999725341797e-05
        },
        {
            "start_logit": 4.640625,
            "end_logit": -5.34375,
            "text": "Lewy",
            "probability": 2.5212764739990234e-05
        },
        {
            "start_logit": -5.94921875,
            "end_logit": 5.203125,
            "text": "precursor protein (APP) is involved in the accumulation of alpha-synuclein, the main component of Lewy bodies.",
            "probability": 2.4080276489257812e-05
        },
        {
            "start_logit": -6.3671875,
            "end_logit": 5.203125,
            "text": "synuclein, the main component of Lewy bodies.",
            "probability": 1.5914440155029297e-05
        },
        {
            "start_logit": -4.109375,
            "end_logit": 2.53125,
            "text": "accumulation of alpha-synuclein,",
            "probability": 1.049041748046875e-05
        }
    ],
    "550c3d45a103b78016000008_12": [
        {
            "start_logit": 3.59765625,
            "end_logit": 5.2109375,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration.",
            "probability": 0.5146484375
        },
        {
            "start_logit": 3.59765625,
            "end_logit": 4.6875,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.302490234375
        },
        {
            "start_logit": 2.041015625,
            "end_logit": 5.2109375,
            "text": "Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration.",
            "probability": 0.10784912109375
        },
        {
            "start_logit": 2.041015625,
            "end_logit": 4.6875,
            "text": "Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.06390380859375
        },
        {
            "start_logit": -0.91748046875,
            "end_logit": 5.2109375,
            "text": ".",
            "probability": 0.00560760498046875
        },
        {
            "start_logit": 3.59765625,
            "end_logit": -0.5986328125,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques",
            "probability": 0.0015392303466796875
        },
        {
            "start_logit": -2.24609375,
            "end_logit": 5.2109375,
            "text": "a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration.",
            "probability": 0.0014848709106445312
        },
        {
            "start_logit": -2.24609375,
            "end_logit": 4.6875,
            "text": "a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.0008797645568847656
        },
        {
            "start_logit": 2.041015625,
            "end_logit": -0.5986328125,
            "text": "Lewy bodies in synucleinopathies and senile plaques",
            "probability": 0.0003235340118408203
        },
        {
            "start_logit": -3.841796875,
            "end_logit": 5.2109375,
            "text": ", is centrally involved in neurodegeneration.",
            "probability": 0.0003006458282470703
        },
        {
            "start_logit": -3.841796875,
            "end_logit": 4.6875,
            "text": ",",
            "probability": 0.0001780986785888672
        },
        {
            "start_logit": -4.6328125,
            "end_logit": 5.2109375,
            "text": "senile plaques in Alzheimer disease, is centrally involved in neurodegeneration.",
            "probability": 0.00013649463653564453
        },
        {
            "start_logit": -4.75,
            "end_logit": 5.2109375,
            "text": "of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration.",
            "probability": 0.0001214742660522461
        },
        {
            "start_logit": -4.765625,
            "end_logit": 5.2109375,
            "text": "in Alzheimer disease, is centrally involved in neurodegeneration.",
            "probability": 0.0001195669174194336
        },
        {
            "start_logit": -4.86328125,
            "end_logit": 5.2109375,
            "text": "in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration.",
            "probability": 0.00010800361633300781
        },
        {
            "start_logit": -5.08984375,
            "end_logit": 5.2109375,
            "text": "synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration.",
            "probability": 8.678436279296875e-05
        },
        {
            "start_logit": -4.6328125,
            "end_logit": 4.6875,
            "text": "senile plaques in Alzheimer disease,",
            "probability": 8.088350296020508e-05
        },
        {
            "start_logit": -4.75,
            "end_logit": 4.6875,
            "text": "of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 7.194280624389648e-05
        },
        {
            "start_logit": 3.59765625,
            "end_logit": -3.67578125,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in",
            "probability": 7.086992263793945e-05
        },
        {
            "start_logit": -4.765625,
            "end_logit": 4.6875,
            "text": "in Alzheimer disease,",
            "probability": 7.086992263793945e-05
        }
    ],
    "550c3d45a103b78016000008_13": [
        {
            "start_logit": 8.78125,
            "end_logit": 5.37109375,
            "text": "The main component of Lewy bodies is alpha-synuclein.",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.78125,
            "end_logit": -1.7509765625,
            "text": "The",
            "probability": 0.0008039474487304688
        },
        {
            "start_logit": 8.78125,
            "end_logit": -3.515625,
            "text": "The main component of Lewy bodies is",
            "probability": 0.00013756752014160156
        },
        {
            "start_logit": 8.78125,
            "end_logit": -5.23046875,
            "text": "The main component of Lewy bodies is alpha-synuclein",
            "probability": 2.467632293701172e-05
        },
        {
            "start_logit": 8.78125,
            "end_logit": -5.33984375,
            "text": "The main component",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 8.78125,
            "end_logit": -5.8984375,
            "text": "The main component of Lewy bodies is alpha-",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": -2.646484375,
            "end_logit": 5.37109375,
            "text": ".",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": 8.78125,
            "end_logit": -6.1015625,
            "text": "The main component of Lewy bodies",
            "probability": 1.0371208190917969e-05
        },
        {
            "start_logit": 8.78125,
            "end_logit": -6.43359375,
            "text": "The main component of",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": 8.78125,
            "end_logit": -6.5625,
            "text": "The main component of Lewy bodies is alpha",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": 8.78125,
            "end_logit": -6.76171875,
            "text": "The main",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": -5.26953125,
            "end_logit": 5.37109375,
            "text": "Lewy bodies is alpha-synuclein.",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 5.37109375,
            "text": "main component of Lewy bodies is alpha-synuclein.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.421875,
            "end_logit": 5.37109375,
            "text": "alpha-synuclein.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 5.37109375,
            "text": "of Lewy bodies is alpha-synuclein.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.26953125,
            "end_logit": -3.515625,
            "text": "Lewy bodies is",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -3.515625,
            "text": "main component of Lewy bodies is",
            "probability": 0.0
        },
        {
            "start_logit": -6.9140625,
            "end_logit": -3.515625,
            "text": "of Lewy bodies is",
            "probability": 0.0
        },
        {
            "start_logit": -5.26953125,
            "end_logit": -5.23046875,
            "text": "Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -5.26953125,
            "end_logit": -5.8984375,
            "text": "Lewy bodies is alpha-",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_14": [
        {
            "start_logit": 3.708984375,
            "end_logit": 6.0859375,
            "text": "alpha-synuclein.",
            "probability": 0.59814453125
        },
        {
            "start_logit": 2.841796875,
            "end_logit": 6.0859375,
            "text": "the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.251220703125
        },
        {
            "start_logit": 2.076171875,
            "end_logit": 6.0859375,
            "text": "In Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.11688232421875
        },
        {
            "start_logit": 0.002895355224609375,
            "end_logit": 6.0859375,
            "text": "inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.01468658447265625
        },
        {
            "start_logit": -0.904296875,
            "end_logit": 6.0859375,
            "text": ".",
            "probability": 0.005908966064453125
        },
        {
            "start_logit": -1.4033203125,
            "end_logit": 6.0859375,
            "text": "Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0035991668701171875
        },
        {
            "start_logit": -1.5361328125,
            "end_logit": 6.0859375,
            "text": "is alpha-synuclein.",
            "probability": 0.00315093994140625
        },
        {
            "start_logit": -2.25390625,
            "end_logit": 6.0859375,
            "text": "as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0015354156494140625
        },
        {
            "start_logit": -2.33984375,
            "end_logit": 6.0859375,
            "text": "Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0014085769653320312
        },
        {
            "start_logit": -2.958984375,
            "end_logit": 6.0859375,
            "text": ", the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0007576942443847656
        },
        {
            "start_logit": -3.05859375,
            "end_logit": 6.0859375,
            "text": "referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0006866455078125
        },
        {
            "start_logit": 3.708984375,
            "end_logit": -0.82177734375,
            "text": "alpha-synuclein",
            "probability": 0.0005965232849121094
        },
        {
            "start_logit": 2.841796875,
            "end_logit": -0.82177734375,
            "text": "the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.00025081634521484375
        },
        {
            "start_logit": -4.15625,
            "end_logit": 6.0859375,
            "text": "bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.00022912025451660156
        },
        {
            "start_logit": -4.39453125,
            "end_logit": 6.0859375,
            "text": "to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.00017976760864257812
        },
        {
            "start_logit": -4.609375,
            "end_logit": 6.0859375,
            "text": "are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0001456737518310547
        },
        {
            "start_logit": 2.076171875,
            "end_logit": -0.82177734375,
            "text": "In Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.00011616945266723633
        },
        {
            "start_logit": 2.841796875,
            "end_logit": -2.01171875,
            "text": "the inclusion bodies are referred to as Lewy bodies and",
            "probability": 7.617473602294922e-05
        },
        {
            "start_logit": -5.75,
            "end_logit": 6.0859375,
            "text": "their main component is alpha-synuclein.",
            "probability": 4.655122756958008e-05
        },
        {
            "start_logit": -5.91015625,
            "end_logit": 6.0859375,
            "text": "bodies and their main component is alpha-synuclein.",
            "probability": 3.9517879486083984e-05
        }
    ],
    "550c3d45a103b78016000008_15": [
        {
            "start_logit": 5.93359375,
            "end_logit": 5.6796875,
            "text": "alpha-Synuclein, the main component of LBs,",
            "probability": 0.99609375
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -1.193359375,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140),",
            "probability": 0.00103759765625
        },
        {
            "start_logit": -1.12890625,
            "end_logit": 5.66796875,
            "text": ".",
            "probability": 0.00084686279296875
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -1.7451171875,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140)",
            "probability": 0.0005955696105957031
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -3.443359375,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two",
            "probability": 0.0001093745231628418
        },
        {
            "start_logit": -3.375,
            "end_logit": 5.6796875,
            "text": "LBs,",
            "probability": 9.065866470336914e-05
        },
        {
            "start_logit": -3.375,
            "end_logit": 5.66796875,
            "text": "LBs, is expressed as two main isoforms (112 and 140), but little is known about their differential expression in the brain.",
            "probability": 8.994340896606445e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -3.73046875,
            "text": "alpha-Synuclein,",
            "probability": 8.189678192138672e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -3.904296875,
            "text": "alpha-Synuclein, the main component of LBs, is",
            "probability": 6.890296936035156e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -3.953125,
            "text": "alpha-Synuclein, the main component",
            "probability": 6.580352783203125e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -3.984375,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as",
            "probability": 6.377696990966797e-05
        },
        {
            "start_logit": -3.82421875,
            "end_logit": 5.6796875,
            "text": "the main component of LBs,",
            "probability": 5.805492401123047e-05
        },
        {
            "start_logit": -3.892578125,
            "end_logit": 5.6796875,
            "text": ",",
            "probability": 5.412101745605469e-05
        },
        {
            "start_logit": -3.892578125,
            "end_logit": 5.66796875,
            "text": ", is expressed as two main isoforms (112 and 140), but little is known about their differential expression in the brain.",
            "probability": 5.328655242919922e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -4.3203125,
            "text": "alpha-Synuclein",
            "probability": 4.5239925384521484e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -4.390625,
            "text": "alpha",
            "probability": 4.2498111724853516e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -4.4140625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main",
            "probability": 4.118680953979492e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -4.7578125,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms",
            "probability": 2.9206275939941406e-05
        },
        {
            "start_logit": 5.93359375,
            "end_logit": -4.859375,
            "text": "alpha-Synuclein, the main component of LBs, is expressed",
            "probability": 2.658367156982422e-05
        },
        {
            "start_logit": -4.765625,
            "end_logit": 5.6796875,
            "text": "of LBs,",
            "probability": 2.2590160369873047e-05
        }
    ],
    "550c3d45a103b78016000008_16": [
        {
            "start_logit": 1.0595703125,
            "end_logit": 3.3671875,
            "text": "Lewy bodies and dystrophic neurites; alpha-synuclein also accumulates in the cytoplasm of glial cells",
            "probability": 0.9404296875
        },
        {
            "start_logit": -2.8125,
            "end_logit": 3.3671875,
            "text": "dystrophic neurites; alpha-synuclein also accumulates in the cytoplasm of glial cells",
            "probability": 0.01959228515625
        },
        {
            "start_logit": -3.091796875,
            "end_logit": 3.3671875,
            "text": "glial cells",
            "probability": 0.0148468017578125
        },
        {
            "start_logit": -3.51953125,
            "end_logit": 3.3671875,
            "text": ", alpha-synuclein is the main component of Lewy bodies and dystrophic neurites; alpha-synuclein also accumulates in the cytoplasm of glial cells",
            "probability": 0.00966644287109375
        },
        {
            "start_logit": -4.20703125,
            "end_logit": 3.3671875,
            "text": "alpha-synuclein is the main component of Lewy bodies and dystrophic neurites; alpha-synuclein also accumulates in the cytoplasm of glial cells",
            "probability": 0.004856109619140625
        },
        {
            "start_logit": -5.30078125,
            "end_logit": 3.3671875,
            "text": "Lewy body dementia, alpha-synuclein is the main component of Lewy bodies and dystrophic neurites; alpha-synuclein also accumulates in the cytoplasm of glial cells",
            "probability": 0.0016279220581054688
        },
        {
            "start_logit": -5.37109375,
            "end_logit": 3.3671875,
            "text": "of glial cells",
            "probability": 0.0015163421630859375
        },
        {
            "start_logit": -5.53125,
            "end_logit": 3.3671875,
            "text": "cells",
            "probability": 0.0012922286987304688
        },
        {
            "start_logit": -5.6953125,
            "end_logit": 3.3671875,
            "text": "cytoplasm of glial cells",
            "probability": 0.0010967254638671875
        },
        {
            "start_logit": -5.73828125,
            "end_logit": 3.3671875,
            "text": "of Lewy bodies and dystrophic neurites; alpha-synuclein also accumulates in the cytoplasm of glial cells",
            "probability": 0.0010509490966796875
        },
        {
            "start_logit": -5.83984375,
            "end_logit": 3.3671875,
            "text": "neurites; alpha-synuclein also accumulates in the cytoplasm of glial cells",
            "probability": 0.0009489059448242188
        },
        {
            "start_logit": 1.0595703125,
            "end_logit": -3.91796875,
            "text": "Lewy bodies and dystrophic neurites",
            "probability": 0.000644683837890625
        },
        {
            "start_logit": -6.23828125,
            "end_logit": 3.3671875,
            "text": "and dystrophic neurites; alpha-synuclein also accumulates in the cytoplasm of glial cells",
            "probability": 0.000637054443359375
        },
        {
            "start_logit": -6.26171875,
            "end_logit": 3.3671875,
            "text": "bodies and dystrophic neurites; alpha-synuclein also accumulates in the cytoplasm of glial cells",
            "probability": 0.0006222724914550781
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 3.3671875,
            "text": "in the cytoplasm of glial cells",
            "probability": 0.0005688667297363281
        },
        {
            "start_logit": -6.37109375,
            "end_logit": 3.3671875,
            "text": "the cytoplasm of glial cells",
            "probability": 0.0005578994750976562
        },
        {
            "start_logit": 1.0595703125,
            "end_logit": -5.203125,
            "text": "Lewy bodies and dystrophic neurites;",
            "probability": 0.00017833709716796875
        },
        {
            "start_logit": 1.0595703125,
            "end_logit": -6.66015625,
            "text": "Lewy bodies and dystrophic neurites; alpha-synuclein also",
            "probability": 4.1365623474121094e-05
        },
        {
            "start_logit": 1.0595703125,
            "end_logit": -6.96875,
            "text": "Lewy bodies",
            "probability": 3.0517578125e-05
        },
        {
            "start_logit": 1.0595703125,
            "end_logit": -7.109375,
            "text": "Lewy bodies and dystrophic neurites; alpha-synuclein",
            "probability": 2.6524066925048828e-05
        }
    ],
    "550c3d45a103b78016000008_17": [
        {
            "start_logit": 2.5078125,
            "end_logit": -2.966796875,
            "text": "the inclusion bodies are referred to as Lewy bodies and",
            "probability": 0.437255859375
        },
        {
            "start_logit": 1.3427734375,
            "end_logit": -2.966796875,
            "text": "inclusion bodies are referred to as Lewy bodies and",
            "probability": 0.136474609375
        },
        {
            "start_logit": 1.056640625,
            "end_logit": -2.966796875,
            "text": "In Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and",
            "probability": 0.1024169921875
        },
        {
            "start_logit": 2.5078125,
            "end_logit": -4.97265625,
            "text": "the inclusion bodies are referred to",
            "probability": 0.058807373046875
        },
        {
            "start_logit": 2.5078125,
            "end_logit": -5.33984375,
            "text": "the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.040740966796875
        },
        {
            "start_logit": -0.44921875,
            "end_logit": -2.966796875,
            "text": "Lewy bodies and",
            "probability": 0.0227203369140625
        },
        {
            "start_logit": 2.5078125,
            "end_logit": -5.98828125,
            "text": "the inclusion bodies are referred to as Lewy bodies and their",
            "probability": 0.0213165283203125
        },
        {
            "start_logit": 2.5078125,
            "end_logit": -6.0390625,
            "text": "the inclusion bodies are referred to as Lewy bodies",
            "probability": 0.0202484130859375
        },
        {
            "start_logit": 2.5078125,
            "end_logit": -6.10546875,
            "text": "the",
            "probability": 0.018951416015625
        },
        {
            "start_logit": 1.3427734375,
            "end_logit": -4.97265625,
            "text": "inclusion bodies are referred to",
            "probability": 0.0183563232421875
        },
        {
            "start_logit": 2.5078125,
            "end_logit": -6.1953125,
            "text": "the inclusion bodies are referred",
            "probability": 0.0173187255859375
        },
        {
            "start_logit": 2.5078125,
            "end_logit": -6.25,
            "text": "the inclusion bodies are referred to as",
            "probability": 0.0164031982421875
        },
        {
            "start_logit": 2.5078125,
            "end_logit": -6.38671875,
            "text": "the inclusion bodies are referred to as Lewy bodies and their main",
            "probability": 0.01430511474609375
        },
        {
            "start_logit": 1.056640625,
            "end_logit": -4.97265625,
            "text": "In Parkinson's disease, the inclusion bodies are referred to",
            "probability": 0.01378631591796875
        },
        {
            "start_logit": 1.3427734375,
            "end_logit": -5.33984375,
            "text": "inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.012725830078125
        },
        {
            "start_logit": 2.5078125,
            "end_logit": -6.68359375,
            "text": "the inclusion bodies are referred to as Lewy",
            "probability": 0.01062774658203125
        },
        {
            "start_logit": -1.27734375,
            "end_logit": -2.966796875,
            "text": "as Lewy bodies and",
            "probability": 0.00994873046875
        },
        {
            "start_logit": 2.5078125,
            "end_logit": -6.78515625,
            "text": "the inclusion bodies are referred to as Lewy bodies and their main component",
            "probability": 0.0095977783203125
        },
        {
            "start_logit": 1.056640625,
            "end_logit": -5.33984375,
            "text": "In Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0095672607421875
        },
        {
            "start_logit": 2.5078125,
            "end_logit": -6.8984375,
            "text": "the inclusion bodies are",
            "probability": 0.008575439453125
        }
    ],
    "550c3d45a103b78016000008_18": [
        {
            "start_logit": 7.89453125,
            "end_logit": -2.634765625,
            "text": "The",
            "probability": 0.5576171875
        },
        {
            "start_logit": 7.89453125,
            "end_logit": -4.39453125,
            "text": "The main component of Lewy bodies is",
            "probability": 0.09613037109375
        },
        {
            "start_logit": 7.89453125,
            "end_logit": -4.546875,
            "text": "The main component of Lewy bodies is alpha-synuclein (AS)",
            "probability": 0.08258056640625
        },
        {
            "start_logit": 7.89453125,
            "end_logit": -4.71484375,
            "text": "The main component of Lewy bodies is alpha-synuclein (AS",
            "probability": 0.06976318359375
        },
        {
            "start_logit": 7.89453125,
            "end_logit": -4.83203125,
            "text": "The main component of Lewy bodies is alpha-synuclein",
            "probability": 0.062103271484375
        },
        {
            "start_logit": 7.89453125,
            "end_logit": -5.3828125,
            "text": "The main component of Lewy bodies is alpha-synuclein (",
            "probability": 0.0357666015625
        },
        {
            "start_logit": 7.89453125,
            "end_logit": -5.90625,
            "text": "The main component",
            "probability": 0.021209716796875
        },
        {
            "start_logit": 7.89453125,
            "end_logit": -6.01171875,
            "text": "The main component of Lewy bodies is alpha-",
            "probability": 0.019073486328125
        },
        {
            "start_logit": 7.89453125,
            "end_logit": -6.2734375,
            "text": "The main component of Lewy bodies",
            "probability": 0.01468658447265625
        },
        {
            "start_logit": 7.89453125,
            "end_logit": -6.3828125,
            "text": "The main component of Lewy bodies is alpha",
            "probability": 0.0131683349609375
        },
        {
            "start_logit": 7.89453125,
            "end_logit": -6.5546875,
            "text": "The main component of",
            "probability": 0.01108551025390625
        },
        {
            "start_logit": 7.89453125,
            "end_logit": -6.57421875,
            "text": "The main",
            "probability": 0.0108795166015625
        },
        {
            "start_logit": 7.89453125,
            "end_logit": -7.1796875,
            "text": "The main component of Lewy",
            "probability": 0.0059356689453125
        },
        {
            "start_logit": -6.546875,
            "end_logit": -4.39453125,
            "text": "Lewy bodies is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.546875,
            "end_logit": -4.546875,
            "text": "Lewy bodies is alpha-synuclein (AS)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.546875,
            "end_logit": -4.71484375,
            "text": "Lewy bodies is alpha-synuclein (AS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.546875,
            "end_logit": -4.83203125,
            "text": "Lewy bodies is alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.83984375,
            "end_logit": -4.546875,
            "text": "alpha-synuclein (AS)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.078125,
            "end_logit": -4.39453125,
            "text": "main component of Lewy bodies is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.83984375,
            "end_logit": -4.71484375,
            "text": "alpha-synuclein (AS",
            "probability": 5.960464477539063e-08
        }
    ],
    "550c3d45a103b78016000008_19": [
        {
            "start_logit": 4.53125,
            "end_logit": 4.4140625,
            "text": "alpha-Synuclein, the main component of LBs,",
            "probability": 0.9970703125
        },
        {
            "start_logit": 4.53125,
            "end_logit": -2.994140625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140)",
            "probability": 0.0006055831909179688
        },
        {
            "start_logit": -3.931640625,
            "end_logit": 4.4140625,
            "text": "LBs,",
            "probability": 0.0002110004425048828
        },
        {
            "start_logit": 4.53125,
            "end_logit": -4.1015625,
            "text": "alpha-Synuclein,",
            "probability": 0.0001996755599975586
        },
        {
            "start_logit": 4.53125,
            "end_logit": -4.18359375,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two",
            "probability": 0.00018465518951416016
        },
        {
            "start_logit": 4.53125,
            "end_logit": -4.28515625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140),",
            "probability": 0.00016558170318603516
        },
        {
            "start_logit": 4.53125,
            "end_logit": -4.29296875,
            "text": "alpha-Synuclein",
            "probability": 0.00016558170318603516
        },
        {
            "start_logit": 4.53125,
            "end_logit": -4.296875,
            "text": "alpha-Synuclein, the main component of LBs, is",
            "probability": 0.00016427040100097656
        },
        {
            "start_logit": 4.53125,
            "end_logit": -4.6015625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as",
            "probability": 0.00012111663818359375
        },
        {
            "start_logit": 4.53125,
            "end_logit": -4.7109375,
            "text": "alpha-Synuclein, the main component",
            "probability": 0.00010859966278076172
        },
        {
            "start_logit": 4.53125,
            "end_logit": -4.765625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main",
            "probability": 0.00010281801223754883
        },
        {
            "start_logit": 4.53125,
            "end_logit": -5.16796875,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms",
            "probability": 6.902217864990234e-05
        },
        {
            "start_logit": 4.53125,
            "end_logit": -5.18359375,
            "text": "alpha",
            "probability": 6.794929504394531e-05
        },
        {
            "start_logit": 4.53125,
            "end_logit": -5.22265625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed",
            "probability": 6.4849853515625e-05
        },
        {
            "start_logit": 4.53125,
            "end_logit": -5.30078125,
            "text": "alpha-Synuclein, the main",
            "probability": 5.996227264404297e-05
        },
        {
            "start_logit": -5.25390625,
            "end_logit": 4.4140625,
            "text": ",",
            "probability": 5.632638931274414e-05
        },
        {
            "start_logit": -5.39453125,
            "end_logit": 4.4140625,
            "text": "of LBs,",
            "probability": 4.8995018005371094e-05
        },
        {
            "start_logit": -5.41796875,
            "end_logit": 4.4140625,
            "text": "the main component of LBs,",
            "probability": 4.744529724121094e-05
        },
        {
            "start_logit": 4.53125,
            "end_logit": -5.640625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and",
            "probability": 4.285573959350586e-05
        },
        {
            "start_logit": 4.53125,
            "end_logit": -5.68359375,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112",
            "probability": 4.124641418457031e-05
        }
    ],
    "550c3d45a103b78016000008_20": [
        {
            "start_logit": 0.55224609375,
            "end_logit": 6.2890625,
            "text": "two Lewy body protein components that may",
            "probability": 0.73046875
        },
        {
            "start_logit": -1.0791015625,
            "end_logit": 6.2890625,
            "text": "alpha-Synuclein and ubiquitin are two Lewy body protein components that may",
            "probability": 0.143310546875
        },
        {
            "start_logit": -1.666015625,
            "end_logit": 6.2890625,
            "text": "Lewy body protein components that may",
            "probability": 0.07977294921875
        },
        {
            "start_logit": -2.435546875,
            "end_logit": 6.2890625,
            "text": "may",
            "probability": 0.036865234375
        },
        {
            "start_logit": -5.28515625,
            "end_logit": 6.2890625,
            "text": "that may",
            "probability": 0.002132415771484375
        },
        {
            "start_logit": -5.609375,
            "end_logit": 6.2890625,
            "text": "-Synuclein and ubiquitin are two Lewy body protein components that may",
            "probability": 0.0015420913696289062
        },
        {
            "start_logit": -5.77734375,
            "end_logit": 6.2890625,
            "text": "and ubiquitin are two Lewy body protein components that may",
            "probability": 0.0013036727905273438
        },
        {
            "start_logit": -5.890625,
            "end_logit": 6.2890625,
            "text": "components that may",
            "probability": 0.0011644363403320312
        },
        {
            "start_logit": -6.046875,
            "end_logit": 6.2890625,
            "text": "are two Lewy body protein components that may",
            "probability": 0.000995635986328125
        },
        {
            "start_logit": -6.08984375,
            "end_logit": 6.2890625,
            "text": "Synuclein and ubiquitin are two Lewy body protein components that may",
            "probability": 0.0009541511535644531
        },
        {
            "start_logit": -6.59765625,
            "end_logit": 6.2890625,
            "text": "protein components that may",
            "probability": 0.0005741119384765625
        },
        {
            "start_logit": -6.65625,
            "end_logit": 6.2890625,
            "text": "body protein components that may",
            "probability": 0.00054168701171875
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 6.2890625,
            "text": "ubiquitin are two Lewy body protein components that may",
            "probability": 0.0004665851593017578
        },
        {
            "start_logit": 0.55224609375,
            "end_logit": -2.3671875,
            "text": "two Lewy body protein components that may play",
            "probability": 0.0001270771026611328
        },
        {
            "start_logit": -1.0791015625,
            "end_logit": -2.3671875,
            "text": "alpha-Synuclein and ubiquitin are two Lewy body protein components that may play",
            "probability": 2.5033950805664062e-05
        },
        {
            "start_logit": 0.55224609375,
            "end_logit": -4.1796875,
            "text": "two",
            "probability": 2.0742416381835938e-05
        },
        {
            "start_logit": 0.55224609375,
            "end_logit": -4.31640625,
            "text": "two Lewy body protein components that",
            "probability": 1.817941665649414e-05
        },
        {
            "start_logit": -1.666015625,
            "end_logit": -2.3671875,
            "text": "Lewy body protein components that may play",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": 0.55224609375,
            "end_logit": -4.75390625,
            "text": "two Lewy body protein components that may play antagonistic",
            "probability": 1.1622905731201172e-05
        },
        {
            "start_logit": 0.55224609375,
            "end_logit": -4.96484375,
            "text": "two Lewy body protein components that may play antagonistic roles",
            "probability": 9.47713851928711e-06
        }
    ],
    "550c3d45a103b78016000008_21": [
        {
            "start_logit": 1.1640625,
            "end_logit": -4.26953125,
            "text": "Lewy neurites",
            "probability": 0.30810546875
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -2.712890625,
            "text": "Recently",
            "probability": 0.301513671875
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -4.26953125,
            "text": "Recently, the presynaptic protein alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites",
            "probability": 0.0635986328125
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -4.30859375,
            "text": "Recently, the presynaptic protein alpha-synuclein was shown",
            "probability": 0.0611572265625
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -4.39453125,
            "text": "Recently, the presynaptic protein alpha-synuclein was shown to be a major",
            "probability": 0.056121826171875
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -5.1015625,
            "text": "Recently,",
            "probability": 0.0276641845703125
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -5.18359375,
            "text": "Recently, the presynaptic protein alpha-synuclein was shown to be a major component",
            "probability": 0.025482177734375
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -5.26953125,
            "text": "Recently, the presynaptic protein alpha-synuclein was",
            "probability": 0.0233917236328125
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -5.28125,
            "text": "Recently, the presynaptic protein alpha-synuclein was shown to",
            "probability": 0.023101806640625
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -5.328125,
            "text": "Recently, the presynaptic protein alpha-synuclein was shown to be a",
            "probability": 0.0220489501953125
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -5.35546875,
            "text": "Recently, the presynaptic",
            "probability": 0.021453857421875
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -5.62890625,
            "text": "Recently, the presynaptic protein alpha-synuclein was shown to be",
            "probability": 0.016326904296875
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -6.28125,
            "text": "Recently, the presynaptic protein",
            "probability": 0.00850677490234375
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -6.41796875,
            "text": "Recently, the presynaptic protein alpha-synuclein",
            "probability": 0.007415771484375
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -6.4375,
            "text": "Recently, the presynaptic protein alpha",
            "probability": 0.00727081298828125
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -6.5859375,
            "text": "Recently, the presynaptic protein alpha-synuclein was shown to be a major component of",
            "probability": 0.0062713623046875
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -6.609375,
            "text": "Recently, the presynaptic protein alpha-",
            "probability": 0.00612640380859375
        },
        {
            "start_logit": -2.984375,
            "end_logit": -4.26953125,
            "text": ", the presynaptic protein alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites",
            "probability": 0.004863739013671875
        },
        {
            "start_logit": -0.4140625,
            "end_logit": -6.84765625,
            "text": "Recently, the",
            "probability": 0.00482940673828125
        },
        {
            "start_logit": -2.984375,
            "end_logit": -4.30859375,
            "text": ", the presynaptic protein alpha-synuclein was shown",
            "probability": 0.00467681884765625
        }
    ],
    "550c3d45a103b78016000008_22": [
        {
            "start_logit": 7.58984375,
            "end_logit": -1.4208984375,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and",
            "probability": 0.72119140625
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -3.603515625,
            "text": "Alpha",
            "probability": 0.08135986328125
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -4.015625,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation is a key event in the pathogenesis of PD",
            "probability": 0.053924560546875
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -5.07421875,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation is",
            "probability": 0.0186920166015625
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -5.2734375,
            "text": "Alpha-synuclein (AS)",
            "probability": 0.01531982421875
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -5.359375,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation is a",
            "probability": 0.01406097412109375
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -5.39453125,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation is a key event in the",
            "probability": 0.013580322265625
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -5.51171875,
            "text": "Alpha-synuclein (AS) is the main component",
            "probability": 0.0120697021484375
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -5.87890625,
            "text": "Alpha-synuclein (AS) is",
            "probability": 0.00836181640625
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -5.8828125,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its",
            "probability": 0.008331298828125
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -5.92578125,
            "text": "Alpha-synuclein (AS) is the main",
            "probability": 0.0079803466796875
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -6.02734375,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies",
            "probability": 0.007205963134765625
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -6.0859375,
            "text": "Alpha-synuclein (AS",
            "probability": 0.006801605224609375
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -6.0859375,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation is a key event in the pathogenesis",
            "probability": 0.006801605224609375
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -6.1484375,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation is a key",
            "probability": 0.00638580322265625
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -6.171875,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation is a key event in the pathogenesis of",
            "probability": 0.0062408447265625
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -6.21875,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation",
            "probability": 0.005954742431640625
        },
        {
            "start_logit": 7.58984375,
            "end_logit": -6.2265625,
            "text": "Alpha-synuclein (",
            "probability": 0.005908966064453125
        },
        {
            "start_logit": -3.828125,
            "end_logit": -1.4208984375,
            "text": "Lewy bodies and",
            "probability": 7.927417755126953e-06
        },
        {
            "start_logit": -6.08203125,
            "end_logit": -1.4208984375,
            "text": "of Lewy bodies and",
            "probability": 8.344650268554688e-07
        }
    ],
    "550c3d45a103b78016000008_23": [
        {
            "start_logit": 4.4921875,
            "end_logit": 4.51171875,
            "text": "alpha-synuclein antiaggregatory agents for dementia with Lewy bodies.",
            "probability": 0.98095703125
        },
        {
            "start_logit": 0.0699462890625,
            "end_logit": 4.51171875,
            "text": "dementia with Lewy bodies.",
            "probability": 0.01183319091796875
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -1.0830078125,
            "text": "alpha-synuclein antiaggregatory agents",
            "probability": 0.0036640167236328125
        },
        {
            "start_logit": -1.8330078125,
            "end_logit": 4.51171875,
            "text": ".",
            "probability": 0.0017652511596679688
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -2.80859375,
            "text": "alpha-synuclein antiaggregatory agents for dementia with Lewy bodies",
            "probability": 0.0006518363952636719
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -3.078125,
            "text": "alpha-synuclein",
            "probability": 0.0004978179931640625
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -3.904296875,
            "text": "alpha-synuclein antiaggregatory",
            "probability": 0.000217437744140625
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -3.998046875,
            "text": "alpha-synuclein anti",
            "probability": 0.00019812583923339844
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -4.46875,
            "text": "alpha-synuclein antiaggreg",
            "probability": 0.0001239776611328125
        },
        {
            "start_logit": -5.09765625,
            "end_logit": 4.51171875,
            "text": "for dementia with Lewy bodies.",
            "probability": 6.73532485961914e-05
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -5.109375,
            "text": "alpha-synuclein antiaggregatory agents for",
            "probability": 6.532669067382812e-05
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -5.2890625,
            "text": "alpha",
            "probability": 5.453824996948242e-05
        },
        {
            "start_logit": -5.50390625,
            "end_logit": 4.51171875,
            "text": "The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies.",
            "probability": 4.488229751586914e-05
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -5.83984375,
            "text": "alpha-",
            "probability": 3.159046173095703e-05
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -6.484375,
            "text": "alpha-synuclein antiaggregatory agents for dementia with Lewy",
            "probability": 1.6510486602783203e-05
        },
        {
            "start_logit": -6.75,
            "end_logit": 4.51171875,
            "text": "of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies.",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": 4.4921875,
            "end_logit": -6.76171875,
            "text": "alpha-synuclein antiaggregatory agents for dementia with",
            "probability": 1.2576580047607422e-05
        },
        {
            "start_logit": -6.84765625,
            "end_logit": 4.51171875,
            "text": "with Lewy bodies.",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 4.51171875,
            "text": "Lewy bodies.",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 4.51171875,
            "text": "aggregatory agents for dementia with Lewy bodies.",
            "probability": 8.344650268554688e-06
        }
    ],
    "5c7aae9dd774d0424000000a_1": [
        {
            "start_logit": 8.265625,
            "end_logit": 6.65234375,
            "text": "activation of type I interferons in response to cytosolic nucleic acid ligands. Recent evidence indicates involvement of the STING pathway in the induction of antitumor immune response.",
            "probability": 0.5
        },
        {
            "start_logit": 8.265625,
            "end_logit": 6.65234375,
            "text": "activation of type I interferons in response to cytosolic nucleic acid ligands.",
            "probability": 0.5
        },
        {
            "start_logit": 8.265625,
            "end_logit": -1.333984375,
            "text": "activation of type I interferons",
            "probability": 0.0001690387725830078
        },
        {
            "start_logit": 8.265625,
            "end_logit": -2.396484375,
            "text": "activation of type I interferons in response to cytosolic nucleic acid ligands. Recent evidence indicates involvement of the STING pathway in the induction of antitumor immune response",
            "probability": 5.841255187988281e-05
        },
        {
            "start_logit": 8.265625,
            "end_logit": -2.591796875,
            "text": "activation",
            "probability": 4.8041343688964844e-05
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -1.333984375,
            "text": "Stimulator of interferon genes (STING) is an adaptor protein that plays an important role in the activation of type I interferons",
            "probability": 3.832578659057617e-05
        },
        {
            "start_logit": -1.30859375,
            "end_logit": 6.65234375,
            "text": ".",
            "probability": 3.457069396972656e-05
        },
        {
            "start_logit": -1.30859375,
            "end_logit": 6.65234375,
            "text": ". Recent evidence indicates involvement of the STING pathway in the induction of antitumor immune response.",
            "probability": 3.457069396972656e-05
        },
        {
            "start_logit": -1.30859375,
            "end_logit": 6.65234375,
            "text": ".",
            "probability": 3.457069396972656e-05
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -2.591796875,
            "text": "Stimulator of interferon genes (STING) is an adaptor protein that plays an important role in the activation",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": -2.693359375,
            "end_logit": 6.65234375,
            "text": "interferons in response to cytosolic nucleic acid ligands. Recent evidence indicates involvement of the STING pathway in the induction of antitumor immune response.",
            "probability": 8.702278137207031e-06
        },
        {
            "start_logit": -2.693359375,
            "end_logit": 6.65234375,
            "text": "interferons in response to cytosolic nucleic acid ligands.",
            "probability": 8.702278137207031e-06
        },
        {
            "start_logit": 8.265625,
            "end_logit": -5.06640625,
            "text": "activation of type I interferons in response to",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": 8.265625,
            "end_logit": -5.12109375,
            "text": "activation of type I interferons in response to cytosolic nucleic acid ligands",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 8.265625,
            "end_logit": -5.421875,
            "text": "activation of type I interferons in response",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": 8.265625,
            "end_logit": -5.48046875,
            "text": "activation of type I interferons in",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -4.1875,
            "text": "Stimulator of interferon genes (STING) is an adaptor protein that",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -4.1484375,
            "end_logit": 6.65234375,
            "text": "the activation of type I interferons in response to cytosolic nucleic acid ligands.",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -4.51953125,
            "text": "Stimulator of interferon genes (STING) is an adaptor protein that plays an important role",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 6.77734375,
            "end_logit": -4.578125,
            "text": "Stimulator",
            "probability": 1.4901161193847656e-06
        }
    ],
    "62005e02c9dfcb9c09000018_1": [
        {
            "start_logit": 9.0546875,
            "end_logit": 8.9921875,
            "text": "MBPpred",
            "probability": 1.0
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -1.830078125,
            "text": "MBP",
            "probability": 1.996755599975586e-05
        },
        {
            "start_logit": -1.7705078125,
            "end_logit": 8.9921875,
            "text": "d",
            "probability": 1.9848346710205078e-05
        },
        {
            "start_logit": -5.4609375,
            "end_logit": 8.9921875,
            "text": "pred",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -6.78125,
            "text": "MBPpred:",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.0859375,
            "text": "MBPpred: Proteome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.0859375,
            "text": "MBPpred: Proteome-wide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.18359375,
            "text": "MBPpre",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.19921875,
            "text": "MBPpred: Proteome-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.23046875,
            "text": "MBPpred: Proteome-wide detection of membrane lipid-",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.25390625,
            "text": "MBPpred: Proteome-wide detection",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.265625,
            "text": "MBPpred: Proteome-wide detection of membrane lipid-binding proteins",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.26953125,
            "text": "MBPpred: Proteome-wide detection of membrane lipid-binding proteins using",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.27734375,
            "text": "MBPpred: Proteome-wide detection of membrane lipid-binding",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.296875,
            "text": "MBPpred: Proteome-wide detection of membrane lipid-binding proteins using profile Hidden Markov Models.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.3046875,
            "text": "MBPpred: Proteome-wide detection of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.0546875,
            "end_logit": -7.3046875,
            "text": "MBPpred: Proteome-wide detection of membrane lipid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.7705078125,
            "end_logit": -6.78125,
            "text": "d:",
            "probability": 0.0
        },
        {
            "start_logit": -1.7705078125,
            "end_logit": -7.0859375,
            "text": "d: Proteome",
            "probability": 0.0
        },
        {
            "start_logit": -1.7705078125,
            "end_logit": -7.0859375,
            "text": "d: Proteome-wide",
            "probability": 0.0
        }
    ],
    "62005e02c9dfcb9c09000018_2": [
        {
            "start_logit": 9.2421875,
            "end_logit": 9.046875,
            "text": "MBPpred",
            "probability": 1.0
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -1.2890625,
            "text": "MBP",
            "probability": 3.272294998168945e-05
        },
        {
            "start_logit": -1.619140625,
            "end_logit": 9.046875,
            "text": "d",
            "probability": 1.9371509552001953e-05
        },
        {
            "start_logit": -4.13671875,
            "end_logit": 9.046875,
            "text": "pred",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -5.546875,
            "text": "MBPpred. The method identifies MBPs that contain one or more of the Membrane Binding Domains (MBDs) that",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.26953125,
            "text": "MBPpred. The method identifies MBPs that contain one or more of the Membrane Binding Domains (MBDs)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.078125,
            "end_logit": 9.046875,
            "text": "called MBPpred",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.30078125,
            "text": "MBPpred.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.3046875,
            "text": "MBPpred. The method identifies MBPs that contain one or more of the Membrane Binding Domains (MBDs) that have",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.42578125,
            "text": "MBPpred. The method identifies MBPs that contain one or more of the Membrane Binding Domains (MBDs) that have been",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.44140625,
            "text": "MBPpred. The method identifies MBPs that contain one or more of the Membrane Binding Domains (MBDs) that have been described",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.5625,
            "text": "MBPpred. The method identifies MBPs that contain one or more of the",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.5703125,
            "text": "MBPpred. The method identifies MBPs that contain one or more of the Membrane Binding Domains (MBDs) that have been described to date",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.69921875,
            "text": "MBPpred. The method identifies MBPs that contain one or more of the Membrane Binding Domains (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.2421875,
            "end_logit": -6.71484375,
            "text": "MBPpred. The method identifies MBPs that contain one or more of the Membrane Binding Domains (MBDs",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 9.046875,
            "text": "profile Hidden Markov Model based method capable of detecting Membrane Binding Proteins (MBPs) from information encoded in their amino acid sequence, called MBPpred",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.619140625,
            "end_logit": -5.546875,
            "text": "d. The method identifies MBPs that contain one or more of the Membrane Binding Domains (MBDs) that",
            "probability": 0.0
        },
        {
            "start_logit": -6.078125,
            "end_logit": -1.2890625,
            "text": "called MBP",
            "probability": 0.0
        },
        {
            "start_logit": -1.619140625,
            "end_logit": -6.26953125,
            "text": "d. The method identifies MBPs that contain one or more of the Membrane Binding Domains (MBDs)",
            "probability": 0.0
        },
        {
            "start_logit": -1.619140625,
            "end_logit": -6.30078125,
            "text": "d.",
            "probability": 0.0
        }
    ],
    "603219c21cb411341a000133_1": [
        {
            "start_logit": 5.35546875,
            "end_logit": 3.189453125,
            "text": "DNA transfer involving extracellular vesicles is still under appreciated.",
            "probability": 0.435791015625
        },
        {
            "start_logit": 5.35546875,
            "end_logit": 3.1875,
            "text": "DNA transfer involving extracellular vesicles is still under appreciated. However, this widespread phenomenon has been observed in the three domains of life.",
            "probability": 0.435791015625
        },
        {
            "start_logit": 5.35546875,
            "end_logit": 1.3076171875,
            "text": "DNA transfer involving extracellular vesicles",
            "probability": 0.06634521484375
        },
        {
            "start_logit": 3.16796875,
            "end_logit": 3.189453125,
            "text": "'Vesiduction' as a fourth mode of intercellular DNA transfer.",
            "probability": 0.04888916015625
        },
        {
            "start_logit": 1.498046875,
            "end_logit": 3.189453125,
            "text": "Vesiduction' as a fourth mode of intercellular DNA transfer.",
            "probability": 0.009185791015625
        },
        {
            "start_logit": 3.16796875,
            "end_logit": -0.74609375,
            "text": "'Vesiduction' as a fourth mode of intercellular DNA transfer",
            "probability": 0.0009531974792480469
        },
        {
            "start_logit": -1.3427734375,
            "end_logit": 3.189453125,
            "text": "term 'Vesiduction' as a fourth mode of intercellular DNA transfer.",
            "probability": 0.0005369186401367188
        },
        {
            "start_logit": 5.35546875,
            "end_logit": -3.515625,
            "text": "DNA transfer involving extracellular vesicles is",
            "probability": 0.0005326271057128906
        },
        {
            "start_logit": -2.091796875,
            "end_logit": 3.189453125,
            "text": ".",
            "probability": 0.00025343894958496094
        },
        {
            "start_logit": -2.091796875,
            "end_logit": 3.189453125,
            "text": ".",
            "probability": 0.00025343894958496094
        },
        {
            "start_logit": -2.091796875,
            "end_logit": 3.189453125,
            "text": ". Here, we propose the term 'Vesiduction' as a fourth mode of intercellular DNA transfer.",
            "probability": 0.00025343894958496094
        },
        {
            "start_logit": -2.091796875,
            "end_logit": 3.1875,
            "text": ". However, this widespread phenomenon has been observed in the three domains of life.",
            "probability": 0.00025272369384765625
        },
        {
            "start_logit": -2.091796875,
            "end_logit": 3.1875,
            "text": ".",
            "probability": 0.00025272369384765625
        },
        {
            "start_logit": 1.498046875,
            "end_logit": -0.74609375,
            "text": "Vesiduction' as a fourth mode of intercellular DNA transfer",
            "probability": 0.00017905235290527344
        },
        {
            "start_logit": -2.859375,
            "end_logit": 3.189453125,
            "text": "intercellular DNA transfer.",
            "probability": 0.00011748075485229492
        },
        {
            "start_logit": -3.068359375,
            "end_logit": 3.189453125,
            "text": "the term 'Vesiduction' as a fourth mode of intercellular DNA transfer.",
            "probability": 9.590387344360352e-05
        },
        {
            "start_logit": 5.35546875,
            "end_logit": -5.23828125,
            "text": "DNA",
            "probability": 9.512901306152344e-05
        },
        {
            "start_logit": 5.35546875,
            "end_logit": -5.34375,
            "text": "DNA transfer involving extracellular vesicles is still",
            "probability": 8.589029312133789e-05
        },
        {
            "start_logit": -3.451171875,
            "end_logit": 3.189453125,
            "text": "gene transfer mechanisms transformation, transduction and conjugation, DNA transfer involving extracellular vesicles is still under appreciated.",
            "probability": 6.4849853515625e-05
        },
        {
            "start_logit": -3.498046875,
            "end_logit": 3.189453125,
            "text": "Here, we propose the term 'Vesiduction' as a fourth mode of intercellular DNA transfer.",
            "probability": 6.192922592163086e-05
        }
    ],
    "601bde6e1cb411341a000006_1": [
        {
            "start_logit": 8.7578125,
            "end_logit": 1.35546875,
            "text": "Multisystem Disease with Abnormal Neurodevelopment",
            "probability": 0.83984375
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -1.09765625,
            "text": "Multisystem Disease with Abnormal Neurodevelopment.",
            "probability": 0.07257080078125
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -1.349609375,
            "text": "Multisystem Disease",
            "probability": 0.056304931640625
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -2.103515625,
            "text": "Multis",
            "probability": 0.026580810546875
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -4.546875,
            "text": "Multisystem Disease with Abnormal",
            "probability": 0.0023059844970703125
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -4.83203125,
            "text": "Multisystem Disease with Abnormal Neurodevelop",
            "probability": 0.0017337799072265625
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -6.85546875,
            "text": "Multisystem",
            "probability": 0.00022995471954345703
        },
        {
            "start_logit": 8.7578125,
            "end_logit": -7.0859375,
            "text": "Multisystem Disease with",
            "probability": 0.0001819133758544922
        },
        {
            "start_logit": -4.953125,
            "end_logit": 1.35546875,
            "text": "with Abnormal Neurodevelopment",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -5.58203125,
            "end_logit": 1.35546875,
            "text": "De Novo VPS4A Mutations Cause Multisystem Disease with Abnormal Neurodevelopment",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -5.80859375,
            "end_logit": 1.35546875,
            "text": "ystem Disease with Abnormal Neurodevelopment",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 1.35546875,
            "text": "Cause Multisystem Disease with Abnormal Neurodevelopment",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 1.35546875,
            "text": "Novo VPS4A Mutations Cause Multisystem Disease with Abnormal Neurodevelopment",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.328125,
            "end_logit": 1.35546875,
            "text": "VPS4A Mutations Cause Multisystem Disease with Abnormal Neurodevelopment",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.33203125,
            "end_logit": 1.35546875,
            "text": "Disease with Abnormal Neurodevelopment",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.953125,
            "end_logit": -1.09765625,
            "text": "with Abnormal Neurodevelopment.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.4765625,
            "end_logit": -1.09765625,
            "text": ".",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.58203125,
            "end_logit": -1.09765625,
            "text": "De Novo VPS4A Mutations Cause Multisystem Disease with Abnormal Neurodevelopment.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.80859375,
            "end_logit": -1.09765625,
            "text": "ystem Disease with Abnormal Neurodevelopment.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.58203125,
            "end_logit": -1.349609375,
            "text": "De Novo VPS4A Mutations Cause Multisystem Disease",
            "probability": 5.960464477539063e-08
        }
    ],
    "5aacd487fcf4565872000007_1": [
        {
            "start_logit": 8.3828125,
            "end_logit": 8.5625,
            "text": "POLQ gene",
            "probability": 1.0
        },
        {
            "start_logit": -1.4033203125,
            "end_logit": 8.5625,
            "text": "the POLQ gene",
            "probability": 5.650520324707031e-05
        },
        {
            "start_logit": -2.392578125,
            "end_logit": 8.5625,
            "text": "gene",
            "probability": 2.110004425048828e-05
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -2.830078125,
            "text": "POL",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -4.61328125,
            "text": "POLQ",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -4.6171875,
            "text": "POLQ gene in",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -5.1484375,
            "text": "POLQ gene in mammalian genomes.",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -6.4453125,
            "text": "POLQ gene in mammalian",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 8.5625,
            "text": "Q gene",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 8.5625,
            "text": "DNA polymerase theta (pol \u03b8) is an evolutionarily conserved protein encoded by the POLQ gene",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.2109375,
            "end_logit": 8.5625,
            "text": "by the POLQ gene",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.3828125,
            "end_logit": -7.19140625,
            "text": "POLQ gene in mammalian genomes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 8.5625,
            "text": "protein encoded by the POLQ gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 8.5625,
            "text": "encoded by the POLQ gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.53515625,
            "end_logit": 8.5625,
            "text": "(pol \u03b8) is an evolutionarily conserved protein encoded by the POLQ gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 8.5625,
            "text": "polymerase theta (pol \u03b8) is an evolutionarily conserved protein encoded by the POLQ gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.6875,
            "end_logit": 8.5625,
            "text": "pol \u03b8) is an evolutionarily conserved protein encoded by the POLQ gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.4033203125,
            "end_logit": -2.830078125,
            "text": "the POL",
            "probability": 0.0
        },
        {
            "start_logit": -1.4033203125,
            "end_logit": -4.61328125,
            "text": "the POLQ",
            "probability": 0.0
        },
        {
            "start_logit": -1.4033203125,
            "end_logit": -4.6171875,
            "text": "the POLQ gene in",
            "probability": 0.0
        }
    ],
    "58a2df9c60087bc10a000006_1": [
        {
            "start_logit": 9.34375,
            "end_logit": 9.0,
            "text": "8%",
            "probability": 1.0
        },
        {
            "start_logit": 9.34375,
            "end_logit": -0.5888671875,
            "text": "8",
            "probability": 6.866455078125e-05
        },
        {
            "start_logit": -1.4013671875,
            "end_logit": 9.0,
            "text": "%",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": 9.34375,
            "end_logit": -5.87109375,
            "text": "8% and that of sickle cell trait ranging from 1 to 32% in various districts.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.34375,
            "end_logit": -6.796875,
            "text": "8% and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.07421875,
            "text": "8% and that",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.078125,
            "text": "8% and that of sickle cell trait ranging from 1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.08203125,
            "text": "8% and that of sickle cell trait ranging",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.10546875,
            "text": "8% and that of sickle cell trait ranging from 1 to 32%",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.1328125,
            "text": "8% and that of sickle cell trait ranging from 1 to 32% in",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.34375,
            "end_logit": -7.16015625,
            "text": "8% and that of sickle cell trait ranging from 1 to 32",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.234375,
            "end_logit": 9.0,
            "text": ", the incidence of beta-thalassemia trait being 8%",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.28125,
            "end_logit": 9.0,
            "text": "the incidence of beta-thalassemia trait being 8%",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 9.0,
            "text": "being 8%",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.34375,
            "end_logit": 9.0,
            "text": "Hemoglobinopathies are very common in Greece, the incidence of beta-thalassemia trait being 8%",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 9.0,
            "text": "incidence of beta-thalassemia trait being 8%",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.4013671875,
            "end_logit": -5.87109375,
            "text": "% and that of sickle cell trait ranging from 1 to 32% in various districts.",
            "probability": 0.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": -0.5888671875,
            "text": ", the incidence of beta-thalassemia trait being 8",
            "probability": 0.0
        },
        {
            "start_logit": -7.28125,
            "end_logit": -0.5888671875,
            "text": "the incidence of beta-thalassemia trait being 8",
            "probability": 0.0
        },
        {
            "start_logit": -7.3046875,
            "end_logit": -0.5888671875,
            "text": "being 8",
            "probability": 0.0
        }
    ],
    "5c910ae0ecadf2e73f000007_1": [
        {
            "start_logit": 8.15625,
            "end_logit": 8.625,
            "text": "Bristol-Myers Squibb",
            "probability": 0.9970703125
        },
        {
            "start_logit": 8.15625,
            "end_logit": 2.90625,
            "text": "Bristol-Myers Squibb) of nivolumab",
            "probability": 0.0032749176025390625
        },
        {
            "start_logit": -2.16015625,
            "end_logit": 8.625,
            "text": "b",
            "probability": 3.30805778503418e-05
        },
        {
            "start_logit": 8.15625,
            "end_logit": -3.08984375,
            "text": "Br",
            "probability": 8.165836334228516e-06
        },
        {
            "start_logit": -5.11328125,
            "end_logit": 8.625,
            "text": "(Bristol-Myers Squibb",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -5.5,
            "end_logit": 8.625,
            "text": "istol-Myers Squibb",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -5.94921875,
            "end_logit": 8.625,
            "text": "the manufacturer (Bristol-Myers Squibb",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.3046875,
            "end_logit": 8.625,
            "text": "Squibb",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 8.625,
            "text": "the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Bristol-Myers Squibb",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.71875,
            "end_logit": 8.625,
            "text": "ol-Myers Squibb",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.3203125,
            "text": "Bristol-Myers Squibb)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.8203125,
            "end_logit": 8.625,
            "text": "ibb",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.43359375,
            "text": "Bristol-Myers Squib",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.93359375,
            "end_logit": 8.625,
            "text": "-Myers Squibb",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -1.2587890625,
            "end_logit": 2.90625,
            "text": "nivolumab",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.984375,
            "end_logit": 8.625,
            "text": ", the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Bristol-Myers Squibb",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.5625,
            "text": "Bristol-Myers Squibb) of nivolumab (Opdivo",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.6328125,
            "text": "Bristol-Myers",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.6796875,
            "text": "Bristol-Myers Squibb) of nivolumab (",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.15625,
            "end_logit": -6.73046875,
            "text": "Bristol-Myers Squibb) of nivolumab (Opdivo\u00ae",
            "probability": 2.384185791015625e-07
        }
    ]
}
